0001564590-22-009635.txt : 20220310 0001564590-22-009635.hdr.sgml : 20220310 20220310160617 ACCESSION NUMBER: 0001564590-22-009635 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220310 DATE AS OF CHANGE: 20220310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 22729087 BUSINESS ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 10-K 1 dmtk-10k_20211231.htm 10-K dmtk-10k_20211231.htm
10-K false FY 0001651944 --12-31 0.5 0.25 P3Y 0.25 0.25 P10Y P2Y P5Y P3Y P7Y P7Y P7Y P4Y P5Y 0.25 0.25 0.25 0.0052 0.0036 0.0168 0.7488 0.6403 0.7230 P6Y29D 0.0139 0.0169 0.0250 0.8332 0.7344 0.7350 P5Y14D P6Y3M P6Y7D P6Y29D 0.0005 0.0018 0.6455 0.6934 P5M26D P6M P5M26D 0.46 0.22 1.40 85.85 69.79 64.06 P2Y7M28D P3Y7M28D P4Y8M1D 0.85 0.33 1.66 90.70 79.26 66.68 P3Y5M1D P4Y5M1D P5Y P7Y9M18D P8Y10M28D P8Y3M21D P8Y3M21D P7Y7M2D P9Y3M29D P2Y4M2D 0001651944 2021-01-01 2021-12-31 iso4217:USD 0001651944 2021-06-30 xbrli:shares 0001651944 2022-03-08 0001651944 2021-12-31 0001651944 2020-12-31 iso4217:USD xbrli:shares 0001651944 dmtk:AssayMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractualActivitiesMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractualActivitiesMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractualActivitiesMember 2019-01-01 2019-12-31 0001651944 2020-01-01 2020-12-31 0001651944 2019-01-01 2019-12-31 0001651944 dmtk:SeriesC2ConvertiblePreferredStockMember 2018-12-31 0001651944 us-gaap:CommonStockMember 2018-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001651944 us-gaap:RetainedEarningsMember 2018-12-31 0001651944 2018-12-31 0001651944 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001651944 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001651944 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001651944 dmtk:SeriesC2ConvertiblePreferredStockMember us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001651944 us-gaap:CommonStockMember us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001651944 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-12-31 0001651944 us-gaap:CommonStockMember 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001651944 us-gaap:RetainedEarningsMember 2019-12-31 0001651944 2019-12-31 0001651944 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember dmtk:SeriesAAndBConvertibleNoteMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:SeriesAAndBConvertibleNoteMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember dmtk:SeriesAAndBConvertibleNoteMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001651944 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001651944 us-gaap:RetainedEarningsMember 2020-12-31 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember 2020-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember 2020-12-31 0001651944 us-gaap:CommonStockMember 2021-12-31 0001651944 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001651944 dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001651944 us-gaap:CommonStockMember dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-12-31 0001651944 dmtk:PublicFollowOnOfferingMember 2021-01-01 2021-12-31 xbrli:pure 0001651944 2019-08-29 2019-08-29 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember dmtk:PublicOfferingMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember dmtk:PrivatePlacementOfferingMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 dmtk:Warrant 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-01-01 2020-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember 2021-01-01 2021-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2021-01-01 2021-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2020-01-01 2020-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2019-01-01 2019-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2020-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-01-01 2021-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2020-01-01 2020-12-31 dmtk:Revenue_Stream 0001651944 dmtk:ContractRevenueSmartStickersMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueSmartStickersMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueSmartStickersMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2019-01-01 2019-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueCustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001651944 srt:MaximumMember dmtk:AssayRevenuePayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001651944 srt:MaximumMember dmtk:AssayRevenuePayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:AssayRevenuePayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:ContractRevenueCustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember 2021-12-31 0001651944 srt:MaximumMember 2021-12-31 0001651944 dmtk:AssayMember 2021-12-31 0001651944 dmtk:AssayMember 2020-12-31 0001651944 dmtk:ContractualActivitiesMember 2021-12-31 0001651944 dmtk:ContractualActivitiesMember 2020-12-31 dmtk:Segment 0001651944 dmtk:ConversionOfPreferredStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001651944 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001651944 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001651944 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-12-31 0001651944 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember srt:MinimumMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember srt:MaximumMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2019-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001651944 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2019-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2019-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-12-31 0001651944 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2019-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2019-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-12-31 0001651944 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2019-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:MunicipalNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:MunicipalNotesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:MunicipalNotesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001651944 us-gaap:MunicipalNotesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2019-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2020-01-01 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2021-01-01 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member dmtk:RestrictedCashMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member dmtk:RestrictedCashMember 2020-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:MunicipalNotesMember 2020-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2018-11-30 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2018-11-30 2018-11-30 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember srt:MinimumMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2019-09-23 2019-09-23 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-06-05 2019-06-10 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-06-10 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember srt:MaximumMember 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember srt:MaximumMember 2019-09-24 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember srt:MaximumMember 2019-09-23 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember srt:MaximumMember 2019-09-24 2019-09-24 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-23 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-08-29 2019-08-29 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2020-08-10 2020-08-10 0001651944 2020-08-10 2020-08-10 0001651944 dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001651944 us-gaap:CommonStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 us-gaap:CommonStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-03-02 2020-03-02 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-05-27 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-05-27 2020-05-27 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-08-10 2020-08-10 0001651944 dmtk:AtTheMarketOfferingMember dmtk:CowenLimitedLiabilityCompanyMember 2020-11-10 2020-11-10 0001651944 dmtk:AtTheMarketOfferingMember dmtk:CowenLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001651944 dmtk:AtTheMarketOfferingMember dmtk:CowenLimitedLiabilityCompanyMember 2021-01-06 2021-01-06 0001651944 dmtk:AtTheMarketOfferingMember dmtk:CowenLimitedLiabilityCompanyMember 2021-01-11 2021-01-11 0001651944 dmtk:AtTheMarketOfferingMember dmtk:CowenLimitedLiabilityCompanyMember 2021-01-11 0001651944 2021-01-11 2021-01-11 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2020-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2020-12-31 0001651944 dmtk:SeriesCWarrantsMember srt:MinimumMember dmtk:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember dmtk:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-01-01 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2015-01-01 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-01-01 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2020-12-31 0001651944 dmtk:IncentiveAndNonStatutoryStockOptionsMember srt:MinimumMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:IncentiveStockOptionsMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:IncentiveStockOptionsMember srt:MinimumMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTenStockPlanMember 2021-12-31 0001651944 dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:IncentiveAndNonQualifiedStockOptionsMember srt:MinimumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 dmtk:IncentiveStockOptionsMember srt:MinimumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2019-12-31 0001651944 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:EmployeeStockMember 2020-12-31 0001651944 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember srt:MaximumMember 2021-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-02-28 2021-02-28 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-08-31 2021-08-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 0001651944 dmtk:ManagementWarrantsMember 2021-12-31 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001651944 dmtk:ManagementWarrantsMember 2020-12-31 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2020-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2020-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2021-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2020-12-31 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2020-12-31 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2020-12-31 0001651944 us-gaap:DomesticCountryMember 2021-12-31 0001651944 us-gaap:DomesticCountryMember 2020-12-31 0001651944 us-gaap:DomesticCountryMember 2019-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001651944 srt:MinimumMember 2020-12-31 0001651944 srt:MinimumMember 2019-12-31 0001651944 us-gaap:InterestIncomeMember 2021-01-01 2021-12-31 0001651944 us-gaap:InterestIncomeMember 2020-01-01 2020-12-31 0001651944 us-gaap:InterestIncomeMember 2019-01-01 2019-12-31 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 2021-07-01 utr:sqft 0001651944 dmtk:KilroyRealtyLPMember 2021-01-01 2021-12-31 iso4217:USD utr:sqft 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember 2021-12-31 0001651944 dmtk:KilroyRealtyLPMember us-gaap:LetterOfCreditMember dmtk:RestrictedCashMember 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember us-gaap:StandbyLettersOfCreditMember 2021-12-31 0001651944 2021-01-01 0001651944 dmtk:CowenMember 2019-09-04 2019-09-04 0001651944 dmtk:CowenMember 2019-09-04 0001651944 dmtk:CowenMember 2021-01-01 2021-12-31 0001651944 dmtk:CowenMember 2021-12-31 0001651944 dmtk:CowenMember 2020-09-02 0001651944 dmtk:SpouseOfChiefCommercialOfficerMember dmtk:EVERSANALifeScienceServicesLLCMember 2021-01-01 2021-12-31 0001651944 dmtk:SpouseOfChiefCommercialOfficerMember dmtk:EVERSANALifeScienceServicesLLCMember 2020-01-01 2020-12-31 0001651944 dmtk:SpouseOfChiefCommercialOfficerMember dmtk:EVERSANALifeScienceServicesLLCMember 2019-01-01 2019-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-11-11 2020-11-11 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember srt:MaximumMember 2019-10-01 2019-10-01 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-05-01 2020-05-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-06-01 2020-06-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-07-01 2020-07-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-08-01 2020-08-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-09-01 2020-09-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-02-26 2021-02-26 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-02

1GG

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10‑K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: December 31, 2021

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-38118

 

DERMTECH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

incorporation or organization)

84-2870849

(IRS Employer

Identification No.)

 

 

11099 N. Torrey Pines Road,

Suite 100

La Jolla, CA

92037

(Zip Code)

 

Registrant’s telephone number, including area code: (858) 450‑4222

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

DMTK

The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well‑known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐  No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐  No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b‑2 of the Exchange Acts.

 

Large accelerated filer

 

☒

 

Accelerated filer

 

☐

 

 

 

 

 

 

 

Non-accelerated filer

 

☐

 

Smaller reporting company

 

☒

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes ☐  No ☒

The aggregate market value of the registrant’s common stock, $0.0001 par value, held by non‑affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $978,378,259 (based on the closing price of the registrant’s common stock on June 30, 2021 of $41.57 per share).

The number of shares outstanding of the registrant’s common stock, $0.0001 par value as of March 8, 2022 was 29,850,730.

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2021. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.

 

 

Auditor Firm ID: 185

Auditor Name: KPMG LLP

 

Auditor Location: San Diego, CA

 

 

i

 

DERMTECH, INC

ANNUAL REPORT ON FORM 10‑K

YEAR ENDED DECEMBER 31, 2021

TABLE OF CONTENTS

 

 

 

Page No.

Part I

 

3

Item 1.

Business.

3

Item 1A.

Risk Factors.

28

Item 1B.

Unresolved Staff Comments.

56

Item 2.

Properties.

56

Item 3.

Legal Proceedings.

56

Item 4.

Mine Safety Disclosures.

56

Part II

 

57

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

57

Item 6.

[Reserved]

57

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

58

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

66

Item 8.

Financial Statements and Supplementary Data.

67

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

105

Item 9A.

Controls and Procedures.

105

Item 9B.

Other Information.

106

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspection.

107

Part III

 

108

Item 10.

Directors, Executive Officers and Corporate Governance.

108

Item 11.

Executive Compensation.

108

Item 12.

Security and Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

108

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

108

Item 14.

Principal Accountant Fees and Services.

108

Part IV

 

109

Item 15.

Exhibits and Financial Statement Schedules.

109

Item 16.

Form 10-K Summary.

111

SIGNATURES

112

 

 

ii

 

Special Note Regarding Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. Words such as, but not limited to “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and similar expressions or variations thereof are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. These statements include, among other things, statements regarding:

 

•

our ability to attain profitability;

 

•

our estimates regarding our future performance, including without limitation estimates of potential future revenues;

 

•

our ability to maintain commercial reimbursement for our tests;

 

•

our ability to efficiently bill for and collect revenue resulting from our tests;

 

•

our anticipated need to raise additional capital to fund our operations, commercialize our products, and expand our operations;

 

•

our ability to market and sell our tests to physicians and other clinical practitioners;

 

•

our ability to continue to develop our existing test and develop and commercialize additional novel tests;

 

•

our dependence on third parties for the manufacture of our products;

 

•

our ability to meet market demand for our current and planned future tests;

 

•

our reliance on our sole laboratory facility and the harm that may result if this facility became damaged or inoperable;

 

•

our ability to compete with our competitors and their competing products;

 

•

the importance of our executive management team;

 

•

our ability to retain and recruit key personnel;

 

•

our dependence on third parties for the supply of our laboratory substances, equipment and other materials;

 

•

the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these lawsuits to cause us to suspend sales of our products;

 

•

the possibility that a third party may claim we have infringed or misappropriated our intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;

 

•

the potential consequences of our expanding our operations internationally;

 

•

our ability to continue to comply with applicable privacy laws and protect confidential information from breaches;

 

•

how changes in federal health care policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our tests;

 

•

our ability to continue to comply with federal and local laws concerning our business and operations and the consequences resulting from our failure to comply with such laws;

 

•

the possibility that we may be required to conduct additional clinical studies or trials for our tests and the consequences resulting from the delay in obtaining necessary regulatory approvals;

 

•

the harm resulting from the potential loss, suspension, or other restriction on one or more of our licenses, permits, certifications or accreditations, or the imposition of a fine or penalty on us under federal, state, or foreign laws;

 

•

our ability to maintain and our intellectual property protections;

 

•

how recent and potential future changes in tax policy could negatively impact our business and financial condition;

 

•

how recent and potential future changes in healthcare policy could negatively impact our business and financial condition;

1

 

 

•

our ability to maintain Nasdaq listing; and

 

•

our ability to manage the increased expenses and administrative burdens as a public company.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risk Factors” below, as well as those discussed elsewhere in this report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We file reports with the Securities and Exchange Commission (the “SEC”), and our electronic filings with the SEC (including our quarterly reports on Form 10-Q and current reports on Form 8-K, and any amendments to these reports) are available free of charge on the SEC’s website at http://www.sec.gov.

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition and results of operations. We qualify all of our forward-looking statements by this special note.

We own registered or unregistered trademark rights to DermTech™, DermTech Melanoma Test™, DermTech Stratum™, Smart Sticker™, Luminate™ and our company name and logo among others. Any other service marks, trademarks and trade names appearing in this report are the property of their respective owners. We do not use the ® or ™ symbol in each instance in which one of our trademarks appears in this report, but this should not be construed as any indication that we will not assert our rights thereto to the fullest extent under applicable law.

2

PART I

Item 1.  Business

Unless specifically noted otherwise, as used throughout this Business section, “we,” “our,” “us,” or the “Company” refers to the business, operations and financial results of DermTech Operations prior to, and the Company and its subsidiaries subsequent to, the completion of the Business Combination as the context requires. “Constellation” refers to the Company prior to the completion of the Business Combination.

Business Overview

We are a molecular diagnostic company developing and marketing novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Our technology provides a highly accurate alternative to surgical biopsy, minimizing patient discomfort, scarring, and risk of infection, while maximizing convenience. Our scalable genomics assays have been designed to work with our adhesive patch called the DermTech Smart StickerTM (the “Smart Sticker”) which is used to non-invasively collect tissue samples for analysis.

We are initially commercializing tests that will address unmet needs in the diagnostic pathway of pigmented skin lesions, such as moles or dark colored skin spots. Our DermTech Melanoma Test (the “DMT”) facilitates the clinical assessment of pigmented skin lesions for melanoma. We have initially marketed this test directly to a concentrated group of dermatology clinicians and are currently expanding marketing efforts to a broader group of dermatology clinicians. The simple application of Smart Stickers to collect samples non-invasively may allow us to eventually market the DermTech Melanoma Test to primary care physicians more broadly, beyond integrated primary care networks, and expand our efforts through telemedicine channels. We process our tests in our high complexity molecular laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”), and licensed by the State of California as well as other states requiring out-of-state licensure, including New York. We also provide laboratory services to several pharmaceutical companies that access our technology on a contract basis within their clinical trials or other studies to better advance new drugs.

 

 

Business Combination, Reverse Split and Domestication

On August 29, 2019, the Company, formerly known as Constellation Alpha Capital Corp. (“Constellation”), and DermTech Operations, Inc., formerly known as DermTech, Inc. (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc. (“Merger Sub), and DermTech Operations. We refer to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as our wholly owned subsidiary. We refer to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, Constellation re-domiciled out of the British Virgin Islands and continued as a company incorporated in the State of Delaware.

On August 29, 2019, immediately following the completion of the Business Combination, we amended and restated our certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to change the name of the Company to DermTech, Inc. Prior to the completion of the Business Combination, the Company was a shell company. Following the Business Combination, the business of DermTech Operations is the business of the Company.

On August 29, 2019, in connection with and immediately following the completion of the Business Combination, we filed a certificate of amendment (the “Certificate of Amendment”) to the Amended and Restated Certificate of Incorporation to effect a one-for-two reverse stock split of our common stock on August 29, 2019 (the “Reverse Stock Split”). As a result of the Reverse Stock

3

Split, the number of issued and outstanding shares of our common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every two shares of our common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of our common stock.

Our Business

We are a molecular diagnostic company developing and marketing novel non-invasive genomics tests that seek to transform the practice of dermatology and related fields. Our platform may change the diagnostic paradigm in dermatology from one that is subjective, invasive, less accurate and higher-cost, to one that is objective, non-invasive, more accurate and lower-cost. Our initial focus is skin cancer. We currently offer the DMT for the enhanced early detection of melanoma and are developing a product for non-melanoma skin cancer. We are also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Our scalable genomics platform has been designed to work with our Smart Sticker, which provides a skin sample collected easily and non-invasively, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. We also provide our services and technology platform on a contract basis to pharmaceutical companies who use the technology in their clinical trials to test for the existence of genomic targets of various diseases and to measure the response of new drugs under development. We process our tests in our commercial laboratory that is CLIA certified, CAP accredited and licensed by the California Department of Public Health as well as other states that require out-of-state licensure. As described below, our technology platform is easy to use and integrates seamlessly into the current clinical diagnostic pathway by providing (i) simple and rapid tissue collection and shipping via standard express mail, (ii) sample processing via quantitative polymerase chain reaction (“qPCR”), or other technologies and (iii) physician reporting within 48 to 72 hours. In addition, physicians can bill for their services using existing Evaluation and Management (“E&M”), codes for the visit during which our tests are ordered.

Dermatology is one of the largest medical markets in the United States. The skin cancer segment alone has over 15 million surgical diagnostic procedures performed each year in the United States, with an average annual spend of $8.1 billion, according to the American Academy of Dermatology (“AAD”). Current dermatologic diagnosis is primarily based on subjective visual assessments and subsequent surgical diagnostic procedures. This legacy paradigm is prone to error and results in a substantial number of unnecessary and invasive surgical procedures. Our platform provides a non-invasive alternative that minimizes patient discomfort, scarring, and risk of infection. Further, because our testing results utilize genomic analysis, we provide more accurate, objective diagnostic information than the currently prevailing diagnostic procedures. As described below, the DMT has been demonstrated in a study published in JAMA Dermatology and conducted prior to our introduction of the option to order DMT with an additional test (formerly known as PLAplus) for the presence of telomerase reverse transcriptase gene driver mutations (“TERT”) to lower the cost to diagnose melanoma while providing a more accurate and less invasive alternative to current methods based on assessing genomic atypia.

 

4

 

 

The general genomic testing market is highly saturated with other genomic diagnostic tests that are primarily marketed to pathology and oncology specialists. We are the first company to offer non-invasive genomic tests to the clinical dermatology market. We believe our technology platform will transform the practice of dermatology and will expand the base of clinicians that can practice high quality precision dermatology (e.g., primary care clinicians). As healthcare delivery diverges to support more convenient delivery models, such as pharmacy-based/retail clinics and telemedicine, we believe our platform will facilitate the migration of dermatologic care to these alternative models. We believe our platform may allow for expanded consumer-based sample collection shipped directly to our laboratory, positively impacting the ease of use and convenience of providing dermatologic care.

We originally marketed the DMT under the name Pigmented Lesion Assay or PLA. The PLA assessed pigmented skin lesions, moles or dark skin spots for melanoma and enhances early detection. In particular, the PLA detected expression of the LINC00518 (“LINC”) and preferentially expressed antigen in melanoma (“PRAME”) genes using an amplification process called reverse transcription-polymerase chain reaction (“RT-PCR”). In the second quarter of 2018, we introduced our Nevome product, an adjunctive reflex test for the PLA. The Nevome test was used with histopathology to identify additional risk factors for melanoma and to confirm the diagnosis of melanoma in PLA positive tests, which are subjected to surgical biopsy. The Nevome test analyzed early-stage melanoma driver mutations in the v-Raf murine sarcoma viral oncogene homolog B (“BRAF”), neuroblastoma RAS viral oncogene homolog (“NRAS”) and TERT genes. The Nevome test utilized the same genomic material collected from the initial Smart Sticker sample used for the PLA and did not require additional sampling. We discontinued our Nevome product in November 2020, and replaced it with the introduction of our second-generation PLA test, PLAplusTM, in April 2021. The PLAplus test could identify the presence of TERT using a DNA sequencing technique and adding the TERT promoter mutation analyses to the PLA gene expression test improved the sensitivity of the test to up to 97%. We no longer test for BRAF or NRAS genes, which we tested for in our Nevome product. We have since rebranded our PLA and PLAplus tests as the DermTech Melanoma Test or the DMT. The DMT tests for LINC and PRAME, as it did while branded as the PLA, and may be ordered with or without the add-on test for TERT formerly known as PLAplus. Positive results for LINC, PRAME, or TERT correlate with the presence of melanoma. If the biomarkers are not detected (meaning negative results), this result indicates a greater than 99% probability that the mole being tested is not melanoma.

In March 2019, Medicare’s Molecular Diagnostic Services program, administered by Palmetto GBA (“MolDX”), which performs technology assessments for genomic tests, issued a favorable Local Coverage Determination (“LCD”) draft (the “Draft LCD”) for the DMT (without the add-on test for TERT). Each reference to the DMT in this paragraph refers only to the DMT without the add-on test for TERT. In October 2019, the American Medical Association (“AMA”) provided us with a Current Procedural Technology Proprietary Laboratory Analysis code for the DMT of 0089U (the “PLA Code”). Pricing of $760 for the PLA Code was published on December 24, 2019 as part of the Centers for Medicare and Medicaid Services (“CMS”) Clinical Laboratory Fee Schedule (“CLFS”), for 2020, which has been confirmed for 2022. The Medicare final LCD (the “Final LCD”) first made available on December 26, 2019 expanded the coverage proposal in the Draft LCD from one test per date of service to two tests per date of service for a certain percentage of patients, and allows clinicians to order the DMT if they have sufficient skill and experience to decide whether a pigmented lesion should be biopsied or assessed using the DMT. The DMT became eligible for Medicare reimbursement effective on February 10, 2020. Our local Medicare Administrative Contractor, Noridian Healthcare Solutions, LLC (“Noridian”) relies upon MolDX for technology assessments of genomic-based tests and has adopted the Final LCD issued by MolDX. Noridian has issued its own LCD announcing coverage of the DMT. Even though the effective date of Noridian’s LCD is June 7, 2020, Noridian began reimbursing us for the DMT as of February 10, 2020. No LCD covers the optional add-on test for TERT available to those ordering the DMT.

Of the approximate 4.0 million surgical biopsies performed each year on pigmented skin lesions, over 90% are negative for melanoma and represent avoidable surgical procedures. The DMT improves the assessment of pigmented lesions by reducing the probability of missing melanoma to less than 1.0% (versus approximately 11-17% with the existing standard of care) and by reducing the number of surgical biopsies required to diagnose melanoma by five to tenfold (from about 25:1 to about 2.5-5.0:1). In addition, the DMT improves the positive predictive value (“PPV”) approximately five-fold (from 3-4% with the current surgical techniques to 18.7% with DMT).

The performance of the DMT is supported by numerous investigational studies, which enrolled an aggregate of over 9,000 patients and yielded a total of 22 peer-reviewed publications in top-rated medical dermatology journals. A study published in JAMA Dermatology and conducted prior to our introduction of the option to order DMT with the add-on test for TERT demonstrated that the DMT (referred to as the PLA in this study) significantly lowers the cost to diagnose melanoma while providing a more accurate and less invasive alternative to current methods. The current AAD melanoma guidelines indicate that non-invasive gene expression testing can be used as a part of the initial clinical assessment for pigmented lesions. In January 2021, the National Comprehensive Cancer Network® (“NCCN”) updated their NCCN Clinical Practice Guidelines in Oncology (“NCCN Guidelines®”) for cutaneous melanoma to recommend that the use of pre-diagnostic noninvasive genomic patch testing may be helpful to guide biopsy decisions for cutaneous melanoma. The NCCN reaffirmed their recommendation in January 2022 that pre-diagnostic noninvasive patch testing may be helpful to guide biopsy decisions for cutaneous melanoma. The NCCN’s recommendation indicated that there is uniform consensus that the intervention is appropriate. In addition, an independent panel of melanoma experts has produced consensus recommendations for use of the DMT. We believe the DMT can be used as an alternative for the majority of these surgical biopsy procedures. In 2019, our platform became available for use in Canada based on Health Canada compliance and we have established a non-exclusive partnership with

5

DermTech Canada. We are working with two Canadian provinces, British Columbia, and Ontario, who are evaluating our technology for coverage and reimbursement.

We initiated the commercialization of the DMT in the second quarter of 2016. We currently market our tests directly to dermatologists in the United States with a team of approximately 70 sales representatives throughout the United States and could expand our team into more areas throughout the United States during 2022. With our Medicare coverage, contracts with several large insurers associated with the Blue Cross Blue Shield Association (“Blues plans”) and growth of testing volume and physician users, we believe the DMT is being reviewed for coverage by key United States commercial payors. We believe we will achieve successful coverage outcomes from these efforts over the next 24 to 36 months, although no assurances can be given that any reimbursement coverage approvals will be obtained.

We are expanding our sales efforts as we obtain reimbursement coverage to provide sales coverage to a majority of over 13,000 healthcare professionals specializing in dermatology in the United States.

We believe the total annual United States market opportunity for the DMT exceeds $2.5 billion, and that the select annual worldwide market consisting of Australia, Europe, and Canada exceeds an additional $750 million. We currently only offer the DMT throughout the United States.

We have additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), currently under development. In the United States, approximately 12 million surgical biopsies are performed each year to diagnose approximately 5.4 million non-melanoma skin cancers. Many of the initial surgical procedures for these skin cancers are performed on cosmetically sensitive areas of the body, such as the face, neck and chest, creating significant demand for a non-invasive alternative. We believe the total market opportunity for our non-melanoma skin cancer products exceeds $3 billion in the United States and $1 billion in select world-wide markets.

We are also working on tests to facilitate the assessment of inflammatory skin diseases, such as atopic dermatitis and psoriasis, which will facilitate the appropriate diagnosis and treatment of these inflammatory diseases. The prevalence of atopic dermatitis in the United States is reported to be approximately 12% in children and 7.0% in adults with approximately 6.6 million patients having moderate-to-severe disease. The prevalence of psoriasis in the United States is approximately 2.2% with approximately 1.3 million patients having moderate to severe disease.

We also make our non-invasive molecular skin analysis platform available to pharmaceutical companies to facilitate the development of new targeted therapies in dermatology and cancer, including biologics. These partners use our platform and services to assess treatment response, monitor side effects and identify likely responders to the therapy under development. We have completed and have ongoing research collaborations with large pharmaceutical companies to facilitate their development of new targeted therapeutics in dermatology. We have initiated programs across the spectrum of pharmaceutical development stages from Phase 1 through Phase 3. We believe that some of these collaborations may lead to a complementary or companion diagnostic product for the pharmaceutical partner’s therapeutic candidate, if it reaches the commercial market. We have booked over $0.7 million of orders pursuant to research contracts in 2021, and many of these contracts are multi-year in length.

We offer our genomic tests through our CLIA certified and CAP accredited commercial laboratory located in La Jolla, California, which is licensed by the State of California and all states requiring out-of-state licensure, including New York, which has the most rigorous licensing process for clinical diagnostic laboratories. We can scale our current laboratory facility to handle approximately 150,000 DMT tests per year. We are in the process of converting office space into a new laboratory facility with the ability to scale to over 1,000,000 tests per year based on the processes and equipment currently used for the DMT.

Our sample collection technology maximizes collection of relevant tissue with minimal patient discomfort using adhesive patches. We have developed significant intellectual property and know-how around the use of adhesives for non-invasive biopsy and the transportation and handling of this type of sample. We have developed a proprietary process that allows us to extract genomic material from the patches with sufficient quality and quantity to perform gene expression, DNA mutation, transcriptomic analyses and other technologies. We believe our technology can be utilized to assess the microbiome of the skin with superior performance to existing methods that use swabs. The results of these efforts will allow us to introduce our sample collection technology to facilitate the diagnosis of a broad array of dermatologic conditions and other conditions where the skin serves as a surrogate target organ.

6

Our Competitive Advantages

Enhancing early detection for superior patient care at a lower cost. The DMT is used to assess pigmented lesions that may harbor melanoma at the earliest stages (melanoma in situ or stage 1a), the most difficult lesions to diagnose. In our clinical studies, the DMT has demonstrated a sensitivity of 91-97% and a specificity of 69-91% in differentiating these early-stage melanomas from non-melanoma using histopathology as the reference standard. This leads to a very high negative predictive value (“NPV”) of greater than 99%, which is the probability the DMT correctly ruled out melanoma. We completed a long-term follow-up study of the DMT (without the add-on test for TERT) that further confirmed the 99% NPV of the DMT by reevaluating and retesting lesions that were DMT negative 12 to 24 months prior to each subject’s enrollment in the study. We also completed a study that demonstrated that the DMT (without the add-on test for TERT) increases the PPV for melanoma diagnosis by approximately fivefold, from 3-4% for the current pathway to 18.7% for the DMT. In addition, the DMT (without the add-on test for TERT) has demonstrated an approximate tenfold reduction in unnecessary surgical procedures, relative to the current visual assessment and histopathology standard of care. Such a reduction can result in significant cost savings for the health care system and reduces patient morbidity as compared to other diagnostic approaches. Table 1 below compares the DMT (without the add-on test for TERT, except for sensitivity) with other techniques and the existing standard of care for assessing early-stage melanoma in pigmented skin lesions.

 

 

 

The DMT

 

Visual

Assessment &

Pathology

(Current

Standard)

Mechanism

 

Tumor

Biology

 

Pattern

Recognition

Surgical Procedure Required

 

No

 

Yes

Platform Technology

 

Yes

 

N/A

Multiple Dermatologic Indications

 

Yes

 

Yes

Physician Payment

 

Yes

 

Yes

Simple Practice Integration

 

Yes

 

N/A

Ease of Use

 

Yes

 

N/A

Number Needed to Biopsy(1)

 

2.7

 

>25

Number Needed to Excise(2)

 

1.6

 

5.2

Better Performance

 

 

 

 

NPV(3)

 

>99%

 

>81-89%

PPV(4)

 

18.7%

 

4%

Sensitivity(5)

 

91-97%

 

65-84%

Cost

 

$760(6)

 

$947

Capital Equipment

 

No

 

No

 

Table 1. The data summarized above compares the DMT with the existing standard of care for assessing early-stage melanoma in pigmented skin lesions.

 

Footnotes to Table 1:

 

(1)

Number of surgical biopsies required to diagnose one melanoma.

 

(2)

Number of wide excision surgical procedures per melanoma diagnosed.

 

(3)

NPV measures the probability that a negative result is truly negative.

 

(4)

PPV measures the probability that a positive result is truly positive.

 

(5)

Sensitivity measures the proportion of actual positives that are correctly identified as such.

 

(6)

Figure represents a projected United States reimbursed price, though this price has not yet been negotiated with major United States payors. Pricing of $760 for the PLA Code was published on December 24, 2019 as part of the CMS Laboratory Fee Schedule for 2020 and confirmed for 2021. The Medicare Final Coverage Decision was made available on December 26, 2019 and the DMT (without the add-on test for TERT) became eligible for Medicare reimbursement on February 10, 2020.

Our technology platform has the potential to transform dermatologic practice. We are the first and only company to offer non-invasive genomic testing to clinicians that practice dermatology. Current dermatologic practice is based on subjective visual assessments of cellular change that are prone to inaccuracy and lead to invasive surgical procedures that drive unnecessary costs. Our technology platform seeks to dramatically transform this paradigm by enhancing early detection at the genome level where cancer

7

begins providing non-invasive, objective, and more accurate information, thereby broadening the base of clinicians that can practice dermatology while also improving the performance of specialists.

Superior ease of use. Our non-invasive biopsy sample collection procedure can be performed in less than five minutes. All the necessary items, including Smart Stickers, instructions, a marking pen for outlining, and a preaddressed and prepaid return shipping label, are contained in our kit. The collection procedure, when a clinician orders the test, can also be performed at the patient’s home with clinician guidance.

Simple integration into clinical practice. Our tests use a Smart Sticker that replaces the scalpel traditionally used in the initial clinical assessment. Unlike other technologies, our platform does not require the installation and maintenance of capital equipment. The nursing support, documentation, specimen processing, and requisition post procedure are substantially similar to current practice. These issues are critical in a busy clinical practice where clinicians see patients every five to seven minutes.

Strong intellectual property protection. We have seven issued or allowed United States patents, one of which is broadly directed to the use of an adhesive to collect samples containing RNA from the skin for analysis. In addition, we have been awarded patents on unique gene expression profiles and classifiers that differentiate melanoma from non-melanoma, one of which will not expire until 2029, and the other will not expire until 2030. Additional efforts to further expand our patent portfolio are ongoing and a number of provisional and non-provisional patent applications have been filed. We have also developed unique know-how and proprietary processes that allow us to extract sufficient quantities of low-quality genomic material from adhesive patch samples suitable for analysis.

Our Strategy

Our goal is to become the global leader in non-invasive genomics testing for dermatologic conditions. We believe our robust intellectual property portfolio, platform technology, first-to-market advantage, and groundbreaking research will facilitate the achievement of this goal. Specifically, we will focus on the following objectives:

Build a specialized sales force to introduce our products into the dermatology market. We have expanded our existing direct specialty sales force as additional reimbursement coverage has been achieved. Consistent with our current sales strategy, we will continue to recruit experienced sales representatives, primarily those from the dermatology sector who have existing physician relationships. We believe we could also leverage this sales force by establishing distribution relationships with laboratory companies that do business with clinical dermatologists or sell molecular tests.

Secure broad reimbursement coverage for our assays. We have targeted regional and national commercial payors to secure favorable coverage decisions for the reimbursement of our tests. The DMT has completed the necessary analytical validity, clinical validity, and clinical utility studies that payors require molecular tests to undertake. As discussed above, we also published a United States health economic impact study of the DMT (without the add-on test for TERT) in JAMA Dermatology, which shows that the DMT significantly reduces the relative cost to assess a pigmented lesion. The cost to fully adjudicate a pigmented lesion suspicious for melanoma is $947 in the United States. We believe the DMT could lead to cost savings of greater than $650 million per year in aggregate savings, based on approximately 4 million surgical biopsies performed per year to rule out melanoma, and assuming the DMT was to become the standard of care in the United States.

As discussed above, in March 2019, MolDX, which performs technology assessments for genomic tests, issued a favorable Draft LCD for the DMT (without the add-on test for TERT). Each reference to the DMT in this paragraph refers only to the DMT without the add-on test for TERT. In late October 2019, the AMA provided us with the PLA Code. Pricing of $760 for the PLA Code was released on December 24, 2019 as part of the CLFS for 2020. The Final LCD, first made available on December 26, 2019, expanded the coverage proposal in the Draft LCD from one test per date of service to two tests per date of service for a certain percentage of patients, and allowed clinicians to order the DMT if they have sufficient skill and experience to decide whether a pigmented lesion should be biopsied or assessed by the DMT. The DMT became eligible for Medicare reimbursement on February 10, 2020. Our local Medicare Administrative Contractor, Noridian, relies upon MolDX for technology assessments of genomic-based tests and has adopted the Final LCD issued by MolDX. Noridian has issued its own LCD announcing coverage of the DMT. Even though the effective date of Noridian’s LCD is June 7, 2020, Noridian began reimbursing us for the DMT as of February 10, 2020. No LCD covers the optional add-on test for TERT available to those ordering the DMT.

In addition to our demonstrated clinical validity, clinical utility is the most important attribute of a test for establishing coverage policies with payors because it demonstrates how frequently physicians adhere to the recommendation of the test and the resulting improvement in clinical outcomes. In 2020, we completed and published our largest clinical utility study of the DMT (without the add-on test for TERT) based on real-world commercial usage. This most recent clinical utility study on 3,418 cases corroborates earlier utility studies and demonstrates that clinicians adhere to the recommendation of the DMT more than 98% of the time. The DMT significantly reduces surgical procedures and improves the diagnostic pathway for pigmented lesion assessment. Lesions clinically suspicious for melanoma have negative DMT results in over 90% of cases, leading to an approximately 90% reduction in surgical biopsies in our 2020 study. In January of 2021, we published additional registry study data highlighting that use of the DMT (without the add-on test for TERT) enriches biopsied samples for melanoma almost 5-fold. We believe our body of clinical evidence and utility will

8

lead to securing coverage policies from the major commercial payors over the next 24 to 36 months, although no assurances can be given that any reimbursement coverage approvals will be obtained.

We have secured several contracts with major preferred provider networks. We have submitted clinical and technology assessment packages to eviCore healthcare, LLC, which provides consultative services for payors. We are in direct discussion with several national commercial payors which have the DMT currently under review.

Integrate our products into the standard of care. We conduct rigorous clinical research and basic science research and publish the results of this research in peer-reviewed journals. Overall, our research has yielded 22 publications in top peer-reviewed journals; 21 regarding DMT without the add-on test for TERT and one regarding DMT with the add-on test for TERT. The DMT’s (referred to as the PLA in these studies) performance is supported by over ten investigational studies, which enrolled an aggregate of over 9,000 patients. A study published in JAMA Dermatology demonstrated that the DMT (without the add-on test for TERT) significantly lowers the cost to diagnose melanoma while providing a more accurate and less invasive alternative to the current methods. Our research is frequently highlighted at clinical meetings and has several times been accepted for peer-reviewed late-breaking presentations at major medical society meetings.

The AAD melanoma guidelines updated every 5-7 years have indicated that non-invasive gene expression testing can be used as a part of the initial clinical assessment for pigmented lesions. In January 2021, NCCN recommended that there is uniform NCCN consensus to recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma, and it added the intervention to its NCCN Guidelines for cutaneous melanoma. In January 2022, NCCN reaffirmed its unanimous consensus recommendation that pre-diagnostic noninvasive patch testing may be helpful to guide biopsy decisions for cutaneous melanoma. In addition, an independent panel of melanoma experts produced consensus recommendations for use of the DMT (without the add-on test for TERT), which were published in 2019.

We have established an extensive advisory board of eight Key Opinion Leaders (“KOLs”) in dermatology, including two former presidents of the AAD. These KOLs speak extensively about our technology platform and the DMT at various clinical and research meetings. In addition, these KOLs participate in our clinical studies and publish findings in peer-reviewed journals.

Establish alternate care delivery channels. We continue to expand our efforts in alternate care delivery channels including telemedicine, integrated primary care networks, and on-site and near-site employer health and retail clinics. During 2021, we launched our new telemedicine mobile application, DermTech Connect, where permitted by law and applicable standards of care and practice guidelines. Using DermTech Connect, a patient can submit photos of suspicious lesions to an independent clinician who are subscribed to the DermTech Connect platform. The clinician can determine, if they deem it medically necessary, to order the DMT, in which case a Smart Sticker Collection Kit is mailed to the patient, followed by at home self-collection with remote virtual supervision by a DermTech patient liaison.

In December 2021, we entered into an agreement with BioIQ (an analytics-driven population health company) to offer the DMT via our DermTech Connect platform through BioIQ employee and member health programs. Under the agreement with BioIQ, the clinician’s telemedicine services fee and the DMT cost if ordered by the clinician, would be covered by the member health program.

These channels can help to democratize access to high quality dermatologic care, alleviate certain capacity limitations currently within dermatology and the related long lead times for dermatology specialist appointment availability, and improve the delivery of care to patients with ease of use, improved commute and wait times, and reduced patient fear that can accompany referrals to dermatology specialists.

Establish distribution partnerships for primary care. A substantial portion of dermatology is practiced in primary care. Based on the adoption progress we make within dermatology and integrated primary care networks, we plan to eventually access the primary care market more broadly by potentially establishing distribution relationships with companies that focus on this physician call point. An ideal partner would have several hundred sales professionals in the aggregate who access the primary care market, and ideally have experience selling genomic diagnostic products. Alternatively, we may plan to hire sales representatives to make direct calls to primary care offices.

Expand our product offerings. We have developed a platform that provides genomic analysis of the skin using our noninvasive Smart Sticker platform as the sample collection method. This platform can be used to develop multiple products based on the same sample collection method, and it only requires different genomic markers to be assayed in our CLIA-certified laboratory. We are currently working to complete development of additional products, which includes an assessment of non-pigmented lesions for basal cell and squamous cell cancers as well as products that assess precancerous genomic changes associated with sun UV exposure to the skin. In addition, we are working to develop tests for inflammatory diseases of the skin.

Expand our marketing of research services to pharmaceutical companies. Our platform is used by several pharmaceutical companies to facilitate their development of new targeted therapeutics in dermatology. Our Smart Sticker helps identify biomarker treatment responses, track side effects, and identify patients that respond to the therapy. We plan to hire additional business development professionals to sell these services to the pharmaceutical industry. We have recently branded our service offering as DermTech Stratum and are now offering additional services and capabilities. These efforts will include the participation in additional industry conferences and the presentation of our platform and data at additional medical conferences. Additionally, our collaborations with pharmaceutical

9

partners may result in the introduction of complementary or companion diagnostic products for the partners’ therapeutic candidates that reach the commercial market.

Market Opportunity – Skin Cancer

Melanoma is currently one of the fastest growing cancers and the subject of significant attention in the medical community. The incidence of melanoma has doubled from 1982 to 2011. While there has been a 32% decline in cancer deaths overall since 1991, melanoma is one of three cancers facing increasing death rates. According to a study from the Mayo Clinic, the incidence of melanoma increased eightfold among women under 40 and fourfold among men under 40 from 1970 to 2009.

Melanoma is one of the deadliest forms of skin cancer. On average, melanoma causes more than one death every hour of every day of the year in the United States. The Skin Cancer Foundation projects that approximately 7,650 people will die from melanoma in 2022. If diagnosed and removed early in its evolution, when confined to the outermost skin layer and deemed to be “in situ” (Stage 0), patients are expected to have a survival rate of almost 100%. Invasive melanomas that are thin and extend into the uppermost regions of the second skin layer (Stage 1) still have cure rates greater than 90%. However, once the cancer advances into the deeper layers of skin, the risk of it spreading to other parts of the body, or metastasis, and death increases. The table below depicts the survival rate of melanoma based on the stage of the cancer at initial diagnosis.

 

 

From Balch CM, Buzaid AC, Soong S-j et al: Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Journal of Clinical Oncology, August 2001.

An estimated 197,700 cases of melanoma will be diagnosed in the U.S. in 2022. Of those, it is estimated that 97,920 cases will be in situ (noninvasive), confined to the epidermis (the top layer of skin), and 99,780 cases will be invasive, penetrating the epidermis into the skin’s second layer (the dermis). On average, 25 surgical biopsies are performed per early-stage melanoma diagnosed, creating a total market opportunity of approximately 4.0 million surgical procedures per year. Outside the United States, the incidence of melanoma is highest in Western Europe, Australia, and Canada. We estimate that these select worldwide markets perform over 1.5 million surgical biopsies annually to diagnose approximately 75,000 melanomas, creating additional market opportunity that we believe exceeds $750 million per annum.

Over 5.4 million non-melanoma skin cancers (basal cell and squamous cell carcinomas) are diagnosed in the United States annually. The number of surgical biopsies needed to diagnose one non-melanoma skin cancer is approximately 2.5-3.0 among dermatologists and can be considerably higher when diagnosed by other clinicians such as nurse practitioners and primary care physicians. While these cancers are not as deadly as melanoma, they commonly occur on the face, head, neck, and other cosmetically sensitive areas, creating an important unmet medical need for a non-invasive alternative, and a potential market opportunity of approximately $3.0 billion in the United States per annum based on the approximately 10-12 million surgical biopsies performed to diagnosis of basal and squamous cell skin cancers.

Limitations of Current Melanoma Diagnostic Pathway

The estimated prevalence of pigmented lesions (moles) ranges from 2% to 8% in fair-skinned persons.

Pigmented lesions may be classified as clinically atypical by meeting one or more of the American Cancer Society’s ABCDE criteria, which includes Asymmetric, irregular Border, variegated or dark Color, Diameter greater than 6 mm, or Evolving mole. Atypical pigmented lesions are at risk for harboring melanoma. A meta-analysis of case-control studies found that the relative risk of melanoma is 1.45 in patients with one atypical mole vs. those with none, and this risk increases to 6.36 in those patients with five atypical moles. Management of atypical pigmented lesions involves ruling out melanoma via a visual assessment followed by surgical biopsy and histopathology. Ideally, when melanomas are identified, they are found at the earliest stages (melanoma in situ or stage 1a) when a high cure rate is possible by wide excision. Since a biopsy only partially removes a lesion for histopathologic analysis, early-stage

10

melanomas diagnosed histopathologically from biopsy material are treated with follow-up wide excision procedures (generally with 0.5-1.0 cm margins).

While the purpose of the visual assessment or surgical biopsy is to rule out melanoma, the poor performance metrics of this diagnostic pathway leads to a low NPV for early-stage disease (Table 2 below). This is related to the low specificity of the visual assessment (3-10%), which results in a high number of biopsies on benign atypical nevi. During histopathologic assessment, a small number of melanomas must be identified from this large pool of biopsied atypical nevi. However, there is significant overlap in the histopathologic diagnostic criteria between atypical nevi and early-stage melanoma, invariably leading to false negative diagnoses and a relatively low sensitivity (65-84%). Elmore et al. BMJ (2017) 357:j2183, concluded that the diagnosis of early stage melanoma was not accurate after finding that 35% of slide interpretations for melanoma in situ or stage 1a melanomas by 187 pathologists received a false negative diagnosis as benign. With the prevalence of early-stage melanoma in biopsied lesions at approximately 5%, the negative predictive value ranges from 75-89%.

Welch and colleagues’ most recent N Engl J Med article (2021, 384:72-79) points out that melanoma diagnoses have increased more than 6-fold over the last 40 years. The authors attribute this increase to more frequent enhanced screening, lower pathological thresholds to label the morphologic changes as cancer, and importantly heightened clinical awareness to biopsy pigmented lesions. However, the article fails to address the main limitations of the current care standard for evaluating pigmented lesions relies primarily on visual atypia to guide biopsy decisions. About 4 million pigmented lesions are biopsied each year in the US alone to diagnose fewer than 200,000 cutaneous melanomas (about 25 biopsies to detect 1 melanoma based on Anderson et al. JAMA Dermatol. (2018) 154(5):569-573. Using non-invasive assessment of genomic atypia offered by the DMT rather than visual atypia alone to guide pigmented lesion biopsy decisions reduces avoidable biopsies while missing fewer melanomas. Precision genomics is currently used in other areas of oncology and has changed the paradigm of treatment. Integrating use of the DMT and precision genomics to enhance early detection non-invasively into standard practice rather than performing fewer skin examinations appears to be a superior solution to the conundrum highlighted by Welch and colleagues.

According to several published papers, the real NPV of the visual assessment or surgical biopsy pathway is likely 80% to 85%. In a study by Malvehy et al., BJD (2014) 171:1099, 206 in situ and stage 1a (thickness less than 0.75 mm) melanomas were diagnosed with a sensitivity of 81% and a specificity of 10%. The prevalence of early melanoma in the study was about 10%, yielding an NPV of 83%. In addition, the current pathway using visual atypia to guide biopsy decisions suffers from a low PPV of approximately 4% for melanoma diagnosis. The addition of the DMT (without the add-on test for TERT) to the visual assessment by clinicians increased the PPV for a melanoma diagnosis by approximately five-fold to 18.7%.

 

 

 

 

Current Pathway

 

 

PLA

 

Test Purpose

 

Rule-out melanoma

 

 

Rule-out melanoma

 

Type

 

Surgical biopsy/ histopathology

 

 

Non-invasive gene expression

 

NPV

 

83%

 

 

99%

 

Probability of Missed Mel

 

17%

 

 

1%

 

Probability of Mel Diagnosis

 

4%

 

 

18.7%

 

Number Needed to Biopsy

 

25

 

 

2.7

 

Number Needed to Excise

 

5.2

 

 

1.6

 

Cost per Lesion Tested

 

$

947

 

 

$

760

 

 

Table 2. Data summarized above compares the key performance metrics of the DMT (without the add-on test for TERT) versus the current pathway (visual assessment and surgical biopsy/histopathology) for managing pigmented skin lesions.

This low NPV for the current pathway is accompanied by a high number of unnecessary surgical procedures, again driven by the poor specificity of the visual assessment. The number of surgical biopsies needed to identify one melanoma averages 25 and ranges from eight to greater than 30 depending on the clinical setting. Further, the histopathologic review of biopsied lesions is extremely limited with 2% or less of the lesion sectioned and evaluated, leaving doubt as to what may be occurring in the rest of the lesion. Consequently, lesions that have cellular atypia and positive margins are often clinically managed conservatively and subjected to full excisions with margins. However, only 0.2% to less than 1.0% of lesions with atypia and positive margins that undergo excision are diagnostically upgraded, most commonly to a higher level of atypia and rarely to melanoma in situ, and such excisions can be considered unnecessary. Approximately 5.2 excisions with margins are performed per melanoma identified, emphasizing how the current pathway of surgical biopsy and limited histopathology assessment leads to more complex and invasive excisions.

11

Our Products

DermTech Melanoma Test (formerly the PLA and/or PLAplus)

The DMT is a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The performance of the PLA is supported by over ten investigational studies, which enrolled over 9,000 patients and yielded 22 peer-reviewed publications in top rated medical dermatology journals; 21 regarding DMT without the add-on test for TERT and one regarding DMT with the add-on test for TERT. Key studies and manuscripts are summarized in Table 3 below. The DMT is based on a new platform technology for non-invasive genomic testing of the skin, which allows the molecular analysis of samples collected from adhesive patches. In contrast to the current pathway, the DMT has a very high NPV (greater than 99%) and high sensitivity (91-95% without the add-on test for TERT), ensuring a very low probability of missing melanoma. The DMT’s high specificity (69-91% without the add-on test for TERT) effectively reduces the number of false positive samples undergoing histopathologic review. This improves the overall sensitivity of the pathway and greatly increases the NPV.

The NPV of the DMT (without the add-on test for TERT) is supported by a 12-month follow-up study of 734 patients, which demonstrated that no melanomas were missed in the 12-month period following initial testing. In the third quarter of 2019 we initiated the TRUST study, which further examined long-term follow up of lesions previously tested negative by the DMT, and incorporated repeat testing of the previously tested lesion. This study more definitively confirmed the high NPV of the DMT in a real-world setting, and we announced those topline results in December 2020. Of the lesions evaluated by means of repeat testing with the DMT (n=302), none were found to have clinically obvious melanoma upon the subject’s return to the clinic, confirming the results of the initial chart review. Eighty-nine percent of these lesions were negative on repeat testing with the DMT and 11.2% were positive. Positive lesions were biopsied and subjected to a single read histopathologic review. One percent of lesions (n=3) that tested positive on repeat testing were diagnosed as Stage 0, in situ. Photographic review of the three Stage 0 cases identified changes in clinical appearance since the initial test. The pathology reports from the remaining biopsied lesions indicated a variety of non-melanoma diagnoses, including compound nevi with mild to moderate atypia. Given the early stage (in situ) of the melanomas detected on repeat testing, and length of time from the initial test (an average of 15 months), it is difficult to determine whether these melanomas evolved after the initial test or were present at the time of the initial test. In any case, the finding of three melanomas in a cohort of 302 lesions subjected to repeat testing further confirms an NPV of the DMT of at least 99.0% and is consistent with the results from the full long-term follow‑up cohort. These results exemplify how the DMT repeat testing of lesions that may have evolved over time after the initial negative PLA test have potential to identify early-stage melanoma and benefit patients. TRUST study findings corroborating the DMT’s high NPV were complemented by most recent registry data on the DMT’s high PPV (Brouha et al., SKIN, January 2021, 5(1):13-18). This data show that 316 lesions clinically suspicious for melanoma that were biopsied based on guidance offered by genomic atypia (positive DMT results rather than visual atypia alone) were enriched approximately five-fold for histopathologic features of melanoma.  

In addition, the non-invasive sampling leads to a dramatic reduction in surgical biopsies and subsequent excisions. Consequently, our studies have shown that the number of surgical biopsies needed to find one melanoma using the DMT (without the add-on test for TERT) is markedly reduced by almost tenfold to approximately 2.7 and the number of excisions needed is reduced to 1.6. Our studies have shown that the DMT can reduce unnecessary surgical biopsies of lesions clinically suspicious for melanoma by 90%, which is consistent with a 2017 review of 18,715 biopsied pigmented lesions that found that approximately 90% of surgical biopsies to rule out melanoma are performed on pigmented lesions that are not melanoma. Non-invasive gene expression testing has been added to the most recent AAD melanoma guidelines as part of the initial clinical assessment for clinically concerning lesions and non-invasive patch testing is recommended by the NCCN Guidelines as of January 2022. In addition, an independent expert committee has developed and published consensus use criteria for the DMT (without the add-on test for TERT).

During the second quarter of 2021, we announced the launch of the optional add-on test for TERT (then known as PLAplus) available to those ordering the DMT, which delivers objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma. This add-on test combines TERT promoter DNA driver mutation analyses as a reflex test to the DMT’s standard RNA gene expression test. TERT is individually associated with histopathologic features of aggressiveness and poor survival in melanoma. The combined tests elevate the sensitivity from 91% to 97% and maintain a negative predictive value of >99%, resulting in a less than 1% probability of missing melanoma. By combining RNA gene expression and DNA mutation analyses, the DMT provides a highly accurate non-invasive genomic test for enhanced early melanoma detection.

12

 

Study

 

Status

 

Size (n)

 

Publication

Analytical Validation

 

Complete

 

125

 

Yao Z et al. Analytical characteristics of a noninvasive gene expression assay for pigmented skin lesions. Assay Drug Dev Technol. 2016;14(6):355-363.

Clinical Validation-Pathology

 

Complete

 

555

 

Gerami P et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76(1):114-120.e2.

Clinical Validation-Driver Mutations

 

Complete

 

626

 

Ferris L et al. Noninvasive analysis of high-risk driver mutations and gene expression profiles in primary cutaneous melanoma. J Invest Dermatol. 2019; 139(5):1127-1134.

Clinical Utility

 

Complete

 

45 Derms

 

Ferris L et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 2017;153(7):675-680.

Real-World Clinical Utility

 

Complete

 

381

 

Ferris L et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. Melanoma Res. 2018; 28(5):478-482.

Real-World Clinical Utility

 

Complete

 

1535

 

Skelsey et al, Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. SKIN. 2021 Sep; 5(5).

1-Year Follow Up

 

Complete

 

734

 

Ferris L et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatology Online Journal. 2019; 25(5).

Real-World Utility Registry

 

Complete

 

1575

 

Ferris L et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatology Online Journal. 2019; 25(5).

Real-World Utility Registry

 

Complete

 

3418

 

Brouha B et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study. J Drugs Dermatol. 2020; 19(3).

 

Brouha B et al. Genomic atypia to enrich melanoma positivity in biopsied lesions: gene expression and pathology findings from a large U.S. registry study. SKIN 2021; 5(1):13-18.

Adhesive Patch Validation

 

Complete

 

N/A

 

Yao Z et al. An adhesive patch-based skin biopsy device for molecular diagnostics and skin microbiome studies. J Drugs Dermatol. 2017; 16(10):611-618.

Association With Severe Atypia

 

Complete

 

103

 

Jackson S et al. Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses. SKIN. 2020 March; 4(2).

Recommendations that Support DMT Use

 

Complete

 

N/A

 

Berman B et al. Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified Delphi process assessment. SKIN The Journal of Cutaneous Medicine. 2019; 3(5):291-306.

 

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous Melanoma. Version 1.2022 at ME-11

 

Swetter SM et al. Melanoma: Clinical features and diagnosis. UpToDate. Waltham, MA. September 11 2020

TERT Validation

 

Complete

 

103

 

Jackson Cullison, S. R., Jansen, B., Yao, Z., & Ferris, L. K. (2020). Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses. SKIN The Journal of Cutaneous Medicine, 4(2), 124–129

13

Health Economics

 

Complete

 

319

 

Hornberger J, Siegel D. Clinical and economic implications of a noninvasive molecular pathology assay for early detection of melanoma. JAMA Dermatol. 2018;154(9):1-8.

Genome Screen

 

Complete

 

202

 

Wachsman W et al., Noninvasive genomic detection of melanoma. British Journal of Dermatology. 2011; 164:797-806.

 

Table 3. Summarizes key clinical studies and publications supporting the DMT. Additional publications can be found on our Company website.

Smart Sticker

We are the inventor and owner of the intellectual property for the Smart Sticker collection kit (pictured below). We have contracted with a Food and Drug Administration (“FDA”) registered supplier to produce our kit under applicable quality systems requirements, and we control the exclusive distribution rights for the kit. Our Smart Sticker allows for the collection of skin samples with minimal patient discomfort. A single kit contains all of the necessary components to complete the sample collection for our analysis, including the Smart Stickers, instructions for use, a marking pen for lesion outlining, and a pre-addressed and prepaid return shipping pack. The unique properties of the Smart Sticker maximize the collection of informative cellular material for the DMT. The sample collection in the clinician’s office usually takes less than five minutes.

 

            

 

Telemedicine Option for the DermTech Melanoma Test

Telemedicine is typically considered to be the provision of health-related services via electronic information and telecommunication technologies. Telemedicine is sometimes used interchangeably with telehealth, but some organizations define telemedicine in a more limited sense to describe remote clinical services, such as diagnosis, treatment and monitoring. Telemedicine enables patient and clinician interaction when rural settings, lack of transport, a lack of mobility, decreased funding, a lack of staff or other limitations such as social distancing guidelines related to the COVID-19 pandemic restrict or make difficult in-person access to healthcare.

Early detection of melanoma, the most deadly and aggressive form of skin cancer, is critical for best patient outcomes. The DMT is the first non-invasive genomic diagnostic test for ruling out melanoma that, in addition to in-office sample collection, enables a patient’s sample collection remotely via telemedicine. For patients who cannot easily attend an in-office visit, we offer two telemedicine solutions that enable dermatologists to conduct a virtual office visit with a patient to collect a skin sample, remote telemedicine collection and DermTech Connect.   

Using the remote telemedicine collection option, a clinician can choose to assess the patient’s skin and suspicious lesion(s) via a telemedicine appointment they arrange with their patient and, if indicated, submit a patient-specific order to DermTech for the DMT. In this case, a Smart Sticker Collection Kit is then mailed to the patient directly. During a follow-up telemedicine appointment, a clinician instructs and supervises the patient to collect their sample with the easy-to-use DermTech Smart Sticker. The patient then returns the collected sample(s) back to DermTech via a pre-labeled shipping envelope for analysis. Test results are made available to the ordering clinician within a few days.

Another telemedicine option is available to patients through the DermTech Connect mobile application, where permitted by law and consistent with applicable standards of care and practice guidelines. DermTech Connect enables a user to take a picture of a suspicious lesion with their phone and submit the picture to an independent clinician to assess the lesion. As of the date of this report, DermTech Connect is only available to patients of clinicians subscribed to DermTech Connect in eight states and remains limited in operations. Subscribing clinicians utilizing DermTech Connect charge a pre-determined amount for the patient services and no claims

14

are submitted for reimbursement of the clinical telemedicine services. These subscribing clinicians pay DermTech a fixed amount for use of the DermTech Connect platform. The clinician can also determine, if they deem it medically necessary, to order the DMT, in which case a Smart Sticker Collection Kit is mailed to the patient, followed by at-home self-collection with remote virtual supervision by a DermTech patient liaison. Many state laws and regulations impose various requirements on the practice of telemedicine, the regulatory landscape is evolving and DermTech Connect is not and may not become available in all states. The telemedicine market is relatively new and unproven, especially within dermatology, and it is uncertain whether the telemedicine options for the DMT will achieve and sustain high levels of demand, consumer acceptance and market adoption.

In May 2020, SKIN, the official journal of the National Society for Cutaneous Medicine, published proof-of-concept data demonstrating that patients are able to reliably perform remote self-sampling of concerning moles using the DMT (without the add-on test for TERT) under clinical supervision via telemedicine, enabling actionable molecular testing for accurate melanoma detection. As part of the Institutional Review Board (“IRB”) approved pilot study, 258 eligible melanoma survivors were contacted, and of the 211 who expressed interest in the DMT, there were seven cases of self-identified concerning lesions, which were confirmed by a clinician to be suspicious of melanoma. These patients then conducted sample collections using DermTech’s Smart Sticker at home under the supervision of a clinician via telemedicine. Results from the study showed that skin samples collected by patients enabled successful DMT testing to objectively rule out melanoma in all of the cases evaluated. These findings are in line with sample collection results by licensed providers.

Clinical Research Products

Research on the genomic basis of diseases has increased significantly over the last decade. Genomic analysis can facilitate drug development by identifying drug targets and stratifying patients into groups that will maximize drug response. Genomic analysis is part of the effort to personalize medical therapy to patients’ individual needs. Consequently, tools to facilitate this type of research are in high demand.

We offer a suite of products to facilitate clinical research using our technology platform. We have developed a proprietary process that allows us to extract genomic and protein material from our Smart Sticker with sufficient quality and quantity to perform gene expression, DNA mutation analysis, DNA methylation, and transcriptomic analyses. In addition, our platform can be utilized to assess the microbiome of the skin with superior performance to existing methods that use swabs. We have developed gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. We market these assays to pharmaceutical companies developing drug products in dermatology. In addition, we develop custom gene assays to support development for these pharmaceutical partners. We have completed and have ongoing research collaborations with large pharmaceutical companies to facilitate their development of new targeted therapeutics in dermatology. Our technology platform has been deployed in Phase 1 through Phase 3 clinical programs. These efforts may also lead to the introduction of complementary and companion diagnostic products.

Leveraging Our Platform for Other Indications

We believe our Smart Sticker specimen collection platform is applicable to numerous other indications in dermatology. While we are focused initially on skin cancer products, we believe there are significant business development opportunities in other areas. We have undertaken a number of pilot development activities in inflammatory diseases, and skin aging. This effort will also focus on potential licensing and partnering opportunities for the development of complementary and companion diagnostics for the pharmaceutical partners’ drug product candidates, should they reach the commercial market. In addition, because the processing of samples is the same regardless of the disease indication, our development activities will leverage our existing laboratory operations.

UV Damage DNA Risk Assessment Product (Luminate)

We are currently developing a test to assess precancerous genomic changes that develop in UV damaged skin. We intend that this product will assess mutations in key genes associated with UV damage and increased risk of skin cancer. Depending on the level of precancerous DNA mutations, and based on a clinician’s further evaluation, there are various procedures or treatment options to remove the damaged skin cells and potentially reduce an associated risk of future skin cancer including chemical peels, photodynamic therapy, laser therapy, topical pharmaceuticals, dietary supplements, and increased sunscreen use.

Based upon our market research, there are approximately 84 million Americans between the ages of 30 and 50, of which approximately 70% are interested in learning their precancerous risk due to UV damage. Of this population, approximately 30% have household incomes of at least $100,000 that would be most likely to consider using this product. We believe this age-group has significant aging anxiety due to the high prevalence of extrinsic signs of aging and are increasingly using anti-aging products to look younger. The assessment of these targeted DNA mutations will allow individuals to proactively make data driven, fact-based decisions about their skin health.

15

Non-Melanoma Skin Cancer Diagnostic Products

To complement the DMT, we are also utilizing our platform technology to develop products to rule out non-melanoma skin cancer including squamous cell and basal cell carcinoma. We identified differentially expressed genes that allow the identification of these cancers, and we are currently conducting analytical and clinical validation studies. Nearly 5.4 million basal and squamous cell carcinoma skin cancers are diagnosed each year making skin cancer the most common of all types of cancer. The majority of these cancers occur in cosmetically sensitive areas such as the head, neck and face. The number of skin cancer cases is increasing due to better skin cancer detection, people living longer, and increased sun exposure.

More than 80% of skin cancers are basal cell carcinomas. These cancers usually develop in sun-exposed areas, especially the head and neck, and tend to grow slowly. It is very rare for a basal cell cancer to spread to other parts of the body. If left untreated, basal cell cancers can grow into nearby areas and invade other tissues beneath the skin. If not removed completely, basal cell carcinoma can recur in the same place on the skin. People who have had basal cell skin cancers are also more likely to develop basal cell skin cancers in other places.

About 10% of skin cancers are squamous cell carcinomas. These cancers also commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips, and backs of the hands. These cancers can also develop in scars or chronic skin sores elsewhere. Squamous cell cancers are more likely to grow into deeper layers of skin and spread to other parts of the body than basal cell cancers, although this is still uncommon.

Cutaneous T Cell Lymphoma

We are currently exploring a Cutaneous T-cell lymphoma (“CTCL”) rule out test. CTCL is a rare type of skin cancer in which T-cells become immunologically active and attack the skin. CTCL results in rash-like skin redness, slightly raised or scaly round patches on the skin, and, sometimes, skin tumors. These features can resemble much more common inflammatory skin conditions.  

Several types of cutaneous T-cell lymphoma exist including mycosis fungoides and Sezary syndrome. Mycosis fungoides is the most common form of CTCL while Sezary syndrome is less common but causes skin redness across larger areas of the body. The definitive diagnosis of CTCL is often challenging because of its nonspecific clinical and pathologic features, which requires integration of clinical, histopathologic, immunophenotyping, and molecular data by the treating physician.

Inflammatory Indications

Atopic dermatitis and psoriasis are chronic inflammatory skin diseases that affect millions of people and are characterized by both local and systemic inflammation. We have investigated gene expression profiles in the skin of atopic dermatitis and psoriasis. Responses to biologic therapy used in moderate to severe forms of these diseases can be variable and may wane over time. For example, only 30-40% of patients have a robust response to either anti-TNF alpha drugs used in psoriasis or the Th2 targeting (anti-IL-4R or anti-IL-13) drugs used in atopic dermatitis. The low response rate of these drugs creates an unmet need for drug companion and complementary diagnostic products that identify responders to a specific therapy and that monitor responses over time.

Atopic dermatitis and psoriasis are largely characterized by significant epidermal inflammation that can be used to assess benefit of interventional therapies. Due to their existing aberrant and damaged skin barrier, patients are unlikely to consent to repeated surgical biopsy procedures for the purposes of assessing therapy response. Our non-invasive genomics platform is therefore ideal for these types of conditions because it specifically samples tissue from the epidermis. Moreover, we have demonstrated in clinical studies that our platform is superior to surgical biopsy and blood testing for assessing biomarkers related to inflammatory diseases.

In our psoriasis research, for example, we have identified subsets of patients with different gene expression profiles. These different profiles may identify patients that respond more robustly to an expanding group of biologic therapies available for this condition. In addition, we have shown in a pilot clinical investigation that only subsets of patients with atopic dermatitis appear to have high gene expression levels of IL-13. The proportion of patients that are high expressers of IL-13 is approximately 40%, which is consistent with the response rate of approximately 30-40% to the anti-IL4Ralpha (additionally blocks IL-13 signaling) drug dupilumab and anti-IL-13 drug tralokinumab.

Microbiome Indications

The study of bacterial microbes that inhabit the skin and their relationship to health and disease has been the subject of intense investigation over the last several years. Numerous products are under development that seek to alter the composition and populations of these microbes for therapeutic purposes. We have demonstrated in development studies that our platform can be used to assess the genomics of skin microbes and that the quantity of microbial genomic material and the measurements of microbial variability are superior to the swab-based methods currently in use. In addition, our platform (which simultaneously and non-invasively collects skin host and microbiome samples) has the potential to separate and assess microbial populations at different depth levels in the epidermis. Given the growing interest in this area, we may look to develop products for this market in the future.

16

Sales and Marketing

The vast majority of molecular diagnostic tests are sold to pathology and oncology practitioners. These markets are quickly becoming saturated with products, services, and sales calls. We believe that we have a unique opportunity as the first company to market a novel non-invasive molecular diagnostic test to dermatologists and other clinical practitioners of dermatology. We believe there are fewer barriers to adoption in this customer base than in other medical markets because our product fits within the current diagnostic and reimbursement pathway for various skin conditions.

We have established a highly experienced team of sales professionals possessing extensive backgrounds in selling dermatology products. Our Chief Commercial Officer spent 24 years at Allergan plc and rose to lead their dermatology and ophthalmology product sales for the entire United States. We expanded our specialty sales force in 2020 and 2021, and could continue to expand our specialty sales force in 2022 as we secure reimbursement coverage from additional commercial payors.

There are approximately 13,000 healthcare professionals specializing in dermatology in the United States. We segment these practices into three categories: primarily cosmetic practices (10-15%), mixed medical and cosmetic practices (50-75%), and medical only practices (15-25%). We focus much of our effort on practices that deliver some medical dermatology services. We have initially focused our selling activity on these accounts, which typically have a shorter adoption cycle.

Our sales and marketing expansion includes multi-site group practices and integrated dermatology networks. Multi-site group practices and large integrated dermatology networks make up approximately 25% and 15%, respectively, of the remaining dermatology market. We are actively working to integrate the DMT in large dermatology networks in order to penetrate this market opportunity.

A portion of dermatology is also practiced in primary care. We may plan to access the primary care market by establishing distribution relationships with companies that focus on this physician call point. These potential partners have should have 400-600 sales professionals in the aggregate who access the primary care market, and ideally have experience offering a diagnostic or genomics product. Alternatively, we may plan to hire sales representative to call on primary care doctors.

Our marketing is focused on a mix of professional targeted campaigns including in person physician education, dermatology symposia, publication distribution, peer to peer education, consumer engagement and education campaigns including a mix of digital platforms. We participate as an exhibitor and sponsor at key dermatology conferences and will expand this effort to primary care conferences. We often submit scientific abstracts for presentation at the conferences we attend. Our KOLs speak on our behalf at various medical conferences, present data from our clinical studies, and chair continuing medical education courses on genomics in dermatology, which include our products.

These efforts extend to supporting our policy coverage review process with payors. Our KOL group includes four former AAD presidents and numerous melanoma, skin cancer and inflammatory disease experts.

We continuously expand and improve on the validation of our tests by conducting additional clinical trials, and we publish the results of our scientific and clinical work in peer-reviewed medical journals. Through these efforts, we elevated our positioning in the AAD guidelines, obtained a recommendation from NCCN Guidelines, and recent consensus group recommendations. We also utilize advertising in medical journals and social media campaigns to rally the extensive patient advocacy support that exists today for a variety of skin conditions and melanoma sufferers. Because dermatology practitioners often sell cosmetic procedures to their patients, they are very service oriented and responsive to their patient’s requests. We believe direct-to-consumer advertising will engage the patient to request our skin cancer assessment tests and allow us to capitalize on the unique non-invasive benefits our platform provides patients.

In 2019, our technology platform became available for use in Canada based on Health Canada compliance and we have established a non-exclusive partnership with DermTech Canada. We are working to secure coverage and reimbursement from two Canadian provinces, British Columbia and Ontario. We plan to engage in the marketing of our product in other countries outside the United States only after we have established the United States and Canadian markets. We will focus our efforts in regions that have a high incidence of melanoma and skin cancers such as Australia and Western Europe. We will likely seek distribution partners in these select countries for the sales and marketing of our tests. While we have demonstrated that the stability of the skin samples collected with our Smart Sticker sampling device is suitable for shipping from countries outside the United States, we will likely establish clinical laboratories or laboratory partnerships in some of these countries.

During the various waves of the COVID‑19 pandemic, we transitioned our sales teams to make sales calls remotely, with limited in-person interaction until the pandemic environments and access to clinician offices improve, and in-person appointments can continue. We have also participated in various web-based dermatology conferences to highlight the easy-to-use, non-invasive sample collection kit that enables physicians to rule out melanoma without the need to see a patient in person at a clinic.

Reimbursement Strategy

On January 1, 2020, the AMA released a Proprietary Laboratory Analysis code, (0089U), for the DMT (without the add-on test for TERT). This code uniquely identifies the DMT (without the add-on test for TERT) and enables us to bill commercial and government payors when our test is ordered by a clinician.  

17

On February 10, 2020, Medicare Administrative Contractor Palmetto GBA/MolDx issued an LCD for the Pigmented Lesion Assay (L38051), now referred to as the DMT (without the add-on test for TERT). On June 10, 2020 Noridian, which is our Medicare Administrative Contractor, harmonized its LCD with MolDx, in effect making our test nationally covered and available for all Medicare and Medicare Advantage enrollees. The published reimbursement for our PLA code, 0089U, is $760 and was included in the 2021 and 2022 CLFS.

We have developed in-house reimbursement capabilities, including claims submittal, follow-up and appeals functions to bill and collect reimbursement for services provided. We are currently out of network with many commercial payors and our initial claims are commonly denied. In situations where payment is denied, we work through the claims appeals process to secure payment for services performed. The appeals process can require several cycles and can culminate in an independent committee review for blocks of claims. Currently, we are not routinely successful in winning appealed claims.

To improve our allowed claim rate and payment, we are seeking contractual relationships and reimbursement coverage policy decisions from commercial payors. Reimbursement coverage decisions for clinical tests are primarily supported by clinical utility studies, increases in the patient experience and inclusion in guidelines.

The DermTech Melanoma Test:

 

 

•

Demonstrates high clinical utility among clinicians. Over 4,500 patients have been included in four (4) clinical utility studies that highlight that clinicians followed the guidance of the test in over 98% of cases. This resulted in 90% fewer biopsies (i.e. avoidable biopsies). Clinical validation and supportive studies were conducted on an additional 3,000 patients.

 

 

•

Extensively studied. The DermTech Melanoma Test has been studied in over 9,000 patients and results have been summarized in 22 peer reviewed manuscripts published in leading journals; 21 regarding DMT without the add-on test for TERT and one regarding DMT with the add-on test for TERT. To date, we have processed approximately 107,000 billable DermTech Melanoma Tests since commercialization. During 2021, we had approximately 2,800 unique ordering clinicians utilize the DermTech Melanoma Test.

 

 

•

Saves money and increased the patient experience. The DMT saves money by reducing the costs of unnecessary biopsies and excisions performed on benign lesions. Also, it allows for earlier detection of melanoma which can reduce the early-stage and late-stage costs of treating melanoma. The patient experience is enhanced because in 90% of the cases, they avoid a surgical procedure.

 

 

•

Included in the NCCN Guidelines Version 1.2021. The NCCN (2a) recommendation listed under “Common Follow-up Recommendation for all Patients” states that genomic adhesive patch testing, like ours, may be helpful to guide biopsy decisions. A (2a) recommendation from the NCCN indicates there is uniform consensus that the intervention is appropriate.

 

 

•

NCCN Guidelines reaffirmed and clarified consensus support in Version 1.2022. The NCCN (2a) recommendation listed under “Common Follow-up Recommendation for all Patients” clarified its support for adhesive patch testing, like ours, by creating a standalone comment which states that adhesive patch testing may be helpful to guide biopsy decisions.

 

 

•

Can be used in a telemedicine encounter. Based on a study published in May 2020, patients can reliably perform self-sample collection under remote physician supervision.

We have currently secured several contracts with major preferred provider networks. We have submitted clinical and technology assessment packages to eviCore healthcare, which provides consultative services for payors, and several national commercial payors which have the DermTech Melanoma Test currently under review.

Competition

The molecular diagnostics market is highly competitive. We compete with a number of manufacturers and distributors of molecular diagnostic tests as well as new and traditional medical devices and other technologies that are used to assist physicians with the assessment of pigmented lesions and the diagnosis of skin cancer. We are currently the only company to offer a non-invasive genomics test to clinical dermatology professionals. However, LEO Pharma A/S, a large Danish pharmaceutical company, and Mindera Corporation, a small early-stage start-up, are also working on minimally invasive genomic tests. In the area of pigmented lesions, Castle Biosciences, Inc. recently launched gene expression assays as CLIA laboratory tests for surgical biopsy tissue specimens. Castle Biosciences, Inc. also markets a product to determine metastatic potential in later stage melanoma by utilizing surgical tissue samples.

There are several companies that market or are developing medical devices and imaging tools to detect melanoma as skin cancer. In general, medical devices have capital equipment costs and maintenance requirements, do not integrate well into clinical practice, and do not have clear mechanisms to provide physician payment. Strata Sciences, Inc. owns the rights to Melafind, an FDA-approved device that utilizes varying wavelengths of light to capture lesion images at different depths and conducts an algorithmic image analysis to determine the degree of lesion disorganization and the need for biopsy. The clinical trials of this device demonstrated marginal

18

improvement in the assessment of pigmented lesions, and the device has not been adopted in the United States largely due to its specificity of less than 10%, which hampered clinical use. SciBase AB is marketing an epidermal electrical impedance spectrometer to assess pigmented lesions, which received FDA approval in 2018. Verisante Technology, Inc. has received regulatory approval in Europe and Australia to market a device that uses real-time Raman spectroscopy to assess changes in the chemical composition of skin tissue. Welch-Allen, Inc. and various others manufacture dermatoscopes, which provide magnified views of a pigmented lesion during diagnosis. Caliber I.D. and others offer confocal microscopy solutions for enhanced imaging of pigmented skin lesions.

Research and Development

We have expertise in the development of gene expression profiles and other genomic analyses for the diagnosis of dermatologic disease. In addition, we have developed know-how related to the collection of skin samples using adhesives. We have also developed expertise in statistical programs and algorithms that are used to process genomic data.

Our product development process involves several stages. The first stage involves a genome-wide screen for differential gene expression or screens for differences in mutations, methylation patterns, micro-RNAs and other factors. In case of gene expression, differentially expressed genes are then narrowed down to specific gene sets that categorize disease states. These genes sets are then validated by comparison to clinical reference standards to produce a clinical product. We have developed substantial expertise in designing and conducting clinical validation and utility studies.

We have identified additional gene targets that may further improve the performance of the DMT. The qPCR assays for these genes are under development and may be added to our platform in the future if their performance is validated in additional clinical studies. We plan to expand the use of our platform to include products to diagnose or support the diagnosis of non-melanoma skin cancers as well as a variety of inflammatory skin conditions. We have identified gene expression profiles for other conditions, such as psoriasis, atopic dermatitis, and aging of the skin. Should we determine that there are viable market opportunities for products treating these conditions, we plan to consider developing genomic tests for these conditions. Alternatively, we may seek development partners or licensing opportunities for these potential products.

Intellectual Property

We have developed a comprehensive portfolio of intellectual property, comprising seven issued or allowed U.S. utility patents, 12 pending U.S. utility patent applications, four pending U.S. design patent applications, six issued foreign patents, 11 pending foreign patent applications, and two Patent Cooperation Treaty (“PCT”) applications.

The portfolio includes patents or patent applications directed to aspects of our assays, a sample collection system using adhesive, methods for automated scanning and cutting of cells from skin collection kits, telemedicine methods, methods of detecting nucleic acid expression, methods of quantifying a mutation burden, and methods of diagnosing or treating various skin conditions including melanoma and non-melanoma skin cancers, cutaneous T cell lymphoma, UV damage and autoimmune disorders.

In addition, our intellectual property portfolio includes trademarks, design patents, trade secrets and know-how. We believe our intellectual property adequately protects our products and technology, and may prevent others from commercializing products or laboratory methods substantially similar to ours.

Laboratory Operations

Our CLIA laboratory located in La Jolla, California, occupies approximately 9,000 square feet and is divided into an accession area, pre-qPCR-laboratory and post-qPCR-laboratory area as per CLIA standards. Access to all areas is controlled and requires gowning. The laboratory employs commercial state-of-the-art equipment including high-throughput qPCR machines. We use a laboratory information system to track all of our samples. We employ clinical laboratory scientists holding appropriate state licenses to perform all testing.

The DermTech Melanoma Test assay utilizes qPCR techniques that requires the extraction and purification of genomic material from the skin adhered to our Smart Stickers. This extraction process is extremely challenging, and we have developed a proprietary method involving customized reagents and tools to provide suitable material yields reliably. In general the process involves three main steps:

 

•

RNA extraction using our proprietary process to maximize the yields and quantity of RNA from the cells on the Smart Sticker;

 

•

reverse transcription, which converts the RNA into complementary DNA; and

 

•

expression level quantification, using qPCR to determine the expression levels of the target genes in our expression profile.

After testing is complete, a laboratory report is prepared and reviewed by one of our California-licensed and American Board of Medical Genetics and Genomics-certified Laboratory Directors. This report is made available to the ordering physician by fax, via an internet portal, or via electronic medical record system while adhering to requirements of the Health Insurance Portability and

19

Accountability Act (“HIPAA”). The reports are generated in industry-standard PDF format that allows for high-definition figures to be reproduced clearly.

We continuously work to automate various steps in our end-to-end test processes. Much of this automation will come from purchasing and qualifying off-the-shelf and customized laboratory equipment such as liquid handlers and pipetting robots. We have developed a laser-cutting robot to automate the cutting of the lesion area circumscribed on the Smart Sticker by the clinician. We expect these automation efforts to improve assay throughput by reducing processing time compared to manual processing, reducing the need for direct labor, and improving quality by reducing the potential for human error.

Third-Party Suppliers and Manufacturers

We are the owner of intellectual property for the Smart Sticker with our logo and have contracted with an FDA-registered supplier to produce our kits. We believe this kit is considered a Class I medical device and is exempt from FDA premarket notification requirements. This product is manufactured according to the FDA’s applicable quality system manufacturing requirements. Our FDA-registered supplier conducts the assembly and labeling of this kit. Most of our suppliers are high-quality medical component and finished-product suppliers accustomed to working on high volume disposable FDA-regulated products. Our product has a shelf life tested to three years that allows us to build inventory to mitigate against disruptions.

We currently have a sole source provider for the adhesive used in our Smart Sticker. We are actively working to identify second source suppliers for this component. We currently have sufficient adhesive supplies and inventory to meet our plans and objectives.

Governmental Regulation

The services that we provide are regulated by federal, state and foreign governmental authorities. Failure to comply with the applicable laws and regulations can subject us to repayment of amounts previously paid to us, significant civil and criminal penalties, loss of licensure, certification, or accreditation, or exclusion from government health care programs.

We believe our Smart Sticker, as a specimen collection device, is a Class I medical device that is exempt from obtaining premarket approval or clearance from the FDA. The FDA could declare our Smart Sticker a Class II device or as non-exempt. This would require us to submit an application for premarket clearance or approval, which may require us to develop additional clinical data to support premarket clearance or approval of the specimen collection product that could come at substantial expense and could disrupt our current business or affect our results of operations.

Our qPCR gene expression assay is a laboratory developed test (“LDT”) that is currently regulated under CLIA. Although the FDA has asserted that it has authority to regulate LDTs, it has generally exercised enforcement discretion and is not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. We have commercialized our test as an LDT and will process all tests in our single CLIA-certified central laboratory. We may at some time in the future seek FDA clearance or approval for our qPCR gene expression assay. We believe the data we have collected in the development of our LDT will support any FDA medical device clearance or approval process, but cannot guarantee that the FDA will find these data sufficient to support clearance or approval as a medical device under the applicable FDA regulations. This may require us to collect additional clinical data, which could come at substantial expense and could affect our results of operations.

CLIA and State Regulation of Laboratories

Clinical laboratories must hold certain federal, state, and local licenses, certifications, and permits to conduct business. Laboratories that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease are subject to CLIA. CLIA requires such laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality, and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private insurers, for laboratory testing services.

Standards for testing under CLIA vary based on the test and level of test complexity. Laboratories performing high complexity testing must comply with more stringent requirements than laboratories performing waived or moderate complexity testing. In addition, CLIA requires each certified laboratory to enroll in an approved proficiency-testing program if it performs testing in any category for which proficiency testing is required. Such laboratories must periodically test specimens received from an outside proficiency testing organization and then must submit the results back to that organization for evaluation. A laboratory that fails to achieve a passing score on a proficiency test may lose its right to perform testing in the category at issue. Further, failure to comply with other proficiency testing regulations, such as the prohibition on referral of a proficiency- testing specimen to another laboratory for analysis, can result in revocation of the referring laboratory’s CLIA certification.

20

As a condition of CLIA certification, our laboratory is subject to survey and inspection every other year, in addition to being subject to additional unannounced inspections. Because we have obtained accreditation by the CAP, which is a CMS-approved accreditation organization, our biennial survey is conducted by CAP.

Our laboratory must comply with all CLIA requirements as well as with any additional requirements imposed by CAP. We also hold a laboratory permit from the State of California, as well as certain states that require an out-of-sate laboratory doing business in its state to be licensed. One such state is New York, which has state licensure standards that are more stringent than CLIA and its implementing regulations.

Our laboratory is licensed by the appropriate state agencies in the states in which we do business, if such licensure is required. If a laboratory is out of compliance with state laws or regulations governing licensed laboratories, penalties for violation vary from state to state but may include suspension, limitation, revocation or annulment of the license, assessment of financial penalties or fines, or imprisonment. We believe that we are in material compliance with all applicable licensing laws and regulations.

We may become aware from time to time of other states that require out-of-state laboratories to obtain licensure to accept specimens from patients within the state, and other states may impose such requirements in the future. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow all instructions from the state regulators regarding compliance with such requirements.

The FDA

Although the FDA has asserted that it has the authority to regulate LDTs that are validated by the developing laboratory and performed only by that laboratory, it has generally exercised enforcement discretion by not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. Nevertheless, the FDA has, for the past decade, been introducing proposals to end enforcement discretion and to bring LDTs clearly under existing FDA regulatory frameworks. In July 2010, the FDA held a two-day public meeting to obtain input from stakeholders on how it should apply its authority to implement a reasonable, risk-based, and effective regulatory framework for LDTs, including genetic tests. Subsequently, FDA issued draft guidance and a 2017 Discussion Paper to allow for further public discussion about an appropriate LDT oversight approach and to give congressional committees the opportunity to develop a legislative solution. Since 2017, Congress has been working on legislation to create an LDT and in vitro diagnostic (“IVD”) regulatory framework that would be separate and distinct from the existing medical device regulatory framework. In August 2018, the FDA recommended changes to draft legislation that had been released by Congress in 2017. The agency’s comments addressed the need for a requirement that new tests undergo FDA review to demonstrate analytical and clinical validity and suggested other changes to the draft language. FDA’s recommendations, if included in enacted law, would give the FDA authority to revoke approval, request raw data, and take corrective action against test developers.

In December 2018, legislators released a discussion draft of a bill that incorporated many of FDA’s suggestions and provided opportunities for additional stakeholders to also provide input on the proposed reform legislation. On March 5, 2020, U.S. Representatives Diana DeGette (D-CO) and Dr. Larry Bucshon (R-IN) formally introduced the long-awaited legislation, called the Verifying Accurate, Leading-edge IVCT Development (“VALID”) Act. An identical version of the bill was also introduced in the Senate and is sponsored by U.S. Senators Michael Bennet (D-CO) and Richard Burr (R-NC), demonstrating both bicameral and bipartisan support for the effort to overhaul how the FDA reviews and approves diagnostic tests going forward. The VALID Act would codify into law the term “in vitro clinical test” (“IVCT”), to create new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. A substantively unchanged version of the VALID Act was re-introduced in both houses of Congress on June 24, 2021. It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by the President. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government’s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval.

Most recently, in August 2020, the United States Department of Health and Human Services (“HHS”) published a policy announcement that FDA must go through the formal notice-and-comment rulemaking process before requiring premarket review of LDTs rather than making such changes through guidance documents, compliance manuals, or other informal policy statements. HHS’s policy statement did not affect proposed legislation for the regulation of LDTs, such as the VALID Act described above. In November 2021, the Biden Administration withdrew that HHS policy announcement and ostensibly restored FDA’s regulatory oversight of LDTs.

If the FDA decides to regulate LDTs, such as the DMT, as medical devices through notice-and-comment rulemaking or the VALID Act or other new federal legislation is passed reforming the government’s regulation of LDTs, or alternatively, if the FDA disagrees with our assessment that our tests fall within the definition of an LDT, we will be subject to increased regulatory burdens such as registration and listing requirements, medical device reporting requirements and quality control requirements. Any legislation or formal FDA regulatory framework affecting LDTs is also likely to have premarket application requirements prohibiting commercialization without

21

FDA authorization and controls regarding modification to the tests that may require further FDA submissions. The process would likely be costly and time-consuming. We cannot assure that the DMT, or any new tests that we may develop or new uses for our products that we develop will be cleared or approved by the FDA in a timely or cost-effective manner, if cleared or approved at all. Even if such tests are cleared or approved, the products may not be cleared or approved for all indications. This could significantly limit the market for that product and may adversely affect our results of operations.

We believe that the Smart Sticker we provide for collection and transport of skin samples from a healthcare provider (or in our recently launched telemedicine option, from a patient at home with supervised collection) to our clinical laboratory is a Class I medical device subject to FDA regulations, although currently exempt from premarket review by the FDA. It is manufactured by a third party on our behalf. Class 1 products like our specimen collection kit are required to meet FDA’s general controls for in vitro diagnostic products, including that they be manufactured in compliance with applicable Quality System Regulations for medical devices, adhere to device labeling requirements, and be listed with FDA upon commercial distribution, among other regulatory controls.

HIPAA and Other Privacy and Data Security Laws

HIPAA established for the first time comprehensive federal protection for the privacy and security of health information. The HIPAA standards apply to three types of organizations (“Covered Entities”): health plans, healthcare clearing houses, and healthcare providers that conduct certain healthcare transactions electronically. Title II of HIPAA, the Administrative Simplification Act, contains provisions that address the privacy of health data, the security of health data, the standardization of identifying numbers used in the healthcare system and the standardization of certain healthcare transactions. The privacy regulations protect medical records and other protected health information by limiting their use and release, giving patients a variety of rights, including the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the implementation of administrative, physical, and technical safeguards and the adoption of written security policies and procedures. HIPAA requires Covered Entities to enter into business associate agreements with individuals or organizations who provide services to Covered Entities involving the use or disclosure of protected health information, also known as Business Associates.

In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act (“HITECH”) provisions of the American Recovery and Reinvestment Act of 2009. HITECH amended HIPAA and, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements for Covered Entities and Business Associates. Regulations implementing major provisions of HITECH were finalized on January 25, 2013 through publication of the HIPAA Omnibus Rule (the “Omnibus Rule”). The Omnibus Rule contained significant changes for Covered Entities and Business Associates with respect to permitted uses and disclosures of Protected Health Information.

Under HITECH’s breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of the United States Department of Health and Human Services (the “Secretary”). Required breach notices must be made as soon as is reasonably practicable, but no later than sixty days following discovery of the breach. Reports must be made to affected individuals and to the Secretary and in some cases, they must be reported through local and national media, depending on the size of the breach. We are currently subject to the HIPAA regulations as a Covered Entity and maintain an active compliance program. We are subject to audit under the United States Department of Health and Human Services’ HITECH-mandated audit program. We may also be investigated in connection with a privacy or data security complaint. We are subject to prosecution and/or administrative enforcement and increased civil and criminal penalties for non-compliance, including a new, four-tiered system of monetary penalties adopted under HITECH. These fines are adjusted for inflation each year. We are also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH. To avoid penalties under the HITECH breach notification provisions, we must ensure that breaches of unsecured protected health information are promptly detected and reported within the company, so that we can make all required notifications to the government on a timely basis. However, even if we make required reports on a timely basis, we may still be subject to penalties for the underlying breach and at risk of significant reputational harm if we experience a large-scale data breach.

In addition to the federal privacy regulations, there are a number of state laws regarding the privacy and security of health information and personal data that are applicable to clinical laboratories. The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely and new privacy and security laws in this area are evolving. For example, several states, such as California, have implemented comprehensive privacy laws and regulations. The California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition to the California Confidentiality of Medical Information Act, California also recently enacted the California Consumer Privacy Act of 2018 (“CCPA”) which became effective January 1, 2020. The CCPA has been characterized as the first “GDPR-like” privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the E.U. General Data Protection Regulation (described further below). The CCPA establishes a new privacy framework for covered businesses in the State of California, by creating an expanded

22

definition of personal information, establishing new data privacy rights for consumers imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. In November of 2020, California voters approved the California Privacy Rights Act (“CPRA”), which will take full effect in January of 2023. The CPRA modifies the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply, and additional potential for harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which is tasked with enacting new regulations under the CPRA and will have expanded enforcement authority. In addition, both Virginia and Colorado enacted new data privacy laws which will take effect in 2023 that have similarities to the CCPA and CPRA, but also have significant differences, creating compliance challenges across different jurisdictions.

Many states, such as Massachusetts, have also implemented genetic testing and privacy laws imposing specific patient consent requirements and requirements for protecting test results. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.

The applicability and requirements of these laws and penalties for violations vary widely. We believe that we have taken the steps required of us to comply with applicable health information privacy and security statutes and regulations in all jurisdictions, both state and federal. However, we may not be able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance, or changes in state or federal laws regarding privacy or security, could result in civil and/or criminal penalties and could have a material adverse effect on our business, financial condition, results of operation and cash flows.

We anticipate expanding our business internationally, which would implicate international laws governing the privacy of health information and personal data as well as restrictions on the cross-border transfer of these data. We currently receive samples from Canada and must comply with applicable Canadian federal and provincial laws. Compliance with these laws and with other international regulatory requirements is a complex, time and expense consuming endeavor. Our failure to comply could have a material adverse effect on our business, financial condition, results of operation and cash flows.

Federal and State Self-Referral Prohibitions

We are subject to the federal self-referral prohibitions, commonly known as the Stark Law or the Physician Self-Referral Law, and to similar state restrictions such as California’s Physician Ownership and Referral Act, commonly known as PORA. Together these restrictions generally prohibit us from billing the Medicare or Medicaid program or any patient or commercial payor for a test when the physician ordering the test, or any member of such physician’s immediate family, has an investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition.

Both the Stark Law and PORA contain an exception for compensation paid to a physician for personal services rendered by the physician, provided that certain conditions are satisfied. We have compensation arrangements with a number of physicians for personal services, such as speaking engagements. We have structured these arrangements with terms intended to comply with the requirements of the personal services exception to the Stark Law and PORA. However, we cannot be certain that regulators would find these arrangements to be in compliance with the Stark Law, PORA or similar state laws.

These prohibitions apply regardless of the reasons for the financial relationship and the referral. No finding of intent to violate the Stark Law is required to commit a violation. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act.

Sanctions for a violation of the Stark Law include the following:

 

•

denial of payment for the services provided in violation of the prohibition;

 

•

refunds of amounts collected by an entity in violation of the Stark Law;

 

•

a substantial civil penalty for each service arising out of the prohibited referral;

 

•

exclusion from federal healthcare programs, including the Medicare and Medicaid programs; and

 

•

substantial civil penalties for parties entering into a scheme to circumvent the Stark Law’s prohibition.

 

23

 

Further, a violation of PORA is a misdemeanor and could result in civil penalties and criminal fines. Finally, other states have self-referral restrictions with which we have to comply that differ from those imposed by federal and California law. While we have attempted to comply with the Stark Law, PORA and similar laws of other states, it is possible that some of our financial arrangements with physicians could be subject to regulatory scrutiny at some point in the future, and we cannot provide an assurance that we will be found to be in compliance with these laws following any such regulatory review.

Federal and State Fraud and Abuse Laws

Because of the significant federal funding involved in Medicare and Medicaid, Congress and the states have enacted, and actively enforce, a number of laws to eliminate fraud and abuse in federal health care programs. Our business is subject to compliance with these laws.

Anti-Kickback Statutes

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid.

The definition of “remuneration” has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payment of cash, and waivers of payments. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of services covered by the federal health care programs, the statute has been violated. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment, and possible exclusion from Medicare, Medicaid and other federal healthcare programs. In addition, kickback allegations can give rise to violations of the federal False Claims Act, as discussed in more detail below.

Recognizing that the Anti- Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements, Congress authorized the Office of Inspector General (“OIG”) for the United States Department of Health and Human Services to issue a series of regulations known as “safe harbors.” These safe harbors set forth provisions that, if all their applicable requirements are met, immunize the parties to the transaction or arrangement from prosecution under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, transactions and business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities such as OIG.

Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of recipients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs. In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”) was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (“SUPPORT Act”). EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA’s exceptions are inconsistent with the Anti-Kickback Statute regulations. Significantly, EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA’s exceptions or adding additional exceptions, but such regulations have not yet been issued. Further, there is no agency guidance or court precedent to indicate how and to what extent it will be applied and enforced. We cannot assure you that our relationships with physicians, sales representatives, hospitals, customers, or any other party will not be subject to scrutiny or will survive regulatory challenge under such laws. If imposed for any reason, sanctions under the EKRA could have a negative effect on our business.

Government officials have focused their enforcement efforts on the marketing of healthcare services and products, among other activities, and recently have pursued cases against companies, and certain individual sales, marketing, and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.

Federal False Claims Act

Another development affecting the healthcare industry is the increased use of the federal False Claims Act, and in particular, action brought pursuant to the False Claims Act’s “whistleblower” or “qui tam” provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the False Claims Act and to share in any monetary recovery.

In addition, various states have enacted false claims law analogous to the False Claims Act, many of these state laws apply where a claim is submitted to any commercial payor and not merely a federal healthcare program.

24

When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate instance of false claim, as set by statute. The civil penalty amounts are adjusted annually for inflation.

While we are unaware of any current matters, we are unable to predict whether we will be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the costs of defending such claims, as well as any sanctions imposed, could significantly affect our financial performance.

Physician Sunshine Laws

The federal Physician Payments Sunshine Act imposes reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them (and in some cases their distributors) to physicians, teaching hospitals and certain advanced non-physician health care practitioners, as well as ownership and investment interests held by physicians and their immediate family members. The reporting program (known as the Open Payments program) is administered by CMS. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe we are exempt from these reporting requirements. We may become subject to such reporting requirements under the terms of current CMS regulations, however, if the FDA requires us to obtain premarket clearance or approval for our tests.

Corporate Practice of Medicine

Numerous states prohibit business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. The prohibition against the corporate practice of medicine is designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. For example, California’s Medical Board has indicated that determining the appropriate diagnostic tests for a particular condition and taking responsibility for the ultimate overall care of a patient, including providing treatment options available to the patient, constitutes the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against the business corporation and/or the professional through licensure proceedings.

Civil Monetary Penalties Law

The federal Civil Monetary Penalties Law (the “CMP Law”), prohibits, among other things, (1) the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal health care program; (3) billing for services requested by an unlicensed physician or an excluded provider; and (4) billing for medically unnecessary services.  The penalties for violating the CMP Law include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense.

Reimbursement and Billing

Reimbursement and billing for diagnostic services is highly complex.  Laboratories must bill various payors, such as commercial insurers, including managed care organizations (“MCO”) as well as state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements.  Additionally, the audit requirements with which laboratories must comply to ensure compliance with applicable laws and regulations, as well as internal compliance policies and procedures, add further complexity to the billing process.  

In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (“PAMA”), which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, certain clinical laboratories are required to report to CMS commercial payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. Further, under PAMA, Medicare reimbursement for diagnostic tests are based on the weighted- median of the payments made by commercial payors for these tests, rendering commercial payor payment levels even more significant. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of commercial payors to recognize the value of diagnostic tests generally and any given test individually.

In March 2020, Congress passed the Coronavirus Aid, Relief, and Economic Security Act, which included a provision that delays the next PAMA reporting period for clinical laboratory tests that are not advanced diagnostic tests to January 1, 2022 through March 31, 2022. Then, on December 10, 2021, the Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610) delayed the reporting requirement as well as the application of the 15% phase-in reduction until 2023. The next round of CLFS rates thus will not be implemented until 2022.

25

We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or how any such legislation or regulation may affect us. For instance, the changes to reimbursement amounts paid by Medicare for tests such as ours based on the procedure set forth in PAMA could limit the prices we would be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare policy changes could be amended or additional healthcare initiatives could be implemented in the future.

Other Laws Applicable to Our Business

In some cases, we are prohibited from conducting certain tests without a certification of patient consent by the clinician ordering the test.

In addition, we are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste, and radioactive materials. For example, the United States Occupational Safety and Health Administration (“OSHA”) has established extensive requirements relating specifically to workplace safety for healthcare employers in the United States. This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, such as HIV and hepatitis B and C, including preventing or minimizing any exposure through needle stick injuries. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the United States Department of Transportation, the United States Public Health Service, the United States Postal Service, and the International Air Transport Association. We generally use third-party vendors to dispose of regulated medical waste, hazardous waste, and radioactive materials and contractually requires them to comply with applicable laws and regulations.

Advertising of Laboratory Services or LDTs

Our physician-directed advertising for the DermTech Melanoma Test, the Smart Sticker and our laboratory services, as well as our direct-to-consumer advertising and social media presence, are subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (“FTC”) as well as comparable state consumer protection laws. Under the Federal Trade Commission Act, the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.

Foreign Corrupt Practices Act

In general, the Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”) prohibits offering to pay, paying, promising to pay, or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business for or with, or in order to direct business to, any person. The prohibitions apply not only to payments made to “any foreign official,” but also those made to “any foreign political party or official thereof,” to “any candidate for foreign political office” or to any person, while knowing that all or a portion of the payment will be offered, given, or promised to anyone in any of the foregoing categories. “Foreign officials” under the FCPA include officers or employees of a department, agency, or instrumentality of a foreign government. The term “instrumentality” is broad and can include state-owned or state-controlled entities. Importantly, United States authorities deem most healthcare professionals and other employees of foreign hospitals, clinics, research facilities and medical schools in countries with public healthcare and/or public education systems to be “foreign officials” under the FCPA. When we interact with foreign healthcare professionals and researchers in testing and marketing our products abroad, we must have policies and procedures in place sufficient to prevent us and agents acting on our behalf from providing any bribe, gift or gratuity, including excessive or lavish meals, travel or entertainment in connection with marketing our products and services or securing required permits and approvals. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. We have a policy entitled “Anti-Bribery and Anti-Corruption” that seeks to fully comply with the FCPA.

Foreign Regulations

When we market our tests outside of the United States, we will be subject to foreign regulatory requirements governing laboratory licensure, human clinical testing, use of tissue, privacy and data security, and marketing approval for our tests. These requirements vary by jurisdiction, differ from those in the United States, and may require us to implement additional compliance measures or perform additional pre-clinical or clinical testing. In the European Union, we may be subject to newly enacted legislation that imposes

26

requirements and restrictions on medical devices and in vitro diagnostics; that legislation will become effective in 2020 (for medical devices) and 2022 (for in vitro diagnostics). In light of the ongoing COVID‑19 pandemic, European legislators have voted to delay the effective date of the new Medical Devices Regulation by one year (to May 26, 2021), although to date the May 2022 effective date for the In Vitro Diagnostic Regulation has not been delayed.

In addition, we will also be subject to the E.U. General Data Protection Regulation (the “GDPR”) that significantly regulates the possession, use, and disclosure of personal information. In many countries outside of the United States, coverage, pricing, and reimbursement approvals are also required. We are also required to maintain accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, our books and records provisions, and our anti-bribery provisions.

Employees

As of December 31, 2021, we had 258 employees, 255 of which were full-time employees, including 21 engaged in research and development, 16 in clinical operations, 70 in general and administrative, 36 in laboratory operations, and 115 in sales and marketing. We also engage consultants in various areas. None of our employees are represented by a labor union and we believe that our relationships with our employees and contractors are good.

Corporate and Other Information

We incorporated in the British Virgin Islands in 2015 and domesticated in the state of Delaware in 2019. DermTech Operations was incorporated in California in 1995 and reincorporated in the state of Delaware on May 15, 2014. Our principal offices are located at 11099 North Torrey Pines Road, Suite 100, La Jolla, California 92037. Our telephone number is (858) 450-4222 and our website address is www.dermtech.com. We regularly post copies of our press releases as well as other information about us on our website. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investor Relations section of our website as soon as reasonably practicable after such materials have been electronically files with, or furnished to, the SEC. The SEC maintains an internet site (http://www.sec/gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The information contained on, or that can be accessed through, our website is not a part of this report, and our reference to the address for our website is intended to be an inactive textual reference only.

27

Item 1A.  Risk Factors.

The Company is in a market environment that cannot be predicted and that involves significant risks, many of which are beyond our control. Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in this report, as well as the other information we file with the SEC. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment. Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition or results of operations.

Summary Risk Factors

Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled “Risk Factors,” that represent challenges that we face in connection with the successful implementation of our strategy and growth of our business. The occurrence of one or more of the events or circumstances described in the section entitled “Risk Factors,” alone or in combination with other events or circumstances, may have an adverse effect on our business, financial condition, results of operations, and prospects. Such risks include, but are not limited to:

Risks Relating to Our Financial Condition and Capital Requirements

 

•

We have a history of net losses; we expect to incur net losses in the future and may never achieve profitability.

 

•

We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make our future performance difficult to predict.

 

•

Our financial condition, commercialization efforts and results of operations could be adversely affected by the ongoing COVID‑19 pandemic.

 

•

Our commercial success could be compromised if customers do not pay our invoices or if commercial payors, including managed care organizations and Medicare, do not provide coverage and reimbursement, breach, rescind, or modify their contracts or reimbursement policies, reimburse at a low rate, or delay payments for the DMT and our planned tests.

 

•

We will need to raise additional capital to fund our existing operations, commercialize our products, and expand our operations.

 

•

If clinicians, including dermatologists, decide not to order the DMT or our future tests, we may be unable to generate sufficient revenue to sustain our business.

 

•

We expect to continue to incur significant expenses to develop and market our existing and planned tests, which could make it difficult for us to achieve and sustain profitability.

 

•

We may not be able to generate sufficient revenue from the commercialization of the DMT, or successfully develop and commercialize other tests to achieve or sustain profitability.

 

•

If we are unable to successfully execute our marketing strategy for the DMT and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our business.

 

•

The telemedicine market is immature and unpredictable, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity or if limitations on reimbursement or difficulties in obtaining regulatory approvals impede our ability to adopt telemedicine, the growth of our business will be harmed.

 

•

If we cannot develop tests to keep pace with rapid advances in technology, medicine and science, our operating results and competitive position could be harmed.

 

•

Our future success will depend in part upon our ability to enhance the DMT, and to develop, introduce, and commercialize other novel innovative and non-invasive diagnostics tests and services; new test development involves a lengthy and complex process and we may be unable to commercialize new or improved tests or any other products we may develop on a timely basis, or at all.

 

•

We rely on a limited number of suppliers and, in some cases, a single supplier, for certain of our laboratory substances, equipment and other materials, and any delays or difficulties securing these materials could disrupt our laboratory operations and materially harm our business.

 

•

The DMT employs a novel diagnostic platform and may never be accepted by its intended markets.

 

•

If the DMT and our planned tests do not to perform as expected, as a result of human error or otherwise, it could have a material adverse effect on our operating results, reputation, and business.

28

 

•

If our sole laboratory facility becomes damaged or inoperable, or we are required to vacate the facility, our ability to sell and provide molecular tests and pursue our research and development (“R&D”) efforts may be jeopardized.

 

•

If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenues or achieve and sustain profitability.

 

•

We may encounter manufacturing problems or delays that could result in lost revenue.

 

•

If we cannot support demand for the DMT and our planned future tests, including successfully managing the evolution of our technology and manufacturing platforms, our business could suffer.

 

•

If we were to be sued for product or professional liability, we could face substantial liabilities that exceed our resources.

 

•

We may acquire other businesses, form joint ventures, or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt, or cause us to incur significant expense.

 

•

International expansion of our business would expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.

 

•

Declining general economic and business conditions as a result of the COVID‑19 pandemic have had a negative impact on our business, and the extent and duration of the effects of the COVID‑19 pandemic and economic downturn are difficult to predict, which makes our future performance more difficult to predict.

 

•

Intrusions into our computer systems could compromise confidential information and our ability to continue operations.

 

•

We rely on FedEx Corporation (“FedEx”) and United Parcel Service, Inc. (“UPS”) to distribute our Smart Sticker to customers and transport specimens back to our laboratory facility, and any damage to their facilities or inability to deliver our products could have an adverse effect on our results of operations and business.

 

•

We have identified material weaknesses in our internal control over financial reporting. If not remediated, our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations.

Regulatory Risks Related to Our Business

 

•

Changes in health care law and policy may have an adverse effect on our financial condition, results of operations, and cash flows.

 

•

Our business could be adversely impacted by our failure or clinicians’ failure to comply with the International Classification of Diseases, Tenth Revision, Clinical Modification (“ICD-10-CM”) Code Set.

 

•

Billing for the DMT is complex, and we must dedicate substantial time and resources to the billing process to be paid for the DMT; long payment cycles of Medicare, Medicaid, and/or other commercial payors, or other payment delays, could hurt our cash flows and increase our need for working capital.

 

•

Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal, and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.

 

•

If the FDA were to begin requiring approval or clearance of the DMT and our planned future tests, or our proprietary Smart Sticker, we could incur substantial costs and time delays associated with meeting the requirements.

 

•

If we were to be required by the FDA to conduct additional clinical studies or trials before continuing to offer tests that we have developed or may develop as LDTs those studies or trials could lead to delays or failure to obtain necessary regulatory clearance or approval, which could cause significant delays in commercializing any future products and harm our ability to achieve profitability.

 

•

We are subject to numerous federal, local and foreign laws and regulations; complying with laws pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and a material adverse effect to our business and operations.

Intellectual Property Risks Related to Our Business

 

•

If we are unable to maintain intellectual property protection, our competitive position could be harmed.

Risks Related to Our Securities

 

•

Future issuances of equity securities may dilute the interests of our security holders and reduce the price of our securities.

29

 

Risks Relating to Our Financial Condition and Capital Requirements

We are a company with a history of net losses; we expect to incur net losses in the future and may never achieve profitability.

We have historically incurred substantial net losses in each year since our inception, including net losses of $78.3 million for the twelve months ended December 31, 2021. As of December 31, 2021, we had an accumulated deficit of $206.4 million.

We expect our losses to continue as a result of costs relating to ongoing R&D and for increased sales and marketing costs for existing and planned products. These losses have had, and will continue to have, an adverse effect on our working capital, total assets, and stockholders’ equity. Because of the numerous risks and uncertainties associated with our commercialization efforts, we are unable to predict when we will become profitable, and we may never become profitable. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations, and cash flows.

We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make our future performance difficult to predict.

We are an emerging molecular diagnostics company with a limited operating history. Our operations to date have been primarily focused on developing and market testing our technology. We have not obtained regulatory approvals from the FDA for any of our existing and planned tests as we operate a clinical laboratory under the CLIA guidelines and believe the DMT is an LDT that is not currently being regulated by the FDA. Consequently, if regulatory approval is determined to be necessary or if Congress enacts legislation that alters the regulatory framework for LDTs, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or more commercialized products. Our financial condition and operating results have varied significantly in the past and will continue to fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include other factors described elsewhere in this report and also include:

 

•

our ability to obtain additional funding to develop and market our existing and planned products and tests;

 

•

the market adoption and demand for our existing and planned tests;

 

•

the existence of favorable or unfavorable clinical guidelines for our existing and planned tests;

 

•

the reimbursement of our existing or planned tests by Medicare and commercial payors;

 

•

our ability to obtain and maintain any necessary regulatory approval for any of our existing and planned tests in the United States and foreign jurisdictions, if required;

 

•

potential side effects of our existing and planned tests that could delay or prevent commercialization, limit the use of our existing and planned tests, or cause any of our commercialized tests to be taken off the market;

 

•

our dependence on third-party suppliers and manufacturers, to supply or manufacture our specimen collection products;

 

•

our ability to establish or maintain collaboration, licensing, or other arrangements;

 

•

our ability to maintain and grow an effective sales and marketing infrastructure, either through the expansion of our commercial infrastructure or through strategic collaborations;

 

•

competition from existing and planned tests or new tests that may emerge;

30

 

 

•

the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our existing and planned tests;

 

•

our ability to leverage our proprietary technology platform to discover and develop additional test candidates;

 

•

our ability to successfully obtain, maintain, defend, and enforce intellectual property rights important to our business;

 

•

our ability to attract and retain key personnel to manage our business effectively;

 

•

our ability to build our finance infrastructure and improve our accounting systems and controls;

 

•

potential product liability claims;

 

•

potential liabilities associated with hazardous materials; and

 

•

our ability to obtain and maintain adequate insurance policies.

Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.

Our financial condition, commercialization efforts and results of operations could be adversely affected by the ongoing COVID‑19 pandemic.

Any outbreak of a contagious disease, such as the current COVID‑19 pandemic, or other adverse public health developments, could have a material and adverse effect on our business operations. Such adverse effects could include disruptions or restrictions on the ability of our, our collaborators’, or our suppliers’ personnel to travel, and could result in temporary closures of our facilities or the facilities of our collaborators or suppliers, including our sole laboratory.

As COVID‑19 continues to affect individuals and businesses around the globe, we will likely experience disruptions that could severely impact our business, including, but not limited to:

 

•

closure of or reduced access to clinician offices, which would limit our ability to market the DMT to clinicians and limit clinicians’ ability to offer the DMT to patients;

 

•

patient concerns about going to clinicians’ offices to have the DMT administered in person, even if offices are open;

 

•

difficulties in transitioning to marketing our telemedicine option for the DermTech Melanoma Test or processing test results for our telemedicine option, which we recently initiated on an accelerated basis due to the COVID‑19 environment;

 

•

dependence to a substantial extent on the willingness of clinicians and their patients to use our telemedicine option, as well as on our ability to demonstrate the value of our telemedicine option to payors;

 

•

limitations on reimbursement, which could impede its adoption by clinicians and patients;

 

•

limitations on employee resources that would otherwise be focused on our commercialization and sales efforts, including because of sickness of employees or their families or requirements imposed on employees to avoid contact with large groups of people;

 

•

delays in our third-party suppliers’ ability to manufacture our Smart Sticker, including because of interruptions in shipping that may affect the transport of required materials;

 

•

delays or difficulties marketing the DMT to new commercial payors, including due to layoffs, furloughs or diversion of attention of payor employees responsible for negotiating coverage contracts for the DMT;

 

•

interruptions in our laboratory operations, including because of the inability of our suppliers to timely obtain laboratory reagents, equipment or other materials due to increased global demand;

 

•

loss of patient insurance coverage due to unemployment caused by COVID‑19, which would likely result in a decline in our sales growth if and as we secure additional insurance contracts; and

 

•

interruption of our clinical studies due to quarantines or other limitations on travel or access to facilities imposed or recommended by federal, state or local governments, employers or others; and

 

•

interruptions to our product pipeline because of the inability of our suppliers to timely obtain laboratory substances, including reagents, as well as for the sequencers and various other equipment and materials we use in our development activities due to disruptions in supply chains globally and in global shipping.

In addition, the continued spread of COVID‑19 globally and implementation of mitigation measures could adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and may accordingly be subject to restrictions on export to the U.S. or other disruptions. Additionally, our results of operations have been adversely affected by COVID‑19 and such effects could be expected to worsen to the extent that the COVID‑19 pandemic persists and continues to harm the U.S. economy in general. The extent to which COVID‑19 affects our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, additional information that may emerge concerning the severity of COVID‑19 and ongoing actions to contain COVID‑19 or mitigate its impact, among others, which could have a further adverse effect on our business, financial condition, results of operations, and cash flows.

31

 

We expect to continue to incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.

As a public company, we incur and expect to continue to incur additional significant legal, accounting and other expenses in relation to our status as a public reporting company. We expect that these expenses will further increase as a result of our recent transition to no longer being an “emerging growth company.” We may need to hire additional accounting, finance and other personnel in connection with our continuing efforts to comply with the requirements of being a public company, and our management and other personnel will need to continue to devote a substantial amount of time towards maintaining compliance with these requirements. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”), we are required to furnish a report by our management on our internal controls over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have been and will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. We have identified material weaknesses in our internal control over financial reporting as more fully described in Item 9A—Controls and Procedures, which could result in an adverse reaction in the financial markets due to any loss of confidence in the reliability of our consolidated financial statements. We plan to implement or improve documentation of alternative control procedures to remediate these material weaknesses. These remediation measures may be time consuming and costly and there is no assurance that these measures will ultimately have the intended effects.

Our commercial success could be compromised if customers do not pay our invoices or if commercial payors, including managed care organizations and Medicare, do not provide coverage and reimbursement, breach, rescind, or modify their contracts or reimbursement policies, reimburse at a low rate, or delay payments for the DMT and our planned future tests.

Clinicians, including dermatologists, may not order the DMT or our planned tests unless commercial payors, such as managed care organizations and federal health care programs (e.g., Medicare and Medicaid), pay a substantial portion of the test price. Coverage and reimbursement by a commercial payor may depend on a number of factors, including a payor’s determination that tests using our technologies are:

 

•

not experimental or investigational;

 

•

medically necessary;

 

•

appropriate for the specific patient;

 

•

cost-effective;

 

•

deemed to require prior authorization;

 

•

supported by peer-reviewed publications; and

 

•

included in clinical practice guidelines.

Uncertainty surrounds commercial payor reimbursement of any test incorporating new technology, including tests developed using our technologies. Technology assessments of new medical tests conducted by research centers and other entities may be disseminated to interested parties for informational purposes. Commercial payors may use such technology assessments as grounds to deny coverage for a test or procedure. Technology assessments can include evaluation of clinical utility studies, which define how a test is used in a particular clinical setting or situation.

32

Because each payor generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse the DMT, seeking payor approvals is a time-consuming and costly process. We cannot be certain that coverage for the DMT and our planned future tests will be provided in the future by additional commercial payors or that existing policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. In addition, the coding procedure used by all commercial payors with respect to establishing payment rates for various procedures, including the DMT, is complex, does not currently adapt well to the genetic tests we perform and may not enable coverage or adequate reimbursement rates for the DMT. If we cannot obtain or maintain coverage and reimbursement from commercial payors and federal health care programs such as Medicare and Medicaid for the DMT, or new tests or test enhancements that we may develop in the future, our ability to generate revenues could be limited, which may have a material adverse effect on our financial condition, results of operations, and cash flows. Measures have been undertaken to reduce payment rates for and decrease utilization of the clinical laboratory testing generally, including PAMA, which has resulted in reduced rates on the CLFS. These reductions may also impact the DMT and tests we develop in the future. Because of the cost-trimming trends, commercial payors that cover and provide reimbursement for the DMT and our planned tests may suspend, revoke, or discontinue coverage at any time, or may reduce the reimbursement rates payable to us. Any such action could have a negative impact on our revenues, which may have a material adverse effect on our financial condition, results of operations, and cash flows. Additionally, if we are not able to obtain sufficient clinical information in support of the DMT, commercial payors could designate the DMT as experimental or investigational and decline to cover and reimburse the DMT because of this designation. As a result of these factors, obtaining approvals from commercial payors to cover the DMT and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may never be successful. Further, we have experienced in the past, and will likely experience in the future, delays and interruptions in the receipt of payments from commercial payors due to missing documentation and/or other issues, which could cause delay in recognizing our revenue.

Additionally, we are currently considered a “non-contracted provider” or “out of network” by most commercial payors because we have not entered into a specific contract to provide tests to their insured patients at specified rates of reimbursement. We also may be considered now or later to be designated as an “out of network” lab by private commercial payors, who may deny our claims in whole or in part as a result.  If we were to become a contracted provider with one or more payors in the future, the amount of overall reimbursement we receive would likely decrease because we could be reimbursed less money per test performed at a contracted rate than at a non-contracted rate, which could have a negative impact on our revenues. Further, we pursue payment of patient co-payments, co-insurance and deductibles, but we typically do not collect substantial payments from patients and therefore experience overall loss to revenue as a result.

We will need to raise additional capital to fund our existing operations, commercialize our products, and expand our operations.

As of December 31, 2021, our cash and cash equivalents totaled approximately $176.9 million and short-term marketable securities totaled $48.4 million. On February 28, 2020, we entered into a securities purchase agreement with certain institutional investors for a private placement, which closed on March 4, 2020, of our equity securities for aggregate gross proceeds of approximately $65.0 million, and net proceeds to the Company of approximately $59.9 million, after deducting estimated offering expenses payable by the Company. On November 10, 2020, we entered into a sales agreement to sell shares of our common stock having aggregate sales proceeds of up to $50.0 million from time to time. In connection with this sales agreement, we raised aggregate gross proceeds of approximately $44.5 million, and net proceeds to the Company of approximately $42.9 million during 2020 and 2021. On January 11, 2021, the Company completed an underwritten public offering of our common stock for aggregate gross proceeds of approximately $143.7 million, and net proceeds to the Company of approximately $134.6 million, after deducting offering expenses payable by the Company.

Based on our current business operations and the additional financing completed in January 2021, we believe our current cash and cash equivalents will be sufficient to meet our anticipated cash requirements for at least the next twelve months. We anticipate that we will need to raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements in the future in order to satisfy our anticipated liquidity requirements. We may also consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities, or for other reasons, including to:

 

•

increase our efforts to drive market adoption of the DMT and address competitive developments;

 

•

fund research and development activities and efforts of commercializing future products;

 

•

acquire, license, or invest in technologies;

 

•

acquire or invest in complementary businesses or assets; and

 

•

finance capital expenditures and general and administrative expenses.

33

 

Our present and future funding requirements will depend on many factors, including:

 

•

our revenue growth rate and ability to generate cash flows from operating activities;

 

•

our sales and marketing and R&D activities;

 

•

effects of competing technological and market developments;

 

•

costs of and potential delays in product development;

 

•

changes in regulatory oversight applicable to the DMT; and

 

•

timing of and costs related to future international expansion.

The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity securities issued also could provide for rights, preferences, or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences, and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products, or grant licenses on terms that are not favorable to us. Additional equity or debt financing might not be available on reasonable terms, if at all. If we cannot secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more R&D programs or sales and marketing initiatives. In addition, we may have to work with a partner on one or more of our development programs, which could lower the economic value of those programs to us. We will also need to raise additional capital to expand our business to meet our long-term business objectives. Additional financing may be from the sale of equity or convertible or other debt securities in a public or private offering, from a credit facility or strategic partnership coupled with an investment in us, or a combination of both. For further discussion of our liquidity requirements as they relate to our long-term plans, see the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations –Liquidity and Capital Resources.”

Our cash, cash equivalents and short-term marketable securities are subject to economic risk.

The Company invests its cash, cash equivalents and short-term marketable securities in domestic bank deposits, money market funds, U.S. Government debt securities, corporate debt, and certificates of deposit. Certain types of these investments are subject to general credit, liquidity, market and interest rate risks. In the event these risks caused a decline in value of any of the Company’s investments, it could adversely affect the Company’s financial condition.

If clinicians, including dermatologists, decide not to order the DermTech Melanoma Test, or our future tests, we may be unable to generate sufficient revenue to sustain our business.

To generate demand for the DMT and our planned tests, we will need to educate dermatologists and other health care professionals on the clinical utility, benefits, and value of the tests we provide through published papers, presentations at scientific conferences, educational programs, and one-on-one education sessions by members of our sales force. In addition, we need to assure dermatologists of their ability to obtain and maintain adequate reimbursement coverage from commercial payors for office visits during which the specimens for the DMT are collected. Medical professionals are influenced by standard-setting bodies that influence and/or dictate the standard of care. If we are not successful in changing current guidelines from legacy standards to new molecular-based approaches our market adoption will suffer. If we cannot convince medical practitioners to order the DMT and our planned tests, we will likely be unable to create demand in sufficient volume for us to achieve profitability or meet our anticipated revenue projections.

We expect to continue to incur significant expenses to develop and market our existing and planned tests, which could make it difficult for us to achieve and sustain profitability.

In recent years, we have incurred significant costs in connection with the development of our existing and planned tests. For the twelve months ended December 31, 2021, our R&D expenses were $16.3 million, our sales and marketing expenses were $37.6 million and our general and administrative expenses were $24.8 million. For the twelve months ended December 31, 2020, our R&D expenses were $5.3 million, our sales and marketing expenses were $16.1 million and our general and administrative expenses were $13.8 million. For the twelve months ended December 31, 2019, our R&D expenses were $2.5 million, our sales and marketing expenses were $6.3 million and our general and administrative expenses were $8.9 million. We expect our expenses to continue to increase for the foreseeable future as we conduct studies of our existing test and planned tests, grow our sales and marketing organization, drive adoption of and reimbursement for the DMT, and develops new tests. As a result, we need to generate significant revenues in order to achieve profitability.

34

We may not be able to generate sufficient revenue from the commercialization of the DermTech Melanoma Test, or successfully develop and commercialize other tests to achieve or sustain profitability.

We launched the DMT, without the add-on test for TERT, during the first half of 2016 and the DMT with the add-on test for TERT in the second quarter of 2021. We are in varying stages of R&D for other tests that we may offer in the future. We believe that our commercialization success is dependent upon our ability to significantly increase the number of customers who are using the DMT. In addition, demand for the DMT may not increase as quickly as planned and we may be unable to increase our revenue levels as expected. We are currently not profitable. Even if we succeed in increasing adoption of the DermTech Melanoma Test by dermatologists, in maintaining and creating relationships with our existing and new customers, and developing and commercializing additional molecular diagnostic testing products, we may not be able to generate sufficient revenue to achieve or sustain profitability.

If we are unable to successfully execute our marketing strategy for the DermTech Melanoma Test and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our business.

Although we believe that the DMT and planned future tests represent a promising commercial opportunity, the DMT may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for the DMT and build that market through clinician education, awareness programs, and the publication of clinical trial results. Gaining acceptance in medical communities requires publication in leading peer-reviewed journals of results from studies using the DMT and/or our planned future tests. The process of publication in leading medical journals is subject to a peer-review process and peer-reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would limit the adoption of the DMT and our planned tests.

Our ability to successfully market the tests that we develop will depend on numerous factors, including:

 

•

conducting clinical utility studies of such tests in collaboration with key thought leaders to demonstrate their use and value in important medical decisions such as treatment selection;

 

•

the success of our sales force;

 

•

whether health care providers believe such tests provide clinical utility;

 

•

whether the medical community accepts that such tests are sufficiently sensitive and specific to be meaningful in patient care and treatment decisions; and

 

•

whether health insurers, government health care programs, and other commercial payors will cover and pay for such tests and, if so, whether they will adequately reimburse us.

Failure to achieve widespread market acceptance of the DMT and our planned future tests would materially harm our business, financial condition, and results of operations.

The telemedicine market is immature and unpredictable, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity or if limitations on reimbursement or difficulties in obtaining regulatory approvals impede our ability to utilize a telemedicine channel, the growth of our business will be harmed.

The DMT, can be ordered via telemedicine channels given the sample collection can be achieved at-home using the Smart Sticker Collection Kit. The telemedicine channels consist of clinicians (i) use of third-party telemedicine technologies to assess their patients and (ii) subscribing to our DermTech Connect platform to assess their patients. However, it is uncertain whether these solutions, or telemedicine generally, will achieve and sustain high levels of demand, consumer acceptance and market adoption. Our success will depend to a substantial extent on the willingness of clinicians and their patients to use a telemedicine solution, as well as on our ability to demonstrate the value of a telemedicine solution to commercial payors and other purchasers of healthcare for beneficiaries. To the extent the COVID-19 pandemic subsides, as a result of the distribution of an effective vaccine or otherwise, and patient access to clinician offices for in-person testing improves, the demand for a telemedicine channel could be adversely affected. Negative publicity concerning use of a telemedicine solution or the telemedicine market as a whole could limit market acceptance. If clinicians or their patients do not believe that a telemedicine channel can provide accurate evaluation of suspicious lesions and testing using the DMT, as our clinical studies have already demonstrated, or if clinicians or their patients are not willing to utilize the clinician-supervised remote collection process due to technological limitations or otherwise then an adoption of a telemedicine solution to access the DMT may be slow to develop, or may not develop at all. Changes by state professional licensing boards to the standards of care or other requirements governing the practice of telemedicine, including any such requirements from federal regulatory bodies, could impact the growth or even adoption of a telemedicine solution. Additionally, reimbursement from governmental and commercial payors may not be available or may be too limited for physician services or laboratory testing ordered through a telemedicine channel. Similarly, individual and healthcare industry concerns or negative publicity regarding patient confidentiality and privacy in the context of telemedicine could limit market acceptance for telemedicine. If any of these events occurs, it could have a material adverse effect on our business, financial condition or results of operations, especially given the ongoing COVID-19 pandemic and patients’ reduced access to clinician offices for testing.

35

The DermTech Connect telemedicine platform is dependent on relationships with subscribing health professionals and provider organizations, which we do not own, to provide patient services, and the DermTech Connect business would be harmed if those relationships were disrupted.

There is a risk that U.S. state authorities in some jurisdictions may find that our contractual relationships with health providers providing telemedicine services utilizing DermTech Connect violates laws prohibiting the corporate practice of medicine. These laws generally prohibit the practice of medicine by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing a physician’s professional judgment. The extent to which each state considers particular actions or contractual relationships to constitute improper influence of professional judgment varies across the states and is subject to change and to evolving interpretations by state boards of medicine and state attorneys general, among others. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of the corporate practice of medicine laws will not circumscribe our business operations. State corporate practice of medicine doctrines also often impose penalties on physicians themselves for aiding the corporate practice of medicine, which could discourage health professionals from subscribing to utilize the DermTech Connect telemedicine platform with their patients.

If we cannot develop tests to keep pace with rapid advances in technology, medicine and science, our operating results and competitive position could be harmed.

In recent years, there have been numerous advances in technologies relating to the molecular diagnosis for cancer and other medical conditions. Several new cancer drugs have been approved, including several for melanoma, and a number of new drugs in clinical development may increase patient survival time. There have also been advances in methods used to identify patients likely to benefit from these drugs based on analysis of biomarkers. We must continuously develop new tests and enhance any existing test to keep pace with evolving standards of care. The DMT and our planned tests could become obsolete unless we continually innovate and expand them to demonstrate benefit in the diagnosis, monitoring, or prognosis of patients with cancer and other dermatologic conditions. If we cannot adequately demonstrate the applicability of the DMT and our planned future tests to new diagnostic and treatment developments, sales of the DMT could decline, which would have a material adverse effect on our business, financial condition, results of operations and cash flows.

Our future success will depend in part upon our ability to enhance the DermTech Melanoma Test, and to develop, introduce, and commercialize other novel innovative and non-invasive diagnostics tests and services; new test development involves a lengthy and complex process and we may be unable to commercialize new or improved tests or any other products we may develop on a timely basis, or at all.

Our future success will depend in part upon our ability to enhance the DermTech Melanoma Test, and to develop new innovative products. Our failure to successfully develop new products on a timely basis could have a material adverse effect on our revenue, results of operations, and business.

The development of new or enhanced tests is a complex and uncertain process requiring precise technological execution. In addition, the successful development of new products may depend on the development of new technologies. We may be required to undertake time-consuming and costly development activities. We may experience difficulties that could delay or prevent the successful development, commercialization, and marketing of these new products. Before we can commercialize any new products, we will need to expend significant funds in order to conduct substantial R&D, including validation studies.

Our product development process involves a high degree of risk, and product development efforts may fail for many reasons, including a failure to demonstrate the performance of the product or an inability to obtain any required certification or regulatory approval, if required.

As we develop new tests and other products, we will have to make significant investments in product development, as well as sales and marketing resources. In addition, competitors may develop and commercialize competing products faster than we are able to do so, which could have a material adverse effect on our revenue, results of operations and business.

We rely on a limited number of suppliers and, in some cases, a single supplier, for certain of our laboratory substances, equipment and other materials, and any delays or difficulties securing these materials could disrupt our laboratory operations and materially harm our business.

We rely on a limited number of suppliers for certain of our laboratory substances, including reagents, as well as for the sequencers and various other equipment and materials we use in our laboratory operations. In particular, we rely on Thermo Fisher and VWR for supplies and Adhesive Research for our adhesive tape material. We do not have long-term supply agreements with any of our suppliers and, as a result, they could cease supplying these materials and equipment to us at any time due to an inability to reach agreement with us on supply terms, disruptions in their operations (including as a result of the ongoing COVID-19 pandemic), a determination to pursue other activities or lines of business, or for other reasons, or they could fail to provide us with sufficient quantities of materials that meet our specifications. Transitioning to a new supplier or locating a temporary substitute, if any are available, would be time-consuming and expensive, could result in interruptions in or otherwise affect the performance specifications of our laboratory operations, or could require that we revalidate the DMT. In addition, the use of equipment or materials provided by a replacement supplier could require us to alter our laboratory operations and procedures as well as our research and development activities. Moreover, we believe there are

36

currently only a few manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for our laboratory operations, including sequencers and various associated reagents. As a result, replacement equipment and materials that meet our quality control and performance requirements may not be available on reasonable terms, in a timely manner or at all. If we encounter delays or difficulties securing, reconfiguring or revalidating the equipment, reagents and other materials we require for the DMT, our operations could be materially disrupted and our business, financial condition, results of operations, and reputation could be adversely affected. As we introduce any new test, we may experience supply issues as we ramp test volume. Moreover, the COVID-19 pandemic has disrupted supply chains globally, and could adversely affect our ability to source essential reagents, equipment and other materials in a timely manner or at all.

The DMT employs a novel diagnostic platform and may never be accepted by its intended markets.

Our future success depends on our ability to successfully commercialize the DermTech Melanoma Test, as well as our ability to develop and market other tests that use our proprietary technology platform. The scientific discoveries that form the basis of our proprietary technology platform and the DMT is relatively new. We are not aware of any other genomic tests such as ours and there can be no assurance that clinicians will be willing to use them. If we do not successfully develop and commercialize the DMT based upon our technological approach, we may not become profitable and the value of our common stock may decline.

The novel nature of our existing and planned tests also means that fewer people are trained in or experienced with products of this type, which may make it difficult to find, hire, and retain capable personnel for research, development, and clinical laboratory positions.

Further, our focus solely on genomic tests, as opposed to multiple, more proven technologies for patient diagnosis, increases the risks associated with the ownership of our common stock. If we do not achieve market acceptance for the DMT, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.

If the DMT and our planned tests do not to perform as expected, as a result of human error or otherwise, it could have a material adverse effect on our operating results, reputation, and business.

Our success depends on the market’s confidence that we can provide reliable, high-quality diagnostic results. There is no guarantee that any accuracy we have demonstrated to date will continue, particularly as the number of tests using our assays increases and as the number of different tests that we develop and commercialize expands. We believe that our customers are likely to be particularly sensitive to test defects and errors. As a result, the failure of our current or planned tests to perform as expected could significantly impair our reputation and the public image of our tests. As a result, the failure or perceived failure of our products to perform as expected could have a material adverse effect on our business, financial condition, results of operations and cash flows.

We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.

As part of our strategy, we expect to increase our number of employees as our business grows. This future growth could create strain on our organizational, administrative, and operational infrastructure, including laboratory operations, quality control, customer service, and sales and marketing. Our ability to manage our growth properly will require us to continue to improve our operational, financial, and management controls, as well as our reporting systems and procedures. If our current infrastructure is unable to handle our growth, we may need to further expand our infrastructure and staff and implement new reporting systems. The time and resources required to implement such expansion and systems could adversely affect our operations. Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, and integrate additional employees. Our future financial performance and our ability to commercialize our products and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.

If our sole laboratory facility becomes damaged or inoperable, or we are required to vacate the facility, our ability to sell and provide molecular tests and pursue our R&D efforts may be jeopardized.

We do not have any clinical reference laboratory facilities outside of our facility in La Jolla, California. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, flooding, pandemics or other disease outbreaks and power outages, which may render it difficult or impossible for us to perform our diagnostic test for some period of time. The inability to perform the DMT, our planned tests, or the backlog of tests that could develop if our facility is inoperable for even a short period of time may result in the loss of customers or harm to our reputation or relationships with scientific or clinical collaborators, and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our R&D work could be costly and time-consuming to repair or replace.

The San Diego area has recently experienced serious fires and power outages, and is considered to lie in an area with earthquake risk. If our sole laboratory facility is destroyed or otherwise rendered inoperable, we may have difficulty replacing or rebuilding this facility and there can be no assurance we could do so in a timely manner, on terms favorable to us or at all.

Additionally, a key component of our R&D process involves using biological samples as the basis for the development of our diagnostic tests. In some cases, these samples are difficult to obtain. If the parts of our laboratory facility where we store these biological samples were damaged or compromised, our ability to pursue our R&D projects, as well as our reputation, could be jeopardized. We carry insurance for damage to our property and the disruption of our business, but this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.

37

Further, if our CLIA-certified laboratory became inoperable or was destroyed, we may not be able to license or transfer our technology to another facility with the necessary state licensure and CLIA certification under which the DMT and our planned future tests could be performed. Even if we find a facility with such qualifications to perform the DMT, it may not be available to us on commercially reasonable terms. In addition, the use of a third-party laboratory to perform the DMT could affect their classification as LDTs and require us to seek FDA market authorization for the test prior to the completion of such a transfer.

On July 1, 2021, we entered into a lease with respect to a building also located in San Diego, California, which will serve as the Company’s new principal office and laboratory facility (the “New Lab”). We are in the process of building out the New Lab and expect to move our operations and equipment to the New Lab in the fourth quarter of 2022. Our current or new facilities and equipment could be harmed or rendered inoperable during the move and we may experience delays or difficulties in transitioning to our New Lab which could adversely affect our ability to perform our tests. We are required to notify our applicable regulatory and accrediting entities, CAP, CMS and applicable state agencies, of the move of our laboratory facility. We do not anticipate any impact to our certification or any licensing status as a result of these notifications. However, validation of our facility move will be subject to evaluation at the time of our next on-site inspection for the purposes of both our certification under CLIA and our California state laboratory licensure. All regulatory and accrediting entities will continue to have the right to inspect our laboratory facilities at any time.

If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenues or achieve and sustain profitability.

Our principal competition comes from mainstream clinical diagnostic methods, used by dermatologists for many years, which focus on visual tumor tissue analysis. It may be difficult to change the methods or behavior of dermatologists to incorporate the DMT and Smart Sticker into their practices in conjunction with, or instead of, tissue biopsies and analysis. In addition, companies offering capital equipment and kits or reagents to local dermatologists represent another source of potential competition. These tests are used directly by the dermatologists, which can facilitate adoption. We plan to focus our marketing and sales efforts on medical dermatologists rather than pathologists.

We also face competition from companies that offer device products or are conducting research to develop device products for analysis of pigmented lesions. In particular, MELA Sciences, Inc., used to market its MelaFind® device to dermatologists, but we believe they no longer actively market this product. Scibase AB and Verisante Technology, Inc. have devices under development and may market their medical products directly to dermatologists if and when they obtain FDA approval. In addition to these companies, our competitors also include other device companies selling photographic technologies, whole body photography services, dermatoscopes, or confocal microscopy, such as Fotofinder, Molemate, Canfield Scientific, MedX, and Caliber I.D. Many of these groups, in addition to operating R&D laboratories, are selling equipment and devices.

In addition to these device companies, Castle Biosciences, Inc. offers an expression test for melanoma that is used on surgical biopsy specimens. Castle Biosciences, Inc. could also try and market their test as a biopsy aid at the point-of-care. Genomic testing is a relatively new area of science, especially in dermatology and we cannot predict what tests others will develop that may compete with or provide results similar or superior to the results we are able to achieve with the tests we develop. There are a number of companies that are focused on the oncology diagnostic market and expression tests including Exact Sciences Corporation, Veracyte, Inc., Guardant Health and others.

Additionally, projects related to cancer diagnostics and particularly genomics have received increased government funding, both in the United States and internationally. As more information regarding cancer genomics becomes available to the public, we anticipate that more products aimed at analyzing pigmented lesions and identifying melanoma may be developed and that these products may compete with ours. In addition, competitors may develop their own versions of our current or planned tests in countries where we did not apply for patents or where our patents have not issued or have expired and may compete with us in those countries, including encouraging the use of their test by clinicians or patients in other countries. In addition, one or more competitors may seek to invalidate or render unenforceable any of our patents in a court of competent jurisdiction or at the United States Patent and Trademark Office (“USPTO”). If any such proceeding were to be successful and result in the invalidation or unenforceability of one or more patents in our intellectual property portfolio, we may be unable to prevent unlicensed third-party competition in the marketplace with respect to our current and planned future tests.

Some of our present and potential competitors have widespread brand recognition and substantially greater financial and technical resources and development, production, and marketing capabilities than we do. Others may develop lower-priced, less complex tests that payors and dermatologists could view as functionally equivalent to our current or planned tests, which could force us to lower the list price of our tests and impact our operating margins and ability to achieve and maintain profitability. In addition, technological innovations that result in the creation of enhanced diagnostic tools that are more sensitive or specific than ours may enable other clinical laboratories, hospitals, clinicians, or medical providers to provide specialized diagnostic tests similar to ours in a more patient-friendly, efficient, or cost-effective manner than is currently possible. If we cannot compete successfully against current or future competitors, we may be unable to increase or create market acceptance and sales of our current or planned tests, which could prevent us from increasing or sustaining our revenues or achieving or sustaining profitability.

38

Our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and distribution strategies and as new companies enter the market with new technologies and distribution strategies. We may not be able to compete effectively against these organizations. Our ability to compete successfully and to increase our market share is dependent upon our reputation for providing responsive, professional, and high-quality products and services and achieving strong customer satisfaction. Increased competition in the future could adversely affect our revenue, revenue growth rate, if any, margins and market share.

If we are unable to identify collaborators willing to work with us to conduct clinical utility studies, or the results of those studies do not demonstrate that a test provides clinically meaningful information and value, commercial adoption of the DMT may be slow, which would negatively impact our business.

We believe clinical utility studies will show how the DermTech Melanoma Test changes the decision-making of the dermatologist when making a surgical biopsy decision, particularly to avoid performing a surgical biopsy when the test is negative. Clinical utility studies also show the impact of the test results on patient care and management. Clinical utility studies are typically performed with collaborating dermatologists at medical centers and hospitals, analogous to a clinical trial, and generally result in peer-reviewed publications.

We are currently conducting a variety of clinical trials for the DermTech Melanoma Test and other non-melanoma tests with investigators at multiple sites in the U.S. We will need to conduct additional studies for these tests, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, including dermatologists and oncologists, adoption of our existing and planned tests could be impaired and we may not be able to obtain reimbursement for them.

We are undergoing a management transition.

Since the beginning of 2019, we have added a number of new executives. Our management reporting structure may continue to change. Such a management transition subjects us to a number of risks, including risks pertaining to coordination of responsibilities and tasks, creation of new management systems and processes, differences in management style, effects on corporate culture, and the need for transfer of historical knowledge. In addition, our operations will be adversely affected if our management does not work together harmoniously, efficiently allocate responsibilities between themselves, or implement and abide by effective controls.

The loss of key members of our executive management team could adversely affect our business.

Our success in implementing our business strategy depends largely on the skills, experience, and performance of key members of our executive management team and others in key management positions, including John Dobak, M.D., the Company’s Chief Executive Officer. The collective efforts of our executive management team are critical to us as we continue to develop our technologies, tests, and R&D and sales programs. As a result of the difficulty in locating qualified new management, the loss or incapacity of existing members of our executive management team could adversely affect our operations. If we were to lose one or more of these key employees, we could experience difficulties in finding qualified successors, competing effectively, developing our technologies, and implementing our business strategy. Each member of our executive management team has an employment agreement; however, the existence of an employment agreement does not guarantee retention of the members of our executive management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. We do not maintain “key person” life insurance on any of our employees.

In addition, we rely on collaborators, consultants, and advisors, including scientific, clinical and payor advisors, to assist us in formulating our commercialization strategy. Our collaborators, consultants, and advisors are generally employed by employers other than us and may have commitments under agreements with other entities that may limit their availability to us.

The loss of a key employee, the failure of a key employee to perform in his or her current position, or our inability to attract and retain skilled employees could result in our inability to continue to grow our business or to implement our business strategy.

Most of our management has limited experience in operating a public company.

Most of our management team has limited experience in the management of a publicly traded company. Our management team may not successfully or effectively manage our transition to operating as a public company that is subject to significant regulatory oversight and reporting obligations under federal securities laws. Our limited experience in dealing with the increasingly complex laws pertaining to public companies could be a significant disadvantage in that it is likely that an increasing amount of our time may be devoted to these activities which will result in less time being devoted to the management and growth of the Company. It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company which will increase our operating costs in future periods. 

39

There is a scarcity of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy.

The specialized nature of our industry results in an inherent scarcity of experienced personnel in the field. Our future success depends upon our ability to attract and retain highly skilled personnel, including scientific, technical, laboratory, sales, marketing, business, regulatory, and administrative personnel necessary to support our anticipated growth, develop our business, and perform certain contractual obligations. Given the scarcity of professionals with the scientific knowledge that we require and the competition for qualified personnel among life science businesses, we may not succeed in attracting or retaining the personnel we require to continue and grow our operations.

Our inability to attract, hire, and retain a sufficient number of qualified sales professionals would hamper our ability to launch and increase demand for the DMT, to expand geographically, and to successfully commercialize any other tests or products we may develop.

To succeed in selling the DMT, and any other tests or products that we are able to develop, we must expand our sales force in the United States and/or internationally by recruiting sales representatives with extensive experience in dermatology and close relationships with medical dermatologists, dermatopathologists, and other hospital personnel. To achieve our marketing and sales goals, we will need to substantially build our sales and commercial infrastructure, with which to date we have had little experience. Sales professionals with the necessary technical and business qualifications are in high demand, and there is a risk that we may be unable to attract, hire, and retain the number of sales professionals with the right qualifications, scientific backgrounds, and relationships with decision-makers and potential customers needed to achieve our sales goals. We expect to face competition from other companies in our industry, some of whom are much larger than us and who can pay greater compensation and benefits than we can, in seeking to attract and retain qualified sales and marketing employees. If we are unable to hire and retain qualified sales and marketing personnel, our business will suffer.

We may encounter manufacturing problems or delays that could result in lost revenue.

The Smart Stickers specimen collection kits we distribute are produced by a third-party supplier. This contractor assembles several components, including the key adhesive patch trifold, into a finished product, then labels, stores, and ships this finished product. The adhesive tape subcomponent of the Smart Sticker is provided by a single-source third party. This tape is assembled into the individual Smart Stickers by another third-party supplier.

We believe we have arranged for adequate manufacturing capacity for the Smart Sticker through our third-party manufacturer. If demand for the DMT and our planned future tests increases significantly, we will need to either expand manufacturing capabilities through our existing third-party manufacturers or outsource to other manufacturers. If our third-party or other manufacturers engaged by us fail to manufacture and deliver the Smart Sticker or certain reagents in a timely manner for any reason, including as a result of the ongoing COVID-19 pandemic or supply chain failures, or they are unable to fulfil our orders due to regulatory non-compliance or other quality-related issues, our relationships with our customers could be seriously harmed. We cannot assure you that manufacturing or quality control problems will not arise as we attempt to increase the production of the Smart Sticker or that we can increase our manufacturing capabilities and maintain quality control in a timely manner or at commercially reasonable costs. If we cannot have the Smart Sticker manufactured consistently on a timely basis because of these or other factors, it could have a significant negative impact on our ability to perform tests and generate revenues.

If we cannot support demand for the DMT and our planned future tests, including successfully managing the evolution of our technology and manufacturing platforms, our business could suffer.

As the DMT volume grows, we will need to increase the DMT testing capacity, implement automation, increase our scale and related processing, customer service, billing, collection, and systems process improvements, and expand our internal quality assurance program and technology to support testing on a larger scale. We will also need additional technicians, certified laboratory scientists, and other scientific and technical personnel to process these additional tests. Any increases in scale, related improvements and quality assurance may not be successfully implemented and appropriate personnel may not be available. As additional tests are commercialized, we may need to implement new equipment, systems, technology, controls and procedures, and hire personnel with different qualifications. Failure to implement necessary procedures or to hire the necessary personnel could result in a higher cost of processing or an inability to meet market demand. We cannot assure you that we will be able to perform tests on a timely basis at a level consistent with demand, that our efforts to scale our commercial operations will not negatively affect the quality of the DMT results or that we will respond successfully to the growing complexity of the DMT testing operations. If we encounter difficulty meeting market demand or quality standards for the DMT and our planned future tests, our reputation could be harmed and our future prospects and business could suffer, which may have a material adverse effect on our financial condition, results of operations, and cash flows.

If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.

The marketing, sale, and use of the DMT and our planned future diagnostic tests could lead to the filing of product liability claims against us if someone alleges that our tests failed to perform as designed. We may also be subject to liability for errors in the test results we provide to clinicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.

40

Although we believe that our existing product and professional liability insurance is adequate, our insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, result in the recall of tests, or cause current partners to terminate existing agreements and potential partners to seek other partners, any of which could impact our results of operations.

If we use biological and hazardous materials in a manner that causes injury or violates laws or regulations, we could be liable for damages or subject to enforcement actions.

Our activities currently require the controlled use of potentially harmful biological and hazardous materials and chemicals. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations may become significant and could have a material adverse effect on our financial condition, results of operations and cash flows. In the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits or approvals or be held liable for damages or penalized with fines.

We may acquire other businesses, form joint ventures, or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt, or cause us to incur significant expense.

As part of our business strategy, we may pursue acquisitions of businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our core technology and industry experience to expand our offerings or distribution. We have no experience with acquiring other companies and limited experience with forming strategic alliances and joint ventures. We may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, or joint venture.

To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.

International expansion of our business would expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.

Our business strategy contemplates possible international expansion, including partnering with academic and commercial testing laboratories, and introducing the DermTech Melanoma Test or other future products outside the United States and exporting the Smart Sticker. We are currently testing samples through a distributor in Canada. Doing business internationally involves a number of risks, including:

 

•

multiple, conflicting, and changing laws and regulations such as tax laws, export and import restrictions, privacy, data security and data transfer laws, employment laws, intellectual property laws, regulatory requirements, and other governmental approvals, permits and licenses;

 

•

failure by us or our distributors to obtain regulatory approvals for the sale or use of the DMT and our planned future tests in various countries, if required;

 

•

difficulties in managing foreign operations;

 

•

complexities associated with managing government payor systems, multiple payor-reimbursement regimes, or self-pay systems;

 

•

logistics and regulations associated with shipping blood samples, including infrastructure conditions and transportation delays;

 

•

limits on our ability to penetrate international markets if the DMT and our planned future diagnostic tests cannot be processed by an appropriately qualified local laboratory;

41

 

•

financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;  

 

•

reduced protection for intellectual property rights, or lack of them in certain jurisdictions, forcing more reliance on any trade secrets we may have, if such protection is available;

 

•

natural or man-made disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease (such as the ongoing COVID‑19 pandemic), boycotts, curtailment of trade, and other business restrictions; and

 

•

failure to comply with the Foreign Corrupt Practices Act, including its books and records provisions and its anti-bribery provisions, by maintaining accurate information and control over sales activities and distributors’ activities, as well as similar foreign anti-bribery and anti-corruption laws that may become applicable to our business.

Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our financial condition, results of operations, and cash flows.

Intrusions into the computer systems that we use could result in compromise of confidential information and our ability to continue operations (in event of a cyber-attack).

Despite the implementation of security measures, our technology or systems that we interface with, including the Internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, or similar problems. Any of these might result in confidential medical, business, or payment information, including as may be disclosed as part of a credit card transaction, or other information of other persons or of us, including employees, being revealed to unauthorized persons. Additional use of remote working technology as a result of the COVID‑19 pandemic may increase these vulnerabilities.

If the security measures with respect to our telemedicine solution or the telemedicine platforms of third-party vendors that offer one or more of our tests fail or are breached, it could result in unauthorized persons accessing sensitive customer or patient data (including PHI), a loss of or damage to our data, an inability to access data sources, or process data or provide our services to our customers. Such failures or breaches of our or our third-party vendors’ security measures, or our or our third-party vendors’ inability to effectively resolve such failures or breaches in a timely manner, could severely damage our reputation, adversely affect customer or investor confidence in us, and reduce the demand for our services from existing and potential customers. In addition, we could face litigation, damages for contract breach, monetary penalties, or regulatory actions for violation of applicable laws or regulations, and incur significant costs for remedial measures to prevent future occurrences and mitigate past violations.

We may have to comply with laws governing the use and disclosure of genetic testing information.

Many states have adopted laws governing genetic testing and the use and disclosure of genetic test results. These laws impose specific testing consent requirements and patient authorization requirements for the use and disclosure of test results, and some impose limits on the retention and secondary use of patient samples. Many of these laws are vaguely written and some are overly broad. We must analyze and ensure compliance with the genetic testing laws in the jurisdictions from which we obtain samples and may be required to expend significant capital and other resources to ensure ongoing compliance. Our failure to comply could interfere with our ability to operate and/or lead to sanctions, fines, or other regulatory actions as well as civil claims.

We depend on our information technology and telecommunications systems, and any failure of these systems could harm our business.

We depend on information technology and telecommunications systems for significant aspects of our operations, including technology and telecommunications systems for the operation of our telehealth platforms. In addition, our third-party billing and collections provider depends upon telecommunications and data systems provided by outside vendors and information we provide on a regular basis. These information technology and telecommunications systems support a variety of functions, including test processing, sample tracking, quality control, customer service and support, billing and reimbursement, R&D activities, and our general and administrative activities. Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses, and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems, or those used by our third-party service providers could prevent us from processing tests, providing test results to oncologists, pathologists, billing payors, processing reimbursement appeals, handling patient or clinician inquiries, conducting R&D activities, and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have a material effect on our business, financial condition, results of operations and cash flows.

42

We rely on FedEx and UPS for the distribution of our Smart Stickers to customers and to transport specimens back to our laboratory facility and, if FedEx or UPS incurs any damage to their facilities or is unable to deliver our products as needed, it could have a material adverse effect on our results of operations and business.

We rely on FedEx and UPS for the distribution of our Smart Stickers to customers, as well as to transport patient specimens back to our laboratory facility for processing. The FedEx or UPS facilities involved in such distribution may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, power outages, communications failure, infectious disease outbreaks, severe weather, or terrorism. Any material destruction to their facilities could adversely affect the ability of FedEx or UPS to meet the needs of our customers. In addition, a disruption or slowdown in the operations of FedEx or UPS, including as a result of the COVID‑19 pandemic and restrictions on business activity, damage to the facilities of FedEx or UPS or a strike by FedEx or UPS employees, could cause delays in our ability to fulfill customer orders and may cause orders to be cancelled, lost, or delivered late, our shipments to be returned, or receipt of shipments to be refused, any of which could adversely affect our business and our results of operations. If our shipping costs were to increase as a result of an increase by FedEx or UPS or as a result of obtaining a new third-party logistics company and if we are unable to pass on these higher costs to our customers, it could have a material adverse effect on our results of operations and business, financial condition, results of operations and cash flows.

We have identified material weaknesses in our internal control over financial reporting. If not remediated, our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

During the course of preparing the annual report 10-K for the year ended December 31, 2021, we identified material weaknesses in our internal control over financial reporting related to our assay revenue and accounts receivable process. Further detail surrounding these material weaknesses can be found in Item 9A—Controls and Procedures. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

As a result of these material weaknesses, our management concluded that our internal control over financial reporting was not effective as of December 31, 2021. This control deficiency resulted in no adjustment to our consolidated financial statements. We continue to evaluate steps to remediate these material weaknesses. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects.

 

Regulatory Risks Related to Our Business

Changes in health care law and policy may have a material adverse effect on our financial condition, results of operations, and cash flows.

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the “ACA”), became law. This law substantially changed the way health care is financed by both governmental and commercial payors, and continues to significantly impact our industry. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the United States Supreme Court upheld the ACA when it dismissed a legal challenge to the Act’s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although the new Democrat-led presidential administration has been taking steps to strengthen the ACA and the 117th Congress is not expected to have the same interest in repealing the law, in part due to the healthcare economic impacts of the ongoing COVID-19 pandemic on many subsets of the U.S. population. Future changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the U.S. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels and the number of insured individuals, may lead to delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. Further, if reimbursement levels are inadequate, our business and results of operations could be adversely affected.

In addition to the ACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while expanding individual health care benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for the DMT or the amounts of reimbursement available for the DMT from governmental or commercial payors. Any future changes to legal or regulatory requirements or new cost containment initiatives could have a materially adverse effect on our business, financial condition, results of operation, and cash flows.

Our business could be adversely impacted by our failure or the failure of clinicians to comply with the ICD-10-CM Code Set.

Compliance with ICD-10-CM is required for all claims with dates of service on or after October 1, 2015. We believe we have fully implemented ICD-10-CM. However, our failure to effectively implement and apply the new code set could adversely impact our business. In addition, if clinicians fail to provide appropriate codes for desired tests, we may not be reimbursed for tests we perform.

43

Billing for the DMT is complex, and we must dedicate substantial time and resources to the billing process to be paid for the DMT; long payment cycles of Medicare, Medicaid, and/or other commercial payors, or other payment delays, could hurt our cash flows and increase our need for working capital.

Billing for clinical laboratory testing services is complex, time-consuming, and expensive. Depending on the billing arrangement and applicable law, we will bill various payors, including Medicare, Medicaid, and commercial payors, all of which have different billing requirements. As required by law or contract, we routinely bill patients for co-payments, co-insurance, and deductible amounts owed. We may also face increased risks in our collection efforts, including potential write-offs of doubtful accounts, long collection cycles, and failure by third parties to properly process payment of claims in a timely manner that could adversely affect our business, results of operations, and financial condition. Several factors make the billing practice complex, including:

 

•

differences between the list price for the DMT and the reimbursement rates of payors;

 

•

compliance with complex federal regulations related to Medicare billing;

 

•

disputes among payors as to which party is responsible for payment and resistance by patients to cover any substantial amount of the payment;

 

•

differences in coverage among payors and effect of patient co-payments, co-insurance, or deductibles;

 

•

differences in information and billing requirements among payors;

 

•

incorrect or missing billing information; and

 

•

the resources required to manage the billing and claims appeals process.

Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payors also conduct external audits to evaluate payments and may seek refunds depending on the audit results, which adds further complexity to the billing process.

Failure to comply with these billing requirements may result in non-payment, refunds, exclusion from government healthcare programs, and civil or criminal liabilities, any of which may have a material adverse effect on our revenues and earnings. These billing complexities and the related uncertainties in obtaining reimbursement could negatively affect our cash flow and our ability to achieve profitability.

Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal, and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.

The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality, and proficiency testing requirements intended to ensure that testing services are accurate, reliable, and timely. Our clinical laboratory must be certified under CLIA in order for us to perform testing on human specimens. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs. Further, many commercial payors require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CLIA certification and/or CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens.

We have a current CLIA certificate of accreditation from the CMS to perform high-complexity testing and a state license issued by California Laboratory Field Services (“CA LFS”). To renew our CLIA certificate, we are subject to survey and inspection every two years. We hold a certificate of accreditation because we are accredited by CAP, which sets standards that are higher than the CLIA regulations. CAP is an independent, non-governmental organization of board-certified pathologists that accredits laboratories nationwide on a voluntary basis. Because CAP has deemed status with CLIA, our biennial inspections are performed by CAP. Sanctions for failure to comply with CAP or CLIA requirements may include suspension, revocation, or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant fines or criminal penalties. In addition, we are subject to regulation under state laws and regulations governing laboratory licensure. Two states, one of which is New York, have enacted state licensure laws that are more stringent than CLIA.

Failure to maintain CLIA certification, CAP accreditation, or required state licenses could have a material adverse effect on the sales of the DMT and the results of our operations. If we were to lose our CLIA certification, CAP accreditation or California laboratory license, whether as a result of a revocation, suspension, or limitation, we would no longer be able to offer the DMT, which would limit our revenues and harm our business. If we were to lose our license in any other state where we are required to hold a license, we would not be able to test specimens from those states. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries. We receive specimens from all 50 U.S. states and certain provinces in Canada. Some states maintain independent licensure, registration, or certification procedures that

44

apply to out-of-state laboratories with which we must maintain compliance in order to receive and test samples from those states. Maintaining compliance with the myriad state and foreign requirements is time consuming and resource intensive and failure to maintain compliance could result in sanctions.

Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business, financial condition, results of operations and cash flows. If the CLIA certificate of our laboratory is revoked, that could also impact our licensure or certification in the states or in foreign jurisdictions.

If the FDA were to begin requiring approval or clearance of the DMT and our planned future tests, or our proprietary specimen collection kit, we could incur substantial costs and time delays associated with meeting requirements for premarket clearance or approval.

The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the federal Food, Drug, and Cosmetic Act (“FDCA”), the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories’ tests, as medical devices, it has generally exercised enforcement discretion and was not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. In addition, in August 2020, HHS published a policy announcement that FDA must go through the formal notice-and-comment rulemaking process before requiring premarket review of LDTs rather than making such changes through guidance documents, compliance manuals, or other informal policy statements. In November 2021, the Biden Administration withdrew that HHS policy announcement and ostensibly restored FDA’s regulatory oversight of LDTs.

The FDA could, at any time, engage in notice-and-comment rulemaking with regard to this matter or Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs. For example, the VALID Act introduced in Congress in 2020 has bipartisan support and would codify into law the term “in vitro clinical test” in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs, as discussed further below.

We believe that our tests, as utilized in our clinical laboratory, are and would be LDTs. As a result, we believe that we are not required to obtain regulatory clearances or approvals from the FDA for our LDTs. In addition, we believe the Smart Sticker we provide for collection and transport of skin samples from a health care provider (or in our recently launched telemedicine option, from the patient directly) to our clinical laboratory is considered a Class I medical device subject to the FDA’s general device controls but exempt from premarket review. However, the FDA could assert the Smart Sticker is non-exempt or is a Class II device, which would subject it to premarket clearance or approval processes, which could be time-consuming and expensive. While we believe that we are currently in material compliance with applicable laws and regulations, we cannot assure you that the FDA, or other regulatory agencies, would agree with our determinations. Any determination by the government that we have violated the FDCA or any FDA regulations, or a public announcement that we are being investigated for possible violations of these laws, could adversely affect our business, prospects, results of operations, or financial condition.

Even though we commercialize the DMT as an LDT, the DMT may in the future become subject to more onerous regulation by the FDA. For example, Congress has recently been working on legislation to create an LDT and in vitro diagnostic regulatory framework that would be separate and distinct from the existing medical device regulatory framework. In March 2020, U.S. Representatives Diana DeGette (D-CO) and Dr. Larry Bucshon (R-IN) formally introduced the VALID Act in the House and an identical version of the bill was introduced in the U.S. Senate by Senators Michael Bennet (D-CO) and Richard Burr (R-NC). As anticipated from a discussion draft of the legislation released for stakeholder comment in December 2018, the VALID Act would codify into law the term “in vitro clinical test,” or IVCT, to create a new medical product category separate from medical devices, and bring all such products within the scope of FDA’s oversight. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. A substantively unchanged version of the VALID Act was re-introduced in both houses of Congress on June 24, 2021. It is unclear whether the VALID Act would be passed by Congress in its current form (if reintroduced in the 117th Congress) or signed into law by the President.

Whether as a result of new legislative authority or following formal notice-and-comment rulemaking, if the FDA begins to enforce its medical device requirements for LDTs, or if the FDA disagrees with our assessment that the DMT is an LDT, the DMT could for the first time be subject to a variety of regulatory requirements, including registration and listing, medical device reporting, and quality control, and we could be required to obtain premarket clearance or approval for our existing test and any new tests we may develop, which may force us to cease marketing the DMT until we obtain the required clearance or approval. The premarket review process for diagnostic products can be lengthy, expensive, time-consuming, and unpredictable. Further, obtaining premarket clearance or approval

45

may involve, among other things, successfully completing clinical trials. Clinical trials require significant time and cash resources and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. If we are required to obtain premarket clearance or approval and/or conduct premarket clinical trials, our development costs could significantly increase, our introduction of any new tests we may develop may be delayed, and sales of our existing test could be interrupted or stopped. Any of these outcomes could reduce our revenue or increase our costs and materially adversely affect our business, prospects, results of operations, or financial condition. Moreover, any cleared or approved labeling claims may not be consistent with our current claims or adequate to support continued adoption of and reimbursement for the DMT. For instance, if we are required by the FDA to label the DMT as investigational, or if labeling claims the FDA allows us to make are limited, order levels may decline and reimbursement may be adversely affected. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our existing test or from tests we may develop. Until the FDA finalizes its regulatory position regarding LDTs, or federal legislation is passed concerning regulation of LDTs, it is unknown how the FDA may regulate the DMT in the future and what testing and data may be required to support any required clearance or approval as a medical device or an “in vitro clinical test” (as that category is being defined in the as introduced VALID Act).

The requirement of premarket review could negatively affect our business until such review is completed and regulatory clearance or approval is obtained. The FDA could require that we stop selling the DMT pending premarket clearance or approval. The regulatory authorization process may involve, among other things, successfully completing additional clinical trials and making a premarket submission, such as a 510(k) notification, a premarket approval (“PMA”), application or a de novo device classification request to the FDA. If the FDA requires any form of premarket review, the DMT may not be cleared or approved on a timely basis, if at all. We may also decide voluntarily to pursue FDA premarket review and authorization of the DMT if we determine that doing so would be appropriate.

Additionally, should future regulatory actions affect any of the reagents we obtain from suppliers and use in conducting the DMT, our business could be adversely affected in the form of increased costs of testing or delays, limits, or prohibitions on the purchase of reagents necessary to perform DMT testing. While we qualify all materials used in our products in accordance with the regulations and guidelines of CLIA, the FDA could promulgate regulations or guidance documents impacting our ability to purchase materials necessary for the performance of the DMT. If any of the reagents we obtain from suppliers and use in the DMT are affected by future regulatory actions, our business could be adversely affected, including by increasing the cost of testing or delaying, limiting, or prohibiting the purchase of reagents necessary to perform testing with our products. The ongoing COVID-19 pandemic and high demand for laboratory testing services may also have an impact on the supply chain for such reagents and other supplies and cause an adverse effect on our business.

Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions by the FDA, including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.

If we were to be required by the FDA to conduct additional clinical studies or trials before continuing to offer tests that we have developed or may develop as LDTs, those studies or trials could lead to delays or failure to obtain necessary regulatory clearance or approval, which could cause significant delays in commercializing any future products and harm our ability to achieve profitability.

If the FDA decides to require that we obtain 510(k) clearance, premarket approvals pursuant to a PMA, or any other type of premarket authorization in order for us to commercialize our current Melanoma Test or our planned future tests, whether as a result of new legislative authority or following formal notice-and-comment rulemaking or based on its determination that any of those tests does not meet the definition of an LDT, we may be required to conduct additional clinical testing before submitting a regulatory submission for commercial marketing authorization. In addition, as part of our long-term strategy we may plan to seek FDA clearance or approval for certain genomic tests in order to permit them to be offered by other clinical laboratories in addition to our own; however, we would need to conduct additional clinical validation activities on the DMT before we could submit an application for FDA approval or clearance. Clinical trials must be conducted in compliance with FDA regulations or the FDA may take certain enforcement actions or reject the data. We believe it would likely take two years or more to conduct the clinical studies and trials necessary to obtain approval from the FDA to commercially launch the DMT and our planned future tests outside of our clinical laboratory.

Even if clinical trials are completed as planned, we cannot be certain that their results would be able to support the DMT claims or that the FDA or foreign authorities will agree with our conclusions regarding the results of our clinical trials. Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior clinical trials and studies. If we are required to conduct clinical trials to support a premarket submission to the FDA, whether using prospectively acquired samples or archival samples, delays in the commencement or completion of clinical testing could significantly increase the DMT development costs and delay commercialization. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. Moreover, the clinical trial process may fail to demonstrate that the DMT and our planned future tests are effective for the proposed indications for use, which could cause us to abandon a test candidate and may delay development of other tests.

46

We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which would increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials properly. If these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness, or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or approvals as a result of the failure to perform by third parties, our R&D costs would increase, and we may not be able to obtain regulatory clearance or approval for the DMT and our planned future tests, if needed. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market the DMT outside of the LDT context or to achieve profitability.

We are subject to numerous federal, local and foreign laws and regulations; complying with laws pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and a material adverse effect to our business and operations.

Our operations are subject to extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among other things:

 

•

CLIA, which requires that laboratories obtain certification from the federal government, and state licensure laws;

 

•

FDA laws and regulations;

 

•

HIPAA, which imposes comprehensive federal standards with respect to the privacy and security of protected health information (“PHI”), and requirements for the use of certain standardized electronic transactions; amendments to HIPAA under HITECH, which strengthened and expanded HIPAA privacy and security compliance requirements, increased penalties for violators, extended enforcement authority to state attorneys general and imposed requirements for breach notification;

 

•

state laws regulating genetic testing and protecting the privacy of genetic test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;

 

•

the federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;

 

•

the Eliminating Kickbacks in Recovery Act, which is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory;

 

•

the federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;

 

•

the CMP Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;

 

•

other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any commercial payor, including private insurers;

 

•

PAMA, which requires applicable laboratories to report commercial payor data in a timely and accurate manner every three years (and in some cases annually);

 

•

state laws that impose reporting and other compliance-related requirements; and

 

•

similar foreign laws and regulations that apply to us in the countries in which we operate.

As a clinical laboratory, our business practices may face heightened scrutiny from government enforcement agencies such as the Department of Justice, the OIG and CMS. The OIG has issued fraud alerts in recent years that identify certain arrangements between clinical laboratories and referring physicians as implicating the Anti-Kickback Statute. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from the patient. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the federal self-referral prohibition, commonly known as the Stark Law or the Physician Self-Referral Law, unless the arrangement meets all criteria of an applicable exception. The government has actively enforced these laws against clinical laboratories in recent years.

47

These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. Our failure to comply could lead to significant civil or criminal penalties, exclusion from participation in state and federal health care programs, individual imprisonment, disgorgement of profits, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law, curtailment or restructuring of our operations, or prohibitions or restrictions on our laboratories’ ability to provide or receive payment for our services, any of which could adversely affect our ability to operate our business and pursue our strategy. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private commercial payors.

The growth of our business and our expansion outside of the United States may increase the potential of violating similar foreign laws or our internal policies and procedures. The risk of us being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Any of the foregoing consequences could seriously harm our business and our financial results.

We must comply with complex and overlapping laws protecting the privacy and security of health information and personal data.

There are a number of state, federal and international laws protecting the privacy and security of health information and personal data. Under the administrative simplification provisions of HIPAA, the HHS has issued regulations which establish uniform standards governing the conduct of certain electronic health care transactions and protecting the privacy and security of PHI used or disclosed by health care providers and other covered entities.

The privacy regulations regulate the use and disclosure of PHI by health care providers engaging in certain electronic transactions or “standard transactions.” They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered health care provider, including the right to access or amend certain records containing PHI or to request restrictions on the use or disclosure of PHI. The HIPAA security regulations establish administrative, physical, and technical standards for maintaining the integrity and availability of PHI in electronic form. These standards apply to covered health care providers and also to “business associates” or third parties providing services involving the use or disclosure of PHI. The HIPAA privacy and security regulations establish a uniform federal “floor” and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI. For example, California recently enacted the CCPA, which became effective January 1, 2020. The CCPA establishes a new privacy framework for covered businesses in the State of California, by creating an expanded definition of personal information, establishing new data privacy rights for consumers imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. In November of 2020, California voters approved the California Privacy Rights Act (“CPRA”), which will take full effect in January of 2023. The CPRA modifies the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply, and additional potential for harm and liability for failure to comply. In addition, both Virginia and Colorado enacted new data privacy laws which will take effect in 2023 that have similarities to the CCPA and CPRA, but also have significant differences, creating compliance challenges across different jurisdictions. As a result, we may be required to comply with both HIPAA privacy regulations and varying state privacy and security laws.

Moreover, HITECH, among other things, established certain health information security breach notification requirements. In the event of a breach of unsecured PHI, a covered entity must notify each individual whose PHI is breached, federal regulators and in some cases, must publicize the breach in local or national media. Breaches affecting 500 individuals or more are publicized by federal regulators who publicly identify the breaching entity, the circumstances of the breach and the number of individuals affected.

These laws contain significant fines and other penalties for wrongful use or disclosure of PHI. Given the complexity of HIPAA and HITECH and their overlap with state privacy and security laws, and the fact that these laws are rapidly evolving and are subject to changing and potentially conflicting interpretation, our ability to comply with the HIPAA, HITECH and state privacy requirements is uncertain and the costs of compliance are significant. Adding to the complexity is that our operations are evolving and the requirements of these laws will apply differently depending on such things as whether or not we bill electronically for our services, or provide services involving the use or disclosure of PHI and incur compliance obligations as a business associate. The costs of complying with any changes to the HIPAA, HITECH and state privacy restrictions may have a negative impact on our operations. Noncompliance could subject us to criminal penalties, civil sanctions and significant monetary penalties as well as reputational damage.

We also are required to collect and maintain personal information about our employees, and we collect information about customers as part of some of our marketing programs, as well as receive and transfer certain payment information, to accept payments from our customers, including credit card information. Most states have adopted laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure

48

ongoing protection of personal information. Activities outside of the United States implicate local and national data protection standards, impose additional compliance requirements, and generate additional risks of enforcement for non-compliance. The collection and use of such information may be subject to contractual obligations as well. If the security and information systems that we or our outsourced third-party providers use to store or process such information are compromised or if we, or such third parties, otherwise fail to comply with these laws, regulations, and contractual obligations, we could face litigation and the imposition of penalties that could adversely affect our financial performance.

We must comply with all applicable privacy and data security laws in order to operate our business and may be required to expend significant capital and other resources to ensure ongoing compliance, to protect against security breaches and hackers or to alleviate problems caused by such breaches. Breaches of health information and/or personal data may be extremely expensive to remediate, may prompt federal or state investigation, fines, civil and/or criminal sanctions and significant reputational damage.

Our services present the potential for embezzlement, identity theft or other similar illegal behavior by our employees, consultants, service providers or commercial partners.

Our operations involve the use and disclosure of personal and business information that could be used to impersonate third parties or otherwise gain access to their data or funds. If any of our employees, consultants, service providers or commercial partners takes, converts or misuses these funds or data, we could be liable for any resulting damages, which could harm our financial condition and damage our business reputation.

Clinical research is heavily regulated and failure to comply with human subject protection regulations may disrupt our research program leading to significant expense, regulatory enforcement, private lawsuits, and reputational damage.

Clinical research is subject to federal, state, and, for studies conducted outside of the United States, international regulation. At the federal level, HHS imposes regulations for the protection of human subjects and requirements such as initial and ongoing institutional review board review, informed consent requirements, adverse event reporting and other protections to minimize the risk and maximize the benefit to research participants. Clinical studies done under an investigational device exemption for purposes of an anticipated FDA premarket submission are subject to an additional layer of human subject protection regulations. Many states also impose human subject protection laws that mirror or in some cases exceed federal requirements. HIPAA and other privacy laws also regulate the use and disclosure of PHI in connection with research activities. Research conducted overseas is subject to a variety of national protections such as mandatory ethics committee review, as well as laws regulating the use, disclosure and cross-border transfer of personal data. The costs of compliance with these laws may be significant and compliance with regulatory requirements may result in delay. Noncompliance may disrupt our research and result in data that is unacceptable to regulatory authorities, data lock, or other sanctions that may significantly disrupt our operations.

We could be adversely affected by alleged violations of the Federal Trade Commission Act or other truth-in-advertising and consumer protection laws.

Our advertising for laboratory services and tests is subject to federal truth-in-advertising laws enforced by the FTC as well as comparable state consumer protection laws. Under the Federal Trade Commission Act, the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution. Our direct-to-consumer advertising and social media presence, as well as our physician-directed advertising, are subject to these federal and state truth-in-advertising laws. Any actual or perceived non-compliance with those laws could lead to an investigation by the FTC or a comparable state agency, or could lead to allegations of misleading advertising by private plaintiffs. Any such action against us would disrupt our business operations, cause damage to our reputation, and result in a material adverse effects on our business, financial condition, results of operation, and cash flows.

Medical product manufacturers’ use of social media platforms presents new risks.

We believe that our customer base and potential patient populations are active on social media and we have begun engaging through those platforms to elevate our national marketing presence. Social media practices in the pharmaceutical, biotechnology and medical device industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, one of our products, which could result in reporting obligations or the need for us to conduct an investigation. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us or our products on any social networking website. If any of these events were to occur or we otherwise fail to comply with any applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.

49

Intellectual Property Risks Related to Our Business

Our collaborators may assert ownership or commercial rights to inventions we develop from our use of the biological materials which they provide to us, or otherwise arising from the collaboration.

We collaborate with several institutions, clinicians, and researchers in scientific matters. Also, we rely on numerous third parties to provide us with adhesive patch samples and biological materials that we use to develop tests. If we cannot successfully negotiate sufficient ownership, licensing, and/or commercial rights to any inventions that result from our use of a third-party collaborator’s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator’s samples, or data developed in a collaborator’s study, our ability to capitalize on the market potential of these inventions or developments may be limited or precluded altogether.

If we are unable to maintain intellectual property protection, our competitive position could be harmed.

Our ability to protect our discoveries and technologies affects our ability to compete and to achieve profitability. Currently, we rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, confidentiality or non-disclosure agreements, material transfer agreements, licenses, consulting agreements, work-for-hire agreements, and invention assignment agreements to protect our intellectual property rights. We also maintain certain company know-how, trade secrets, and technological innovations designed to provide us with a competitive advantage in the marketplace as trade secrets. As of February 18, 2022, we own seven issued or allowed U.S. patents, 12 pending U.S. patent applications (four provisional and eight non-provisional), several corresponding foreign counterpart patents and applications, and two PCT applications, and four design patent applications, relevant to DMT testing methodology and expression profiles. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if patents are issued, third parties may independently develop similar or competing technology that avoids our patents. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information as well as the misuse of our patents and other intellectual property, particularly in foreign countries where we have not filed for patent protection.

From time-to-time the U.S. Supreme Court, other federal courts, or the USPTO, may change the standards of patentability, and any such changes could have a negative impact on our business. For instance, in 2008, the Court of Appeals for the Federal Circuit issued a decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical transformation. The U.S. Supreme Court later reversed that decision in Bilski v. Kappos, 561 U.S. 593 (2010), finding that the “machine-or-transformation” test is not the only test for determining patent eligibility. The Court, however, declined to specify how and when processes are patentable. In 2012, in the case Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 55 (2012), the U.S. Supreme Court reversed the Federal Circuit’s application of Bilski and invalidated a patent focused on a diagnostic process because the patent claim embodied a law of nature.

In 2013, in Association for Molecular Pathology v. Myriad Genetics, the U.S. Supreme Court unanimously ruled that, “[a] naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,” thereby invalidating Myriad Genetics’ patents on the BRCA1 and BRCA2 breast cancer genes. However, the U.S. Supreme Court also held that manipulation of a gene to create something not found in nature, such as a strand of synthetically-produced complementary DNA (“cDNA”) could still be eligible for patent protection. The U.S. Supreme Court noted that method patents, which concern technical procedures for carrying out a certain process, are not affected by the ruling.

More recently, the Federal Circuit has ruled on several patent cases—such as Univ. of Utah Research Found. v. Ambry Genetics Corp., 774 F.3d 755 (Fed. Cir. 2014), Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), Genetic Tech. Ltd. v. Merial LLC, 818 F.3d 1369 (Fed. Cir. 2016), and Cleveland Clinic Found. v. True Health Diagnostics, 859 F.3d 1352 (Fed. Cir. 2017)—that some diagnostic method claims are patent ineligible. These decisions have narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. Some aspects of our technology involve processes that may be subject to this evolving standard and we cannot guarantee that any of our pending process claims will be patentable as a result of such evolving standards. In addition, this combination of decisions has created uncertainty as to the value of certain issued patents, in particular patents in the molecular biology analysis and diagnostic space. Moreover, there is additional uncertainty around the evolving standard in light of the USPTO Revised Patent Subject Matter Eligibility Guidance issued in Jan. 2019.

It should also be noted that in 2010, the Secretary’s Advisory Committee on Genetics, Health and Society voted to approve a report entitled “Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests.” That report defines “patent claims on genes” broadly to include claims to isolated nucleic acid molecules as well as methods of detecting particular sequences or mutations. The report also contains six recommendations, including the creation of an exemption from liability for infringement of patent claims on genes for anyone making, using, ordering, offering for sale, or selling a test developed under the patent for patient care purposes, or for anyone using the patent-protected genes in the pursuit of research. The report also recommended that HHS should explore, identify, and implement mechanisms that will encourage more voluntary adherence to current guidelines that promote nonexclusive in-licensing of diagnostic genetic and genomic technologies. It is unclear whether HHS will act upon these recommendations, or if the recommendations would result in a change in law or process that could negatively impact our patent portfolio or future R&D. If acted upon, implementation of such provisions could have a material negative impact on our business.

50

We may face intellectual property infringement claims that could be time-consuming and costly to defend, and could result in the loss of significant rights, the implementation of an injunction, and the assessment of treble damages.

From time-to-time we may face intellectual property infringement or misappropriation claims from third parties. Some of these claims may lead to litigation. The outcome of any such litigation can never be guaranteed, and an adverse outcome could affect us negatively. For example, were a third party to succeed on an infringement claim against us, we may be required to pay substantial damages, including treble damages if such infringement were found to be willful. In addition, we could face an injunction barring us from conducting the allegedly infringing activity, including an order preventing us from offering the DMT and future planned tests in the marketplace. The outcome of the litigation could require us to enter into a license agreement which may not be pursuant to acceptable or commercially reasonable or practical terms or which may not be available at all.

It is also possible that an adverse finding of infringement against us may require us to dedicate substantial resources and time in developing non-infringing alternatives, which may or may not be possible. In the case of diagnostic tests, we would also need to include non-infringing technologies, which would require us to re-validate the test. Any such re-validation, in addition to being costly and time-consuming, may be unsuccessful. Finally, we may initiate claims to assert or defend our own intellectual property against third parties. Any intellectual property litigation, irrespective of whether we are the plaintiff or the defendant, and regardless of the outcome, is expensive and time-consuming, and could divert and distract our management’s attention from our business and negatively affect our operating results or financial condition.

Tax Risks Related to Our Business

Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.

Our U.S federal net operating loss (“NOL”), carryforwards, may be unavailable to offset future taxable income because of restrictions under U.S. tax law. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law, and therefore could expire unused. Under tax legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”), as modified by the Coronavirus Aid, Relief, and Economic Security Act (“CARES”) Act, our U.S. federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely and NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, under the TCJA, as modified by the CARES Act, for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in taxable years beginning after December 31, 2017 is limited to 80% of current year taxable income. States do and do not conform to the TCJA, as modified by the CARES Act, dependent on the applicable jurisdiction.

In addition, under Section 382 of the Internal Revenue Code of 1986, as amended (the “IRC”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize tax attribute carryforwards to offset future taxable income. Our existing NOL and R&D tax credit carryforwards may be subject to limitations arising from previous ownership changes, and if we underwent an ownership change in connection with or after the Business Combination, our ability to utilize NOLs could be further limited by Section 382 of the IRC. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the IRC. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing and any future NOLs could expire or otherwise be unavailable to offset future income tax liabilities. We have not conducted a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since inception due to the significant complexity and cost associated with such a study. In addition, we have not performed an R&D tax credit study to confirm the accuracy of applicable carryforwards and completion of such a study may reduce carryforward available to offset future taxable income.

U.S. federal income tax reform could adversely affect our business and financial condition.

On December 22, 2017, President Trump signed into law the TCJA that significantly reforms the IRC. The TCJA, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation on the deductibility of interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for NOLs generated in taxable years beginning after December 31, 2017 to 80% of current year taxable income, elimination of NOL carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, reduction or elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. The CARES Act modifies certain provisions of the TCJA. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021, and increases the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020. Notwithstanding the reduction in the corporate income tax rate, the overall future impact of the TCJA, as modified by the CARES Act, and any federal and state tax reform, enacted in future years, is uncertain and our business and our financial condition could be adversely affected. The impact of the TCJA, as modified by the CARES Act, on holders of our common stock is also uncertain and could be adverse. You are urged to consult with your legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock.

51

Risks Related to Our Securities

There is no assurance that we will continue satisfying the listing requirements of the Nasdaq Capital Market.

Our common stock is listed on the Nasdaq Capital Market. To maintain our listing we are required to satisfy continued listing requirements. There can be no assurance we will continue satisfying such continued listing requirements, which include that the closing bid price of our common stock be at least $1 per share, that we have at least 300 round lot holders and at least 500,000 publicly held shares, that the market value of our publicly held securities be at least $1 million, and that we meet one of these standards: stockholders’ equity of at least $2.5 million; market value of listed securities of at least $35 million; or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. The delisting of our common stock for whatever reason could, among other things, substantially impair our ability to raise additional capital; result in the loss of interest from institutional investors, the loss of confidence in our company by investors and employees, and in fewer financing, strategic and business development opportunities; and result in potential breaches of agreements under which we made representations or covenants relating to our compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of our management’s time and attention and could have a material adverse effect on our financial condition, business and results of operations. In addition, the delisting of our common stock for whatever reason may materially impair our stockholders’ ability to buy and sell shares of our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. 

Future issuances of equity securities may dilute the interests of our security holders and reduce the price of our securities.

Any future issuance of our equity securities could dilute the interests of our then existing security holders and could substantially decrease the trading price of our securities. We may issue equity or equity-linked securities for a number of reasons, including to finance our operations and business strategy, to adjust our ratio of debt to equity, to satisfy our obligations upon the exercise of then-outstanding options or other equity-linked securities, if any, or for other reasons. We currently have the ability to offer and sell up to $5.5 million of common stock, preferred stock, warrants, senior debt, subordinated debt, rights or units under an effective universal shelf registration statement. Sales of substantial amounts of shares of our common stock or other securities under our current universal shelf registration statement could lower the market price of our common stock and impair our ability to raise capital.

We may amend the terms of our publicly traded warrants currently trading on the Pink Market under the ticker symbol “DMTKW,” or the publicly traded warrants, in a manner that may be adverse to holders with the approval by the holders of a majority of the then outstanding publicly traded warrants, and as a result, the exercise price of the publicly traded warrants could be increased, the exercise period could be shortened and the number of shares purchasable upon exercise of a publicly traded warrant could be decreased, all without your approval.

Our publicly traded warrants are subject to the Warrant Agreement. The Warrant Agreement provides that the terms of the publicly traded warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of a majority of the then outstanding publicly traded warrants to make any change that adversely affects the interests of the registered holders. Accordingly, we may amend the terms of the publicly traded warrants in a manner adverse to a holder if holders of a majority of the then outstanding publicly traded warrants approve of such amendment. Although our ability to amend the terms of the publicly traded warrants with the consent of a majority of the then outstanding publicly traded warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the publicly traded warrants, shorten the exercise period or decrease the number of shares of common stock purchasable upon exercise of the publicly traded warrants.

We may redeem your unexpired publicly traded warrants prior to their exercise at a time that is disadvantageous to you, thereby making your publicly traded warrants worthless.

We have the ability to redeem our outstanding publicly traded warrants at any time prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of our common stock equals or exceeds $36.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date we give notice of redemption. To the extent that the publicly traded warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding publicly traded warrants could force you (i) to exercise your publicly traded warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) to sell your publicly traded warrants at the then-current market price when you might otherwise wish to hold your publicly traded warrants or (iii) to accept the nominal redemption price which, at the time the outstanding publicly traded warrants are called for redemption, is likely to be substantially less than the market value of your publicly traded warrants.

Because we have no current plans to pay cash dividends on our shares for the foreseeable future, you may not receive any return on investment unless you sell your shares for a price greater than that which you paid for it.

We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our shares unless you sell your shares of the Company for a price greater than that which you paid for them.

52

If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.

The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. If no securities or industry analysts publish reports about us, our share price and trading volume would likely be negatively impacted. If any of the analysts who may cover us change their recommendation regarding our shares of common stock adversely, or provide more favorable relative recommendations about our competitors, the price of our shares of common stock would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for you to change our management.

Provisions in our Amended and Restated Certificate of Incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control that our stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our board of directors. These provisions include:

 

•

a classified board of directors so that not all directors are elected at one time;

 

•

a prohibition on stockholder action through written consent;

 

•

no cumulative voting in the election of directors;

 

•

the exclusive right of our board of directors to elect a director to fill a vacancy however created, whether by the expansion of our board of directors, the resignation, death or removal of a director, or otherwise;

 

•

a requirement that special meetings of our stockholders be called only by our board of directors, the chairman of our board of directors, the chief executive officer or, in the absence of a chief executive officer, the president;

 

•

an advance notice requirement for stockholder proposals and nominations;

 

•

the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine; and

 

•

a requirement of approval of at least 75% of all outstanding shares of our capital stock entitled to vote to amend any bylaws by stockholder action, or to amend specific provisions of our certificate of incorporation.

In addition, Delaware law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, together with his, her or its affiliates, owns or within the last three years has owned 15% or more of the company’s voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Delaware law may discourage, delay or prevent a change in control of the Company.

In addition, our Amended and Restated Certificate of Incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum (the “Delaware Chancery forum provision”), for: any derivative action or proceeding brought on our behalf; any action or proceeding asserting a breach of fiduciary duty owed to us, our stockholders, or any of our current or former directors, officers or other employees; any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to the Delaware General Corporation Law, our Amended and Restated Certificate of Incorporation, or our bylaws; any action or proceeding to interpret, apply, enforce or determine the validity of our Amended and Restated Certificate of Incorporation or our Bylaws; any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction.

The Delaware Chancery forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the exclusive forum provisions contained in our Amended and Restated Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.

Further, on March 18, 2020, the Delaware Supreme Court ruled that provisions of a Delaware corporation’s certificate of incorporation that designate a federal forum for securities claims brought pursuant to the Securities Act, or federal forum provisions, are valid and enforceable under Delaware law (the “March 2020 Ruling”). Consistent with the March 2020 Ruling, on April 12, 2020, our board of directors approved a Certificate of Amendment to our Amended and Restated Certificate of Incorporation (the “2020 Certificate of Amendment”), which was approved by our stockholders at our 2020 annual meeting of stockholders on May 26, 2020. We filed the 2020 Certificate of Amendment with the Delaware Secretary of State on May 27, 2020. The 2020 Certificate of

53

Amendment added a federal forum provision to our Amended and Restated Certificate of Incorporation, which now provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Various U.S. Supreme Court cases offer support for the argument that federal forum provisions do not violate federal policy. However, the March 2020 Ruling applies only to claims brought in Delaware state courts, and it is not binding on any other state court or the federal courts. Therefore, we are unable to predict whether a state court in any other state or a federal court would enforce a federal forum provision such as the one set forth in the 2020 Certificate of Amendment.

We adopted the 2020 Certificate of Amendment to reduce the costs and inefficiencies to the Company that would result from a Securities Act claim being litigated in both state and federal courts, which was permissible under our Amended and Restated Certificate of Incorporation before the 2020 Certificate of Amendment was adopted. Such simultaneous state and federal litigation could also result in inconsistent judgments and rulings, and the adoption of the 2020 Certificate of Amendment could reduce this risk. However, the federal forum provision set forth in the 2020 Certificate of Amendment may discourage Securities Act claims or limit a stockholder’s ability to submit claims in a judicial forum that the stockholder finds favorable, and may result in additional costs for a stockholder seeking to bring such a claim.

Provisions in our charter and other provisions of Delaware law could limit the price that investors are willing to pay in the future for shares of our common stock.

We expect the price of our common stock may be volatile and may fluctuate substantially.

The stock market in general and, especially in recent history, the market for life sciences companies in particular, have experienced extreme volatility that has often been unrelated to companies’ operating performance. During the 12-month period ending December 31, 2021, the closing prices of our common stock as reported on the Nasdaq Capital Market were in the range of $15.79 to $79.76 per share. In addition, the stock market in general has recently experienced relatively large price and volume fluctuations in response to the COVID-19 pandemic, the macroeconomic environment, and geopolitical concerns. The market price for our common stock may be influenced by many factors, including:

 

•

the results of our efforts to develop and commercialize the DMT;

 

•

actual or anticipated results from, and any delays in, any future clinical trials, as well as results of regulatory reviews relating to the approval of any test candidates we may choose to develop that require such approval;

 

•

commencement or termination of any collaboration or licensing arrangement;

 

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technology;

 

•

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures and capital commitments;

 

•

additions or departures of key scientific or management personnel;

 

•

variations in our financial results or those of companies that are perceived to be similar to us;

 

•

new products, product candidates or new uses for existing products introduced or announced by our competitors, and the timing of these introductions or announcements;

 

•

results of clinical trials of product candidates of our competitors;

 

•

general economic and market conditions and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;

 

•

regulatory or legal developments in the United States and other countries;

 

•

changes in the structure of healthcare payment systems;

 

•

conditions or trends in the life sciences industry;

 

•

actual or anticipated changes in earnings estimates, development timelines or recommendations by securities analysts;

 

•

announcement or expectation of additional financing efforts;

 

•

sales of common stock by us or our stockholders in the future, as well as the overall trading volume of our common stock; and

 

•

other factors described in this “Risk Factors” section.

54

 

In the past, following periods of volatility in companies’ stock prices, securities class-action litigation has often been instituted against such companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business and financial condition.

55

Item 1B.  Unresolved Staff Comments.

None.

Item 2.  Properties.

We currently occupy approximately 28,655 square feet of leased space in La Jolla, California and have leased approximately 95,997 square feet of space in San Diego, California. See Note 6 in the Notes to Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for further discussion surrounding our leased facilities.

We believe these facilities are adequate to meet our current and reasonably foreseeable requirements. We believe that we would be able to obtain additional space, if required, on commercially reasonable terms.

We may be subject to legal proceedings and claims arising in the ordinary course of business. We do not believe that the outcome of any of these matters will have a material effect on our consolidated financial position, results of operations or cash flows.

Item 4.  Mine Safety Disclosures.

Not applicable.

 

 

56

 

PART II

Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information.

Our common stock is currently listed on the Nasdaq Capital Market under the symbol “DMTK”.

Holders of Our Common Stock

As of March 8, 2022, there were 29,850,730 shares of our common stock outstanding held by approximately 172 holders of record.

Recent Sales of Unregistered Securities

Between January 4, 2021 through March 27, 2021, we issued 54,169 shares of common stock pursuant to the exercise of warrants that were issued in connection with DermTech Operations’ Series C Convertible Preferred Stock financing and assumed by us in connection with the Business Combination. These warrants had an exercise price of $9.54 per share and were exercised for an aggregate exercise price of $521,065.

On March 23, 2021, we issued 2,000 shares of common stock pursuant to the exercise of management warrants that were issued by DermTech Operations and assumed by us in connection with the Business Combination. These warrants had an exercise price of $1.08 per share and were exercised for an aggregate exercise price of $2,160.

Between January 5, 2021 and April 8, 2021, we issued 5,852 shares of common stock pursuant to the exercise of placement agent warrants. These warrants had exercise prices of $8.68 or $9.54 per share and were exercised for an aggregate exercise price of $52,822.

Between January 3, 2021 and February 12, 2021, we issued an aggregate of 11,957 shares of common stock upon the cashless exercise of placement agent warrants. The holder who elected to exercise the placement agent warrants on a cashless basis paid the exercise price by surrendering the warrants for that number of shares equal to the quotient obtained by dividing (x) the product of the number of shares underlying the warrants, multiplied by the difference between the exercise price of the warrants ($8.68 or $9.54) and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for purposes of the placement agent warrants is the closing bid price of our common stock or the closing price quoted on the national securities exchange on which our common stock is listed, as applicable, on the first trading day preceding the date of determination of the fair market value.

The issuances of the above shares were deemed to be exempt from registration under the Securities Act in reliance on Sections 3(a)(9) or 4(a)(2) of the Securities Act. The recipients of the shares represented their intention to acquire the securities for investment only and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends were affixed to the securities.

Item 6.  [Reserved]

 

57

 

Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following Discussion and Analysis of Financial Condition and Results of Operations of DermTech, Inc. (together with its subsidiaries, “DermTech,” “we,” “us,” “our” or the “Company”) should be read in conjunction with the consolidated financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. For a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

Overview

We are a molecular diagnostic company developing and marketing novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Our technology provides a highly accurate alternative to surgical biopsy, minimizing patient discomfort, scarring, and risk of infection, while maximizing convenience. Our scalable genomics assays have been designed to work with our Smart Sticker that are used to non-invasively collect a tissue sample for analysis.

We are initially commercializing tests that will address unmet needs in the diagnostic pathway of pigmented skin lesions, such as moles or dark colored skin spots. The DMT facilitates the clinical assessment of pigmented skin lesions for melanoma. We have initially marketed this test directly to a concentrated group of dermatology clinicians and are currently expanding marketing efforts to a broader group of dermatology clinicians. The simple application of our Smart Sticker to collect samples non-invasively may allow us to eventually market the DMT to primary care physicians more broadly, beyond integrated primary care networks, and expand our efforts through telemedicine channels. We process our tests in our high complexity molecular laboratory that is certified under CLIA, CAP accredited and New York licensed. We also provide laboratory services to several pharmaceutical companies that access our technology on a contract basis within their clinical trials or other studies to better advance new drugs.

Events, Trends and Uncertainties

The DMT (without the add-on test for TERT) became eligible for Medicare reimbursement on February 10, 2020. Each reference to the DMT in this paragraph refers only to the DMT without the add-on test for TERT. In late October 2019, the AMA provided us with a PLA Code. Pricing of $760 for the PLA Code was published on December 24, 2019 as part of the CLFS for 2020. The Final LCD expanded the coverage proposal in the Draft LCD from one to two tests per date of service and it allows clinicians to order the DMT if they have sufficient skill and experience to decide whether a pigmented lesion should be biopsied. Our local Medicare Administrative Contractor, Noridian has issued its own Local Coverage Decision (“Noridian’s LCD”) announcing coverage of the DMT. Even though the effective date of Noridian’s LCD was June 7, 2020, Noridian began reimbursing us for the DMT as of February 10, 2020. With Medicare coverage granted, we have the opportunity to approach commercial payors, and as a result, we believe that the DMT may generate significant revenues in 2022 and 2023. No LCD currently covers the optional add-on test for TERT available to those ordering the DMT.

Despite the grant of Medicare coverage for the DMT (without the add-on test for TERT), uncertainty surrounds commercial payor reimbursement, including governmental and commercial payors, of any test incorporating new technology, including tests developed using our technologies. Because each payor generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse our tests, seeking payor approvals is a time-consuming and costly process. We cannot be certain that coverage for our current test and our planned future tests will be provided in the future by additional commercial payors or that existing policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. If we cannot obtain or maintain coverage and reimbursement from private and governmental payors such as Medicare and Medicaid for our current test, or new tests or test enhancements that we may develop in the future, our ability to generate revenues could be limited. This may have a material adverse effect on our business, financial condition, results of operation, and cash flows.

Revenue Effects Related to COVID-19 Pandemic

Assay Revenue

Beginning in March 2020 and continuing through the end of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by our sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received relative to our pre-pandemic expectations. April 2020 billable sample volume was down by approximately 80%, commensurate with the closure of dermatology offices, compared to the average monthly billable sample volume for the two months preceding the beginning of the COVID-19 stay-at-home orders. Despite the downturn in billable samples in April 2020, we saw a stabilization of billable sample volume throughout the rest of the second quarter of 2020 and through the end of 2021 as various states and dermatology offices opened throughout the country. Despite not all dermatology practices returning to full operations, billable sample volume first exceeded pre‑pandemic levels in July 2020. Billable sample volume for the three months ended December 31, 2021 was 1% higher than billable sample volume for the three months ended September 30, 2021 despite the Delta and Omicron

58

variants that drove the surge of COVID-19 cases during the fourth quarter of 2021. Billable sample volume for the twelve months ended December 31, 2021 was 86% higher than billable sample volume for the twelve months ended December 31, 2020. Billable sample volume for the three months ended December 31, 2021 was 42% higher than billable sample volume for the three months ended December 31, 2020. Billable sample volumes could continue to be impacted by the ongoing COVID-19 pandemic and further impacted by a potential resurgence of the virus or its variants in the future.

In April 2020, we made available a remote telemedicine collection option for the DMT. Using the remote telemedicine collection option, a clinician can choose to assess the patient’s skin and suspicious lesion(s) via a teledermatology telemedicine appointment and, if indicated, submit a patient-specific order to DermTech for the DMT. In this case, a Smart Sticker Collection Kit is then mailed to the patient directly. During a follow-up telemedicine appointment, a clinician instructs and supervises the patient to collect their sample with the Smart Sticker. The patient then returns the collected sample(s) back to DermTech via a pre-labeled shipping envelope for analysis. Test results are made available to the ordering clinician within a few days.

In July 2021, we launched another telemedicine option available to patients through the DermTech Connect mobile application, where permitted by law and consistent with applicable standards of care and practice guidelines. DermTech Connect enables a user to take a picture of a suspicious lesion with their phone and submit the picture to an independent clinician to assess the lesion. As of the date of this report, DermTech Connect is only available to patients of clinicians subscribed to DermTech Connect in eight states and remains limited in operations. Subscribing clinicians utilizing DermTech Connect charge a pre-determined amount for the patient services and no claims are submitted for reimbursement of the clinical telemedicine services. These subscribing clinicians pay DermTech a fixed amount for use of the DermTech Connect platform. The clinician can also determine, if they deem it medically necessary, to order the DMT, in which case a Smart Sticker Collection Kit is mailed to the patient, followed by at-home self-collection with remote virtual supervision by a DermTech patient liaison. Many state laws and regulations impose various requirements on the practice of telemedicine, the regulatory landscape is evolving and DermTech Connect is not, and may not become, available in all states. The telemedicine market is relatively new and unproven, especially within dermatology, and it is uncertain whether the telemedicine options for the DMT will achieve and sustain high levels of demand, consumer acceptance and market adoption, as well as face challenges in the regulatory landscape, which is complex and evolving.

While the COVID-19 pandemic is ongoing (including as a result of clinician offices closing again due to a COVID-19 outbreak within the practice, or patients avoiding in-person visits to the dermatology clinic for fear of contracting COVID-19 or any of its viral variants), we expect that our revenues will depend to an extent on the willingness of clinicians and their patients to use our telemedicine option for the DMT, as well as on our ability to demonstrate the value of our telemedicine option to health plans and other purchasers of healthcare for beneficiaries. We also expect that the duration and extent of the effects of the ongoing COVID-19 pandemic will continue to adversely affect our revenues by reducing access to clinician offices by patients for in-person testing and by our sales force for in-office sales calls.

Contract Revenue

Contract revenues with pharmaceutical companies relate to ongoing clinical trial contracts and new contracts. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors. Many of our contracts with third parties are structured to contain milestone billing payments, which typically are advance payments on work yet to be performed. These advanced payments are structured to help fund operations and are included in deferred revenue as the work has not yet been performed. These advance payments will remain in deferred revenue until we process the laboratory portion of the contracts allowing us to recognize the revenue.

The ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect our pharmaceutical customers’ clinical trials. The extent of such effect on our future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on our pharmaceutical customers’ clinical trials.

Optional Add-on Test for TERT (formerly known as PLAplus)

During the second quarter of 2021, we announced the launch of the optional add-on test for TERT (then known as PLAplus) available to those ordering the DMT, which delivers objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma. This add-on test combines TERT promoter DNA driver mutation analyses as a reflex test to the DMT’s standard RNA gene expression test. TERT is individually associated with histopathologic features of aggressiveness and poor survival in melanoma. The combined tests elevate the sensitivity from 91% to 97% and maintain a negative predictive value of >99%, resulting in a less than 1% probability of missing melanoma. By combining RNA gene expression and DNA mutation analyses, the DMT provides a highly accurate non-invasive genomic test for enhanced early melanoma detection. For a discussion of the effects of the ongoing COVID-19 pandemic on recognized revenue derived from the DMT, refer to “Assay Revenue” under “Revenue Effects Related to COVID-19 Pandemic” above.

59

Financial Overview

Revenue

We generate revenue through laboratory services that are billed to Medicare, private medical insurance companies and to pharmaceutical companies who order our laboratory services, which can include sample collection kits, assay development, genomic analysis, data analysis and reporting. Our revenue is generated from two revenue streams: contract revenue and assay revenue. Assay revenue can be highly variable as it is based on payments received by private insurance payors that are not under contract and can vary based on patient insurance coverage, deductibles and co-pays. As much of our assay revenue is driven by the samples that are sent by physicians to our central lab for testing, a key performance measure for us is samples that are received and processed by our central lab successfully, also known as billable samples. Our laboratory services are ordered by customers on projects that may span over several years, which makes our contract revenue highly variable. Segments of these contracts may be increased, delayed or eliminated based on the success of each customers’ clinical trials or other factors.

Operating Expenses

Sales and Marketing Expenses

Sales and marketing expenses are primarily related to our specialty field sales force, market research, reimbursement efforts, trade show attendance, public relations, and general marketing. We expect these expenses to increase significantly as we expand our direct consumer marketing efforts and continue to add to our specialty sales force, marketing and payor access teams throughout 2022.

Research and Development Expenses

Our R&D expenses consist primarily of salaries and fringe benefits, clinical trials, consulting costs, facilities costs, laboratory costs, equipment expense, and depreciation. We also conduct clinical trials to validate the performance characteristics of our tests and to show medical cost benefit in support of our reimbursement efforts. We expect these expenses to increase significantly as we continue to develop new products and expand the use of our existing products.

General and Administrative Expenses

Our general and administrative expenses consist of senior management compensation, consulting, legal, billing and collections, human resources, information technology, accounting, insurance, and general business expenses. We expect our general and administrative expenses, especially employee-related costs, including stock-based compensation, insurance, accounting, and legal fees, to continue to increase due to operating as a publicly traded company.  

Financing Activities

Business Combination

On August 29, 2019, the Company and DermTech Operations consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, Merger Sub and DermTech Operations. We refer to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. We refer to this transaction as the Business Combination.

Immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc. and effected the Reverse Stock Split. Prior to the closing of the Business Combination, the Company’s stock was listed on the Nasdaq Capital Market under the ticker symbol “CNAC.” On August 30, 2019, the Company’s common stock commenced trading on the Nasdaq Capital Market under the ticker symbol “DMTK.”

2019 PIPE Financing

On August 29, 2019, immediately prior to the completion of the Business Combination, the Company issued to certain accredited investors, in a private placement transaction (the “2019 PIPE Financing”) an aggregate of 3,076,925 shares of common stock and 1,231 shares of Series A Convertible Preferred Stock for aggregate gross proceeds of $24.0 million, or $6.50 per share of common stock on an as-converted basis. The 2019 PIPE Financing was conducted pursuant to the terms of separate Subscription Agreements and Amended and Restated Subscription Agreements, dated between May 22, 2019 and August 1, 2019, entered into by the Company and the investors. After giving effect to the Reverse Stock Split, each share of Series A Convertible Preferred Stock was convertible into 500 shares of the Company’s common stock, subject to conditions and adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock.

60

On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. (the “Farallon Entities”) converted an aggregate of 1,231 shares of Series A Preferred Stock into 615,385 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series A Convertible Preferred Stock.

2020 PIPE Financing

On February 28, 2020, the Company entered into a securities purchase agreement with certain institutional investors for a private placement of the Company’s equity securities (the “2020 PIPE Financing”). Cowen and Company, LLC (“Cowen”) served as lead placement agent for the 2020 PIPE Financing with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent. The 2020 PIPE Financing closed on March 4, 2020.

Pursuant to the 2020 PIPE Financing, on March 4, 2020 the Company issued an aggregate of 2,467,724 shares of common stock at a purchase price of $10.50 per share, 3,199 shares of Series B-1 Convertible Preferred Stock (the “Series B-1 Shares”) at a purchase price of $10.50 per share of common stock issuable upon conversion thereof, which were convertible into an aggregate of up to 3,198,942 shares of common stock, and 524 shares of Series B-2 Convertible Preferred Stock (the “Series B-2 Shares”) at a purchase price of $10.50 per share of common stock issuable upon conversion thereof, which are convertible into an aggregate of up to 523,809 shares of common stock, for aggregate gross proceeds of approximately $65.0 million.

At the Company’s annual meeting held on May 26, 2020, the Company’s stockholders voted to approve the 2020 PIPE Financing, which resulted in the automatic conversion of the Series B-1 Shares into 3,198,949 shares of common stock on May 27, 2020. Each Series B-2 Share was convertible into 1,000 shares of the Company’s common stock, subject to conditions and adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock. On August 10, 2020, the Farallon Entities converted an aggregate of 524 shares of Series B‑2 Preferred Stock into 523,814 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock and Certificate of Elimination of Series B-2 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-1 and B-2 Convertible Preferred Stock.

2020 At-The-Market Offering  

On November 10, 2020, the Company entered into a sales agreement with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the sales agreement at a weighted average purchase price of $20.97, resulting in aggregate gross proceeds of approximately $20.0 million. During 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the sales agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million. The Company did not issue or sell any shares of common stock pursuant to the sales agreement in the fourth quarter of 2021.  

2021 Underwritten Public Offering  

On January 6, 2021, the Company, entered into an Underwriting Agreement with Cowen and William Blair & Company, L.L.C. as representatives of several underwriters (the “Underwriters”). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company.

On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company’s aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $143.7 million.

 

Results of Operations

Comparison of the Fiscal Years Ended December 31, 2021 and 2020

Assay Revenue

Assay revenues grew $6.8 million or 160% to $11.0 million for fiscal year 2021 compared to $4.2 million for fiscal year 2020. Billable samples increased to approximately 44,620 for fiscal year 2021 compared to approximately 24,000 for fiscal year 2020, and to approximately 13,700 for fiscal year 2019. Sample volume is dependent on two major factors: the number of clinicians who order an assay in any given quarter and the number of assays ordered by each clinician during the period. The number of ordering clinicians and the utilization per clinician can vary based on a number of factors including the types of patients presenting skin cancer conditions, clinician reimbursement, office workflow, market awareness, clinician education and other factors. The ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect our assay revenue by, among other things, limiting patient access to

61

clinician offices for in-person testing and limiting access by our sales force for in-office sales calls. Additionally, assay revenue increased due, in part, to our new contracts with Blue Shield of California, Blue Cross Blue Shield of Texas, and Blue Cross Blue Shield of Illinois.

Contract Revenue

Contract revenues with pharmaceutical companies decreased $0.8 million to $0.8 million for fiscal year 2021, or 50%, compared to $1.6 million for fiscal year 2020. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors. The ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect our pharmaceutical customers’ clinical trials. The extent of such effect on our future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on our pharmaceutical customers’ clinical trials. Many of our contracts with third parties are structured to contain milestone billing payments, which typically are advanced payments on work yet to be performed. These advanced payments are structured to help fund operations and are included in deferred revenue as the work has not yet been performed. As of December 31, 2021, the deferred revenue amount for these contracts, which is the advanced payments minus the value of work performed, was $1.4 million. These advanced payments will remain in deferred revenue until we process the laboratory portion of the contracts allowing us to recognize the revenue.

Cost of Revenue

Cost of revenues increased $4.6 million, or 77%, to $10.6 million for fiscal year 2021 compared to $6.0 million for fiscal year 2020. The increase was largely attributable to a higher billable sample volume in 2021, and higher consulting, software and equipment costs. As of December 31, 2021, a large portion of the costs of revenue are fixed, and these costs include the CLIA facility, quality assurance, management and supervision and equipment calibration and depreciation. The variable cost of revenue expenses incurred primarily relate to compensation-related costs for our laboratory scientists and technicians, laboratory supplies, shipping costs, equipment maintenance, and utilities. We remain committed to continuing the automation of our laboratory processes in order to become more cost efficient and productive.

Operating Expenses

Sales and Marketing

Sales and marketing expenses increased $21.5 million, or 134%, to $37.6 million for fiscal year 2021 compared to $16.1 million for fiscal year 2020. The increase was primarily attributable to higher compensation-related costs from the expansion of the commercial team, increased spending on marketing and payor infrastructure and activities, and additional consulting, software, and travel expenses. We expect to add to our specialty sales force, marketing and payor access teams throughout 2022 and 2023, and increase spending on direct-to-consumer marketing campaigns, which collectively would significantly increase our sales and marketing expenses.

Research and Development

R&D expenses increased $11.0 million, or 207%, to $16.3 million for fiscal year 2021 compared to $5.3 million for fiscal year 2020. The increase was due to higher compensation and recruiting costs of expanding the R&D team, including the addition of a new Chief Scientific Officer and Chief Medical Officer, increased clinical trial costs, increased consulting, software and travel expenses and increased spending on laboratory supplies to support new product development. We expect these expenses to increase as we continue to grow the R&D team and focus on the development of our Luminate test, our basal and squamous cell skin cancer assays and other products in our pipeline.

General and Administrative

General and administrative expenses increased $11.0 million, or 80%, to $24.8 million for fiscal year 2021 compared to $13.8 million for fiscal year 2020. The increase was primarily due to higher payroll-related costs and stock-based compensation as we continue to add additional infrastructure such as human resources, billing, information technology and legal resources, higher insurance, taxes, public company costs, audit fees, consulting expenses, and facility costs, offset by lower loss contingency and legal fees.

Interest Income, net

Interest income, net for fiscal year 2021 was $0.2 million compared to interest income, net of $40,000 for fiscal year 2020. Interest income, net for 2021 consists primarily of interest earned on our short-term marketable securities.

62

Change in Fair Value of Warrant Liability

Change in fair value of warrant liability for fiscal year 2021 was a loss of $1.1 million compared to a loss of $1.2 million for fiscal year 2020. The change in fair value of warrant liability is calculated by adjusting the value of the outstanding Private SPAC Warrants held by original holders to the current market value at each reporting period.

Liquidity and Capital Resources

We have never been profitable and have historically incurred substantial net losses, including net losses of $20.1 million for the twelve months ended December 31, 2019, $36.5 million for the twelve months ended December 31, 2020, and $78.3 million for the twelve months ended December 31, 2021. As of December 31, 2021, our accumulated deficit was $206.4 million, and for the twelve months ended December 31, 2021, we had negative operating cash flow of $62.1 million. We completed the 2020 PIPE Financing in March 2020, which raised a total of $65.0 million in gross proceeds. At the end of 2020 and throughout 2021, we raised approximately $44.5 million in gross proceeds facilitated through our At-the-Market Offering. In addition, we completed the 2021 Underwritten Public Offering in January 2021, which raised a total of $143.7 million in gross proceeds. We have historically financed operations through private placement and public equity offerings.

We expect our losses to continue as a result of costs relating to ongoing R&D expenses, increased general and administrative expenses and increased sales and marketing costs for existing and planned products. These losses have had, and will continue to have, an adverse effect on our working capital. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.

As of December 31, 2021, our cash and cash equivalents totaled approximately $176.9 million and short-term marketable securities totaled approximately $48.4 million. Based on our current business operations, we believe our current cash and cash equivalents will be sufficient to meet our anticipated cash requirements for at least the next 12 months. While we believe we have enough capital to fund anticipated operating costs for at least the next 12 months, we expect to incur significant additional operating losses over at least the next several years. We anticipate that we will raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements in order to support our planned operations and to continue developing and commercializing genomic tests. We may also consider raising additional capital in the future to expand our business, to pursue strategic investments or to take advantage of financing opportunities. Our present and future funding requirements will depend on many factors, including:

 

•

our revenue growth rate and ability to generate cash flows from operating activities;

 

•

the willingness of clinicians and their patients to use our telemedicine option for the DMT and the duration and extent of the effects of the ongoing COVID-19 pandemic in reducing patient access to clinician offices for in-person testing and access by our sales force for in-office sales calls;

 

•

the duration and extent of the effects of the ongoing COVID-19 pandemic on our pharmaceutical customers’ clinical trials;

 

•

our sales and marketing and R&D activities;

 

•

effects of competing technological and market developments;

 

•

costs of and potential delays in product development;

 

•

changes in regulatory oversight applicable to our tests; and

 

•

timing of and costs related to future international expansion.

There can be no assurances as to the availability of additional financing or the terms upon which additional financing may be available to us. If we are unable to obtain sufficient funding at acceptable terms, we may be forced to significantly curtail our operations, and the lack of sufficient funding may have a material adverse impact on our ability to continue as a going concern.

Cash Flow Analysis

Fiscal Year Ended December 31, 2021

Net cash used in operating activities for the twelve months ended December 31, 2021 totaled $62.1 million, primarily driven by the $78.3 million net loss offset partially by non-cash related items, including $13.3 million in stock-based compensation, $1.1 million from the change in fair value of warrant liability, $1.3 million in amortization of operating lease right of use assets and $1.0 million in depreciation. In addition, we had a cash inflow of $4.3 million from the increase in accounts payable and accrued compensation which was offset by cash outflows of $2.4 million through the increase of accounts receivable, $1.7 million through the increase of prepaid expenses and other assets and $1.4 million through the decrease of the operating lease liability.

Net cash used in investing activities for the twelve months ended December 31, 2021 totaled $12.5 million, which related to the cash outflows of $48.1 million from the purchase of marketable securities and $2.7 million from the purchase of equipment partially

63

offset by the cash inflow from the sale and maturity of marketable securities of $38.3 million. Additional laboratory equipment investment will be needed to install complex automation systems and other genomic testing equipment needed to expand testing capacity.

Net cash provided by financing activities for the twelve months ended December 31, 2021 totaled $230.3 million, which was driven by $134.6 million in net proceeds raised from the 2021 Underwritten Public Offering, $23.8 million in net proceeds from the sale of securities under our At-the-Market Offering and $70.3 million in proceeds from the exercise of warrants, predominately from the exercise of 12.1 million of our outstanding SPAC Warrants.

 

Fiscal Year Ended December 31, 2020

Net cash used in operating activities for the twelve months ended December 31, 2020 totaled $28.7 million, primarily driven by the $36.5 million net loss offset by non-cash related items, including $5.0 million in stock-based compensation, $1.2 million from the change in fair value of warrant liability, and $0.5 million in depreciation. In addition, we had a cash inflow of $0.8 million through the increase of accounts payable and accrued compensation as well as a $1.6 million of cash inflow through the increase of accrued liabilities and deferred revenues. This was offset by the cash outflow through the increase of prepaid expenses and other assets of $0.5 million as well as an increase in accounts receivable of $0.8 million.

Net cash used in investing activities totaled $41.3 million for the twelve months ended December 31, 2020, primarily related to the purchase of $41.7 million in short-term marketable securities and $1.8 million in purchases of property and equipment. This was offset by cash inflows from the sale and maturity of marketable securities of $2.2 million. As we scale our sales force, the expected timing of a corresponding increase in assay volume is uncertain due, in part, to challenges presented by the ongoing COVID-19 pandemic, such as related limits on patient access to clinician offices for in-person testing. Additional laboratory equipment investment will be needed to install complex automation systems and other genomic testing equipment needed to expand testing capacity.

Net cash provided by financing activities totaled $78.9 million for the twelve months ended December 31, 2020, which was predominantly driven by the $59.9 million and $19.1 million in net proceeds raised from the 2020 PIPE Financing and At-the-Market Offering, respectively, and $1.3 million from the exercise of stock options and warrants. This was offset by the payment made by the Company of the deferred underwriting fees of $1.4 million.

 

Off-Balance Sheet Arrangements

As of December 31, 2021 and 2020, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Significant Judgments and Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.

The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. While our significant accounting policies are more fully described in Note 1 of our consolidated financial statements included in this report, we believe that the following accounting policies and judgments are most critical to aid in fully understanding and evaluating our reported financial results based upon the SEC’s defined criteria.

64

Revenue Recognition

Our revenue is generated from two revenue streams, contract revenue and assay revenue. We account for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

(a)

Assay Revenue

We generate revenues from the DMT we provide to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. We provide prescribing clinicians with our Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. We also offer a telemedicine solution where a clinician can choose to assess the patient’s skin and suspicious lesion(s) via a telemedicine appointment and, if indicated, submit a patient-specific order to DermTech for the DMT. A patient can also initiate the process by downloading our telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by a clinician to assess if a DMT is warranted. The DermTech Connect app was initially beta tested in Florida and we have subsequently expanded into seven additional states. We plan to make DermTech Connect available in more states where legally permitted in the future as we expand the clinician network to review pictures of suspicious lesions.

Once the sample is collected by the healthcare clinician or the patient via the telemedicine solution, it is returned to our CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not. A detailed historical analysis of payments made to us by private health insurance payors is used to estimate the expected receipt of funds for payment of billed amounts. These payments can vary widely from payor to payor and can be halted for routine audits or other reasons.

(b)

Contract Revenue

Contract revenue is generated from the sale of laboratory services and Smart Stickers to third party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using our Smart Stickers, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.

See Note 1(l) of our consolidated financial statements for a full discussion of our revenue recognition policy around assay revenue and contract revenue.

 

Stock-Based Compensation

Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis. We grant stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.

The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of our common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future.

We account for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years.

65

Restricted stock units (“RSUs”) are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. We recognize stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years.

 

Recent Accounting Pronouncements

See Note 1(u) of our consolidated financial statements for a discussion of the impact of new accounting pronouncements on our consolidated financial statements.

Management’s Remediation Plan

To remediate these material weaknesses in our internal control over financial reporting related to assay revenue and accounts receivable described in Item 9A—Controls and Procedures, we plan to implement or improve documentation of alternative internal control procedures to verify the completeness and accuracy of customer contracts received and the delivery of test results.

 

Item 7A.  Quantitative and Qualitative Disclosures About Market Risk.

Our cash, cash equivalents, and short-term marketable securities are subject to economic risk which could affect our results of operations, financial condition and cash flows. We manage our exposure to this market risk through our regular operating and financing activities.

Interest Rate Risk

The primary objective of our investment activities is capital preservation to fund operations, while at the same time maximizing investment income without significantly increasing investment risk. To achieve these objectives, our investment policy allows for a portfolio of cash equivalents and investments in a variety of securities, including money market funds, U.S. government debt and corporate debt securities. Due to the short-term and conservative nature of our investments, we do not believe that we have a material exposure to interest rate risk. A 100 basis point change in interest rates would not have a significant impact on the total value of our portfolio.

 

66

 

Item 8.  Consolidated Financial Statements and Supplementary Data

DERMTECH, INC.

Index to Consolidated Financial Statements

 

 

67

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors

DermTech, Inc.:

 

Opinion on Internal Control Over Financial Reporting

 

We have audited DermTech, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weaknesses, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated March 10, 2022 expressed an unqualified opinion on those consolidated financial statements.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses related to the following have been identified and included in management’s assessment:

 

 

●

The Company did not have an effective risk assessment process that successfully identified and assessed risks of misstatement to ensure controls related to the assay revenue and accounts receivable process, including controls performed by a third-party service organization, were designed and implemented to respond to those risks.  The Company did not adequately communicate to its service organization to ensure controls were designed and implemented at the service organization to respond to those risks.

 

●

The Company did not successfully select and develop control activities that sufficiently mitigated the financial reporting risks related to the assay revenue and accounts receivable process.

The material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2021 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.

 

Basis for Opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in

68

accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

San Diego, California

March 10, 2022

 

69

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors

DermTech, Inc.:

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of DermTech, Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 10, 2022 expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting.

 

Change in Accounting Principle

 

As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2021 due to the adoption of Accounting Standards Codification Topic 842 (ASC 842), Leases.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Measurement of assay revenue

 

As discussed in Note 1 of the consolidated financial statements, the Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company generates assay revenue from its DermTech Melanoma Test it provides to healthcare clinicians. The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both. The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.  The Company recorded $11,023 thousand of assay revenue for the year ended December 31, 2021.

 

70

 

We identified the evaluation of the measurement of assay revenue as a critical audit matter. Evaluating the measurement of assay revenue, specifically the estimate of revenue expected to be collected, involved complex auditor judgment.

 

The following are the primary procedures we performed to address this critical audit matter. For a sample of tests performed in the current period, we evaluated the claims included within the Company’s assay revenue recognition model by comparing them to certain relevant documentation, including test requisition forms, test results, payor contracts, and proof of delivery to the physician. For a sample of payments received in the current period, we evaluated the payments included within the Company’s assay revenue recognition model by agreeing them to payments received. We tested the accuracy of the Company’s assay revenue recognition model, which includes the collection history used by management in assessing the current period revenue realization percentages, by payor. We performed a sensitivity analysis over the estimated revenue realization percentages applied to each payor group, using actual collection history, to assess its impact on the Company’s measurement of assay revenue. We further evaluated the estimate of assay revenue expected to be collected by inquiring of individuals of the Company responsible for monitoring and tracking the status of collections and developing the estimate.

/s/ KPMG LLP

We have served as the Company’s auditor since 2016.

San Diego, California

March 10, 2022

71

DERMTECH, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

 

December 31, 2021

 

 

December 31, 2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

176,882

 

 

$

24,248

 

Short-term marketable securities

 

 

48,449

 

 

 

39,529

 

Accounts receivable

 

 

3,847

 

 

 

1,480

 

Inventory

 

 

480

 

 

 

104

 

Prepaid expenses and other current assets

 

 

3,166

 

 

 

1,521

 

Total current assets

 

 

232,824

 

 

 

66,882

 

Property and equipment, net

 

 

4,549

 

 

 

2,731

 

Operating lease right-of-use assets

 

 

7,744

 

 

 

—

 

Restricted cash

 

 

3,025

 

 

 

—

 

Other assets

 

 

167

 

 

 

167

 

Total assets

 

$

248,309

 

 

$

69,780

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,880

 

 

$

1,573

 

Accrued compensation

 

 

5,120

 

 

 

2,075

 

Accrued liabilities

 

 

1,227

 

 

 

763

 

Short-term deferred revenue

 

 

1,380

 

 

 

905

 

Current portion of operating lease liabilities

 

 

1,453

 

 

 

—

 

Current portion of finance lease obligations

 

 

121

 

 

 

109

 

Total current liabilities

 

 

12,181

 

 

 

5,425

 

Warrant liability

 

 

146

 

 

 

1,650

 

Long-term deferred revenue

 

 

—

 

 

 

639

 

Long-term finance lease obligations, less current portion

 

 

136

 

 

 

226

 

Operating lease liabilities, long-term

 

 

6,148

 

 

 

—

 

Total liabilities

 

 

18,611

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value per share; 50,000,000 shares authorized

   as of December 31, 2021 and 2020; 29,772,922 and 20,740,413 shares

   issued and outstanding at December 31, 2021 and 2020, respectively

 

 

3

 

 

 

2

 

Additional paid-in capital

 

 

436,183

 

 

 

189,868

 

Accumulated other comprehensive loss

 

 

(124

)

 

 

(1

)

Accumulated deficit

 

 

(206,364

)

 

 

(128,029

)

Total stockholders’ equity

 

 

229,698

 

 

 

61,840

 

Total liabilities and stockholders’ equity

 

$

248,309

 

 

$

69,780

 

 

See accompanying notes to consolidated financial statements.

72

DERMTECH, INC.

Consolidated Statements of Operations

(in thousands, except share and per share data)

 

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Assay revenue

 

$

11,023

 

 

$

4,241

 

 

$

1,403

 

Contract revenue

 

 

815

 

 

 

1,644

 

 

 

1,961

 

Total revenues

 

 

11,838

 

 

 

5,885

 

 

 

3,364

 

Cost of revenues

 

 

10,564

 

 

 

5,981

 

 

 

3,304

 

Gross profit/(loss)

 

 

1,274

 

 

 

(96

)

 

 

60

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

37,575

 

 

 

16,077

 

 

 

6,303

 

Research and development

 

 

16,261

 

 

 

5,293

 

 

 

2,497

 

General and administrative

 

 

24,836

 

 

 

13,823

 

 

 

8,865

 

Total operating expenses

 

 

78,672

 

 

 

35,193

 

 

 

17,665

 

Loss from operations

 

 

(77,398

)

 

 

(35,289

)

 

 

(17,605

)

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

151

 

 

 

40

 

 

 

(2,657

)

Change in fair value of warrant liability

 

 

(1,088

)

 

 

(1,228

)

 

 

(441

)

Gain on debt extinguishment of convertible notes

 

 

—

 

 

 

—

 

 

 

928

 

Change in fair value of derivative liability

 

 

—

 

 

 

—

 

 

 

(355

)

Total other expense

 

 

(937

)

 

 

(1,188

)

 

 

(2,525

)

Net loss

 

$

(78,335

)

 

$

(36,477

)

 

$

(20,130

)

Weighted average shares outstanding used in computing net loss per share, basic and diluted

 

 

28,884,874

 

 

 

16,979,411

 

 

 

7,005,037

 

Net loss per share of common stock outstanding, basic and diluted

 

$

(2.71

)

 

$

(2.15

)

 

$

(2.87

)

 

See accompanying notes to consolidated financial statements.

73

DERMTECH, INC.

Consolidated Statements of Comprehensive Loss

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss

 

$

(78,335

)

 

$

(36,477

)

 

$

(20,130

)

Unrealized loss on available-for-sale marketable securities

 

 

(123

)

 

 

(1

)

 

 

—

 

Comprehensive loss

 

$

(78,458

)

 

$

(36,478

)

 

$

(20,130

)

 

See accompanying notes to consolidated financial statements.

 

 

 

74

 

DERMTECH, INC.

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share and per share data)

 

 

 

Series A

convertible

preferred stock

 

 

 

Series B-1

convertible

preferred stock

 

 

 

Series B-2

convertible

preferred stock

 

 

 

Series C-2

convertible

preferred stock

 

 

 

Common stock

 

 

Additional

paid-in

 

 

Accumulated

other

comprehensive

 

 

Accumulated

 

 

Total

stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

deficit

 

 

equity (deficit)

 

Balance, December 31, 2018

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

1,524,122

 

 

$

—

 

 

 

 

4,411,567

 

 

$

1

 

 

$

66,021

 

 

$

—

 

 

$

(71,377

)

 

$

(5,355

)

Cumulative effect adjustment of

   accounting method change

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(45

)

 

 

(45

)

Issuance of common stock

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

726,139

 

 

 

—

 

 

 

934

 

 

 

—

 

 

 

—

 

 

 

934

 

Conversion of Series C preferred

   stock to common stock

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

1,524,122

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Conversion of convertible notes to

   common stock

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

(1,524,122

)

 

 

—

 

 

 

 

2,267,042

 

 

 

—

 

 

 

12,687

 

 

 

—

 

 

 

—

 

 

 

12,687

 

Additional paid in capital assumed in

   Business Combination

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

420

 

 

 

—

 

 

 

—

 

 

 

420

 

Issuance of Series A preferred stock

   at $3,250 per share

 

 

1,231

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

4,000

 

 

 

—

 

 

 

—

 

 

 

4,000

 

Issuance of common stock at $6.50 per

   share, net of $0.2 million issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

3,076,923

 

 

 

—

 

 

 

19,802

 

 

 

—

 

 

 

—

 

 

 

19,802

 

Reclassification of stockholders’ equity to

   warrant liability

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

(187

)

 

 

—

 

 

 

—

 

 

 

(187

)

Restricted stock unit release

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

339,025

 

 

 

—

 

 

 

(1,569

)

 

 

—

 

 

 

—

 

 

 

(1,569

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,304

 

 

 

—

 

 

 

—

 

 

 

1,304

 

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(20,130

)

 

 

(20,130

)

Balance, December 31, 2019

 

 

1,231

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

12,344,818

 

 

$

1

 

 

$

103,412

 

 

$

—

 

 

$

(91,552

)

 

$

11,861

 

Issuance of common stock at $10.50

   per share, net of $2.0 million

   in issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

2,467,724

 

 

 

—

 

 

 

23,889

 

 

 

—

 

 

 

—

 

 

 

23,889

 

Issuance of Series B-1 convertible

   preferred stock at $10,500 per share, net

   of $2.6 million in issuance costs

 

 

—

 

 

 

—

 

 

 

 

3,199

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

30,968

 

 

 

—

 

 

 

—

 

 

 

30,968

 

Issuance of Series B-2 convertible

   preferred stock at $10,500 per share, net

   of $0.4 million in issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

524

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

5,071

 

 

 

—

 

 

 

—

 

 

 

5,071

 

Issuance of common stock from

   option exercises and RSU releases

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

319,522

 

 

 

—

 

 

473

 

 

 

—

 

 

 

—

 

 

 

473

 

Issuance of common stock from

   warrant exercises

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

230,619

 

 

 

—

 

 

 

842

 

 

 

—

 

 

 

—

 

 

 

842

 

Issuance costs in connection with

   Form S-1 registration statement

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

(77

)

 

 

—

 

 

 

—

 

 

 

(77

)

Conversion of Series B-1  convertible

   preferred  stock to common stock

 

 

—

 

 

 

—

 

 

 

 

(3,199

)

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

3,198,949

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1

 

Conversion of Series A and B-2

   convertible preferred stock

   to common stock

 

 

(1,231

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

(524

)

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

1,139,199

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock

   from Life Sci settlement

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

87,790

 

 

 

—

 

 

 

1,011

 

 

 

—

 

 

 

—

 

 

 

1,011

 

Issuance of common stock at a

   weighted average price of $20.97

   through at-the-market offering, net

   of $0.9 million in issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

951,792

 

 

 

—

 

 

 

19,104

 

 

 

—

 

 

 

—

 

 

 

19,104

 

Reclassification of warrant liability

   due to Private SPAC Warrants

   not held by original holder

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

206

 

 

 

—

 

 

 

—

 

 

 

206

 

Unrealized loss on available-for-sale

   marketable securities

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1

)

 

 

—

 

 

 

(1

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

4,969

 

 

 

—

 

 

 

—

 

 

 

4,969

 

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(36,477

)

 

 

(36,477

)

Balance, December 31, 2020

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

20,740,413

 

 

$

2

 

 

$

189,868

 

 

$

(1

)

 

$

(128,029

)

 

$

61,840

 

 

75

 

DERMTECH, INC.

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Continued)

(in thousands, except share and per share data)

 

 

 

Series A

convertible

preferred stock

 

 

 

Series B-1

convertible

preferred stock

 

 

 

Series B-2

convertible

preferred stock

 

 

 

Series C-2

convertible

preferred stock

 

 

 

Common stock

 

 

Additional

paid-in

 

 

Accumulated

other

comprehensive

 

 

Accumulated

 

 

Total

stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

deficit

 

 

equity (deficit)

 

Balance, December 31, 2020

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

20,740,413

 

 

$

2

 

 

$

189,868

 

 

$

(1

)

 

$

(128,029

)

 

$

61,840

 

Issuance of common stock at a

   price of $29.50, net of $9.1 million

   in issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

4,872,881

 

 

 

1

 

 

 

134,581

 

 

 

—

 

 

 

—

 

 

 

134,582

 

Issuance of common stock at a

   weighted average price of $46.33

   through at-the-market offering, net

   of $0.7 million in issuance costs

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

530,551

 

 

 

—

 

 

 

23,836

 

 

 

—

 

 

 

—

 

 

 

23,836

 

Issuance of common stock from

   option exercises and RSU releases

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

466,442

 

 

 

—

 

 

 

793

 

 

 

—

 

 

 

—

 

 

 

793

 

Issuance of common stock from

   warrant exercises

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

3,104,520

 

 

 

—

 

 

 

72,429

 

 

 

—

 

 

 

—

 

 

 

72,429

 

Issuance of common stock from

   Employee Stock Purchase Plan

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

58,115

 

 

 

—

 

 

 

966

 

 

 

—

 

 

 

—

 

 

 

966

 

Unrealized loss on available-for-sale

   marketable securities

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(123

)

 

 

—

 

 

 

(123

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

13,276

 

 

 

—

 

 

 

—

 

 

 

13,276

 

Reclassification of warrant liability

   due to Private SPAC Warrants

   not held by original holder

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

434

 

 

 

—

 

 

 

—

 

 

 

434

 

Net loss

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(78,335

)

 

 

(78,335

)

Balance, December 31, 2021

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

—

 

 

$

—

 

 

 

 

29,772,922

 

 

$

3

 

 

$

436,183

 

 

$

(124

)

 

$

(206,364

)

 

$

229,698

 

 

See accompanying notes to consolidated financial statements.

 

 

76

 

DERMTECH, INC.

Consolidated Statements of Cash Flows

(in thousands)

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(78,335

)

 

$

(36,477

)

 

$

(20,130

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

997

 

 

 

486

 

 

 

89

 

Change in fair value of warrant liability

 

 

1,088

 

 

 

1,228

 

 

 

441

 

Gain on extinguishment of convertible notes

 

 

—

 

 

 

—

 

 

 

(928

)

Change in fair value of derivative liability

 

 

—

 

 

 

—

 

 

 

355

 

Amortization of debt discount and issuance costs

 

 

—

 

 

 

—

 

 

 

1,983

 

Amortization of operating lease right-of-use assets

 

 

1,299

 

 

 

—

 

 

 

—

 

Stock-based compensation

 

 

13,276

 

 

 

4,969

 

 

 

1,304

 

Amortization (Accretion) of discount (premium) on marketable securities

 

 

749

 

 

 

(21

)

 

 

—

 

Loss on disposal of equipment

 

 

15

 

 

 

13

 

 

 

—

 

Payment in connection with restricted stock unit release

 

 

—

 

 

 

—

 

 

 

(1,569

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(2,367

)

 

 

(800

)

 

 

(100

)

Inventory

 

 

(376

)

 

 

(69

)

 

 

5

 

Prepaid expenses and other current assets

 

 

(1,700

)

 

 

(487

)

 

 

(1,069

)

Operating lease liabilities, net

 

 

(1,443

)

 

 

—

 

 

 

—

 

Accounts payable and accrued compensation

 

 

4,335

 

 

 

827

 

 

 

1,337

 

Accrued liabilities and deferred revenue

 

 

356

 

 

 

1,647

 

 

 

491

 

Net cash used in operating activities

 

 

(62,106

)

 

 

(28,684

)

 

 

(17,791

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

 

(48,092

)

 

 

(41,706

)

 

 

—

 

Sales of marketable securities

 

 

1,600

 

 

 

—

 

 

 

—

 

Maturities of marketable securities

 

 

36,700

 

 

 

2,200

 

 

 

—

 

Purchases of property and equipment

 

 

(2,720

)

 

 

(1,834

)

 

 

(210

)

Net cash used in investing activities

 

 

(12,512

)

 

 

(41,340

)

 

 

(210

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock in connection with private placement offering, net

 

 

—

 

 

 

23,889

 

 

 

—

 

Proceeds from issuance of common stock in connection with public follow-on offering, net

 

 

134,582

 

 

 

—

 

 

 

—

 

Proceeds from issuance of Series B-1 Convertible Preferred Stock, net

 

 

—

 

 

 

30,968

 

 

 

—

 

Proceeds from issuance of Series B-2 Convertible Preferred Stock, net

 

 

—

 

 

 

5,071

 

 

 

—

 

Payments of deferred underwriting fees

 

 

—

 

 

 

(1,363

)

 

 

—

 

Payments of issuance costs in connection with Form S-1 registration statement

 

 

—

 

 

 

(77

)

 

 

—

 

Proceeds from issuance of common stock in connection with at-the-market offering, net

 

 

23,836

 

 

 

19,104

 

 

 

—

 

Proceeds from issuance of common stock

 

 

—

 

 

 

—

 

 

 

19,802

 

Proceeds from exercise of common stock warrants

 

 

70,271

 

 

 

842

 

 

 

5

 

Proceeds from exercise of stock options

 

 

793

 

 

 

473

 

 

 

929

 

Proceeds from contributions to the employee stock purchase plan

 

 

966

 

 

 

—

 

 

 

—

 

Proceeds from convertible notes payable

 

 

—

 

 

 

—

 

 

 

2,600

 

Payments of notes payable

 

 

—

 

 

 

—

 

 

 

(516

)

Proceeds from issuance of Series A Convertible Preferred Stock

 

 

—

 

 

 

—

 

 

 

4,000

 

Principal repayments of finance lease obligations

 

 

(171

)

 

 

(9

)

 

 

—

 

Proceeds received from close of Business Combination

 

 

—

 

 

 

—

 

 

 

1,802

 

Net cash provided by financing activities

 

 

230,277

 

 

 

78,898

 

 

 

28,622

 

Net increase in cash, cash equivalents and restricted cash

 

 

155,659

 

 

 

8,874

 

 

 

10,621

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

24,248

 

 

 

15,374

 

 

 

4,753

 

Cash, cash equivalents and restricted cash, end of period

 

$

179,907

 

 

$

24,248

 

 

$

15,374

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest on finance lease obligations

 

$

17

 

 

$

2

 

 

$

—

 

Supplemental disclosure of noncash investing and financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock in litigation settlement

 

$

—

 

 

$

1,011

 

 

$

—

 

Purchases of property and equipment recorded in accounts payable

 

$

17

 

 

$

71

 

 

$

641

 

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

$

434

 

 

$

206

 

 

$

—

 

Cashless exercise of common stock warrants

 

$

2,158

 

 

$

—

 

 

$

—

 

Right-of-use assets obtained in exchange for lease obligations

 

$

9,044

 

 

$

—

 

 

$

—

 

Property and equipment acquired under finance leases

 

$

93

 

 

$

342

 

 

$

—

 

Change in unrealized loss on available-for-sale marketable securities

 

$

(123

)

 

$

(1

)

 

$

—

 

Unpaid deferred issuance costs

 

$

—

 

 

$

56

 

 

$

1,363

 

Debt discount and derivative liability at issuance of convertible notes payable

 

$

—

 

 

$

—

 

 

$

270

 

See accompanying notes to consolidated financial statements.

77

DERMTECH, INC.

Notes to Consolidated Financial Statements

 

1. The Company and a Summary of its Significant Accounting Policies

(a)

Nature of Operations

On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock (“Reverse Stock Split”).

The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.

From the end of the first quarter of 2020 and through the fourth quarter of 2021, there has been a widespread worldwide impact from the COVID-19 pandemic. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company has implemented additional safety measures in accordance with Centers for Disease Control and Prevention (“CDC”), Occupational Safety and Health Administration (“OSHA”) and other guidance within its CLIA laboratory operations. Additionally, the Company has transitioned administrative functions to predominantly remote work. Beginning in March 2020 and continuing through the fourth quarter of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by the Company’s sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received during the fourth quarter of 2021 relative to the Company’s pre-pandemic expectations. The Company expects the ongoing COVID-19 pandemic to continue to adversely impact billable sample volume until patient access to in-person testing fully resumes, in-office access by the Company’s sales force returns to pre-pandemic levels, or telemedicine options are more widely adopted. Additionally, the ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect the Company’s pharmaceutical customers’ clinical trials. The extent of such effect on the Company’s future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on the Company’s pharmaceutical customers’ clinical trials.

(b)

Basis of Presentation

The consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”). In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.

(c)

Revision to Prior Period Financial Statements  

As discussed under the heading “Revision to Prior Period Financial Statements” in Note 1 of the Company’s Quarterly Report on Form 10-Q filed on May 13, 2021, during the course of preparing the quarterly report Form 10-Q for the three months ended March 31, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The SEC Statement highlighted challenges associated with the accounting for complex financial instruments that may be common in SPACs, specifically accounting for warrants issued in connection with a SPAC’s formation and initial registered offering. In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity.

78

The Company previously issued warrants to purchase common stock in public and private placement offerings consummated on June 23, 2017 (the “SPAC Warrants”), which were originally classified as equity in the Company’s financial statements. As part of the aforementioned public offering, the Company issued 14,375,000 warrants (the “Public SPAC Warrants”) and as part of the aforementioned private placement offering, the Company issued 561,250 warrants (the “Private SPAC Warrants”). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share. The Company’s SPAC Warrants were accounted for as equity within the Company’s previously reported consolidated balance sheets.

The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement.

Historically, the Private SPAC Warrants were recorded as a component of equity as opposed to liabilities on the Company’s consolidated balance sheets and the Company’s consolidated statements of operations did not include the subsequent non-cash changes in estimated fair value of the Private SPAC Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the recent SEC Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for SPAC Warrants issued on June 23, 2017, in light of the SEC Staff’s published views. After discussion and evaluation, the Company concluded that, as a result of these differences in features between the Public SPAC Warrants and Private SPAC Warrants, the Private SPAC Warrants should be classified as liabilities, if still held by the original Private SPAC Warrant holder, with subsequent changes in fair value reported in the Company’s consolidated statement of operations.

In addition, the Company analyzed the impact of the aforementioned adjustments on its previously issued audited consolidated financial statements for the years ended December 31, 2020 and 2019 and previously issued unaudited consolidated financial statements for the periods ended September 30, 2020 and 2019, June 30, 2020, and March 31, 2020 (such years and periods, the “Affected Periods”). The Company concluded the adjustments are not material to any individual period prior to the period ended March 31, 2021, taking into account the requirements of ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 270, Interim Financial Reporting, ASC Topic 250-S99-1, Assessing Materiality, and ASC Topic 250-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. In accordance with the authoritative guidance, management evaluated the materiality of the adjustments from a quantitative and qualitative perspective. Based on such evaluation, the Company concluded that the effects of these adjustments were not material individually or in the aggregate to the Affected Periods and had no effect on the trend of financial results. While management concluded the adjustment was not material to any prior periods, individually or in the aggregate, based on our qualitative and quantitative analysis, management opted to make the adjustment by revising the respective amounts that were previously reported in the Affected Period. Accordingly, the Company has revised the prior period interim and annual financial information for the Affected Periods to reflect these adjustments.

The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Balance Sheet as of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

628

 

 

 

628

 

Total liabilities

 

 

5,722

 

 

 

628

 

 

 

6,350

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

103,599

 

 

 

(187

)

 

 

103,412

 

Accumulated deficit

 

 

(91,111

)

 

 

(441

)

 

 

(91,552

)

Total stockholders’ equity

 

 

12,489

 

 

 

(628

)

 

 

11,861

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheet as of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

1,650

 

 

 

1,650

 

Total liabilities

 

 

6,290

 

 

 

1,650

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

189,849

 

 

 

19

 

 

 

189,868

 

Accumulated deficit

 

 

(126,360

)

 

 

(1,669

)

 

 

(128,029

)

Total stockholders’ equity

 

 

63,490

 

 

 

(1,650

)

 

 

61,840

 

The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):

79

 

 

Year Ended December 31, 2019

 

 

Year Ended December 31, 2020

 

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Statements of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

$

—

 

 

$

(441

)

 

$

(441

)

 

$

—

 

 

$

(1,228

)

 

$

(1,228

)

Total other income/(expense)

 

 

(2,084

)

 

 

(441

)

 

 

(2,525

)

 

 

40

 

 

 

(1,228

)

 

 

(1,188

)

Net loss

 

$

(19,689

)

 

$

(441

)

 

$

(20,130

)

 

$

(35,249

)

 

$

(1,228

)

 

$

(36,477

)

Net loss per share of common stock

  outstanding, basic and diluted

 

$

(2.81

)

 

$

(0.06

)

 

$

(2.87

)

 

$

(2.08

)

 

$

(0.07

)

 

$

(2.15

)

The consolidated statements of cash flow are not presented because there is no impact on total cash flows from operating activities, investing activities, or financing activities. Certain components of net cash used in operating activities changed, as caused by the revision, such as incorporating the non-cash item from the change in fair value of warrant liability in the adjustments to reconcile net loss to net cash used in operating activities, but the net change amounted to zero for the Affected Periods.

(d)

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to, those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.

(e)

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.

Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

 

 

 

Year Ended December 31, 2021

 

 

Year Ended December 31, 2020

 

 

Year Ended December 31, 2019

 

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

Cash and cash equivalents

 

$

24,248

 

 

$

176,882

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

Restricted cash

 

 

—

 

 

 

3,025

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total cash, cash equivalents and restricted cash

   reported in the consolidated statements of

   cash flows

 

$

24,248

 

 

$

179,907

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

 

(f)   Marketable Securities

The Company considers securities with maturities of greater than 90 days at the time of purchase to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, such marketable securities are classified as current assets on the accompanying consolidated balance sheets even if they have contractual maturities greater than one year from the date of purchase. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost basis, which

80

may occur at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 2021.

(g)

Property and Equipment

Property and equipment is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $1.0 million, $0.5 million, and $0.1 million, for the years ended December 31, 2021, 2020, and 2019, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $0.1 million, $10,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively.

Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the consolidated statement of operations. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. The Company disposed of $0.1 million, $0.1 million, and zero of equipment during the years ended December 31, 2021, 2020, and 2019, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the years ended December 31, 2021, 2020, and 2019.

(h)

Leases

The Company acts as lessee in its lease agreements, which include operating leases for corporate offices and finance leases for certain laboratory and office equipment.

In accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as adopted on January 1, 2021, the Company determines if an arrangement is a lease at inception. Finance leases are included in the consolidated balance sheets as property and equipment, net and finance lease obligations at the present value of the lease payments. Operating leases are included in the consolidated balance sheet as ROU assets and operating lease liabilities at the present value of the lease payments. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.

As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, the Company has used a number of factors including the credit rating, and the lease term.

The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of less than 2 years to 10 years, some of which include options to extend the lease for up to 10 years. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest income, net on the Company’s consolidated statements of operations.

The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.

(i)

Research and Development

Costs incurred in connection with research and development (“R&D”) activities are expensed as incurred. R&D expenses consist of (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; and (ii) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies.

The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses.

81

(j)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2021, the Company maintained $100.1 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $60.2 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of December 31, 2021. The Company has not experienced any losses in such accounts.

(k)

Income Taxes

The Company provides for federal and state income taxes on the asset and liability approach which requires deferred tax assets and liabilities to be recognized based on temporary differences between the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year and prior year operating losses, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2021.

Current and deferred tax assets and liabilities are recognized based on the tax positions taken or expected to be taken in the Company’s income tax returns. U.S. GAAP requires that the tax benefits of an uncertain tax position can only be recognized when it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority. Tax benefits related to tax positions that do not meet this criterion are not recognized in the consolidated financial statements, of which there are none.

The Company recognizes interest and penalties related to income tax matters in income tax expense.  

(l)

Revenue Recognition

The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.  

The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.

Assay Revenue

The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the “DermTech Melanoma Test” or “DMT”, which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus) it provides to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in a limited number of states where permitted by law and applicable standards of practice guidelines.

82

Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.

Contracts

The Company’s customer is the patient. However, the Company does not enter into a formal reimbursement agreement with a patient, as formal reimbursement agreements are more commonly established with insurance payors. Accordingly, the Company establishes an agreement with a patient in accordance with other customary business practices.

 

•

Approval of an agreement is established by the use of the Company’s Smart Sticker on a patient by an ordering clinician, which is then sent to the Company’s central lab for testing.

 

 

•

The Company is obligated to perform the Company’s laboratory services upon receipt of a sample from a clinician, and the patient and/or applicable payor are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.

 

 

•

Payment terms are a function of a patient’s existing insurance benefits.

 

 

•

Once the Company delivers a patient’s test result to the ordering physician, the Company is legally able to collect payment and bill an insurer and/or patient, depending on payor agreement status or patient insurance benefit status.

 

 

•

The Company’s consideration is deemed to be variable, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.

Performance Obligations

A performance obligation is a promise in an agreement to transfer a distinct good or service (or a bundle of goods or services) to the customer. The customer is able to order a DMT, which is treated as a single performance obligation.

Transaction Price

The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both.

The consideration derived from the Company’s agreements is deemed to be variable, though the variability is not explicitly stated in any agreement. Rather, the implied variability is due to several factors, such as the amount of contractual adjustments, any patient co-payments, deductibles or patient compliance incentives, the existence of secondary payors and claim denials.

The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.

The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. Revenue recognized from changes in transaction prices was not material for the years ended December 31, 2021, 2020, and 2019, respectively.

83

The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for an agreement with a patient, it will account for the change as an increase in the estimate of the transaction price (i.e., an upward revenue adjustment) in the period identified. Similarly, if the Company subsequently determines that the amount it expects to collect from a patient is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price (i.e., a downward revenue adjustment), provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of a patient’s test result to the ordering physician, with recognition, generally occurring at the date of cash receipt.

Allocate the Transaction Price

The entire transaction price is allocated entirely to the single performance obligation contained within the agreement with a patient.

Recognize Revenue

The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful test result is delivered to the patient’s ordering physician. The Company considers this date to be the time at which the patient obtains control of the final results of the promised test service.

Contract Revenue

Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.

Contracts

As part of the Company’s contract revenue, the Company has established agreements and work orders with the Company’s third-party partners that fall under the scope of ASC 606.

Performance Obligations

ASC 606 requires an entity to assess the goods or services promised in a contract and identify as a performance obligation each promise to transfer to the customer either a good or service (or a bundle of goods or services) that is distinct, or a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Based upon review of existing contracts, a majority of the Company’s contract revenue agreements contain three performance obligations:

 

(1)

Smart Stickers

 

 

(2)

RNA extractions and analysis

 

 

(3)

Certain project management fees

Many of the Company’s contract revenue agreements contain promises such as start-up activities and quality system setup fees, which are activities that the Company performs to fulfill the agreement and they do not transfer any good or service to the customer. These promises encompass the administrative tasks associated with beginning and initiating a new project or study with a third-party company. In accordance with ASC 606, an entity does not account for these activities as a promised good or service within the agreement nor evaluate whether they are a performance obligation. 

Transaction Price

The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in an agreement with a customer may include fixed amounts, variable amounts, or both.

84

The transaction prices of the Company’s performance obligations are listed in its agreements on a per unit basis and are fixed for adhesive sample collection kits and RNA extractions and analysis. The project management fees are assessed based on a monthly service fee which range within the agreements depending on certain factors which include length of the project and the amount of Smart Stickers or RNA extractions and analysis promised within the agreement. The fixed and variable rates are materially consistent within the Company’s agreements. Therefore, the Company utilizes the prices listed in our agreements as the transaction price for each performance obligation.

In determining the transaction price, ASC 606 requires an entity to adjust the promised amount of consideration for the effects of the time value of money if the agreement contains a significant financing component. The Company’s agreements state fixed transaction prices for each deliverable associated with the agreement and do not qualify for the significant financing component of ASC 606.

Allocate the Transaction Price

The Company’s contracts have a directly observable transaction price pertaining to each promised good or service. Those prices are consistent across agreements for Smart Stickers and RNA extractions and analysis, with the exception of the Company’s project management fees, which the Company’s believes encompass a sufficiently narrow range of prices that are dictated upon factors of each agreement previously discussed above. Therefore, the Company relies on those transaction prices as the basis to allocate the stand-alone selling prices to the performance obligations of the agreement.

Most of the Company’s agreements contain a discount that is allocated to items within the agreement, whether they are performance obligations or not. Those items that are not performance obligations (e.g., quality system setup and start up fees) have the associated discount allocated to the transaction prices of the performance obligations evenly.

Recognize Revenue

An entity should recognize revenue when (or as) it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is transferred when (or as) the customer obtains control of that good or service. The Smart Stickers are recognized at a point in time when shipped to the customer. The RNA extraction and analysis are recognized at a point in time when the extraction and analysis process is complete and the results are sent to the customer. The Company provides its project management service over the life of the agreement, providing equal benefit to the customer throughout the life of the project or study. Therefore, the revenue related to the Company’s project management fees is recognized straight-line over the life of the agreement.

 

(a)

Disaggregation of Revenue

The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

DermTech Melanoma Test

 

$

11,023

 

 

$

4,241

 

 

$

1,403

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Smart Stickers

 

 

348

 

 

 

213

 

 

 

476

 

RNA extractions

 

 

300

 

 

 

1,172

 

 

 

626

 

Project management fees

 

 

166

 

 

 

258

 

 

 

336

 

Other

 

 

1

 

 

 

1

 

 

 

523

 

Total revenues

 

$

11,838

 

 

$

5,885

 

 

$

3,364

 

85

 

 

The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:

 

 

 

Total Revenue

 

 

Accounts Receivable

 

 

 

Year Ended December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payor A

 

 

36

%

 

 

32

%

 

*

 

 

 

23

%

 

 

21

%

Payor B

 

*

 

 

 

11

%

 

 

12

%

 

 

15

%

 

*

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer A

 

*

 

 

 

23

%

 

 

22

%

 

*

 

 

*

 

Customer B

 

*

 

 

*

 

 

*

 

 

*

 

 

 

17

%

Customer C

 

*

 

 

*

 

 

 

29

%

 

*

 

 

*

 

* Less than 10%

There were no other payors or customers that individually accounted for more than 10% of total revenue or accounts receivable for the periods shown in the table above.

(b)

Deferred Revenue and Remaining Performance Obligations

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets.

In a majority of agreements that produce contract revenue, the Company receives a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.

The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of December 31, 2021, and December 31, 2020, was $1.4 million and $0.9 million, respectively. Long-term deferred revenue as of December 31, 2021, and December 31, 2020, was zero and $0.6 million, respectively.

Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of December 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was approximately $0.4 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.

(m)

Accounts Receivable

Assay Accounts Receivable

Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.6 million and $1.0 million of gross assay accounts receivable as of December 31, 2021 and 2020, respectively.

Contract Accounts Receivable

Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of December 31, 2021, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the

86

reserve. The Company recorded $0.2 million and $0.5 million of contract accounts receivable as of December 31, 2021 and 2020, respectively.

(n)

Freight and Shipping Costs

The Company records outbound freight and shipping costs for its contract and assay revenues in cost of revenues.

(o)

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net loss and the components of other comprehensive loss, including unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive loss.

(p)

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.

(q)

Net Loss Per Share

Basic and diluted net loss per share is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the years ended December 31, 2021 and 2020, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the year ended December 31, 2021 excludes the effect of anti-dilutive equity instruments including 734,329 shares of common stock issuable upon the exercise of outstanding common stock warrants and 2,704,035 shares of common stock issuable upon the exercise stock options and release of RSUs. Diluted net loss per share of common stock for the year ended December 31, 2020 excludes the effect of anti-dilutive equity instruments including 3,885,311 shares of common stock then issuable upon the exercise of outstanding warrants and 2,112,980 shares of common stock then issuable upon the exercise of stock options and release of RSUs. Diluted net loss per common share for the year ended December 31, 2019 excludes the effect of anti-dilutive equity instruments including 615,385 shares of common stock issuable upon conversion of the Company’s preferred stock, 4,200,497 shares of common stock issuable upon the exercise of outstanding common stock warrants and 443,547 shares of common stock issuable upon the exercise stock options. The Company did not consider a two-class method of loss per share given that the Company’s convertible participating securities do not participate in losses.

(r)

Stock-Based Compensation

Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis.

The Company grants stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.

The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of the Company’s common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future.

The Company accounts for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years.

RSUs are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. The Company recognizes stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years.

87

All stock options and RSUs granted prior to January 1, 2020 will maintain the estimated forfeiture approach and will be recognized over the requisite service period using the straight-line method.

The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.52% - 1.39%

 

 

0.36% - 1.69%

 

 

1.68% - 2.50%

 

Assumed volatility

 

74.88% - 83.32%

 

 

64.03% - 73.44%

 

 

72.30% - 73.50%

 

Expected option term

 

6.08 years

 

 

5.04 - 6.25 years

 

 

6.02 - 6.08 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Assumed risk-free interest rate

 

0.05% - 0.18%

 

 

0.18%

 

Assumed volatility

 

64.55% - 69.34%

 

 

68.44%

 

Expected option term

 

0.49 - 0.50 years

 

 

0.49 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

The Company recorded stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 Employee Stock Purchase Plan (the “ESPP”), and consultant options of $13.3 million, $5.0 million, and $1.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The total compensation cost related to non-vested awards not yet recognized as of December 31, 2021 was $38.4 million, which is expected to be recognized over a weighted average term of 2.83 years. 

(s) Warrant Liability

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants classified as liabilities and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a component of other income/(expense) in the consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes-Merton valuation model. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of its warrants. At that time, the portion of the warrant liability related to the Company’s warrants will be reclassified to additional paid-in capital.

The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.46% - 0.85%

 

 

0.22% - 0.33%

 

 

1.40% - 1.66%

 

Assumed volatility

 

85.85% - 90.70%

 

 

69.79% - 79.26%

 

 

64.06% - 66.68%

 

Expected term

 

2.66 - 3.42 years

 

 

3.66 - 4.42 years

 

 

4.67 - 5.00 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

88

 

(t) Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):

Fair Value Measurements at Reporting Date

 

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

16,380

 

 

$

—

 

 

$

—

 

 

$

16,380

 

Restricted cash

 

 

3,025

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

15,352

 

 

 

—

 

 

 

15,352

 

Municipal securities

 

 

—

 

 

 

7,412

 

 

 

—

 

 

 

7,412

 

U.S. government debt securities

 

 

—

 

 

 

25,685

 

 

 

—

 

 

 

25,685

 

Total marketable securities, available for sale

 

 

—

 

 

 

48,449

 

 

 

—

 

 

 

48,449

 

Total assets measured at fair value on a recurring basis

 

$

19,405

 

 

$

48,449

 

 

$

—

 

 

$

64,829

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

448

 

 

$

—

 

 

$

—

 

 

$

448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

8,940

 

 

 

—

 

 

 

8,940

 

Municipal securities

 

 

—

 

 

 

7,324

 

 

 

—

 

 

 

7,324

 

U.S. government debt securities

 

 

—

 

 

 

23,265

 

 

 

—

 

 

 

23,265

 

Total marketable securities, available for sale

 

 

—

 

 

 

39,529

 

 

 

—

 

 

 

39,529

 

Total assets measured at fair value on a recurring basis

 

$

448

 

 

$

39,529

 

 

$

—

 

 

$

39,977

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

 

The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.

89

The fair value of the Private SPAC Warrants was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

 

Balance as of December 31, 2019

 

$

628

 

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(206

)

Change in fair value of warrant liability

 

 

1,228

 

Balance as of December 31, 2020

 

 

1,650

 

Derecognition of warrant liability from exercise of Private SPAC Warrants

 

 

(2,158

)

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(434

)

Change in fair value of warrant liability

 

 

1,088

 

Balance as of December 31, 2021

 

$

146

 

As of December 31, 2021 and 2020, the Company maintains letters of credit of $3.0 million and zero, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the Company’s consolidated balance sheets.

The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.

(u)

Accounting Pronouncement Recently Adopted

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes FASB ASC Topic 840, Leases (“ASC 840”), and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted ASC 842 during the third quarter of 2021 effective as of January 1, 2021. The Company has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented.

Adoption of ASU 2016-02 did not result in a cumulative adjustment to the Company’s accumulated deficit as of January 1, 2021. Adoption of ASU 2016-02 resulted in the recording of an operating lease ROU assets and lease liabilities of $2.8 million and $3.1 million, respectively. The difference between the operating lease ROU assets and lease liabilities are due to accrued deferred rent and unamortized lease incentives. Finance lease right-of-use assets and lease liabilities recognized as of January 1, 2021, included preexisting assets and liabilities of $0.3 million, related to finance leases accounted for under ASC 840. Adoption of ASU 2016-02 did not have a material impact on the Company’s results of operations or cash flows.

The Company elected to use the transition package of three practical expedients, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, under ASC 842, the further practical expedient not to separate non-lease components from the lease components to which they relate and instead to combine them and account for them as a single lease component. The Company also elected the accounting policy election to keep leases with a term of 12 months or less off the balance sheet and to recognize payments for those leases on a straight-line basis over the lease term. The underlying assets of the Company’s leases as of the adoption date consisted of operating facilities and laboratory equipment.

Judgment was exercised in the application of ASC 842 with respect to the determination of whether a contract contains a lease. While the ability to control and direct the use of an identified asset indicates that the contract, or portion of a contract, is a lease, a counterparty’s substantive substitution rights typically provide evidence that a lessee does not control the asset. Judgment was also exercised with respect to the determination of the discount rate used to determine the present value of lease payments. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a similar economic environment. The Company has no debt and has not had an established incremental borrowing rate. For the purpose of

90

estimating the incremental borrowing rate in the adoption of ASC 842, required management judgment including the development of a synthetic credit rating and cost of debt as we currently do not carry any debt. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. Previously, when credit losses were measured under U.S. GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires companies to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. 

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted the guidance under ASU 2016-13 during the fourth quarter of 2021 and applied the modified retrospective method of adoption to the Company’s financial statements as of January 1, 2021. Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures and no cumulative adjustment was required to be recorded to the Company’s accumulated deficit as of January 1, 2021.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The Company adopted this guidance during the fourth quarter of 2021 with no material impact to the Company's consolidated financial statements.

 

(v)

Accounting Pronouncements Issued But Not Yet Effective

In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company plans to adopt the standard on January 1, 2022. The Company is currently evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company’s consolidated financial statements.

 

2. Balance Sheet Details

Short-Term Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 were as follows (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

15,385

 

 

$

—

 

 

$

(33

)

 

$

15,352

 

Municipal securities

 

 

7,417

 

 

 

—

 

 

 

(5

)

 

 

7,412

 

U.S. government debt securities

 

 

25,771

 

 

 

1

 

 

 

(87

)

 

 

25,685

 

Total short-term marketable securities,

   available-for-sale

 

$

48,573

 

 

$

1

 

 

$

(125

)

 

$

48,449

 

91

 

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2020 were as follows (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

8,946

 

 

$

—

 

 

$

(6

)

 

$

8,940

 

Municipal securities

 

 

7,325

 

 

 

1

 

 

 

(2

)

 

 

7,324

 

U.S. government debt securities

 

 

23,259

 

 

 

6

 

 

 

—

 

 

 

23,265

 

Total short-term marketable securities,

   available-for-sale

 

$

39,530

 

 

$

7

 

 

$

(8

)

 

$

39,529

 

 

As of December 31, 2021, the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that we held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months. As of December 31, 2020, the estimated market value of debt securities with contractual maturities of less than twelve months was $37.3 million; the remaining debt securities that we held at that date had an estimated market value of $2.3 million and contractual maturities of up to 14 months.

Gross realized gains and losses on our debt securities for the twelve months ended December 31, 2021 and 2020 were not significant.

 

Prepaid Expenses and PP&E

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

Prepaid insurance

 

$

1,801

 

 

$

1,172

 

Prepaid trade shows

 

 

440

 

 

 

—

 

Prepaid software fees

 

 

551

 

 

 

214

 

Deferred issuance costs

 

 

—

 

 

 

56

 

Prepaid employee compensation

 

 

238

 

 

 

—

 

Other current assets

 

 

136

 

 

 

79

 

Total prepaid expenses and other current assets

 

$

3,166

 

 

$

1,521

 

Property and equipment, gross:

 

 

 

 

 

 

 

 

Laboratory equipment

 

$

4,805

 

 

$

2,544

 

Computer equipment

 

 

171

 

 

 

38

 

Furniture and fixtures

 

 

124

 

 

 

109

 

Leasehold improvements

 

 

1,074

 

 

 

727

 

Total property and equipment, gross

 

 

6,174

 

 

 

3,418

 

Less accumulated depreciation

 

 

(1,625

)

 

 

(687

)

Total property and equipment, net

 

$

4,549

 

 

$

2,731

 

 

92

 

 

Accrued Compensation and Accrued Liabilities

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Accrued compensation:

 

 

 

 

 

 

 

 

Accrued paid time off

 

$

1,245

 

 

$

606

 

Accrued bonus and deferred compensation

 

 

3,875

 

 

 

1,469

 

Total accrued compensation

 

$

5,120

 

 

$

2,075

 

Accrued liabilities:

 

 

 

 

 

 

 

 

Accrued consulting services

 

$

775

 

 

$

285

 

Other accrued expenses

 

 

452

 

 

 

478

 

Total accrued liabilities

 

$

1,227

 

 

$

763

 

 

3. Debt

2018 Convertible Bridge Notes

From August to November 2018, DermTech Operations issued $6.8 million aggregate principal amount of convertible bridge notes (“2018 Bridge Notes”), resulting in $6.6 million in net proceeds. The 2018 Bridge Notes carried a 10% interest rate and matured on March 31, 2019. Since the 2018 Bridge Notes were not paid or converted by March 31, 2019, the interest rate increased to 15%.

The 2018 Bridge Notes were subject to automatic conversion into equity securities of DermTech Operations at the closing of a single capital raising transaction or series of related capital raising transactions in which DermTech Operations issued equity securities with aggregate gross proceeds to DermTech Operations of at least $20 million (“Qualified Financing”) that occurred on or prior to the maturity date. Upon automatic conversion of these 2018 Bridge Notes, the note holders were entitled to receive shares of DermTech Operations’ equity securities equal to the quotient obtained by dividing the unpaid principal amount of these 2018 Bridge Notes plus interest accrued but unpaid by the lesser of:

 

1)

the lowest price per share of the new stock paid in the Qualified Financing by investors multiplied by 70%.

 

2)

the price per share obtained by dividing $45 million by DermTech Operations’ fully-diluted capitalization immediately prior to such Qualified Financing assuming exercise or conversion of all outstanding options and issuance of all outstanding restricted stock unit awards, including all shares of common stock reserved and available for future grant under any equity incentive plan of the Company, and/or any equity incentive or similar plan to be created or increased in connection with the Qualified Financing, but excluding any shares issuable upon exercise of the DermTech Operations’ outstanding common stock warrants or conversion of the 2018 Bridge Notes.

Several of the embedded features of the 2018 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2018 Bridge Notes as a derivative liability on the consolidated balance sheet. DermTech Operations assigned a value to the debt component of the 2018 Bridge Notes equal to the difference between the estimated fair value of the 2018 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2018 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2018 Bridge Notes was determined to be $2.5 million. DermTech Operations amortized the debt discount over the contractual life (i.e., March 31, 2019) of the 2018 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2018 Bridge Notes (i.e., the derivative liability) and changes in the fair value are recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were zero and $0.4 million for the years ended December 31, 2020 and 2019, respectively.

On May 23, 2019, DermTech Operations and the various convertible 2018 Bridge Note holders agreed to amend the outstanding convertible notes that were issued in the last half of 2018. As part of the amendment, the maturity dates of the notes were extended to the earliest of (i) September 24, 2019; (ii) the occurrence of an Event of Default (as defined in the 2018 Bridge Notes); (iii) the consummation of a liquidation or dissolution of DermTech Operations (iv) a Liquidation Transaction (as defined in the 2018 Bridge Notes); or (v) the consummation of a merger with or into the Company or any of its subsidiaries.

93

In addition, immediately prior to the consummation of a DermTech Operations merger with or into the Company or any of its subsidiaries substantially on the terms contemplated as of the date of the amendment to the outstanding convertible notes on or before September 24, 2019 (a “Qualifying Merger”), the outstanding principal amount of and all accrued but unpaid interest on each of the convertible notes would automatically be converted into shares of the DermTech Operations’ common stock at a price per share equal to 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means (i) the lesser of $6.46 and (ii) the offering price per share of the private investment in public equity (“PIPE”) transaction to be consummated concurrently with the consummation of the Qualifying Merger multiplied by the Conversion Ratio. For the purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of fully diluted shares of the Company as of immediately after the conversion of the notes.

This new embedded Qualifying Merger feature of the 2018 Bridge Notes was identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract with the previously identified embedded features that met the criteria of being a derivative. In addition, this amendment was accounted for as a debt modification of the existing 2018 Bridge Notes.

2019 Convertible Bridge Notes

Between June 5th and June 10th, 2019, DermTech Operations issued additional convertible bridge notes (the “2019 Bridge Notes”) to existing investors for aggregate gross proceeds of $2.6 million. These convertible bridge notes carried an interest rate of 10% and matured after the earliest to occur of: (i) September 25, 2019; (ii) the occurrence of an Event of Default; (iii) the consummation of a liquidation or dissolution of DermTech Operations; (iv) a Liquidation Transaction; or (v) the consummation of a merger of DermTech Operations with Merger Sub, a subsidiary of the Company, in accordance with the Merger Agreement.

The unpaid principal amount of these convertible bridge notes together with any interest accrued but unpaid thereon, would automatically be converted into shares of DermTech Operations’ common stock immediately prior to the consummation of a Qualifying Merger. Upon the conversion of these notes, the note holders were entitled to receive a number of shares of DermTech Operations’ common stock equal to the quotient obtained by dividing (i) the unpaid principal amount of these notes plus interest accrued but unpaid thereon, by (1) if the Qualifying Merger consummates prior to the maturity date, the lesser of (x) $5.80 and (y) 90% of the Merger Consideration (as defined below), or (2) if the Qualifying Merger consummates on or after the maturity date, the lesser of (x) $4.51 and (y) 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means the offering price per share of the PIPE transaction between Constellation and the investors thereto, consummated substantially concurrently with the consummation of the Qualifying Merger, multiplied by the Conversion Ratio (as defined below). For purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of the Company’s fully diluted shares immediately prior to the consummation of the Qualifying Merger, assuming exercise of all outstanding options, issuance of all common stock underlying outstanding restricted stock unit awards, exercise of all outstanding warrants, and conversion of all outstanding convertible promissory notes, including these notes and any other note of substantially the same form, but excluding all shares of DermTech Operations’ common stock reserved and available for future grant under any equity incentive or similar plan of DermTech Operations, and in each case as adjusted for stock splits, combinations and similar transactions, all calculated in accordance with the final allocation schedule delivered in connection with the Qualifying Merger.

Several of the embedded features of the 2019 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2019 Bridge Notes as a derivative liability on the consolidated balance sheet. The Company assigned a value to the debt component of the 2019 Bridge Notes equal to the difference between the estimated fair value of the 2019 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2019 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2019 Bridge Notes was determined to be $0.3 million. DermTech Operations amortized the debt discount over the contractual life (i.e., September 25, 2019) of the 2019 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2019 Bridge Notes (i.e., the derivative liability) and changes in the fair value were recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were of zero and $14,000 for the years ended December 31, 2020 and 2019, respectively.

Exchange of Convertible Debt for Common Shares

On August 29, 2019, immediately prior to the completion of the Business Combination, all unpaid principal and interest on the 2019 Bridge Notes and the 2018 Bridge Notes (collectively, the “Bridge Notes”) was converted into 2,267,042 common shares of DermTech Operations.

The conversion of the Bridge Notes debt for common shares of DermTech Operations was accounted for as an extinguishment of the Bridge Notes. The conversion resulted in DermTech Operations having legally settled the debt obligations. DermTech Operations’ equity was increased by the settlement-date fair value of the common shares issued. Certain bifurcated embedded derivative instruments also were settled as part of the transaction.

The net carrying amounts of the Bridge Notes, including remaining unamortized debt discount and issuance costs, and the bifurcated embedded derivative liability were extinguished on the date of the Business Combination. A gain on debt extinguishment of

94

$0.9 million was recognized, which represented the unamortized debt discounts and issuance costs remaining at the time of the debt extinguishment.

There was no liability balance for the Company’s 2019 Bridge Notes or 2018 Bridge Notes as of December 31, 2021 and 2020.

4. Convertible Preferred Stock and Stockholders’ Equity

(a)

Classes of Stock

The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share.

(c)

Series A Convertible Preferred Stock Financing  

In connection with the 2019 private placement of equity securities of the Company on August 29, 2019, immediately following the completion of the Business Combination, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series A Convertible Preferred Stock (the “Series A Certificate of Designation”). An aggregate of 1,231 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $4.0 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 1,231 shares of Series A Preferred Stock into 615,385 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series A Convertible Preferred Stock.

(d)

2020 PIPE Financing

On February 28, 2020, the Company entered into a securities purchase agreement with certain institutional investors for a private placement of the Company’s equity securities (the “2020 PIPE Financing”). Cowen and Company, LLC (“Cowen”) served as lead placement agent for the 2020 PIPE Financing, with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent. The 2020 PIPE Financing closed on March 4, 2020.

The 2020 PIPE Financing consisted of 2,467,724 shares of common stock at a price of $10.50 per share, 3,199 shares of Series B-1 Convertible Preferred Stock (the “Series B-1 Shares”) at a price of $10,500 per share, and 524 shares of Series B-2 Convertible Preferred Stock (the “Series B-2 Shares”) at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, reduced by $5.1 million in issuance costs.

Prior to the closing of the 2020 PIPE Financing, the Company designated (i) 3,200 shares of its authorized and unissued preferred stock as Series B-1 Convertible Preferred Stock by filing the Series B-1 Certificate of Designation with the Delaware Secretary of State and (ii) 525 shares of its authorized and unissued preferred stock as Series B-2 Convertible Preferred Stock by filing the Series B-2 Certificate of Designation with the Delaware Secretary of State.

(e)

Series B-1 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing

In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-1 Convertible Preferred Stock (the “Series B-1 Certificate of Designation”). An aggregate of 3,199 shares of Series B-1 Convertible Preferred Stock for an aggregate purchase price of $33.6 million were issued to certain accredited investors.

At the Company’s annual meeting held on May 26, 2020, the Company’s stockholders voted to approve the 2020 PIPE Financing. As a result, on May 27, 2020 the 3,199 outstanding shares of Series B‑1 Convertible Preferred Stock were automatically converted into an aggregate of 3,198,949 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-1 Convertible Preferred Stock.

95

(f)

Series B-2 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing

In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-2 Convertible Preferred Stock (the “Series B-2 Certificate of Designation”). An aggregate of 524 shares of Series B-2 Convertible Preferred Stock for an aggregate purchase price of $5.5 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 524 shares of Series B‑2 Preferred Stock into 523,814 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-2 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-2 Convertible Preferred Stock.

(g)

At-The Market Offering

On November 10, 2020, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million.

(h)

2021 Underwritten Public Offering

On January 6, 2021, the Company entered into an Underwriting Agreement with Cowen and William Blair & Company, L.L.C. as representatives of several underwriters (the “Underwriters”). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.

(i)

Warrants

SPAC Warrants

The Company previously issued a total of 14,936,250 SPAC Warrants to purchase common stock in public offering and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 Public SPAC Warrants and as part of the private placement offering, the Company issued 561,250 Private SPAC Warrants. The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.

The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.

In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 and 14,936,250 as of December 31, 2021 and 2020, respectively. Private SPAC Warrants that were still owned by the original holder totaled 80,350 and 323,500 as of December 31, 2021 and 2020, respectively.

Series C Warrants

In connection with DermTech Operations’ Series C Preferred Stock financing that took place between 2016 and 2018, each investor that purchased at least $1 million of Series C Convertible Preferred Stock in a single closing received a three-year warrant to purchase shares of common stock at an exercise price of $9.54 per share in the amount equal to 20% of shares of Series C Preferred Stock purchased. Outstanding Series C warrants totaled zero and 97,563 as of December 31, 2021 and 2020, respectively.

96

Placement Agent Warrants

In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled and 10,039 and 31,365 as of December 31, 2021 and 2020, respectively.

(j)

Stock-Based Compensation

2010 Stock Plan

In connection with the Business Combination, the Company assumed the DermTech Operations’ Amended and Restated 2010 Stock Plan (the “2010 Plan”), which provided for the granting of incentive and non-statutory stock options and restricted stock purchase rights and bonus awards. Under the 2010 Plan, incentive and non-statutory stock options were granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. For incentive stock options granted to a ten percent shareholder under the 2010 Plan, the exercise price was not less than 110% of the fair market value of a share of stock on the effective date of grant. DermTech Operations initially reserved 1.0 million shares of common stock for issuance to its employees, non-employee directors and consultants. The 2010 Plan included a provision which annually increased the amount of common stock reserved for issuance under the 2010 Plan. The contractual term of options granted under the 2010 Plan was ten years. Vesting provisions varied based on the specific terms of the individual option awards. At the Company’s annual meeting held on May 26, 2020, the Company’s shareholders voted to approve the DermTech, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), which terminated the 2010 Plan. No additional awards will be granted under the 2010 Plan, however, all outstanding awards under the 2010 Plan remain in effect. No shares remained available for issuance pursuant to future grants under the 2010 Plan as of both December 31, 2021 and 2020.

2020 Equity Incentive Plan

On May 26, 2020, the Company’s stockholders approved the adoption of the 2020 Plan, which provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.  

The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards. 602,955 shares remained available for future grant under the 2020 Plan as of December 31, 2021.

97

The following table summarizes stock option transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total options

 

 

Weighted

average

exercise price

 

 

Weighted

average

remaining

contractual term

(in years)

 

 

Aggregate

intrinsic

value (in

thousands)

 

Outstanding at December 31, 2019

 

 

443,547

 

 

$

3.84

 

 

 

7.80

 

 

$

3,796

 

Granted

 

 

1,285,183

 

 

 

12.25

 

 

 

 

 

 

 

 

 

Exercised

 

 

(143,995

)

 

 

3.29

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(32,252

)

 

 

8.28

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

1,552,483

 

 

$

10.76

 

 

 

8.91

 

 

$

33,656

 

Granted

 

 

486,104

 

 

 

43.36

 

 

 

 

 

 

 

 

 

Exercised

 

 

(196,333

)

 

 

5.98

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(121,622

)

 

 

12.78

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options vested and expected to vest as of December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options exercisable as of December 31, 2021

 

 

607,127

 

 

$

10.16

 

 

 

7.59

 

 

$

3,523

 

 

The following table summarizes RSU transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total RSUs

 

 

Weighted

average grant

date fair value

per share

 

Outstanding at December 31, 2019

 

 

—

 

 

$

—

 

Granted

 

 

739,962

 

 

 

12.47

 

Released

 

 

(175,527

)

 

 

11.60

 

Forfeited

 

 

(3,938

)

 

 

11.41

 

Outstanding at December 31, 2020

 

 

560,497

 

 

$

12.75

 

Granted

 

 

718,053

 

 

 

34.09

 

Released

 

 

(277,259

)

 

 

14.20

 

Forfeited

 

 

(17,888

)

 

 

38.03

 

Outstanding at December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested and expected to vest as of December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested, but not yet issued as of December 31, 2021

 

 

12,632

 

 

$

41.81

 

2020 Employee Stock Purchase Plan

On May 26, 2020, the Company’s stockholders approved the adoption of the ESPP, which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. Eligible employees enroll in a six-month offering period during the open enrollment period prior to the start of that offering period. A new offering period begins approximately every March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period.

The ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors, subject to adjustment upon changes in capitalization of the Company. On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the ESPP. As of December 31, 2020, 400,000 shares of common stock were reserved for future issuance under the ESPP. On January 1, 2021, an additional 207,404 shares became available under the ESPP pursuant to an automatic annual increase. 549,289 shares remained available for future grant under the ESPP as of December 31, 2021.

98

Management Warrants

Warrants to purchase DermTech Operations common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten year life and are exercisable for Company common stock at $1.08 per share. The Management Warrants vested monthly over a four-year period. Outstanding Management Warrants totaled 20,320 and 22,320 at December 31, 2021 and 2020, respectively.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Warrants to purchase common stock

 

 

31

 

 

 

151

 

SPAC Warrants to purchase common stock*

 

 

704

 

 

 

3,734

 

Stock options issued and outstanding

 

 

1,721

 

 

 

1,552

 

Restricted stock units issued and outstanding

 

 

983

 

 

 

560

 

Authorized for future equity grants

 

 

603

 

 

 

935

 

Authorized for future ESPP purchases

 

 

549

 

 

 

400

 

Total common stock reserved for future issuance

 

 

4,591

 

 

 

7,332

 

 

*

Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.   

5. Income Taxes

The Company has reported net losses since inception, and therefore, the minimum provision for state income taxes has been recorded. The following table provides a reconciliation between income taxes computed at the federal statutory rate of 21% at December 31, 2021, 2020, and 2019, and the Company’s provision for income taxes.

 

 

 

Year ended December 31

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax at statutory rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State tax, net of federal tax benefit

 

 

4.8

 

 

 

4.9

 

 

 

—

 

Permanent items

 

 

1.1

 

 

 

(0.1

)

 

 

(0.8

)

Tax credits

 

 

0.6

 

 

 

0.4

 

 

 

0.2

 

Other

 

 

(0.4

)

 

 

(0.5

)

 

 

—

 

Valuation allowance (decrease) increase

 

 

(27.1

)

 

 

(25.7

)

 

 

(20.4

)

Income tax expense

 

 

—

%

 

 

—

%

 

 

—

%

99

 

Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31, 2021, 2020, and 2019 are shown below (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

 

December 31,

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss

 

$

46,886

 

 

$

28,422

 

 

$

20,336

 

Research and development credits

 

 

2,411

 

 

 

1,631

 

 

 

1,400

 

Depreciation and amortization

 

 

—

 

 

 

14

 

 

 

33

 

Stock based compensation

 

 

2,126

 

 

 

653

 

 

 

119

 

Accruals and other

 

 

719

 

 

 

422

 

 

 

194

 

Operating lease liability

 

 

1,935

 

 

 

—

 

 

 

—

 

Deferred revenue

 

 

340

 

 

 

—

 

 

 

—

 

Total deferred tax assets

 

 

54,417

 

 

 

31,142

 

 

 

22,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

(32

)

 

 

—

 

 

 

—

 

Operating lease right-of-use assets

 

 

(1,972

)

 

 

—

 

 

 

—

 

Total deferred tax liabilities

 

 

(2,004

)

 

 

—

 

 

 

—

 

Net deferred tax assets before valuation allowance

 

 

52,413

 

 

 

31,142

 

 

 

22,082

 

Less: valuation allowance

 

 

(52,413

)

 

 

(31,142

)

 

 

(22,082

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

$

—

 

 

The Company maintains a full valuation allowance against its net deferred tax assets as realization of such assets is not more likely than not.

At December 31, 2021, 2020, and 2019, the Company had federal tax net operating loss (“NOL”) carryforwards of approximately $184.0 million, $110.8 million, and $79.4 million, respectively, as well as state tax NOL carryforwards at December 31, 2021, 2020, and 2019 of approximately $141.1 million, $84.3 million, and $53.4 million, respectively. Federal NOL carryforwards began to expire during 2021 while the Company’s state NOL carryforwards begin to expire during various years, dependent on the jurisdiction.

The Company also had federal income tax R&D and other tax credit carryforwards at December 31, 2021, 2020, and 2019 of approximately $1.4 million, $0.9 million, and $0.8 million, respectively, and state income tax R&D and other tax credits of approximately $1.3 million, $0.9 million, and $0.8 million at December 31, 2021, 2020, and 2019, respectively. The federal credit carryforwards began to expire during 2021 and the state credit carryforwards do not expire. The Company has not performed a formal study validating its federal and state R&D tax credits and upon preparation, such tax credit carryforwards could vary from what was originally claimed on applicable income tax returns.

The utilization of NOL and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (IRC), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.

The Company conducts intensive research and experimentation activities, generating research tax credits for federal and state purposes under IRC Section 41. The Company has not performed a formal study validating such credits claimed on its tax returns. Once a study is completed, the amount of R&D tax credits available could vary from what was originally claimed on the tax returns.

Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination for all years since inception.

The Company records uncertain tax positions on the basis of a two-step process in which it determines whether it is more likely than not tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more likely than not recognition threshold the Company would recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it has no uncertain tax positions as of December 31, 2021, 2020, and 2019. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.

On December 27, 2020, President Trump signed into law the Consolidated Appropriations Act, 2021 (“CAA 2021”), which included a number of provisions including, but not limited to the extension of numerous employment tax credits, the extension of the

100

Section 179D deduction, enhanced business meals deductions, and the deductibility of expenses paid with Paycheck Protection Program (“PPP”) loan funds that are forgiven. The effects of the CAA 2021 have been incorporated into the income tax provision for the year ended December 31, 2021. These provisions did not have a material impact on the income tax provision.

6. Leases, Commitments and Contingencies

Finance Leases

The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net on the accompanying consolidated balance sheets. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Total finance lease interest expense was approximately $17,000, $3,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively, and is included within interest income, net on the consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Gross finance lease obligations

 

$

274

 

 

$

362

 

Less: imputed interest

 

 

(17

)

 

 

(27

)

Present value of net minimum lease payments

 

 

257

 

 

 

335

 

Less: current portion of finance lease obligations

 

 

(121

)

 

 

(109

)

Total long-term finance lease obligations

 

$

136

 

 

$

226

 

 

Operating Leases

Del Mar Heights Lease

On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Lease will serve as the Company’s new principal office.

The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease (the “Lease Commencement Date”). The Company has the option to extend the term of the Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.

As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.

During the year ended December 31, 2021, the Company took initial possession of the first phase of what is expected to become its corporate headquarters, and the Company capitalized a right-of-use asset and related lease liability of $5.7 million associated with the first phase. The extension option periods were not considered in the determination of the right-of-use asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $63.3 million related to corporate office facilities that were in the process of being built-out as of December 31, 2021. The lease liabilities and the corresponding right-of-use assets associated with these lease obligations will be recorded upon the commencement date of the operating leases.

101

In connection with this operating lease, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit totaling $3.0 million and is included in restricted cash on the consolidated balance sheet based on the term of the underlying lease. As of December 31, 2021, none of the standby letter of credit amount has been used.

 

Torrey Pines Lease

In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.

The lease term for all leased space has an expiration date of April 30, 2023, and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term. On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a right-of-use asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The right-of-use asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a right-of-use asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.

The components of lease expense for the year ended December 31, 2021 was as follows (in thousands):

 

Lease Cost

 

Year Ended

December 31, 2021

 

Operating lease cost

 

 

 

 

Operating lease cost

 

$

1,517

 

Variable lease costs

 

 

657

 

Total operating lease cost

 

$

2,174

 

 

 

 

 

 

Finance lease cost

 

 

 

 

Amortization of leased assets

 

$

75

 

Interest on lease liabilities

 

 

17

 

Total finance lease cost

 

$

92

 

 

 

 

 

 

Other information

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities

 

 

 

 

Operating cash flows from operating leases

 

$

2,619

 

Operating cash flows from finance leases

 

$

17

 

Financing cash flows from finance leases

 

$

171

 

Right-of-use assets obtained in exchange for new operating lease obligations

 

$

9,044

 

Right-of-use assets obtained in exchange for new finance lease obligations

 

$

93

 

 

 

 

 

 

Weighted-average remaining lease term of operating leases (in years)

 

 

9.33

 

Weighted-average remaining lease term of finance leases (in years)

 

 

2.34

 

Weighted-average discount rate for operating leases

 

 

5.78

%

Weighted-average discount rate for finance leases

 

 

5.63

%

 

102

 

The Company’s future minimum lease payments under operating and finance leases at December 31, 2021 are as follows (in thousands):

 

 

 

2022

 

 

2023

 

 

2024

 

 

2025

 

 

2026

 

 

Thereafter

 

 

Total

 

Operating lease obligations, including interest

 

$

1,802

 

 

$

1,149

 

 

$

688

 

 

$

709

 

 

$

730

 

 

$

4,928

 

 

$

10,006

 

Finance lease obligations, including interest

 

 

132

 

 

 

122

 

 

 

8

 

 

 

8

 

 

 

4

 

 

 

—

 

 

 

274

 

Total future minimum lease payments

 

$

1,934

 

 

$

1,271

 

 

$

696

 

 

$

717

 

 

$

734

 

 

$

4,928

 

 

$

10,280

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of December 31, 2021.

 

Deferred Underwriting Fees

In connection with the execution of the Merger Agreement, the Company, DermTech Operations and Cowen entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which the Company agreed to assign to DermTech Operations, and DermTech Operations agreed to assume, the Company’s obligations under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among the Company and Cowen. On September 4, 2019, the Company, DermTech Operations and Cowen amended the Deferred Underwriting Fee Assignment Agreement, pursuant to which the Company paid Cowen $0.8 million for the reduction of the balance owed by the Company to Cowen under the Underwriting Agreement to $1.4 million.

Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, as amended, if the Company were to raise at least $15.0 million in proceeds received from equity financings consummated prior to the one-year anniversary of the Business Combination, excluding the proceeds received from any financing consummated prior to or simultaneous with the Business Combination, then the Company would pay to the underwriters $1.4 million within one week of the one-year anniversary of the Business Combination. In connection with the Company’s 2020 PIPE Financing, the Company raised $65.0 million in gross proceeds, which satisfied this condition of the Deferred Underwriting Fee Assignment Agreement. On September 2, 2020, the Company paid the underwriters $1.4 million in satisfaction of the Company’s obligation of the deferred underwriting fees in full. No further payment will be required of the Company in connection with the deferred underwriting fees.

Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business.  Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

7. Retirement Plan

The Company has an IRC Section 401(k) retirement plan, covering all eligible employees. The Company did not offer a contribution percentage match during 2021 and 2020.

8. Related Party Transactions

During 2019, 2020, and 2021, the Company engaged EVERSANA Life Science Services, LLC, (“EVERSANA”), to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $2.6 million, $1.3 million, and $0.4 million in costs for the year ended December 31, 2021, 2020, and 2019, respectively.

On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month for the period May 11, 2020 through September 30, 2020 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2020 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of $20,000. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred $0.1 million, $0.2 million, and $20,000 in costs for the year ended December 31, 2021, 2020, and 2019, respectively.  

There were no other related party transactions identified for the years ended December 31, 2021, 2020, or 2019.

103

9. Subsequent Events

The Company considered subsequent events through March 10, 2022, the date the consolidated financial statements were available to be issued.

104

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

 

Item 9A.  Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

As required by Rules 13a‑15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our principal executive officer and principal financial officer, conducted an evaluation as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a‑15(e) and 15d-15(e) under the Exchange Act.

Based on that evaluation, our principal executive officer and principal financial officer have concluded that, as of December 31, 2021, our disclosure controls and procedures to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure were not effective due to material weaknesses in internal control over financial reporting, as discussed below.

Management’s Annual Report on Internal Control over Financial Reporting.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers and effected by the Company’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  In conducting our evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021 under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on our assessment, we concluded that there are material weaknesses in the Company’s internal control over financial reporting and that our internal control over financial reporting was not effective as of December 31, 2021.

The Company’s internal control over financial reporting includes those policies and procedures that:

 

•

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

•

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

 

•

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by management or employees in the normal course of performing their assigned functions. The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021. Management’s assessment identified the following material weaknesses in the Company’s internal control over financial reporting.

105

 

•

The Company did not have an effective risk assessment process that successfully identified and assessed risks of misstatement to ensure controls related to the assay revenue and accounts receivable process, including controls performed by a third-party service organization, were designed and implemented to respond to those risks. The Company did not adequately communicate to its service organization to ensure controls were designed and implemented at the service organization to respond to those risks.

 

•

The Company did not successfully select and develop control activities that sufficiently mitigated the financial reporting risks related to the assay revenue and accounts receivable process.

Accordingly, controls to verify the completeness and accuracy of customer contracts, expected rates used in our revenue recognition model and delivery of test results via fax, were not sufficient or did not have adequate documentation to demonstrate design and operating effectiveness. As a result, the Company could not conclude that controls over the completeness, existence and accuracy of assay revenue and accounts receivable were designed and operating effectively as of December 31, 2021.

After giving full consideration to the material weaknesses referenced above, and the additional analyses and other procedures that we performed to ensure that our consolidated financial statements included in this Annual Report on Form 10-K were prepared in accordance with U.S. GAAP, our management has concluded that no adjustment was required related to the material weakness, and our consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.

Our independent registered public accounting firm, KPMG LLP, who audited the consolidated financial statements included in this Annual Report on Form 10-K, issued an adverse opinion on the effectiveness of the Company’s internal control over financial reporting. KPMG LLP’s report appears on page 68 of this Annual Report on Form 10-K.

Management’s Remediation Plan.

We are taking steps to remediate these material weaknesses and will continue to take further steps until such remediation is complete. These steps include enhancing our risk assessment process, enhancing communications with our third-party service organization, and reassessing the assay revenue and accounts receivable process to ensure appropriate design and operating effectiveness of controls.

The material weaknesses will not be considered remediated, however, until the controls are designed, implemented and operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Remediation of Material Weakness Related to SPAC Warrants.

Due to the events that led to the revision of our financial statements, the Company identified a material weakness in its controls over the financial reporting for the Private SPAC Warrants. Management identified the need to reassess the accounting for the Private SPAC Warrants when the SEC Staff issued the SEC Statement that addresses certain accounting and reporting considerations related to similar warrants. This control deficiency resulted in an immaterial error in the Company’s accounting for the Private SPAC Warrants as more fully described in Note 1—The Company and a Summary of its Significant Accounting Policies—Revision to Prior Period Financial Statements within Part II, Item 8—Financial Statements and Supplementary Data.

To remediate the material weakness in our internal control over financial reporting related to SPAC Warrants, we improved our processes to identify and evaluate the appropriate accounting technical pronouncements and other literature for significant or unusual transactions so that they are effectively evaluated in the context of the increasingly complex accounting standards. After giving full consideration to the material weakness referenced above, and the additional analyses and other procedures that we performed to ensure that our consolidated financial statements included in this Annual Report on Form 10-K were prepared in accordance with U.S. GAAP, our management has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.

Changes in Internal Control over Financial Reporting.

Other than the changes made to remediate the material weakness related to SPAC Warrants described above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) under the Exchange Act during the quarter ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B.  Other Information.

None.

 

106

 

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

Not applicable.

107

PART III

Item 10.  Directors, Executive Officers and Corporate Governance.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Management and Corporate Governance,” “Delinquent Selection of 16(a) Reports,” and “Code of Conduct and Ethics” in our proxy statement for the 2022 annual meeting of stockholders.

Item 11.  Executive Compensation.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Compensation of Directors and Executive Directors,” “Compensation Discussion and Analysis,” “Management and Corporate Governance – Compensation Committee Interlocks and Insider Participation,” “Compensation Committee Report” and “Risks Related to Compensation Practices and Policies” in our proxy statement for the 2022 annual meeting of stockholders.

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in our proxy statement for the 2022 annual meeting of stockholders.

The response to this item is incorporated by reference form the discussion responsive thereto under the captions “Interest of Certain Persons in Matters to Be Acted Upon” and “Management and Corporate Governance” in our proxy statement for the 2022 annual meeting of stockholders.

Item 14.  Principal Accountant Fees and Services.

The response to this item is incorporated by reference form the discussion responsive thereto under the caption “Ratify the Selection of our Independent Registered Public Accounting Firm” in our proxy statement for the 2022 annual meeting of stockholders.

 

108

 

PART IV

Item 15.  Exhibits and Financial Statement Schedules.

(a)

The following documents are filed as part of this Form 10‑K:

 

(1)

Financial Statements (see “Consolidated Financial Statements and Supplementary Data” at Item 8 and incorporated herein by reference).

 

(2)

Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto).

 

(3)

Exhibits

 

Exhibit

Number

 

Exhibit Description

 

Filed with

this Report

 

Incorporated by

Reference herein

from Form or

Schedule

 

Filing Date

 

SEC File/

Registration

Number

2.1

 

Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DermTech Operations, Inc. and DT Merger Sub, Inc., as amended, included as Annex A to the proxy statement/prospectus/information statement forming a part of the referenced filing

 

 

 

S-4/A

 

8/7/2019

 

333-232181

2.2

 

First Amendment to Agreement and Plan of Merger, dated as of August 1, 2019, by and among the Company, DermTech Operations, Inc. and DT Merger Sub, Inc.

 

 

 

S-4/A

 

8/2/2019

 

333-232181

3.1

 

Amended and Restated Certificate of Incorporation of the Company, as amended

 

 

 

10-Q

 

11/10/2020

 

001-38118

3.2

 

Bylaws of the Company

 

 

 

10-K

 

3/11/2020

 

001-38118

4.1

 

Specimen Stock Certificate

 

 

 

10-Q

 

8/5/2020

 

001-38118

4.2

 

Specimen Warrant Certificate of the Company

 

 

 

S-1/A

 

6/9/2017

 

333-218093

4.3

 

Warrant Agreement, dated June 19, 2017, between the Company and Continental Stock Transfer & Trust Company

 

 

 

8-K

 

6/23/2017

 

001-38118

4.4*

 

Form of Management Warrant

 

 

 

8-K

 

9/5/2019

 

001-38118

4.5

 

Form of Series C Warrant

 

 

 

8-K

 

9/5/2019

 

001-38118

4.6

 

Form of Placement Agent Warrant 2015 and July 2016

 

 

 

8-K

 

9/5/2019

 

001-38118

4.7

 

Form of Placement Agent Warrant December 2016

 

 

 

S-1

 

5/4/2020

 

333-237991

4.8

 

Form of Placement Agent Warrant 2017 and 2018

 

 

 

S-1

 

5/4/2020

 

333-237991

4.9

 

Form of 2020 Placement Agent Warrant

 

 

 

S-1/A

 

2/6/2020

 

333-235780

4.10

 

Form of Omnibus Warrant Amendment for 2015 and July 2016 Placement Agent Warrants

 

 

 

S-1

 

5/4/2020

 

333-237991

4.11

 

Omnibus Warrant Amendment for December 2016, 2017 and 2018 Placement Agent Warrants, dated as of March 30, 2020 by and between the Company and Paulson Investment Company, LLC

 

 

 

S-1

 

5/4/2020

 

333-237991

4.12

 

Description of Securities

 

 

 

10-K

 

3/5/2021

 

001-38118

10.1

 

Sales Agreement, dated November 10, 2020, by and between the Company and Cowen and Company, LLC

 

 

 

8-K

 

11/10/2020

 

001-38118

10.3

 

Form of Registration Rights Agreement, dated March 4, 2020, by and among the Company and the Purchasers

 

 

 

8-K

 

3/2/2020

 

001-38118

10.4

 

Registration Rights Agreement, dated August 29, 2019, by and among the Company, certain stockholders of the Company and certain stockholders of DermTech Operations, Inc.

 

 

 

8-K

 

9/5/2019

 

001-38118

109

10.5*

 

Employment Agreement, dated June 26, 2012, between DermTech Operations and John Dobak

 

 

 

S-4

 

6/18/2019

 

333-232181

10.6*

 

Amendment to Employment Agreement, dated February 28, 2014, between DermTech Operations and John Dobak

 

 

 

S-4

 

6/18/2019

 

333-232181

10.7*

 

Offer of Employment Letter, dated October 1, 2015, from DermTech Operations to Burkhard Jansen

 

 

 

S-4

 

6/18/2019

 

333-232181

10.8*

 

Offer of Employment Letter, dated December 7, 2018, from DermTech Operations to Todd Wood

 

 

 

S-4

 

6/18/2019

 

333-232181

10.9*

 

Offer of Employment Letter, dated August 14, 2019, from the Company to Kevin Sun

 

 

 

8-K

 

9/17/2019

 

001-38118

10.10*

 

Offer of Employment Letter, dated September 23, 2019, from the Company to Claudia Ibarra

 

 

 

8-K

 

3/24/2020

 

001-38118

10.11*

 

Offer of Employment Letter, dated October 14, 2020, from the Company to Ray Akhavan

 

 

 

10-K

 

3/5/2021

 

001-38118

10.12*

 

DermTech, Inc. 2020 Equity Incentive Plan

 

 

 

8-K

 

5/27/2020

 

001-38118

10.13*

 

DermTech, Inc. 2020 Employee Stock Purchase Plan

 

 

 

8-K

 

5/27/2020

 

001-38118

10.14*

 

Form of Stock Option Agreement and Forms of Stock Option Grant Notice under the DermTech, Inc. 2020 Equity Incentive Plan

 

 

 

8-K

 

5/27/2020

 

001-38118

10.15*

 

Form of Restricted Stock Unit Agreement and Forms of Restricted Stock Unit Award Grant Notice under the DermTech, Inc. 2020 Equity Incentive Plan

 

 

 

8-K

 

5/27/2020

 

001-38118

10.16*

 

Amended and Restated 2010 Stock Plan of the Company, included as Annex E to the proxy statement/prospectus/information statement forming a part of the referenced filing

 

 

 

S-4/A

 

8/7/2019

 

333-232181

10.17*

 

Form of Stock Option Grant Notice and Stock Option Agreement under the Amended and Restated 2010 Stock Plan of the Company

 

 

 

S-1

 

1/3/2020

 

333-235780

10.18*

 

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Agreement under the Amended and Restated 2010 Stock Plan of the Company

 

 

 

S-1

 

1/3/2020

 

333-235780

10.19*

 

2020 Form of Stock Option Agreement and Forms of Stock Option Grant Notice under Amended and Restated 2010 Stock Plan

 

 

 

8-K

 

1/21/2020

 

001-38118

10.20*

 

2020 Form of Restricted Stock Unit Agreement and Forms of Restricted Stock Unit Award Grant Notice under Amended and Restated 2010 Stock Plan

 

 

 

8-K

 

1/21/2020

 

001-38118

10.21*

 

Form of Indemnification Agreement

 

 

 

8-K

 

9/5/2019

 

001-38118

10.22*

 

2020 Corporate Bonus Plan of the Company

 

 

 

8-K

 

3/24/2020

 

001-38118

10.23*

 

Resignation Letter, dated June 30, 2021, by and between the Company and Scott Pancoast

 

 

 

8-K

 

7/2/2021

 

001-38118

10.24*

 

DermTech, Inc. Change in Control and Severance Plan

 

 

 

8-K

 

4/1/2021

 

001-38118

10.25*

 

Form of Participation Agreement under the DermTech, Inc. Change in Control and Severance Plan

 

 

 

10-Q

 

5/13/2021

 

001-38118

10.26*

 

Amended and Restated Non-Employee Director Compensation Policy

 

 

 

10-Q

 

5/13/2021

 

001-38118

10.28

 

Standard Multi-Tenant Officer Lease–Net and Addendum to Lease, dated January 25, 2013, by and between DermTech Operations and AG/Touchstone TP, LLC

 

 

 

8-K

 

9/5/2019

 

001-38118

10.29

 

First Amendment to Standard Rental Lease, Storage Lease and Signage to Expand and Extend Term, dated January 30, 2014, by and between DermTech Operations and AG/Touchstone TP, LLC

 

 

 

8-K

 

9/5/2019

 

001-38118

110

 

10.30

 

Assignment, Consent to Assignment, and Second Amendment to Standard Multi-Lease–Net, dated November 21, 2016, by and between DermTech Operations and AG/Touchstone TP, LLC

 

 

 

8-K

 

9/5/2019

 

001-38118

10.31

 

Third Amendment to Lease, dated August 6, 2019, by and between DermTech Operations and HCP Torrey Pines, LLC

 

 

 

8-K

 

9/5/2019

 

001-38118

10.32

 

Fourth Amendment to Lease, dated as of September 10, 2019, by and between the Company and HCP Torrey Pines, LLC

 

 

 

8-K

 

9/23/2019

 

001-38118

10.33

 

Fifth Amendment to Lease and Signage Lease, dated February 5, 2020, by and between the Company and HCP Torrey Pines, LLC

 

 

 

S-1/A

 

2/6/2020

 

333-235780

10.34

 

Office Lease, dated July 1, 2021, by and between the Company and Kilroy Realty, L.P.

 

 

 

8-K

 

7/7/2021

 

001-38118

21.1

 

Subsidiaries of the Company

 

 

 

S-1

 

1/3/2020

 

333-235780

23.1

 

Consent of KPMG LLP, independent registered public accounting firm

 

X

 

 

 

 

 

 

24.1

 

Powers of Attorney (included on signature page)

 

X

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

X

 

 

 

 

 

 

31.2

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

X

 

 

 

 

 

 

32.1**

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

X

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document

 

X

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

X

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

X

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

X

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

X

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

X

 

 

 

 

 

 

104

 

The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2021 has been formatted in Inline XBRL

 

X

 

 

 

 

 

 

 

*

Management contract or compensatory plan or arrangement.

**

This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing.

Item 16.  Form 10-K Summary

None.

111

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DERMTECH, INC.

 

 

 

 

Date: March 10, 2022

By:

 

/s/ John Dobak, M.D.

John Dobak, M.D.
Chief Executive Officer

 

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of DermTech, Inc., hereby severally constitute and appoint John Dobak, M.D. and Kevin Sun, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for her or him and in her or his name, place and stead, and in any and all capacities, to sign any and all amendments to this Annual Report on Form 10‑K, and generally to do all things in our names and on our behalf in such capacities to enable DermTech, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.

Pursuant to the requirements of the Securities and Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ John Dobak, M.D.

John Dobak, M.D.

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

March 10, 2022

 

 

 

 

 

/s/ Kevin Sun

Kevin Sun

 

Chief Financial Officer and Treasurer

(Principal Financial and Accounting Officer)

 

March 10, 2022

 

 

 

 

 

/s/ Cynthia Collins

Cynthia Collins

 

Director

 

March 10, 2022

 

 

 

 

 

/s/ Monica Tellado

Monica Tellado

 

Director

 

March 10, 2022

 

 

 

 

 

/s/ Nathalie Gerschtein Keraudy

Nathalie Gerschtein Keraudy

 

Director

 

March 10, 2022

 

 

 

 

 

/s/ Enrico Picozza

Enrico Picozza

 

Director

 

March 10, 2022

 

 

 

 

 

/s/ Matthew Posard

Matthew Posard

 

Director

 

March 10, 2022

 

 

 

 

 

/s/ Herm Rosenman

Herm Rosenman

 

Director

 

March 10, 2022

 

 

 

 

 

 

 

 

 

 

 

112

 EX-23.1 2 dmtk-ex231_8.htm EX-23.1 dmtk-ex231_8.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statements (Nos. 333-234745, 333-235967, 333-239232, and 333-256464) on Form S-8 and in the registration statements (Nos. 333-235780, 333-237991, 333-248642, and 333-248657) on Form S-3 of our reports dated March 10, 2022, with respect to the consolidated financial statements of DermTech, Inc. and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

San Diego, California

March 10, 2022

 

 EX-31.1 3 dmtk-ex311_9.htm EX-31.1 dmtk-ex311_9.htm

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Dobak, certify that:

1.

I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of DermTech, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 10, 2022

By:

/s/ John Dobak

 

 

John Dobak

 

 

Chief Executive Officer

 

 

(principal executive officer)

 

 

 EX-31.2 4 dmtk-ex312_6.htm EX-31.2 dmtk-ex312_6.htm

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin Sun, certify that:

1.

I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of DermTech, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 10, 2022

By:

/s/ Kevin Sun

 

 

Kevin Sun

 

 

Chief Financial Officer

 

 

(principal financial and accounting officer)

 

 

 EX-32.1 5 dmtk-ex321_7.htm EX-32.1 dmtk-ex321_7.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K for the year ended December 31, 2021 of DermTech, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies in his capacity as the specified officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 10, 2022

 

By:

/s/ John Dobak

 

 

 

John Dobak

 

 

 

Chief Executive Officer

 

 

 

(principal executive officer)

 

 

 

 

Date: March 10, 2022

 

By:

/s/ Kevin Sun

 

 

 

Kevin Sun

 

 

 

Chief Financial Officer

 

 

 

(principal financial and accounting officer)

 

This certification accompanies the Annual Report on Form 10-K to which it relates and shall not be deemed filed with the Securities and Exchange Commission or incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 

 

 GRAPHIC 6 g4lv1dgrulou000004.jpg GRAPHIC begin 644 g4lv1dgrulou000004.jpg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g4lv1dgrulou000005.jpg GRAPHIC begin 644 g4lv1dgrulou000005.jpg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end GRAPHIC 8 g4lv1dgrulou000002.jpg GRAPHIC begin 644 g4lv1dgrulou000002.jpg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

US_WTO_Q-'_"(V'_/:Y_[Z7_X MFM^BCZI1_E#V]3N8'_"(V'_/:Y_[Z7_XFC_A$;#_ )[7/_?2_P#Q-;]%'U2C M_*'MZG

IW,#_ M (1&P_Y[7/\ WTO_ ,31_P (C8?\]KG_ +Z7_P")K?HH^J4?Y0]O4[F!_P ( MC8?\]KG_ +Z7_P")H_X1&P_Y[7/_ 'TO_P 36_11]4H_RA[>IW,#_A$;#_GM M<_\ ?2__ !-'_"(V'_/:Y_[Z7_XFM^BCZI1_E#V]3N8'_"(V'_/:Y_[Z7_XF MC_A$-/\ ^>US_P!]+_\ $UOT4?5*/\H>WJ=SG_\ A$-/_P">US_WTO\ \32? M\(?I_P#SVNO^^E_^)KH:*/JM'^4/;U.YSW_"':?_ ,]KK_OI?_B:/^$.T[_G MM=?]]+_\370T4?5:/\H_K%7N<[_PANG?\]KK_OI?_B:/^$,T[_GM=?\ ?:__ M !-=%11]5H_RA]8J_P QSG_"%Z=_SVNO^^U_^)H_X0O3O^>]U_WVO_Q-='13 M^JT?Y0^L5?YCF_\ A"M-_P">]W_WVO\ \31_PA.F_P#/>[_[[7_XFNDHH^JT M?Y1_6:O\QS7_ A.F_\ />[_ .^U_P#B:/\ A"--_P">]W_WVO\ \372T4?5 MJ/\ *'UFM_,]W_WVO\ \37344?5 MJ/\ *'UJM_,]W_WVO\ \373T4?5 MJ7\H_K5;^8YC_A!=+_Y[WG_?:_\ Q-)_P@FE_P#/>\_[[7_XFNHHH^K4OY0^ MM5OYCE_^$#TO_GO>?]]K_P#$TG_"!Z7_ ,_%Y_WVO_Q-=311]6I?RA];K_S' M+?\ "!:5_P _%Y_WVO\ \32?\(#I7_/Q>?\ ?:__ !-=513^K4OY1_6Z_P#, MSG]-\(:?I>H17L$URTD>7,]OYHBECN-I9EKR7X%>(KC4=#O='NI&D-@RM"6.2(VS\OT!'ZUH^+/C+HOAR_ET^TM MI-3O(3MD$;A(U;NI?!Y'L#Z4Y6B["C=GI-%>1:/\?-*N[I8M4TF>P1F $L>M2>'OCKH^IWA@U:P?2E*DK-YWG)P,X.%!'MP: /5ZR=?\3:1 MX7LX[O6;O[-!))Y:-Y;OEL$XPH)Z UYG-^T!IJ:EY46AW,EB&QYYF"N1ZA,8 M_P#'A7:ZUH.B?$[PS8/)=70L787,3V[*K$X(P=RGU.1ZBC6UT/2]F5?^%O\ M@3_H._\ DI/_ /$4?\+?\"?]!W_R4G_^(KR#XI?#_2O!$.F/IMQ>RFZ:0/\ M:75L;=N,;5'J:O\ PS^&.B^,_#D^HZC=:A%-'=-"%MY$5[Z-K>G>(=,CU'2[C[1:2$A9-C)D@X/# 'K[5H5R,9T#X5^#EBFNY_ ML,+MY?FD-+(S$G: 3_ )-<)-^T);KR$D M[79[317*^#?'^C^-8I?L!DAN81F2VF #@>HP<$5F^,OBMHOA"[:P\J6^U!5R MT,) 6/C@,QZ$^P-#TW!:['>51U?6+#0=,EU+4Y_(M(<;Y-C-C) '"@GJ1VKR M:R_:#LY)PM]X>G@A_OP7(E;\BJ_SKH?B-K%CKWP>O]2TV<3VLPB*N!C_ ):K MD$=B/2E*Z5QQ2\9:!XJDGCT6_^U- 9!Y,B;0-=,\%+K%UJ"RR/,D2PPQ+EG(+9Y/ KTCPI\:]/\0:U#IEYIDFGR7#!(9// M$JLQZ _*N,]!UJ[7=D3M=L]2IDTJ6\$DTK;8XU+,<9P!R:?5+6/^0)?_ /7O M)_Z":SD[1;*BKM(Y7_A;_@3_ *#O_DI/_P#$4Z/XM^!I95C775#,0 6MIE'X MDI@?C7S-H4.ESZW:Q:UMS&0%';!*)_6JV"VMCZLM;NWOK6.ZM)XY[>0;DDC8,K#V(J:O-/@IIVJZ; MX,F_M&*6&.:X,EM%*""%P,G!Z G_ ![UDV7Q[M)=2:"^T-K6W0.6F6[\PY4$ M@!=@R20!U[TY)*5A1NU<]6U34[/1M-GU'4)O)M8%W22;2VT9QT )K+\/^-/# M_BF::'1=0^U20*&D'DR)M!X'WE%<&GQ-M/&'A/Q(]YX9=M.LH5:2,WI'G!FP M%)505/&>,]*3X/:MX?U'4M371?#/]D2)"AD?[?)<>8,G PPXI).]F#TC?S_R M/7**\HF^-D%KXNET2ZT=8;>&[:WDO&O.%56(+[=GMG&:J7?[0&G1:B8K71+B M>S#8,[3A&(SU";3^I'X4)W2:&TTVF>Q45B0>+-(G\*#Q+]IV::8O-+L.5QP0 M1ZYXQZUYJW[05@-0V+H%R;+/^N-PHDQZ[,8_\>HZV$M5<]EHKR1?CI:7/B2# M3;'1FGMIYXXH[IKDH?F(&2A3L2>,]NM=OXQ\;:5X*L([C4?,DDF)6&"$ N^. MIYX &1DT/17#=V.DHKQ^7XW7UO:Q7T_@B^BTZ5@([IYV"./8F/!..V?QKT'P MEXNTSQEI)O\ 36==C;)890 \;>AQ^AIV!Z&_6!X@\:^'O"T\,.M:A]EDF4M& M/)D?I%V#0P1DJ%SP>(F_G7>^!/#WPW/BVTG\.Z_J=YJ-N&E2&9"JD8P&/%EQH;:&)UA9 ;@WFS.Y0<[=AQC/KVJIK7QZTN MQU%K?3-*EU"%&*M<&?RE/NHVDD=>N*E.ZN4TT['K9(523T R:Y73/B3X2UG5 M(=-T_5O.O)F*QQ_9I5R0">I4#MZU=\->*;#Q?X>_M/3]ZH=R21R#YHW Y!Q] M0?QKYE\#ZK::'XZL-2OY#':V\CO(P4D_=;H!WS0OCY6&\')'UQ17CB?M Z&UUZZN!&/X!#_.NL\$_%;2?&-\-.^S36.H%" MRQ2,'5\=0K#'(]P*:5]@>FYWU%>=>/?BI_PA&N0Z;_8WVWS(!-YGVKR\99AC M&P^GK65J_P =]*L5MTL=,>_F:-'F G"1QDC)4-M)8@\= *E.ZN-IIV/6J*Y; MP1XYT_QOITMQ:1O!<0$+/;R$$H3T((Z@X//'3I69XR^*VB^$+MK#RI;[4%7+ M0PD!8^. S'H3[ TWH[,2UV.\HKQBR_:#LY)PM]X>G@A_OP7(E;\BJ_SKU2P\ M0:5J6A+K=M>1G3S&9#,QVA0.N[/3'>BVEPZV-.BO']6^/VF6UT8M+T>>^B4D M&6680@^X&UCCZXK;\(??%%_%IT]O+IU]+Q&LC!XW;^Z&XY^H%"UV!Z;GH MM0W=U#8V1O;/ M8=S7EUW\<[#6-)U/3[K1I[3[1;2Q12).)1EE(&X87'..F:EO1VW*2U5]CTO0 MO'WACQ+J!L-(U/[3*]$\*Q02ZU>_94G8K&?*=]Q'7[H-4-&^(GA3Q!J<>G:7JHGNY M 2D?V>5,X&3RR@=*X+]H+_D%:)_UWD_]!%>6^'I)/#'B3PUK+-B&9EF+?['F M-&X_('\ZFG[SL^]BIJT;KL?4'B#Q1HWA:VBN-9O1:QS/LC/ENY8XST4$UFZ/ M\1_">O:G%INF:KY]W-G9']GE7. 2>64#H#WKRWXWWCZMXOT;0;=MS)&#@'C? M*V!^@'YUS/PJA^S_ !8T^ MN\MYTSCKB-Q13]YZ^?X!/177]7/J&BN2\9?$3 M1?!0CCO3)/>2C$]2U>/2K35O,OI)#&L7V>498=1DKCMZUKZ#K^G>)=(CU+3) MO-MWR.1AE8=58=C7S5X&_P"2NZ?_ -?[_P#LU"3]HHL3^!R1]445R?C/X@Z1 MX)CA6^$L]U.,QV\(&XKW8D\ 5Y\O[0J[P&\,$)GDB^R:>)4> XF@E #(>W3@@XZUPVD?'BQO=3-OJ.D#3[54=FN/M?F M'Y02 %V#))XZ]Z>SL+I<]>HKQR/]H'3FU(1OH5REB6QY_G@R >NS&/\ QZO6 M%U.R;2EU3[3&+$P^?Y['"[,9W9],4=+AUL6Z*\@U?X^Z5:W1BTO2)[^-2099 M)O(!]U&UCCZXK>\'_%S1?%=['I\D,NGW\@^2.5@R2'T5AW^H&:%KL#TW/0:* MXKXA?$#_ (0..P?^S/MWVLN,?:/*V;=+M])M)XM+DGOYDWR6 MRS@)#R1@R;>3CG 6E<=F>MT5Y?IWQQ\.W.BW%Y>P3VEW#C%H")#*3_<;@'WS MC%5M!^.NFZIK$5E?:5+8132"..<3B0 DX&X;1M'3IFJ2;=A=+GK-%<_XM\8Z M7X-TQ;S4F=C(VV&&(9>1O;V]S7F&6:,'Y6:^VDCW'EG'YFIN.S MM<]LHKC_ 3\1=)\;^=%:QS6UY H9X)<$E?52.HSQVKL*IIHFYC^(/%.C>%K M>&?6;S[+',Y2-O*=\D#/\(-8'_"W_ G_ $'?_)2?_P"(KEOV@/\ D :1_P!? M3?\ H--WMK6[?SK1UEM[A1M+ M*1D?X'\:^FK?Q18#P;;>([^9;:UDMDG=F_A) X'J<\ 56CCS(5FI,9[O5G\,QQ2016;AI)%G.V?ZT5PGC/XJ:+X/NFL3')?:@%RT$) "<DH/&/Z5YGK_QVT;3;R2VTO3YM3\MMK2^:(HV]=IP2?R'^(]'9B2NKH]7 MHKR?0OCOHVHW<=OJFG3:;YC;1*)!+&OH6.%(_(U1^-OC.:U@C\-VL;H+F)+A MKJ*X*[D)8%"H'(./7\*4KI#BKL]:LM5L-1EN([*\AN&MGV3>4X8(WH2.,^U9 M?B#QOX=\+7,5OK.H_9994WHODR/EQKY MWG[/+SA?N[3GUZBNO^+^K^'=.UO3TUGPO_:\K6Y*2?VA);[%W'C"CGZTY:6\ M_P#((ZWO_6IZOIVHVNK:=!J%C+YMK.F^)]I7K_ !]TJUNC%I>D3W\:D@RR3>0#[J-K''UQ M3E92L*-W&YZ_17GW@_XN:+XKO8]/DAET^_D'R1RL&20^BL._U S4?CWXJ?\ M"$:Y#IO]C?;?,@$WF?:O+QEF&,;#Z>M)Z;@M=CT6BO)=7^.^E6*VZ6.F/?S- M&CS 3A(XR1DJ&VDL0>.@%=CX(\HKG4UC>(/%>B>%8H)=:O?LJ3L5C/E.^XCK]T&MFO,_C#J6B:=I^EMK6@ M?VPCRN(T^V/;^6<#)RHYS4R=BHJ[.[T37=-\1::NH:5<_:+5F*B38R9(Z\, M:T:\Q\/>+M-T/X1R>(-*T#[-:P3$"Q^V,^27"D^8RD]\]*IV'QWTJ;2KN[O] M,>VGB=4AMHI_-:;.M45Y;X4^->G^(=:ATR]TR33I+ MA@D,GGB52QZ _*N,]!UK,^-_C&>RB7PS!%)&;B-+A[F.<+]W:<^O45[)XQ^(>B>"UCCO6DGO)!N2U@ +[?4YX ^O MX54E9)B5V['645XQ:_M!VCW&V\\.SPP?WX;H2-_WR54?K7J^B:WI_B'2HM2T MRX$UM*."."I[@CL1Z46=KAUL:%(S*B%G8*JC)). !2U\_?&SQC/=ZL_AF.*2 M"*S<-)(LYVS[D5@"F!TSZFI;MH5%7/=M/U.RU6W:XT^ZBN8 Y3S(FW*2.N#T M/X5S[_$KPC'K!TEM6Q?"?[.8OLTO^LW;<9VXZ]\XKS7X->._)>P\'_V;GS9) M7^U^?TX+8V;?;'6N!U6XBM/BO=W,[[(8M99W8]E$N2:JWOQ3V9/V6^J_X)]9 MT5X[>?M :;%J/E6FB7%Q9AL&=IA&Q&>H3!_4C\*]2T;6K+7M%M]6L9-UK.F] M2W!7U!]"""#]*72X/1V-"BO*?$'QTT;2[R2VTNPEU,QMM:7S1%&?7:<,3^6* M?X<^..C:Q>Q6>HV,NF22MM20R"2+)Z9; (_+%"][8'IN>IT451UE;Y]%O4TS M:+]H66 NV '(P"3[=:3=D-:LR-9^('A70+DVVI:U!%.IPT2*TK*?]H("1^-/ MT3QWX8\13B#2]8@FG)(6)@T;MCT5P"?PKRCPC\&=0;Q-,_BZU$M@L9<-'V\.3.L5N49=LA8PR]2H;.>#COD'CM36Z3Z MA:][=#ZPK+U[Q'I/AFQ6\UB\6U@9PBL49B6/8!03V]*R/$?B>[\,?#\:Y-:K M/>1PP^9$S;1O;:#SCL37SSXQU+Q7XCBMM?UZ&2.RE8QV@V[(AQD[%)R1_M M1M\;Y-.OX[?7_"&H:8KC=\TA+X]0C(F1U[UT7CGQY!HW@:'6=.C^V1:A^YAD MCF,93"K^?R8=?@5SWFCDB7_OIU _6NN5E= Z,&5AD$'((KPSQ=\#H= M/T0W7AVXOKN\C9=]O-M;S 3@[< 8QUYSQ78_"72O%.AZ'-8>(8/*ME8-:*TJ MNZ ]5."<#H0/K5*S3$]+'H=%>;>+/C+HOAR_ET^TMI-3O(3MD$;A(U;NI?!Y M'L#Z5EZ/\?-*N[I8M4TF>P1F $L?L M\O.%^[M.?7J*[WQ=\9/^$6\3W>C?V#]J^S[?WWVS9NW*&Z;#CKZU36WF)7=S MU.BN4\:>-/\ A$/#%OK/]G_:_.E2/R?.\O&Y2.O\ A.=-O+O^ MSOL7V:41[//\S=D9SG:,4N_D'1/N=A17CUE\>[274F@OM#:UMT#EIEN_,.5! M( 78,DD =>];7ACXHW'BJQUJYLO#KC^S8?-13=9\X\X7[GRD@'UHZ7^8VFG8 M]'HKS;P-\6H_&6OG27TC["YA:1'^U>9N(Q\N-B]LG\*D\>?%:+P5K4.F)I/V MZ1X1*[?:?+V9) &-K9Z9H>EK]1+6]NAZ+15/2KN;4-(L[RXMOLTL\*R-!OW> M62,XS@9Q]*N4VK.S$G=704444AA1110 4444 %%%% !1110 4444 %4M8_Y ME_\ ]>\G_H)J[5>_@:ZTZYMT(#RQ,BENF2".:F:O%I%1=I(^5?AG_P E'T/_ M *^/_937L7QSU.U@\%)I[2I]JN;A"D08;MJY);'IT'XUPG_"@_%/_/\ Z-_W M^E_^-U;L/@!K3SXU'5["&'CFW#RL?7A@N*J7O)1$M)_ _.N$\$-JS>+K>71]/M-2U)=SQPWC#:3CEN67)'7K7U'X:\- MZ?X5T6+2].C(B3YG=^6D8]68^M>:^)O@I+/K,FK>%]32QF>3S1!)N01OG)*. MN2H]L<>OHV[3NMK6$E>+1S_B_P +?$GQI<6]QJ'A6P@G@4J)+6>)6<''#%I3 MG';ZFNDU+3=5T?\ 9[NM.UF$PWD"!2AD5\+YP*\J2.A]:S(/@IXAU>_2?Q5X ME%PB$#,$OM_P^N/#.C""V!B2* 2DA%"L#R0">Q[=: MF2]QI=2HOWTWT/'/@EXU"?4[2&[CM8%V13H'3M=5XWT*Z\2^#]0TBSDACN+A5"-,2$&&!Y(!/;TIU=8V0J>D[ON>+?!# M0-*UK5M5DU.Q@O!;PH(TGC#J-Q.3@\9XKD+C2K1OB;)I"Q[+-M6-N(U/1/-V MX'X5[=\+?A[JW@BZU*74KBRE6Z1%3[,[L1M)SG:9]E M.I?:]GFR;]GF;L8V8SCW_&J5O:1?3_@B^S+^NAB_'#0=)T6\T4Z7I]M9^;%( ML@@C"!MI7!('?D\]:]+^#[,WPRTO<2<-*!]/,:J/Q2^'^K>-YM,?3;BRB%JL M@?[2[KG=MQC:I]#71^ O#UWX6\'V>D7TD$EQ"SEF@8E#N[_Z_P!__0$K0^*7@35/&\.F)IL]G$;5 MI"_VEV7.[;C&U3Z&M#X9^$;_ ,&>')].U&:VEFDNFF#6[,RX*J/XE'/!HIZ* M5_ZU0YZJ-OZW/.?V@9;C^UM&A);[.('91V+[@#^F*;X0E^(">"H+/1?">B7F MDW"-F25DW3Y)R7_?#)[<@=*]6\:>"[#QKHXLKMFAFC;?!<(N6C;Z=P>XKRU/ M@[XXL(I;'3O%$$>GN?FC6ZGB#YZY15(_4U$59.+&W=ID/P[^'WC+P[XXL=1O M-*^SV:[UF87,3 *5(Z!R3SBN.T9(=3^+,":QATFU1O.$G1CO/!]LX%>W_#_X M76?@N:2^FN?MNI.I02;-JQKW"CGD]S_DY7C?X-0>(=5EU;1[U+&[F)>6*1"8 MW?\ O CE23UX/K];O:47V)^*,EM;X/:LOAIK V2O'D6>W:&\Q,YQWZ=>>EXA77_$T M,UO$,(QGEN&0<<*' _.N]U?X?1K\,Y_">A-%$S[");EB-[!PS,Q4'DX]/2I M:]UE1=I(\O\ @AH&E:UJVJ2ZG8P7@MX4\M)XPZ L3D[3QGBN4O[6'3OBG+:V MD8BA@U?;$B]% EX KVKX6_#W5O!%UJ4NI7%E*MTB*GV9W8C:3G.Y1ZUSFI?! M[Q#>>.Y]]6G^\B^G_!)?P27];'MM4M8_Y ME_\ ]>\G_H)J[5>_@:ZTZYMT(#RQ,BENF2".:SFKQ:147:2/D3P?H]OX@\6Z M;I5V\J07,NQVB(# 8)X)!';TKO\ XD?"[0O!_AM=2L-2NS.9E00W3HWF ]=N MU1R.O>H/^%!^*?\ G_T;_O\ 2_\ QNI(/@%XC:91<:GI4<7\31O([#Z H,_G M5/560EH[G1? SQ'J6HP:GI5["-)EMXIC(?" M6HZ3:/$D]S'L1I20H.0>2 3V]*X[X7?#O5_!-_J$^I7-C*MS$J(+9W8@@YYW M**F&DVWV"7P)+O\ Y'B^L6L=[\4[RTF!,4^L-&X![&7!KN/CAX>T?1(M#?2] M-MK,OYJ/Y$83>%VXSCJ>3R>:T+CX/>(9?'DFNK>:8+5M1^UA#+)OV>9NQC9C M./>NJ^*7@35/&\.F)IL]G$;5I"_VEV7.[;C&U3Z&IM^[BNII=>TD^G_#GG;> M>_[.*^66*+?_ #X_N[_\2*VO@"=/^QZT',/VTLFX-C=Y6#^F<:;X,^'>KW[S0^.#;V2'+6 MUW&L,N/02.0#^"FKO[TO/_)&=O=5^_ZG-'['_P +37^S]GV/^V!Y/E_=V^;Q MCVKVGXN>"9?%-E97=I=V\-W:;U$=Q($653@D GH1BO%-/M;6;XG6UMHJM)9C M5%%M@ELQB3@Y^@SFO??B%\-[7QPEO.EU]CU" ;%FV;E=,YVL,COT/N:FW[J/ M]=BF_P!Y+^NYY";_ .(_AW0;=;FW-UH<(5T$L$-Y;[5P5.\!L*.,'(]C7JGP ML\>GQA8W5M<64-K>6>TM]G7;'(K9Y ['CFN9A^&_Q'BT,^'AXFTY-%;*-&"Q M;83D@'R\_P# =V.U=UX"\ V?@;3YHXYVNKRY(,\[+M!QT"CL!D_G5I[W(:VL M=?7@?[0/_(;T;_KW?_T(5[Y7F7Q1^'6K^-M1T^XTVYL8DMXF1QYQ_P //A3H7BWPE%JM_=ZC'.\KH5@D0+A3@<%"?UKT7PK\*]#\ M(:R-4T^ZU&6<1M'MN)$*X/7H@/ZUY9_PH/Q3_P _^C?]_I?_ (W6QX4^#/B+ M0O%6FZI=7NEO!:SK(ZQ2R%B!Z90#/XUHG=]B'MW.+^+G_)3M6^L7_HM:[?XI M^%=#T7X;Z5/I^FV\%PDT2&=(P'<%&)W-U;D=ZL>.?A%K_B;QC?:Q97FFQV\^ MS:LTL@<80*<@(1U'K79?$'P?J'BOP?:Z1836L=Q#-&[-.S!"%4@X(4GOZ5G; M]VEUNC5M>TOTL_R.4^ I/_"+:RN>!<@@?\ KRGP)IMKJ_P 0-+L;V(2VTEP= M\9Z, "<'VXKWKX9>"-2\&:/J%GJ,]I+)\9 M6&L7=YICV]O(SNL4LA<@J1P"@'?UK16]I?R1G_R[:Z_\.V= VYP#SD_= MP._O[T_XG?#36?&FO6M]IUS81116PA87,CJQ.YCQM4\U7X8OK?P\TC0;J M\C@U#34&R>,%XR>A'."0?PZ5FK^S:\_\RG;G3\OT1RWA35/$VJ:==/X)\)Z/ MH^FSR,9KFXE+@MQP,GH!VVD=>EB/ M+)YOE9/!^3&[!]<9K2-E-,B7P-'/_'K_ )'>S_Z\$_\ 0WK MTB^G_#'G?[/Q/]K:TN>#!&<).C'>>#[9P*]A M^%WP[U?P3?ZA/J5S8RK=RBH/&_P:@\0ZK+JVCWJ6-W,2\L4B M$QN_]X$O!]?K;=IQEV_S(2O&4>_^1UOC&'PBME9R>*H[46R3A+O''-<7\1+G15^$ETGA-[+[ ;J-)A8E=HR>=V.Y.WK[5B'X+^+]7N( M5U_Q-#-;Q#",9Y;AD''"AP /SKU33_!6C:?X0;PRL!DL'0K+O/S2$]6)_O9_ M+ ]*EJ\6-.TD>$_"^?Q=:"_G\*:'INH2959I;EE#QCG &9%.#_2I=6^'GQ!U M;7Y=8/ANWM+B202%;2YA1%88Y ,A()(SUZUT,OP4\2Z/J#S>%_$J0(^1O>62 MWD"]@3&#N_3ITK5\+?!=[368]7\3:FNH7"/YGDIN96<'@L[2?#? MX7:WX/\ %#:GJ%UI\L)MWBVV\CLV21ZH!CCUKUNM)/1$+=GC7[07_(*T3_KO M)_Z"*XGQ%I7F?!SPGJR#F"6>!S[-(Q'ZJ?SKUSXH^!]3\;66G0Z;/:1-;2.[ MFY=E!! '&U3Z5$OP^O9/A"/",\]K]O0%DE5F,0?S"XYVYQCCI6:TB^]T:75X M_P!=SRWP#+=>,_BQ8W]Z S0()I,'@") J_\ CP4_C47PT_Y+);?]=[C_ - > MO3_A?\-M0\%7NH7FJ3V$/A1KN@>/H=>N[O3 MGM4DE-[^&*QU3Q1 VGQ_=C^U M33!,=,(R@?J*RBO<467)^]S(Z/X/>%?$GA7^UH=:LC;03^6T0\]'!8;@>%8X MXQ7E?@;_ )*[I_\ U_O_ .S5]#^#O!]AX,T7^S[(M([MOFG< -*WK[#T%>;^ M'/A#K^C^.K77+B\TQK6*Y:9DCED+D'/0% ,\^M:7_>ID?\NY+N:'Q5\5>%-* MU!++4/#EOK&J&'EGPGE(82Z/I&B>&XXHS'!NW M3,F5VX))Y)[D*>M=7\1_A1+XNU0:OIE]%!>F,1R1W .Q\=#D D''L>W2L:V^ M#.O7FDO;:]XGDN!#$RV=HDTCPQOC"DEN@'H%K-+W7C G!]N*]E^&?PYUSP7J.H2ZA<:=+ M!=6XC'V>1RP8'(X* 8ZUC>#O@_X@\/>,K#6+N\TQ[>WD9W6*60N05(X!0#OZ MUHKCZ;H_BVT33;*"SCELU=XX(PBEMS#.!P. *ZOQ+/ M?^93:YT_+_(\X_9_ MMK)K76+@JC7RNB9/WEC(/3V)S^5>??$".'3_ (HZD-) C\NY1XQ$,;9,*3C' M^UFN\N/@IXATB_>?PMXE$"/D9DED@D"]@6C!W?I]*V?!OP9CT?5H]7UZ_6_O M(V$B11@[!)UW,QY8YYZ"M$[S4NQ.T6M[F3\?RQL?#Q<88F;/UPE0^$O"VB7/ MP1U/4[C3;>:^>&XD%PZ R(4SMVMU7IVKL/BEX$U3QO#IB:;/9Q&U:0O]I=ES MNVXQM4^AJUX?\&:CI7PNN?#$\UJU[+#/&LB.QCR^<9)4'OSQ6:^"1=U>'E_P M3QKX.Z+I^M^-S%J5K'=0PVKRB*50R%LJ!D'@_>-97Q%L;72OB)JMK80);V\< MJ%(XQA5RBDX'89)KUKX:?##6_!OB674M1NM/EA>V:$+;R.S9+*?XD QP>]9W MC7X0>(/$?C&_UBSO-,2WN&5D6:60.,*HY 0CMZUI=<\7_6Y*V=SHOB5XE\-: M)INGKK>B0ZQ>2INMX9% VCC)+D$J#QT!SCVKDK6Z\6W_ ("NQHOA_1M#\-/; M22,\[EVD4AMQ!))/ME?3!KL_B'\-3XTMK.:VO$MM0M(S&ID!,<@]#CD<]\'K MTKF-&^#/B VRV&N^)W&E(?8U%KJ2!:=_*QX=\-[GQS9^'9CX7\.:3?6LLK"6XG9?,8X'R MG,JG '08[TS1OAUXZM/&MGK+:#':(MZL[K!*UE^#7C+ M1YIH] \410VTOWR)YK=GZ_>5 0>/>NF\"_"&'PUJJZQJUZM_J"K M9/+'K@\?X6G[REV(?PN/MWX M+:3IC>"K74CI]HVH+/*HNC"OF@9QC?C/0XZUT7Q#\$CQOH4=FER+:Y@E\V&1 MERI.""#['/6N0\!?#7Q=X5UZUGN]YE978J1G85"]\Y]JFGIS) ME3U2\CR(/J-U\1)'2UAO=1;46*P79&R23>?E;) QGMD5Z%XNT3XF^,[*WMM1 M\):9%Y#[HY;::-7 QC;DS'Y?;V%=+XY^#L7B+59-8T>]2QO9?FDBD4^6[_W@ M1RI]>#Z_7GS\&O&&L31IXA\4QS6\?W3Y\UPR_0. !Q[THKW5%]!R?O.2+NDZ M-XC\*?!;Q)9ZI;M;3C>T*B57(C8*&P5)Q_%7._ >UL9_%E[+<(CW,-MNM]W; M+ ,1[XQ^=>WZ-X8TO0_#BZ%;0![+84D$G)EW?>+>I->6:G\#M2LM4:^\*:ZM MK\^8EF=XWB!Z@2)DG\A_C5[3;\K$VO"WG<[3Q)'\.XO$8;Q&FFKJDD"MFZ!P M4!(!.?ESG/OCVKG_ (S6>DR_#^WU*RMK)V$L,<%S#&A/E8.%5A_#[ XK+TKX M'ZE>:L+[Q9K:W7S[I%A=Y'F [&1P"/R/'Z>E^+/"EOXF\)S:$KBU0JODLJY$ M97[O'IQC%3)>YYE)^\>:? C2=,O=*U"ZN]/M+BZ@NT,,TL*L\?RY&TD9'/I6 M5\?_ /D9-*_Z]#_Z&:U/"_PE\8^'MXF'G*ISADV@'/3 MD]ZW?BA\-]8\:ZO97>FW-C%'! 8V%S(ZDG<3QM4\4ZFO*U_6@H:73_K4QO$< MMQ%^SII8@+!7C@64C^YN_P <4W]G^VLFM=8N"J-?*Z)D_>6,@]/8G/Y5Z/H_ MA=(O 5KX:UA(KA5MA!.(R=K>X) /T/%>9W'P4\0Z1?O/X6\2B!'R,R2R02!> MP+1@[OT^E-NTY/N2E>$5V.#^($<.G_%'4AI($?EW*/&(AC;)A2<8_P!K-;_Q MU+'QE8EQACIR9^N]Z[;P;\&8]'U:/5]>OUO[R-A(D48.P2==S,>6.>>@H^)G MPQUKQGXC@U'3KJPBACMEA*W$CJV0S'^%#QR*EJT8Q[?Y%IWE)^7ZF/J/A30[ M?X!QZC'IMN+\VT4_VKRQYNYG7/S=<8)&.E5/V?2?[7UI<\&",X_X$:]$U#P? MJ%U\)T\*I-:B^6UBA,C,WE;E92>=N<<>E9'PN^'>K^";_4)]2N;&5;F)406S MNQ!!SSN45:?[R3Z$/^&EU_X8]-KQK]H+_D%:)_UWD_\ 017LM,\5WEO\.M7B^$5QX3:YL3?R2[Q('?RL>8&Z M[<]!Z4_X6_#W5O!%UJ4NI7%E*MTB*GV9W8C:3G.Y1ZUHK]>G^,?#,?B[PSZ5J%U=Z?:7%U! M=H89I859X_ER-I(R.?2N#\>L;GXLZ@NI,1#]M2-BQ^[%\H'X;:[OPO\ "7QC MX>URWFCU^UAL%N$EGBM[B8>C/\ #[B$M'$@^,-CIJ?#*3]S"GV=XA:;5 VG)X'L(?]6HGFG\O MM\J, !Q[UZYX5\+:=X1T5--TY6*YWR2O]Z1SU8T1TYGW"6J2[&W7B7Q]L+.& MVTJ\BM(([J>9Q+.D8#R *,;FZG'O7MMFVUF7\U'\B,)O"[<9QU/)Y/-:GAB>YB_9VU)[=F$BI M. 5ZA2WS?H373?%+P)JGC>'3$TV>SB-JTA?[2[+G=MQC:I]#6MX#\)W'AOP6 M-#U4VUPQ>3S!$2R,K'I\P';VJ$FX27:JE_P"+ MM<%Z0V7CB=Y&E Z R/@@?A^-5\5A?#>QZIX9@OK;POI=OJ2E;V*UC292P8A@ MH!Y!(-:M-CC2&)(HT"1HH5548 Z 5E>)[+4=2\-7]CI,T4-[<1&..25BJKG M@G(!/3...M*:\C_ &@/ M^0!H_P#U]-_Z#7I^@6$NE>'=-T^=D::UM8X7*$E254 XSCCBN4^*'@G4O&VF M6%MIL]I$]O,9'-R[*""N.-JFE471=P@^K*?P/_Y)XO\ U]R_TKDOB9X U(^+ MG\0:+>VIFGDC?R7NDAECEX"[=Q .2!CG.:](^'/A>^\(>%1I>H2V\LXG>3=; MLQ7!QCJ <\>E##E<]>AYJIOWTT3# M2+3\_P SA;[QC\0/#=]!-XDT^*X*+LB;4+!",'!(610#S@9^:O7(M4T[QW\, M9=4N--@9?LTK"&=%D$4J*PRN1V['KS7)7_PS\>>*?LUKXH\464EE;G<@@0LV M>F<;$R<9Y)/ZUZ=HOAVPT+PY%H=JK&UCC,9+'YGW9W$GU))I25X-?<4G:2?W MGSK\'M/L=3\>);:A9V]W ;:0^5<1+(N1C!P1C-?3L,,5O!'!!$D4,:A4C10J MJ!T Z"O"'^"'B?3-6:XT#7K6%%)\J8S2PS*#V^13V]#S7MFC6EQ8:+96EW< M?:+B"!(Y)B2?,8#!;GGFJO>)-K2*?BZPEU3P?K%C ,S36DBH/5MIP*^$O(0 K,.,D].<#\:^IZ\F\8_!.TUO4IM2T:]2PFF):2W M>/,;,>X(Y7)Z\&H3Y97*:4H\IV?CCQ?;^#_#DNH%HGN6PMM Q_UK$^W.,9.: MPO"GQ(;QKHFK?9M+GM+VSM6?<'#QEB#M /!SQG&/QKSZT^ .OO.!>ZMIL,/= MH3)(WY%5'ZU[/X4\)Z=X0T9=.T]68$[I9GQNE;U/]!3<;Q=^H7LU8^8O!#:L MWBZWET?3[34M27<\<-XPVDXY;EER1UZUW/B_PM\2?&EQ;W&H>%;"">!2HDM9 MXE9P<<,6E.<=OJ:Z#Q-\%)9]9DU;POJ:6,SR>:()-R"-\Y)1UR5'MCCU]*$' MP4\0ZO?I/XJ\2BX1"!F.62>0KW :0#;^M"U2!Z-LO:QINJZ/^SU/IVLPF&\@ M*J4,BOA?/!7E21T/K7,?!#0-*UK5M4EU.Q@O!;PIY:3QAT!8G)VGC/%>N>*O M"!U+X?3>&=%$%L-D:0B5B$4*P/) )['MUK"^%OP]U;P1=:E+J5Q92K=(BI]F M=V(VDYSN4>M4G[\FQ/\ AI(\5O[6'3OBG+:VD8BA@U?;$B]% EX KV/XY6%F M?!@OS:0&\6XCC%P8QY@3YOEW=<>U8>I?![Q#>>.Y]GVEQ=07:&&:6%6>/YURWFCU^UAL%N$EGBM[B8>@Z5"M2\%:3?VFI3VDLEQ,)$-L[, -N.=RBC^?S_X M!+VBNW_!/ _"&E0:W\0=/T^Z7=;RW9\Q?[RC+$?CC%?5>GZ1IND121:;I]K9 MQR'S33 M1V\+S3.J11J6=V. H'4FC102*GK4;1\T:S:M\._C%'/'^[M%NEN(SCCR7/S# M\ 67\*D6,?$/XV.5Q-9-=;B1RI@BX_(A1_WU70?'#4?#FKV.EW.G:M9W=_%( MR%;:99/W9&3N*DXP0,9]35[X">'S%::AX@F3!F/V: D?PCEB/J<#\#12Z7^S M?]+?UZA4\OM'LX P!@"EHHI""BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH @O+.VU"SEM+N%)K>92DD;C(8'L:\ZN_@ M7X1N9S)%)J5JN/\ 5PSJ5_\ 'U8_K7IE%%NH[G*>%_ASX<\)3"YT^U=[L+M^ MTW#[W [XZ 9]@*ZNBBG>X@HHHI %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %1SPI:5PD<:E MF8] !R30 ^BO%=9^*^MZGJ36?AJW\J,MMB80^;-)[A2"!],&JL/Q,\9:%>+' MK=N90WS&*ZMO('X=:%Q'!9R+E MGG<((SG!#$\ @\5,FNZ1)9O>1ZK8M:QMM>9;A"BGT+9P#7.X23LT6FFKHOT5 M7@OK2ZM?M5O=036^"?-CD#)QUY'%>;ZO\4RGBRWTK3_L@L1,CMOO8)4\D#. -P"C/:CV;Y>8+ZI'1450C MUO29K.2\BU.R>UC.'F6X0HI]"V<"I;?4K&[M3=6U[;36ZYS+'*K(,>X.*AIH M=RU152RU73M3#?8+^UN]GWO(F5]OUP:XK7+WQ%'XM:*T\7Z'9V7F1@65Q+&) M@,#(P4)R><<]Q5PIN4N783E97/0**S[O7='T^?R+W5;&VF SYBHY[B&VA::XFCBB499Y&"J![DU4L];T MG49#'8ZI97,@ZK!<(Y'X TDFQE^BD)"J68@ #))[5S7B'Q+;)X8U:YT;5;26 M\M82P\F5)3&<]QS^HH2;V Z:BO.?A9XHUGQ(=4_M:\^T>1Y7E_ND3;G=G[H' MH*]&JZM-TI$:U\0/%\/BB_P!/L=16]K&3@//*$&?J34$NNZ/!;17 M,VJV,=O+_JY7N$"O]#G!H2;V T**I3:QIEM9Q7D^I6<5K+_JYGG54?OPQ.#3 M7UO28K..\DU.R2UD.$G:X0(WT;.#1ROL%R_14<$\-S"LUO*DL3C*O&P96'L1 M5>]U?3--*B_U&TM2WW1/.J9^F319WL!\A6:UGBGB;H\3AE/XBHKW M4K#345[Z]MK56. T\JH#^9HL[V M454LM5T[4@QL+^UN@OWO(F5\?7!KC?'? MQ%7PRZ6>G);7=XX;>3*"(",<,HYR<]"151IRE+E2U%=6N=[17/:-KT>L^%5G M@U.S;4!9*\S+(I$,A3.7 SM .>H[5D>"[O7KC5)UU7Q3HVK0B'*PV,J,ZMD? M,=J+QU'XU7LG[U^@N963[G<455O=2L--17OKVVM58X#3RJ@/YFBRU*PU%"]C M>VUT@."T$JN!^1K.SM+;2X MBO(HXKZVP7\O(5U/0@'H>.:WJ86<(\VCL9JHF[':T54O=3T_355K^^MK56.% M,\RH#^9J2TO;2_A\ZSNH+F(]'AD#K^8KGL[7-">BO(/'GC;Q#HWC5]/T_4/) MM0L9$?DQMU SR5)KU&\UC3--*+?ZE9VKN,J)YUC+#VR:TE1E&,9=R>9RQK)GG+89"<'Z]JV>'FI*,M"%---KH=]13%;; M KR.O"Y9\\=.OTJC#K^C7-S]F@U:PEGSCRDN49L_0'-8V;V*OIMZ3-9R7D6IV3VL9P\RW"%%/H6S@46>XR_15> MSOK/4(?.LKJ"YBSC?#('7\Q5BDU;< HKR+Q_\2-1L=96P\/WUL(40%YXPDI+ M'.5R<@8X]ZZ_X?WVNZAHL]SKUU;W#&7$,D+Q.-H SS$=O7\:V="2I^T>Q/.N M;E.NHK.7Q!HK77V9=7T\W&<>4+E-^?3&47*%5)Z G. 35Z">&Z@2>WECFA<922- M@RL/4$=:'%K<5T245POQ0\0ZIX=T>RGTJZ^SRR7&QV\M7R-I./F!KSJ#QQ\1 M+JS:\MY[N6U4D--'IZ,@QURP3%;T\-*I'F35B93478]_HKS/P!\2KC7=072- M72(73@F&>,;0Y R58>O4Y'Y5Z/<75O9P-/=3Q01+RTDKA5'U)K.K2E3ERR'& M2DM"6BJ-EK.EZB[)8ZE9W3KU6"=7(_(T^^U73M,"&_O[6T$F=AN)ECW8ZXR> M:CE=[%7+=%4#KFD!X$.J60:X ,*FX3,H/3;SSGVH?6])COOL+ZI9+>%@OV=K MA!)D]!MSG)HY7V%=%^BJ1UC3!??83J-F+S./L_GKYF?]W.:+K6-,LKA+>[U& MSMYG^['+.J,WT!.31RL=R[11U&16;<>(M$M)FAN=9T^&5>J272*P_ FA)O8# M2HJM_:%E]B-[]LM_L@7<9_-78!Z[LXQ7G%I\4SJ'C6'3_P#1++2%DD62XEE! MWA5;!W'"@$@?XU<*4YWLMA.22NSU"BHXIX9[=;B&6.2%UW+(C JP]0>F*I1^ M(-%EN?LT6KV#W&2/*6Y0MD=1C.:BS'?:! L9C_=(FW);/W0/05I&E*4'-;(F4DK>9Z3 M152]U73M-V_;[^UM=WW?/F5,_3)J6UO+:]A$UI<0W$1Z/$X=3^(K.SM:A9:=$);Z\M[6,G >>4(,_4FH)==T>"VBN9M5L8[>7_5RO<(%?Z'.#0DWL M!H45GSZ]H]K%#+<:M8Q1SKNB>2X11(/523R/I5E;RU>S^V)-_,_P"$(UCRL[OLK]/3'/Z9K?IDT4=Q#)#* M@>.12KJ>A!X(IIV=QK<\3^"_V?\ X2.^\S;Y_P!F_=9ZXW#=C]*Z/XT_9_\ MA'M/W;/M'VKY/[VW:=WX?=_2L#6/A1KNF:DUWX;N/-C5MT(6;RIH_;)P/QR* MJP_#3QGKMZKZW<-$J\&:[NO/8+_L@$_D2*]*3ISJ*KSVL<\>:"<;;EC1?-_X M4;K>_.S[3^[SZ9CSC\PY8Y![*/\:]! M\7:/:Z!\)[W3;,'R88T&6ZL?,4DGW)KS7P/8^+);#4+KPM=*CJRQS0Y4%P0< M$;QC(Y[@TX3YX5)1=M=_N!Q<5!/S+7PYGGL/&UQH#3,UM=B:VE"G@E0V&'OP M?SK&U#P[:6GQ#'A^.2?2O1?AY\/=1T?5VUK6RB7 5 MA%"'#L&;JS$<=,]">M9_C/P%XCF\9/KFA1+/YCI,I$J*T3J!V8@'D9[TU6@J M^_37U%RMP=EUT)OB/H=MX<^'.GZ99R3/!%?95IB"W(I^]G;T![UBII4[2DF^;^F:)>_%I:?\.<;X%\)IXLT74X[ MJ_N(8+1M\,41&WS64_,P(YX4"LWP%H0\2ZW)I$][LCX:^#/$&@>*)+S4[#R M+=K9T#^=&WS%E(&%8GL:VE77-4M+2RM]QDHOECIK?]3EO#UN_ASXLP:?;3NR M17AMRQXWH>.?\]13_&__ "5J3_KXM_\ T%*Z/_A"O$/_ M/^V?[/_XE_P!O M\[SO.C^YGKC=G]*9XJ\$^(M2^(CZK::?YED9H6$OG1CA0N>"V>Q[40JQ=2$I M-?#K^ YQ=II+^M3:^(OAKPR?-\0:U>7T>>!?!4_ MBG5//*R0:7!)F24G);N$4XY/J<#_%OB'Q5-<6MFUQ8HJK;YN(U" MC:-V 6!ZY[4RPL/BQIEE#964*PV\2[41?LF /Z_6IHR<:6DU=]WL.HKRM;0Q M/B5K4VH^-IK&[FF73[-UC$B^SR^'9=72=&RYO! M&,>A4H<@Y_\ UUZ?XS^'FJ:EJ4.O:-*BZAM1IHF<(3(H&&4],\>W2J*:%\4M M9NHH]0U.:PA3@RI<(G'?B$_,?K^=52JP4(I-*V^MO^'":;DW8H^+O%5_J/PT MT'?*P>]9UN6!P9/+.WGZ\$U53X?VP^&I\2+>SK>F$S% 1Y>S.-N,9SCW_"O1 M?%W@AM>\*6^G0W3O>6>&AGN7+&0XP=S=>?\ "N'LO!?C^70;C1+B86VF1JS) M;F6-C*W4*".0"<=2!S6<*L7!\C4=;_(?*[QOKH7/@A][6_I#_P"SUZ]7G/PL M\+ZSX;.J?VM9_9_/\KR_WJ/NQNS]TGU%>C5SXN2E6;3OM^15)-1U/G(_\E;_ M .XU_P"UJ]&^,PA_X12U+[?-^UKLSUQM;./TKC]:^'_B^;Q1?ZA8Z1PJ<"6\O!+M!ZXP6/\JZWR25.7,ERDMM3 MEIN6?#1?_A2_B,-G:)SM_*/-:/P8)&GZ\1(L1'EXD89"\/R?I75W_A%K#X:W M7A[24-Q.T6!DA3*Y8$GDX'YUA> O!>KZ?H6OZ=JUN;,W\8CC<2(_\+ GY2>F M16)M-\>VNHM"VH6\=S'-+=^:BE\X+G:6SP2?RKH52&SDFK M?UY&FIC^-&G\0_%%M,N+@QP_:8[6/)XC4XR0/QM[*] MN)K6Y#/Y4[ E77 )X '(([=JZ3QWX=T;6O$\DEAK]C8ZNK*D\%VQC5FP" MZXQTSGZUR?CSP_>:$^G#5-8DU+4)HV,A:1G$:C&T MSC);GCZ5%&::II.WEW MT_IES7O2?]+^MCH?&7_)(?#'^]'_ .BVK.L_!R:I\,Y?$%S?W)FM8W^S0Y'E MJBL,$KVW M+)QGZ9JY5(>TGRM)NUF)1?(O4RO#LUUX,^)PTB"Y>6V:Z%M*O:16X!(]1D'\ MZ3QK:WFG^/KG4->TV>_TUI"4'F,B/&1A5#C[N/3V]ZZSP9\.=2M]>&O^))E: MY5C*D0?>QD/\3D<<>@SS5G7=+^(EKX@^W:3J U"S64O%;,ZQ@ @_*Z_*"!TZ M^AZTO:Q]HM4W:S?_ 1\KM+30YCPM>>!SXKMKFR?6=)N3*!"AE1H3G V$D%L M'IS^8J#XN:';:7X@AO8'F:34 \LH<@A2,#Y< ?$GB;Q+%J>O6ECI M<*%?,CMMN7"^@4MR>F2?Z5T'Q.\&ZCXFAL;G2U26>VW*T+.%+*<=">,\=S2] MI&-6#YO76_XC46U)6&^%O"UCH?@:[U&VEN'FU'3!),LK*54^63\N ,?>/4FN M,^$$WV;7=4G(SY=@[X]<,IKM?".F>+X/#FIZ=KL>$%IY%C%OB)'RL,97ZJ,D M]JROAGX-US0=;O)M7T_R+>6U,0)F1\DL.,*Q[ U+FOWMY)WV_$5O=AIU_P C MC_#.ER_$;QC<-JUY* 8VFD9"-V,@!5SD <^G:NVL/A5>Z+XF2_T?6_L]M$5* M>8I>1A_$K ;00?Z^U95W\.?%'AO7'U#PG.LB$GRP)%5U4_PL'^5@./\ "K&D M>"?&FJ^(5U3Q!J,UF-R^:8[@"1U7D*!&=H'7Z<\5I*HGK":4;;?\ 3B]>979 MZ[7%?$+1]"UZT@M=1UJSTV^BS) \\R*<'@@J2"0<=?:NUKBOB#X&;Q;;03V< ML<5_;Y"^82%=3_"2.GL:\^DTIIMV.A['%)H_Q!\+:1]HTK5HKO3(D,J&WE65 M/+QG(#CICL/P]:Z#P;\2Y]:L]1CU&WB%Y9VKW*M$"%D51R".QZ?GVKCAX%^( M<=NVFH+G["3M,:Z@HA(SUV[^GX5WO@'X>'PU'?ZUNW'P]\5^%];DOO"4ZR1OE4PZ! MU4_PL'^4@//!/B'6?& MKZAI^G^=:E8P)/.C7H!G@L#6]\2_!5_XFAL[K3 CW-LK(T+N%WJ<'@GC.1WQ MUK*%2"5*[VO^1HTW*7HC.\>$#X0:0">2ML!_WQ5'PMH=KKWPAN8;J29%M[F6 MX0Q$ EE3@'(/'-4[KP1X]U3PS':ZA*'2SVBUL/,CW'MDL"!@+TR2:[?P'X::24%0ZMA6 &-U'_3K'_-JN:/X)\>^&=9=]+B14 M,N96(C%J,DUJ5/BYKMV)K#1(I&2U^S+-*JG'F$D@ ^PQ^M5O%'PUM-!\&)K$ M-]/)=1B,S*^W8VX@?+@9&"?4UVWCOP$_BFRM;BTDCAU*VC"#S#\LB_W21T(. M<'WKC9_"7Q(U>RAT:_D T^$@*99X]N!TR5R[>VM7>L?!36$O)&EDM)%A61SDLNY",GOC./RK)\!>#T\6Z-J"W=]8^Y23R< 8'KVI/AEX"5(P?KU_.O=:\D^'7@OQ!H7BQ[[4M/\BW,#H'\Z-N21CA6)KUN MLL9*,JB<7?0JFK7]3YP\=:#:Z'XQ>PM9)GBD"R$RL"V6//0"NE^(*?\ "'^' M]/\ #&E7%P+2X,D\S2,-[C(^7( XZ\?2KWC_ ,%^(-;\9"_T[3_.M?+C7?YT M:\CKPS UUWCOP6OB[3(1#*L-];9,+O\ =(/53CL<#FMO;1Y:?,[]_P!!_9EN60[?**D [1QG.#US^%2^&M;N]1^%GB2PNI'E% ME"/*9SDA6_AS[;?UI&\)_$F;3%\/R,/[+4[1F>+9@1J4D[O3R)A%\T=-MSSKX>>#X?%\] M[%>75Q%:6RJVV%@"7;(!Y!'0'M7OEA90Z;I]O96R[88(Q&@]@,5P/PL\+ZSX M;.J?VM9_9_/\KR_WJ/NQNS]TGU%>C5AC*O-4LG=%4HV5V>9?&O\ Y%[3O^OH M_P#H!J_\(/\ D1S_ -?4G\EJ3XH>'M4\1:/90:5:_:)8[C>Z^8J8&TC/S$5Y MW;^"/B+:6C6EM#>06S$[H8]014.>N5#XK2DHSP[@Y).XIWYTS/T;:OQ4M_L> M/+_M0A-G39O/3VQ5CQ_K3ZMXYN+>_GG73[2?R1'$ 2JCABH) +'GK[5W7@'X M:3Z#J0U;5Y8FN8P1!#$')5%T6$CQ%PC" M0=&4GCG'?'/UK7VU)58J^RW\Q8:K+H5O/;3^&IM6CD0Y%-0F.9I4E\PXQEAM!/YBM:'0/B?K=]$-4U6?3H4P&DCN43 MY>^%A/)^OYUJ?$CPCJ^LZ=HUKI$$MZ;0.LCRSKO.0H!)] M[]&$8N[?D4?AWX"L[K3],\27\]Q+=!_,BB+ QA5)5,9Z^E$=.L;V+RKF&,K(FX-@[B>H)%>>>(/!/ MB*^^)+:M;:?OL3=0R"7SHQ\JAFMOO0G%^QVUT.7^(/A M2#PCJMHEG=7$RSQF0M,07#@\G( JSXL\'QZ9X1TOQ"]_=7-]?%#<>?0TX8A\D&Y:WU]"G!<[TTM^-BOX>N7O?@VHNM9 M_LU5#Q&\92Q1 ^, 9!SCY1@UYZFD>&#!/'9S:YK5TH)1[.U$,:]<;@VYNV>G M2O0(/ NJW?PKCT*=5M-0CG:94>0%6^8X!*DCD'\\5C^'?!WQ MK:31_M*Z7I M?W"L^6*:,GX6P'5[S5M!GFE6QO+, MF18R 00R@$9! .">U8V@^';35/'HT*>2=;7SYH]Z, ^$#$?#GP; MK_AOQ5-<:A8;+5X'B$PFC89W*0+]*\83ZKX?B67,SRPS++& M"N[.05,]NS\4^!KWQ9X< MTU[B:./7;6$!W8_)(2!N!QTYY! KD)/"?Q)O].CT&Z8#3(R%4O/%LPO3)'SD M>@(].*RI5%R)*233U\RY+WD[:6+OAK6[O5/A+XAMKN5Y6LXF2-W.3L*Y SWQ M@_I6?\*[\Z7IGBB_50S6UJDH!Z$@.17<6_@EM$^'6I:+9?Z3?W4+EVR%$DA& M !GH!TYK*^&O@[5=&36(=1)&%,J/O'S;A\I..#4RJ4W&K;K8(Q:4;] MSC/!?AS_ (6#KFH7.L7]Q^[422-&1O=F)QR00 ,>GI1IYN? OQ.&FVET\EO] MICAD&?\ 61OC&1ZC=^8K:;P!XQ\*:O+<^%;A9HI,JI#H&V^CK)\IQZC/X5H> M$_ASJS>(EU_Q1,K3+)YPBWAW:3L6(X '' )Z>E;.K"[ES+EML2XRLU;7N/I2HS35-)V\N^G],6!?%PD_V1!ZH_S? MRWC\*]2\'1J_@;2(95!5[-05;N"/_KUX%=:(Q\83:!8S"6-[WR8V4Y4\X!/T M!/ZU%*U24Z$S>R)B6_D\P>NP<+_ %/XUW]0 M65I%86-O:0C$4$:QH/8# J>N&M4]I-R-(1Y8I!1116984444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% &5XET7_A(?#]UI7VC[/]H"CS=F_;A@>F1GIZUD M^"/!G_"'6]Y%]O\ MGVAU;/D^7MP#_M'/6NKHJU4DHN"V8FDVF^@4445 PHH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XKQ;\-M.\ M4WIOQ+?AMIWBF]-^+F2SO2H5G50ZOCH2O'..."*P].^"MA!HT5M'$58QY8O0EPC)W9RWC#P7#XJTJTL4NOL0 MM7S&RQ;P!C&,9'\ZSO"/PRL?#&HC4);Q[V[0$1L8PBIGC.,GG'?/>NZHI*M4 M47%/1@X1>X4445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XI\5:5X/ MT635-6F*0J=J(@R\K=E4=S6U7B?Q@Q>?$SP-IMWS8/<*61ONL3(H((^@ _&B MSB3D^AWMX+(/$42W VHT5Y)XA_Y-FB_[!5K_-*XKQPT MR?!SX>M;.4G$B&-AV;:<'\Z,>*? -CX+^%' MBB>&]OKV]OXX7NIKJ4-N82+DC '4D] M*%Y1Y*1*I"*!C/"@=\<]*5TKM]!I-VMU_P"!_F>V45\FVEYX<\1:;=Z_XG\; MZE;^*RSO:QQ12%([\4_LX/,M.\$Z.FH:@DT@EE$,442Y+N03C)X P M#S7A_BCP-/9_#"P\=2^(=4FUI(;>10 /TKR[X]7,MGKW@NZAMWN98;IY$@3.Z0AHR%& >3TZ&I=N9+S'#5 M-OLRW)\<=2TN2*3Q#\/]7TJR=MIN)&;@^P>-0?SKUNQO;?4K"WOK202VUQ&L ML3C^)2,@UX9XL\2>.?B+HC>&[;X>:AIHN)$:2>Z+A0%8'JZ(!SCN>.U0?%/1 M;O0=!^'FC6]SB]M9#"DZ<8D_=_,/H::V^:0NN_1O[CZ"HKS;_A ;'P7X+UF* MQ\576ERWQ5[K5KUA(4/0[<%,$Y/.<\]3Q7D/BV?PMH>F:7JO@:?5FU6.X"W. ML!9TCN#C+9+\;BPS@<<'-+2]O0+.Q]3T5XM\0]3U+Q-XS\,^!X=0GT^UU"W6 MXO7A.&<,&^7Z85N.F3R.*V/#7PFN_!_BA+C1/$=TNAO&1@51_ M#@XSUIV?7S_ -/R?WG7Z;XRT_5?&&I>&[5)FN=.B#W$K+A 21\H[GKUZ5:L] M1UF;Q#>V5UH/V;3(5!M]0^V(_P!H/''E@;EZGKZ>]>$^"/AOH\GQ@UG33%YUM?CSXZN&&5BLPY'L!&:46K1;[-_=_7_ M XI7NTNZ1[)17SSX2\&2?&*RU+Q-XAUO4%G%T\5G##(NR# !'!!XY' QTSG MFNJU^X\3?#3X.7"W>M_VAJGFK#!=;3F%7QD;F)+$?-@G';TH?NK7?3\1K5V7 M]6/7**^2[FZ\-Z)HMOK_ (?\<:I-XP!C>X1HY DA)&Y0=RGCDU7+I?SM_7<5SMZ\O^(7QA'@+Q'%I) MT+[<'MUG\W[7Y>,EAC&P_P!WUKU <#%>#?$+38]8^/\ HNG2@&.YT[RV!]") MJC6ZM_6A2M9MGK>N>*;71O!=QXEV>=;QVPN(T#[?,W ;5SSC)(&>:YSX:?$[ M_A8DFI+_ &1_9_V(1G/VGS=^[=_L+C&WWZUYU;ZP^O> O"/@F1E-ZVK_ &*\ MBYR(H&R 7#G+.F2!D]R"IY],5,KQ3ONE<:U:MM>Q[Y17B' MPN\&V\7AC3?'NI7]_<7UI:RFVMS*/)CB4,H7&,] 3UQD]*\_LM0\.>+8;W7/ M&7C34+/Q 96:RB@BD:.# RN,(V!GLI'3UIRTDUV!:J_<^KZCGGCM;>6XF<)% M$A=V/0 #)->>?!7Q3>^)_ V=1F>>[LIS;M,YRTBX!4D]S@XS[4[XV:__ &'\ M.+R*-]MQJ#"TC^C>IF^$/C;!XH\5V^C2Z&]A#=;_ M +-=/<[A*5S@;=@ZX/<\\5ZO7S9XK30-%\ ^#K_1-9TJ?6M$>-Y(K>\C=V+' M>_RJEV'P\UO4[O4]4N]3DMA?3S2S*0TJ(QQC;]TECWSP,$5I_ MCPI8Z;X2B\10RW+7FIQE)D=E,:A)& V@#(Z=R:$M[]+?J#>B:ZG=^+]>O_#F MA&_TW0[G6K@2*GV2VW;\'JWRJQP/I7F4GQUUR'4X],E^'&HIJ$J[H[5KAQ*X MYY">3DC@]NQKVNO&?$7_ "^ M\1:IX,O-.DMKF.!+2ZF:,RAOX@S1C@?0UW^B:E_;&A:?J?E>3]KMXY_+W;MF MY0<9P,XSUQ7!?'G_ ))==?\ 7S#_ .A5YQXB\"2:;\*M-\:-X@U635X+>W>( M>E<3IE]I.A_&'P_%X)AU*QTB_")/#.) M5CN,EAN42'+#&#GU'%5R^_R>=A-^YS>5SZ/HKY_UW2;G7OVB[[2[?4[G3H[F MT1;B:U;;(8Q$K%5/;) YJ7PGIDOP^^.J>%M.U"ZGTJ\MS(T<[@\E"V3@ %@4 MZ@#@U,/>MYW_ O_ )#E[M_*WXV_S/>Z\KU/XS,VJ7-EX7\):IXA6TD,<\]N M&" CTVHY(SGJ!T[UZF0&!!Z$8->$CP?\1_AMJMY-X--OJ>CW$QE^ROM)&>FY M20H!XY /MS795 MY9X!\>:3KOB2^M]1\+Q:'XI6(O.QMPLDRC!.6*A\]#M/8#DUQOA;PLWQJEUC M7_$.LZ@D45TT-G;0.H6$8!'# C&"HX )P235/R72XEUOW/>=6N;VTTNXN-.L M/[0O$7,5KYRQ>:?3>W _&ETRXN[K3+>>_LOL-W(@:6V\T2^4W]W<.&^HKR[6 M?#NM^&/@?X@T_6M:_M618MT3D-F-&=?[1MIXW1)UZD\HH(ZC!)/.0>*Z[Q_;7.L_'C0+2POYK![S3T3[3 M#PZ(WF;MOH2N1GMFG:]K==/PN*^C;[7/?:*^?H-#D^&GQOT/3-)U2^GLM54- M<)V$WQ8^*NN:'J6JWEMH>CKL6VMG"[V! ).01G=D MY(/84EK:WG^&XWI>_E^.Q[K17EVD>'-8^%GAWQ)>_P!N-J.E6]L\MC9SJ6:( MJ,KELX'H0!@]>*\;M[KPYJNAW'B'6O'&J1>,R))($1)-J$9VKN"'&?\ 98 9 M]J+H:3/K6BN+^%7B2Z\4_#^QO[YS)>(6@FD(^^5.-WU(QGWKM* ]3UBV2-7^V6YD"'(R1Q$PX^MPHVQI+:X>55;K@E83SR.*]ENO^/2;_KFW\J\C_9U_Y$G4 M_P#L(M_Z+2B"O>_17_$[M1<-<-<8,9*,VTIM MYQMQU%=S7@/C32[C6OVB;'3K;4)[!I[-5>XMSB14V/N"GL2,C/O2Z-I,GPZ^ M.VG:!I>IWT^G:E 9)TN9 Q_N]<\// MJ7RN.7NO\#TOQ7KW_",>%]0UK[-] MI^R1^9Y/F;-_(&-V#CKZ5YG9_&KQ+J%I'=67PPU:YMI!E)H99'1A[$08-=G\ M5_\ DEVO_P#7M_[,*\Q\":U\6+;P5IL/A_PQI-WI2HWV>>:50[C<X=V4VEQNWJ < _,JGGZ5N5XS\: MI=1G^$&F2ZO;QV^I/=0FYAB.51]CY Y/&?".)>68^I/ KHJ^&_P#L)#_T&LKXIV%SJOQF M\+:?:W%L.B,SA\'UVYJ5K9=W;\+E;7OT5_QL>[T5X1\0XD^%_@ M[2O"N@:G>6EOJ=V[W-[*^Z5$&W=C:!@,G!10>_J0<!4D]>Q%=)2Z!UT/-;SXP6>F_$QO"%]IODPB58OMYN.-S(& M&4V\#)QG=[UK_$;Q]_PK_2;.^_LW[?\ :;CR-GG^5M^4G.=K9Z5XWXI\)MXR M^-?BO387*726GGVQS@&18XL ^QR1^-9OC'QHWB?X7Z18:@Y&M:9J'D72.?G8 M!& &/ M!&E7\NGKJ:J]U<1':VS., CGHK''?BN>\4>%I?@J=,\0^&]8U"2VDNEAO+2Y M=2LN03T4 =%(Y!(XYH6K\KV)UM;K:Y] T5X!XLL[G7OV@;&QL]1N-/%]IZ+) M/ <2",HS,%/8D#&:71=(E^'/QWT[0-+U*\GTW48#)+'<.&+95_O8 !(* YQG MM1%-VOUO^%_\@;LFUTLSWZL>#4=:D\3W%A-H/E:3''NBU/[8C>:W'R^4!N7J M>3_=]ZQ=5^*O@K1-5N-,U'6O)O+=MDL?V69MIZ]50@]>QKCO#[!_VF/$#*9&(3&>P?=^ J?1O# M4>C?!6R^W>*?^$=749A>WMQL)DF5AE8EPP()4 \9/7BF^K6VGX_\ 2[/?7\# MW*BOF2^OO#_A_P <^%KKX?QZG9VMS.L=Q)()EBNQO4<>9RW!.>W([UO?$74; M2U^*4D?CRRU*Z\+/ BV*6\CK$'P,N0K#<0=V<'/3@\4NB\[_ (!W^7XGOM9& M@ZAK&H)='6-"_LEHY2D(^UI/YR?W_E'R_0UQGPKA\,Q#4'\+^)KJ_L9#N739 MF.+09.,*PW#TST/O7(?#G04\3^!?'>CL%W7%]((RW19 ,J?P(%#TOZ7_ !0+ M7[[?F>\T5X!8>/9;#]GR[MWD,>JVDATE5/# GI^29_[YJEXIFNO G@#PCX3B MOY-+74\W&IW<8.] 2I8?+S@;NW)V@4VM6EY?CK^6H+97\_P_X.A]&45\P:?K MGA[P/XOT.3P-XGO]1L+F<1ZC:W*.JX)4;L%%!X)QP2,=:^GZ+:7%?6QP7C+X MGVOAC5TT2PTB]UK6GC\S[):*?E';) )SCG@'WQ5+PW\7H=4U^#0M>\/W_A_4 MKG_4)= [7]!EE4@GG'&/>LWQUX"\5Q>-#XS\$7D:W[Q".>V9]M@\[[7Y^-G#G&S;S]SU'6NSKP+XDZ_; M^%_COI.M72L\5KII;8HY9B)@H_$D"NB^#NGVWB#[;X\U"Y6]UR\F>,CM9J#] MQ1VR,<^F!ZY<5>-_6_WZ!/1_=^6IZ'HFHZS?3WZ:KH/]F1PR[;:3[8DWVA,G MY\*/DZ#@^M;%>#^ O^03\5O^NMQ_*6L'P1\//^$S^%UQ?:AK=_''9M-]AM(F M40HR@L692.223TP<=ZF^E^R3^\:7XMK[CZ6JKJ6I6>D:=/J%_<);VL"%Y)'/ M %>>_ O6K[6?A[F_N))Y+6Z>!))&+,5PK $GKC<16;^T/=7$/@6R@C8K#/?* MLV.X"L0#^(!_"G-.+LO+\14_>W\_P$?XWWEZSS^'O >LZKIR$@W8W*."<\*C MC'U-=GX(^(.C^.[2=]/$L%S;G$]K. '3/0\<$<4M]?R>#_ %K-H6AS:K]FAA MCALK7.YU.!D;58^YXKA?!'CJPNO%NNQGP(N@ZJEG+>WB;7:_X"5Y)/O8]EHKY0LM0\.>+8;W7/&7C34+/Q 96:RB@BD:.# RN, M(V!GLI'3UKI9?%-[XG_9OU4ZC,\]W9745NTSG+2+YB%23W.#C/M2UM?T_$:U M=CZ*HKYLU;P%+_PJ*S\:W&OZE+JMM;0RP)Y@$4,9*JJH ,J0N.0>HZ5T'B?Q MQKQ^$_A&&RO'BU;7=L$EV#AL#Y2<]B25Y'O3:LVNJ=OO$G>SZ--_<>YT5X%X MK^&TOPU\/-XN\/\ B+4_[4M9$:Z,K@I/N8 \ XR0>]:*Z#)\-_C5X?M-+U6_N;;6!_I0NY0S2 M$E@=V >Q&><]Z(ZV\]/F$G:_EK\CV2SU'69O$-[976@_9M,A4&WU#[8C_:# MQQY8&Y>IZ^GO6Q7CWA%Q'^T!XV<]%M5)_*.N;\+>%F^-4NL:_P"(=9U!(HKI MH;.V@=0L(P".&!&,%1P 3@DFDKN*:[7_ !L/K*_>WX'T+17DFIZ#XV\*?![5 M+&'6I]5U)64Q20*QEBA)&]58G<>,X[@=/;A] G^&>J_V;)::OJOA?7T<&XNY M)G+3MCYLN24 +KV#^;9W!Z \?*2.0"0#D=".]=O12:&F>*ZA9_&CQ!ILOAR]M=) MM;65/*FU)) &E3H>C$\CT0?A74WGPSB7X1R^"["X F,8=9Y. \P8/DXZ D8[ MX%>@T4WJFNXEHT^QX'+X5^*^I^ I/"=W9:;;Z?:1!(BLJF:Z"'*(#OV@9 Y( M7@5I>)_ ?B74/AQX+TFUTWS+[39$:[B\^,>6 .>2V#^!->U44[N]_-/[A6TM MZK[SE/B/H]_KWP]U72],@\^]GC01Q[U7<0ZD\L0!P#WIWA30)8/AMI^@:Q;^ M7)]A^S7,6X-C(((R"0>O:NIHJ;:-=RKM6\O^!_D>'Z9X?^+'@6UF\/>'+;3- M0TMY6:WO974- &/7#,O/\/Z/:P1KJVF"&1[9Y5&XJA4J&SMSSZX]Z]=HIN3 M;;[NX+1)=E8PO",WB&X\/PR>*+.VM-4+$/#;ME54=/XFY_$UR'Q/\*:WXB\2 M>$;O2K+[1!I]V9+IO-1/+7?&AZ9KTNBEU3[!T:.(^*O@^^\:^#CIVG3( MEU%.LZ)(VU9, @J3^.1[@5Y_XQ\,?$3QAX+TS2_^$8L=/7363_1UOXVDG8+M M#+C"*H!/!;->[T4DK?F.^WD>6>,_ _B#59?#WBG0/)MO$6F0(KVMPPP^!G;N M!*Y!+#K@@]1BG^'+7XIZQXIMM2\236NB:;;C$EC:,K_:,<]-S@9SR=P/' [U MZA15)V=_ZU)MI;Y'D8\,>-] ^+^H:WHMC976DZO)&+F:60 PQ_+NPNX'=P<8 M##I6GX>\)ZO:?%_Q3K5[9;-*U"W$<$WFH?,X3(V@[AT/4"O2:*2T279-?>$E M>_FT_N/$+'PK\2_AU/?Z=X0M=.U32+N8RQ-.X5X,@#D,Z\XQ_>'RYXZ5T@^' M_B#7?AE=Z#XJUS[7JD["6&7 9;=E^Z-V 6Z.:4GQJL MX[+1%L]%BM;0+&-1D97WHHP,@/N/'H@/%=YXIN_%]CIVGGPWI]EJ5XTRK>>= M\BJF/F909%QSVR:Z>BG?N*W8!TYKS+6O">M7GQTT3Q'#8[](M;7RY;CS4&UL M2<;2=Q^\O0=Z]-HH3LTQ]&NYX_X>^&NHZ;\<=2\12V:KH_[R>UF$B'=)(!D; M0=PQN?J!TJUX!\"ZGIVN>.1K>G^3IVL2L(#YJ/YD;-)GA22.&'7'6O5J*2TC MR^5AMZM]W<\2TWP[\5? 5M+H/AN+3-3TJ25F@N9V"O;AN^"R_7&&'6M:P^&F MH:)\*_$&F*Z7_B#5XVDG9&"AI#T4,V!@<\G')->KT4/5-/KH):-->IR7@#0; MO2_AOIVB:Q;>5<) \4\.]6P&9N,J2#P>QKSW3O#7Q1^'R7>B^%;;3M3TF>9I M()YW4/!GC)#.O/3LPX_"O;Z*;=Y.7<2245'L9/AN/78]$A'B.>TFU(Y,AM$* MH/0S!>YF\]%WL>2-H;?T55R!W->IT4G MJTQK1-'G&H?!#P--IUS'9Z,8+IXF$,HNYCL?'!P7(.#ZUP%WX!\>7WPFL/#D M^C%KRPU/S(E-W"TF76/"&H:0CK'-=6 M3P*S=%8KCGVS7'_"72_&7A_2Y-#\1:=:6VGV:D6DL4BN\I+DDG#'CGC@&O2* M*$]6^XK:)=@KS+6?">MW?QTT3Q)!9;])MK3RYKCS4&UL2C&TGO3:* M$[-,?1KN<-\6_#^J>)_ 5QIFCVOVF\>>)UC\Q4R V3RQ _6J'BOPMK.I?!*W M\/6EGYFJI:VL;0>:@PR%-PW$[>,'O7I%%3;1KNT_N'?5/L>)ZW\._$S:5X'U M.QL8+N_T*WC2XTR:9 &((/#$[>QSSZ8S3M6\-^/=;^)7ASQ7=Z!:PVUJZ*]K M!?)(\"!LL79MH8_,?NYZ?G[515\WO7\[_>3;W;=U8\PA\):XGQ]G\3-8XT=K M7RQ<>:G+>6%QMSNZCTHO?"6N3?'NP\31V.='BM?+>X\U.&\MQC;G=U([5Z?1 M4K2WE^M_\QO6_G_P/\B.>%+FWD@E7='(I1AZ@C!KQ;3O"WQ,^&\MY9>$8-.U MK1YYC)%' ."0<9P*]MHHV=T'2QY9X+\$>)9O&TWC7QE):I?O! MY,-G;-KCX5Z[INM:C_:NLWR?N+=70+$,CY0Y R3[G'3'O M%JGPUU'7OA+H.CLR66NZ4B21;W!4.."I9<\'U&>0*]6HH?\ E^ +_/\ $\KT M:X^,MYJMK!J5GHNGV4)Q-<$"3SE[G:LA.>/]D'0=Z]/HIIV:?85M&NYYAXO\):YJGQ@\+Z[9V/FZ;8H MHN)_-1=F&8_=)#'@CH#5+Q!X.\8^'?'E[XN\#QV=Z=03;.F>_H*OT44V[L$%%%%( HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH CN%+VTJ*,LR$ ?A7G7P7\+:UX3\+WUGK=G]EN);UI43S4?*[%&D MT4T[7\P>JL>87OA+7)OCW8>)H['.CQ6OEO<>:G#>6XQMSNZD=J->\):Y>_'/ M0_$=O8[])M;8)-<>:@VMB3C:3N/WAT'>O3Z*$[6\O^#_ )@];^9XY>^$?'/@ MGQAJVL^!K6PU&RU9_,FM+EPIC?))/+)QDG&&_BZ<9KN_!*^,?[-DD\8RV'VE MVS%#:IS&.I#,#@GG''IU.:ZBBDM%8'J[G-?$'2KW7/ 6L:;IT/G7EQ!LBCWJ MNXY'=B /Q-1_#G2+[0? &DZ9J<'D7EO&RRQ[U;:2['JI(/!'0UU-%"TOY@]; M>1QOQ.\(7'C7P9-IEG)''=I*L\/F$A2RYX)[9!->9ZYX8^+7BKP0FCZE8:?! M#9>6(X(I4\ZZ*X4%FWE "3U'(Z5[]12MOYCOMY'E/CWP1K^M^ /#5OI4$3: MII/DR/;22*-Q6, @-G;D$>N.O-0>-/!_C+QMX*T>]NH+.U\3Z?.TYM8I,(03 MP%)8C=\J]3CKS7KM%4W=M]W?YDQ2BDNRL>">*O"OQ4\:VNE7.L:?I\9M+E2M MC:2HK ?Q2.S.5[ G[W05V'B?PIK>H_&+PQKUK9>9IEE#MN)_-0;#E_X2=Q MZCH#7I=%%[--='?] MHUW5CA/B=X&NO&.EV4VEW$=OJ^FS^?:R2<*>F5)P<= M 1[BLK0;GXPW^M6JZQ9Z-IFGQ8$[8$AF'<@+(QW<>JCYNAKU"BE'0;U1SFJW MGBJ+Q;I5OIFFVL^A2 _;[F1@)(CSC:-X]OX371T44=+!UN>8:/X2URU^.VL> M))K';I%Q;>7%<>:AW-MC&-H.XH[5R?Q8^$&KZOXH76O"]BMP+L9NXA,D> MR0?Q#<0,$>G<'UKWNBA:TT M4T[._P _F3;2WR/+[OPAK3_'G3_$<5@/[&AM/*:X$J#:?+=<;<[NI':EU[PE MKE[\<]#\1V]COTFUM@DUQYJ#:V).-I.X_>'0=Z]/HH3M;R_6_P#F-ZW\]#&N MO"/AJ^NY+J\\.Z3<7,AW/--91N['U)*Y-<=I'A36;3XY:SXBEL@FD7%D(89Q M*GS,!&,;0=P^Z>H[5Z511%V=UY_B.^C1YA\-?"6N>'_&OB_4-4L?(M=0N2]K M)YJ-YB^8YSA22.".N*/ OA+7-&^*'BW6+^Q\FPOW8VTOFHWF9DST!)''J!7I M]%):-/LK"E[R:?5W^X\1\=_"K6M;^)$=YID0&AZDT+:F1,J!2AY)4G)R ", M\DUT?Q8\#:IXFL=&N-#C@FFTF4N+&5@J3+\O SQGY0.<#!/->ET4+1)+H[@] M6WW5CQ#QAX=^(7BS6?#NMR>&K2UCTR=6%A%?QR2CY@S,S':F#M& "379^)7\ M=V^N-)9:-IGB#0)8]G]G-(D$JD@5^ / . MH:=XUU+Q9?Z79Z&ES#Y,&DVDBN(@=N264!?X&;;7DUBS^S M-=:@TT(\U'W(1U^4G'XUZ+13O^5OQN'_ _Z'AVJ?";5[GXN"[A@7_A%KB[C MO[C$JA1(H)*E,Y)+9Y QAZ[+XF^!K[Q5#IFI:)/%!K6E3>;;&4X5AD$@G!YR MH([?G7?T4MDDN@=6^YYGXF444[BL>3>)?!'BS1?'5QXQ\#26LTUW'MN["Y; D/'3) (. ?O @CKS M6=+X1^(7Q"UG2Y?&EOIVE:9I\_F_9[9@S2GCT=^N,9+#'/%>U44H^[;RV'+6 M_F>7Z]X-U;4OCCH?B :'WL=:U/AGX7UGP_P##"YT?5+/[/?NT MY6+S4?.X?+RI(Y^M>C45-M&NZ2^X.WDV_O/.O@SX8UCPGX/N+#6[/[+/* MJ>:CY4JH!RI(Z@UU'C#PM9^,?#5SHUZ2BRX:.51DQN/NL/\ /3-;M%5-\^X1 M]W8\8LK;XS>$;"/1M/LM(UJTA&R"ZDD 9$' 'S.AX'J&^M:O@CX<:Y:>)-4\ M3>+=1MKF_P!2MWMY+>W7Y=K;>IP.R@8 _&O4J*+]7_5P\D>(:=X:^*/P^2[T M7PK;:=J>DSS-)!/.ZAX,\9(9UYZ=F''X5TWB_P /^+_$'PCNM*O5M+[7YFC8 MI:8B3 D4XR[ $@ \\?2O2:*3U5G_ %8%H[H\XU3PMK-S\"H_#<5GNU<6,,)M M_-0?.K*2-V=O8]ZS;OX9:CKGPBT+19G73]=TL"6(LX95<$_*67/!R.1G! KU MFBFW=M]W<%HDNU_QM_D>):CX?^*_CBUC\.^(HM,T[25D4W%Y"RL]P%/7 8G/ M&<87W]*U_&'@74Y_%G@1]$L/,TO1759G\U%\I%9,<,03PIZ UZM10G9IKH[B M:NFO*QYKXY\*ZUK'Q*\(:O867G6.GR;KJ7S47RQO!Z$@G@=@:/&/A76M5^*W MA/6K*R\W3K#_ (^9O-1=GS$_=)!/X UZ512CI;R=PDKW\U8\W\-^%M8L/C%X MHUV[LMFEWT"I;S>:AWGY,C:#N'0]0*YNW\)_$7X=ZIJ4?@NTT_5=)OYC*D=P MX5H#]&=.>W!(.!P*]LHH6B2[*P^K\W<\^T31?B)8>#;Q;K7K2Y\02R;X%N4W MQ0K_ '=P .3ZG('''>N3\2>%_&'CK3XM,U+P1I.GW^Y!+KQNXG+!3R551O ; MDX)[]J]MHH>K#8IZ3IZZ3HUEIR.TBVL"0AVZMM4#/Z5B5RWB3P%I?BG48[Z^N+R.6.(0@0.H& 2>ZGGYC71A94HU+U5=$5% M)KW3SO\ X7#XA_Y\],_[]2?_ !='_"X?$/\ SYZ9_P!^I/\ XNNL_P"%/>'_ M /G\U/\ [^Q__$4?\*>\/_\ /YJ?_?V/_P"(KT_;Y?\ R_@8F?]^I/_ (NC_A'_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^ M(H]OE_\ +^ F?\ ?J3_ .+H_P"%P^(?^?/3/^_4G_Q= M=9_PI[P__P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\ \11[?+_Y?P#EK=SD M_P#A'_ M /G\U/\ [^Q__$4>WR_^7\ Y:W'_^?S4_^_L?_P 11_PI[P__ ,_FI_\ ?V/_ .(H]OE_ M\OX!RUNYR?\ PN'Q#_SYZ9_WZD_^+H_X7#XA_P"?/3/^_4G_ ,776?\ "GO# M_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $4>WR_\ E_ .6MW.3_X7#XA_ MY\],_P"_4G_Q='_"X?$/_/GIG_?J3_XNNL_X4]X?_P"?S4_^_L?_ ,11_P * M>\/_ //YJ?\ W]C_ /B*/;Y?_+^ F?]^I/_ (NC_A'_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^(H]OE_\ +^ F?\ ?J3_ .+H_P"%P^(?^?/3/^_4G_Q==9_PI[P__P _FI_]_8__ M (BC_A3WA_\ Y_-3_P"_L?\ \11[?+_Y?P#EK=SD_P#A'_ /G\U/\ [^Q__$4>WR_^ M7\ Y:W'_^ M?S4_^_L?_P 11_PI[P__ ,_FI_\ ?V/_ .(H]OE_\OX!RUNYR?\ PN'Q#_SY MZ9_WZD_^+H_X7#XA_P"?/3/^_4G_ ,776?\ "GO#_P#S^:G_ -_8_P#XBC_A M3WA__G\U/_O['_\ $4>WR_\ E_ .6MW.3_X7#XA_Y\],_P"_4G_Q='_"X?$/ M_/GIG_?J3_XNNL_X4]X?_P"?S4_^_L?_ ,11_P *>\/_ //YJ?\ W]C_ /B* M/;Y?_+^ F?]^I/_ (NC_A'_P#G\U/_ +^Q_P#Q M%'_"GO#_ /S^:G_W]C_^(H]OE_\ +^ F?\ ?J3_ .+H M_P"%P^(?^?/3/^_4G_Q==9_PI[P__P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_ ML?\ \11[?+_Y?P#EK=SD_P#A'_ /G\U/\ [^Q__$4>WR_^7\ Y:W'_^?S4_^_L?_P 11_PI[P__ M ,_FI_\ ?V/_ .(H]OE_\OX!RUNYR?\ PN'Q#_SYZ9_WZD_^+H_X7#XA_P"? M/3/^_4G_ ,776?\ "GO#_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $4>W MR_\ E_ .6MW.3_X7#XA_Y\],_P"_4G_Q='_"X?$/_/GIG_?J3_XNNL_X4]X? M_P"?S4_^_L?_ ,11_P *>\/_ //YJ?\ W]C_ /B*/;Y?_+^ F?]^I/_ (NC_A'_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^ M(H]OE_\ +^ F?\ ?J3_ .+H_P"%P^(?^?/3/^_4G_Q= M=9_PI[P__P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\ \11[?+_Y?P#EK=SD M_P#A'_ M /G\U/\ [^Q__$4>WR_^7\ Y:W'_^?S4_^_L?_P 11_PI[P__ ,_FI_\ ?V/_ .(H]OE_ M\OX!RUNYR?\ PN'Q#_SYZ9_WZD_^+H_X7#XA_P"?/3/^_4G_ ,776?\ "GO# M_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $4>WR_\ E_ .6MW.3_X7#XA_ MY\],_P"_4G_Q='_"X?$/_/GIG_?J3_XNNL_X4]X?_P"?S4_^_L?_ ,11_P * M>\/_ //YJ?\ W]C_ /B*/;Y?_+^ F?]^I/_ (NC_A'_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^(H]OE_\ +^ F?\ ?J3_ .+H_P"%P^(?^?/3/^_4G_Q==9_PI[P__P _FI_]_8__ M (BC_A3WA_\ Y_-3_P"_L?\ \11[?+_Y?P#EK=SD_P#A O$EYXIT.>^OHH(Y8[EH0(%(& JGN3S\Q MKJ:QO#?ANS\+:=)8V,L\D4DIF)G8$Y( [ >"#_2L7_A#=._Y[77_?2_\ Q-<6 M)AB)3O2>AZ6#J82--JNKNYD_\)EJ/_/&U_[Y;_XJC_A,M1_YXVO_ 'RW_P 5 M6M_PANG?\]KK_OI?_B:/^$-T[_GM=?\ ?2__ !-<_LL9_-^)U>WR[^7\#)_X M3+4?^>-K_P!\M_\ %4?\)EJ/_/&U_P"^6_\ BJUO^$-T[_GM=?\ ?2__ !-' M_"&Z=_SVNO\ OI?_ (FCV6,_F_$/;Y=_+^!D_P#"9:C_ ,\;7_OEO_BJ/^$R MU'_GC:_]\M_\56M_PANG?\]KK_OI?_B:/^$-T[_GM=?]]+_\31[+&?S?B'M\ MN_E_ R?^$RU'_GC:_P#?+?\ Q5'_ F6H_\ /&U_[Y;_ .*K6_X0W3O^>UU_ MWTO_ ,31_P (;IW_ #VNO^^E_P#B:/98S^;\0]OEW\OX&3_PF6H_\\;7_OEO M_BJ/^$RU'_GC:_\ ?+?_ !5:W_"&Z=_SVNO^^E_^)H_X0W3O^>UU_P!]+_\ M$T>RQG\WXA[?+OY?P,G_ (3+4?\ GC:_]\M_\51_PF6H_P#/&U_[Y;_XJM;_ M (0W3O\ GM=?]]+_ /$T?\(;IW_/:Z_[Z7_XFCV6,_F_$/;Y=_+^!D_\)EJ/ M_/&U_P"^6_\ BJ/^$RU'_GC:_P#?+?\ Q5:W_"&Z=_SVNO\ OI?_ (FC_A#= M._Y[77_?2_\ Q-'LL9_-^(>WR[^7\#)_X3+4?^>-K_WRW_Q5'_"9:C_SQM?^ M^6_^*K6_X0W3O^>UU_WTO_Q-'_"&Z=_SVNO^^E_^)H]EC/YOQ#V^7?R_@9/_ M F6H_\ /&U_[Y;_ .*H_P"$RU'_ )XVO_?+?_%5K?\ "&Z=_P ]KK_OI?\ MXFC_ (0W3O\ GM=?]]+_ /$T>RQG\WXA[?+OY?P,G_A,M1_YXVO_ 'RW_P 5 M1_PF6H_\\;7_ +Y;_P"*K6_X0W3O^>UU_P!]+_\ $T?\(;IW_/:Z_P"^E_\ MB:/98S^;\0]OEW\OX&3_ ,)EJ/\ SQM?^^6_^*H_X3+4?^>-K_WRW_Q5:W_" M&Z=_SVNO^^E_^)H_X0W3O^>UU_WTO_Q-'LL9_-^(>WR[^7\#)_X3+4?^>-K_ M -\M_P#%4?\ "9:C_P \;7_OEO\ XJM;_A#=._Y[77_?2_\ Q-'_ ANG?\ M/:Z_[Z7_ .)H]EC/YOQ#V^7?R_@9/_"9:C_SQM?^^6_^*H_X3+4?^>-K_P!\ MM_\ %5K?\(;IW_/:Z_[Z7_XFC_A#=._Y[77_ 'TO_P 31[+&?S?B'M\N_E_ MR?\ A,M1_P">-K_WRW_Q5'_"9:C_ ,\;7_OEO_BJUO\ A#=._P">UU_WTO\ M\31_PANG?\]KK_OI?_B:/98S^;\0]OEW\OX&3_PF6H_\\;7_ +Y;_P"*H_X3 M+4?^>-K_ -\M_P#%5K?\(;IW_/:Z_P"^E_\ B:/^$-T[_GM=?]]+_P#$T>RQ MG\WXA[?+OY?P,G_A,M1_YXVO_?+?_%4?\)EJ/_/&U_[Y;_XJM;_A#=._Y[77 M_?2__$T?\(;IW_/:Z_[Z7_XFCV6,_F_$/;Y=_+^!D_\ "9:C_P \;7_OEO\ MXJC_ (3+4?\ GC:_]\M_\56M_P (;IW_ #VNO^^E_P#B:/\ A#=._P">UU_W MTO\ \31[+&?S?B'M\N_E_ R?^$RU'_GC:_\ ?+?_ !5'_"9:C_SQM?\ OEO_ M (JM;_A#=._Y[77_ 'TO_P 31_PANG?\]KK_ +Z7_P")H]EC/YOQ#V^7?R_@ M9/\ PF6H_P#/&U_[Y;_XJC_A,M1_YXVO_?+?_%5K?\(;IW_/:Z_[Z7_XFC_A M#=._Y[77_?2__$T>RQG\WXA[?+OY?P,G_A,M1_YXVO\ WRW_ ,51_P )EJ/_ M #QM?^^6_P#BJUO^$-T[_GM=?]]+_P#$T?\ "&Z=_P ]KK_OI?\ XFCV6,_F M_$/;Y=_+^!D_\)EJ/_/&U_[Y;_XJC_A,M1_YXVO_ 'RW_P 56M_PANG?\]KK M_OI?_B:/^$-T[_GM=?\ ?2__ !-'LL9_-^(>WR[^7\#)_P"$RU'_ )XVO_?+ M?_%4?\)EJ/\ SQM?^^6_^*K6_P"$-T[_ )[77_?2_P#Q-'_"&Z=_SVNO^^E_ M^)H]EC/YOQ#V^7?R_@9/_"9:C_SQM?\ OEO_ (JC_A,M1_YXVO\ WRW_ ,56 MM_PANG?\]KK_ +Z7_P")H_X0W3O^>UU_WTO_ ,31[+&?S?B'M\N_E_ R?^$R MU'_GC:_]\M_\51_PF6H_\\;7_OEO_BJUO^$-T[_GM=?]]+_\31_PANG?\]KK M_OI?_B:/98S^;\0]OEW\OX&3_P )EJ/_ #QM?^^6_P#BJ/\ A,M1_P">-K_W MRW_Q5:W_ ANG?\ /:Z_[Z7_ .)H_P"$-T[_ )[77_?2_P#Q-'LL9_-^(>WR M[^7\#)_X3+4?^>-K_P!\M_\ %4?\)EJ/_/&U_P"^6_\ BJUO^$-T[_GM=?\ M?2__ !-'_"&Z=_SVNO\ OI?_ (FCV6,_F_$/;Y=_+^!D_P#"9:C_ ,\;7_OE MO_BJ/^$RU'_GC:_]\M_\56M_PANG?\]KK_OI?_B:/^$-T[_GM=?]]+_\31[+ M&?S?B'M\N_E_ R?^$RU'_GC:_P#?+?\ Q5'_ F6H_\ /&U_[Y;_ .*K6_X0 MW3O^>UU_WTO_ ,31_P (;IW_ #VNO^^E_P#B:/98S^;\0]OEW\OX&3_PF6H_ M\\;7_OEO_BJ/^$RU'_GC:_\ ?+?_ !5:W_"&Z=_SVNO^^E_^)H_X0W3O^>UU M_P!]+_\ $T>RQG\WXA[?+OY?P,G_ (3+4?\ GC:_]\M_\51_PF6H_P#/&U_[ MY;_XJM;_ (0W3O\ GM=?]]+_ /$T?\(;IW_/:Z_[Z7_XFCV6,_F_$/;Y=_+^ M!D_\)EJ/_/&U_P"^6_\ BJ/^$RU'_GC:_P#?+?\ Q5:W_"&Z=_SVNO\ OI?_ M (FC_A#=._Y[77_?2_\ Q-'LL9_-^(>WR[^7\#)_X3+4?^>-K_WRW_Q5'_"9 M:C_SQM?^^6_^*K6_X0W3O^>UU_WTO_Q-'_"&Z=_SVNO^^E_^)H]EC/YOQ#V^ M7?R_@9/_ F6H_\ /&U_[Y;_ .*H_P"$RU'_ )XVO_?+?_%5K?\ "&Z=_P ] MKK_OI?\ XFC_ (0W3O\ GM=?]]+_ /$T>RQG\WXA[?+OY?P,G_A,M1_YXVO_ M 'RW_P 51_PF6H_\\;7_ +Y;_P"*K6_X0W3O^>UU_P!]+_\ $T?\(;IW_/:Z M_P"^E_\ B:/98S^;\0]OEW\OX&3_ ,)EJ/\ SQM?^^6_^*H_X3+4?^>-K_WR MW_Q5:W_"&Z=_SVNO^^E_^)H_X0W3O^>UU_WTO_Q-'LL9_-^(>WR[^7\#)_X3 M+4?^>-K_ -\M_P#%4?\ "9:C_P \;7_OEO\ XJM;_A#=._Y[77_?2_\ Q-'_ M ANG?\ /:Z_[Z7_ .)H]EC/YOQ#V^7?R_@9/_"9:C_SQM?^^6_^*J]H_B:] MU#58;66*!4?=DHISPI/K[58_X0W3O^>UU_WTO_Q-6;'PS9:?>1W44MPSIG = MACD$>GO5TZ>+4TY/0BK6P#IR4(ZVTT-FBBBO2/&"BBB@ HHHH ***8\J(<,V M#]* 'T5%]HB_O?H:/M$7][]#3LP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WO MT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP) M:*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB M+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T M1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^A MHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT M-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP): M*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+ M^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1 M?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AH MLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT- M'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):* MB^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^ M]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1?WOT-'VB+^]^AHLP):*B^T1? MWOT-'VB+^]^AHLP):*:CJXRIR*=2 **** "BBB@ HHHH **** "BBB@ HHHH M **1F"KN8X J/[1%_>_0TKI#2;V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB M+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^ MT1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT- M',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V) M:*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1? MWOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB M+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHY MD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+1 M47VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^] M^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1? MWOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@ MY7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B M^T1?WOT-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT M-'VB+^]^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^] M^AHYD'*^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'* M^Q+147VB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-'VB+^]^AHYD'*^Q+147V MB+^]^AH^T1?WOT-',@Y7V):*B^T1?WOT-.6:-FVJV2?:BZ#E?8?1113$%%%% M !1110 53N_]:/\ =JY5.[_UH_W:J.XF04445H2%%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7+3_5'_>J M>H+3_5'_ 'JGK*6Y:"BBBD 4444 %%%% !1110 4444 %%%% $5Q_J&_#^=4 MJNW'^H;\/YU2K&IN;TM@HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ J6W_P!>OX_RJ*I;?_7K^/\ *G'< MF6S+M%%%=!RA1110 4444 %4[O\ UH_W:N53N_\ 6C_=JH[B9!1116A(4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110!J>H+3_5'_>J>LI;EH****0!1110 4444 %%%% !1110 M 4444 17'^H;\/YU2J[O7X'HZ0N/U3/ZTH MGUR GR[NRO%'1)86B8_\"4D?^.TKP?VOS!PDNAT-%82^)1!QJFGW%F.\J_OH MO^^EY ]V K8M[F"[@6:VFCFB;H\;!@?Q%4XM*Y)+1114@%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 445GZCKFG:5@7=TJ2$96)06D;Z*.::3; ML@N:%%-9I"5L--P <;[F3'XA5S^I%9S^(=8@_$#/Z5*2?P MNY5FMSL:*AM;NVO8%GM9XYXFZ/&P8?I4U)JVX@HHHI %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 452OM7L=.*K1_HHR3^55%U' M5+P_Z'I0@C/_ "TOI1&<>H1=Q_ XJU"35PWV-BBLL:=K4P)GUF.+/:TM0,?B MY;/Y4X:'*/\ 6Z[J?UH:UUV YBO[.Y7^Y/ 4)_X$IQ_P".TJ>H+3_5'_>J>LI;EH****0!1110 4444 %%%% !1110 444 M4 17'^H;\/YU2J[ M@[GZ"DVDKL:3D[(GHKE[_P 906^1;P,_NW^'_P!>N0U/XA:N-PMXT3T)Z?EU M_6LG7BMM398:75V/5Z*^?;WXB^)#5TY.IM;[Q3IQAN_P_X)[=16#;K> #;?2CZX;^=32:A>68S,L4Z#J5 M!1OZBI]KI=H/8ZVBT;%%9]IK-E>$*LFR0\;7XY^O2M"M(R4E=&LL<:@R M&&(*,G^$$YR1W],BGS:5&L+A[J\,A!"DS''H#Z4[3?0ERIK>7W+_ (8N45G6 M>B2)&R3W5P\@/#B5EX_.BZLY;1E$-[=Y8@!2/,_F*.6?8%*D]I?A_P .:-%9 M$%]>_9EG)MY8RVS#'RGW=QSQG\JL6^KVL[^6S&*3IMDX_(]#4\UOBT*4+ZQ= M_3^KE^BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;)( MD2%Y'5%'4L<"@-QU%4?[2\WBTMY)A_?/R)^9_I3UCOI?OW=I;CT12Y_,X%2I M7^%7*<.7XG;^NVY;HJN+#=_K-7G/^YL7^E#:=&JDC5;K(Z9=/_B:JT^WY$WI M_P WYEBBJ#Q7,8S#J0D.?NR1J?Y8IHO+V(XEMHY0/XH7 /\ WR?\:3NMT_Z] M"DHOX9+\OSL:-%5;?4+:X?8KE9/^><@VM^1JU0FGL*47%V:"BBBF(**** "I M;?\ UZ_C_*HJEM_]>OX_RIQW)ELR[11170O\J:3;L@)KV^ MMM.M6N+N98HEXR>Y[ #J3["L"6ZU/6.ADTVQ;HJX^T2#W/1![#GW%1VT$EU= M+J&J.KW?_+*(',=N#V7U/JW4^PK2SR,BIE54=(:OO_E_F:QI=9$%K:6NG1LM MK D9;EB.6<^I/4GW-6XV9XB3@8J"1OW@VIFG>:H!PI%=G7C MUJ+*;<1P>U6UN"1D+BG&E7"/,[=1-V.BHHZT5 PHHHH **** "BBB@ J"\O+;3[5[F[F6 M*%.K,?\ .3[5#JFJ6VD6+75RQVYVHBC+2,>BJ.Y-75UJUT+O4,94_N8%. M4B^GJWJWY8%:1A=F/WT@_D@_,_2L:.WCC+,%R MS^OH;1-K-\WIFI;^X^R M6;2+RW05SIL9)R+BYS\_(S686([G5)9#B!3@]ZKK%<3E::VT:K\HZ4Q MEP:M6%8D@MD:W*GG%4I6.TA.@ZUI6C [D)ZBL:7,=Q+%SD]JSJ45/8UA4<=" MQHUWJ,&IM)I]Q);[1\Q0_>^HZ'\:](T/QS#<2K9ZKLM[C.U9EXC<^^?NGZ\> M_:O/](EB@1U9<,>]1D2-<-(J%E.=PQD&N5XB5)\L]5^)T1I1JJ\=SW6BO._# M7B:738EAO&9].!"[F.6MO\4_E].GH8(8 @@@C(([UTIJ2YHNZ.>47%V8M%%% M!(4444 0P7=O %&6XN94BA099W. *P7O]2UAMMLLUA8G MI(4_?RC_ &0>$'NVZI#[G^\_OV[5MQ>*8P,W"L M,>@KL^K3@MKL[(8.HU>2+MCI=A:@^3:M',_WY')>1SZLQR3^=6S9_-UP/K6< M?%=EMW!Z;_PDNG,I922Q]ZGV=9O8V5*HM$C19+=3M$LI;T%.\I=G23ZY%8C> M)[>,Y\K-,E\5#K' 6%4L/6?0M4:KZ&^+'1A[,#6(FJWP;//TW5,-=ONF#^>:/JM6.J9$L&WOJ:D6L76FNL.N1HD;': ME]$,1$]@X_@/Z>XZ5O Y&1TKC7UNX:-DECWHPPRL,@CT-5=-UU]"E6.1)&TE MC]T@L;7W'JGMV[<<5,\))JZ6IRU<).FN9;'>44U'26-9(V5TK>Y_PJ)SY?4TIT^;5Z(FU'Q >8[+ MIWE(Z_0?UKGIW>0EI&9F;J6.2:LR)CD569,YQ7-*[=V=*:2M'1&?G05RVJS?*W- M;5'RHRI+FD<1XBO+FQG,]K(58=0._P#C6GX<^(\L4"?;XR(.A<]/P[C^5S9]$6&H6VI6RSVLJNC M '@],U:KQ+P5J5UILBB*4[.RGI7L.G:C'J$&]?E=?OIZ?_6K6E5YM'N@HC!SUV7YA.:I:+67X+_ #?X%'2;.U6!+M/WLD@S MYS\L?Q[?05;O;DV\&(\&>0[(D/\ $Q_H.I]@:KSG^S]UPBL;=CF9%&2O^V!_ M,?C]:\'D:A=KJ,>R6)/D@E'.<_>;Z=A]#ZUT1BHJR.2=24G>3N7XH3:Q1Q*" MRY^8]R>22?J?YU/@$$GH?45S'CCQ!?>'=%6]M(5D42!99"NXQ \;MN1GTY(K M*\*>-[O5)H[2Y$5S<2KNC\H!.1V/H,9.?;O75'"5)4766R,75BI\CW.[DEC@ MB:25TC4H7J?QQ5J&RD:Z-Q>2K,X \M N$ MB^GJ??\ E65JLK"Z5FN?+B9T5HN[?-@$>EB_A5?5+*WN&1)W"X/)'WB ,D9[5IVMR)+9<,6;'))S_DU#+=1>>R01FXG MQA@I^[]3T'\Z3UT'%]4'C8893[BO,_ .!JNO3M@?\3!1DGIS*37H=XJ7>VYM)8Q<1_=D0YR/ M0^HK*='EUA]W^1U0Q"F[5/O_ ,_ZOZFA156SO/M(9)%\NXC^_'G]1[&K59IW M5S247%V84444Q!3'ECC=$=@&(REMN^1L(I]/<^P MJ];Z3$'66[8W4PY!D'RK]%Z"H1;VRND4,CQ1HG"+PI]ZJ2E88/:L=]7M4P2+L\=-C?X5+'J5L_07(Z=585 ML[XI'>#RR?.//^W0%RAG-9RIQEKU-:=:4--UV+5O^)L@'!!X*GT([&I:J3V\4Y-W9 M2>3OX_P J<=R9;,NT445T'*%%%% !1110 53N_P#6C_=J MY5.[_P!:/]VJCN)D%%%%:$D-U=0V5I+=7#A(8E+.Q[ 5R,1N+^__ +4O8RLC MJ1!"Q_U$9[?[QX)/X=JM:Y<#4M833@9&5=HQV MJM(Q4@'%'*RK7-,W -OE!R/>JPN@0/E ;UJE([Q@;23GM3HY-^,I@BG8.4ML MHE^9QDU(N2NU5I8\E>13]R =:3B0V52FUOFXH*QE61_G5A@JPR"*F;#/IEXFCW+$VT@)LI&/3'6(GV'*^V1VKIZX._D>^@:([HY 0T M;KU1P&*Y@D@F0/%(I1T8<,#P14E% &#H,TEC<2Z!=R,\MLN^VD;K+ M!T'XK]T_@>];U9&O:?/0^S#CZXJYINH0ZIIT-[ 3 MLE7.T]5/=3[@Y!K6?O+G7S]?^")::%NBBBLAA1110 5'//%:V\D\[B.*-2[L MQX '4U)7&>+]1^U7<>CQ-^[CQ-<^YZHG_LQ^@]:J,;O78&[&1=ZA-K.H-?3A MEB&5MHC_ ,LU]3_M'O\ @*0#Z\=*1% XP#T%//'/:J_>^Q3]34< MT^?DCZ&G(#! S]S4W I7NZYF6%.@(S4MY!MB5?05+80GC6.C01Z?&&0;F7).*Y'2+,7.I1JP^5.37>-*=NU.@X% M>;CIIO0[<*FCCM>TU[,%H3A6Z^XJ]X#\0R0E-'OF/EL2+5V['^Y]#U'XCTJQ MJ44MS\K'Y17'>(7_ ++L#<9*[/F4J<$,.1CWS66#Q'LY'K>].!/C9,H[-C^H(/XUN5ZS5G8\P****0#9(TEC:.10R." MK*1D$'J*PM$D?2[V3P_<,2L2^;8R-_'#G[N>Y0\?3%;]96NZ;)?6DF['*G_ &6&0?K6D&OA>S$^YJT52TK4HM5TZ*[B4INX>-OO1N.&4^X/ M%7:AIIV8PHHHI %%%% #)94AB>65PD:*69F. .IKAY9WUV\34Y\BV3/V. C MHO\ ?;_:;]!QZUJ>)9VOKF/2(S^Y51/>$'JN?E3_ ($02?9?>J&0WR>7Y1/ MP<@BO1PM/E7.]V=V#H\S]H^FP,(68[5PP&=HZ4QK>(?,>_\ #BG1H=IVKMVG M '>G*R. 3ZXR1WKKN]KGJ. M(B2:,E$;@9Z5"Z$*S&;;YC$H6[ ^E/G8.0B1PAMBQ@MGY@_8>U3I'$TC!>$5 M<[B.#3LQO81VZGS7/!E?YB3397$)%P!D]!ZU(L7E- MYACU6_M9;:1@0X(C(/3'/7U'6N@\-ZG)J& MG&.Y.;VU;R9_]HCHWT88/Y^E<6)I_;7S/&Q-'V MJ>H+3_5'_>J>LI;EH****0!1110 4444 %%%% !1110 4444 17'^H;\/YU2 MJ[354HWD*M*T1U](0I45QNK2 M[%;D$>E=/K%SY*M^E<=>:7J.I MQ!&>A;EC^%16=W9%X=)*[. UN9=[8/)/2 MIH4\N!$_NJ!702^#H!)OG=Y6'.2:5M$6,X'/?FNC XF.&3;C=LG&47B&E%V2 M.)UMKB*42#KSD]1Z'VK.;2(F !C'Y5&^E(HP(U_ M*N:K-2FY15D;4H=MB'^[ZM^ M K@=.-M8?%/6(FE$<*690,Q_V8_UHC'GE;H@E/V4>;J]O\_\C;UGQ"?,=824 MM22,IP7 XZ_T],5A6FM+;3'4(C(6B<*J+GYCU(('MFFQ+).S0R^4<-S&Y^\/ M;WZ_YS5:&[C74HM.,,8M2,L2@ 4L1[\X%56DXK3_O4_1M/,ZXD%W&9$*D<@%3C M/U(KD_"'@ZXT#QA%?QWEM-9#K,P!' Y]JYS7=,C MU-46.$ 1G*N!EB5XQ]/ZU5.F/J"PFSU2^MG*1RY\UF7G[W7//'KVJ2YT+6(H MFEL-O/7/3GK535- UM[)9&U>-Y8EP D.S=^.>369+I&MW5O;,VIB M5CDD-$-R]-QSGGGO0D3JM#D?#^K0P1:I9I'([W-Y<29(X5%BF6 MT2O'$>#_ 'B#[>G/-3=N2?0[(*/(UU/6M \1+XD@\Z%!#J5L 2N?E8=Q]#^G M%=;:W*7<"RID=F4]5(Z@UXU\/=2BMO&.SW+H3]4;)FMIFL)"3L M&Z%C_$GI]1T_*H^&7DS7XX^:_+_@?EZ%^BBBK,@HHHH ***@O+C[-;-(!N?[ MJ+_>8\ ?G2;LKL:3;LC"\5ZAJ"Z?/::-'%+>E/\ EI*L:C/09)'U_P#UUYBM MK\78@$CU*U15Z!;F( ?^/5[#::-?0[BU[$2YWM^[R23]:EN=,OV0B&^B1O,+ M F'/![5K2C;5[LPKU')\L-E^/F>-&'XP;B?[4MA_V]1__%4KVWQB3;NU.W&> MF;J/D?\ ?5>R_P!FZ@"W^EP[>>L-/.GWC.2;I,;2 #'T^E;JQS^\>*^5\7_^ M@K;?^!4?_P 51Y/Q@/\ S%;;G_IZC_\ BJ]K73KS80US&2<8/E]*/[-O-P8W M,>.X$=)M(I1E_,CR2T7XF>0$NKD23%OO)>Q@$=A]ZK;67Q-CM%:66:-E7+N; MJ+;_ .A5Z'K\0CTZV+D!DN82S@8_C'Z4OB.\MI-"N$BN(WWQV]R+1?.%N9\<[4^4\U7FM= M4P1$UG_K>K(>$QTZ1[?B/?UNSMI0BF[$1D P0B GUJWY$7_/-/R%3-1E'E95. M^NX["PN+R8XC@C:1OH!FK%8'BM]]G:60S_I5T MBMC^XN7/X?*!^-;12;U),C3(Y8K;S+@_Z1.QFF_WVY(_#I] *N.WRYW=:9+* M$XZFJCW#9;)VYZ5SRDY2<59M[I7XW,"/6LV&9[IVB)8;>I]Z?#,879"I(!X8TVNH^4Z* MWF##!;-6,*>,8K&M[L!AP*T1-O8<8I6.><;%HX1<8SFH& "],FG-(0.#4+-S M[UG(S3L128_A09INASM8>(_);B'4$Q[>:@R/S7/_ 'R*D9#U-9^I7(BM5ND/ MS6NAJMJ%C!J=A-9W*[HIEVGU'H1[@\BKA))V> MS$T6:*Q]!OIY(YM.OFSJ%B0DK8QYJ_PR#ZC]0:V*4HN+LQIW"BBBI BN;B.T MM9KB9ML<2%W/H ,FO,X7EN?,NYQ^_N7,S^V>@_ 8'X5U_C6Y\G0?L^<&[F2' MZK]YA^*J1^-U $L*[(Q3;D9CJ3..*CEYC--@8^S][BMB! M<0@52B@)]3K+YS9 ^44^09B(I,$)H<@ M6\9 .?6NA:8(.MR3.Z209]^:Z)[XDG)KE[Y!?>)XE _=P#<3[UA3IV=S>M3DY4TWTT_K^NAYU16D.HHHJB HHHH YZY_XD&NB]7C3M1<)< MCM%-T5_HW"GWP:Z&H+RT@O[*:TN4#PS(4=3Z&LO0+N93-H]\Y:]L< .?^6T1 M^Y)]<<'W!K5^_&_5"V9MT445D,*;)(D43R2,%1%+,3V IU8GBN7&A-;;@IO) M4MLY_A8X;_QW=5PCS241^ASUD99XY-3DR'O7,SJ>JJ>%'X*%'YU<_P!&\E6W M$@#AP#./+R%W8P!G!JU(CPQ%[=AL^Z(_2HYEMY'!CEU.9+GRK6.$^<5&U:4,&;96F(,JM@(2,@ M59$2,V_:IDQC\!2Y];DN>MS%6Q,.G9",6)W$ _A3%LIWPQ8)"5VA78Y)KH+> MTCED,Q=_E_@[4Z:U5AE4X4Y#5'UC6Q/MU>QB^1)]G1DQN8[1CTI\ELUK#;QJ MY=BV&_&KK6\F^-D? 0\CUILD=U''^X16WY8GN,57.V]RN8CM(-TEQ;31_N^" M2II;F!(W,MN 5;DH1T.*;IZRQQR2% LDY^<$Y)Q5NY)B"L<<\@8J;M2)3?,8 MOEM+%(3'M9QDJO4U8\AS%$N"I1:9CO"HF1@8'-16Y1HEN(IG\Y M0<)+QOYJW5=O0IU"K$\=U/$L!"%"3LZ46,QTWQ/#,2%AO?\ 1I!_MY? M^!5941M(DCJBW1&25X.W_.:IZQ:2MI\SVZAI4_>Q,0/Y_RK0N9A;VLLQ_@0M5.T@,-E#&?O!1N^O>L) MZR2.J&D&^^@UQQ5>0>E7&%591S4L$59!QS51U!JW)G'%4Y#MYJ&:H7RP1S43 MP9!P.:3[1C@#./RI1=.>@'XTKH>I6BL?-O848<&0 _G7;LP32..M9K4T;LBHL7DS+)'D%3D$=J]!LK@75G%..KKR/0]_P!:Y(P#: 1U M-;?AZ3$$UOG_ %;[A]#_ /7!JZ7NS]3&K[]/T_K_ "-FBBBNHXPHHHH J7\# MR(L\ _TB$[D_VO5?QJ:WG2YMTFC^ZPS]/:I:S_\ CPO_ $M[EOP23_Z_\ZA^ MZ[]#6/OQY>JV_P C0HHHJS(***9-((8))6Z(I8_A1L"5W8S!=@ZQ)*5)6-3# M&?1N"W^'X5P5GY=Q\7+]9U!5HQD,/:/'ZXKNX]/9;.UD8?.!YCD=?6 M\4T_Q;OTB8H_E@D@?[*5K25H+S.7$2YJK2V6B^1W.K^&UOAYELD/F<9#D@9] M1COTKSG4].U/2[]UO&*RR'+H,G@5B1PM8W/E)$ M$@)&&50 V03DX Y!&/Q%7'N %)/ ')JD[(B45)W+33*58JI/U-<;XCO9+>(\ MKOVX8 UIRZLC3+&7( Z;1DD^@%4C8K[ M/%+6^GNM2:W#EG$=P&"C)W".3I^&*@TSP9=WMV]RX:W^90\DJ=1T.!WKL+*T M*W5MU;H*1+G._P"=;]R1-:J\9!*\ ME1UQ5+SXK56>*/\ >'H6-=L%&<+/J<,I3ISYD]CNM/N?M=C%*?O$8;_>'!JS M7.>$;LS6DT3-E@V[\^/Z#\ZZ.O+LX^Z^FAZLFF^9;/7[]0HHHH$%5;ZW::)9 M(<"XB.^,^_I]#TJU12:35F.,G%W1#:W"W5NLR9&>JGJI[@U-6>_^@7_F]+>Y M;#^BOV/X]/RK0I1;>CW*J12=ULPHHHJB K!UB=VU&T1&Q'%,@?\ WFSC]!^M M;U<[?.L>EVU_)RLM^)&/7"$0R]D9 QS][!'Y<&KJZG8%0?MD'3_ )Z#_&E&IV(' M_'Y;_C**ZG%]CC4X]RNYU;RDV"V\S;\WS'&[\J9_Q.2JX%L'V_,221G\JM_V MG8_\_EO[?O!0-3L#_P OMO@^DJU'+ZFBK12Z$UKY_DK]IV^;_%MZ5,>G%4_[ M3L0?^/RW]_WJTO\ :=CC_C]MR.W[U?\ &CE9#G'R,KQ5&)=-A1P=DES"IP>Q M<"LO6O#6G:?I4MS!&RR)M(.[/\0J]KM];74=I;031RS//9@?Y"MXN44NESDJPA-M[VMJ3R37D5K;FUMEFRJ[LR;<#CV. M>M1VM[JLMSY5$&.9/-!S^%/LM5T^2RA<7D 4H/\ EH!TJR-1L,$_;8/^ M_HK-IWV.J,U9$LTLD:$JFX#WYJC-J-Y&VT6+OF78"K?PXSN.:M?VCI__ #^P M?]_11_:&GG_E]@_[^K2U[#YT%I--/$KR1>43U7/(.:M<54_M#3\9%[;_ %\U M:3^T[#M>0<_]-!_C0T[:(3FBOKQ5=%N9"<&)?,5NZE>X_.J?B+4+-]"NXX[F%G>(JJJX))/L*ELE\FXN[8?=602+]'&?YYK"K&S4N^ MG]?B=.'J.:E#MJOR?Z%VI;?_ %Z_C_*HJEM_]>OX_P JF.YI+9EVBBBN@Y0H MHHH **** "J=W_K1_NUE6639SUS44F MT@ #FN9'X=YLE<>(Q/QEB.]5))Q'-\Q./K3#'',Q9&8Y']^JO[ITJ-D8=S))YC212L3G;M[5 MI:7MBE22Z4\@Y"]:R[F"YMYF^3&6R"3FM"TA>7YS(Y<#H*XVW<39T?VH*V^) M&2/'?O48G:0D[F(]*P)KZX\SRA(PQQBK5K=2Q@AR3FNQ/W1QC3!+=*+F=1(W5EWJ/FI0Y#<&J@E"#CFGPRL_.,#-9 M29S2B73NE7&<57EL4>WEC/\ &I4_B*GC SUJ8A>HJ>MS)OH:WAZ=KGPYILS' M+/:QEOKM&?UK2K)\,?\ (M6'_7+^IK6KNJ?&SB6P4445 !1110!AZ_;RVTD. MN649>YLP1+&HYF@/++]1]X>X]ZU[:XBN[:*Y@-?8'!]MQ%:_%#T_(6S.AHHHK(9R/C']_J&F6W8)+,?8C8 MH_\ 0S7,7 EW[&!"CI72^*&QK]H3VM7Q[9=?\!6;?3\DB,?K3(86NK@L?N"M-$2(;% Q2;"U MR55$: #@"L37/$UEHJ[)COE;D(M7-3U.'2[*2YF8 *.%]:\9U*]EU74I;IR? MG/R@]JAO0N,7L=]:>,[&^-A(QP1W%>Z>%I3-X6TQF. M66W5"?=1M_I7E>E9=GA;G;TKTWP:6/A:UW#H\H''82MC],5ZN'ES4FUW7ZG! M7BXSY6;U%%%69!1110 5BZ_9S@0ZM8(6O;++;!_RVB/WX_QQD>X%;5%5&3B[ M@U<@LKR#4+*&[MG#PS*'1AZ5/7/:)_H_B#5[*T^;3T99#Z13MRZ+ZC&&]BU= M#3J14960D[H*YOQ1LEO=*@?D"22?;GKM7;_[/725ROB6Z-KX@TMS%O4V\Z\> M[19K3#J]1?/\C6DKS7J-MQ"7GMY68K-C:''>HY9+FSMX[6-6G7/^N4YP<]*L M1!A*7V!XU^92>U-T^%4C:)4=(PY;+'-=FSN>KLRU'L !8@,#M)JE+I[?;?\ M1RKB3YBCG&?Q[58FD5;CR]FX9%-GEDM'6='#*/DV8[']:E]T$GH++&/MFX*$ M8$MG?RXQZ58BG69\H,$#G%.AL8;3=+*^Y6.Y2QY0>E5RZ'4/-@<&/ &T5*=R M8ZEVTO#'<,@7,6<,P%7);N&%61.6(R!BLV65HF$BI^Z;J!ZT^:Y,6?+A5ST9 M<]*R<+NYG*&HA#.F6!'.>*JW32?\LY"K'HN:MR_,>. R]/0UC7/G-/#$IE"J M"6<8P1Z5M32ZFL"Y"V=Q*DL@Y(XQ27WF?9EL4=6YL#'_ M ,]'1/S85+46J?ZJW]/M"9_/_&I1UKG?QLZ_^7:^?Z#6'RU7=*M<5&R T-$I MF9*N,XK+N2=^T?4UNRQD\8K%O(R)F/I64D;0=RN,9Q4B1YY_*I((<_,15G:% MC+D?*.@]3Z4DAR:1#;W$5I<)(V<@_P!*>^H++(6+C/H:I, 7))&XU1U&_@LH MB7 =\<)6G-RK4E1YGH:CW6[O41FYZUYQV*T_"R^7>1(#G]R M<_H::D^="Y4J;.QHHHKM//"BBB@ J*X@2YMWAD'RL,?3WJ6BAJZLP3:=T5+" M=W1X)S_I$)VO_M#LWXU;K/O?W=_:21?Z]V\LJ/XD[Y^G6M"H@^CZ&E1+22ZA M5#6I/+T>X;U4+^9 _K5^LCQ,"V@7(7J0 /SHJ? Q4OXB]3 TSQ7+*A$I:.,J M6R><<# ^E8_A,-' M;E8/BIJ#Q[?)FAV@Y !X0C'Y5V(\Q'IMQ(54]:BCG62W\PXZ<\]#23GYY_S[5DZ6PN]:N$1LL TC$<=P*2W& M[J(*D]KA;2T?E?F=CEB/KV^E0B>:-_WB%B3@9[>]:]Y)+93[UA7D8&",'ZUG MR2%Y_,DAY(((& #[BMDS@DKO48;^16,<6]\#H%QS4UE+=/.HGC(B)Y)//T%- M@=GG3? /+0\8]*FU&[:G>JLM]<(Q BPR[$3_9^8^A/7MBE&\MC91L]2."54-N$+$)*^ 021B-ZEN[ MQEC8]R=JCW-95L9'U<1#[C;G)]/D9<_F13[BPN!>AT7A3=#>F,Q; Z-^/2NPKB/"U\]YJ@W8^4'&!CJ#_A M7;UY]7^++U_1'H0_A0]/U84445!04444 1SPI<0/#(,HXP15:PF?#VLYS/!P M3_?7LW^>]7:S]0_=W-I-%_Q\%]@4?QJ?O ^PZU$]/>-:?O+D9H44459D0W@/J*EU3_D%W7_7)OY5!JT@ MBU'31P"\$PSOVX^YT.*JE\;?D362=))]68WV3P=Y802N,=_+?G_QVG26W@V1 M "YPIP/W3_\ Q-:<=^S0@%U\M6VB3[3DD@?[M.:\=[=90Z[2V 5N."?^^:Z> M>76Q*R8R"&N>/QPM'/+N'LH=CF)Y_##7-P% MTV8JW\:!N3G QE?QIIN_#*VL*'3IQC'RJC$KVY^6NBN+U)I97#KYJG!1;O Z M<_PTQ'3Y2TAQC"_Z:3DXQ_=HYY=P]E#L8UK=^&[)Y7@MKE&4;5(5LD?]\U.= MH^[VK6\Z ;C]H.W."?M1X/ITJ-%"X<2L _'_'X3P#S MCY:3;>Y2C%*R1A"Z\-!&(TV;YI 2"K=P>?N^P_.B4^%I)7S9SX)).%;!Z?[/ MU_*M_P Q7P#+C+Y/^EGH0?:HO-25][2#<01&!>GY@.O\-',^Y/L8=D82R^&# MRMC<8520"K?-_P".U?@M_"#+YA:1"R\HT3?!@WM(R;#@;;TXR>V=M3 M1.94,?FEL*!D7?(/I]VCF?<7L:?9%%[;P9(H#.2%Z8B?_P")J-[3P6X.9&QM MVG$;]/\ OFKTABM(543R/EO^6EYM/_H-/E.8XMK%=ASQ>'GG_=I\S[C]C#LB MO;S^$[9X)%(WPH%4M"WY_=_6M99X+C4H+FUD62WN;,.CKT8!N#^3568QW F@ MN)#'E2$*W)).!Z8%9W@[GPIX2_[!"?\ H*5C7;<;ONCIPL%&;LNC.GJ6W_UZ M_C_*HJEM_P#7K^/\JSCN:RV9=HHHKH.4**** "BBB@ JG=_ZT?[M7*IW?^M' M^[51W$R"N5\0#9XCLST\ZUD&?7:R'_V8UU5<[XLC*1Z?>#@0W(1S_LN"O_H1 M6MHJ]UY,479IF>R$]33<*N23N/<4]IE5<$?I5)YR6.P<5R)G>E<)"&)-/0UBFMC$U:U8@M""WM6,9IHT^Z5(KK)YD"X7C MMFLFZMEVEL@YIW.B,GU,G^T=ZC>F_''-2I>E8&8#'L*@DM,2;MAQ33$RR #O MVI.*92C?4DL\W$ADQSG@5>)RW;<.H':JACV,/NJ0,EB>E7[7R+J+\IG/%5]6:1M-D@C; M$MQBW3_>-Y5N#_"?XG/LHY_+UJWIFG0Z5IT-G!DK&.6;J['DL?/X"MZM9^ZN1?/U_X EKJ%%%%9#.-\9H4U/3I MOX3#-&?KF,C^1K%BE'K72^.H"VC0W0!S;7"L<>C93^; _A7%13\*<]J\[,(> M]&7E^IVX5Z-&XKJRX-5IK;G='^5113CUJU'*">M<5.K*D[]#HE!36I27(;!& M#3RV!G-6Y85D&Y>#6?*"F0W%>O1Q,:J/.JT90?D-DFZU5"F9\=O6E8$G [U9 MC41I@=:WNS)#T"Q)M%+O7!)X ZU"6_6JFI3F#3;B0'!"&H92/.?%VM2:EJC0 MHY\F([0,]:HZ59>=(&(S@U153/=$]26)XKKM+MUB1>*Y,14Y8Z'9AZ=WO*D^:1ZT.6+L4X98X[Y) M9"#M' J26X8E@G5SR:XZ.\E$L@#_$.]>K>%5V^%]/."/,B\SG_ &B6_K7DC^9]I008\UCL3_>/ _4BO;K6 MW2TM(;:/[D4:QK] ,5[. ;]@V^K_ "7_ 3PL=;VQ+11174<84444 %9>NZE M)I]FL=JH>_NF\FUC/=SW/^RHY/TK2=UC1G=@J*,LQ/ %8.BHVK7TFOSJ1&ZF M*P0_PPYY?'JY&?H!6D$OB>R$^QIZ3IL>DZ=':QL789:21NLCGEF/N35VBBH; M;=V,*YWQ" FL:3,V.1-",],E5;_V2NBK$\4(@T^WO'7>W)AF)+2<+A>E3WUBJ7R/EEC;GY>QJ M/4XXKF +]H\IL?(XZM79&29[$6F0.SBX4LQW@X9@OY#-$5RRW4DD\#%$.1LY M)IL%NQM8L.6*-P2>M3O"9G5)&"1,?F.XALUI*UBY6L6D=KZ.61X0AP1&K'EA M6=9E[=?+FB,SS4):"!GD*M* ?O-S4\-M)+&/,M\2Q MG =.A'O4L.G!8!$6!;'.?K5\ROJ7S:DAU2X@B0K"61^ >U-DNXS8R36^VVF M'#!AEC5:4:BD\:HZB-&Q@J.E6+:R1>6&78Y8GFIY(K43@E[Q/9(RVP,I+2-R M6/6I,$-N8]*?O^; ]ZIZY<&TTBYF7.\1G9CNQX _/%)>](AR6K+7A8?\4] M X_Y:O+,#ZAY&8?H:V:JZ=:"PTRULUZ00I'^0 JU7'4?--L\DN6G^J/^]4]0 M6G^J/^]4]<\MRT%%%%( HHHH **** "BBB@ HHHH **** (KC_4-^'\ZI5=N M/]0WX?SJE6-3.M27T)N+">(=60@?7M52VF$ MUO')_>4&N:6DSK6M->3+5%)Q2@U1(QD%9%_ 5ESCY6K;_*H+F!9$^E3)70XR MLS'0 +CI3+J153KA5'?_ #WITH>/(1=V.E9\MM-.V96/T[5G>QLHWU9RE]KD MLDOEV0*DM][N?I4$L$DC;I"2QZUTXTB"-RZ0J&/4@5%-8#!XK-Q;W-HS45H< MG):_*1BJ4EEUXKIYK7&>,55>W&.E0T6I7.6DLSZ51EMR">*ZN:V'85FW%KU. M*!W.9FAQ1;:MJ.F$_9KJ1%S]P\K^1K5FM^O%95S!CM33U$UTN%DC)!!KZ$^&MN5\.+=,FUI MP&_/G^1%=J]E*"LO>N<;=2+E=Z6.THHHJSG"BBB@ IKNL<;.[!549)/84ZL^ MY_TZ[%F/]3'AYSZ^B_U-3*5D5"/,]=A;!&F=[^52&E&(U/\ G;\3UJ_113B MK*P3ES.X52U;C3G?^XRO^3 U=J*ZA^T6DT/]]"OYBE-7BT@IM*:;'[:"*BL) MOM%A!+W9!GZ]_P!:F-=46FDT<4HN,G%]"O(?+1RV?+QDGTK(E9)#YZM.^ECAC5KC9Y Y.]L#/^?6H8;N*[C)1!Y0Y+J,+^O6G5BW[UA4Y):7**L4M M[F<@@G)'Y8%>7^-]2O=$TZ"ZTZZD@FFG*.ZXRRX)Q_*O5=2@%Q8F&U/&7B 'C5K@?B/\*]_EA@T'1H8S<3W- MUMPTT[??;'/T'L*\@D\#Z3&[)]MO0ZG!RB\'Z5TK:I?W$ET;Z\>:!IF>!2.8 ME/;/?J*G0EZG0C6)+J5]J(K;22^W.WK_ %Q^=9.J37-II\,5Y,LTMUY>7Q@L M4).0,X ^8YZGIT%4+"\?[28H^3*RH/Z5T7B738UTPW4L,@:!D\O(Z MMP/?' MYX]JJ#"2U.=D/G:E;L"<.KG@D?PD_P ZQ]9\1:EH<, MXLDF0><&(PIS@$,.O3BN?\6?+]E7UG_H:<2F6+#XCPNP%]I\T1[E/F'^-=1: M>)-"U$ )<1AB/NN,']:\SD&!PI_*J,^XJP"-TZXIJ;$Z:/HCPI#!_:;2VY4J M8SDC\/\ &NSKS3X*:<]KX.6YEW[[AB^'.<9/&/;:%/XUZ77$WS2E+S_X!V./ M+&,>R_/7]0HHHH$%%%% ",P12S$!0,DGM5&R4W,S7\@(WC;"I_A3U^IZTEV3 M>7*V*']V,/<$>G9?Q_E6@ , 8 J/BEY(U^"/F_R_P"#^7J%%%%69%>^3S-/ MN$[M$P'Y51OEEO+K1GA&]FMI&P2.A$?/(-:QYEIK'[7I\1^_;I<0D_1DQ M^F*<':?JA5%>EZ/\_P#AA_\ 9=V/E50 #G@18Z?[E,BTS4!E6&$!! !BQT]- ME=%R1S2\BN@Y#GCIEVH8*BL>@XCX'_?%-.FZAO4#.W'S.#%S^&RNC_E1C\: M.5&BWXGW9V#/80X8?]^\U*NEWVWYXE)W$@?NN/I\E=+CCI1T]Z .6CTK41N6 M1 PSG)\KT_W*)-+U1RF-RJOW4W1$#C_KGGFNIQSTI,>VU MQ)=6<)3F1&7@FBO:LQFLHG?;(A48XP< M5E7&C,C,PWX[?-75&W60D8S@TDD+$!&Y ]J=]2E59PTUFGEM'-N96&#SS3=+ MLS91>5'N$9/%=9<:8C-G;2PV"+P<>U)ME\Z90MHG<G M-/=+MO+M_.F4_P &1A4_X" !]]:.M:G_9>GF5$\VXD816\(ZR2'H/ZGV!I M-%TS^R]/$I^G8>P%:P]U<_W?Y_(3UT-$ 8 P!T%%%%9 M#"BBB@"KJ-DFHZ;X5YA\ M0M'>QU)=5A4F"Z($H ^[(!_4#\U/K6=>G[6DX]5JOU_KR-:,^2?J9<-P,BKL M,X]:YF&Y''S9';VJ]%=#^]7C.'<]%,Z:.?C -.D2.=<-UK%BNL]ZO17 ..:S MU@[Q*LI*S'?870ED^:H7W1CYEQ6G;2 L>:E98Y,A@#73#'R6YA+"I[& 7):L M_5U>?2[B*,;F9< 5T\VEQ2KE.&K(O9[32P/M,F&'./6NCZY&2]W;=R X]37-7GC8ROY=A'@*?O$54GU.]OP# M<3-C^[FN2IS2>IU4XZ>Z=?<>)+2R4PV$2ENF^N7U/4[R^;Y"7DSWZ"H$Y 1> M2:TK:%(P,XW&L6^1'1&GKFUW.F]EG#4/$\#$9CMO](?CCC[H_P"^N?\ @)KU:N<\ M&:0VF:,)IT*W5V1)(#U5?X5_ <_4FNCKZ:%/V<%3[?GU/G:U3VDW(****9D% M%%4=7U--)TY[ED,DF0D,2]9)#PJCZFFDV[(#-UECK&HIH$+'R<";4'4](\_+ M'GUPZ#V%:=7- MKX5LA+N%%%%9C"H;NUCO;*>UF&8YHVC8>QU%-.VJ \_TN2\\R%;B3_2(7 M-O.S'NIQP/?&?H1727$<3&(-#O\ [O\ LU3U:S6SU^"[91]EO75)#C[DZCY# M_P "'R_4+ZUH,CN^3E$!YYZ\5W.2DE)=3T:-3FAYD"IYB9>/:%;Y0.]4KJ$- MM.QB0W'-:C*'AC()P!Q[UF73OY\)A#>66PYSTJH.^AO%\P3W$[VMO',(PW4@ ME5 J?:%&6V]R>IJ5XW<5::=B@)/#MP.]5+)UCM6GD(!;[V!TJX(UE :-MQQQD5S2T9S22 MN,_>)<)NG!']VI'B43L5Z'K2'R%E*.@$I'6G1.CK@@Y3@GUJ;B#8B#()XZ@& MHO+$K;Q\I!J8XZ4Y%4IP#UZ 4-AX7;)2R$G>FX^H%9E\BZAK&FZ>@RBO]JF'HD9&T?B^W\C5 MJYNDAMI))#MA0;C)GCCJ:3P[!))'-JUPFV:]P40C!2%?N+]3DL?=O:B_)%R. M>O.T>7N;=%%%:?#SPYY^J-J4R9CBX3(_P ] M_P"1KUFNB@F_>9SXF5DH_/\ R"BBBNDY HHHZ4 5[VY^S6^Y5W2L=L:?WF/2 MBSMOLMN$+;I&.Z1_[S'J:KVO^FW9O6_U292 >OJWX]/I6A41]Y\WW&L_<7)] M_P#E\@HHHJS(**** *5B?(NKFT/0-YL?^ZW7\CG\ZN&J6H*T1CO8U): _.!_ M$AZC^OX5:$BNBNI!5AD$=Q5T7IR]C/$1NU4[_G_6HR[MH[B(+(N5QT-<9J&E M:C;7GVE9'N8P28UDDP(\\ X[UVDCDD =!6?J>#'Y8/S,.W85W1JRIQT.#DC. M5S@5US4HIDWRR-(#@[\8%9OC3Q;O6NEO+2/?NV@ M>6,C ]*Y>\TM-0UBS,H/DNQ5L'U"_P#UZRC4_>*26QNHVCJSSV749"BH()0H M3(&P\GC_ .O5SPN)[G4)2UK.FY#MEV<*0<\_7_/>NVO-"FT1]QC%U99ZDMB\TEB*?(XG)"A[-W1R,NC&25G8S'<JY7'(W9X] MR.E=9<:S%XC\+&TCUN&X=)$;:T(CE8 YY&?U KSFQ\2^)=(ES%IETT)QG+\D M?E@_C721RZ)XC@+3V3Z;?GD2JI3YO<=#]1FE:VQ;=]RK'I\\.I)=FY:7!(V$ M8'0CU]ZY[Q*KW+PH1ADDW#\JWWM=6H)VLIS^H_P#KU2N=3L+Y%6>, MJX/*N,$?C3YG?4=NQP\UY>VN2UN^W^\&R/Y4EC?76J7T%C$@,EPXC!R>,]^G M0=:ZB[T^/&^W+$G^!O\ &ND^&/A,76MMJEQ9A%@R$)'7U/\ 3\6K.I/EC=;F MU*'/.SVZ^AZYX>TV/2=!M+.)-B1Q@!?08P!^ P/PK3HHKGBK*QK*7-)L**** M8@J"\N1:VYDQN8G:B#JS'H*GK/@_TZ]-T>8(24A]&/=OZ#\:F3>RW9=.*?O2 MV1/96QMH/G.Z9SOD;U8_TJS113225D3*3D[L****8@KF]7O9]#U>.^AT^YOU ME5@(+9=S[CC) ^BBNDJGJ5JUS:$1Y$R'?&0<'/IGW'%*5UJNA4+.\7U_K\S" M_P"%@7W_ $).O_\ @,?\*/\ A8-]_P!"3K__ (#G_"M;3A%J:-/&;Y,9C=3< M-P>/?TQ5LZ6AG$N;W*\#_2FQ^6:Z%)-71Q2BXNS.>_X6#?\ _0D^(/\ P&/^ M% ^(-^>G@GQ!_P" Q_PKJ#+OIUH^UW>P'^SI,GJ/,7_&@#E?^ M%@W_ /T)/B#_ ,!C_A2_\+ U#_H2?$'_ (#'_"NG%Y?;]HTR3;Z^8O\ C2M> M7JID:=(S'^'S%X_6@#E_^%@:A_T)/B#_ ,!C_A2?\+!O_P#H2?$'_@,?\*ZD M7EX57=IL@)Z_O%XIZ7%TTVQ[-E3^_O4C\J .3_X3J]D_=R>$=:MU?@S30E43 M/J:=%JNGR6DI*[N4D7[T;#D, M/<&N3@FFS+9W8"7T'$JCHWHZ_P"R?_K=J[BLC7-%_M-$GMY!#?P ^3*1P1W1 MAW4_IU%5I)H98UZJ*;;W0=I+>XB:"[BXE@;JI]1ZJ>Q% M3YP@XZURRBXNS-T[ZHJ>43\U/:/<.'Q4TBG;@<5$/E^\:12N1*OE$CU-2.5V M97D_2HW<,<"F@E>CTBM1U!@5B,KS4J9VD@?-2EFQAE^:BXKL0I;)!Q077CG%,M89/$$K06Q: M.Q0[9[I3@OZI&?7U;M]>A3IN;LMB9221)I5G_;>HK,03IUG)D'M/,#^JJ?S/ MTKL:CM[>&TMX[>WC6.&-0J(HX %25U.UK+9&&K=V%%%%(04$X&3THK!UV:2_ MN(M M7*R7*[[J13S%!G!_%ONC\3VJH1YG8&[#-+']N:NVM/S9V^Z&P4]&[/+ M^/0>P]ZZ&F0PQV\,<,*!(XU"HJC@ =!3ZX/-6Z*:;3N@/!=3T"[TB\FM'R98CZ<.IZ,/;^7([5G MK/)$VV0%:]Q\0^'X==M PBNXLF&;&<>Q]5/L*]"+7/%>OE_P#:G5>S'PW8XYK0@N<\@URCR&T"J7\Q^X%:-O=,!G M! ([UYTZ3MH=<:B.OMKGG)-75G!Z&N5COUVCYJO0WX&/FKE]FUT-XR1TT=P M.:P_$5I;W/\ I#IE\$4K:@ ,AA69J&HM<+L6JP].7/H@K27+N<);*([J4'C# M<5H1R%I<=NU9DP:VO94;(9FS^%:6FJ9&R1P*Z:RLPP_PFS;1X7=ZU<7(&?2H M$.%QVJ93E.OX5P3U9V1MN2JV1R<>]='X3T'^U[\74\?^A6S9.1Q+(.B_0<$_ M@/6J'AW0;GQ!-A 8K1&Q-<8Z?[*^K?R_2O5[2U@L;6.UMHEBAB7:B+T KU\% MA72_>SWZ+MY_Y??V/-QN*4_W<-NI-1117<>:%%%% !7.V/\ Q/M;;4VYT^R9 MHK,=I).CR_ARH_$U+K]S+<20Z'9.4N;P$RR*>8(!PS_4_='N?:MBVMH;.UBM MK= D,2A$4=@*U7N1OU?Y"W9+11160PHHHH **** *]]90:C936EPNZ*5=K#N M/<>A'6L+3)KF&633;U@UY;C.X])H^@D'\B.Q_"NEK.U?2EU*%&C?R;R [K>< M#.P]P1W4]"/_ *U;4YV]U[%PFX.Z(3.A!6(8P0"Q'RU#J5KOMQY6>3T7UJ"# M5)+B4Z=<6ZVMY"H:6'.0P_OH?XE_ET-70&6,Q&3+DY7VK9)Q9Z%.2EJC*BMK MB:Y>,NH=%SC/6HXS-:JS3P.OS$-GM^5.E@F%W(T6E0Y+XK0MC]2JF =H^4]1WIL@9HO+1L,3RU2;\/Y:G MY@,Y]:EL+D4T@1<;"#[T.C2VW+&(]JE(WLK'#,.HIKCS"P8@@=/:@!BE\IG& MX#KZTR2QMIQEP5YR5!ZT\@EMA084<$5ERW,VJW+6&E,4"G;=7F,B'_97U?\ MEU/I32N1.:@KL;);C6M3_L^+G2[1@;H]I''(B'J.A;\!W-=15>RLX-/LX[6V M0)%&, =S[D]R>I-6*QJ3YG9;(XI2J>L MI;EH****0!1110 4444 %%%% !1110 4444 17'^H;\/YU2J["#2T5!J8@C-A2WF%M<_ZS^"0#B0?X^U<[7([=#IO[17Z]?\ /_,O=#1D]:9F MG ^E69"TTC ^M.I&ZT 577BJSCUJZP JO*N:EEIE&9>*SIXNM:\BCIBJPJ&PMWBC::;_CXF.Z3V]%^@%1+5\II#W5SOY>O_ "TB+&BH@ 5 M1@ =A2T459F%%%% !1110 =:RX\Z?<"U;_CWD),#?W3W3_"M2HKBWCN86BE7 M*G\P?4>])WO=;C333C+9_P!7&/(B1L[G&.P%8]Q.2^73:Q[=>*G:22"5+>\/ M*_95*?-$X'3E2J7C>RC /0G/&:F"UU&WH=;K=J MR:#?HTKR*4)7?R1[9[UYO;:G-ITZEB2H/#=Q7J.J.LVBW8QMD6,[X\@E?RKR MVZA!RI%4GKJ"6AV5IK=OJUJ;:=D+,,*Q .#].]:$%CI, _TC3I9#VDB<%3], MD8^GZFO.-)MF.K10[F5'R#CZ&NUM]0N=-/EW:F:V/ D Y'UJFD1RVV-PC0]F M!I%QGU,@Y_\ 'ZP-<.A1Z:XFTVY+;@5*G'?_ '\UO1/!/$)87#QGN.U<[XE: M/R,'C!I):CN_^>WYD]+7$VYOF?R.RRA'D6_7_ ""BBBF2%%%1SSI;0/-( M<*@R:&[:@DV[(JW\CR,EE"V))A\[#^!.Y_H*N1QI#$L<:A448 '855L('57N M9Q^_G.YA_='9?PJY415_>9I4:7N+I^844459F%%%% !1110!1,YTFY:7!-G. MV7 /^K?^]]#WJR-/UI[HLB,CJ&5A@@]Q6)=B?2T*@R/;D@1 M.I!*?[)SV]Z496!5Q\C;6S^1J>:U$D:*MZJ,&R6P.: (7\101[=RQC<>5&1GVJ86P$;HVH M+N. &*J,4 0_V^AVYC0;AD@SIQ^M-FU\[O*@A#W#':BB56P??!Z4EXRVUI$B M7>^XSM544%I#Z>WUHL;-XB;BZ?S+IQ@GL@_NBL:E3[,=_P CHHTE;GGM^?\ MP">TMOLT&TMOD8EI'/5F/4U/116:22LC63Z.1'JD:K'G"W<0)B;_>_ MN'Z\>AKNZ1E5U*L RD8((X-5=-6EJ--Q=T<292X#'E<<$5'@,V!_P !Q6;+IFM6GW[*&\0?QVL@5C_P!\?^A&L70?V7 M?\/Z^\U55=2J+=2VYN13TA^?*#BAKQ8GV7%G?0?]=+5\?F 1^M-.M:7'P;Z% M#Z.VT_K4.C4_E97M(]R=HH#JME-S%*9>_[J-GS^0-3Q27LX MQ::3?29Z-)'Y*_\ CY!_(4U0J=@PP*N-!+XG]W^?_#F;J=C L] O-8(DU)7M+$]+8-B64?[9'W1[#GU(Z5UL M,,5O"D,$:QQ(-J(@P%'H!4E%:MZ66B,_-A1114@%%%% !5.RTV&RN;RX5GDF MNI-\CN@6.OVODW: M$.H/ERIPZ'V/].E:E%--IW0'C6H^#Y?#TK/?W(&PGW0\?EBJM"7D_P"[1Y M.]FA/RDBH_(D0?*]=A?>!=;M=Q@2&\7L8GV,?^ MQ_X\:YV]TK5[=MDFF7B' MU\EL?GC'ZUC+"WV5_0M5FC&N+J13LWFKFFW*S#8WW@:RYXY4;,L95B>,FIK. MTO&E1H()).XV*3G\J<,/./V7]PI5>;=D?BJRQ<0W*# ;Y#4NFQA8%^E=1-X; MU76K!8(M*N]V00TD?E@>_P ^*U](^&-X%7^T;V.%!_!$-[8^IP ?P-<];"5) MOMZ_Y;G71Q481L!;J\VSZKOMK8\^2#B1_K_ '1^ MOTKM-(\-Z7H@S:6X,V,&:0[G/X]OH,"M:KHX6E1?,M7W?Z+^OD9U<5.HN79$ M=O;PVEO';V\210QC:B(, "I***Z-SF"BBBD 4444 4[738K6^O+P,\D]TP+, MYSM4# 4>@')_$UDVVJPJLX99(SN MBFC.'C/J#_3H>]9+75QI)5-9B#P+PFH0K\F/^FB]4/ORON.E=)1UK2-1I6>J M*C)Q=T9T?DSQJ\4B.C#*NIR&'UITBD(",;A56;PY;B5I].FET^9CEO(QY;'_ M &HS\I^HP?>JAC\06;L9;>WOXO6V?RW/_ 'X_P#'JV7++9_>=$:Z^T:)*QR* MI^\>]2NX50 <-GFLEM8B1E^UV=_ <='M7('_ )05_6F-KNCCF34K>)CVE;; M_/%5[.3Z&BJ0?4V#.K-MW#\J9-T!CZCK67_;^DLN8;F.1O[T0+Y_[Y!IZ:M) M-'BVTS4+ACP#Y!A7\Y-M"@UN@]I!=31\\]A5>]O[6PA\RZF6)6X&3RQ] .I/ ML*K)I^N7;DR36VG1'M&/.DQ]3A0?P:M"QT*QLIOM.U[B[Q@W-PV^3\"?NCV& M!4N4(];^AG+$+[)0CBU/7$VR"33]//7M<3#_ -IC_P >^E;EK:P65LEO;1+% M"@PJ*, 5-16,ZCEIT.9MMW84445F(**** +EI_JC_O5/4%I_JC_O5/64MRT% M%%%( HHHH **** "BBB@ HHHH **** (KC_4-^'\ZI5=N/\ 4-^'\ZI5C4W- MZ6P4445!J%17%O%=1&.9=R]1Z@^HJ6BAI-68)M.Z,=UN-/SYH:>W'251\RC_ M &A_45-',DJAXV#*>A!S6E5*;3(7K1]#]1T-9.#7PFW/&?Q:/^OZ M_0%/%(>:@*7]OPT2W"_WHCM;\C_0TW^T(4.)EDA/I+&1^O2IYDM]"O9R?PZ^ MA8P.]0..:!>6K_=N(C[;Q3)+B +GSXP/]\4XN25]B&057=>3Q4ANH&.T2 M!SZ(-W\J5;>ZG/[JT<#^]+\@_+K^E3S)[&BA);Z>NAF31X!JYKV3RX$+8 M/)[+]371PZ$I(:[E\S_83Y5_Q-:L<4<,8CB140= HP*:IREOH)U(0VU?X%'3 M-'@TY=P^>8]7(Z?2M&BBMXQ459'/* MQ/8GZ5-112LAMMJP4444Q!1110 4444 %%%% $<\$5S$8ID#H>QKF=5TFZ@C M)BS-"HX./F7Z_P"-=511JG>+LQW37+)77];'G<*/P7(^E8S0!O%UG.N,QR*& M^A->FW>CVMT2^TQ2'^-._P!1T->$;V.[^U6TPD8-NZ#/Y'_$UI&NT_>7W M&3PZ:]Q_?I_P"?5H8CIUS,(U\WRB"V.?SKS.[3#].M>E7K3-I"WR_-[#DTW4@MV"I5'M%_< M\G;\_N_SL>2:=\.] M;UK4&MIU\BW1L.X()(]O3ZG\C7LWAGPEIOABR6&TA4..6?')/1NFH+EA]_4****"0HHHH *AGMDN&B+D[8WW[>Q/ M;-344FD]QIM.Z"BBBF(**** "BBB@ HHHH *1E5U*NH92,$$<&EHH Q+K2GM MP3:HDL.<^4ZY*_[I[_0U5B6)MR(T?EA=IA^RMN5O4X.:Z6J]Q907)#.I$B_= MD0[67Z$4HN4/AV[#DH5/CW[_ .962T:"&:4"/E?FVP-\QQQ[UG6]H\DX2/8& M;_5EK1P /0FKUW#KJ0E;#4TR.GGQ G_Z_P"E9:MXJ3BXUE(CZKI D4?BLN?T MK55H]=#)X>?V=?Z[;EV9)(9#''*J@C#?Z&[ \>H]Z$LG&TL\1+K@'[(PP?4U M6$VL$?-XPLD]I-'9?YR4IEU?'_(Z::3[:5U_\BT_:T_YD1["K_*_N)"DL0"; MP.0&VV3G/H?YTTQQ+*P 8X8_P"A2('_<%344K M(?-+N(JJHPH 'H!2T44Q!1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %1M;PO]^&-OJH-2446N";6Q"+2V!R+>('_<%2JJJ, M*H ] *6BDDD-R;W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I;?\ UZ_C_*HJ MEM_]>OX_RIQW)ELR[11170E1:1KGAP:%=.GDE[[3RCAP.2)P#G MU#;JZPZI?>'AX0T@7D&I+>R&WFO'0YD58RP9<,1DX')SFF([*H;6\M;Z'SK2 MYAN(@Q3?"X==P.",CN#6'J6O75IXWT71(XX3;7T$\DK,IW@H!C!SCOSD&N%\ M%7OC >'YU\/Z9ICVMO?W)D:^E=7N/WC$K$%&!Z9;OVXI7_KYV';^OE<]6FN[ M:WEABGN(HI)VV1([A3(V,X4'J< G J:N&;Q7%JP\(7L6GVQ^WWCQ.MS'ODM7 M5'W;#_"P*D9]*I:U\0;TZU>:?HM]X8LTL9?*FDUN^\MI7QE@B*G]>=CH** MX;4?'LFFKKEY)%;-8VEW'866Z3RS-<$?/N=CM5 3UQQM:LW3?B+?0:M:6^LW MWA:\M[V=8(SHM^9)86;[N]&^\,X!(Z4)W>@VK'I=%%% @HHHH **** "BBB@ M HHHH **** "BBB@ HHHH IZAJ^F:3&LFI:C:62,<*US.L8)] 6(JQ;W$%U MD]M-'-"XRLD;!E8>H(ZUYCJ$&F:3XPUF^\8>'9]2@NG5K34#9?:X8854?NRH M!V$'<>G/-:GAG^P;:+6M<\(:E:R:;);^8VGQ1E4BF4$[]N04W# *[1TI*6EV M4UK9'?45R*>*;YOA9_PE!BM_MW]G&Z\O:WE[]N<8SG'XUGZAXO\ $)U70]+T MBRT^6ZU33#=;K@NJ12?*CY?ZZ_P"1*>E_ZZ?YG?5'//#: MP23W$J10QJ6>21@JJ!U))X KC+WQ!XKEOX= TBTTF76H;5+C4+BX:06L18X" MJ!\Y)P<>@K._X3'6;F#QA9:OI%C&^D:>LGD.IECF8HQ.23\T9P,# ."0:3=D M_G^!2C=V]/Q/1HY$FB26)U>-P&5U.0P/0@]Q3JX>[\4ZFL6AZ-X?L+&35[ZQ M%R5F8QV]M$%')"_-C)P /2K6G^(_$%M9ZK'KV@R-?Z?$)4;38Y)(;P$<"(D9 MW9X(/(ZU3T;)CJEYG75 EY:R7A*]0#7GM]XR\6^'Y; M>]UVU\/)I\\T<1M+>YD^UQ;R!SN&UB,DD 5J:1_R5OQ'_P!@^U_FU);_ -=@ MZ?UWL=K1110 4444 %%%% !1110 4444 %%%% !1110 4454U2*ZGTF\ALI1 M%=O ZPR'^%R#M/YTF[*XTKNQ#+K^C6]^MA-J]A'>-TMWN4$A_P" DYK1KQW3 M'\":3HUOI?BWPQ_9M_@0SW-_IY<2RDE=,=2N/"/A?PY!I^ MH0:M;W6HQ6D=S(I/^CNQVX(;DJ, '/;I37;Y?>+4[RH+:]M;PRBUN89_)D,4 MOE2!MCCJK8Z$>AK%U_7;K2M=\/6,$<+1:E=/#,7!+* A8;<$8.1WS7$>&KKQ M7]O\40>&['365-;G>6?49'"OG'R($YW<=3P,BDGK_7E_F-K2_P#77_(]2N+N MVM!&;FXB@$CB-#*X7]-\2^/+JVUVXT;1KSP[:3V@4W$^MWGE(2PR$15.XG&"3T&<4 M[_U\D_U"W]?-H] HK@K+XEVS>&-7U&\2VDNM*98Y$L;@313L^-GEOZ,3CGI@ MU);ZYXZL[RT?6-#T^2QO9!&HTXRR2VA(.#*,8*YP"5P!0([5[B"-)7>:-5A& M9&+ !!C//IQSS1!/%)+:#QI/J<6BRV ML=QO-=+H7B.Y$WAJVGMK*WL-5TP20"",H(YU4,8P, MX"[3P.ORFA:K[OQ3?Z#>GX_A;_,[.BN1U#QD=-U'7YIDB.D:-;)YC@'S'N&Y MV YQC!7MU;K7,CXG:E8LM_J=WX2FTUF7=:Z?J?F7<*D@9P?EEL03WUI:RP17 M%U!#) (?%"0M,)84*0*<%I6(41Y[?.<9J;>[?\ K7;[R[^];^O,Z.YN M[:RB$EU<101E@@:5PH+$X R>Y/ %"W=L]W):+<1-$."ZJ>A*]0#@\^U M>6>+;WQC_95C'XBT[2TMKC4[4QO83.6@(E4A9 W!XR,KQGMS6C>W6MQ?%/6+ M?0+2TFO9=,MR);V1EAB 9^6V_,2<\ >_--1T^_\ !)BF03QURH[TK,=T>AU'//#;023W$J10QJ6>21@JJ!U))X K@O#?CVZN M->M=&UF[\.WDUX',$^AWAE0,HSM=6^89&<'IQBNC\;_\B)KW_7A-_P"@&E). M*N$&I.P]/&7A:618X_$NCN[$!56^B))/8#=6TK!E#*05(R".]>:Z4?A"]4US1?^$OU/73I0TZUO)Y;K[+ MYGF&<*F0F[C81TSSFER_E?\ &Q5_SL>K5#%=VT\\T$-Q%)- 0)HT<%HR1D;A MU&1SS7"V_B7QS'':ZO?>'[&31[DI_HMBTLMY CXP[#&UL9R0!_*J%M=>(AX] M\8VOANTL'N6EMG>?4'<0H/*'&$^8L>?0"CE?7^MO\QG:]:ZCI%JWVB*TMIUD-J&'^K#!CPS= <8R>M59:DINZ\SO** M\J'Q.U*Q87^I7?A&;36*[K33]3\R\B4D#.#\KD=PN*VM0\4>)[CQC?>'_#]A MILPBM8KA+F\9U2/=G._;DMGC '?)HY6+G1W=%<+8^/;BTT37IO$5E##J&B. ML6&*>XBBDG;9$KN%,C8SA0>IP"<"IJX*+Q:-9MO!M^-.M"VHWCQN) MD\QK=U1]QC;L6:_E<-<2*!N6,)TQTR MW%-Q:T#F7]?/_([NJ]U?6E@L;7EU!;K+((XS-($#N>BC/4GTJKH.IS:QHMM? M7%A<6$\B_O+:X0J\; X(Y R/0]Q7&^*M-/C?Q3/HB/BWTJQ:5FSPMU*,1'ZJ M 6_&E:SLQWTN>B45QEMXNN)?A?<>($2,ZA9VLGG12@E1/&"&! P<9'ZUCS^- M/&=AHMKXFOM'TI=#9(FF@69_M2JY W_W0.0=O)]Z?*[V)YM$STNH[BXAM+>2 MXN9HX8(U+/)(P55 ZDD\ 5S7B#6?$2WJV'AW3[3<(!/+?ZF72V0$X" J,LW7 M@'CBN8O/%-[K?@GQII>J1V(U'3+-EEET^4O!('0D%<\@C!!!J;.S?8I-72/3 MHY(YHDEB=7C=0RNIR&!Z$'N*=7&Z3K=U87?AG3)XXO[/U#3%$,H4[Q.B!BI. M<8*Y(XSD&H-?\=W&C7FNO':PS6&E0P(68E2US*W +9P%52I/&>:N4;2LOZUL M3&5XW?D=S4,%W;733+;W$4QA']3\8SW\/]K6>AW> MFW )6ZTFY8^1QD;P_P!X'IE?RK+?QG_8ND>)+\:=8H]OK)LT\L>2LC-L DF; MGGGEO0"ERN]OZW2_4?,K7_K9O]#T.BN3\/:AXPEOHX];L]&N;&969;W2;ABL M1'0,LAR<\\KFNLI-6&G<****0PHHHH **** "BBB@ J"\OK33K5[J^NH+6W3 M&Z6>0(BY.!DG@G^9Z]17$:9XB\4C5K[P]K-GI::N+%KRSGM#(UO) MSMVL&PPP<9YJ=O&C?\*W/B-(%^V^5L%L0*_$UQK[^']&708M1M+>&2 MZ?4I)%65G'(B1>2 <L:SJ4.AZ+-JVB6<5[+JT%O)!.1.B9<@21D'@ MXY!/(]*:CJO-_J+FT^7Z7.UJ&>[MK5H5N+B*$S.(XA(X7>YZ*N>IX/ KD=5\ M2>(;[Q%=Z'X3M-->:P1&N[K47<1JS@D(JIR3CG/2JL_B:_G@T+^U/#\-M?-K M2V]UEI$CF9AG$84+M'U739-?TO2H]*U*Z2UC6TF=I[=W^[O MR-K<_P!VN^H:=K@G<****105+;_Z]?Q_E452V_\ KU_'^5..Y,MF7:***Z#E M"BBB@ HHHH *IW?^M'^[5RJ=W_K1_NU4=Q,@HHHK0D*Q_%&G7^J>';JUTN]D ML[\@/!*DA3YU((!(YVG&#[&MBBAZC1P$GC?5);5M-O/ .N2ZB\>UHQ CVC-C MO-NV[?PK,F\.:UX=\+>$[E;*34;G1KII[FTMB"P1PV5C'\6W< ![5ZE11Y_U MH'D>=176J:_\0_#VKG0-1L-.BMKE UY%MD#$+]]1D(#T&3D\\51\+:YKOAG0 MY=/N/"&LW4DEY<-:/;Q#:=TC$>9N(,8R<[L$$'->IT4K?U\[A_7X6/+H]%GT M#_A!;*\*?;'U6:XG5#D*[I(Q ]AG%5IM)MO"^O:Q_:W@1_$-I?7;75K>6EA' M=2+OY:-PW*@'.#TYKO9?"MI<>*H?$%Q=WTTT"XM[9Y_]'A)&TLJ8^\03DDFM MVBW7^NG^07_K[_\ ,\SO/#&I7OA&&[M/#^G:7J%IJ::C;:;:(L6]4/"R$?*9 M"N>>G05M:?XKUS7=6M;:R\,:AIULCDWUQJT'E@+@_+%AOF)/?ICM7944_P"O MZ^X70\A>WU3_ (5_XI\.-H>J+>17,LT;BV+1W"O/N'EL,[CCDCM75>/+34HM M*T[7=&M'N=4TF421P(A9I4==CI@<]"#_ ,!KM**5M+#OK?U_$\TU+P5?2_#; M2+:.UBOM3LKA-1GM;C&VZD)+2HV[CGJZM9Q:7\,X=+,4RM=W>I MZ5%$L:CD^45Y9LC@C@=:].HI];_,72P4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% '!?VMKW@W4=1BOM(UC7=+N+DSVES8_Z1+$&ZQ,A(("D<$<8 M-1Z3IVH>(?$FIZ])I,VBV=QIQLXH;A52:X9CGS)%&=N.@!YZUZ#12Y=+/T_" MQ5]=/ZZGD"WFOCX:W7@__A$]5&HVU@]N\[1C[.Z@'E'!)=B.BJ#R:Z'3M/O4 M\:>&)WL[A88=":*60Q,%C?Y/E8XP#P>#SQ7?44^O,]_^ U^I-M++^MO\CA=5 MEU#PGXSO=?$6XET> MZM)KC3(D@M'7,I'EOM!49^8^GOBN[UWP18ZYJ']H)J&JZ7?,@CDN-,NS"\B# M.%;@@CGTS6CH7AZQ\/6LD-H9Y))G\R>XN)3)+,V,;G8]3BIY;II^:^\OFL[K MR_ XN:QU/P]J>A>*;?2;R_C32%L+ZTMU!GC 8,J'&X@Y!'6I]2U'Q?XI\.: MTVFZ3/I,+0*MG'=#RKR5MW[S^(A 5R!GG)SFO0J*J6M_ZWU(C[MOE^!X'KFD MVM[X<%MX;^&FK6=Q%)&T]W>6N)54,"=F2SR$GCCM7IFD6=TGQ,UR\>VG2VEL M+58YFC(1R-V0">"1W%=A10M/Z\K!;^OG<**** "BBB@ HHHH **** "BBB@ MHHHH **** "J&MV,^IZ'>V5K=RVEQ-"RQ7$3E6C;'!!'/6K]%)JZL-.SN9NP >ISTSS61)X4URR\ V'U" MVU@:M_9D#KB)-Y)B0]. >W?.*]6HIZWOU_X-PZ6Z?\"QYM=ZCJGB?Q-X4OHO M#>JV-A:WLAE:]AV2 F-ADH,[4[;F(R2,5#H>LZQX7O/$*W'A76+RUNM8G>UD MLX-Q)..6#$80\8<9'7TKT^BBUMOZV_R"]UK_ %O_ )GD]WI-WI7A_2I]2B6W MOM3\40WLL"ON$1=^$SW( &??-3:QI$6@>,=6U/4O!C>(]-U-DECEMK)+F:WD M"[64JW.TXSD<5VNI>%;35O$%EJ]W=WS_ &(AH;,3XM]X)Q(4QRPSUS6[22T_ MK:R7Z W=_P!;W;_4\RF\+7>O>#-62T\.Z?H$LTT&WNX; M-1NCV]GX;#O=W?G^.YYQ'X2U#6?A3>V=RGE:SJK- M?RI,",2EPZHV>F JKSTQ6;"D%^D6FVOPHM[35\JLT]]I:Z)\)?#M[I$%[XDTMKG6; MH&XNY&N)4_>.2Q&%8 8SCIVJD?">HV5AKWA33+646MO/#J>CO*&,1(8,T)<\ M9W*>ISALUZO12YW>Z_K_ (8?(K:GEWB/6]:\4:9:V<'A+6+0P:A;/=O=0X V MR GR]I)<9Y+< &NGL+2Y3XFZS=M;RK;2:?;(DQ0A&8,^0&Z$C(X]ZZJBCFT MMZ_BK!R_I^#N>7ZGX5O]>OOB!9K;O%]M-HUI+-&1'*R(#@$\$9&#C.,U5A2" M^2+3;7X46]IK&56:>^TN'['%R-S"08WC'0#K7K5%"E;\/P&XW/-_'$&ESWOV M;7?A_J&K6RQJMM>Z5%YLGNI"E60 ]!D@UF6NAZ[#X7TV&:TU PCQ%!/:6LY, MTUK:AN Y&< 5CSWXCV&MP7-GK'ARVDGO9H9-,G M$:DE8Y.5DX[(PSGWIGBKP>UM8^&;BQT>'6(-#!AFT^15;SHF0*2H;@L" <=Z M]%HI)M*R_K^KO[P:N[_U_6WW'GGAN.UU+Q!;7.E_#^#0[*W#--=:AID=O<%\ M841!3D=>6/&.*ZCQA!-<^"]:@MXGEFDLI52.-2S,2AP !R36W11+WE8R.GH#7I]%#E=6]5^H)6=_3]?\SSVU\6>)WL[;1;3PCJ$.LQK'%+&[2Z@\9^+9Y[>6.*>:W,4C1E5DQ$ 2I/7!XXKK M**.;KW_X'^0E&VG8Y#P39W5IJ/BIKFVFA6?5Y)(C)&5$B;5^9<]1[BNOHHI- M[?+\"NX4444AA1110 5D>)]$7Q%X2PI!?)%IMK\*+>TUC*K-/?:7#]CB MY&YA(,;QCH!UKJM)L;F#XFZY87OA;4=:G\>6T<$D,ES9QNB:; M86ATZUBBG:,A'*[L@-T)'&<4O@NRNK6^\6-<6TT*SZM))"9(RHD4HN&7/4>X MKL:*3=_NM^-P2M_7E8\F\.Z1J<&B>!HYM.NXWMM4N))U>!@8E(EPS#'R@Y') M]16AI]WJ?@"[U33G\.:MJMI>7TEW9W&G1"4?O,$I)R-F#W->DT4W*[O_ %T_ MR#EZ_P!=?\S(T:[U9O#ZWFNVD4%\5:1[:U!?8O)5>IW-C&<=3TKBM$^&>B^( MK!M<\6:3)+J^HRO<2+)-+$8E8_+&55AC"X'(S7IE%*^K:"UU9GDU[X:N/#%K MXL\/:-IEY)H^HZ8UQ9K$CRB.<+M>/=R.)FDR"F1M SD8/Y5WU%/F?7R_ %%)W7]7M_D>6>++$IXN2\\0>&M5\0: M0+6-;&&QB,RP2C._?'N R<]3GM6-I^BZDMOX^\OPK<:1#>Z:BV5G%#D, K+@ M;,@N>I4<\_C7ME%'-HT'+K?T_ XC7[.6/X9V=YCR;[2+:&]B\SY2KQ*"5.>F M1N4_6H]#@O(OAY+J$NBIJE[JKM?7-B[A?,$ISM^8$':FT '&<8XK<\0^$[/Q M-/:M?WFH+;09WV<-P4@N.0<2KCYL$>U;P 50J@ 8 ':FY73?=_U]^GW"4;6 M7;^OPU^\\>T?1XI_%NGW?A/PKK_APQW*OJ,EZA@@DAP?"0@+)O&'[D>N.M>AT4N;^OFG^@U'7^O/_,\ MA\.:/$_C&QO?"WAG7O#MLDI?4OMZF&&9-IPJQECDY/88'M7KU%%#E<%&VH44 M45)04444 %%%% !1110 5R?Q(L9]1\$W5K;VLEU(\T'[J.,N6 E4G@=1C.:Z MRBA;IBZ&/;>$_#=G.EQ:^']*@G3E9(K*-67Z$#(K,UFTN9?B+X9NH[>5[>&" M[$LJH2B$JN-QZ#/;-=7133=[BLK6.0N+.Z;XMV5Z+:8VBZ1)&TXC.P.9 0I; MIG':L!M.N#\4!X?C"MI(F&O. ?N/@KL(]#)AZ],D3S(V3%++PT+EX;F]O;JY(,UY?S>;,X'W06P.!V%.+M;R_SO^#_()*]_/_*WY:?, MY;QW%IEUJ+0Z]X!U'5[?8HM[_2X_.E/NP^%]-AFM-0 M,(\103VEK.3--:VH;@.1G ')Y/ ->MT41ER_A^#N$HW_ *\K'GMP^H>"?%^L MZFNB:EJVF:P8I0=-B$LL,JKM(9,@X/7-,OV\1ZY_PC][J&CM:JFO)+%;QH6D MAMPC -,02 <_0#(KT6BA2M;RM^ .-[KO?\3R35[!(?&6J3^)?!VK>(GGE TV M:VB\Z"*$@?(06"QG<.21ZFLFST/65\!>(K5_#US8W,VN0W$=C# 6"QEXS\FT M890 /[*ZO(?#PM;:: M5&6V("OX_RJ*I;?_7K^ M/\J<=R9;,NT445T'*%%%% !1110 53N_]:/]VKE4[O\ UH_W:J.XF04445H2 M%%%% !1110!Q5I'_ &#\4KN +::];"X3GC[1%PX_%2#^%+XD7^W?&VA:$#N MM[0G4[Q>QV_+$I^K$GG^[5OQU;NFD6^M0)FYT>X6\7'4QCB5?Q0M^0J+P0HU M*35O$[9/]JW&+GE_2_KR&_S_ *?X?F4=,\4Z;HWA M%[VTTB6/S=4FM8;.*?>TTYE89W/C&X@GT%:NA>)-9O;YK/6_"MWI$IC,D<@G M6YA8#'!D085O8^EI3>WE^G]>02_5 M_G_7F=WH/BG^V_!O_"0?8_)^25O(\W=]PL/O8'7;Z=ZJ?\)PG_"+Z/JB:;-- M>ZN%%KI\#AF9R"Q&XX )+'%#KSPA#YL6%^09 )52>I ]J;:=VMM/ MU&UK;U_X!VFB^,-0NM'KCP^-3EM)(9T:_O6F*SG82$0RI MZE?9.GTZ]2/X6:_-J$4^JZ/!)<"T$\S*]S:@_+\_WL=0&] *W]4\7-IC6.E: M/HT^J:K/;"=+.*98UBBX&7D;A1V'KBN0*2_\*U\:RV]M/:Z)('.F6\\90K'L M&XJIY52V2!Q]!6E-J$7@WQ8NO:K'.-'U#2X(3>1Q-(MO(G9@H) (/!QUJGY^ M7Y,7IY_FC:L_'32V.KK?Z//I^KZ7;&YFL)I 0Z[204D7(921C./PK-A^)=_) MIEOK;^$;Y=!:)7GOA.A,>?O$18#,@/\ %QG&<5E7MX/%-[XB\2V$,ZZ/!H$M MG#<30F/[2QRY* @':!QDTRW\;V%S\.K;PW#9WKZ]<:6EO%8);/EMR!1(&QMV MEZ!HDFMW[6ZW3(MRD" M)$3@$NW<^@%)-XSN;3PTVL7F@7EHUO6]P=IB0D!I%8 B11G.1UYZ5RGB M:Q\)Z1;:1:>)GU;3KRTL(X(M;LUD .!@H'3=SD$X9>_%:O@07FN:-K5E?7EY MJ>@RXAL+R^B*2SQLF')R 6&>A(I][:V_S([7TO\ Y'4ZWKXTF72H(;?[5/J5 MTMO$@DVX7!9GS@\*H)K9KS7P-]NU3Q&4U*-MWAFW.FK(W265FYD'_;-4_P"^ MC7I5/2W];=/\_F&M[?U?^M/D%%%%( HHHH **** "BBB@ HHHH **** "O.O M#FO:-I'C#QE'J>K6%D[Z@C(MS MNFH(J-)==N[B6TU;PC=Z;=> M4TL!%PD\,F/X3*HPC$]C7->!_%>I6VE^(M0\0Z=):V-K>7$KW3WBS%7# & * M.3MX /0\8JEX/OXV\7V4'A#Q#K&LZ*_F&_2_1VCMAC*[7=5(.>PS[U7"'5?# MOB_PO;!SKD&J2Z@MF\; RQB577!(P0V..>XI];^3_-?\/\O4+:?-?D_Z^?H= M0OQ"U&U\J]UGPC?:;HDS*$OWN(W9-V #)&.4'/O5C5/'5Y;>)[OP_IGAZ?4[ MV&WCGB$5PL:N&SGN:!X@L?"/Q'UE]5$RV0TZT22[CA:18B P&X*"0#ZXQD4?E_P M%MY_\%'4:=XWM9M&U.\U2SGTRYTH?Z?:2D.T?&1M(X8'L1UK,;Q_JUE)#=:O MX/N[#1IY$1+UKR)W7>0%+Q#E1D\\G%8\UYK%Y;>+/%_A^UND%Q;P06.^$B25 M$SOE5#ST8[HQ31/-=7R%DB9-\NU(C(?WX3U)X MV]>*S_#7B/5=.AUV#1_#5SK#1:S=O<,LZ0K&I;/!;[[?[(%:]QJEII/Q>@:^ MD:)-2TN.VM)-C%99?-)VY P#@CKZU<^'8 T_7B ,G6[O/O\ /2C>WR?_ *4@ MD]?FO_27_P ,3R>/]._X1;3];M[:ZN&U%Q#:V4:#SGER04QG Q@Y/3BH]*\9 MW\FL6^D^(O#D^B75V&^RL;A+B*4J,E=Z]&QDX/I7#:)'<6?AGPOXC2VN+NVT MK4KS[3% A=UCD=UWA>IVGT[&M^Y\0V/Q \1>'XO#OGW5II][]LN[PV[I%'M4 M@)E@,L2PX%5N_P"M%_7^025D_G]^HOA#7[3PW\.I]0NTED']I7$<4,*[I)9& MF8*BCN2:U;/QOJ,6J6MIXC\,7.BQ7LOE6EP;E)T=ST5]OW">P.:X^PL[M_ 6 MGZI:6LMV=)\037DMM$NYY(Q*X;:.Y .?PK7UGQ1I_CY]-T7PX+F[D2_AGNY6 MMG1+5(VW'>6 ^;C I1UM\ONLM?S"6[^?WW>ANW_ (UO_P"V;FQT'PW"RFU5]-:5Y3NB./D9EV\;C M\I'8]S6?I_B?3O 6IZUIGB'[1;M=:A)=V)HC#+:R7FJW,L(E7#Q295D)]"& _*B+TOOI?\KK\QR6MO.WYZ_DSO+[ M7?LOB73-$BMO.EO$EED??M\F- /FQ@YRQ QQ6Q7!_#VZN?$=UJ'B>^MVAF=8 M["-&_A$0_>$>QD+?]\BN\JK67]?UL3U_K^MRY:?ZH_[U3U!:?ZH_[U3UC+EL%%%%0:A1110!G:^^H1^'M1?2EWZ@MNYMUQG+[3C]:\MT72?AUK,$+W&L M7,7B8ILEN+O4)8+M)L8.%9@,@D\ $5Z?XCCU63P]>KH"-5M8[/Q+I4G]K;0&TZZTQY)@^,80[2/7!!%./6W_!)ET_I M?U_P3HVUF]\*^%M.36@=3U>1Q:Q)9G+74ASM.6P!\HR2>!S4&D^,]2DUZVT? MQ#X:FT6YO%=K1OM<=PDNP98$KC:<5R,\FMZ'\/M#BU"XU/2M+DNI/MLUMEKF MRM3N,2$X)&. 3C(X%9=C<>'I_B9X4NO#S:K">!P<9I/ W_ "*OB;_L M*7W\S63_ ,VWC_L&?^S5*LE?T_%#3;E;O?\ !G1ZOXZN+'Q0^@:=H,^IWC6: MW4 BG"!\DC#%AA%&/O$]P,5GZSXG;7? /BJSO--FTS5;*Q?[39RN'VAD)5E< M<,IP>?:LX^(K3PW\1GN]0CE%D= MQ+<1Q-)Y/SG!8+D[3TR >U0:K/\ \)#8 M^,O%-I%<1Z6^B_8[:2:,I]HQN8NJGG;R ">O-*45ROY_FPA)N2^7Y(ZE?$LN MD>']"L-.TN;5=5N;!)(K2*18P$5%RSNW"KD@9]35_P /^*)]3OI-+U;2)M(U M:.(3?9I)5E5X\XW(Z\-@\'IC-><^(M$T?[;X>'VT:.WDEA,F+60 M ,'81D':02.];W@#3O"#>()K_P (:#-'9);[/[4DFG"R,3S&B2?>'&2W;I6D MDG)M^?Z_U^1$&U&*79?DCTNBBBL3<**** "BBB@ HHHH **** "BBB@ HHHH M **** .%U""3QGXSO]$GO;B#1]*BC-Q!;2F-KF60$@.RG.P+V&,DT^V^'T7A MO4K&[\(2MI\2S#[;9RW$DD,\1^\<,6PXXP>*BU*Y;P5XSOM;N+2XFT7588_M M%Q;Q&0VTL8(!91SL*]P."*E@^(,'B2]M;/P?$]_OE'VJ\EMI$@MXQ@MDMM)< MCH!ZYJXWTY?Z]?ZV(E;7F_KT_K_Z]3_, M5RP\8Z!X3^*/BO\ MN_^R_:$M/*_36LFV1"%"Q '!P=V3_ ,!JMXB\&S>$XK;Q9::_KVIW&DRB M5XM1N_/7R"<2A> 0=O/7M6FBD[]7_7X[^AE&[@K=$OZ^[\SL/$&;[Q)H&E#) MC69[^< \;8AA<_\ W0_\!KG]-T.V^(XO-6\02W%SIIN9(+/3XYWCA5(V*[V M"D%F)&'IX]:\2ZQK43I);(D5C;.O.0%\QS^+.!_P&L'3=>M?AP;W2 M/$$4]MIHNI)[+4$MWDB>.1MVQB@)5@21R.>*E::/?^OQM8MN^O3_ (?]3=T' MPI<>&-;9-*NV'AZ2#!L9YGD:"4$8,9;.%(SD$^EYU*PMF7PW96KS3W]S"T9G8#*K$#@XZY M)'H!6'X>^'<^IZ4-8OO$GB/3[[56-Y<6]A?>5&I?D#&T\A<#GTH]Z]WT_/I^ MOX![MK+K^77^O4Z;Q#J4&L_"W4]2M6W0W6E22I]#&3CZCI6#HWPI\$2:!I]] M+I1CG:VCF:<7DRE6*@EOOX'/-9UM&WAWPEXT\&2S22K86WD0GGU MPVX'@5J:#\)_!$VC:9>RZ&KSO;Q2N6N9B&8J"'; M;4+.WNX#873&*XB61<@K@X((IQ^)?/\ )DS^%_+\TV6H?V7HFA3:SJ:1++/$DZ01PJW M3=(W&3@X&.U<]K^C6W@#5H?%NAZ=;Q:?D1:K;00*-L1Z2I@?*5[@<$5SWB73 M/"2>-[[6O&%C-=:+J<$,MCJ,1F,49"[2C>4<\\$9%7NE\_\ AOU_X).S9WB^ M. /#^LWMQIV G[W''.*Y^#3O#\'@'QC>^&]!FT_3I;%DBNIII2;L!" M=PCDY51G@]\FK%YXRLM8\"KX6L[2];Q!=Z>EN+ 6SC9N4+YA?&W8 /26T,V=M+-$8S M<$;G+J#@[>0,GK4M))V\]?Z_KJ4F[J_EI^8_Q?XU\3:CX(O+NP\*W-MI=Q C MIJ1U&-'521R(Q\V#T[9!SBO2M"NK^\T6VGU+3O[.NV7Y[;SUFV8.!\R\'(P? MQKDO$L$DWP3>*WA:1AIL)"1KDX 0G ^@KK- UFPU_1;?4=,G\^UD7"OM*\@X M/! /4&JDDKI=&3!MJ,GU7^1I4445F:A1110 5+;_ .O7\?Y5%4MO_KU_'^5. M.Y,MF7:***Z#E"BBB@ HHHH *IW?^M'^[5RJ=W_K1_NU4=Q,@HHHK0D**;)( MD4;22,%1 68GH *X'P9XMU34]=>/577[)JL+WFDKL52D:.5*$CEB5V/SZFA: MNPWM<] HK&\0>*]"\+0QRZUJ,5HLGW%(+,WT502>OI3[+Q1H>HZ(^LVNIV[Z M<@)>X+;53')W9P5//0\T70&M17.Z%X[\,>);Q[/2-7BN+A 28]C(Q ZD;@-P M^F:-<\=^&/#E]'9:MJ\-OUG*YZ%MH.T?7%%P.BHK,NO$.CV6BC6+C4K M9-.90RW.\%&!Z8QU^@JMX?\ &'A_Q4LIT74X[HQ??3:R,H]=K ''OBCK872Y MN45RY^(_A :S_9)UVV^V;]FW#;-W3&_&W.?>KVJ^+M!T.ZDMM3U&.UECM_M+ M"16QY>[;D'&"<\8'/M1=6N.SO8VJ*Y=_B+X1CT1-8;7+?["[^6KA6+%O38!N MSR.U:H\0Z.=#&M_VC;C3"NX7)?"8SCKZYXQUS0(TZ*P/#_C;PWXIDDBT;58K MF6,9:/:R/CUVL 2.>HXJE>?$OP?8'%UK<4;"9H"IBD+!U.&R N0,_P 73WH MZRBN'\:?$/3O#MEH\\%_ 5O[B-O,$;2*;;(\QU*\9 (_/@5V-E>6^HV,%[:R M>9;W$:R1/M(W*1D'!Y''K0M5<">BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** *6KV']JZ+?:=YOE?:H'A\S;NV[E(SCC/6DT73O['T.PTWS M?.^R6Z0^9MV[]H SC)QT]:O44#"J.L6M_>Z7-;Z9J1TV\;'EW0@6;9R,_(W! MR,C\:O44-7!.QC^&_#\/AS2S:I.]S/+*T]S'_LOB[4=>^U M;OMMO%#Y'EXV;,\[L\YSZ"MJBCK/"D\DY;)?.< $DYR.F*ZBBE96L.[OUT#1K72[)2(+=-H+=6/4L?_P!QC:?/E01KC=(^.3C( ')-6N-7\$P2 MW>Z/4],DN+M?+0>9($0@]..2>!@4U%MV_K9O]!.22O\ UT7ZG?T5S>L^/O"W MA_4DT_5-9@@NV('E[6O\6*T[O7=*L=(&K76H6\>GE0RW!D&Q@>F M#WS[5/2X^MBK%X?\OQI<>(OM6?.LDM/L_E]-K%MV[/OTQ^-;=G]:LGFBM>_Z(]&HK$\0>+M \+)&VM:G%:F3[B$,[L/ M4*H)Q[XIT?BS0IO#TNO0ZE%+ID2[I)XP6V?50-P//3&:GI9NT M5RL_Q)\'VPA,^N01^=*T2!D<'@+ ;03QP3GD4)-[#;2W.AHK U7QKX=T2>Z@U+5([:6U1'E5T;(#9V MXP/F)P>!D\57NOB+X1L]+M-2GURW%K=DB%E#,6QU^4 L,=\@8[T6;"Z1T]%9 MEYXBT>PT5=9NM1MX].90Z7!?*N#TVXZD^@YJOX?\7:!XICD?1=3BNO+^^@#* MZCU*L <>^*+,+HVZ*YRU\>>&+W4[73;;54DO;IG2*$1ON)0D-GY?EY4]<9QQ MFH_^%A^$O[;_ +'_ +=M?MQ;9LYV[LXV[\;[O%E_: M'5O,$5K%)]@^S[?)R6^?S/XMV,8[8]ZS?^%E^#?[7_LO^W[;[46V=&\O/IYF M-GZT)-[ VEN=717+-K%]_P +1CT<3_\ $O.DFY,6Q?\ 6>;MW9QGIVSBE^(& MKWVB>%)+W3I_)N!<0('V*W#2*I&&!'0FA*]O/_.P-VOY?Y7.HHH'2N?\0>-_ M#?A:1(M9U6*VE<96(*TCX]=J@D#CJ12#S.@HKBO%OBT+X$_MSPYJ43JUQ"B7 M$85QAI%5@0P.#@DDK$*B_ MBQ%+I]\J3QZ1=W9GU6.V6>8^44# G!8<;<9XP#D<9IV$W8TZ*KP7MMO;+**VN7EM?L;$2^4P#R"3&?D((P/ MO9XSBD!U-%>4Q?$UM8\ Z_?:=J$:ZM8NS+Y=N0(XC+MC/S@@Y7ZGGM78V7CW MPQ>:R-%BUJW?4A\IB&<%NX#8VD^P.:KE8N9'2T5@/J\%IX@U7[3K&8+2R2XD MLOLI_<+\V9-X&6R!]WMM]ZIK\2_!KWUO9#7K?S[A5:,%7 PPR,L1A3[$@TDF M]AMI;FUK^E?VYX?U#2O.\C[7 \/F[-VS<,9QD9_.K&G6G]GZ7:66_P S[/"D M6_&-VT 9QVZ59KSW7]-\7Z39W^K3?$7[-8PAY1'_ &+ Q1<\*"3ECT ]:5PM MK<]"HKA-+?QXO@FR,DD5WKE[."\UQ%'&MG"W=D7;N( Z#)R?:F177BKPKKND MVVMZW#KECJEP;;>+);>6"3:2I 0X9>#G/-5RZV)Y]+G?45D>*;VXTWPGJ][: M2>7<6]I++$^T':P4D'!X//K6-I?Q$\..VG:9>:Y;_P!KS6\1="" 791P6 V MDGIG\*23>Q3:5K_UM_F=A16!K/C7P[X>N)8-5U..UEBC65D9')VL2!C .XY! MX&3Q4&K_ !!\*Z$\":EK$4$DZ+(B;'=MK#()"@E0??%%F#:6YTU%06=Y;:A9 MQ7=G/'/;RKNCEC;*L/8UE:YJD^BWVG74CYTV>86MPNT?NV=9U33C.)3$!M=1OX(VYR..E>I3Z3 M97.JVNIS0[[NT5U@PN<9..N,U:EBCGA>&5 \8]'H]O\]SAM;T^XU;Q!8:[X7U^P@U?[ 0EI=J'6:!CN#8!W*,_P 0!_QQ M_,7Q%IGB/P[X@32]!U.&6WDGU"R9?)EE8@QD[L$G*@;6.377WOP_\+:CI-II MEYI$:'\/_"O MAR^-[I6CQ07)&!*SO(5_W=Y.W\,4[7/ ?A?Q)>I>:MH\-QYLKQ[188VG&=T:QL<. M,[C\O'ITK4T[5-9LO&5MI7BO3]&DO+RVF$&IZ?D.L:@$A]PR!]#C(_&NOO/# M6BW^BKHUSIEM)IR *EOLPJ8Z;<=#[CFJOA_P5X<\+-(^C:7%;22C#R%FD#&U7^TSH%M]IW;_O-Y M>?7R\[/TK>_L>P&M+K M\7ZV_P!F$H=N(\[MNW..O?&:<=TW_6C0/9I?UJF< MAX5M+8?$WQM.((Q*'ME#[1D QY/YGK7!3+=/IFG6L6HQZ99CQ1=I]I>W66.% MLDQY1OE(SG&>AY[5[9:Z18V6HWVH6\&RZOBAN)-['>5&%X)P,#TQ59/"^B)I MEUIITZ*2SNYFGGAES(KR,2_5?Y W>_K^C1Q1T#4[;QEX? MFUSQY'?7:RLUK;+I"1O*NT[ANC.0N.YXZ=ZN_#:QM?[+\13&WC,D^KW:RL5! M+@-@ ^WM6_X?\$>&_"TLDNC:5%;2R##2;F=\>FYB2!QT%:6FZ/8:1!/#8P>5 M'/,\\@WLVYW.6/)/7TZ46TMY/\;?Y"[>O^?^9Y/I9"_"WPAD@*NO1 >@'GO7 MLU8;^#M D\-_\(])IR/I>2P@:1S@EBV0V=P.2>]:EC96^FV%O8VD9CM[>,1Q M(6+;5 P!DDD_C57W];_@O\AO>Z_K5O\ 4L4444A!1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% %RT_U1_WJGJ"T_P!4?]ZIZREN6@HHHI %%%% !1110 4444 %%%% !111 M0!%']+?4+Z<"(#Y$0@O*>RH/XB>PKE+:2&;XOM+J4?ES/I,;::D^ M,KECY@';?TSCM6KI7PY\(Z)J/V_3]$@CN@VY79GDV'U4,2%_#%:>O>&=%\3V MJVVLZ?%=QJ=D[-V/XMN??%&C?\A[X;_P#8%F_]%I7=Z?X3T+2M%GTBPTV*WL;A"DT: M$@R C!W-G<3COG-20^&])M[C39XK3;)ID)M[1O,<^7&0 1UYX Y.334DM/Z^ MU_F*47+^O\/^1YAX0TGQ)J5KK$MIXVATR47]P+ZT;2H961MYY9F.2".F> .. MU16=G;6+>"(9-7CU70O[4NF-RUMY$1F(.P;2<8#;\$<>E>B:S\/_ KX@U%= M0U/1H)[H$$R!F0OC'WMI ;H.N:U;K0M*O='_ +)N=/MY-/"A!;E!L4#I@=L= ML4*5K/T_K_('&[?S_$S;T>'D\70L^T>()+.18]F_<81R=V/EQG&-WX5P4)!^ M"?AO!!_T^V''_7S7H?A_P=X?\++*-%TR*U,O#ON9W8>FYB3CVSBH+?P'X9M( MKF*WTM8H[FX2YE1)I ID0[E(&[ P>PP*(M)KY?@[_K]XI)M/Y_BK?UY&/H7D M?\+7\3?;MG]H>3;_ &+?C=]GV_-L]MV=Y7^K^T M<[NG&[&,X_&O2O$'A'0/%*1KK6F171C^XY+(ZCT#*0<>V:='X4T*+P]+H,.F MQ1:9*NV2",E-_P!6!W$\=V_FVBE"(][+RA!7D$'@@=Z MT*'*]_5O\A1BU;T2_,****DL**** "BBB@ HHHH **** .,^(.;1-"UJ0.;3 M2]22:ZV\[8V!0OCT!8$^V:Z>75M.ATPZE)?6ZV(3?]H,@V;?7/2K4D:2QM'( MBNC##*PR"/0BN33X7^"H]1%^OAZU$X.0"S&,'_KGG9^E-;69+3O=&'K.JVFM M^)/!&I7D+PZ+<23M$MVH4&;;^Z9AD@9Y*Y]1WK0\3_9_^%C^$_LFS^T_,F\_ MR_O_ &?RSG=_LYQC/?I76ZEI&GZQI[6&HV<-S:MC,4BY''3'H1ZBL_P_X-\/ M>%O,.BZ7%:M)P\F6=R/3I6T%M^SO:&&&-"MI;3 JHXDVF@:9 M8Z5/I=M;;+.@HL-'L-,DO9+.#RVO9C<7!WL=\A !/)XX X&!4MZ->5OQN"5OO7Y6/#] M-34+K3O EO#K*:3%NO5@NI;5)T242$*NU_ESMR >OI7;Z?H5_9?$/39M8\;) MJ6I);S;+5-*6%GB( .YXS@ ':1N[CBNL_P"$/T ^'AH+Z9%)I@+,L$A9]I)) M)#$D@Y)Y!XS1X?\ "&@>%DD71=-BM?-^^X9G=O8LQ)Q[9JW-7^_\27 X[P9; MS0_#'7Y=-3%_-/?,C ^*F_3T_ JSZ>?XG-W-_96/B7Q3?2133V,?A^W<9/S M D=^HKGO%,>NP_"EY+K4- TW2'MD^S6%I TC,IP402.W+8ZD#U/O7KO]C:?_ M &C=7YME-S=0K!,S$D/&N<*5)QW/;O7.Q_"KP/$UPR^'KF2-]YO#*D_]_!5[XJ_\B-+_ -?= MM_Z.6NBM] TRUU&'4(;H]:;DKIKH_UN"B^5I]5;\$B^.@KSF&;5=1\6^(Y/#: MZ1IJV\RPWUY?"2:>5U08PNX*D8&?RSZUHP?"+P-;7$<\.A[98G#HWVN&XNUQF3>Z[L=-P4@-T[YI*R8];6/)(Y8I?AAXJ6Z MO(KRV'B%/,N(D")(IDCW,H' !Y/%>A>/Q8?\(UHRZ;]F^U_;[7^RQ'C.=Z_< MQVVYSVQ6ZG@;PU'IUUIT6EQQV=U,D\L$"^E.3*,G:>^T$X7/^R!5W1 MS:R"6#(^XP! (_ FF2:592ZM!JCPYO8(FACEW'Y48@L,9P638?X)>)%SG_3KH''_7Q70?$"SM;+P3I0M[>)!9W]GY " M@>7^\4<>G%;A\">&3)JCC2U4ZIC[8$ED42X.[H&P.>>,5JZGH]AK%DMG?P>= M;I(DBIO9<,A!4Y!!X(%"DE9^:?W6!Q;37K^)P>N?\C-XX_[%Y/Y2U!J%A:0_ ML]!([:)5_LN.; 0??(4EOKGG-=_/H&F7-S?7,UMNFOK<6MRWF,-\0SA>O'WC MR,'FB70-,G\/_P!@R6V[3/)$'D>8P^0# &[.[MUSFE?W;>GX7_S*M[R?]=/\ MBSIQ)TRT).284_\ 017*>+0VL>*_#OAW&;9I&U"['9DBQM4^QW$9.XC;G'7OC-%_?YOZ\OQ)4?B^5-_^1$U[_KPF_\ M0#7(^)]/M+7X$>5%;QJD-C!*@VCA_D.[ZYSS7HE]96^I6%Q978UB,.]A\JXP-P.>P[TD[?A^%Q]4^U_Q MM_D/5M E*:7;Z:] MK=2VTL%KCR2ZGYF0@#().?KFH_B60/A[JO.'*((^GW]Z[?UQ6K-X7T2?1X-) M;3XEL+>198H(B8U5E.0?E([\^_>HM,#389A=7#%A^\9.8T ]- MV&)_V0.]#:EL%%%%0:A1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %2V_^O7\?Y5%4MO\ Z]?Q M_E3CN3+9EVBBBN@Y0HHHH **** "J=W_ *T?[M7*IW?^M'^[51W$R"BBBM"0 MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@"Y:?ZH_[U3U!:?ZH_[U3UE+EL%%%%0:A1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %2V_P#K MU_'^515+;_Z]?Q_E3CN3+9EVBBBN@Y0HHHH **** "J=W_K1_NUF.*<79B91HJY]DC]6_.C[)'ZM^=7S(5BG15S[)'ZM^='V2/U;\Z.9!8IT5< M^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%BG15S[)'ZM^='V2/U; M\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%BG15S[)' MZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHY MD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWY MT?9(_5OSHYD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06* M=%7/LD?JWYT?9(_5OSHYD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]D MC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%BG15S[)'ZM^='V2/U;\Z.9!8IT5< M^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%BG15S[)'ZM^='V2/U; M\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%BG15S[)' MZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWYT?9(_5OSHY MD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06*=%7/LD?JWY MT?9(_5OSHYD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]DC]6_.CF06* M=%7/LD?JWYT?9(_5OSHYD%BG15S[)'ZM^='V2/U;\Z.9!8IT5<^R1^K?G1]D MC]6_.CF06*=%7/LD?JWYT?9(_5OSHYD%@M/]4?\ >J>F1QB-<#/7/-/J'N4% M%%%( HHHH **** "BBB@ HHHH **** (KC_4-^'\ZI5H.H=2IS@^E1?94]6_ M.LYQ;>AK":2U*E%6_LJ>K?G1]E3U;\ZGD9?M(E2BK?V5/5OSH^RIZM^='(P] MI$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM M^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY M&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5 M/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^ M='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45; M^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/ M5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2 MBK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^ MRIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I M$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^ M='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY& M'M(E2BK?V5/5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/ M5OSH^RIZM^='(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^= M'(P]I$J45;^RIZM^='V5/5OSHY&'M(E2BK?V5/5OSH^RIZM^='(P]I$J5+;_ M .O7\?Y5-]E3U;\Z+M8N- \+WFIVJ1//!LVK*"5. MYU4YP0>A]:VZY3XE?\D_U3_ME_Z-2NKK5Q7LHOK=_DB4_>:"BBBLB@HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZ;>R7GVSS%4>3K(T+_ )B?_7_+_2M>LZ3;@FS:O%1J-(****T,0HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#E/B5_R3_5/^V7_HU*ZNN4^)7_)/]4_[9?\ HU*ZNMY? MP(^K_*)*^)_+]0HHHK H**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** ,C0O^8G_P!?\O\ 2M>LC0O^8G_U_P O]*UZRH?PT;XG^*PHHHK4 MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *R/$?B;2?">E-J6L70M[<,$7Y2S.QZ!0.2:UZX#X MI^'[7Q-IFG6*ZS8Z?J\=T)]/2\D4+.XXV[3RW4= ?IS2=^@T5O#WQO\ "'B' M58].1KVRGF8)$;R)561CT *LV#]<=:](KPSQ-JNNVEO:#XF^"K2\TFVN%\O4 M=,N6C\HD8!PK;NO8[0?P%=+?:Q>-\>-!LK?4+G^S)]):8VZS-Y3G]YABN<$\ M#G':K23M;S_*Y+TN_P"M['IQ.!FN=\(>,M.\:V%U>:;#=11VUPUNXN4526 ! MR-K'CFN6M-4U!OC_ *EIK7UR;!-($BVIF;RE;*?,$SC/)YQ7$_"CPQJ'B+PQ MK2P^)-3TF"/49/*33I!$S2[5^9VQDKC'R@CO4K:_E?\ &Q;6GS7XJY[!XQ\8 M:?X(T5-4U*&ZE@:980MLJLVX@D?>8#''K6]#*LT,2I'J,^N*W_ !YXX\GQ;I?AN^\0WFA: M1]A2XO+VS5C/([#Y55E5BO0<@=SFC_/]+B:M;T_6Q[517B/@_P")?V2?Q380 MZQ/X@T[3+%K[3[J[4K,X4#M7- T+QEXI\(VOBRV\8W\.O71\Z& MU>;;8*F\C:T84_PYYY[?6G;KT_K_ "%Y?U_6IZ??^(-,TW5=/TNYN56^U!BM MO !EGP,D^P '4U3/B_3QXX7PGY-S]O-K]J$FU?*V9QC.[.>/2O+/&_A^YO\ MXN^$8[W5M1M;J_@;SFL;HJ+9U3GR"5RH)'.1SFNC:\OQ\=H]$.IWQT_^P\F$ MW#!2V2-^ <;O]KK0E=)^OX7_ ,A2=G]WXV/3Z*\6T7QKJ'A;PIXUTK6;Z>YU M30I&%M/<2L[RK)Q%R>3R0?H16?J_B;6_!_@'PEIM]KUY!>ZRYGOM2G9IY;>$ ME20N8 D8=U4D''3WKV^G;2XKZV"BBBD,**** "BBB@ HHHH **** .4^) M7_)/]4_[9?\ HU*ZNN4^)7_)/]4_[9?^C4KJZWE_ CZO\HDKXG\OU"BBBL"@ MHHHH **** "BBB@#*\2:_:^%_#]WK5]'-);6JAG6!07.2!P"0._K5C1]3@UK M1K+5+99$@NX5FC60 ,%89&<$C//K7*?&'_DE.N_]3;KFVD ;D2 GI^&1C& M.4M5ZWM\O^&%^FYZW17S[<>+?$4_PLMM M]0O#XH_MA],>87#"8["7)WYW=, M#/I6M:^*M2\56_PYTJTU*\BN+DM/J4D,S*[K#\K!R#DAB&SFFE=Z=U^*O?[A M-VW\_P -#VRN)U3XI>'M(\;P^%+D77VV5HT,RHGDHS_=#$MD=1V[BNNOKR#3 MK"XO;EPD%O&TLC'H% R:^6)]=\-ZSX.\1:AJ6JB+Q3?:B+VUC\B0E G")O"[ M1PS#KZ5*:YM=E_G_ ,/]Q5M/4^KZ*\AU[XCZC=?#CPS=:+-'#J>N3QV;S[<^ M0_1R >^[U[&NBTOPCXG\.^(K*>P\47>J:2ZD:A!K-R9'SV:$A./H2/\ "K:M M/T)OI<[RBO(=,?6?B9XH\2*_B'5='TW2;G[+:0Z9,(69P6!9VP2PXSCW]JB\ M?7/C'P[\(E_M;6%&KQ7T<8O=.G=&DC.<;B I![$#C@4EK;SM^)5M;>OX'L=% M>8_%;5-1TZP\)M8W]U:M/JL,4^,'L;#4=/ MT?4/B!KMLL5JJQV&E*[7L[@?ZR250Q.1DX( XS6#X0^(>LZ?X#\97=W<75Z^ MC3".R.H+^^&XE5$O>HHNK-]O\ .Q5G=+N>Z45Y-I'ACQI>^'M)\3:? MXQO9=;NDCN)K6_G_ -!:-@"4$:J=IQCD>_3-7I-1U/P]\:[:UO;VY?2M>LR( M87G9XH;A!R$!X7IV ^]3Y;2Y7OJ3?2Z/2Z*\W\ :AJ/B;QKXIUY[ZY;1X9_L M-C;&9O*RF-SA,[ M#V\4^9)>Z8 A5[0*Q<,P48R0.IYR:TVT72FT0Z0UC;_V;Y7E_9_+&S;C&,5\ MY6DC+\"/&-C'*TMG::LB6Q)S\OF)T_G^-#>Z73_-+]02NT_ZV/I33[V/4M-M M;Z%76*YB69 XPP# $9QWYK$NO&VFVGCJS\(R079U"[@,Z2*B^4%PQY.[.?D/ M;TKS36K+Q'X7^'&F>,K/Q5J+7EK;6Q>Q9E^QF)MH"B/'4 CYB23ST[7W\2:C M>_'#PO''?7<6GWND+JZ#-;W#II=E8)((]J_=:3:A#Y(&03Z]C6W)\4 M-=U'X8Z#+:31PZWJE_\ V;)=!!A"#RX7ID@K^9]JA:K3R_'^M2I>Z[/S_ ]Q MK+L/$.F:IJNH:;97*SW.GE5N@@XC9LX7/K\ISZ5RVG>#_$^@>(+26P\4WFIZ M3*K+J$.KW)DD!/1H2$^7Z$C_ XSX5>'?+^(_BV3^V=7;^S+W9M:ZRMUGS!F M<8^.: MZ"O"-$F\1>(/A9XNFM]F:OZ_XTO_%O MA[P3IFB7\]EJ&N3!KF6UE*/&D?$G(P>N3_P&FE>R7E^*W_,):7^?X'M%%>%> M*?&]K<_$+4=!UGQ;J?A[1=,C6.)M.WB:XEP,EG56.!D\'KBNJ^$/C.X\2VVL M:?QYX&SL9AP<_*>PI1]Y77J#TW/2Z*** "BBB@ HHHH * M*** "BBB@ HHHH R-"_YB?\ U_R_TK7K(T+_ )B?_7_+_2M>LJ'\-&^)_BL* M***U, HHHH **** "J6L:I!HFBWNJ7*R/!:0M-(L8!8JHR<9(&?QJ[7-_$#_ M ))WXB_[!TW_ * :F3M%LJ*O)(T= URV\1Z!9ZS9I,EO=1^8BS !P,D<@$CM MZUSMA\3M%U'PCJWB2&UU!;/3)6BF1XT$C$8^Z-^"/F'4BO-_!>M?%NW\%Z9# MH?A?2;K2UAQ;SS2J'=:_#$+G4-^Z8*%7<0QYW'=G/7BHO$4&N^$_B' MX)TN+Q5K%[IMUG<"NAKPSPWH=WKWQ6\>VL.MW^EV_G* M96L&5)G.3M <@[0.3SS41UBGY7*EI)KSL>B7%Q':VTMQ,P6*)"[L>P R37)^"?B7H?CV:\ATN. M[AEM0K.ETBJ64Y&5VL(1HO@":T2817&IR"U4^B'ESZXV\?C7G M6G^*/"?A_P")/A>[\-:FMQ:26::9J/[B2,#&%5SN49R<$]?NT0]Z5OE\[?\ M#()Z1O\ /^OQ/HZBO+-:U'5O%OQ5F\&VVKWND:78V8N+F6P<1SRN=I #X)4? M,.GOZ\6;FY\4_#OP=XBO-2U*+5[6U4'2YIW9[@9(4";Y0&P2#D$D\TK^[S/^ MN@[/FY5_5STJBO)M(\,>-+WP]I/B;3_&-[+K=TD=Q-:W\_\ H+1L 2@C53M. M,]N!9G1O,:T69C#OR?FV],^^,U?*T^5[Z_@KDWTN MOZUL>ET5Y9IVK:D_QE\8V+ZA=M9V^FJ\-N9F,<;;$Y5T[Q%JWBG696MII$BMOM1\J103GS,G@ "ICJK^5_Q:'+1V_K9,]@H MKY_\6:VD=OJ]_8?$#Q+J>LVCEUCTJ)X[& Y"N "A &7X@]'KY_@>QT5P.G>#O M$VCZO-:P^)[W4/#UU;,DIU&\=KR&4@@-$ZJ..G<=ZY;0_'.HZ+\*/$D>KWBN<\!V&H:=X*TR'5K MRYN]0:(2SRW,S2/N;G&6)/&.AZ@&NNHH:&G8\:F^&OQ"\3B+3_&/C"UFT>-U= MHK2/YY,=C^[3\R6Y[5T7BOP)J\_BC1O$WA6[L8-0TV#[,(+\.8GCY Y7)Z,? MTY%>AT47$>=Z!X'UZQ^)=UXKU74;*Z^U6'D2+"K)LDRN JD'Y %')8G.:Q/# M'@#X@>#M)OX-'U;0C+?7#.\=RLK)&",!T8 '?Z@@C@5Z_11Y?+\;CO\ U^!\ M]_$;PU8>"?A18>&DU!+G5+G4EN9 2 \S$,"P3KM' S7HNO>"M6FUO2_%'AN] MM+;6[2U%M)%>HQ@GCQT;;\PQD]/:NRN-&TNZU"'4+G3;.:]A&(KF2!6DC'^R MQ&1U/3UJ[3OIYW_2WY">MO3];_F<5H7A#6)(-9D\7ZPVH3:M&8I+.WD<6MO& M1@B-6/4^N ?U)YZU\"^/M*T3_A%M*\2:;!H88B.^\N5;Z%"Q;:NT[?;.0>3T MKU:BD!YWXH\":W<:EX9U?P]J-M)J6B1M%G5FD<3@@##'\41:;=6%XMCJVE7 N+.=DW M)GC*L/0X'Y5UU%):))=-1];_ ".(\/\ A_Q?)XE_MSQ5K<&(HO*ATW2I)5M2 M?[[AC\SBBG< HHHI %%%% !1110 4444 %%%% '*?$K_DG^J?\ M;+_T:E=77*?$K_DG^J?]LO\ T:E=76\OX$?5_E$E?$_E^H4445@4%%%% !11 M10 4444 "M2T6QDACN;I%5&G8A!A@>2 3V]*\[T_P?\:-+TZWL M++Q;H<5K;1K%$GEAMJ@8 R;M>ST4+2X[Z6/.]6\":[>W.A>)+35;2+Q; MIUJ(9Y9(RUO=':+KZRN-3@@,%K;6",(( M!SD@O\Q)!/YGKQ7>T4[ZW_K470\RMOAA<6_QAD\6"YM_[*8M.MMN;>)V3:3M MQMQU.U@FNRJ2R7+LH$>I/!]?I2ZA\,]0U;X=7/A_4_$=S?:G/<"Z^VW!9U1P>%52>$QQ@>N<= MJ]'HI=+#OK<\FU?P%XY\2VFA_P!LZKHGF:7=Q2B*U214=%ZLS$$E^!@ *.37 M26WA#4(?BY>>+&FMC83:>+58PS>:&!7DC;C'RGO7:T4[ZW]?Q5B;:6_K>YYQ MJO@CQ+:_$:?Q9X9O]+#7L"P7,6I1NWE@;1E-G4_*#@D56\.?"Z\L[?Q;IVNW MMM>66NLL@G@RLH?DLQ4C:OS'(P3TKU"BETM\BF];GED'@KX@KI%KX9_X2?3[ M71;78J7UDLL=\T:]$Z[5],@]AUYJI\<9M+C\+V4$.IJOB"QN(I+*%9MUPV?E M)Q][D'A?P1I>EL@69(0\^.\C?,WZG'X5TE%%.3N[BBK*P4444AA1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 5A>+_"EAXS\/3:1J&Y45TD:XNB M5$CAU9F;:">@P..P%>D44WJK"6CN>47WP\\9:MH-CX3O]TU2 ML]&TO3KB>XL=-L[6>X.Z:2"!4:0YSEB!DG)/6J4G>_K^5A6]VWR//?\ A!/% MWAVZU:#P=J^EPZ9JLS3R+>QR>;:,W!,17@GTSCH/K6CK'PU;5_!%AHT^N7DV MJ6$HN8=3N6,KF8=20Q)V\XQGC KOJ*GI;T_#8;U=_P"M3@=/\/>.]0U_3[[Q M+KUE;V=@25M=&:9!='UFW$9' XY'7I3=$\':_P"'?B'J^JV-SIDFB:Q,)KI) MA)]H1@&X3'R_>;J3T[5Z!11_7WATL<5\./!]_P"$=,U:UU*6UF:\OY+E/(9F M 1@!@[E'/%8G@;X53>%/'&I:S/=0S66'33849BT*NV3D$ #'3@GJ:]0HIIV= M_*WZ ]4T^]SS_5_!GB"P\8W?BCP=?:='=7\2Q7EIJ2.8G(Z."G(/ X^M;O@[ M0-3T+3I_[9UNXU74+J4S2R22,8X\_P $:D_*H_#^0KHZ*2T5@>KN%%%% !11 M10 4444 %%%% !1110 4444 9&A?\Q/_ *_Y?Z5KUD:%_P Q/_K_ )?Z5KUE M0_AHWQ/\5A1116I@%%%% !1110 5D^*-+GUOPIJNEVS1I/=VLD,;2$A0S*0, MX!./PK6HI-75AIV=S \%Z'<^'/!>F:->/"]Q:P^6[0DE"UYJ=P\L+I(YC4';]X[,@_*>@->L44Y>\VWU_X<4?=22Z'C MGCC1+'0_"'@Y=0URWTK7M(\M+*Z>&62WDD55W*S*ORJ2 0R-)-'HI+V]LBD'.XDDDX.2<=!QZ^[W=E:ZA;/;7MM#VU:1'@2)F+J 3]X%0!U[$TGP]\&ZCX3N_$4M_-:R+J5 M^US#Y#,2JDMPV5&#SVS7<45*T27E8;U=WWN<)K_@:Y\3?$33-5U46%QX?TZW M<)9R NTDK=2RE=NWIW_AJ'QO\*]&U[PO<66AZ3I&FZEN5X+B.V6+!!Y!9%S@ MC/KVKT&BE;2W]=QWUN>9W'@7Q/;ZKI_BG2=0TR/Q*EBMI?QW*NUK_8^!=5U+2]4K'KG!SCM]:[VBF];W_ M *N):6M_5CRR#P5\05TBU\,_\)/I]KHMKL5+ZR66.^:->B==J^F0>PZ\U?\ M$G@?7CXST_Q7X6O[%;^WM?LDL.I[V21.>25RQ//MTSFO1**=W>X61YUH'@/7 M-.\;:YK^HZC9W1U2Q\DF-60K)QT7!P@ P/F)K3^'7A&]\)^!4T+4IH))P\I9 M[9F*X8]BP!S^%=E12Z6\K!UO\_PL>.V/PO\ &&G^%M3\(P:UHZ:'#?#5LU];6GB'P^0UMAR <$!<\< M'UKTZBB[_+\-@_X/X[G#:+H/C.?Q)#K7BK7;2.&UC9(].TAY5MY"1]^3>1N/ M)X(/05YQK&D:9XN^.UK#HE]%?:9.(K[5!;R"2+?%D#)'!R,#'^T:^@.HP:I: M=HVEZ0LBZ9IMG9"0[G%M L>X^IV@9--.TD^W]?\ !!_"UW+M%%%( HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** .4^)7_)/]4_[9?^C4KJZY3XE?\D_U3_ME_P"C4KJZWE_ CZO\ MHDKXG\OU"BBBL"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH R-"_YB?_ %_R_P!*UZR-"_YB?_7_ "_TK7K*A_#1OB?XK"BBBM3 **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$UCQ=H6@7:6NIWWD M3O&)%7R7;*DD9RJD=0:VZ*J+BG[RNON_1B=^ARG_ LKPC_T%O\ R6E_^)H_ MX65X1_Z"W_DM+_\ $UU=%:\U#^5_>O\ Y$5I=_P_X)RG_"RO"/\ T%O_ "6E M_P#B:/\ A97A'_H+?^2TO_Q-=711S4/Y7]Z_^1"TN_X?\$Y3_A97A'_H+?\ MDM+_ /$T?\+*\(_]!;_R6E_^)KJZ*.:A_*_O7_R(6EW_ _X)RG_ LKPC_T M%O\ R6E_^)H_X65X1_Z"W_DM+_\ $UU=%'-0_E?WK_Y$+2[_ (?\$Y3_ (65 MX1_Z"W_DM+_\31_PLKPC_P!!;_R6E_\ B:ZNBCFH?RO[U_\ (A:7?\/^"$?^@M_P"2TO\ \375T4O\ Y$+2[_A_P3E/^%E>$?\ H+?^2TO_ ,31_P +*\(_]!;_ ,EI?_B:ZNBC MFH?RO[U_\B%I=_P_X)RG_"RO"/\ T%O_ "6E_P#B:/\ A97A'_H+?^2TO_Q- M=711S4/Y7]Z_^1"TN_X?\$Y3_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^ M)KJZ*.:A_*_O7_R(6EW_ _X)RG_ LKPC_T%O\ R6E_^)H_X65X1_Z"W_DM M+_\ $UU=%'-0_E?WK_Y$+2[_ (?\$Y3_ (65X1_Z"W_DM+_\31_PLKPC_P!! M;_R6E_\ B:ZNBCFH?RO[U_\ (A:7?\/^"$?^@M_P"2TO\ \375T4O\ Y$+2[_A_P3E/^%E>$?\ MH+?^2TO_ ,31_P +*\(_]!;_ ,EI?_B:ZNBCFH?RO[U_\B%I=_P_X)RG_"RO M"/\ T%O_ "6E_P#B:/\ A97A'_H+?^2TO_Q-=711S4/Y7]Z_^1"TN_X?\$\S M\<>./#NL>#[^PL-1\ZYE\O8GD2+G$BD\E0.@-=#_ ,+*\(_]!;_R6E_^)H^) M7_)/]4_[9?\ HU*ZNMI2H^QC[KW?5=EY$)2YGK_6OF$?^@M_Y+2__ !-=716/-0_E?WK_ .1+M+O^'_!.4_X65X1_Z"W_ M )+2_P#Q-'_"RO"/_06_\EI?_B:ZNBCFH?RO[U_\B%I=_P /^"$?^@M_Y+2__ !-=711S4/Y7]Z_^1"TN_P"'_!.4_P"% ME>$?^@M_Y+2__$T?\+*\(_\ 06_\EI?_ (FNKHHYJ'\K^]?_ "(6EW_#_@G* M?\+*\(_]!;_R6E_^)H_X65X1_P"@M_Y+2_\ Q-=711S4/Y7]Z_\ D0M+O^'_ M 3E/^%E>$?^@M_Y+2__ !-'_"RO"/\ T%O_ "6E_P#B:ZNBCFH?RO[U_P#( MA:7?\/\ @G*?\+*\(_\ 06_\EI?_ (FC_A97A'_H+?\ DM+_ /$UU=%'-0_E M?WK_ .1"TN_X?\$Y3_A97A'_ *"W_DM+_P#$T?\ "RO"/_06_P#):7_XFNKH MHYJ'\K^]?_(A:7?\/^"O_D0M+O^'_!.4_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI? M_B:ZNBCFH?RO[U_\B%I=_P /^"$?^@M_Y M+2__ !-=711S4/Y7]Z_^1"TN_P"'_!.4_P"%E>$?^@M_Y+2__$T?\+*\(_\ M06_\EI?_ (FNKHHYJ'\K^]?_ "(6EW_#_@G*?\+*\(_]!;_R6E_^)H_X65X1 M_P"@M_Y+2_\ Q-=711S4/Y7]Z_\ D0M+O^'_ 3E/^%E>$?^@M_Y+2__ !-' M_"RO"/\ T%O_ "6E_P#B:ZNBCFH?RO[U_P#(A:7?\/\ @G*?\+*\(_\ 06_\ MEI?_ (FC_A97A'_H+?\ DM+_ /$UU=%'-0_E?WK_ .1"TN_X?\$Y3_A97A'_ M *"W_DM+_P#$T?\ "RO"/_06_P#):7_XFNKHHYJ'\K^]?_(A:7?\/^"O_D0M+O^'_!. M4_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:ZNBCFH?RO[U_\B%I=_P / M^"9^CZYIVOVCW6F7'GP)(8V;8RX8 '&& /0BM"BBL96OIL4K]0HHHI %%%% M!1110 4444 %%%% !1110!#=74-G;M<7#[(DQN;!.,G';ZUG?\)-H_\ S^?^ M0G_PK7HJ)*=_=:^[_@HT@Z:7OIOT=OT9D?\ "3:/_P _G_D)_P#"C_A)M'_Y M_/\ R$_^%:]%3:K_ #+[O^"7S4/Y7]Z_^1,C_A)M'_Y_/_(3_P"%'_"3:/\ M\_G_ )"?_"M>BBU7^9?=_P $.:A_*_O7_P B9'_"3:/_ ,_G_D)_\*/^$FT? M_G\_\A/_ (5KT46J_P R^[_@AS4/Y7]Z_P#D3(_X2;1_^?S_ ,A/_A1_PDVC M_P#/Y_Y"?_"M>BBU7^9?=_P0YJ'\K^]?_(F1_P )-H__ #^?^0G_ ,*/^$FT M?_G\_P#(3_X5KT46J_S+[O\ @AS4/Y7]Z_\ D3(_X2;1_P#G\_\ (3_X4?\ M"3:/_P _G_D)_P#"M>BBU7^9?=_P0YJ'\K^]?_(F1_PDVC_\_G_D)_\ "C_A M)M'_ .?S_P A/_A6O11:K_,ON_X(O_D3(_P"$FT?_ )_/_(3_ .%' M_"3:/_S^?^0G_P *UZ*+5?YE]W_!#FH?RO[U_P#(F1_PDVC_ //Y_P"0G_PH M_P"$FT?_ )_/_(3_ .%:]%%JO\R^[_@AS4/Y7]Z_^1,C_A)M'_Y_/_(3_P"% M'_"3:/\ \_G_ )"?_"M>BBU7^9?=_P $.:A_*_O7_P B9'_"3:/_ ,_G_D)_ M\*/^$FT?_G\_\A/_ (5KT46J_P R^[_@AS4/Y7]Z_P#D3(_X2;1_^?S_ ,A/ M_A1_PDVC_P#/Y_Y"?_"M>BBU7^9?=_P0YJ'\K^]?_(F1_P )-H__ #^?^0G_ M ,*/^$FT?_G\_P#(3_X5KT46J_S+[O\ @AS4/Y7]Z_\ D3(_X2;1_P#G\_\ M(3_X4?\ "3:/_P _G_D)_P#"M>BBU7^9?=_P0YJ'\K^]?_(F1_PDVC_\_G_D M)_\ "C_A)M'_ .?S_P A/_A6O11:K_,ON_X(O_D3(_P"$FT?_ )_/ M_(3_ .%'_"3:/_S^?^0G_P *UZ*+5?YE]W_!#FH?RO[U_P#(F1_PDVC_ //Y M_P"0G_PH_P"$FT?_ )_/_(3_ .%:]%%JO\R^[_@AS4/Y7]Z_^1,C_A)M'_Y_ M/_(3_P"%'_"3:/\ \_G_ )"?_"M>BBU7^9?=_P $.:A_*_O7_P BO_D3(_P"$FT?_ )_/_(3_ .%'_"3:/_S^?^0G M_P *UZ*UM5_F7W?\$QYJ'\K^]?\ R)D?\)-H_P#S^?\ D)_\*/\ A)M'_P"? MS_R$_P#A6O11:K_,ON_X(O_D3(_X2;1_^?S_R$_\ A1_PDVC_ //Y M_P"0G_PK7HHM5_F7W?\ !#FH?RO[U_\ (F1_PDVC_P#/Y_Y"?_"C_A)M'_Y_ M/_(3_P"%:]%%JO\ ,ON_X(O\ Y$R/^$FT?_G\_P#(3_X4?\)-H_\ MS^?^0G_PK7HHM5_F7W?\$.:A_*_O7_R)D?\ "3:/_P _G_D)_P#"C_A)M'_Y M_/\ R$_^%:]%%JO\R^[_ ((O_ )$R/^$FT?\ Y_/_ "$_^%'_ DV MC_\ /Y_Y"?\ PK7HHM5_F7W?\$.:A_*_O7_R)D?\)-H__/Y_Y"?_ H_X2;1 M_P#G\_\ (3_X5KT46J_S+[O^"'-0_E?WK_Y$R/\ A)M'_P"?S_R$_P#A1_PD MVC_\_G_D)_\ "M>BBU7^9?=_P0YJ'\K^]?\ R)D?\)-H_P#S^?\ D)_\*/\ MA)M'_P"?S_R$_P#A6O11:K_,ON_X(O_D3(_X2;1_^?S_R$_\ A1_P MDVC_ //Y_P"0G_PK7HHM5_F7W?\ !#FH?RO[U_\ (F1_PDVC_P#/Y_Y"?_"C M_A)M'_Y_/_(3_P"%:]%%JO\ ,ON_X(O\ Y$R/^$FT?_G\_P#(3_X4 M?\)-H_\ S^?^0G_PK7HHM5_F7W?\$.:A_*_O7_R)D?\ "3:/_P _G_D)_P#" MC_A)M'_Y_/\ R$_^%:]%%JO\R^[_ ((O_ )$R/^$FT?\ Y_/_ "$_ M^%'_ DVC_\ /Y_Y"?\ PK7HHM5_F7W?\$.:A_*_O7_R)D?\)-H__/Y_Y"?_ M H_X2;1_P#G\_\ (3_X5KT46J_S+[O^"'-0_E?WK_Y$R/\ A)M'_P"?S_R$ M_P#A1_PDVC_\_G_D)_\ "M>BBU7^9?=_P0YJ'\K^]?\ R)D?\)-H_P#S^?\ MD)_\*FM==TV\N%M[>YWROG:NQAG SW'M6C10E5OJU]W_ 1.5&VD7]Z_^1"B MBBM3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3X ME?\ )/\ 5/\ ME_Z-2NKKE/B5_R3_5/^V7_HU*ZNMY?P(^K_ "B2OB?R_4** M**P*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(T+_F) M_P#7_+_2M>LC0O\ F)_]?\O]*UZRH?PT;XG^*PHHHK4P"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BF2DB)R."%->1?"[QA/8_"[6=?UZ[O]06RO9-S/(99=@5,*N]O4 M],BA=?)7';1>MCV"BO/9?C'X;A@LKM[36!IUT%']H?8C]GB8C.QGS@L.AV[N M0:Z"/QGITGC3_A%C%/:B[BF95\J9/]DALYZ]0.AIV9-T=%17-)XYTE_%N MH>'0MP)]/MOM-U73==BTJ639'JTE@1:L? M4-G)Z$=*2UV'L>B45R_B'QYI7AZZM[+[/J&IZA<1^=%9Z9;F>4Q_W\9 _'M M4-AXVTOQ/H&LM9/?65W90.+FWGA,=S;':<$KGKQQ@]1U%)NR;[#2NTNYUU%> M6^%/'EAH7@#P[D:=/?%OQQ9OHVD+X:\4P-@Y]&E?\?P5Q-V^[];'H-%<9?_ M !-T.R\03Z/%;:I?S6O_ !^36%FTT=K_ -=".1^ /0UR_BSXBVWB3X5^(]2\ M-SZA9R6$\< N PB8GS%Y1D8G!!]NM2WI1:I?^*?B' MXVU?P]X?UQ]"TC2,1W%W"A,LLI[ @@C!!'!'3OFM?PAX?\?>&O$GV34=>37/ M#YBR;BZ8B=7YZ9W,><=6Q@\=*F.JOW&]/D>C45Q.K?%'1=-U6XTZVL=7U::T M.+MM,M#,EM_OMD8[],]#6G_PG7AS_A$CXG&HH=* YE"DG=G&W;UW9XQ1TN'6 MQT=%<3I?Q/TF_P!7M=-N],UO1Y[P[;1M4LC"EP?1#D^W7'45S=M\2M3F^,=W MHDFE:NVFPQBWCMX;/YE&/BY:S:==7DEC:V<<\]BLS M>2Z;F#DIG'3OCC@]J-+I/J'1L][HKR/X@>*)[C4/A[>Z)J=U#8ZE?*7$$S() M4+1_*X!YZD8/O79>(OB!I/AW4DTO[/J&IZHZ>9]ATRV,\RI_>(R !^-.VFO= MK[@].USJJ*YO1?'&BZ_HU[J5D\W^@JQNK66/9/"5!)5E/0\'OC(ZUSJ_&CP[ M)HT.JPZ?K5!M[6U\YY\KN_=A23@#J6V@9'-, MB^*N@S^$K[Q%!;:C)#82B*[M1"HG@)./F4L!CZ$_H:72X^MCN:*YK7_'.C^' M?"D'B.Y\^:RN/+\E8%4O)O&1@$@=.>O:JVM?$/3=%NK>Q&G:OJ&I30"X-AI] MKYTT2'NX!P/3K0] W.NHKE-(^(OAW6/#U]K27$MM;Z>2+R.ZB*20,.S+SSVX MSSQ6=9_%C1+B]M8;K3-W]B8K>*:(&:9P<815+9Y![]JL^'/'VE>(]1DTP6NHZ9J:)YGV+4[?R)63^\HR0 M1^-.SO85]+G54444AA1110 4444 %%%% !1110!D:%_S$_\ K_E_I6O61H7_ M #$_^O\ E_I6O65#^&C?$_Q6%%%%:F 4444 %%%% !1110 4444 %%%>8?"G M5=1U'Q#XVBOK^ZNH[;4S' D\S.(EW/PH)^4<#@>E"U=OZZ?Y@]%<]/HJMJ&H M6FE6$]]?3I!:P(7DEGN;<3V>L6-C=/LMM2O+(QVLQ/3:^>_N M!TH6KL@>BN=]16#9^+=/O/%FH>&Q%<17ME"L[-*JB.6-L?,A!)(&1G(%9WA_ MXDZ!XDT[6;^S-Q'!I!;[09E494 G$B9&Y^[DLV@5LGKQUQU%.SO8+Z7.YHKR>Y^).IQ_&(Z&= M+U=],@A,8MX+/+O(6 \X\Y,0[-TYZ5ZQ26J4NX/1M!1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 R7_4R?[IKYW\*?\FZ^+O^OJ3^4=?19 (P1D&LZ+P_HL&G3:=#I%A' M8SDM+;);((I"<9+*!@]!U':DUI)=U;\2D[6\G<\@\7*J_LQZ;@ ?Z/:'@=]R MU>\?6\ND^'_!OCBUC+3Z,(!6;=XPT97TVGC'M52;NVNKN0ELGM M9H\H\!27NG> _$_C][8S:GJC37L43 Y\M-VQ?7&<_ABN \7Z])XC^&4.I:GX MV-]J5Q,K_P!CVRQQI Q^^JC<<#H6/<=:^F;>V@M+:.VMH(X;>-0B11H%55' M0 #@#VK/7PSH"1W4::'IJQW?_'PHM(P)N<_.,?-SSS2=KZ;:6^12?5^=_F>6 M^,--\/7^IZ'=J]2>C=^0:7P?XH\0ZE%XPT3 M5-4M=37J]SH>D7EA'876EV4]G$ ([>6W1H MT Z *1@8J2VTO3[*Q-C:V%K!9D%3;Q0JL>#U&T#'-$M5)=[_ (BCI;RM^!X_ MX6\.#Q3^SUV-A9Z9:):6%I!:6R9VPP1B-%R%8P[GJQP.3[U3E>;EW_ #V_)BM[MOZWO^A\[>')-1T%?%5E>>/H M?#DT%Y*]Q93Z=%-)= C[Z%R"VX= /8]Z]9^$&G#3?AW9)'-=RV\KO- ;NV$# MA&/'RAW&#R0<\@]*ZN^T+1]3N(KC4-*L;N:$YCDN+=)&3Z$C(Z=JO@ # ' M04HNRMZ+[ARU=_F+1112 **** "BBB@ HHHH **** "BBB@#E/B5_P D_P!4 M_P"V7_HU*ZNN4^)7_)/]4_[9?^C4KJZWE_ CZO\ *)*^)_+]0HHHK H**** M"BBB@ HHHH **** "O'OB7H]AKWQ;\&:9J<'GV=Q%.)8][+N &>JD$<@=#7L M-59M,T^YOH+Z>QMI;RW!$-Q)"K219Z[6(R,^U"^)-] Z-=SPGXL_#[POX2TG M1[W0]+^R7$NI1Q._VB63*X8XP[$=0*ZG5?\ DX_0/^P0_P#[4KTR_P!*T[58 MHX]1L+6\CC<2(MQ"L@5AT8!@<'WH?2]/DU*/4GL+5K^-/+2Z,*F55Y^4-C(' M)XSWIIV_'\5835[^:7X.YY'\-M.O^$FFU.QNO M"^J1[B;1M8L-LUF,GY4>)#O %MH'AN[TS5C;ZM)?W+75YYL ,3N M2#@( MQ).GVQ)R3$O\A4-SHVEWFG1Z?=:;9SV,84);2P*T:[>F%(P,=JNJJHH50 H& M . *MRNY/N[D):1796/%M.UZT^%OQ*\30>(_.M]-UF87EI>")G4G))4[03Q MNQP.,>]=;H?Q4TCQ5XI_L30;6\O8?),CWZQ[(XNOW@V#CIVY)Z5VE_IUCJEL M;;4+*WN[(](\3:A;Z?JL.H/+-]KD"-,I48*Y^]T)P,]1ZUE>&M+TB MZ^&?B:[\2RW.G>']4U4SVX7^AZ1JLL4NHZ797DD M1S&]Q;I(4/L6!Q5TQH8O***8R-NTCC'IBC=:]DONM_D-O6_G?\_\SP*QUWQ# MX1UW0K'2?'EEXNL;VY6!K0,)9D0DG^'=$TF=Y]-T;3[*9QAI+:U2-F^I4#-27> MC:5J%W!=WNFV=S/P*_GGUKT71=0L_"GQL\5-XCNH;+^T8D MELKJZ<)&\8ZJ&/ [#'^S7JEYH^EZC4(,E3WQM;GW'K3?"BJ/V8=2PHYMKLGCJ=S5[3'96 ML5G]CCMH4M0FP0+& FWIC;TQ[5!%HVE0:6VEPZ99QZ>P*M:) HB(/4% ,<_2 MI:]UQ79+\_\ ,=]4WWO^%CR[0M/\$81SGC'RKVQV%>Q6EI;6%K':V= MO%;V\8Q'%"@1$'H .!44^F:?=7MO>7%C;375MGR)Y(59XL]=K$97\*OF]_F\ M[_F1R^YR^5CR_P %JI^/GCAB!N$,8!QR.$JG\.=.@U?Q%\3M,N5#6]S>M$ZG MIAFE%>N0Z5IUM?SW\%A:Q7EP )KB.%5DD Z;F R?QHM-*T[3Y[B>RL+6VFN6 MWSR0PJC2MSRQ RQY/)]:E6Y5%]K?B5U;75IGSWX4AU'Q#XDT#P%J,;^1X8NY MY[IF'$BHW[O\,G'T:NS\2>,-1E^)]SX9N/$T7A?2+6U6;[0R1A[DD X#R<+U M/3^Z1SV]2ATS3[>^GOH+&VBO+@ 37"0JLDF.FY@,G\:COM%TK4YH9M0TRSNY M8#F)[B!9&C/JI(X_"G=NU_GZ]P22;M\O(\&^'\>A7/AWXB0:S?W4FD27*F2[ MVM),8RSE92%4DGHV=N/7BHFUG6/ T.GR^%_B':>);.6=(HM)D(DFVL/E7;EF M7& .-N#VYQ7T#!I6G6MW<7=O86L-S<@">:.%5>7'3<0,M^-5[3PWH5A?->V> MBZ=;7;9W3PVJ)(<\G+ 9YH3LT_3\!=&O7\3SW);]I*$LNUCH>2/3DUQ/C8:A MX3\4^(_"NF0N8?%IADM=H^5&9\2#\?F''J*^@/[,T_\ M/\ M+[#;?;PGEBZ M\E?-V?W=^,X]LTMQIFGW=Y;W=S8VTUU;$F":2%6>+/7:Q&5_"EII?;6_HW<> MNOR^](\9^*.@3>'[+P(+.]-CIVE3""2]\D2K;N=FV5D/!Y5CS2Z)$^K?%[29 M7\;2>);NPMVD:>STR%+>.-@P*O(DO7)_NMR1[U[9-#%<0M#/$DL3C#(ZAE8> MX-5=-T?3-'B:+2].M+&-SN9+6!8@Q]2% IIM.[[M_?\ U^@FM++M;^OZ\R[1 M112&%%%% !1110 4444 %%%% &1H7_,3_P"O^7^E:]9&A?\ ,3_Z_P"7^E:] M94/X:-\3_%84445J8!1110 4444 %%%% !1110 5X'X"\<^'/"'BKQM'KNH_ M9&N-5=HAY$DFX!WS]Q3CJ.M>^5AS>"_"MS/)//X9T:6:1B[R/81,S,>222O) M-"NG?^NG^0.S5OZZGGGQ$\1:=\0?A=J__")WCW_V*6*2Z1(9$.P')X91GIGC MTJGX^\6>'-?^$=MI.CW=M=ZA>BVBMK&!@\R,"O!0CZJYXO\0O[0\!/X<\0A6>ZDT=](NW!_Y:>7\A_[ZR?^ UR^M:7?>!+:VT.Q M@8-XIT>WMY,'I<;QO_1B/^!5]*ZAI>GZM L&I6%K>PJP<1W,*R*&'0X8$9]Z M2ZTG3;VXMKB[T^UN)[5MUO)+"K-">.4)&5/ Z>E.]W=]_P -=/O8;))=%^.E MG^ FD:=%H^C66FP?ZJU@2%?HH KR4:S;_#+XL^(+G7UEBTC7@DT%ZL3.JLN< MJ=HSW;H">GK7L]5[VPL]2M6MKZT@NK=_O13QAT/U!XI-OFYOZU!)1Q%(X,D\GW=_Q/-[F^M-+_ &C3-J%S#:13Z.J1//($5V+8 M"@GOD'BO6ZHWVC:7J5()]NYHB PVL&&,@CJ/2M"M7).DH]4W^-O\ (FWO7"BB MBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R-"_P"8 MG_U_R_TK7JO:6<=GY_ELY\Z9IFW'H3UQ[<58K.E%Q@DS6M-3FY(****T,@HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH *K7UXMC;>:4:1F941%ZLQ. *LU6O[,7UMY7F- M&ZLKI(HR593D''>@"N=1N+>"YDOK,1>2F\&*3S%?V!(!SGMCN*A.LRO;V+06 MB-/16AWE6P 2IR ,@#J#0 Z36K*.1HO,/ MFKQM*,%W8SMW8VAL=LYJO9^([>>$O-&\1RH5$#2LV45SPHSQN]*;+H#R-)&+ MS%J\WV@QF/+[_P#>STSSC&?>JW_")( C>?!+(F !<6PD3&Q4.5)Z_(#G/'O0 M@--M>TU60&YSOV898V9?F^[E@, GT-2VNJ6=[*8X)69MNX;HV4,N<94D ,/< M9K!N-$O$<65HC?997A>=S'&J?)C)&&!7( X"=>]:.D:"FE3!U-L0L?EH8[58 MW(SU9N2QX]A[4P)KK7["U$X,C/)$&^58V(9@,E0V,9]LYJ2/4O\ B2#49XO+ M_=>88P23[#D Y/':J,_AYYED@^V8M6E>98_*^978'^+/(!8G&,^]7;G2UNK& MVLY)6$,14R!M%LX)KG?#)+N'E*C2,K+]X?*#TI MXUW3F5F6'DAO#+%/UH MS>(=/CB9DE+.(VD"F*3@ D' M=A25P1@Y'%2G6].25XGN55T4LV5;:,#)&[&"0#G'7VJDGAP);W$8GB0SVS0' MRK=45223D*#[XQUXZTYM#N0ES%!J;0P3EG*K$-V\@#[V>G&<#!]Z +)U[3@! MF64,7V",V\F_.-V-NW/3GI2W>JK'IL5Y:*MPLSHD>7* [F"@DX)'7TJE8^'3 M::@MV;F,XD\PI'!L&=A7^\3WSSFK#:(CZ+!ILDJNDV*L7FB126T<%D(;1%DWM&L/R2<$895*YZYZ]JHP^%VA2-%O5VJ%##R,9"R MF08PW'4BA;@:!U_30FXSOU;GO4#Z!*M]=7=M>B*2ZW*^Z'< I X'(Y&.O3GI3(/#;V4AELK MT1R89 9(MXV%5&,9'(V Y_2A 7FUS3EE6,7&YG*A65&926^Z-P&,D&QLUD^PB:*61Y%3&5 !P M=V>=HXV]>^*LP^&&B>W(O0!$B*S)#MD;:,8W _=/HP;ZT= +=GXAL;J*V)9X MI)U4[&C?"EN@+8P,]L]>U7+F_BMK![QED**.%V%6)S@#!QR3ZUD0^&I8WM6- M\F8%1-Z0;)"J'@!@W0C&1QZT,$5I M]5O+.WEENM.50B!U,<^Y3R!@G:,'GT(]ZN7-Y]GN[2#9N^T,R[MV-N%+?CTJ ME<:7?7EI-!/4#VHNM*O;U8S/?PK)&7VM#;EWK6TD$$,(FN)R0B%]J@ M9))P< ?0]:K0:(EC.LVGS-$1%Y169GF4J",=6XQST]:LWUD]S)!/!.(;B DH MQ3.E22>(+!5F M"39>,/\ ?1U4E/O#=M/3';)]JANM"GOE)N=0WR-%)&2(<*-Q7H,]!M[DGGK3 M;CP[Y]G]G^U;?WD[[O+S_K P]>V[\<4= +IUO3DE>)[E5=%+-E6VC R1NQ@D M YQU]J8FM6\UW;P0*[&60H^]&C:/"%AE6 /(JNVAW(2YB@U-H8)RSE5B&[>0 M!][/3C.!@^]-L?#IM-06[-S&<2>84C@V#.PK_>)[YYS0+4TK6]%Q+>(4V"VE M\LMNSGY5;/MU_2J&]B2& MZDWLI@)=?E"\-O [>E9J>%95D$O]H(L@$?SI;X)*-D,'].DTZP83AA-*Y8JS!BBCA%R.#A0*@_X1O_1Y MXOM?^MA:+/E],R%\]??%'4"TVOZ:N 9I-Q8J$$$A;( )^7;GH0?I0?$&F X% MP6P%.4B=A\PRO(&,GL.IJGC7%O+.=$\PL79X]P3Y%4#&X$YQVZ4Z+PVM MO"R0W;!Q)'+&[)G:R#'(SR#SZ=: +R:S821R.L^!&C2/N1@5"G!R",Y'IUIK M:[IR%]T[*$#$L8GVG:,L <8)'.0.>#5.3PX)O*>6[)F^T&:9E3 D!QE,9X7Y M5[GI43^%(V-P%DMU6428?[(IE!<'J^TV5U19W#,P3YH77 M!/3.1QGL3U[4AU_3 C.;A@J@$$Q. P)"@KQ\PR1R,CFHY]"$_G[I\":6%S\G M3R\<=>^/PJG!X52!%19;90A38T=HJN0KAOF;.6)VXSP.^#0!?AUVUN=2BLX% ME8NCL6,3KL*D<$$<'GOCMZBI-0U5-/GMHFC+^:WSD''EKD#VDF<2HP1@(G(W$9 R!C)'0=Z#KNFA$?SV*L-Q(B<[!G M&6X^3D$?-CH:@BT-U97EN_,?[3'<,WEXW%4"XZ]\9JH?"F/TP>X MK4CD2:))8V#QN RL.A![UA/X:^:U[*W MEM8$ADG\Y4155F!WG Y+'/.?P_&F!9HHHI %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%(>E !FC-?/FNW.N7_Q"O\ 2]/OIQ))>/'$GFE5 M'7CVJ]-X9^(>E1-=K/<-Y8R?+N-Y_*NOZKHKR2N9^T\CW:BO-OAUX_GUR02./X5D!-6))DB0O(RJHZEC@5%F,DHJM)J%G%#YLES"L><;BXQ2B^M6" M$7$7S@%?G'(/3%%F%RQ15-]5L(Y_(>[@64_P%QFI9[RWMHO,GF2-/[S, *=F M!/29JO;WUK>*3;7$3SKXGND621G" G"@G..M5&*;]YV$ MV^AZ+FC->&^'- U?7]=UG3?^$@NXO[-E\O?N)W_,RY_\=KT'PYX>F\)W%QPNM0FL(+F-[J#_ %L0 M/*_7\ZO5Y?X3=8_BUXH9V"J$;))P!\RUZ'%JVGSR>7%>0.V<8$@SFM*D.5V1 M,971=HHHK,H**** "BBB@ HHJCJ^J1Z1I[74D;RL76..*/&Z1V8*JC/')(Y- M %ZBL+^W;RP@NYMU"">T.JZ0EG: MWD@BAD2Z\UD=L[1*NT!<]/E+#)Q[T =!17))XMU 6L6H7&DVJ:=+>?9%>.^9 MILF4Q ^68@.O) 8G'K5B'Q<)3!9BQ(UA[HVTEEYO^KVX+2%L?<"$,#CG50RC! V_>]3P": ZV.@HK"_MC5;6WNY-2T>*(0VSSH] MO=^;&VT9V$E%*L?]TCWJ6ZUMX8=(:*U5Y-2<1JK2[0A,32#)VG(^7'3OGVH# M^ON-BBN>TK6=;OM6NK.XTG3X([.18YY(]0>0_,@<;5,*Y^\.I'>H-=\8#2[Q MK2UM%N98_P#6M(\BJOR[B!Y<<=:KW/C6.V\-IJITVY>5I6A:!!D(RR>6Q+XP%!Z'OV%%@.IHK/UO4CH^ MB7FHK")FMXBXC+[=V.V<''Y&LN;Q'?Z:SQZMIEO#(UO+/;FVNS,DAC7<4),: ME3CD<$<&DW;4%J['245AV6IZW+:B\O-+T^&U,!F!AU!Y'^[D#:85'Z_G5*S\ M4:DRZ1/J&E6D%KJC(D+6]\TLBED++N0Q+Q@.!V2U_KN/\ K[CKJ*YU=9UVXU&ZL[32-.=K01B9I=1= M!N90Q"X@;('3)QGT%33ZUJ#7\EAINFPW-S;QH]T9;HQ1QE@<*K;&+-QG[H&, M9(SB@#5Y? MV>ZDM_O9W;#C/3C/I1_7XV#^OU+]%8OB3Q /#UE%3#(K;=L8!9WZ' MA5!.._ [U.-75O$$6EI$&62S-T)@_& P7&,>^E &O17+-XNFMX+I;O3HTN[6]M[26.&Y\R/]\R@,'* G ;)!4'CWS5C^W]1N MOM%QI6CI>6,$CQ-(UUY6 M'D%/LT4,F\MRV_=QC'&-OKWK$N/%6J#1['5+72+.6WNGCBQ+?M&ZN\FP<")@ M1D@YSGKQZG6P+4ZRBNU\*2ZU]@E62.#S3:SGRV!_NL<''/?!HZ7#K8V:*YP>(-1M-1CLM4 MTVUA>>WEFA:UO&F!\L D-NC0KU&#R*ET?5=:U&VM;VXTNP@LIX1-NCOWDD4% M(X)_?(% CZ8 M^\V#@'%2:-K&MZO#;WG]E:?%8S$G?_:#M(%R1G9Y(&>.F[\: .AHKD?^$MU) M-/\ [4FTBT73/M)@+I?LTW^M,>1&8@"<\XW?G6A_PDFW3M5GDM-MUI\S0FV6 M7)D;@QX./XPRXXXSCG%']?U]X&]17.0:UKM]=WL5EI&GM%:3^0S3ZBZ,6VJQ MP!"PQ\WKVI)?$&K&^U2.ST>VN+?3I DC&^*2O^[5SL3RRIX; RPSCM0"UV.D MHJO8WD.HV%O>VS;H+B-98VQC*L,BK%#5G9@G<**** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJCK.H?V3HE M]J.S?]EMWFVYZ[5)Q^E)NRN-*[LB]17)>&-4FO+N$7&NS7,TUMYKVLUCY*;N M,M ^U=R#.#R_4E(9X-:_P#)<3_V$G_K7O!'%>!IV@V%R(;&.5HAE M]JL5^\['TX.!5?PTL_C3XI'5?**P1S_:GS_ J_YTG5KP MV,?VAT-PR;@,DE2>1P>.?>NM1CS+FW2,[NWD=#K/PY;1-,?4=-UN*>>W7S'1 M3L; ZE2#SBKOZU'-&23 M;N[K6UAZHI>$_"&K>,K=TCNQ#8VS]9"2N\]0!ZXQ3_'EK/I'B:QLHY29K2RM MHU=.[*,9'XBO1/@T!_PAMP?^GY__ $!*XSXF_P#)2HO]R#^=.-5RQ#B]E<'& MT+AJ_P +]7L=!FUB:^26YB0SS19)8 Z>)Q_P 4EK/_ %XS?^@&O-?@C_Q\:U_NP_\ L]9PKSE1E-[K M8;@E)(YC4]/U?X9^);9X;K>& D1D)"RKG!5A_GK7T%:SK=6D-PF=DJ*ZY]", MBO'_ (V?\A72?^N,G_H0KU;0?^1=TS_KTB_] %8XA\]*$WNRX:2:/./!=]%I MGB;QY?3_ .JMY7D;'H'D-5M"T=OB!-+KOB2_9+5I"MO:)(% _IV]3S4.C64 MVHWGQ&M(%+32-($4=R))"!^.,5'X#\%^&O%&A^;<370OX7*SQI*!CGY2 1T( M_4&M9:5[/3\B%=V1>\1>%T\'P_P!O>%M0:-KG#%YJ8\N$==C='^N",?7%4=:^'G@OP_IS7VHW5_%""%_UH))/8#;S6 M3XMTVTTWPGX8U/2%N)-,M+DR@3#YL.P8$\# .T_F*B/)-QOKKO8>JN;VE?"J MRGLEN-?N+FZU&4;I3YG"$]O?%.T3PYK_ (0\51P6#R7OA^?&\.XS#GO@]Q[= M17>6%];:C8PWEK()8)E#(P/4&LV[\6:39Z_;Z(\S-?SXVQQH6QGU(Z<<\]JP M=6I*Z>I?*D>71Z#-XC^*FN6 NI+>UWL]R8S@N@*_+^)(_*NAUOX4:5!ID]SI M4MQ!=P1,\9+Y!8BW_\ R#[G_KDW\C6M6M., MEROHB8Q36IS7PWUR?7O",,UTY>X@=H)'/\6,$'\B*ZZO.?@Q_P BA=?]?K?^ M@)7HU8UTE4DD7!WB@HHHK(H**** "LW7-,?5=-\B&80W$P=-U MS4Y;*'53816UI.D[/;2.SW#)RN590(QG!(RW3&>]='10#U.=\/\ A/3])C6X MFTW3CJ8FED-W' OF'>[$?.0&S@@59AT9X_&-WK1$/ES645NN!^\!5W)SQT(* M]^U;-% =#B&\!1"V:\AM]/37HK^6\@NO*!W[I&8)(VW)!4[3P<=1T%7I_#%W M<7NJ79G@BFFN[>[M3RX1XD52&''!P1QV.>M=311_7]?<-N[;?4XV3PM>ZAJ- MUJ5Q9:187>==J+IU$<014"QR>43N(498KQDX[&KU]HMW?>#&TE+:SLIL(J113- M)$@5P?O%%)X']WK^=='11_7W ]3,\1:?/JOAV_L+8QB>>$HAD8A<^Y ) _ U MD7NC:QKC>9J,=C:^1;3QV\4%P\P:21-FYF,:X !/ !Z]>U=512:NK,%H[G'Z M-X;GT^/RAX9\.V+FV,+7EG,3*?EQT\A>"<9^;\Z;IW@B+19=%OM,M=/M[^UB M6WO2D85;A"H#D$+G<",@X&>AZ\=E157UO_77_,5M+'!6W@2]BFLF>ZMQ$BS& MYB4DB5]\C0'I_#YK$^X'6MBT\/7=O8>%8'D@+:0%\\ACAL0-'\O'/+#KCBNE MHH3LK#>IQNH^%YKCQ#?W[^'M U:.Y\ORWU"4K)'M7!&/)?C//6M!]/UFQU&: M_P!,AT]S=PQK/;3SNBQ.@(#(RH=PP0,%5Z#D=*Z*BDMK 8#&V1$V3M4 ^]=I10M-OZW_ M ,V#UW.6M++Q'8ZUJ5['8:5*E^T4C*VH2*8BL:JP'[D[AD'!X^@J]KN@0Z[> M:6;NWM;FTM9GDFAN$#ALQLHP"""02#S6W10!Q@\'7-II?NG:<]\'&,TMYX6O&T^YT>.ST>^TZ6:6:%[X$O:M(220FTAR" MS8.Y#@X]Z[*BAZJS_K;_ ""]MOZ_JYRMMX)TYM1EFU2PT_4(UM+>W@:XMUD9 M?+#!CA@< Y'0T^/PW@P.*Z>BG=WO\Q)) M*QSVOZ3?:A-\MII>J6+Q[6LM1^14<$G>KB-R2>!@CL"".[)?#MT_@.30#<)- M'K2:* 1/J%G-FH+=^]= MG11_7]?>!Q]KX:U)M;L+Z[ATN*XM6)FU&TRL]Z-I&UTV *"2"1N;D<8[1>'_ M O<:/+:F3PUX<,T3G=J,F[\:[6B@#B$\!QVUK;7MK;:=' MKUM=R7*W/EC$H:1B4=MN>4;&<$@]*V[K06N/$EMJ0E5;<(#&O#NI&XNO/BN+R8K*@VJ /\ 4/C!4GAN]73I MWB&VU#6390Z:8=1E619Y;EP\/[I$/[L1X;!7/WAGVKJ:*.EOE_7W#O9W,_2K M%M)LK738E5K.UMDB24R'>Q48Y7&,8 .<]^E:%%%-MMW8EH%%%%( HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O M;2'4+&XL[A=T,\;12#U4C!J>BAZ@G;4P+#P_=1:G:7FH:C'=_887AM1';^40 M&V@ESN.YL*.@4=>/3?HHHN 4444 >9:S\(DU?6KS43K!B-S*TFS[/G;D],[J MJP_!*V$@,^M2NG<) %)_$D_RKU>BMUBJJ5E(CV<>QDZ#X'+%_L=N2I#A=YR&#$GGDG%=1 M15RKU)--O82A%'.^#O"P\):-)IZW9N=\[3;RFW&0!C&3_=K&\2_#A?$7B1=8 M.I& JJ#RO)W?=]\BN[HJ55FI.2>K#E5K%/4['^T=)O+ OY?VF!X=^,[=RD9Q M^-LM^;K[2$!S%LV[<^Y]:["BI4Y*+BMF.RO&8ZE+YAC\O;Y?S,V,YY^]^E96M_#6.YU1]5T/4IM(OG)+F' M.UB>IP"",]^WM7>452JS4N:XN56/.;7X83WE]%=>)M%? 5GX;N)+Z2>2^U*3(:YFZC/7 YQGUR377454JTY*S8 ME!+4YC2/"(TKQ;J>NB\,AO@08?+QLR0>N>>E=%<1>?!)%G&]"N?3(J6BHE)R M=V-)(YSP;X5'A'2); 79N1),9=Y3;C( QC)]*Z.BBE*3D[L$K*R"BBBD,*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B =BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D! end GRAPHIC 9 g4lv1dgrulou000003.jpg GRAPHIC begin 644 g4lv1dgrulou000003.jpg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

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 176,882,000 $ 24,248,000
Short-term marketable securities 48,449,000 39,529,000
Accounts receivable 3,847,000 1,480,000
Inventory 480,000 104,000
Prepaid expenses and other current assets 3,166,000 1,521,000
Total current assets 232,824,000 66,882,000
Property and equipment, net 4,549,000 2,731,000
Operating lease right-of-use assets 7,744,000  
Restricted cash 3,025,000  
Other assets 167,000 167,000
Total assets 248,309,000 69,780,000
Current liabilities:    
Accounts payable 2,880,000 1,573,000
Accrued compensation 5,120,000 2,075,000
Accrued liabilities 1,227,000 763,000
Short-term deferred revenue 1,380,000 905,000
Current portion of operating lease liabilities 1,453,000  
Current portion of finance lease obligations 121,000 109,000
Total current liabilities 12,181,000 5,425,000
Warrant liability 146,000 1,650,000
Long-term deferred revenue 0 639,000
Long-term finance lease obligations, less current portion 136,000 226,000
Operating lease liabilities, long-term 6,148,000  
Total liabilities 18,611,000 7,940,000
Stockholders’ equity:    
Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of December 31, 2021 and 2020; 29,772,922 and 20,740,413 shares issued and outstanding at December 31, 2021 and 2020, respectively 3,000 2,000
Additional paid-in capital 436,183,000 189,868,000
Accumulated other comprehensive loss (124,000) (1,000)
Accumulated deficit (206,364,000) (128,029,000)
Total stockholders’ equity 229,698,000 61,840,000
Total liabilities and stockholders’ equity $ 248,309,000 $ 69,780,000
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 29,772,922 20,740,413
Common stock, shares outstanding 29,772,922 20,740,413
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Total revenues $ 11,838 $ 5,885 $ 3,364
Cost of revenues 10,564 5,981 3,304
Gross profit/(loss) 1,274 (96) 60
Operating expenses:      
Sales and marketing 37,575 16,077 6,303
Research and development 16,261 5,293 2,497
General and administrative 24,836 13,823 8,865
Total operating expenses 78,672 35,193 17,665
Loss from operations (77,398) (35,289) (17,605)
Other income/(expense):      
Interest income, net 151 40 (2,657)
Change in fair value of warrant liability (1,088) (1,228) (441)
Gain on debt extinguishment of convertible notes     928
Change in fair value of derivative liability     (355)
Total other expense (937) (1,188) (2,525)
Net loss $ (78,335) $ (36,477) $ (20,130)
Weighted average shares outstanding used in computing net loss per share, basic and diluted 28,884,874 16,979,411 7,005,037
Net loss per share of common stock outstanding, basic and diluted $ (2.71) $ (2.15) $ (2.87)
Assay Revenue      
Revenues:      
Total revenues $ 11,023 $ 4,241 $ 1,403
Contract Revenue      
Revenues:      
Total revenues $ 815 $ 1,644 $ 1,961
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Net loss $ (78,335) $ (36,477) $ (20,130)
Unrealized loss on available-for-sale marketable securities (123) (1)  
Comprehensive loss $ (78,458) $ (36,478) $ (20,130)
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Cumulative Effect Adjustment of Accounting Method Change
Convertible notes
LifeSci Capital LLC
Private Placement
At-The Market Offering
Series A convertible preferred stock
Series A convertible preferred stock
Series A and B Convertible Preferred Stock
Series B-1 Convertible Preferred Stock
Series C-2 Convertible Preferred Stock
Series C-2 Convertible Preferred Stock
Convertible notes
Series B-2 Convertible Preferred Stock
Series B-2 Convertible Preferred Stock
Series A and B Convertible Preferred Stock
Common stock
Common stock
Series A and B Convertible Preferred Stock
Common stock
Convertible notes
Common stock
LifeSci Capital LLC
Common stock
Private Placement
Common stock
At-The Market Offering
Additional paid-in capital
Additional paid-in capital
Convertible notes
Additional paid-in capital
LifeSci Capital LLC
Additional paid-in capital
Private Placement
Additional paid-in capital
At-The Market Offering
Accumulated deficit
Accumulated deficit
Cumulative Effect Adjustment of Accounting Method Change
Accumulated other comprehensive loss
Balance at Dec. 31, 2018 $ (5,355) $ (45)                       $ 1           $ 66,021         $ (71,377) $ (45)  
Balance, Shares at Dec. 31, 2018                   1,524,122       4,411,567                          
Issuance of common stock, net of issuance costs 934       $ 19,802                             934     $ 19,802        
Issuance of common and preferred stock, net of issuance costs, Shares             1,231             726,139       3,076,923                  
Issuance of common stock through conversion     $ 12,687                                   $ 12,687            
Issuance of common stock through conversion, Shares                     (1,524,122)     1,524,122   2,267,042                      
Additional paid in capital assumed in Business Combination 420                                     420              
Issuance of Series A preferred stock at $3,250 per share 4,000                                     4,000              
Reclassification of stockholders’ equity to warrant liability (187)                                     (187)              
Restricted stock unit release (1,569)                                     (1,569)              
Restricted stock unit release, Shares                           339,025                          
Stock-based compensation 1,304                                     1,304              
Net loss (20,130)                                               (20,130)    
Balance at Dec. 31, 2019 11,861                         $ 1           103,412         (91,552)    
Balance, Shares at Dec. 31, 2019             1,231             12,344,818                          
Issuance of common stock, net of issuance costs       $ 1,011 $ 23,889 $ 19,104                               $ 1,011 $ 23,889 $ 19,104      
Issuance of common and preferred stock, net of issuance costs, Shares                 3,199     524         87,790 2,467,724 951,792                
Issuance of Series B-1 convertible preferred stock 30,968                                     30,968              
Issuance of Series B-2 convertible preferred stock 5,071                                     5,071              
Issuance of common stock from option exercises and RSU releases 473                                     473              
Issuance of common stock from option exercises and RSU releases, Shares                           319,522                          
Issuance of common stock from warrant exercises 842                                     842              
Issuance of common stock from warrant exercises, Shares                           230,619                          
Issuance costs in connection with Form?S-1?registration statement (77)                                     (77)              
Issuance of common stock through conversion 1                         $ 1                          
Issuance of common stock through conversion, Shares               (1,231) (3,199)       (524) 3,198,949 1,139,199                        
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 206                                     206              
Unrealized loss on available-for-sale securities (1)                                                   $ (1)
Stock-based compensation 4,969                                     4,969              
Net loss (36,477)                                               (36,477)    
Balance at Dec. 31, 2020 61,840                         $ 2           189,868         (128,029)   (1)
Balance, Shares at Dec. 31, 2020                           20,740,413                          
Issuance of common stock, net of issuance costs 134,582         $ 23,836               $ 1           134,581       $ 23,836      
Issuance of common and preferred stock, net of issuance costs, Shares                           4,872,881         530,551                
Issuance of common stock from option exercises and RSU releases 793                                     793              
Issuance of common stock from option exercises and RSU releases, Shares                           466,442                          
Issuance of common stock from warrant exercises 72,429                                     72,429              
Issuance of common stock from warrant exercises, Shares                           3,104,520                          
Issuance of common stock from Employee Stock Purchase Plan 966                                     966              
Issuance of common stock from Employee Stock Purchase Plan, Shares                           58,115                          
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 434                                     434              
Unrealized loss on available-for-sale securities (123)                                                   (123)
Stock-based compensation 13,276                                     13,276              
Net loss (78,335)                                               (78,335)    
Balance at Dec. 31, 2021 $ 229,698                         $ 3           $ 436,183         $ (206,364)   $ (124)
Balance, Shares at Dec. 31, 2021                           29,772,922                          
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
At-The Market Offering      
Issuance costs $ 0.7    
Issuance price per share $ 46.33    
Common Stock      
Issuance price per share $ 29.50 $ 10.50 $ 6.50
Issuance costs $ 9.1 $ 2.0 $ 0.2
Common Stock | At-The Market Offering      
Issuance costs   $ 0.9  
Issuance price per share   $ 20.97  
Series A Convertible Preferred Stock      
Issuance price per share     $ 3,250
Series B-1 Convertible Preferred Stock      
Issuance price per share   $ 10,500  
Issuance costs   $ 2.6  
Series B-2 Convertible Preferred Stock      
Issuance price per share   $ 10,500  
Issuance costs   $ 0.4  
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net loss $ (78,335) $ (36,477) $ (20,130)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 997 486 89
Change in fair value of warrant liability 1,088 1,228 441
Gain on extinguishment of convertible notes     (928)
Change in fair value of derivative liability     355
Amortization of debt discount and issuance costs     1,983
Amortization of operating lease right-of-use assets 1,299    
Stock-based compensation 13,276 4,969 1,304
Amortization (Accretion) of discount (premium) on marketable securities 749 (21)  
Loss on disposal of equipment 15 13  
Payment in connection with restricted stock unit release     (1,569)
Changes in operating assets and liabilities:      
Accounts receivable, net (2,367) (800) (100)
Inventory (376) (69) 5
Prepaid expenses and other current assets (1,700) (487) (1,069)
Operating lease liabilities, net (1,443)    
Accounts payable and accrued compensation 4,335 827 1,337
Accrued liabilities and deferred revenue 356 1,647 491
Net cash used in operating activities (62,106) (28,684) (17,791)
Cash flows from investing activities:      
Purchases of marketable securities (48,092) (41,706)  
Sales of marketable securities 1,600    
Maturities of marketable securities 36,700 2,200  
Purchases of property and equipment (2,720) (1,834) (210)
Net cash used in investing activities (12,512) (41,340) (210)
Cash flows from financing activities:      
Proceeds from issuance of common stock     19,802
Proceeds from issuance of Convertible Preferred Stock     4,000
Payments of deferred underwriting fees   (1,363)  
Payments of issuance costs in connection with Form S-1 registration statement   (77)  
Proceeds from exercise of common stock warrants 70,271 842 5
Proceeds from exercise of stock options 793 473 929
Proceeds from contributions to the employee stock purchase plan 966    
Proceeds from convertible notes payable     2,600
Payments of notes payable     (516)
Principal repayments of finance lease obligations (171) (9)  
Proceeds received from close of Business Combination     1,802
Net cash provided by financing activities 230,277 78,898 28,622
Net increase in cash, cash equivalents and restricted cash 155,659 8,874 10,621
Cash, cash equivalents and restricted cash, beginning of period 24,248 15,374 4,753
Cash, cash equivalents and restricted cash, end of period 179,907 24,248 15,374
Supplemental cash flow information:      
Cash paid for interest on finance lease obligations 17 2  
Supplemental disclosure of noncash investing and financing activities:      
Issuance of common stock in litigation settlement   1,011  
Purchases of property and equipment recorded in accounts payable 17 71 641
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder 434 206  
Cashless exercise of common stock warrants 2,158    
Right-of-use assets obtained in exchange for lease obligations 9,044    
Property and equipment acquired under finance leases 93 342  
Change in unrealized loss on available-for-sale marketable securities (123) (1)  
Unpaid deferred issuance costs   56 1,363
Debt discount and derivative liability at issuance of convertible notes payable     $ 270
Series B-1 Convertible Preferred Stock      
Cash flows from financing activities:      
Proceeds from issuance of Convertible Preferred Stock   30,968  
Series B-2 Convertible Preferred Stock      
Cash flows from financing activities:      
Proceeds from issuance of Convertible Preferred Stock   5,071  
Private Placement      
Cash flows from financing activities:      
Proceeds from issuance of common stock   23,889  
Public Follow on Offering      
Cash flows from financing activities:      
Proceeds from issuance of common stock 134,582    
At-The Market Offering      
Cash flows from financing activities:      
Proceeds from issuance of common stock $ 23,836 $ 19,104  
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
The Company and a Summary of its Significant Accounting Policies

1. The Company and a Summary of its Significant Accounting Policies

(a)

Nature of Operations

On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock (“Reverse Stock Split”).

The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.

From the end of the first quarter of 2020 and through the fourth quarter of 2021, there has been a widespread worldwide impact from the COVID-19 pandemic. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company has implemented additional safety measures in accordance with Centers for Disease Control and Prevention (“CDC”), Occupational Safety and Health Administration (“OSHA”) and other guidance within its CLIA laboratory operations. Additionally, the Company has transitioned administrative functions to predominantly remote work. Beginning in March 2020 and continuing through the fourth quarter of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by the Company’s sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received during the fourth quarter of 2021 relative to the Company’s pre-pandemic expectations. The Company expects the ongoing COVID-19 pandemic to continue to adversely impact billable sample volume until patient access to in-person testing fully resumes, in-office access by the Company’s sales force returns to pre-pandemic levels, or telemedicine options are more widely adopted. Additionally, the ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect the Company’s pharmaceutical customers’ clinical trials. The extent of such effect on the Company’s future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on the Company’s pharmaceutical customers’ clinical trials.

(b)

Basis of Presentation

The consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”). In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.

(c)

Revision to Prior Period Financial Statements  

As discussed under the heading “Revision to Prior Period Financial Statements” in Note 1 of the Company’s Quarterly Report on Form 10-Q filed on May 13, 2021, during the course of preparing the quarterly report Form 10-Q for the three months ended March 31, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The SEC Statement highlighted challenges associated with the accounting for complex financial instruments that may be common in SPACs, specifically accounting for warrants issued in connection with a SPAC’s formation and initial registered offering. In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity.

The Company previously issued warrants to purchase common stock in public and private placement offerings consummated on June 23, 2017 (the “SPAC Warrants”), which were originally classified as equity in the Company’s financial statements. As part of the aforementioned public offering, the Company issued 14,375,000 warrants (the “Public SPAC Warrants”) and as part of the aforementioned private placement offering, the Company issued 561,250 warrants (the “Private SPAC Warrants”). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share. The Company’s SPAC Warrants were accounted for as equity within the Company’s previously reported consolidated balance sheets.

The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement.

Historically, the Private SPAC Warrants were recorded as a component of equity as opposed to liabilities on the Company’s consolidated balance sheets and the Company’s consolidated statements of operations did not include the subsequent non-cash changes in estimated fair value of the Private SPAC Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the recent SEC Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for SPAC Warrants issued on June 23, 2017, in light of the SEC Staff’s published views. After discussion and evaluation, the Company concluded that, as a result of these differences in features between the Public SPAC Warrants and Private SPAC Warrants, the Private SPAC Warrants should be classified as liabilities, if still held by the original Private SPAC Warrant holder, with subsequent changes in fair value reported in the Company’s consolidated statement of operations.

In addition, the Company analyzed the impact of the aforementioned adjustments on its previously issued audited consolidated financial statements for the years ended December 31, 2020 and 2019 and previously issued unaudited consolidated financial statements for the periods ended September 30, 2020 and 2019, June 30, 2020, and March 31, 2020 (such years and periods, the “Affected Periods”). The Company concluded the adjustments are not material to any individual period prior to the period ended March 31, 2021, taking into account the requirements of ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 270, Interim Financial Reporting, ASC Topic 250-S99-1, Assessing Materiality, and ASC Topic 250-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. In accordance with the authoritative guidance, management evaluated the materiality of the adjustments from a quantitative and qualitative perspective. Based on such evaluation, the Company concluded that the effects of these adjustments were not material individually or in the aggregate to the Affected Periods and had no effect on the trend of financial results. While management concluded the adjustment was not material to any prior periods, individually or in the aggregate, based on our qualitative and quantitative analysis, management opted to make the adjustment by revising the respective amounts that were previously reported in the Affected Period. Accordingly, the Company has revised the prior period interim and annual financial information for the Affected Periods to reflect these adjustments.

The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Balance Sheet as of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

628

 

 

 

628

 

Total liabilities

 

 

5,722

 

 

 

628

 

 

 

6,350

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

103,599

 

 

 

(187

)

 

 

103,412

 

Accumulated deficit

 

 

(91,111

)

 

 

(441

)

 

 

(91,552

)

Total stockholders’ equity

 

 

12,489

 

 

 

(628

)

 

 

11,861

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheet as of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

1,650

 

 

 

1,650

 

Total liabilities

 

 

6,290

 

 

 

1,650

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

189,849

 

 

 

19

 

 

 

189,868

 

Accumulated deficit

 

 

(126,360

)

 

 

(1,669

)

 

 

(128,029

)

Total stockholders’ equity

 

 

63,490

 

 

 

(1,650

)

 

 

61,840

 

The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):

 

 

Year Ended December 31, 2019

 

 

Year Ended December 31, 2020

 

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Statements of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

$

—

 

 

$

(441

)

 

$

(441

)

 

$

—

 

 

$

(1,228

)

 

$

(1,228

)

Total other income/(expense)

 

 

(2,084

)

 

 

(441

)

 

 

(2,525

)

 

 

40

 

 

 

(1,228

)

 

 

(1,188

)

Net loss

 

$

(19,689

)

 

$

(441

)

 

$

(20,130

)

 

$

(35,249

)

 

$

(1,228

)

 

$

(36,477

)

Net loss per share of common stock

  outstanding, basic and diluted

 

$

(2.81

)

 

$

(0.06

)

 

$

(2.87

)

 

$

(2.08

)

 

$

(0.07

)

 

$

(2.15

)

The consolidated statements of cash flow are not presented because there is no impact on total cash flows from operating activities, investing activities, or financing activities. Certain components of net cash used in operating activities changed, as caused by the revision, such as incorporating the non-cash item from the change in fair value of warrant liability in the adjustments to reconcile net loss to net cash used in operating activities, but the net change amounted to zero for the Affected Periods.

(d)

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to, those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.

(e)

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.

Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

 

 

 

Year Ended December 31, 2021

 

 

Year Ended December 31, 2020

 

 

Year Ended December 31, 2019

 

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

Cash and cash equivalents

 

$

24,248

 

 

$

176,882

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

Restricted cash

 

 

—

 

 

 

3,025

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total cash, cash equivalents and restricted cash

   reported in the consolidated statements of

   cash flows

 

$

24,248

 

 

$

179,907

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

 

(f)   Marketable Securities

The Company considers securities with maturities of greater than 90 days at the time of purchase to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, such marketable securities are classified as current assets on the accompanying consolidated balance sheets even if they have contractual maturities greater than one year from the date of purchase. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost basis, which

may occur at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 2021.

(g)

Property and Equipment

Property and equipment is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $1.0 million, $0.5 million, and $0.1 million, for the years ended December 31, 2021, 2020, and 2019, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $0.1 million, $10,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively.

Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the consolidated statement of operations. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. The Company disposed of $0.1 million, $0.1 million, and zero of equipment during the years ended December 31, 2021, 2020, and 2019, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the years ended December 31, 2021, 2020, and 2019.

(h)

Leases

The Company acts as lessee in its lease agreements, which include operating leases for corporate offices and finance leases for certain laboratory and office equipment.

In accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as adopted on January 1, 2021, the Company determines if an arrangement is a lease at inception. Finance leases are included in the consolidated balance sheets as property and equipment, net and finance lease obligations at the present value of the lease payments. Operating leases are included in the consolidated balance sheet as ROU assets and operating lease liabilities at the present value of the lease payments. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.

As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, the Company has used a number of factors including the credit rating, and the lease term.

The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of less than 2 years to 10 years, some of which include options to extend the lease for up to 10 years. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest income, net on the Company’s consolidated statements of operations.

The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.

(i)

Research and Development

Costs incurred in connection with research and development (“R&D”) activities are expensed as incurred. R&D expenses consist of (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; and (ii) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies.

The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses.

(j)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2021, the Company maintained $100.1 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $60.2 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of December 31, 2021. The Company has not experienced any losses in such accounts.

(k)

Income Taxes

The Company provides for federal and state income taxes on the asset and liability approach which requires deferred tax assets and liabilities to be recognized based on temporary differences between the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year and prior year operating losses, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2021.

Current and deferred tax assets and liabilities are recognized based on the tax positions taken or expected to be taken in the Company’s income tax returns. U.S. GAAP requires that the tax benefits of an uncertain tax position can only be recognized when it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority. Tax benefits related to tax positions that do not meet this criterion are not recognized in the consolidated financial statements, of which there are none.

The Company recognizes interest and penalties related to income tax matters in income tax expense.  

(l)

Revenue Recognition

The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.  

The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.

Assay Revenue

The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the “DermTech Melanoma Test” or “DMT”, which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus) it provides to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in a limited number of states where permitted by law and applicable standards of practice guidelines.

Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.

Contracts

The Company’s customer is the patient. However, the Company does not enter into a formal reimbursement agreement with a patient, as formal reimbursement agreements are more commonly established with insurance payors. Accordingly, the Company establishes an agreement with a patient in accordance with other customary business practices.

 

•

Approval of an agreement is established by the use of the Company’s Smart Sticker on a patient by an ordering clinician, which is then sent to the Company’s central lab for testing.

 

 

•

The Company is obligated to perform the Company’s laboratory services upon receipt of a sample from a clinician, and the patient and/or applicable payor are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.

 

 

•

Payment terms are a function of a patient’s existing insurance benefits.

 

 

•

Once the Company delivers a patient’s test result to the ordering physician, the Company is legally able to collect payment and bill an insurer and/or patient, depending on payor agreement status or patient insurance benefit status.

 

 

•

The Company’s consideration is deemed to be variable, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.

Performance Obligations

A performance obligation is a promise in an agreement to transfer a distinct good or service (or a bundle of goods or services) to the customer. The customer is able to order a DMT, which is treated as a single performance obligation.

Transaction Price

The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both.

The consideration derived from the Company’s agreements is deemed to be variable, though the variability is not explicitly stated in any agreement. Rather, the implied variability is due to several factors, such as the amount of contractual adjustments, any patient co-payments, deductibles or patient compliance incentives, the existence of secondary payors and claim denials.

The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.

The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. Revenue recognized from changes in transaction prices was not material for the years ended December 31, 2021, 2020, and 2019, respectively.

The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for an agreement with a patient, it will account for the change as an increase in the estimate of the transaction price (i.e., an upward revenue adjustment) in the period identified. Similarly, if the Company subsequently determines that the amount it expects to collect from a patient is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price (i.e., a downward revenue adjustment), provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of a patient’s test result to the ordering physician, with recognition, generally occurring at the date of cash receipt.

Allocate the Transaction Price

The entire transaction price is allocated entirely to the single performance obligation contained within the agreement with a patient.

Recognize Revenue

The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful test result is delivered to the patient’s ordering physician. The Company considers this date to be the time at which the patient obtains control of the final results of the promised test service.

Contract Revenue

Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.

Contracts

As part of the Company’s contract revenue, the Company has established agreements and work orders with the Company’s third-party partners that fall under the scope of ASC 606.

Performance Obligations

ASC 606 requires an entity to assess the goods or services promised in a contract and identify as a performance obligation each promise to transfer to the customer either a good or service (or a bundle of goods or services) that is distinct, or a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Based upon review of existing contracts, a majority of the Company’s contract revenue agreements contain three performance obligations:

 

(1)

Smart Stickers

 

 

(2)

RNA extractions and analysis

 

 

(3)

Certain project management fees

Many of the Company’s contract revenue agreements contain promises such as start-up activities and quality system setup fees, which are activities that the Company performs to fulfill the agreement and they do not transfer any good or service to the customer. These promises encompass the administrative tasks associated with beginning and initiating a new project or study with a third-party company. In accordance with ASC 606, an entity does not account for these activities as a promised good or service within the agreement nor evaluate whether they are a performance obligation. 

Transaction Price

The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in an agreement with a customer may include fixed amounts, variable amounts, or both.

The transaction prices of the Company’s performance obligations are listed in its agreements on a per unit basis and are fixed for adhesive sample collection kits and RNA extractions and analysis. The project management fees are assessed based on a monthly service fee which range within the agreements depending on certain factors which include length of the project and the amount of Smart Stickers or RNA extractions and analysis promised within the agreement. The fixed and variable rates are materially consistent within the Company’s agreements. Therefore, the Company utilizes the prices listed in our agreements as the transaction price for each performance obligation.

In determining the transaction price, ASC 606 requires an entity to adjust the promised amount of consideration for the effects of the time value of money if the agreement contains a significant financing component. The Company’s agreements state fixed transaction prices for each deliverable associated with the agreement and do not qualify for the significant financing component of ASC 606.

Allocate the Transaction Price

The Company’s contracts have a directly observable transaction price pertaining to each promised good or service. Those prices are consistent across agreements for Smart Stickers and RNA extractions and analysis, with the exception of the Company’s project management fees, which the Company’s believes encompass a sufficiently narrow range of prices that are dictated upon factors of each agreement previously discussed above. Therefore, the Company relies on those transaction prices as the basis to allocate the stand-alone selling prices to the performance obligations of the agreement.

Most of the Company’s agreements contain a discount that is allocated to items within the agreement, whether they are performance obligations or not. Those items that are not performance obligations (e.g., quality system setup and start up fees) have the associated discount allocated to the transaction prices of the performance obligations evenly.

Recognize Revenue

An entity should recognize revenue when (or as) it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is transferred when (or as) the customer obtains control of that good or service. The Smart Stickers are recognized at a point in time when shipped to the customer. The RNA extraction and analysis are recognized at a point in time when the extraction and analysis process is complete and the results are sent to the customer. The Company provides its project management service over the life of the agreement, providing equal benefit to the customer throughout the life of the project or study. Therefore, the revenue related to the Company’s project management fees is recognized straight-line over the life of the agreement.

 

(a)

Disaggregation of Revenue

The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

DermTech Melanoma Test

 

$

11,023

 

 

$

4,241

 

 

$

1,403

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Smart Stickers

 

 

348

 

 

 

213

 

 

 

476

 

RNA extractions

 

 

300

 

 

 

1,172

 

 

 

626

 

Project management fees

 

 

166

 

 

 

258

 

 

 

336

 

Other

 

 

1

 

 

 

1

 

 

 

523

 

Total revenues

 

$

11,838

 

 

$

5,885

 

 

$

3,364

 

 

 

The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:

 

 

 

Total Revenue

 

 

Accounts Receivable

 

 

 

Year Ended December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payor A

 

 

36

%

 

 

32

%

 

*

 

 

 

23

%

 

 

21

%

Payor B

 

*

 

 

 

11

%

 

 

12

%

 

 

15

%

 

*

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer A

 

*

 

 

 

23

%

 

 

22

%

 

*

 

 

*

 

Customer B

 

*

 

 

*

 

 

*

 

 

*

 

 

 

17

%

Customer C

 

*

 

 

*

 

 

 

29

%

 

*

 

 

*

 

* Less than 10%

There were no other payors or customers that individually accounted for more than 10% of total revenue or accounts receivable for the periods shown in the table above.

(b)

Deferred Revenue and Remaining Performance Obligations

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets.

In a majority of agreements that produce contract revenue, the Company receives a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.

The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of December 31, 2021, and December 31, 2020, was $1.4 million and $0.9 million, respectively. Long-term deferred revenue as of December 31, 2021, and December 31, 2020, was zero and $0.6 million, respectively.

Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of December 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was approximately $0.4 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.

(m)

Accounts Receivable

Assay Accounts Receivable

Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.6 million and $1.0 million of gross assay accounts receivable as of December 31, 2021 and 2020, respectively.

Contract Accounts Receivable

Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of December 31, 2021, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the

reserve. The Company recorded $0.2 million and $0.5 million of contract accounts receivable as of December 31, 2021 and 2020, respectively.

(n)

Freight and Shipping Costs

The Company records outbound freight and shipping costs for its contract and assay revenues in cost of revenues.

(o)

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net loss and the components of other comprehensive loss, including unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive loss.

(p)

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.

(q)

Net Loss Per Share

Basic and diluted net loss per share is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the years ended December 31, 2021 and 2020, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the year ended December 31, 2021 excludes the effect of anti-dilutive equity instruments including 734,329 shares of common stock issuable upon the exercise of outstanding common stock warrants and 2,704,035 shares of common stock issuable upon the exercise stock options and release of RSUs. Diluted net loss per share of common stock for the year ended December 31, 2020 excludes the effect of anti-dilutive equity instruments including 3,885,311 shares of common stock then issuable upon the exercise of outstanding warrants and 2,112,980 shares of common stock then issuable upon the exercise of stock options and release of RSUs. Diluted net loss per common share for the year ended December 31, 2019 excludes the effect of anti-dilutive equity instruments including 615,385 shares of common stock issuable upon conversion of the Company’s preferred stock, 4,200,497 shares of common stock issuable upon the exercise of outstanding common stock warrants and 443,547 shares of common stock issuable upon the exercise stock options. The Company did not consider a two-class method of loss per share given that the Company’s convertible participating securities do not participate in losses.

(r)

Stock-Based Compensation

Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis.

The Company grants stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.

The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of the Company’s common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future.

The Company accounts for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years.

RSUs are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. The Company recognizes stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years.

All stock options and RSUs granted prior to January 1, 2020 will maintain the estimated forfeiture approach and will be recognized over the requisite service period using the straight-line method.

The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.52% - 1.39%

 

 

0.36% - 1.69%

 

 

1.68% - 2.50%

 

Assumed volatility

 

74.88% - 83.32%

 

 

64.03% - 73.44%

 

 

72.30% - 73.50%

 

Expected option term

 

6.08 years

 

 

5.04 - 6.25 years

 

 

6.02 - 6.08 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Assumed risk-free interest rate

 

0.05% - 0.18%

 

 

0.18%

 

Assumed volatility

 

64.55% - 69.34%

 

 

68.44%

 

Expected option term

 

0.49 - 0.50 years

 

 

0.49 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

The Company recorded stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 Employee Stock Purchase Plan (the “ESPP”), and consultant options of $13.3 million, $5.0 million, and $1.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The total compensation cost related to non-vested awards not yet recognized as of December 31, 2021 was $38.4 million, which is expected to be recognized over a weighted average term of 2.83 years. 

(s) Warrant Liability

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants classified as liabilities and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a component of other income/(expense) in the consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes-Merton valuation model. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of its warrants. At that time, the portion of the warrant liability related to the Company’s warrants will be reclassified to additional paid-in capital.

The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.46% - 0.85%

 

 

0.22% - 0.33%

 

 

1.40% - 1.66%

 

Assumed volatility

 

85.85% - 90.70%

 

 

69.79% - 79.26%

 

 

64.06% - 66.68%

 

Expected term

 

2.66 - 3.42 years

 

 

3.66 - 4.42 years

 

 

4.67 - 5.00 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

 

(t) Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):

Fair Value Measurements at Reporting Date

 

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

16,380

 

 

$

—

 

 

$

—

 

 

$

16,380

 

Restricted cash

 

 

3,025

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

15,352

 

 

 

—

 

 

 

15,352

 

Municipal securities

 

 

—

 

 

 

7,412

 

 

 

—

 

 

 

7,412

 

U.S. government debt securities

 

 

—

 

 

 

25,685

 

 

 

—

 

 

 

25,685

 

Total marketable securities, available for sale

 

 

—

 

 

 

48,449

 

 

 

—

 

 

 

48,449

 

Total assets measured at fair value on a recurring basis

 

$

19,405

 

 

$

48,449

 

 

$

—

 

 

$

64,829

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

448

 

 

$

—

 

 

$

—

 

 

$

448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

8,940

 

 

 

—

 

 

 

8,940

 

Municipal securities

 

 

—

 

 

 

7,324

 

 

 

—

 

 

 

7,324

 

U.S. government debt securities

 

 

—

 

 

 

23,265

 

 

 

—

 

 

 

23,265

 

Total marketable securities, available for sale

 

 

—

 

 

 

39,529

 

 

 

—

 

 

 

39,529

 

Total assets measured at fair value on a recurring basis

 

$

448

 

 

$

39,529

 

 

$

—

 

 

$

39,977

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

 

The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.

The fair value of the Private SPAC Warrants was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

 

Balance as of December 31, 2019

 

$

628

 

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(206

)

Change in fair value of warrant liability

 

 

1,228

 

Balance as of December 31, 2020

 

 

1,650

 

Derecognition of warrant liability from exercise of Private SPAC Warrants

 

 

(2,158

)

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(434

)

Change in fair value of warrant liability

 

 

1,088

 

Balance as of December 31, 2021

 

$

146

 

As of December 31, 2021 and 2020, the Company maintains letters of credit of $3.0 million and zero, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the Company’s consolidated balance sheets.

The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.

(u)

Accounting Pronouncement Recently Adopted

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes FASB ASC Topic 840, Leases (“ASC 840”), and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted ASC 842 during the third quarter of 2021 effective as of January 1, 2021. The Company has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented.

Adoption of ASU 2016-02 did not result in a cumulative adjustment to the Company’s accumulated deficit as of January 1, 2021. Adoption of ASU 2016-02 resulted in the recording of an operating lease ROU assets and lease liabilities of $2.8 million and $3.1 million, respectively. The difference between the operating lease ROU assets and lease liabilities are due to accrued deferred rent and unamortized lease incentives. Finance lease right-of-use assets and lease liabilities recognized as of January 1, 2021, included preexisting assets and liabilities of $0.3 million, related to finance leases accounted for under ASC 840. Adoption of ASU 2016-02 did not have a material impact on the Company’s results of operations or cash flows.

The Company elected to use the transition package of three practical expedients, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, under ASC 842, the further practical expedient not to separate non-lease components from the lease components to which they relate and instead to combine them and account for them as a single lease component. The Company also elected the accounting policy election to keep leases with a term of 12 months or less off the balance sheet and to recognize payments for those leases on a straight-line basis over the lease term. The underlying assets of the Company’s leases as of the adoption date consisted of operating facilities and laboratory equipment.

Judgment was exercised in the application of ASC 842 with respect to the determination of whether a contract contains a lease. While the ability to control and direct the use of an identified asset indicates that the contract, or portion of a contract, is a lease, a counterparty’s substantive substitution rights typically provide evidence that a lessee does not control the asset. Judgment was also exercised with respect to the determination of the discount rate used to determine the present value of lease payments. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a similar economic environment. The Company has no debt and has not had an established incremental borrowing rate. For the purpose of

estimating the incremental borrowing rate in the adoption of ASC 842, required management judgment including the development of a synthetic credit rating and cost of debt as we currently do not carry any debt. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. Previously, when credit losses were measured under U.S. GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires companies to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. 

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted the guidance under ASU 2016-13 during the fourth quarter of 2021 and applied the modified retrospective method of adoption to the Company’s financial statements as of January 1, 2021. Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures and no cumulative adjustment was required to be recorded to the Company’s accumulated deficit as of January 1, 2021.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The Company adopted this guidance during the fourth quarter of 2021 with no material impact to the Company's consolidated financial statements.

 

(v)

Accounting Pronouncements Issued But Not Yet Effective

In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company plans to adopt the standard on January 1, 2022. The Company is currently evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company’s consolidated financial statements.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Details

2. Balance Sheet Details

Short-Term Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 were as follows (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

15,385

 

 

$

—

 

 

$

(33

)

 

$

15,352

 

Municipal securities

 

 

7,417

 

 

 

—

 

 

 

(5

)

 

 

7,412

 

U.S. government debt securities

 

 

25,771

 

 

 

1

 

 

 

(87

)

 

 

25,685

 

Total short-term marketable securities,

   available-for-sale

 

$

48,573

 

 

$

1

 

 

$

(125

)

 

$

48,449

 

 

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2020 were as follows (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

8,946

 

 

$

—

 

 

$

(6

)

 

$

8,940

 

Municipal securities

 

 

7,325

 

 

 

1

 

 

 

(2

)

 

 

7,324

 

U.S. government debt securities

 

 

23,259

 

 

 

6

 

 

 

—

 

 

 

23,265

 

Total short-term marketable securities,

   available-for-sale

 

$

39,530

 

 

$

7

 

 

$

(8

)

 

$

39,529

 

 

As of December 31, 2021, the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that we held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months. As of December 31, 2020, the estimated market value of debt securities with contractual maturities of less than twelve months was $37.3 million; the remaining debt securities that we held at that date had an estimated market value of $2.3 million and contractual maturities of up to 14 months.

Gross realized gains and losses on our debt securities for the twelve months ended December 31, 2021 and 2020 were not significant.

 

Prepaid Expenses and PP&E

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

Prepaid insurance

 

$

1,801

 

 

$

1,172

 

Prepaid trade shows

 

 

440

 

 

 

—

 

Prepaid software fees

 

 

551

 

 

 

214

 

Deferred issuance costs

 

 

—

 

 

 

56

 

Prepaid employee compensation

 

 

238

 

 

 

—

 

Other current assets

 

 

136

 

 

 

79

 

Total prepaid expenses and other current assets

 

$

3,166

 

 

$

1,521

 

Property and equipment, gross:

 

 

 

 

 

 

 

 

Laboratory equipment

 

$

4,805

 

 

$

2,544

 

Computer equipment

 

 

171

 

 

 

38

 

Furniture and fixtures

 

 

124

 

 

 

109

 

Leasehold improvements

 

 

1,074

 

 

 

727

 

Total property and equipment, gross

 

 

6,174

 

 

 

3,418

 

Less accumulated depreciation

 

 

(1,625

)

 

 

(687

)

Total property and equipment, net

 

$

4,549

 

 

$

2,731

 

 

 

 

Accrued Compensation and Accrued Liabilities

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Accrued compensation:

 

 

 

 

 

 

 

 

Accrued paid time off

 

$

1,245

 

 

$

606

 

Accrued bonus and deferred compensation

 

 

3,875

 

 

 

1,469

 

Total accrued compensation

 

$

5,120

 

 

$

2,075

 

Accrued liabilities:

 

 

 

 

 

 

 

 

Accrued consulting services

 

$

775

 

 

$

285

 

Other accrued expenses

 

 

452

 

 

 

478

 

Total accrued liabilities

 

$

1,227

 

 

$

763

 

 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Debt

3. Debt

2018 Convertible Bridge Notes

From August to November 2018, DermTech Operations issued $6.8 million aggregate principal amount of convertible bridge notes (“2018 Bridge Notes”), resulting in $6.6 million in net proceeds. The 2018 Bridge Notes carried a 10% interest rate and matured on March 31, 2019. Since the 2018 Bridge Notes were not paid or converted by March 31, 2019, the interest rate increased to 15%.

The 2018 Bridge Notes were subject to automatic conversion into equity securities of DermTech Operations at the closing of a single capital raising transaction or series of related capital raising transactions in which DermTech Operations issued equity securities with aggregate gross proceeds to DermTech Operations of at least $20 million (“Qualified Financing”) that occurred on or prior to the maturity date. Upon automatic conversion of these 2018 Bridge Notes, the note holders were entitled to receive shares of DermTech Operations’ equity securities equal to the quotient obtained by dividing the unpaid principal amount of these 2018 Bridge Notes plus interest accrued but unpaid by the lesser of:

 

1)

the lowest price per share of the new stock paid in the Qualified Financing by investors multiplied by 70%.

 

2)

the price per share obtained by dividing $45 million by DermTech Operations’ fully-diluted capitalization immediately prior to such Qualified Financing assuming exercise or conversion of all outstanding options and issuance of all outstanding restricted stock unit awards, including all shares of common stock reserved and available for future grant under any equity incentive plan of the Company, and/or any equity incentive or similar plan to be created or increased in connection with the Qualified Financing, but excluding any shares issuable upon exercise of the DermTech Operations’ outstanding common stock warrants or conversion of the 2018 Bridge Notes.

Several of the embedded features of the 2018 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2018 Bridge Notes as a derivative liability on the consolidated balance sheet. DermTech Operations assigned a value to the debt component of the 2018 Bridge Notes equal to the difference between the estimated fair value of the 2018 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2018 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2018 Bridge Notes was determined to be $2.5 million. DermTech Operations amortized the debt discount over the contractual life (i.e., March 31, 2019) of the 2018 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2018 Bridge Notes (i.e., the derivative liability) and changes in the fair value are recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were zero and $0.4 million for the years ended December 31, 2020 and 2019, respectively.

On May 23, 2019, DermTech Operations and the various convertible 2018 Bridge Note holders agreed to amend the outstanding convertible notes that were issued in the last half of 2018. As part of the amendment, the maturity dates of the notes were extended to the earliest of (i) September 24, 2019; (ii) the occurrence of an Event of Default (as defined in the 2018 Bridge Notes); (iii) the consummation of a liquidation or dissolution of DermTech Operations (iv) a Liquidation Transaction (as defined in the 2018 Bridge Notes); or (v) the consummation of a merger with or into the Company or any of its subsidiaries.

In addition, immediately prior to the consummation of a DermTech Operations merger with or into the Company or any of its subsidiaries substantially on the terms contemplated as of the date of the amendment to the outstanding convertible notes on or before September 24, 2019 (a “Qualifying Merger”), the outstanding principal amount of and all accrued but unpaid interest on each of the convertible notes would automatically be converted into shares of the DermTech Operations’ common stock at a price per share equal to 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means (i) the lesser of $6.46 and (ii) the offering price per share of the private investment in public equity (“PIPE”) transaction to be consummated concurrently with the consummation of the Qualifying Merger multiplied by the Conversion Ratio. For the purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of fully diluted shares of the Company as of immediately after the conversion of the notes.

This new embedded Qualifying Merger feature of the 2018 Bridge Notes was identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract with the previously identified embedded features that met the criteria of being a derivative. In addition, this amendment was accounted for as a debt modification of the existing 2018 Bridge Notes.

2019 Convertible Bridge Notes

Between June 5th and June 10th, 2019, DermTech Operations issued additional convertible bridge notes (the “2019 Bridge Notes”) to existing investors for aggregate gross proceeds of $2.6 million. These convertible bridge notes carried an interest rate of 10% and matured after the earliest to occur of: (i) September 25, 2019; (ii) the occurrence of an Event of Default; (iii) the consummation of a liquidation or dissolution of DermTech Operations; (iv) a Liquidation Transaction; or (v) the consummation of a merger of DermTech Operations with Merger Sub, a subsidiary of the Company, in accordance with the Merger Agreement.

The unpaid principal amount of these convertible bridge notes together with any interest accrued but unpaid thereon, would automatically be converted into shares of DermTech Operations’ common stock immediately prior to the consummation of a Qualifying Merger. Upon the conversion of these notes, the note holders were entitled to receive a number of shares of DermTech Operations’ common stock equal to the quotient obtained by dividing (i) the unpaid principal amount of these notes plus interest accrued but unpaid thereon, by (1) if the Qualifying Merger consummates prior to the maturity date, the lesser of (x) $5.80 and (y) 90% of the Merger Consideration (as defined below), or (2) if the Qualifying Merger consummates on or after the maturity date, the lesser of (x) $4.51 and (y) 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means the offering price per share of the PIPE transaction between Constellation and the investors thereto, consummated substantially concurrently with the consummation of the Qualifying Merger, multiplied by the Conversion Ratio (as defined below). For purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of the Company’s fully diluted shares immediately prior to the consummation of the Qualifying Merger, assuming exercise of all outstanding options, issuance of all common stock underlying outstanding restricted stock unit awards, exercise of all outstanding warrants, and conversion of all outstanding convertible promissory notes, including these notes and any other note of substantially the same form, but excluding all shares of DermTech Operations’ common stock reserved and available for future grant under any equity incentive or similar plan of DermTech Operations, and in each case as adjusted for stock splits, combinations and similar transactions, all calculated in accordance with the final allocation schedule delivered in connection with the Qualifying Merger.

Several of the embedded features of the 2019 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2019 Bridge Notes as a derivative liability on the consolidated balance sheet. The Company assigned a value to the debt component of the 2019 Bridge Notes equal to the difference between the estimated fair value of the 2019 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2019 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2019 Bridge Notes was determined to be $0.3 million. DermTech Operations amortized the debt discount over the contractual life (i.e., September 25, 2019) of the 2019 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2019 Bridge Notes (i.e., the derivative liability) and changes in the fair value were recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were of zero and $14,000 for the years ended December 31, 2020 and 2019, respectively.

Exchange of Convertible Debt for Common Shares

On August 29, 2019, immediately prior to the completion of the Business Combination, all unpaid principal and interest on the 2019 Bridge Notes and the 2018 Bridge Notes (collectively, the “Bridge Notes”) was converted into 2,267,042 common shares of DermTech Operations.

The conversion of the Bridge Notes debt for common shares of DermTech Operations was accounted for as an extinguishment of the Bridge Notes. The conversion resulted in DermTech Operations having legally settled the debt obligations. DermTech Operations’ equity was increased by the settlement-date fair value of the common shares issued. Certain bifurcated embedded derivative instruments also were settled as part of the transaction.

The net carrying amounts of the Bridge Notes, including remaining unamortized debt discount and issuance costs, and the bifurcated embedded derivative liability were extinguished on the date of the Business Combination. A gain on debt extinguishment of

$0.9 million was recognized, which represented the unamortized debt discounts and issuance costs remaining at the time of the debt extinguishment.

There was no liability balance for the Company’s 2019 Bridge Notes or 2018 Bridge Notes as of December 31, 2021 and 2020.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity
 12 Months Ended
Dec. 31, 2021
Stockholders Equity Note [Abstract]  
Convertible Preferred Stock and Stockholders' Equity

4. Convertible Preferred Stock and Stockholders’ Equity

(a)

Classes of Stock

The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share.

(c)

Series A Convertible Preferred Stock Financing  

In connection with the 2019 private placement of equity securities of the Company on August 29, 2019, immediately following the completion of the Business Combination, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series A Convertible Preferred Stock (the “Series A Certificate of Designation”). An aggregate of 1,231 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $4.0 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 1,231 shares of Series A Preferred Stock into 615,385 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series A Convertible Preferred Stock.

(d)

2020 PIPE Financing

On February 28, 2020, the Company entered into a securities purchase agreement with certain institutional investors for a private placement of the Company’s equity securities (the “2020 PIPE Financing”). Cowen and Company, LLC (“Cowen”) served as lead placement agent for the 2020 PIPE Financing, with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent. The 2020 PIPE Financing closed on March 4, 2020.

The 2020 PIPE Financing consisted of 2,467,724 shares of common stock at a price of $10.50 per share, 3,199 shares of Series B-1 Convertible Preferred Stock (the “Series B-1 Shares”) at a price of $10,500 per share, and 524 shares of Series B-2 Convertible Preferred Stock (the “Series B-2 Shares”) at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, reduced by $5.1 million in issuance costs.

Prior to the closing of the 2020 PIPE Financing, the Company designated (i) 3,200 shares of its authorized and unissued preferred stock as Series B-1 Convertible Preferred Stock by filing the Series B-1 Certificate of Designation with the Delaware Secretary of State and (ii) 525 shares of its authorized and unissued preferred stock as Series B-2 Convertible Preferred Stock by filing the Series B-2 Certificate of Designation with the Delaware Secretary of State.

(e)

Series B-1 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing

In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-1 Convertible Preferred Stock (the “Series B-1 Certificate of Designation”). An aggregate of 3,199 shares of Series B-1 Convertible Preferred Stock for an aggregate purchase price of $33.6 million were issued to certain accredited investors.

At the Company’s annual meeting held on May 26, 2020, the Company’s stockholders voted to approve the 2020 PIPE Financing. As a result, on May 27, 2020 the 3,199 outstanding shares of Series B‑1 Convertible Preferred Stock were automatically converted into an aggregate of 3,198,949 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-1 Convertible Preferred Stock.

(f)

Series B-2 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing

In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-2 Convertible Preferred Stock (the “Series B-2 Certificate of Designation”). An aggregate of 524 shares of Series B-2 Convertible Preferred Stock for an aggregate purchase price of $5.5 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 524 shares of Series B‑2 Preferred Stock into 523,814 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-2 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-2 Convertible Preferred Stock.

(g)

At-The Market Offering

On November 10, 2020, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million.

(h)

2021 Underwritten Public Offering

On January 6, 2021, the Company entered into an Underwriting Agreement with Cowen and William Blair & Company, L.L.C. as representatives of several underwriters (the “Underwriters”). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.

(i)

Warrants

SPAC Warrants

The Company previously issued a total of 14,936,250 SPAC Warrants to purchase common stock in public offering and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 Public SPAC Warrants and as part of the private placement offering, the Company issued 561,250 Private SPAC Warrants. The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.

The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.

In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 and 14,936,250 as of December 31, 2021 and 2020, respectively. Private SPAC Warrants that were still owned by the original holder totaled 80,350 and 323,500 as of December 31, 2021 and 2020, respectively.

Series C Warrants

In connection with DermTech Operations’ Series C Preferred Stock financing that took place between 2016 and 2018, each investor that purchased at least $1 million of Series C Convertible Preferred Stock in a single closing received a three-year warrant to purchase shares of common stock at an exercise price of $9.54 per share in the amount equal to 20% of shares of Series C Preferred Stock purchased. Outstanding Series C warrants totaled zero and 97,563 as of December 31, 2021 and 2020, respectively.

Placement Agent Warrants

In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled and 10,039 and 31,365 as of December 31, 2021 and 2020, respectively.

(j)

Stock-Based Compensation

2010 Stock Plan

In connection with the Business Combination, the Company assumed the DermTech Operations’ Amended and Restated 2010 Stock Plan (the “2010 Plan”), which provided for the granting of incentive and non-statutory stock options and restricted stock purchase rights and bonus awards. Under the 2010 Plan, incentive and non-statutory stock options were granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. For incentive stock options granted to a ten percent shareholder under the 2010 Plan, the exercise price was not less than 110% of the fair market value of a share of stock on the effective date of grant. DermTech Operations initially reserved 1.0 million shares of common stock for issuance to its employees, non-employee directors and consultants. The 2010 Plan included a provision which annually increased the amount of common stock reserved for issuance under the 2010 Plan. The contractual term of options granted under the 2010 Plan was ten years. Vesting provisions varied based on the specific terms of the individual option awards. At the Company’s annual meeting held on May 26, 2020, the Company’s shareholders voted to approve the DermTech, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), which terminated the 2010 Plan. No additional awards will be granted under the 2010 Plan, however, all outstanding awards under the 2010 Plan remain in effect. No shares remained available for issuance pursuant to future grants under the 2010 Plan as of both December 31, 2021 and 2020.

2020 Equity Incentive Plan

On May 26, 2020, the Company’s stockholders approved the adoption of the 2020 Plan, which provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.  

The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards. 602,955 shares remained available for future grant under the 2020 Plan as of December 31, 2021.

The following table summarizes stock option transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total options

 

 

Weighted

average

exercise price

 

 

Weighted

average

remaining

contractual term

(in years)

 

 

Aggregate

intrinsic

value (in

thousands)

 

Outstanding at December 31, 2019

 

 

443,547

 

 

$

3.84

 

 

 

7.80

 

 

$

3,796

 

Granted

 

 

1,285,183

 

 

 

12.25

 

 

 

 

 

 

 

 

 

Exercised

 

 

(143,995

)

 

 

3.29

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(32,252

)

 

 

8.28

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

1,552,483

 

 

$

10.76

 

 

 

8.91

 

 

$

33,656

 

Granted

 

 

486,104

 

 

 

43.36

 

 

 

 

 

 

 

 

 

Exercised

 

 

(196,333

)

 

 

5.98

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(121,622

)

 

 

12.78

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options vested and expected to vest as of December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options exercisable as of December 31, 2021

 

 

607,127

 

 

$

10.16

 

 

 

7.59

 

 

$

3,523

 

 

The following table summarizes RSU transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total RSUs

 

 

Weighted

average grant

date fair value

per share

 

Outstanding at December 31, 2019

 

 

—

 

 

$

—

 

Granted

 

 

739,962

 

 

 

12.47

 

Released

 

 

(175,527

)

 

 

11.60

 

Forfeited

 

 

(3,938

)

 

 

11.41

 

Outstanding at December 31, 2020

 

 

560,497

 

 

$

12.75

 

Granted

 

 

718,053

 

 

 

34.09

 

Released

 

 

(277,259

)

 

 

14.20

 

Forfeited

 

 

(17,888

)

 

 

38.03

 

Outstanding at December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested and expected to vest as of December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested, but not yet issued as of December 31, 2021

 

 

12,632

 

 

$

41.81

 

2020 Employee Stock Purchase Plan

On May 26, 2020, the Company’s stockholders approved the adoption of the ESPP, which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. Eligible employees enroll in a six-month offering period during the open enrollment period prior to the start of that offering period. A new offering period begins approximately every March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period.

The ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors, subject to adjustment upon changes in capitalization of the Company. On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the ESPP. As of December 31, 2020, 400,000 shares of common stock were reserved for future issuance under the ESPP. On January 1, 2021, an additional 207,404 shares became available under the ESPP pursuant to an automatic annual increase. 549,289 shares remained available for future grant under the ESPP as of December 31, 2021.

Management Warrants

Warrants to purchase DermTech Operations common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten year life and are exercisable for Company common stock at $1.08 per share. The Management Warrants vested monthly over a four-year period. Outstanding Management Warrants totaled 20,320 and 22,320 at December 31, 2021 and 2020, respectively.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Warrants to purchase common stock

 

 

31

 

 

 

151

 

SPAC Warrants to purchase common stock*

 

 

704

 

 

 

3,734

 

Stock options issued and outstanding

 

 

1,721

 

 

 

1,552

 

Restricted stock units issued and outstanding

 

 

983

 

 

 

560

 

Authorized for future equity grants

 

 

603

 

 

 

935

 

Authorized for future ESPP purchases

 

 

549

 

 

 

400

 

Total common stock reserved for future issuance

 

 

4,591

 

 

 

7,332

 

 

*

Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.   
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

5. Income Taxes

The Company has reported net losses since inception, and therefore, the minimum provision for state income taxes has been recorded. The following table provides a reconciliation between income taxes computed at the federal statutory rate of 21% at December 31, 2021, 2020, and 2019, and the Company’s provision for income taxes.

 

 

 

Year ended December 31

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax at statutory rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State tax, net of federal tax benefit

 

 

4.8

 

 

 

4.9

 

 

 

—

 

Permanent items

 

 

1.1

 

 

 

(0.1

)

 

 

(0.8

)

Tax credits

 

 

0.6

 

 

 

0.4

 

 

 

0.2

 

Other

 

 

(0.4

)

 

 

(0.5

)

 

 

—

 

Valuation allowance (decrease) increase

 

 

(27.1

)

 

 

(25.7

)

 

 

(20.4

)

Income tax expense

 

 

—

%

 

 

—

%

 

 

—

%

 

Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31, 2021, 2020, and 2019 are shown below (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

 

December 31,

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss

 

$

46,886

 

 

$

28,422

 

 

$

20,336

 

Research and development credits

 

 

2,411

 

 

 

1,631

 

 

 

1,400

 

Depreciation and amortization

 

 

—

 

 

 

14

 

 

 

33

 

Stock based compensation

 

 

2,126

 

 

 

653

 

 

 

119

 

Accruals and other

 

 

719

 

 

 

422

 

 

 

194

 

Operating lease liability

 

 

1,935

 

 

 

—

 

 

 

—

 

Deferred revenue

 

 

340

 

 

 

—

 

 

 

—

 

Total deferred tax assets

 

 

54,417

 

 

 

31,142

 

 

 

22,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

(32

)

 

 

—

 

 

 

—

 

Operating lease right-of-use assets

 

 

(1,972

)

 

 

—

 

 

 

—

 

Total deferred tax liabilities

 

 

(2,004

)

 

 

—

 

 

 

—

 

Net deferred tax assets before valuation allowance

 

 

52,413

 

 

 

31,142

 

 

 

22,082

 

Less: valuation allowance

 

 

(52,413

)

 

 

(31,142

)

 

 

(22,082

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

$

—

 

 

The Company maintains a full valuation allowance against its net deferred tax assets as realization of such assets is not more likely than not.

At December 31, 2021, 2020, and 2019, the Company had federal tax net operating loss (“NOL”) carryforwards of approximately $184.0 million, $110.8 million, and $79.4 million, respectively, as well as state tax NOL carryforwards at December 31, 2021, 2020, and 2019 of approximately $141.1 million, $84.3 million, and $53.4 million, respectively. Federal NOL carryforwards began to expire during 2021 while the Company’s state NOL carryforwards begin to expire during various years, dependent on the jurisdiction.

The Company also had federal income tax R&D and other tax credit carryforwards at December 31, 2021, 2020, and 2019 of approximately $1.4 million, $0.9 million, and $0.8 million, respectively, and state income tax R&D and other tax credits of approximately $1.3 million, $0.9 million, and $0.8 million at December 31, 2021, 2020, and 2019, respectively. The federal credit carryforwards began to expire during 2021 and the state credit carryforwards do not expire. The Company has not performed a formal study validating its federal and state R&D tax credits and upon preparation, such tax credit carryforwards could vary from what was originally claimed on applicable income tax returns.

The utilization of NOL and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (IRC), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.

The Company conducts intensive research and experimentation activities, generating research tax credits for federal and state purposes under IRC Section 41. The Company has not performed a formal study validating such credits claimed on its tax returns. Once a study is completed, the amount of R&D tax credits available could vary from what was originally claimed on the tax returns.

Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination for all years since inception.

The Company records uncertain tax positions on the basis of a two-step process in which it determines whether it is more likely than not tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more likely than not recognition threshold the Company would recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it has no uncertain tax positions as of December 31, 2021, 2020, and 2019. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.

On December 27, 2020, President Trump signed into law the Consolidated Appropriations Act, 2021 (“CAA 2021”), which included a number of provisions including, but not limited to the extension of numerous employment tax credits, the extension of the

Section 179D deduction, enhanced business meals deductions, and the deductibility of expenses paid with Paycheck Protection Program (“PPP”) loan funds that are forgiven. The effects of the CAA 2021 have been incorporated into the income tax provision for the year ended December 31, 2021. These provisions did not have a material impact on the income tax provision.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Leases, Commitments and Contingencies

6. Leases, Commitments and Contingencies

Finance Leases

The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net on the accompanying consolidated balance sheets. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Total finance lease interest expense was approximately $17,000, $3,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively, and is included within interest income, net on the consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Gross finance lease obligations

 

$

274

 

 

$

362

 

Less: imputed interest

 

 

(17

)

 

 

(27

)

Present value of net minimum lease payments

 

 

257

 

 

 

335

 

Less: current portion of finance lease obligations

 

 

(121

)

 

 

(109

)

Total long-term finance lease obligations

 

$

136

 

 

$

226

 

 

Operating Leases

Del Mar Heights Lease

On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Lease will serve as the Company’s new principal office.

The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease (the “Lease Commencement Date”). The Company has the option to extend the term of the Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.

As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.

During the year ended December 31, 2021, the Company took initial possession of the first phase of what is expected to become its corporate headquarters, and the Company capitalized a right-of-use asset and related lease liability of $5.7 million associated with the first phase. The extension option periods were not considered in the determination of the right-of-use asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $63.3 million related to corporate office facilities that were in the process of being built-out as of December 31, 2021. The lease liabilities and the corresponding right-of-use assets associated with these lease obligations will be recorded upon the commencement date of the operating leases.

In connection with this operating lease, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit totaling $3.0 million and is included in restricted cash on the consolidated balance sheet based on the term of the underlying lease. As of December 31, 2021, none of the standby letter of credit amount has been used.

 

Torrey Pines Lease

In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.

The lease term for all leased space has an expiration date of April 30, 2023, and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term. On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a right-of-use asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The right-of-use asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a right-of-use asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.

The components of lease expense for the year ended December 31, 2021 was as follows (in thousands):

 

Lease Cost

 

Year Ended

December 31, 2021

 

Operating lease cost

 

 

 

 

Operating lease cost

 

$

1,517

 

Variable lease costs

 

 

657

 

Total operating lease cost

 

$

2,174

 

 

 

 

 

 

Finance lease cost

 

 

 

 

Amortization of leased assets

 

$

75

 

Interest on lease liabilities

 

 

17

 

Total finance lease cost

 

$

92

 

 

 

 

 

 

Other information

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities

 

 

 

 

Operating cash flows from operating leases

 

$

2,619

 

Operating cash flows from finance leases

 

$

17

 

Financing cash flows from finance leases

 

$

171

 

Right-of-use assets obtained in exchange for new operating lease obligations

 

$

9,044

 

Right-of-use assets obtained in exchange for new finance lease obligations

 

$

93

 

 

 

 

 

 

Weighted-average remaining lease term of operating leases (in years)

 

 

9.33

 

Weighted-average remaining lease term of finance leases (in years)

 

 

2.34

 

Weighted-average discount rate for operating leases

 

 

5.78

%

Weighted-average discount rate for finance leases

 

 

5.63

%

 

 

The Company’s future minimum lease payments under operating and finance leases at December 31, 2021 are as follows (in thousands):

 

 

 

2022

 

 

2023

 

 

2024

 

 

2025

 

 

2026

 

 

Thereafter

 

 

Total

 

Operating lease obligations, including interest

 

$

1,802

 

 

$

1,149

 

 

$

688

 

 

$

709

 

 

$

730

 

 

$

4,928

 

 

$

10,006

 

Finance lease obligations, including interest

 

 

132

 

 

 

122

 

 

 

8

 

 

 

8

 

 

 

4

 

 

 

—

 

 

 

274

 

Total future minimum lease payments

 

$

1,934

 

 

$

1,271

 

 

$

696

 

 

$

717

 

 

$

734

 

 

$

4,928

 

 

$

10,280

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of December 31, 2021.

 

Deferred Underwriting Fees

In connection with the execution of the Merger Agreement, the Company, DermTech Operations and Cowen entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which the Company agreed to assign to DermTech Operations, and DermTech Operations agreed to assume, the Company’s obligations under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among the Company and Cowen. On September 4, 2019, the Company, DermTech Operations and Cowen amended the Deferred Underwriting Fee Assignment Agreement, pursuant to which the Company paid Cowen $0.8 million for the reduction of the balance owed by the Company to Cowen under the Underwriting Agreement to $1.4 million.

Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, as amended, if the Company were to raise at least $15.0 million in proceeds received from equity financings consummated prior to the one-year anniversary of the Business Combination, excluding the proceeds received from any financing consummated prior to or simultaneous with the Business Combination, then the Company would pay to the underwriters $1.4 million within one week of the one-year anniversary of the Business Combination. In connection with the Company’s 2020 PIPE Financing, the Company raised $65.0 million in gross proceeds, which satisfied this condition of the Deferred Underwriting Fee Assignment Agreement. On September 2, 2020, the Company paid the underwriters $1.4 million in satisfaction of the Company’s obligation of the deferred underwriting fees in full. No further payment will be required of the Company in connection with the deferred underwriting fees.

Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business.  Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Retirement Plan
 12 Months Ended
Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]  
Retirement Plan

7. Retirement Plan

The Company has an IRC Section 401(k) retirement plan, covering all eligible employees. The Company did not offer a contribution percentage match during 2021 and 2020.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

8. Related Party Transactions

During 2019, 2020, and 2021, the Company engaged EVERSANA Life Science Services, LLC, (“EVERSANA”), to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $2.6 million, $1.3 million, and $0.4 million in costs for the year ended December 31, 2021, 2020, and 2019, respectively.

On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month for the period May 11, 2020 through September 30, 2020 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2020 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of $20,000. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred $0.1 million, $0.2 million, and $20,000 in costs for the year ended December 31, 2021, 2020, and 2019, respectively.  

There were no other related party transactions identified for the years ended December 31, 2021, 2020, or 2019.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

9. Subsequent Events

The Company considered subsequent events through March 10, 2022, the date the consolidated financial statements were available to be issued.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Nature of Operations

(a)

Nature of Operations

On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock (“Reverse Stock Split”).

The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.

From the end of the first quarter of 2020 and through the fourth quarter of 2021, there has been a widespread worldwide impact from the COVID-19 pandemic. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company has implemented additional safety measures in accordance with Centers for Disease Control and Prevention (“CDC”), Occupational Safety and Health Administration (“OSHA”) and other guidance within its CLIA laboratory operations. Additionally, the Company has transitioned administrative functions to predominantly remote work. Beginning in March 2020 and continuing through the fourth quarter of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by the Company’s sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received during the fourth quarter of 2021 relative to the Company’s pre-pandemic expectations. The Company expects the ongoing COVID-19 pandemic to continue to adversely impact billable sample volume until patient access to in-person testing fully resumes, in-office access by the Company’s sales force returns to pre-pandemic levels, or telemedicine options are more widely adopted. Additionally, the ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect the Company’s pharmaceutical customers’ clinical trials. The extent of such effect on the Company’s future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on the Company’s pharmaceutical customers’ clinical trials.
Basis of Presentation

(b)

Basis of Presentation

The consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”). In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.

Revision to Prior Period Financial Statements

(c)

Revision to Prior Period Financial Statements  

As discussed under the heading “Revision to Prior Period Financial Statements” in Note 1 of the Company’s Quarterly Report on Form 10-Q filed on May 13, 2021, during the course of preparing the quarterly report Form 10-Q for the three months ended March 31, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The SEC Statement highlighted challenges associated with the accounting for complex financial instruments that may be common in SPACs, specifically accounting for warrants issued in connection with a SPAC’s formation and initial registered offering. In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity.

The Company previously issued warrants to purchase common stock in public and private placement offerings consummated on June 23, 2017 (the “SPAC Warrants”), which were originally classified as equity in the Company’s financial statements. As part of the aforementioned public offering, the Company issued 14,375,000 warrants (the “Public SPAC Warrants”) and as part of the aforementioned private placement offering, the Company issued 561,250 warrants (the “Private SPAC Warrants”). The SPAC Warrants have a five-year life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share. The Company’s SPAC Warrants were accounted for as equity within the Company’s previously reported consolidated balance sheets.

The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement.

Historically, the Private SPAC Warrants were recorded as a component of equity as opposed to liabilities on the Company’s consolidated balance sheets and the Company’s consolidated statements of operations did not include the subsequent non-cash changes in estimated fair value of the Private SPAC Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the recent SEC Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for SPAC Warrants issued on June 23, 2017, in light of the SEC Staff’s published views. After discussion and evaluation, the Company concluded that, as a result of these differences in features between the Public SPAC Warrants and Private SPAC Warrants, the Private SPAC Warrants should be classified as liabilities, if still held by the original Private SPAC Warrant holder, with subsequent changes in fair value reported in the Company’s consolidated statement of operations.

In addition, the Company analyzed the impact of the aforementioned adjustments on its previously issued audited consolidated financial statements for the years ended December 31, 2020 and 2019 and previously issued unaudited consolidated financial statements for the periods ended September 30, 2020 and 2019, June 30, 2020, and March 31, 2020 (such years and periods, the “Affected Periods”). The Company concluded the adjustments are not material to any individual period prior to the period ended March 31, 2021, taking into account the requirements of ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 270, Interim Financial Reporting, ASC Topic 250-S99-1, Assessing Materiality, and ASC Topic 250-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. In accordance with the authoritative guidance, management evaluated the materiality of the adjustments from a quantitative and qualitative perspective. Based on such evaluation, the Company concluded that the effects of these adjustments were not material individually or in the aggregate to the Affected Periods and had no effect on the trend of financial results. While management concluded the adjustment was not material to any prior periods, individually or in the aggregate, based on our qualitative and quantitative analysis, management opted to make the adjustment by revising the respective amounts that were previously reported in the Affected Period. Accordingly, the Company has revised the prior period interim and annual financial information for the Affected Periods to reflect these adjustments.

The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Balance Sheet as of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

628

 

 

 

628

 

Total liabilities

 

 

5,722

 

 

 

628

 

 

 

6,350

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

103,599

 

 

 

(187

)

 

 

103,412

 

Accumulated deficit

 

 

(91,111

)

 

 

(441

)

 

 

(91,552

)

Total stockholders’ equity

 

 

12,489

 

 

 

(628

)

 

 

11,861

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheet as of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

1,650

 

 

 

1,650

 

Total liabilities

 

 

6,290

 

 

 

1,650

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

189,849

 

 

 

19

 

 

 

189,868

 

Accumulated deficit

 

 

(126,360

)

 

 

(1,669

)

 

 

(128,029

)

Total stockholders’ equity

 

 

63,490

 

 

 

(1,650

)

 

 

61,840

 

The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):

 

 

Year Ended December 31, 2019

 

 

Year Ended December 31, 2020

 

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Statements of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

$

—

 

 

$

(441

)

 

$

(441

)

 

$

—

 

 

$

(1,228

)

 

$

(1,228

)

Total other income/(expense)

 

 

(2,084

)

 

 

(441

)

 

 

(2,525

)

 

 

40

 

 

 

(1,228

)

 

 

(1,188

)

Net loss

 

$

(19,689

)

 

$

(441

)

 

$

(20,130

)

 

$

(35,249

)

 

$

(1,228

)

 

$

(36,477

)

Net loss per share of common stock

  outstanding, basic and diluted

 

$

(2.81

)

 

$

(0.06

)

 

$

(2.87

)

 

$

(2.08

)

 

$

(0.07

)

 

$

(2.15

)

The consolidated statements of cash flow are not presented because there is no impact on total cash flows from operating activities, investing activities, or financing activities. Certain components of net cash used in operating activities changed, as caused by the revision, such as incorporating the non-cash item from the change in fair value of warrant liability in the adjustments to reconcile net loss to net cash used in operating activities, but the net change amounted to zero for the Affected Periods.
Use of Estimates

(d)

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to, those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

(e)

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.

Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

 

 

 

Year Ended December 31, 2021

 

 

Year Ended December 31, 2020

 

 

Year Ended December 31, 2019

 

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

Cash and cash equivalents

 

$

24,248

 

 

$

176,882

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

Restricted cash

 

 

—

 

 

 

3,025

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total cash, cash equivalents and restricted cash

   reported in the consolidated statements of

   cash flows

 

$

24,248

 

 

$

179,907

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

 
Marketable Securities

(f)   Marketable Securities

The Company considers securities with maturities of greater than 90 days at the time of purchase to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, such marketable securities are classified as current assets on the accompanying consolidated balance sheets even if they have contractual maturities greater than one year from the date of purchase. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost basis, which

may occur at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 2021.
Property and Equipment Property and Equipment

Property and equipment is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $1.0 million, $0.5 million, and $0.1 million, for the years ended December 31, 2021, 2020, and 2019, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $0.1 million, $10,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively.

Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the consolidated statement of operations. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. The Company disposed of $0.1 million, $0.1 million, and zero of equipment during the years ended December 31, 2021, 2020, and 2019, respectively. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the years ended December 31, 2021, 2020, and 2019.
Leases

(h)

Leases

The Company acts as lessee in its lease agreements, which include operating leases for corporate offices and finance leases for certain laboratory and office equipment.

In accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as adopted on January 1, 2021, the Company determines if an arrangement is a lease at inception. Finance leases are included in the consolidated balance sheets as property and equipment, net and finance lease obligations at the present value of the lease payments. Operating leases are included in the consolidated balance sheet as ROU assets and operating lease liabilities at the present value of the lease payments. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.

As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, the Company has used a number of factors including the credit rating, and the lease term.

The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of less than 2 years to 10 years, some of which include options to extend the lease for up to 10 years. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest income, net on the Company’s consolidated statements of operations.

The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.
Research and Development

(i)

Research and Development

Costs incurred in connection with research and development (“R&D”) activities are expensed as incurred. R&D expenses consist of (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; and (ii) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies.

The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses.

Concentration of Credit Risk

(j)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2021, the Company maintained $100.1 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $60.2 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of December 31, 2021. The Company has not experienced any losses in such accounts.

Income Taxes

(k)

Income Taxes

The Company provides for federal and state income taxes on the asset and liability approach which requires deferred tax assets and liabilities to be recognized based on temporary differences between the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year and prior year operating losses, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2021.

Current and deferred tax assets and liabilities are recognized based on the tax positions taken or expected to be taken in the Company’s income tax returns. U.S. GAAP requires that the tax benefits of an uncertain tax position can only be recognized when it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority. Tax benefits related to tax positions that do not meet this criterion are not recognized in the consolidated financial statements, of which there are none.

The Company recognizes interest and penalties related to income tax matters in income tax expense.  
Revenue Recognition

(l)

Revenue Recognition

The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.  

The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.

Assay Revenue

The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLAplus (now referred to as the “DermTech Melanoma Test” or “DMT”, which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLAplus) it provides to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in a limited number of states where permitted by law and applicable standards of practice guidelines.

Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the clinician detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.

Contracts

The Company’s customer is the patient. However, the Company does not enter into a formal reimbursement agreement with a patient, as formal reimbursement agreements are more commonly established with insurance payors. Accordingly, the Company establishes an agreement with a patient in accordance with other customary business practices.

 

•

Approval of an agreement is established by the use of the Company’s Smart Sticker on a patient by an ordering clinician, which is then sent to the Company’s central lab for testing.

 

 

•

The Company is obligated to perform the Company’s laboratory services upon receipt of a sample from a clinician, and the patient and/or applicable payor are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.

 

 

•

Payment terms are a function of a patient’s existing insurance benefits.

 

 

•

Once the Company delivers a patient’s test result to the ordering physician, the Company is legally able to collect payment and bill an insurer and/or patient, depending on payor agreement status or patient insurance benefit status.

 

 

•

The Company’s consideration is deemed to be variable, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.

Performance Obligations

A performance obligation is a promise in an agreement to transfer a distinct good or service (or a bundle of goods or services) to the customer. The customer is able to order a DMT, which is treated as a single performance obligation.

Transaction Price

The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both.

The consideration derived from the Company’s agreements is deemed to be variable, though the variability is not explicitly stated in any agreement. Rather, the implied variability is due to several factors, such as the amount of contractual adjustments, any patient co-payments, deductibles or patient compliance incentives, the existence of secondary payors and claim denials.

The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.

The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. Revenue recognized from changes in transaction prices was not material for the years ended December 31, 2021, 2020, and 2019, respectively.

The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for an agreement with a patient, it will account for the change as an increase in the estimate of the transaction price (i.e., an upward revenue adjustment) in the period identified. Similarly, if the Company subsequently determines that the amount it expects to collect from a patient is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price (i.e., a downward revenue adjustment), provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of a patient’s test result to the ordering physician, with recognition, generally occurring at the date of cash receipt.

Allocate the Transaction Price

The entire transaction price is allocated entirely to the single performance obligation contained within the agreement with a patient.

Recognize Revenue

The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful test result is delivered to the patient’s ordering physician. The Company considers this date to be the time at which the patient obtains control of the final results of the promised test service.

Contract Revenue

Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.

Contracts

As part of the Company’s contract revenue, the Company has established agreements and work orders with the Company’s third-party partners that fall under the scope of ASC 606.

Performance Obligations

ASC 606 requires an entity to assess the goods or services promised in a contract and identify as a performance obligation each promise to transfer to the customer either a good or service (or a bundle of goods or services) that is distinct, or a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Based upon review of existing contracts, a majority of the Company’s contract revenue agreements contain three performance obligations:

 

(1)

Smart Stickers

 

 

(2)

RNA extractions and analysis

 

 

(3)

Certain project management fees

Many of the Company’s contract revenue agreements contain promises such as start-up activities and quality system setup fees, which are activities that the Company performs to fulfill the agreement and they do not transfer any good or service to the customer. These promises encompass the administrative tasks associated with beginning and initiating a new project or study with a third-party company. In accordance with ASC 606, an entity does not account for these activities as a promised good or service within the agreement nor evaluate whether they are a performance obligation. 

Transaction Price

The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in an agreement with a customer may include fixed amounts, variable amounts, or both.

The transaction prices of the Company’s performance obligations are listed in its agreements on a per unit basis and are fixed for adhesive sample collection kits and RNA extractions and analysis. The project management fees are assessed based on a monthly service fee which range within the agreements depending on certain factors which include length of the project and the amount of Smart Stickers or RNA extractions and analysis promised within the agreement. The fixed and variable rates are materially consistent within the Company’s agreements. Therefore, the Company utilizes the prices listed in our agreements as the transaction price for each performance obligation.

In determining the transaction price, ASC 606 requires an entity to adjust the promised amount of consideration for the effects of the time value of money if the agreement contains a significant financing component. The Company’s agreements state fixed transaction prices for each deliverable associated with the agreement and do not qualify for the significant financing component of ASC 606.

Allocate the Transaction Price

The Company’s contracts have a directly observable transaction price pertaining to each promised good or service. Those prices are consistent across agreements for Smart Stickers and RNA extractions and analysis, with the exception of the Company’s project management fees, which the Company’s believes encompass a sufficiently narrow range of prices that are dictated upon factors of each agreement previously discussed above. Therefore, the Company relies on those transaction prices as the basis to allocate the stand-alone selling prices to the performance obligations of the agreement.

Most of the Company’s agreements contain a discount that is allocated to items within the agreement, whether they are performance obligations or not. Those items that are not performance obligations (e.g., quality system setup and start up fees) have the associated discount allocated to the transaction prices of the performance obligations evenly.

Recognize Revenue

An entity should recognize revenue when (or as) it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is transferred when (or as) the customer obtains control of that good or service. The Smart Stickers are recognized at a point in time when shipped to the customer. The RNA extraction and analysis are recognized at a point in time when the extraction and analysis process is complete and the results are sent to the customer. The Company provides its project management service over the life of the agreement, providing equal benefit to the customer throughout the life of the project or study. Therefore, the revenue related to the Company’s project management fees is recognized straight-line over the life of the agreement.

 

(a)

Disaggregation of Revenue

The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

DermTech Melanoma Test

 

$

11,023

 

 

$

4,241

 

 

$

1,403

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Smart Stickers

 

 

348

 

 

 

213

 

 

 

476

 

RNA extractions

 

 

300

 

 

 

1,172

 

 

 

626

 

Project management fees

 

 

166

 

 

 

258

 

 

 

336

 

Other

 

 

1

 

 

 

1

 

 

 

523

 

Total revenues

 

$

11,838

 

 

$

5,885

 

 

$

3,364

 

 

 

The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:

 

 

 

Total Revenue

 

 

Accounts Receivable

 

 

 

Year Ended December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payor A

 

 

36

%

 

 

32

%

 

*

 

 

 

23

%

 

 

21

%

Payor B

 

*

 

 

 

11

%

 

 

12

%

 

 

15

%

 

*

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer A

 

*

 

 

 

23

%

 

 

22

%

 

*

 

 

*

 

Customer B

 

*

 

 

*

 

 

*

 

 

*

 

 

 

17

%

Customer C

 

*

 

 

*

 

 

 

29

%

 

*

 

 

*

 

* Less than 10%

There were no other payors or customers that individually accounted for more than 10% of total revenue or accounts receivable for the periods shown in the table above.

(b)

Deferred Revenue and Remaining Performance Obligations

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets.

In a majority of agreements that produce contract revenue, the Company receives a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.

The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of December 31, 2021, and December 31, 2020, was $1.4 million and $0.9 million, respectively. Long-term deferred revenue as of December 31, 2021, and December 31, 2020, was zero and $0.6 million, respectively.

Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of December 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was approximately $0.4 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.
Accounts Receivable

(m)

Accounts Receivable

Assay Accounts Receivable

Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.6 million and $1.0 million of gross assay accounts receivable as of December 31, 2021 and 2020, respectively.

Contract Accounts Receivable

Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of December 31, 2021, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the

reserve. The Company recorded $0.2 million and $0.5 million of contract accounts receivable as of December 31, 2021 and 2020, respectively.

Freight and Shipping Costs

(n)

Freight and Shipping Costs

The Company records outbound freight and shipping costs for its contract and assay revenues in cost of revenues.

Comprehensive Loss

(o)

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net loss and the components of other comprehensive loss, including unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive loss.

Segment Reporting

(p)

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment.

Net Loss Per Share

(q)

Net Loss Per Share

Basic and diluted net loss per share is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the years ended December 31, 2021 and 2020, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the year ended December 31, 2021 excludes the effect of anti-dilutive equity instruments including 734,329 shares of common stock issuable upon the exercise of outstanding common stock warrants and 2,704,035 shares of common stock issuable upon the exercise stock options and release of RSUs. Diluted net loss per share of common stock for the year ended December 31, 2020 excludes the effect of anti-dilutive equity instruments including 3,885,311 shares of common stock then issuable upon the exercise of outstanding warrants and 2,112,980 shares of common stock then issuable upon the exercise of stock options and release of RSUs. Diluted net loss per common share for the year ended December 31, 2019 excludes the effect of anti-dilutive equity instruments including 615,385 shares of common stock issuable upon conversion of the Company’s preferred stock, 4,200,497 shares of common stock issuable upon the exercise of outstanding common stock warrants and 443,547 shares of common stock issuable upon the exercise stock options. The Company did not consider a two-class method of loss per share given that the Company’s convertible participating securities do not participate in losses.

Stock-Based Compensation

(r)

Stock-Based Compensation

Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis.

The Company grants stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.

The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of the Company’s common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future.

The Company accounts for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years.

RSUs are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. The Company recognizes stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years.

All stock options and RSUs granted prior to January 1, 2020 will maintain the estimated forfeiture approach and will be recognized over the requisite service period using the straight-line method.

The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.52% - 1.39%

 

 

0.36% - 1.69%

 

 

1.68% - 2.50%

 

Assumed volatility

 

74.88% - 83.32%

 

 

64.03% - 73.44%

 

 

72.30% - 73.50%

 

Expected option term

 

6.08 years

 

 

5.04 - 6.25 years

 

 

6.02 - 6.08 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Assumed risk-free interest rate

 

0.05% - 0.18%

 

 

0.18%

 

Assumed volatility

 

64.55% - 69.34%

 

 

68.44%

 

Expected option term

 

0.49 - 0.50 years

 

 

0.49 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

The Company recorded stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 Employee Stock Purchase Plan (the “ESPP”), and consultant options of $13.3 million, $5.0 million, and $1.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The total compensation cost related to non-vested awards not yet recognized as of December 31, 2021 was $38.4 million, which is expected to be recognized over a weighted average term of 2.83 years. 

Warrant Liability

(s) Warrant Liability

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants classified as liabilities and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a component of other income/(expense) in the consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes-Merton valuation model. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of its warrants. At that time, the portion of the warrant liability related to the Company’s warrants will be reclassified to additional paid-in capital.

The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.46% - 0.85%

 

 

0.22% - 0.33%

 

 

1.40% - 1.66%

 

Assumed volatility

 

85.85% - 90.70%

 

 

69.79% - 79.26%

 

 

64.06% - 66.68%

 

Expected term

 

2.66 - 3.42 years

 

 

3.66 - 4.42 years

 

 

4.67 - 5.00 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 
Fair Value Measurements

(t) Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):

Fair Value Measurements at Reporting Date

 

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

16,380

 

 

$

—

 

 

$

—

 

 

$

16,380

 

Restricted cash

 

 

3,025

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

15,352

 

 

 

—

 

 

 

15,352

 

Municipal securities

 

 

—

 

 

 

7,412

 

 

 

—

 

 

 

7,412

 

U.S. government debt securities

 

 

—

 

 

 

25,685

 

 

 

—

 

 

 

25,685

 

Total marketable securities, available for sale

 

 

—

 

 

 

48,449

 

 

 

—

 

 

 

48,449

 

Total assets measured at fair value on a recurring basis

 

$

19,405

 

 

$

48,449

 

 

$

—

 

 

$

64,829

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

448

 

 

$

—

 

 

$

—

 

 

$

448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

8,940

 

 

 

—

 

 

 

8,940

 

Municipal securities

 

 

—

 

 

 

7,324

 

 

 

—

 

 

 

7,324

 

U.S. government debt securities

 

 

—

 

 

 

23,265

 

 

 

—

 

 

 

23,265

 

Total marketable securities, available for sale

 

 

—

 

 

 

39,529

 

 

 

—

 

 

 

39,529

 

Total assets measured at fair value on a recurring basis

 

$

448

 

 

$

39,529

 

 

$

—

 

 

$

39,977

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

 

The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.

The fair value of the Private SPAC Warrants was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

 

Balance as of December 31, 2019

 

$

628

 

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(206

)

Change in fair value of warrant liability

 

 

1,228

 

Balance as of December 31, 2020

 

 

1,650

 

Derecognition of warrant liability from exercise of Private SPAC Warrants

 

 

(2,158

)

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(434

)

Change in fair value of warrant liability

 

 

1,088

 

Balance as of December 31, 2021

 

$

146

 

As of December 31, 2021 and 2020, the Company maintains letters of credit of $3.0 million and zero, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the Company’s consolidated balance sheets.

The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.
Accounting Pronouncement Recently Adopted

(u)

Accounting Pronouncement Recently Adopted

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes FASB ASC Topic 840, Leases (“ASC 840”), and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted ASC 842 during the third quarter of 2021 effective as of January 1, 2021. The Company has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented.

Adoption of ASU 2016-02 did not result in a cumulative adjustment to the Company’s accumulated deficit as of January 1, 2021. Adoption of ASU 2016-02 resulted in the recording of an operating lease ROU assets and lease liabilities of $2.8 million and $3.1 million, respectively. The difference between the operating lease ROU assets and lease liabilities are due to accrued deferred rent and unamortized lease incentives. Finance lease right-of-use assets and lease liabilities recognized as of January 1, 2021, included preexisting assets and liabilities of $0.3 million, related to finance leases accounted for under ASC 840. Adoption of ASU 2016-02 did not have a material impact on the Company’s results of operations or cash flows.

The Company elected to use the transition package of three practical expedients, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, under ASC 842, the further practical expedient not to separate non-lease components from the lease components to which they relate and instead to combine them and account for them as a single lease component. The Company also elected the accounting policy election to keep leases with a term of 12 months or less off the balance sheet and to recognize payments for those leases on a straight-line basis over the lease term. The underlying assets of the Company’s leases as of the adoption date consisted of operating facilities and laboratory equipment.

Judgment was exercised in the application of ASC 842 with respect to the determination of whether a contract contains a lease. While the ability to control and direct the use of an identified asset indicates that the contract, or portion of a contract, is a lease, a counterparty’s substantive substitution rights typically provide evidence that a lessee does not control the asset. Judgment was also exercised with respect to the determination of the discount rate used to determine the present value of lease payments. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a similar economic environment. The Company has no debt and has not had an established incremental borrowing rate. For the purpose of

estimating the incremental borrowing rate in the adoption of ASC 842, required management judgment including the development of a synthetic credit rating and cost of debt as we currently do not carry any debt. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. Previously, when credit losses were measured under U.S. GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires companies to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. 

Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted the guidance under ASU 2016-13 during the fourth quarter of 2021 and applied the modified retrospective method of adoption to the Company’s financial statements as of January 1, 2021. Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures and no cumulative adjustment was required to be recorded to the Company’s accumulated deficit as of January 1, 2021.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The Company adopted this guidance during the fourth quarter of 2021 with no material impact to the Company's consolidated financial statements.

 
Accounting Pronouncements Issued But Not Yet Effective

(v)

Accounting Pronouncements Issued But Not Yet Effective

In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company plans to adopt the standard on January 1, 2022. The Company is currently evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company’s consolidated financial statements.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Schedule of Revision to Prior Period Financial Statements

The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Balance Sheet as of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

628

 

 

 

628

 

Total liabilities

 

 

5,722

 

 

 

628

 

 

 

6,350

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

103,599

 

 

 

(187

)

 

 

103,412

 

Accumulated deficit

 

 

(91,111

)

 

 

(441

)

 

 

(91,552

)

Total stockholders’ equity

 

 

12,489

 

 

 

(628

)

 

 

11,861

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheet as of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

 

—

 

 

 

1,650

 

 

 

1,650

 

Total liabilities

 

 

6,290

 

 

 

1,650

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

189,849

 

 

 

19

 

 

 

189,868

 

Accumulated deficit

 

 

(126,360

)

 

 

(1,669

)

 

 

(128,029

)

Total stockholders’ equity

 

 

63,490

 

 

 

(1,650

)

 

 

61,840

 

The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):

 

 

Year Ended December 31, 2019

 

 

Year Ended December 31, 2020

 

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

 

As Previously

Reported

 

 

Adjustments

 

 

As Revised

 

Consolidated Statements of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

$

—

 

 

$

(441

)

 

$

(441

)

 

$

—

 

 

$

(1,228

)

 

$

(1,228

)

Total other income/(expense)

 

 

(2,084

)

 

 

(441

)

 

 

(2,525

)

 

 

40

 

 

 

(1,228

)

 

 

(1,188

)

Net loss

 

$

(19,689

)

 

$

(441

)

 

$

(20,130

)

 

$

(35,249

)

 

$

(1,228

)

 

$

(36,477

)

Net loss per share of common stock

  outstanding, basic and diluted

 

$

(2.81

)

 

$

(0.06

)

 

$

(2.87

)

 

$

(2.08

)

 

$

(0.07

)

 

$

(2.15

)
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):

 

 

 

Year Ended December 31, 2021

 

 

Year Ended December 31, 2020

 

 

Year Ended December 31, 2019

 

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

 

Beginning of

period

 

 

End of

period

 

Cash and cash equivalents

 

$

24,248

 

 

$

176,882

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 

Restricted cash

 

 

—

 

 

 

3,025

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total cash, cash equivalents and restricted cash

   reported in the consolidated statements of

   cash flows

 

$

24,248

 

 

$

179,907

 

 

$

15,374

 

 

$

24,248

 

 

$

4,753

 

 

$

15,374

 
Schedule of Revenues Disaggregated by Revenue Source

The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

DermTech Melanoma Test

 

$

11,023

 

 

$

4,241

 

 

$

1,403

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Smart Stickers

 

 

348

 

 

 

213

 

 

 

476

 

RNA extractions

 

 

300

 

 

 

1,172

 

 

 

626

 

Project management fees

 

 

166

 

 

 

258

 

 

 

336

 

Other

 

 

1

 

 

 

1

 

 

 

523

 

Total revenues

 

$

11,838

 

 

$

5,885

 

 

$

3,364

 

 

 
Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers

The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:

 

 

 

Total Revenue

 

 

Accounts Receivable

 

 

 

Year Ended December 31,

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

Assay Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payor A

 

 

36

%

 

 

32

%

 

*

 

 

 

23

%

 

 

21

%

Payor B

 

*

 

 

 

11

%

 

 

12

%

 

 

15

%

 

*

 

Contract Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer A

 

*

 

 

 

23

%

 

 

22

%

 

*

 

 

*

 

Customer B

 

*

 

 

*

 

 

*

 

 

*

 

 

 

17

%

Customer C

 

*

 

 

*

 

 

 

29

%

 

*

 

 

*

 

* Less than 10%
Assumptions Used to Estimate Fair Value of Each Option for Employees on Date of Grant

The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.52% - 1.39%

 

 

0.36% - 1.69%

 

 

1.68% - 2.50%

 

Assumed volatility

 

74.88% - 83.32%

 

 

64.03% - 73.44%

 

 

72.30% - 73.50%

 

Expected option term

 

6.08 years

 

 

5.04 - 6.25 years

 

 

6.02 - 6.08 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 

The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Assumed risk-free interest rate

 

0.05% - 0.18%

 

 

0.18%

 

Assumed volatility

 

64.55% - 69.34%

 

 

68.44%

 

Expected option term

 

0.49 - 0.50 years

 

 

0.49 years

 

Expected dividend yield

 

 

—

 

 

 

—

 
Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model

The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Assumed risk-free interest rate

 

0.46% - 0.85%

 

 

0.22% - 0.33%

 

 

1.40% - 1.66%

 

Assumed volatility

 

85.85% - 90.70%

 

 

69.79% - 79.26%

 

 

64.06% - 66.68%

 

Expected term

 

2.66 - 3.42 years

 

 

3.66 - 4.42 years

 

 

4.67 - 5.00 years

 

Expected dividend yield

 

 

—

 

 

 

—

 

 

 

—

 
Summary of Assets Measured at Fair Value On Recurring Basis The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

16,380

 

 

$

—

 

 

$

—

 

 

$

16,380

 

Restricted cash

 

 

3,025

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

15,352

 

 

 

—

 

 

 

15,352

 

Municipal securities

 

 

—

 

 

 

7,412

 

 

 

—

 

 

 

7,412

 

U.S. government debt securities

 

 

—

 

 

 

25,685

 

 

 

—

 

 

 

25,685

 

Total marketable securities, available for sale

 

 

—

 

 

 

48,449

 

 

 

—

 

 

 

48,449

 

Total assets measured at fair value on a recurring basis

 

$

19,405

 

 

$

48,449

 

 

$

—

 

 

$

64,829

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

146

 

 

$

146

 

 

 

 

December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

448

 

 

$

—

 

 

$

—

 

 

$

448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities, available for sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

—

 

 

 

8,940

 

 

 

—

 

 

 

8,940

 

Municipal securities

 

 

—

 

 

 

7,324

 

 

 

—

 

 

 

7,324

 

U.S. government debt securities

 

 

—

 

 

 

23,265

 

 

 

—

 

 

 

23,265

 

Total marketable securities, available for sale

 

 

—

 

 

 

39,529

 

 

 

—

 

 

 

39,529

 

Total assets measured at fair value on a recurring basis

 

$

448

 

 

$

39,529

 

 

$

—

 

 

$

39,977

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

Total liabilities measured at fair value on a recurring basis

 

$

—

 

 

$

—

 

 

$

1,650

 

 

$

1,650

 

 
Summary of Changes in Fair Value of Level 3 Liabilities

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):

 

Balance as of December 31, 2019

 

$

628

 

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(206

)

Change in fair value of warrant liability

 

 

1,228

 

Balance as of December 31, 2020

 

 

1,650

 

Derecognition of warrant liability from exercise of Private SPAC Warrants

 

 

(2,158

)

Reclassification of warrant liability due to Private SPAC Warrants not held by original holder

 

 

(434

)

Change in fair value of warrant liability

 

 

1,088

 

Balance as of December 31, 2021

 

$

146

 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Schedule of Short-Term Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 were as follows (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

15,385

 

 

$

—

 

 

$

(33

)

 

$

15,352

 

Municipal securities

 

 

7,417

 

 

 

—

 

 

 

(5

)

 

 

7,412

 

U.S. government debt securities

 

 

25,771

 

 

 

1

 

 

 

(87

)

 

 

25,685

 

Total short-term marketable securities,

   available-for-sale

 

$

48,573

 

 

$

1

 

 

$

(125

)

 

$

48,449

 

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2020 were as follows (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Gross Unrealized

Gain

 

 

Gross Unrealized

Loss

 

 

Estimated Market

Value

 

Short-term marketable securities, available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

8,946

 

 

$

—

 

 

$

(6

)

 

$

8,940

 

Municipal securities

 

 

7,325

 

 

 

1

 

 

 

(2

)

 

 

7,324

 

U.S. government debt securities

 

 

23,259

 

 

 

6

 

 

 

—

 

 

 

23,265

 

Total short-term marketable securities,

   available-for-sale

 

$

39,530

 

 

$

7

 

 

$

(8

)

 

$

39,529

 
Schedule of Prepaid Expenses and PP&E

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

Prepaid insurance

 

$

1,801

 

 

$

1,172

 

Prepaid trade shows

 

 

440

 

 

 

—

 

Prepaid software fees

 

 

551

 

 

 

214

 

Deferred issuance costs

 

 

—

 

 

 

56

 

Prepaid employee compensation

 

 

238

 

 

 

—

 

Other current assets

 

 

136

 

 

 

79

 

Total prepaid expenses and other current assets

 

$

3,166

 

 

$

1,521

 

Property and equipment, gross:

 

 

 

 

 

 

 

 

Laboratory equipment

 

$

4,805

 

 

$

2,544

 

Computer equipment

 

 

171

 

 

 

38

 

Furniture and fixtures

 

 

124

 

 

 

109

 

Leasehold improvements

 

 

1,074

 

 

 

727

 

Total property and equipment, gross

 

 

6,174

 

 

 

3,418

 

Less accumulated depreciation

 

 

(1,625

)

 

 

(687

)

Total property and equipment, net

 

$

4,549

 

 

$

2,731

 
Schedule of Accrued Compensation and Accrued Liabilities

Consolidated balance sheet details are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Accrued compensation:

 

 

 

 

 

 

 

 

Accrued paid time off

 

$

1,245

 

 

$

606

 

Accrued bonus and deferred compensation

 

 

3,875

 

 

 

1,469

 

Total accrued compensation

 

$

5,120

 

 

$

2,075

 

Accrued liabilities:

 

 

 

 

 

 

 

 

Accrued consulting services

 

$

775

 

 

$

285

 

Other accrued expenses

 

 

452

 

 

 

478

 

Total accrued liabilities

 

$

1,227

 

 

$

763

 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Stockholders Equity Note [Abstract]  
Summary of Stock Options transactions

The following table summarizes stock option transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total options

 

 

Weighted

average

exercise price

 

 

Weighted

average

remaining

contractual term

(in years)

 

 

Aggregate

intrinsic

value (in

thousands)

 

Outstanding at December 31, 2019

 

 

443,547

 

 

$

3.84

 

 

 

7.80

 

 

$

3,796

 

Granted

 

 

1,285,183

 

 

 

12.25

 

 

 

 

 

 

 

 

 

Exercised

 

 

(143,995

)

 

 

3.29

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(32,252

)

 

 

8.28

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

1,552,483

 

 

$

10.76

 

 

 

8.91

 

 

$

33,656

 

Granted

 

 

486,104

 

 

 

43.36

 

 

 

 

 

 

 

 

 

Exercised

 

 

(196,333

)

 

 

5.98

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(121,622

)

 

 

12.78

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options vested and expected to vest as of December 31, 2021

 

 

1,720,632

 

 

$

20.37

 

 

 

8.31

 

 

$

5,698

 

Options exercisable as of December 31, 2021

 

 

607,127

 

 

$

10.16

 

 

 

7.59

 

 

$

3,523

 
Summary of Restricted Stock units Award Transactions

The following table summarizes RSU transactions for the years ended December 31, 2021 and 2020:

 

 

 

Total RSUs

 

 

Weighted

average grant

date fair value

per share

 

Outstanding at December 31, 2019

 

 

—

 

 

$

—

 

Granted

 

 

739,962

 

 

 

12.47

 

Released

 

 

(175,527

)

 

 

11.60

 

Forfeited

 

 

(3,938

)

 

 

11.41

 

Outstanding at December 31, 2020

 

 

560,497

 

 

$

12.75

 

Granted

 

 

718,053

 

 

 

34.09

 

Released

 

 

(277,259

)

 

 

14.20

 

Forfeited

 

 

(17,888

)

 

 

38.03

 

Outstanding at December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested and expected to vest as of December 31, 2021

 

 

983,403

 

 

$

27.46

 

RSUs vested, but not yet issued as of December 31, 2021

 

 

12,632

 

 

$

41.81

 
Summary of Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Warrants to purchase common stock

 

 

31

 

 

 

151

 

SPAC Warrants to purchase common stock*

 

 

704

 

 

 

3,734

 

Stock options issued and outstanding

 

 

1,721

 

 

 

1,552

 

Restricted stock units issued and outstanding

 

 

983

 

 

 

560

 

Authorized for future equity grants

 

 

603

 

 

 

935

 

Authorized for future ESPP purchases

 

 

549

 

 

 

400

 

Total common stock reserved for future issuance

 

 

4,591

 

 

 

7,332

 

 

*

Four SPAC Warrants are needed to purchase one share of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.   
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Reconciliation of Income Tax Rate The following table provides a reconciliation between income taxes computed at the federal statutory rate of 21% at December 31, 2021, 2020, and 2019, and the Company’s provision for income taxes

 

 

 

Year ended December 31

 

 

 

2021

 

 

2020

 

 

2019

 

Income tax at statutory rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State tax, net of federal tax benefit

 

 

4.8

 

 

 

4.9

 

 

 

—

 

Permanent items

 

 

1.1

 

 

 

(0.1

)

 

 

(0.8

)

Tax credits

 

 

0.6

 

 

 

0.4

 

 

 

0.2

 

Other

 

 

(0.4

)

 

 

(0.5

)

 

 

—

 

Valuation allowance (decrease) increase

 

 

(27.1

)

 

 

(25.7

)

 

 

(20.4

)

Income tax expense

 

 

—

%

 

 

—

%

 

 

—

%
Schedule of Deferred Tax Assets and Liabilities from Federal and State income Taxes

Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31, 2021, 2020, and 2019 are shown below (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

 

December 31,

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss

 

$

46,886

 

 

$

28,422

 

 

$

20,336

 

Research and development credits

 

 

2,411

 

 

 

1,631

 

 

 

1,400

 

Depreciation and amortization

 

 

—

 

 

 

14

 

 

 

33

 

Stock based compensation

 

 

2,126

 

 

 

653

 

 

 

119

 

Accruals and other

 

 

719

 

 

 

422

 

 

 

194

 

Operating lease liability

 

 

1,935

 

 

 

—

 

 

 

—

 

Deferred revenue

 

 

340

 

 

 

—

 

 

 

—

 

Total deferred tax assets

 

 

54,417

 

 

 

31,142

 

 

 

22,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

(32

)

 

 

—

 

 

 

—

 

Operating lease right-of-use assets

 

 

(1,972

)

 

 

—

 

 

 

—

 

Total deferred tax liabilities

 

 

(2,004

)

 

 

—

 

 

 

—

 

Net deferred tax assets before valuation allowance

 

 

52,413

 

 

 

31,142

 

 

 

22,082

 

Less: valuation allowance

 

 

(52,413

)

 

 

(31,142

)

 

 

(22,082

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

$

—

 

 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Schedule of Long Term Finance Lease Obligations Long-term finance lease obligations are as follows (in thousands):

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Gross finance lease obligations

 

$

274

 

 

$

362

 

Less: imputed interest

 

 

(17

)

 

 

(27

)

Present value of net minimum lease payments

 

 

257

 

 

 

335

 

Less: current portion of finance lease obligations

 

 

(121

)

 

 

(109

)

Total long-term finance lease obligations

 

$

136

 

 

$

226

 

 
Components of Lease Expense

The components of lease expense for the year ended December 31, 2021 was as follows (in thousands):

 

Lease Cost

 

Year Ended

December 31, 2021

 

Operating lease cost

 

 

 

 

Operating lease cost

 

$

1,517

 

Variable lease costs

 

 

657

 

Total operating lease cost

 

$

2,174

 

 

 

 

 

 

Finance lease cost

 

 

 

 

Amortization of leased assets

 

$

75

 

Interest on lease liabilities

 

 

17

 

Total finance lease cost

 

$

92

 

 

 

 

 

 

Other information

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities

 

 

 

 

Operating cash flows from operating leases

 

$

2,619

 

Operating cash flows from finance leases

 

$

17

 

Financing cash flows from finance leases

 

$

171

 

Right-of-use assets obtained in exchange for new operating lease obligations

 

$

9,044

 

Right-of-use assets obtained in exchange for new finance lease obligations

 

$

93

 

 

 

 

 

 

Weighted-average remaining lease term of operating leases (in years)

 

 

9.33

 

Weighted-average remaining lease term of finance leases (in years)

 

 

2.34

 

Weighted-average discount rate for operating leases

 

 

5.78

%

Weighted-average discount rate for finance leases

 

 

5.63

%

 

 
Schedule of Future Minimum Lease Payments Under Operating and Finance Leases

The Company’s future minimum lease payments under operating and finance leases at December 31, 2021 are as follows (in thousands):

 

 

 

2022

 

 

2023

 

 

2024

 

 

2025

 

 

2026

 

 

Thereafter

 

 

Total

 

Operating lease obligations, including interest

 

$

1,802

 

 

$

1,149

 

 

$

688

 

 

$

709

 

 

$

730

 

 

$

4,928

 

 

$

10,006

 

Finance lease obligations, including interest

 

 

132

 

 

 

122

 

 

 

8

 

 

 

8

 

 

 

4

 

 

 

—

 

 

 

274

 

Total future minimum lease payments

 

$

1,934

 

 

$

1,271

 

 

$

696

 

 

$

717

 

 

$

734

 

 

$

4,928

 

 

$

10,280

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Aug. 29, 2019
Dec. 31, 2021
USD ($)
Warrant
Revenue_Stream
Segment
$ / shares
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
The Company and Summary of its Significant Accounting Policies [Line Items]        
Conversion ratio of reverse stock split 0.5      
Description of reverse stock split of common stock   one-for-two     
Net change in net cash used in operating activities   $ 0    
Depreciation expense   997,000 $ 486,000 $ 89,000
Gross assets   6,174,000 3,418,000  
Accumulated amortization   100,000 10,000  
Disposal of plant or equipment   100,000 100,000 0
Impairment losses   0 0 0
Sweep account   100,100,000    
Insured amount by FDIC   250,000    
Cash held in excess of FDIC limit   $ 60,200,000    
Number of revenue streams | Revenue_Stream   2    
Short-term deferred revenue   $ 1,380,000 905,000  
Long-term deferred revenue   0 639,000  
Accounts receivable   $ 3,847,000 1,480,000  
Number of operating segments | Segment   1    
Stock-based compensation expense   $ 13,300,000 5,000,000.0 $ 1,300,000
Compensation cost related to non-vested awards not yet recognized   $ 38,400,000    
Weighted average term expected to be recognized   2 years 9 months 29 days    
Level 1 | Restricted Cash        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Letters of credit   $ 3,000,000.0 $ 0  
Conversion of Preferred Stock        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per common share | shares       615,385
Common Stock Warrants        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per common share | shares   734,329 3,885,311 4,200,497
Stock Options        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per common share | shares       443,547
Stock Options and Restricted Stock Units        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per common share | shares   2,704,035 2,112,980  
Assay Revenue        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Accounts receivable gross   $ 3,600,000 $ 1,000,000.0  
Contract Revenue        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Accounts receivable   $ 200,000 500,000  
Minimum        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Useful life of the assets   2 years    
Remaining lease term   2 years    
Minimum | Stock Options        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Requisite service period   3 years    
Minimum | Restricted Stock Units        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Requisite service period   2 years    
Maximum        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Useful life of the assets   5 years    
Remaining lease term   10 years    
Extend lease term   10 years    
Maximum | Stock Options        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Requisite service period   4 years    
Maximum | Restricted Stock Units        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Requisite service period   4 years    
Amortization of Laboratory Equipment Acquired under Finance Leases        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Depreciation expense   $ 100,000 10,000 $ 0
Assets Recorded under Finance Leases        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Gross assets   400,000 300,000  
Accumulated amortization   $ 100,000 $ 10,000  
SPAC Warrants        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Warrants expiration period   5 years    
Number of warrants entitle holder to purchase one share | Warrant   4    
Number of shares issued for each warrant | shares   0.25    
Exercise price of warrant | $ / shares   $ 23.00    
SPAC Warrants | Public Offering        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Warrants issued to purchase common stock | shares   14,375,000    
SPAC Warrants | Private Placement Offering        
The Company and Summary of its Significant Accounting Policies [Line Items]        
Warrants issued to purchase common stock | shares   561,250    
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Long term liabilities:        
Warrant liability   $ 1,650 $ 628  
Total liabilities $ 18,611 7,940 6,350  
Stockholders’ equity:        
Additional paid-in capital 436,183 189,868 103,412  
Accumulated deficit (206,364) (128,029) (91,552)  
Total stockholders’ equity $ 229,698 61,840 11,861 $ (5,355)
As Previously Reported        
Long term liabilities:        
Total liabilities   6,290 5,722  
Stockholders’ equity:        
Additional paid-in capital   189,849 103,599  
Accumulated deficit   (126,360) (91,111)  
Total stockholders’ equity   63,490 12,489  
Adjustments        
Long term liabilities:        
Warrant liability   1,650 628  
Total liabilities   1,650 628  
Stockholders’ equity:        
Additional paid-in capital   19 (187)  
Accumulated deficit   (1,669) (441)  
Total stockholders’ equity   $ (1,650) $ (628)  
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Other income/(expense):      
Change in fair value of warrant liability $ (1,088) $ (1,228) $ (441)
Total other income/(expense) (937) (1,188) (2,525)
Net loss $ (78,335) $ (36,477) $ (20,130)
Net loss per share of common stock outstanding, basic and diluted $ (2.71) $ (2.15) $ (2.87)
As Previously Reported      
Other income/(expense):      
Total other income/(expense)   $ 40 $ (2,084)
Net loss   $ (35,249) $ (19,689)
Net loss per share of common stock outstanding, basic and diluted   $ (2.08) $ (2.81)
Adjustments      
Other income/(expense):      
Change in fair value of warrant liability   $ (1,228) $ (441)
Total other income/(expense)   (1,228) (441)
Net loss   $ (1,228) $ (441)
Net loss per share of common stock outstanding, basic and diluted   $ (0.07) $ (0.06)
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]      
Cash and cash equivalents, beginning of period $ 24,248 $ 15,374 $ 4,753
Cash, cash equivalents and restricted cash, beginning of period 24,248 15,374 4,753
Cash and cash equivalents, end of period 176,882 24,248 15,374
Restricted cash, end of period 3,025    
Cash, cash equivalents and restricted cash, end of period $ 179,907 $ 24,248 $ 15,374
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Total revenues $ 11,838 $ 5,885 $ 3,364
Assay Revenue      
Disaggregation Of Revenue [Line Items]      
Total revenues 11,023 4,241 1,403
Contract Revenue, Smart Stickers      
Disaggregation Of Revenue [Line Items]      
Total revenues 348 213 476
Contract Revenue, RNA Extractions      
Disaggregation Of Revenue [Line Items]      
Total revenues 300 1,172 626
Contract Revenue, Project Management Fees      
Disaggregation Of Revenue [Line Items]      
Total revenues 166 258 336
Contract Revenue, Other      
Disaggregation Of Revenue [Line Items]      
Total revenues $ 1 $ 1 $ 523
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) - Customer Concentration Risk
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Assay Revenue Payor A | Total Revenue      
Product Information [Line Items]      
Concentration risk, percentage 36.00% 32.00%  
Assay Revenue Payor A | Accounts Receivable      
Product Information [Line Items]      
Concentration risk, percentage 23.00% 21.00%  
Assay Revenue Payor B | Total Revenue      
Product Information [Line Items]      
Concentration risk, percentage   11.00% 12.00%
Assay Revenue Payor B | Accounts Receivable      
Product Information [Line Items]      
Concentration risk, percentage 15.00%    
Contract Revenue Customer A | Total Revenue      
Product Information [Line Items]      
Concentration risk, percentage   23.00% 22.00%
Contract Revenue Customer B | Accounts Receivable      
Product Information [Line Items]      
Concentration risk, percentage   17.00%  
Contract Revenue Customer C | Total Revenue      
Product Information [Line Items]      
Concentration risk, percentage     29.00%
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details) - Customer Concentration Risk
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Total Revenue | Assay Revenue Payor A      
Product Information [Line Items]      
Concentration risk, percentage 36.00% 32.00%  
Total Revenue | Assay Revenue Payor B      
Product Information [Line Items]      
Concentration risk, percentage   11.00% 12.00%
Total Revenue | Contract Revenue Customer A      
Product Information [Line Items]      
Concentration risk, percentage   23.00% 22.00%
Total Revenue | Contract Revenue Customer C      
Product Information [Line Items]      
Concentration risk, percentage     29.00%
Accounts Receivable | Assay Revenue Payor A      
Product Information [Line Items]      
Concentration risk, percentage 23.00% 21.00%  
Accounts Receivable | Assay Revenue Payor B      
Product Information [Line Items]      
Concentration risk, percentage 15.00%    
Accounts Receivable | Contract Revenue Customer B      
Product Information [Line Items]      
Concentration risk, percentage   17.00%  
Maximum | Total Revenue | Assay Revenue Payor A      
Product Information [Line Items]      
Concentration risk, percentage     10.00%
Maximum | Total Revenue | Assay Revenue Payor B      
Product Information [Line Items]      
Concentration risk, percentage 10.00%    
Maximum | Total Revenue | Contract Revenue Customer A      
Product Information [Line Items]      
Concentration risk, percentage 10.00%    
Maximum | Total Revenue | Contract Revenue Customer B      
Product Information [Line Items]      
Concentration risk, percentage 10.00% 10.00% 10.00%
Maximum | Total Revenue | Contract Revenue Customer C      
Product Information [Line Items]      
Concentration risk, percentage 10.00% 10.00%  
Maximum | Accounts Receivable | Assay Revenue Payor B      
Product Information [Line Items]      
Concentration risk, percentage   10.00%  
Maximum | Accounts Receivable | Contract Revenue Customer A      
Product Information [Line Items]      
Concentration risk, percentage 10.00% 10.00%  
Maximum | Accounts Receivable | Contract Revenue Customer B      
Product Information [Line Items]      
Concentration risk, percentage 10.00%    
Maximum | Accounts Receivable | Contract Revenue Customer C      
Product Information [Line Items]      
Concentration risk, percentage 10.00% 10.00%  
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1)
$ in Millions
Dec. 31, 2021
USD ($)
The Company and Summary of its Significant Accounting Policies [Line Items]  
Remaining performance obligation, estimated revenue expected to be recognized $ 0.4
Minimum  
The Company and Summary of its Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 2 years
Maximum  
The Company and Summary of its Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 years
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
2020 Equity Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Assumed risk-free interest rate,minimum 0.52% 0.36% 1.68%
Assumed risk-free interest rate,maximum 1.39% 1.69% 2.50%
Assumed volatility,minimum 74.88% 64.03% 72.30%
Assumed volatility,maximum 83.32% 73.44% 73.50%
Expected option term 6 years 29 days    
2020 Equity Incentive Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected option term   5 years 14 days 6 years 7 days
2020 Equity Incentive Plan | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected option term   6 years 3 months 6 years 29 days
2020 Employee Stock Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Assumed risk-free interest rate,minimum 0.05%    
Assumed risk-free interest rate,maximum 0.18%    
Assumed volatility,minimum 64.55%    
Assumed volatility,maximum 69.34%    
Expected option term   5 months 26 days  
Assumed risk-free interest rate   0.18%  
Assumed volatility   68.44%  
2020 Employee Stock Purchase Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected option term 5 months 26 days    
2020 Employee Stock Purchase Plan | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected option term 6 months    
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details)
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Assumed Risk-free Interest Rate | Minimum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Warrant liability, fair value measurement inputs 0.46 0.22 1.40
Assumed Risk-free Interest Rate | Maximum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Warrant liability, fair value measurement inputs 0.85 0.33 1.66
Assumed Volatility | Minimum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Warrant liability, fair value measurement inputs 85.85 69.79 64.06
Assumed Volatility | Maximum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Warrant liability, fair value measurement inputs 90.70 79.26 66.68
Expected Term | Minimum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Expected term (years) 2 years 7 months 28 days 3 years 7 months 28 days 4 years 8 months 1 day
Expected Term | Maximum      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]      
Expected term (years) 3 years 5 months 1 day 4 years 5 months 1 day 5 years
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Assets:    
Restricted cash $ 3,025  
Marketable securities, available for sale:    
Marketable securities, available for sale 48,449 $ 39,529
Fair Value, Recurring    
Assets:    
Cash equivalents 16,380 448
Marketable securities, available for sale:    
Marketable securities, available for sale 48,449 39,529
Total assets measured at fair value on a recurring basis 64,829 39,977
Liabilities:    
Warrant liability 146 1,650
Total liabilities measured at fair value on a recurring basis 146 1,650
Fair Value, Recurring | Level 1    
Assets:    
Cash equivalents 16,380 448
Restricted cash 3,025  
Marketable securities, available for sale:    
Total assets measured at fair value on a recurring basis 19,405 448
Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Marketable securities, available for sale 48,449 39,529
Total assets measured at fair value on a recurring basis 48,449 39,529
Fair Value, Recurring | Level 3    
Liabilities:    
Warrant liability 146 1,650
Total liabilities measured at fair value on a recurring basis 146 1,650
Corporate Debt Securities    
Marketable securities, available for sale:    
Marketable securities, available for sale 15,352 8,940
Corporate Debt Securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Marketable securities, available for sale 15,352 8,940
Corporate Debt Securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Marketable securities, available for sale 15,352 8,940
Municipal Securities    
Marketable securities, available for sale:    
Marketable securities, available for sale 7,412 7,324
Municipal Securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Marketable securities, available for sale 7,412 7,324
Municipal Securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Marketable securities, available for sale 7,412 7,324
U.S. Government Debt Securities    
Marketable securities, available for sale:    
Marketable securities, available for sale 25,685 23,265
U.S. Government Debt Securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Marketable securities, available for sale 25,685 23,265
U.S. Government Debt Securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Marketable securities, available for sale $ 25,685 $ 23,265
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) - Level 3 - Warrant Liability - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Balance $ 1,650 $ 628
Reclassification of warrant liability due to Private SPAC Warrants not held by original holder (434) (206)
Change in fair value of warrant liability 1,088 1,228
Balance 146 $ 1,650
Derecognition of warrant liability from exercise of Private SPAC Warrants $ (2,158)  
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Investment Holdings [Line Items]    
Amortized Cost $ 48,573 $ 39,530
Gross Unrealized Gain 1 7
Gross Unrealized Loss (125) (8)
Marketable securities, available for sale 48,449 39,529
Corporate Debt Securities    
Investment Holdings [Line Items]    
Amortized Cost 15,385 8,946
Gross Unrealized Loss (33) (6)
Marketable securities, available for sale 15,352 8,940
Municipal Securities    
Investment Holdings [Line Items]    
Amortized Cost 7,417 7,325
Gross Unrealized Gain   1
Gross Unrealized Loss (5) (2)
Marketable securities, available for sale 7,412 7,324
U.S. Government Debt Securities    
Investment Holdings [Line Items]    
Amortized Cost 25,771 23,259
Gross Unrealized Gain 1 6
Gross Unrealized Loss (87)  
Marketable securities, available for sale $ 25,685 $ 23,265
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Additional Information (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]    
Estimated market value of debt securities with contractual maturities of less than 12 months $ 21.2 $ 37.3
Estimated market value of remaining debt securities with contractual maturities of up to 14 months   $ 2.3
Estimated market value of remaining debt securities with contractual maturities of up to 23 months $ 27.2  
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Prepaid expenses and other current assets:    
Prepaid insurance $ 1,801 $ 1,172
Prepaid trade shows 440  
Prepaid software fees 551 214
Deferred issuance costs   56
Prepaid employee compensation 238  
Other current assets 136 79
Total prepaid expenses and other current assets 3,166 1,521
Property and equipment, gross:    
Laboratory equipment 4,805 2,544
Computer equipment 171 38
Furniture and fixtures 124 109
Leasehold improvements 1,074 727
Total property and equipment, gross 6,174 3,418
Less accumulated depreciation (1,625) (687)
Total property and equipment, net $ 4,549 $ 2,731
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Accrued compensation:    
Accrued paid time off $ 1,245 $ 606
Accrued bonus and deferred compensation 3,875 1,469
Total accrued compensation 5,120 2,075
Accrued liabilities:    
Accrued consulting services 775 285
Other accrued expenses 452 478
Total accrued liabilities $ 1,227 $ 763
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt - Additional Information (Details)
 12 Months Ended
Jan. 11, 2021
USD ($)
Sep. 24, 2019
$ / shares
Sep. 23, 2019
USD ($)
$ / shares
Aug. 29, 2019
USD ($)
shares
Jun. 10, 2019
USD ($)
Nov. 30, 2018
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]                  
Gross proceeds from issuance of equity securities $ 134,600,000               $ 19,802,000
Proceeds from issuance of convertible note                 2,600,000
Convertible debt converted in to common shares | shares       2,267,042          
Gain on debt extinguishment       $ 900,000         928,000
2018 Convertible Bridge Notes                  
Debt Instrument [Line Items]                  
Convertible note, principal amount           $ 6,800,000      
Proceeds from issuance of convertible note           $ 6,600,000      
Debt instrument, interest rate           10.00%      
Debt maturity date           Mar. 31, 2019      
Increase in interest rate if bridge notes not paid or converted             15.00%    
Percentage of multiplier on price per share of new stock paid in qualified financing by investors             70.00%    
Denominator for calculating capitalization value for price per share             $ 45,000,000    
Debt discount             $ 2,500,000    
Maturity date, description             As part of the amendment, the maturity dates of the notes were extended to the earliest of (i) September 24, 2019; (ii) the occurrence of an Event of Default (as defined in the 2018 Bridge Notes); (iii) the consummation of a liquidation or dissolution of DermTech Operations (iv) a Liquidation Transaction (as defined in the 2018 Bridge Notes); or (v) the consummation of a merger with or into the Company or any of its subsidiaries.    
Convertible notes conversion ratio     0.70            
Description of merger consideration             “Merger Consideration” means (i) the lesser of $6.46 and (ii) the offering price per share of the private investment in public equity (“PIPE”) transaction to be consummated concurrently with the consummation of the Qualifying Merger multiplied by the Conversion Ratio.    
Merger consideration maximum price per share | $ / shares     $ 6.46            
Debt Conversion Ratio Number Used As Numerator to Derive Quotient     $ 8,000,000            
Liability balance             $ 0 $ 0  
2018 Convertible Bridge Notes | Other Expense                  
Debt Instrument [Line Items]                  
Loss on change in fair value of derivative liability               0 400,000
2018 Convertible Bridge Notes | Minimum                  
Debt Instrument [Line Items]                  
Gross proceeds from issuance of equity securities             20,000,000    
2019 Convertible Bridge Notes                  
Debt Instrument [Line Items]                  
Debt instrument, interest rate         10.00%        
Debt discount             $ 300,000    
Maturity date, description             These convertible bridge notes carried an interest rate of 10% and matured after the earliest to occur of: (i) September 25, 2019; (ii) the occurrence of an Event of Default; (iii) the consummation of a liquidation or dissolution of DermTech Operations; (iv) a Liquidation Transaction; or (v) the consummation of a merger of DermTech Operations with Merger Sub, a subsidiary of the Company, in accordance with the Merger Agreement.    
Debt Conversion Ratio Number Used As Numerator to Derive Quotient     $ 8,000,000            
Proceeds from issuance of convertible note         $ 2,600,000        
Debt conversion feature             Upon the conversion of these notes, the note holders were entitled to receive a number of shares of DermTech Operations’ common stock equal to the quotient obtained by dividing (i) the unpaid principal amount of these notes plus interest accrued but unpaid thereon, by (1) if the Qualifying Merger consummates prior to the maturity date, the lesser of (x) $5.80 and (y) 90% of the Merger Consideration (as defined below), or (2) if the Qualifying Merger consummates on or after the maturity date, the lesser of (x) $4.51 and (y) 70% of the Merger Consideration.    
Liability balance             $ 0 0  
2019 Convertible Bridge Notes | Other Expense                  
Debt Instrument [Line Items]                  
Loss on change in fair value of derivative liability               $ 0 $ 14,000
2019 Convertible Bridge Notes | Maximum                  
Debt Instrument [Line Items]                  
Convertible notes conversion ratio   0.70 0.90            
Convertible notes conversion price | $ / shares   $ 4.51 $ 5.80            
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders Equity - Additional Information (Details) - USD ($)
 12 Months Ended 24 Months Ended 36 Months Ended
Aug. 31, 2021
Feb. 28, 2021
Jan. 11, 2021
Jan. 06, 2021
Nov. 10, 2020
Aug. 10, 2020
May 27, 2020
Mar. 02, 2020
Feb. 28, 2020
Aug. 29, 2019
Jun. 23, 2017
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2016
Dec. 31, 2018
Jan. 01, 2021
Class of Stock [Line Items]                                  
Common stock, shares authorized                       50,000,000 50,000,000        
Preferred stock, shares authorized                       5,000,000          
Common stock, par value per share                       $ 0.0001 $ 0.0001        
Preferred stock, par value per share                       $ 0.0001          
Issuance of preferred stock, total offering amount                       $ 134,582,000   $ 934,000      
Issuance of common stock through conversion, Shares           615,385                      
Preferred stock, issuance costs                         $ 77,000        
Net proceeds from issuance of common stock     $ 134,600,000                     19,802,000      
Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses     $ 143,700,000                            
Proceeds from exercise of common stock warrants                       $ 70,271,000 $ 842,000 $ 5,000      
Common stock available for issuance                       4,591 7,332        
2010 Stock Plan                                  
Class of Stock [Line Items]                                  
Common stock initially reserved for issuance                       1,000,000.0          
Contractual term of options granted                       10 years          
Options remain available for future grant                       0          
2010 Stock Plan | Incentive Stock Options                                  
Class of Stock [Line Items]                                  
Options granted to shareholder, percentage                       10.00%          
2020 Equity Incentive Plan                                  
Class of Stock [Line Items]                                  
Common stock, shares authorized                       1,900,000          
Contractual term of options granted                       10 years          
Options remain available for future grant                       602,955          
Common stock outstanding percentage                       3.50%          
2020 Employee Stock Purchase Plan                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period 18,155 39,960                              
Options remain available for future grant                       549,289 400,000       207,404
Shares, issued                       300,000          
Percentage of price at shares purchased                       85.00%          
Minimum | 2010 Stock Plan | Incentive and Non-statutory Stock Options                                  
Class of Stock [Line Items]                                  
Options granted, exercise price expressed as a percentage of fair market value                       100.00%          
Minimum | 2010 Stock Plan | Incentive Stock Options                                  
Class of Stock [Line Items]                                  
Options granted, exercise price expressed as a percentage of fair market value                       110.00%          
Minimum | 2020 Equity Incentive Plan | Incentive Stock Options                                  
Class of Stock [Line Items]                                  
Options granted, exercise price expressed as a percentage of fair market value                       110.00%          
Minimum | 2020 Equity Incentive Plan | Incentive and Non-qualified Stock Options                                  
Class of Stock [Line Items]                                  
Options granted, exercise price expressed as a percentage of fair market value                       100.00%          
Minimum | 2018 Convertible Bridge Notes                                  
Class of Stock [Line Items]                                  
Net proceeds from issuance of common stock                       $ 20,000,000          
Maximum | 2020 Equity Incentive Plan                                  
Class of Stock [Line Items]                                  
Term of the option                       5 years          
Shares, issued                       1,400,000          
Maximum | 2020 Employee Stock Purchase Plan                                  
Class of Stock [Line Items]                                  
Common stock available for issuance                       400,000          
SPAC Warrants                                  
Class of Stock [Line Items]                                  
Warrants issued to purchase common stock                     14,936,250            
Warrants expiration period                       5 years          
Total number exercised of public warrants                       12,120,397          
Common shares issued upon exercise of warrants                       3,030,092          
Proceeds from exercise of common stock warrants                       $ 69,700,000          
Warrants outstanding                       2,815,853 14,936,250        
Public SPAC Warrants                                  
Class of Stock [Line Items]                                  
Warrants issued to purchase common stock                     14,375,000            
Private SPAC Warrants                                  
Class of Stock [Line Items]                                  
Warrants issued to purchase common stock                     561,250            
Warrants outstanding                       80,350 323,500        
Series C Warrants                                  
Class of Stock [Line Items]                                  
Warrants expiration period                       3 years          
Warrants outstanding                       0 97,563        
Placement Agent Warrants                                  
Class of Stock [Line Items]                                  
Warrants issued to purchase common stock                             168,522 72,658  
Warrants expiration period                             7 years 7 years  
Warrants outstanding                         31,365        
Placement Agent Warrants | 2018 Convertible Bridge Notes                                  
Class of Stock [Line Items]                                  
Warrants issued to purchase common stock                         15,724        
Warrants expiration period                         7 years        
Warrants outstanding                       10,039          
Management Warrants                                  
Class of Stock [Line Items]                                  
Warrants expiration period                       10 years          
Warrants outstanding                       20,320 22,320        
Common Stock                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period                       4,872,881   726,139      
Issuance of preferred stock, total offering amount                       $ 1,000          
Issuance of common stock through conversion, Shares                         3,198,949 1,524,122      
Common Stock | SPAC Warrants                                  
Class of Stock [Line Items]                                  
Number of shares issued for each warrant                       0.25          
Exercise price of warrant                       $ 23.00          
Common Stock | Series C Warrants                                  
Class of Stock [Line Items]                                  
Exercise price of warrant                       9.54          
Common Stock | Placement Agent Warrants                                  
Class of Stock [Line Items]                                  
Number of shares issued for each warrant                             1 1  
Exercise price of warrant                             $ 8.68 $ 9.54  
Common Stock | Placement Agent Warrants | 2018 Convertible Bridge Notes                                  
Class of Stock [Line Items]                                  
Number of shares issued for each warrant                         1        
Exercise price of warrant                         $ 9.54        
Common Stock | Management Warrants                                  
Class of Stock [Line Items]                                  
Exercise price of warrant                       $ 1.08          
Warrants vesting period                       4 years          
Securities Purchase Agreement                                  
Class of Stock [Line Items]                                  
Gross proceeds from PIPE financing                 $ 65,000,000.0                
Preferred stock, issuance costs                 $ 5,100,000                
2020 PIPE Financing | Securities Purchase Agreement                                  
Class of Stock [Line Items]                                  
PIPE financing closing date                       Mar. 04, 2020          
2020 PIPE Financing | Securities Purchase Agreement | Common Stock                                  
Class of Stock [Line Items]                                  
Issuance of stock                 2,467,724                
Issuance price per share                 $ 10.50                
At-The Market Offering                                  
Class of Stock [Line Items]                                  
Issuance of preferred stock, total offering amount                       $ 23,836,000 $ 19,104,000        
Issuance price per share                       $ 46.33          
Net proceeds from issuance of common stock                       $ 23,836,000 $ 19,104,000        
At-The Market Offering | Cowen and Company LLC                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period       4,237,288 951,792             530,551          
Issuance of preferred stock, total offering amount         $ 50,000,000.0                        
Issuance of stock     4,872,881 4,872,881                          
Issuance price per share         $ 20.97             $ 46.33          
Gross proceeds from issuance of common stock         $ 20,000,000.0             $ 24,600,000          
Decrease in issuance costs         900,000             700,000          
Net proceeds from issuance of common stock         $ 19,100,000             $ 23,800,000          
Shares purchased by underwriters     635,593 635,593                          
Number of days granted to underwriters option to purchase       30 days                          
Public offering price     $ 29.50                            
At-The Market Offering | Common Stock                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period                       530,551 951,792        
Issuance price per share                         $ 20.97        
Series A Convertible Preferred Stock                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period           1,231       1,231       1,231      
Issuance of preferred stock, total offering amount                   $ 4,000,000.0              
Series B-1 Convertible Preferred Stock                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period                         3,199        
Issuance of common stock through conversion, Shares                         (3,199)        
Series B-1 Convertible Preferred Stock | 2020 PIPE Financing                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period               3,199                  
Issuance of preferred stock, total offering amount               $ 33,600,000                  
Issuance of common stock through conversion, Shares             3,198,949                    
Convertible preferred stock, shares outstanding             3,199                    
Series B-1 Convertible Preferred Stock | 2020 PIPE Financing | Securities Purchase Agreement                                  
Class of Stock [Line Items]                                  
Issuance of stock                 3,199                
Issuance price per share                 $ 10,500                
Preferred stock designated shares authorized and unissued                 3,200                
Series B-2 Convertible Preferred Stock                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period                         524        
Series B-2 Convertible Preferred Stock | 2020 PIPE Financing                                  
Class of Stock [Line Items]                                  
Preferred stock, shares issued during period           524           524          
Issuance of preferred stock, total offering amount                       $ 5,500,000          
Issuance of common stock through conversion, Shares           523,814                      
Series B-2 Convertible Preferred Stock | 2020 PIPE Financing | Securities Purchase Agreement                                  
Class of Stock [Line Items]                                  
Issuance of stock                 524                
Issuance price per share                 $ 10,500                
Preferred stock designated shares authorized and unissued                 525                
Series C Convertible Preferred Stock | Series C Warrants                                  
Class of Stock [Line Items]                                  
Percentage of warrants issued in connection with preferred stock purchased                       20.00%          
Series C Convertible Preferred Stock | Series C Warrants | Minimum                                  
Class of Stock [Line Items]                                  
Preferred stock value of shares purchased in single closing                       $ 1,000,000          
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details) - Stock Option [Member] - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Beginning balance 1,552,483 443,547  
Granted 486,104 1,285,183  
Exercised (196,333) (143,995)  
Forfeited (121,622) (32,252)  
Ending balance 1,720,632 1,552,483 443,547
Options vested and expected to vest 1,720,632    
Options exercisable 607,127    
Weighted average exercise, Beginning balance $ 10.76 $ 3.84  
Weighted average exercise Granted 43.36 12.25  
Weighted average exercise, Exercised 5.98 3.29  
Weighted average exercise, Forfeited 12.78 8.28  
Weighted average exercise, Ending balance 20.37 $ 10.76 $ 3.84
Options vested and expected to vest, Weighted average exercise price 20.37    
Options exercisable, Weighted average exercise price $ 10.16    
Weighted average remaining contractual term (in years) 8 years 3 months 21 days 8 years 10 months 28 days 7 years 9 months 18 days
Options vested and expected to vest, Weighted average remaining contractual term (in years) 8 years 3 months 21 days    
Options exercisable, Weighted average remaining contractual term (in years) 7 years 7 months 2 days    
Aggregate intrinsic value, outstanding $ 5,698 $ 33,656 $ 3,796
Options vested and expected to vest, Aggregate intrinsic value 5,698    
Options exercisable, Aggregate intrinsic value $ 3,523    
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details) - Restricted Stock Units - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Beginning balance 560,497    
Granted 718,053 739,962  
Released (277,259) (175,527)  
Forfeited (17,888) (3,938)  
Ending balance 983,403 560,497  
RSUs vested and expected to vest 983,403    
RSUs vested, but not yet issued 12,632    
Beginning balance, Weighted average grant date fair value per share $ 12.75    
Granted, Weighted average grant date fair value per share 34.09   $ 12.47
Released, Weighted average grant date fair value per share 14.20   11.60
Forfeited, Weighted average grant date fair value per share 38.03   $ 11.41
Ending balance, Weighted average grant date fair value per share 27.46 $ 12.75  
RSUs vested and expected to vest, Weighted average grant date fair value per share 27.46    
RSUs vested, but not yet issued, Weighted average grant date fair value per share $ 41.81    
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail) - shares
Dec. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]    
Common stock reserved for future issuance 4,591 7,332
Warrants to Purchase Common Stock    
Class of Stock [Line Items]    
Common stock reserved for future issuance 31 151
SPAC Warrants to Purchase Common Stock    
Class of Stock [Line Items]    
Common stock reserved for future issuance 704 3,734
Stock Options    
Class of Stock [Line Items]    
Common stock reserved for future issuance 1,721 1,552
Restricted Stock Units    
Class of Stock [Line Items]    
Common stock reserved for future issuance 983 560
Authorized for Future Equity Grants    
Class of Stock [Line Items]    
Common stock reserved for future issuance 603 935
Authorized for Future ESPP Purchases    
Class of Stock [Line Items]    
Common stock reserved for future issuance 549 400
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details)
Dec. 31, 2021
shares
SPAC Warrants | Common Stock  
Class of Stock [Line Items]  
Number of shares issued for each warrant 0.25
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Loss Carryforwards [Line Items]      
Federal statutory rate 21.00% 21.00% 21.00%
Uncertain tax positions $ 0 $ 0 $ 0
Minimum      
Operating Loss Carryforwards [Line Items]      
Ownership interest 50.00% 50.00% 50.00%
Uncertain tax positions percentage 50.00%    
Domestic tax authority      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards $ 184,000,000.0 $ 110,800,000 $ 79,400,000
Tax credit carryforwards 1,400,000 900,000 800,000
State and local jurisdiction      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards 141,100,000 84,300,000 53,400,000
Tax credit carryforwards $ 1,300,000 $ 900,000 $ 800,000
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]      
Income tax at statutory rate 21.00% 21.00% 21.00%
State tax, net of federal tax benefit 4.80% 4.90%  
Permanent items 1.10% (0.10%) (0.80%)
Tax credits 0.60% 0.40% 0.20%
Other (0.40%) (0.50%)  
Valuation allowance (decrease) increase (27.10%) (25.70%) (20.40%)
Income tax expense 0.00% 0.00% 0.00%
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:      
Net operating loss $ 46,886 $ 28,422 $ 20,336
Research and development credits 2,411 1,631 1,400
Depreciation and amortization 0 14 33
Stock based compensation 2,126 653 119
Accruals and other 719 422 194
Operating lease liability 1,935 0 0
Deferred revenue 340 0 0
Total deferred tax assets 54,417 31,142 22,082
Deferred tax liabilities:      
Depreciation and amortization (32) 0 0
Operating lease right-of-use assets (1,972) 0 0
Total deferred tax liabilities (2,004) 0 0
Net deferred tax assets before valuation allowance 52,413 31,142 22,082
Less: valuation allowance (52,413) (31,142) (22,082)
Net deferred tax assets $ 0 $ 0 $ 0
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies - Additional Information (Details)
 12 Months Ended
Jul. 01, 2021
USD ($)
ft²
$ / ft²
Sep. 04, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 01, 2021
USD ($)
Sep. 02, 2020
USD ($)
Commitments And Contingencies [Line Items]              
Percentage of useful lives of assets     75.00%        
Gross assets     $ 6,174,000 $ 3,418,000      
Accumulated amortization     100,000 10,000      
Finance lease interest expense     $ 17,000        
Lessee, operating lease, description     In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations.        
Option to extend the lease term     an option to extend the lease term on all leased space for one additional three-year term        
Operating lease right-of-use assets     $ 7,744,000     $ 2,800,000  
Lease liability           3,100,000  
Estimated future lease payment obligation     10,006,000        
Tenant improvement allowance     $ 300,000     $ 300,000  
Lease expiration date     Apr. 30, 2023        
Remaining lease term           28 months  
Estimated discount rate           4.04%  
Payments for deferred underwriting fees       1,363,000      
Cowen              
Commitments And Contingencies [Line Items]              
Payments for deferred underwriting fees   $ 800,000          
Underwriting fees   $ 1,400,000 $ 1,400,000       $ 1,400,000
Maximum              
Commitments And Contingencies [Line Items]              
Increase in tenant improvement allowance     $ 100,000        
Kilroy Realty, L.P              
Commitments And Contingencies [Line Items]              
Lease commencement date Jul. 01, 2021            
Area of building | ft² 95,997            
Lessee, operating lease, description     The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease (the “Lease Commencement Date”). The Company has the option to extend the term of the Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.        
Tenant improvement allowance per rentable square foot | $ / ft² 125.00            
Tenant improvements $ 12,000,000.0            
Option to extend the lease term     five-year        
Operating lease right-of-use assets     $ 5,700,000        
Lease liability     5,700,000        
Estimated future lease payment obligation     63,300,000        
Kilroy Realty, L.P | Letter of Credit | Restricted Cash              
Commitments And Contingencies [Line Items]              
Security deposit $ 3,000,000.0            
Kilroy Realty, L.P | Standby Letter of Credit              
Commitments And Contingencies [Line Items]              
Security deposit     0        
Interest Income, Net              
Commitments And Contingencies [Line Items]              
Finance lease interest expense     17,000 3,000 $ 0    
Assets Recorded under Finance Leases              
Commitments And Contingencies [Line Items]              
Gross assets     400,000 300,000      
Accumulated amortization     $ 100,000 $ 10,000      
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Finance Lease Liability [Abstract]    
Gross finance lease obligations $ 274 $ 362
Less: imputed interest (17) (27)
Present value of net minimum lease payments 257 335
Less: current portion of finance lease obligations (121) (109)
Long-term finance lease obligations, less current portion $ 136 $ 226
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies - Components of Lease Expense (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Operating lease cost  
Operating lease cost $ 1,517
Variable lease costs 657
Total operating lease cost 2,174
Finance lease cost  
Amortization of leased assets 75
Finance lease interest expense 17
Total finance lease cost 92
Cash paid for amounts included in the measurement of lease liabilities  
Operating cash flows from operating leases 2,619
Finance lease interest expense 17
Financing cash flows from finance leases 171
Right-of-use assets obtained in exchange for lease obligations 9,044
Right-of-use assets obtained in exchange for new finance lease obligations $ 93
Weighted-average remaining lease term of operating leases (in years) 9 years 3 months 29 days
Weighted-average remaining lease term of finance leases (in years) 2 years 4 months 2 days
Weighted-average discount rate for operating leases 5.78%
Weighted-average discount rate for finance leases 5.63%
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
Operating lease obligations, including interest payments due in 2022 $ 1,802  
Operating lease obligations, including interest payments due in 2023 1,149  
Operating lease obligations, including interest payments due in 2024 688  
Operating lease obligations, including interest payments due in 2025 709  
Operating lease obligations, including interest payments due in 2026 730  
Operating lease obligations, including interest payments due thereafter 4,928  
Operating lease obligations, including interest payments due, Total 10,006  
Finance lease obligations, including interest payments due in 2022 132  
Finance lease obligations, including interest payments due in 2023 122  
Finance lease obligations, including interest payments due in 2024 8  
Finance lease obligations, including interest payments due in 2025 8  
Finance lease obligations, including interest payments due in 2026 4  
Gross finance lease obligations 274 $ 362
Total future minimum lease payments due in 2022 1,934  
Total future minimum lease payments due in 2023 1,271  
Total future minimum lease payments due in 2024 696  
Total future minimum lease payments due in 2025 717  
Total future minimum lease payments due in 2026 734  
Total future minimum lease payments due thereafter 4,928  
Total future minimum lease payments $ 10,280  
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases, Commitments and Contingencie - Additional Information (Details) - Cowen - USD ($)
 12 Months Ended
Dec. 31, 2021
Sep. 02, 2020
Sep. 04, 2019
Commitments And Contingencies [Line Items]      
Proceeds from equity financing $ 15,000,000.0    
Underwriting fees 1,400,000 $ 1,400,000 $ 1,400,000
Gross proceeds from PIPE financing 65,000,000.0    
Deferred underwriting fee equity payable if equity financing limit not raised $ 0    
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 26, 2021
Nov. 11, 2020
Oct. 01, 2019
Sep. 30, 2020
Aug. 31, 2020
Jul. 31, 2020
Jun. 30, 2020
May 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jan. 02, 2021
Related Party Transaction [Line Items]                        
Common stock, shares issued                 29,772,922 20,740,413    
Related party transaction, other                 $ 0 $ 0 $ 0  
EVERSANA | Leana Wood                        
Related Party Transaction [Line Items]                        
Related party certain marketing cost                 2,600,000 1,300,000 400,000  
DermTech,Inc. | Michael Dobak                        
Related Party Transaction [Line Items]                        
Related party certain marketing cost $ 20,000 $ 15,000   $ 15,000 $ 15,000 $ 15,000 $ 15,000 $ 15,000 $ 100,000 $ 200,000 $ 20,000  
Common stock, shares issued                       5,000
DermTech,Inc. | Michael Dobak | Maximum                        
Related Party Transaction [Line Items]                        
Related party certain marketing cost     $ 100,000                  
XML 70 dmtk-10k_20211231_htm.xml IDEA: XBRL DOCUMENT 0001651944 2021-01-01 2021-12-31 0001651944 2021-06-30 0001651944 2022-03-08 0001651944 2021-12-31 0001651944 2020-12-31 0001651944 dmtk:AssayMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractualActivitiesMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractualActivitiesMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractualActivitiesMember 2019-01-01 2019-12-31 0001651944 2020-01-01 2020-12-31 0001651944 2019-01-01 2019-12-31 0001651944 dmtk:SeriesC2ConvertiblePreferredStockMember 2018-12-31 0001651944 us-gaap:CommonStockMember 2018-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001651944 us-gaap:RetainedEarningsMember 2018-12-31 0001651944 2018-12-31 0001651944 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001651944 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001651944 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001651944 us-gaap:ConvertibleDebtMember dmtk:SeriesC2ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:ConvertibleDebtMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001651944 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001651944 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-12-31 0001651944 us-gaap:CommonStockMember 2019-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001651944 us-gaap:RetainedEarningsMember 2019-12-31 0001651944 2019-12-31 0001651944 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesAAndBConvertibleNoteMember dmtk:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesAAndBConvertibleNoteMember dmtk:SeriesB2ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001651944 dmtk:SeriesAAndBConvertibleNoteMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 dmtk:LifeSciMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 dmtk:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001651944 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001651944 us-gaap:CommonStockMember 2020-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001651944 us-gaap:RetainedEarningsMember 2020-12-31 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember 2020-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember 2020-12-31 0001651944 us-gaap:CommonStockMember 2021-12-31 0001651944 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001651944 dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001651944 us-gaap:CommonStockMember dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-12-31 0001651944 dmtk:PublicFollowOnOfferingMember 2021-01-01 2021-12-31 0001651944 2019-08-29 2019-08-29 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember dmtk:PublicOfferingMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember dmtk:PrivatePlacementOfferingMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-01-01 2019-12-31 0001651944 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-01-01 2020-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0001651944 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember 2021-01-01 2021-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2021-01-01 2021-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2020-01-01 2020-12-31 0001651944 dmtk:AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember 2019-01-01 2019-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2020-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2021-01-01 2021-12-31 0001651944 dmtk:AssetsHeldUnderFinanceLeasesMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueSmartStickersMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueSmartStickersMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueSmartStickersMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2019-01-01 2019-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0001651944 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueCustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorAMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001651944 dmtk:AssayRevenuePayorBMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:AssayRevenuePayorBMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerAMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerAMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerAMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerBMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerBMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerBMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001651944 dmtk:ContractRevenueCustomerBMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerCMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerCMember srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 dmtk:ContractRevenueCustomerCMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001651944 dmtk:ContractRevenueCustomerCMember srt:MaximumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember 2021-12-31 0001651944 srt:MaximumMember 2021-12-31 0001651944 dmtk:AssayMember 2021-12-31 0001651944 dmtk:AssayMember 2020-12-31 0001651944 dmtk:ContractualActivitiesMember 2021-12-31 0001651944 dmtk:ContractualActivitiesMember 2020-12-31 0001651944 dmtk:ConversionOfPreferredStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001651944 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001651944 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001651944 dmtk:StockOptionsAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2019-01-01 2019-12-31 0001651944 srt:MinimumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2020-01-01 2020-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2020-01-01 2020-12-31 0001651944 srt:MinimumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2019-01-01 2019-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001651944 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001651944 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2019-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2020-01-01 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2020-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2021-01-01 2021-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2021-12-31 0001651944 dmtk:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001651944 dmtk:RestrictedCashMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:MunicipalNotesMember 2021-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2021-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001651944 us-gaap:MunicipalNotesMember 2020-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2018-11-30 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2018-11-30 2018-11-30 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2019-09-23 2019-09-23 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-06-05 2019-06-10 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-06-10 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-23 0001651944 srt:MaximumMember dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-24 0001651944 srt:MaximumMember dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-23 2019-09-23 0001651944 srt:MaximumMember dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-24 2019-09-24 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2019-09-23 2019-09-23 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001651944 dmtk:TwoThousandNineteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2019-08-29 2019-08-29 0001651944 dmtk:SeriesAConvertiblePreferredStockMember 2020-08-10 2020-08-10 0001651944 2020-08-10 2020-08-10 0001651944 dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001651944 us-gaap:CommonStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 us-gaap:CommonStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 0001651944 dmtk:SecuritiesPurchaseAgreementMember 2020-02-28 2020-02-28 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-03-02 2020-03-02 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-05-27 0001651944 dmtk:SeriesB1ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-05-27 2020-05-27 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesB2ConvertiblePreferredStockMember dmtk:TwoThousandAndTwentyPIPEFinancingMember 2020-08-10 2020-08-10 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2020-11-10 2020-11-10 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2021-01-01 2021-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2021-01-06 2021-01-06 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2021-01-11 2021-01-11 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2021-01-11 0001651944 2021-01-11 2021-01-11 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2020-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2020-12-31 0001651944 srt:MinimumMember dmtk:SeriesCWarrantsMember dmtk:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember dmtk:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001651944 dmtk:SeriesCWarrantsMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-01-01 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2015-01-01 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-01-01 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:CommonStockMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2021-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2020-12-31 0001651944 srt:MinimumMember dmtk:IncentiveAndNonStatutoryStockOptionsMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:IncentiveStockOptionsMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:IncentiveStockOptionsMember dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTenStockPlanMember 2021-12-31 0001651944 dmtk:TwoThousandTenStockPlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:IncentiveAndNonQualifiedStockOptionsMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 srt:MinimumMember dmtk:IncentiveStockOptionsMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001651944 dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEquityIncentivePlanMember 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2019-12-31 0001651944 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001651944 us-gaap:EmployeeStockMember 2020-12-31 0001651944 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2021-12-31 0001651944 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001651944 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001651944 srt:MaximumMember dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-12-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-02-28 2021-02-28 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-08-31 2021-08-31 0001651944 dmtk:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 0001651944 dmtk:ManagementWarrantsMember 2021-12-31 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2021-12-31 0001651944 dmtk:ManagementWarrantsMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001651944 dmtk:ManagementWarrantsMember 2020-12-31 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 dmtk:WarrantsToPurchaseCommonStockMember 2020-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember 2020-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2021-12-31 0001651944 us-gaap:EmployeeStockOptionMember 2020-12-31 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureEquityGrantsMember 2020-12-31 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2021-12-31 0001651944 dmtk:AuthorizedForFutureESPPPurchasesMember 2020-12-31 0001651944 us-gaap:DomesticCountryMember 2021-12-31 0001651944 us-gaap:DomesticCountryMember 2020-12-31 0001651944 us-gaap:DomesticCountryMember 2019-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001651944 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001651944 srt:MinimumMember 2020-12-31 0001651944 srt:MinimumMember 2019-12-31 0001651944 us-gaap:InterestIncomeMember 2021-01-01 2021-12-31 0001651944 us-gaap:InterestIncomeMember 2020-01-01 2020-12-31 0001651944 us-gaap:InterestIncomeMember 2019-01-01 2019-12-31 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember 2021-01-01 2021-12-31 0001651944 dmtk:KilroyRealtyLPMember 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember 2021-12-31 0001651944 dmtk:KilroyRealtyLPMember dmtk:RestrictedCashMember us-gaap:LetterOfCreditMember 2021-07-01 0001651944 dmtk:KilroyRealtyLPMember us-gaap:StandbyLettersOfCreditMember 2021-12-31 0001651944 2021-01-01 0001651944 dmtk:CowenMember 2019-09-04 2019-09-04 0001651944 dmtk:CowenMember 2019-09-04 0001651944 dmtk:CowenMember 2021-01-01 2021-12-31 0001651944 dmtk:CowenMember 2021-12-31 0001651944 dmtk:CowenMember 2020-09-02 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2021-01-01 2021-12-31 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2020-01-01 2020-12-31 0001651944 dmtk:EVERSANALifeScienceServicesLLCMember dmtk:SpouseOfChiefCommercialOfficerMember 2019-01-01 2019-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-11-11 2020-11-11 0001651944 srt:MaximumMember dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2019-10-01 2019-10-01 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-05-01 2020-05-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-06-01 2020-06-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-07-01 2020-07-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-08-01 2020-08-31 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2020-09-01 2020-09-30 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-02-26 2021-02-26 0001651944 dmtk:DermTechOperationsIncMember dmtk:BrotherOfChiefExecutiveOfficerMember 2021-01-02 iso4217:USD shares iso4217:USD shares pure dmtk:Warrant dmtk:Revenue_Stream dmtk:Segment utr:sqft iso4217:USD utr:sqft 10-K false FY 0001651944 --12-31 0.5 0.25 P3Y 0.25 0.25 P10Y P2Y P5Y P3Y P7Y P7Y P7Y P4Y P5Y 0.25 0.25 0.25 0.0052 0.0036 0.0168 0.7488 0.6403 0.7230 P6Y29D 0.0139 0.0169 0.0250 0.8332 0.7344 0.7350 P5Y14D P6Y3M P6Y7D P6Y29D 0.0005 0.0018 0.6455 0.6934 P5M26D P6M P5M26D 0.46 0.22 1.40 85.85 69.79 64.06 P2Y7M28D P3Y7M28D P4Y8M1D 0.85 0.33 1.66 90.70 79.26 66.68 P3Y5M1D P4Y5M1D P5Y P7Y9M18D P8Y10M28D P8Y3M21D P8Y3M21D P7Y7M2D P9Y3M29D P2Y4M2D true 2021-12-31 2021 false 001-38118 DERMTECH, INC. DE 84-2870849 11099 N. Torrey Pines Road Suite 100 La Jolla CA 92037 858 450‑4222 Common Stock, par value $0.0001 per share DMTK NASDAQ No No Yes Yes Large Accelerated Filer true false true false 978378259 29850730 <p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p> <p style="margin-bottom:2pt;margin-top:4pt;text-indent:4.54%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2021. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.</p> 185 KPMG LLP San Diego, CA 176882000 24248000 48449000 39529000 3847000 1480000 480000 104000 3166000 1521000 232824000 66882000 4549000 2731000 7744000 3025000 167000 167000 248309000 69780000 2880000 1573000 5120000 2075000 1227000 763000 1380000 905000 1453000 121000 109000 12181000 5425000 146000 1650000 639000 136000 226000 6148000 18611000 7940000 0.0001 0.0001 50000000 50000000 29772922 29772922 20740413 20740413 3000 2000 436183000 189868000 -124000 -1000 -206364000 -128029000 229698000 61840000 248309000 69780000 11023000 4241000 1403000 815000 1644000 1961000 11838000 5885000 3364000 10564000 5981000 3304000 1274000 -96000 60000 37575000 16077000 6303000 16261000 5293000 2497000 24836000 13823000 8865000 78672000 35193000 17665000 -77398000 -35289000 -17605000 151000 40000 -2657000 1088000 1228000 441000 928000 355000 -937000 -1188000 -2525000 -78335000 -36477000 -20130000 28884874 16979411 7005037 -2.71 -2.15 -2.87 -78335000 -36477000 -20130000 -123000 -1000 -78458000 -36478000 -20130000 1524122 4411567 1000 66021000 -71377000 -5355000 -45000 -45000 726139 934000 934000 1524122 -1524122 2267042 12687000 12687000 420000 420000 3250 1231 4000000 4000000 6.50 200000 3076923 19802000 19802000 -187000 -187000 339025 -1569000 -1569000 1304000 1304000 -20130000 -20130000 1231 12344818 1000 103412000 -91552000 11861000 10.50 2000000.0 2467724 23889000 23889000 10500 2600000 3199 30968000 30968000 10500 400000 524 5071000 5071000 319522 473000 473000 230619 842000 842000 -77000 -77000 -3199 3198949 1000 1000 -1231 -524 1139199 87790 1011000 1011000 20.97 900000 951792 19104000 19104000 206000 206000 -1000 -1000 4969000 4969000 -36477000 -36477000 20740413 2000 189868000 -1000 -128029000 61840000 20740413 2000 189868000 -1000 -128029000 61840000 29.50 9100000 4872881 1000 134581000 134582000 46.33 700000 530551 23836000 23836000 466442 793000 793000 3104520 72429000 72429000 58115 966000 966000 -123000 -123000 13276000 13276000 434000 434000 -78335000 -78335000 29772922 3000 436183000 -124000 -206364000 229698000 -78335000 -36477000 -20130000 997000 486000 89000 1088000 1228000 441000 928000 355000 1983000 1299000 13276000 4969000 1304000 -749000 21000 -15000 -13000 1569000 2367000 800000 100000 376000 69000 -5000 1700000 487000 1069000 -1443000 4335000 827000 1337000 356000 1647000 491000 -62106000 -28684000 -17791000 48092000 41706000 1600000 36700000 2200000 2720000 1834000 210000 -12512000 -41340000 -210000 23889000 134582000 30968000 5071000 1363000 77000 23836000 19104000 19802000 70271000 842000 5000 793000 473000 929000 966000 2600000 -516000 4000000 171000 9000 1802000 230277000 78898000 28622000 155659000 8874000 10621000 24248000 15374000 4753000 179907000 24248000 15374000 17000 2000 1011000 17000 71000 641000 434000 206000 2158000 9044000 93000 342000 -123000 -1000 56000 1363000 270000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and a Summary of its Significant Accounting Policies</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock (“Reverse Stock Split”). </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the end of the first quarter of 2020 and through the fourth quarter of 2021, there has been a widespread worldwide impact from the COVID-19 pandemic. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company has implemented additional safety measures in accordance with Centers for Disease Control and Prevention (“CDC”), Occupational Safety and Health Administration (“OSHA”) and other guidance within its CLIA laboratory operations. Additionally, the Company has transitioned administrative functions to predominantly remote work. Beginning in March 2020 and continuing through the fourth quarter of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by the Company’s sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received during the fourth quarter of 2021 relative to the Company’s pre-pandemic expectations. The Company expects the ongoing COVID-19 pandemic to continue to adversely impact billable sample volume until patient access to in-person testing fully resumes, in-office access by the Company’s sales force returns to pre-pandemic levels, or telemedicine options are more widely adopted. Additionally, the ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect the Company’s pharmaceutical customers’ clinical trials. The extent of such effect on the Company’s future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on the Company’s pharmaceutical customers’ clinical trials.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Presentation</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”). In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.<span style="font-size:11pt;"> </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revision to Prior Period Financial Statements  </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed under the heading “Revision to Prior Period Financial Statements” in Note 1 of the Company’s Quarterly Report on Form 10-Q filed on May 13, 2021, during the course of preparing the quarterly report Form 10-Q for the three months ended March 31, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The SEC Statement highlighted challenges associated with the accounting for complex financial instruments that may be common in SPACs, specifically accounting for warrants issued in connection with a SPAC’s formation and initial registered offering. In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company previously issued warrants to purchase common stock in public and private placement offerings consummated on June 23, 2017 (the “SPAC Warrants”), which were originally classified as equity in the Company’s financial statements. As part of the aforementioned public offering, the Company issued 14,375,000 warrants (the “Public SPAC Warrants”) and as part of the aforementioned private placement offering, the Company issued 561,250 warrants (the “Private SPAC Warrants”). The SPAC Warrants have a <span style="-sec-ix-hidden:F_000449">five-year</span> life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase <span style="-sec-ix-hidden:F_000451_2">one</span> whole share of common stock at an exercise price of $23.00 per whole share.<span style="font-size:11pt;"> </span>The Company’s SPAC Warrants were accounted for as equity within the Company’s previously reported consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Private SPAC Warrants were recorded as a component of equity as opposed to liabilities on the Company’s consolidated balance sheets and the Company’s consolidated statements of operations did not include the subsequent non-cash changes in estimated fair value of the Private SPAC Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, <span style="font-style:italic;">Derivatives and Hedging, Contracts in Entity’s Own Equity</span> (“ASC 815-40”). The views expressed in the recent SEC Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for SPAC Warrants issued on June 23, 2017, in light of the SEC Staff’s published views. After discussion and evaluation, the Company concluded that, as a result of these differences in features between the Public SPAC Warrants and Private SPAC Warrants, the Private SPAC Warrants should be classified as liabilities, if still held by the original Private SPAC Warrant holder, with subsequent changes in fair value reported in the Company’s consolidated statement of operations. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company analyzed the impact of the aforementioned adjustments on its previously issued audited consolidated financial statements for the years ended December 31, 2020 and 2019 and previously issued unaudited consolidated financial statements for the periods ended September 30, 2020 and 2019, June 30, 2020, and March 31, 2020 (such years and periods, the “Affected Periods”). The Company concluded the adjustments are not material to any individual period prior to the period ended March 31, 2021, taking into account the requirements of ASC Topic 250, <span style="font-style:italic;">Accounting Changes and Error Corrections</span>, ASC Topic 270, <span style="font-style:italic;">Interim Financial Reporting</span>, ASC Topic 250-S99-1, <span style="font-style:italic;">Assessing Materiality</span>, and ASC Topic 250-S99-2, <span style="font-style:italic;">Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</span>. In accordance with the authoritative guidance, management evaluated the materiality of the adjustments from a quantitative and qualitative perspective. Based on such evaluation, the Company concluded that the effects of these adjustments were not material individually or in the aggregate to the Affected Periods and had no effect on the trend of financial results. While management concluded the adjustment was not material to any prior periods, individually or in the aggregate, based on our qualitative and quantitative analysis, management opted to make the adjustment by revising the respective amounts that were previously reported in the Affected Period. Accordingly, the Company has revised the prior period interim and annual financial information for the Affected Periods to reflect these adjustments.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,350</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,599</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,111</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,489</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,861</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,360</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,669</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,029</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100.4%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income/(expense):</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income/(expense)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,084</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share of common stock</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  outstanding, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.08</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.07</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of cash flow are not presented because there is no impact on total cash flows from operating activities, investing activities, or financing activities. Certain components of net cash used in operating activities changed, as caused by the revision, such as incorporating the non-cash item from the change in fair value of warrant liability in the adjustments to reconcile net loss to net cash used in operating activities, but the net change amounted to zero for the Affected Periods.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Use of Estimates </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to, those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Cash, Cash Equivalents and Restricted Cash </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   reported in the consolidated statements of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(f)<span style="font-weight:normal;font-style:normal;">   </span><span style="color:#000000;">Marketable Securities</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.1%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers securities with maturities of greater than 90 days at the time of purchase to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, such marketable securities are classified as current assets on the accompanying consolidated balance sheets even if they have contractual maturities greater than one year from the date of purchase. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost basis, which </p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occur</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 202</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, <span style="color:#000000;">office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. </span>Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $1.0 million, $0.5 million, and $0.1 million, for the years ended December 31, 2021, 2020, and 2019, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $0.1 million, $10,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the consolidated statement of operations. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. The Company disposed of $0.1 million, $0.1 million, and zero of equipment during the years ended December 31, 2021, 2020, and 2019, respectively. <span style="Background-color:#FFFFFF;color:#000000;">The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the years ended December 31, 2021, 2020, and 2019.</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(h)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices and finance leases for certain laboratory and office equipment.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In accordance with Accounting Standards Update (“ASU”) No. 2016-02, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases</span><span style="Background-color:#FFFFFF;"> (Topic 842), as adopted on January 1, 2021, the Company determines if an arrangement is a lease at inception. Finance leases are included in the consolidated balance sheets as property and equipment, net and finance lease obligations at the present value of the lease payments. Operating leases are included in the consolidated balance sheet as ROU assets and operating lease liabilities at the present value of the lease payments. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, the Company has used a number of factors including the credit rating, and the lease term.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of less than <span style="-sec-ix-hidden:F_000535">2 years to 10 years</span>, some of which include options to extend the lease for up to 10 years. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest income, net on the Company’s consolidated statements of operations.</span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with research and development (“R&amp;D”) activities are expensed as incurred. R&amp;D expenses consist of (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; and (ii) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Concentration of Credit Risk </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2021, the Company maintained $100.1 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $60.2 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of December 31, 2021. The Company has not experienced any losses in such accounts. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for federal and state income taxes on the asset and liability approach which requires deferred tax assets and liabilities to be recognized based on temporary differences between the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to reverse. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year and prior year operating losses, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2021. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and deferred tax assets and liabilities are recognized based on the tax positions taken or expected to be taken in the Company’s income tax returns. U.S. GAAP requires that the tax benefits of an uncertain tax position can only be recognized when it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority. Tax benefits related to tax positions that do not meet this criterion are not recognized in the consolidated financial statements, of which there are none. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to income tax matters in income tax expense.  </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue Recognition </p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with ASC Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers </span>(“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. <span style="font-size:11pt;color:#000000;"> </span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Assay Revenue </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLA</span><span style="font-style:italic;Background-color:#FFFFFF;">plus</span><span style="Background-color:#FFFFFF;"> (now referred to as the “DermTech Melanoma Test” or “DMT”, which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLA</span><span style="font-style:italic;Background-color:#FFFFFF;">plus</span><span style="Background-color:#FFFFFF;">) it provides to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in a limited number of states where permitted by law and applicable standards of practice guidelines.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Once the sample is collected by the patient via the telemedicine solution</span><span style="Background-color:#FFFFFF;"> or by a healthcare clinician in person</span><span style="Background-color:#FFFFFF;">, it is returned to the Company’s CLIA laboratory for analysis. The patient’s </span><span style="Background-color:#FFFFFF;">ribonucleic acid (“</span><span style="Background-color:#FFFFFF;">RNA</span><span style="Background-color:#FFFFFF;">”)</span><span style="Background-color:#FFFFFF;"> and </span><span style="Background-color:#FFFFFF;">deoxyribonucleic acid (“</span><span style="Background-color:#FFFFFF;">DNA</span><span style="Background-color:#FFFFFF;">”)</span><span style="Background-color:#FFFFFF;"> are extracted from the </span><span style="Background-color:#FFFFFF;">S</span><span style="Background-color:#FFFFFF;">mart </span><span style="Background-color:#FFFFFF;">S</span><span style="Background-color:#FFFFFF;">ticker </span><span style="Background-color:#FFFFFF;">and analyzed using gene expression </span><span style="Background-color:#FFFFFF;">and sequencing </span><span style="Background-color:#FFFFFF;">technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the </span><span style="Background-color:#FFFFFF;">clinician</span><span style="Background-color:#FFFFFF;"> detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.</span></p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s customer is the patient. However, the Company does not enter into a formal reimbursement agreement with a patient, as formal reimbursement agreements are more commonly established with insurance payors. Accordingly, the Company establishes an agreement with a patient in accordance with other customary business practices.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of an agreement is established by the use of <span style="color:#000000;">the Company’s </span>Smart Sticker on a patient by an ordering clinician, which is then sent to <span style="color:#000000;">the Company’s </span>central lab for testing.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to perform <span style="color:#000000;">the Company’s </span>laboratory services upon receipt of a sample from a clinician, and the patient and/or applicable payor are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms are a function of a patient’s existing insurance benefits.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the Company delivers a patient’s test result to the ordering physician, the Company is legally able to collect payment and bill an insurer and/or patient, depending on payor agreement status or patient insurance benefit status.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s <span style="color:#000000;">consideration is deemed to be variable, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.</span></p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in an agreement to transfer a distinct good or service (or a bundle of goods or services) to the customer. The customer is able to order a DMT, which is treated as a single performance obligation. </p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transaction Price</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration derived from the Company’s agreements is deemed to be variable, though the variability is not explicitly stated in any agreement. Rather, the implied variability is due to several factors, such as the amount of contractual adjustments, any patient co-payments, deductibles or patient compliance incentives, the existence of secondary payors and claim denials.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. Revenue recognized from changes in transaction prices was not material for the years ended December 31, 2021, 2020, and 2019, respectively.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for an agreement with a patient, it will account for the change as an increase in the estimate of the transaction price (i.e., an upward revenue adjustment) in the period identified. Similarly, if the Company subsequently determines that the amount it expects to collect from a patient is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price (i.e., a downward revenue adjustment), provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of a patient’s test result to the ordering physician, with recognition, generally occurring at the date of cash receipt.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocate the Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The entire transaction price is allocated entirely to the single performance obligation contained within the agreement with a patient.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recognize Revenue</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful test result is delivered to the patient’s ordering physician. The Company considers this date to be the time at which the patient obtains control of the final results of the promised test service.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Revenue </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company’s contract revenue, the Company has established agreements and work orders with the Company’s third-party partners that fall under the scope of ASC 606.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 606 requires an entity to assess the goods or services promised in a contract and identify as a performance obligation each promise to transfer to the customer either a good or service (or a bundle of goods or services) that is distinct, or a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Based upon review of existing contracts, a majority of the Company’s contract revenue agreements contain three performance obligations:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA extractions and analysis</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain project management fees</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Many of the Company’s contract revenue agreements contain promises such as start-up activities and quality system setup fees, which are activities that the Company performs to fulfill the agreement and they do not transfer any good or service to the customer. These promises encompass the administrative tasks associated with beginning and initiating a new project or study with a third-party company. In accordance with ASC 606, an entity does not account for these activities as a promised good or service within the agreement nor evaluate whether they are a performance obligation.</span> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in an agreement with a customer may include fixed amounts, variable amounts, or both.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction prices of the Company’s performance obligations are listed in its agreements on a per unit basis and are fixed for adhesive sample collection kits and RNA extractions and analysis. The project management fees are assessed based on a monthly service fee which range within the agreements depending on certain factors which include length of the project and the amount of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or RNA extractions and analysis promised within the agreement. The fixed and variable rates are materially consistent within the Company’s agreements. Therefore, the Company utilizes the prices listed in our agreements as the transaction price for each performance obligation.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the transaction price, ASC 606 requires an entity to adjust the promised amount of consideration for the effects of the time value of money if the agreement contains a significant financing component. The Company’s agreements state fixed transaction prices for each deliverable associated with the agreement and do not qualify for the significant financing component of ASC 606.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocate the Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s contracts have a directly observable transaction price pertaining to each promised good or service. Those prices are consistent across agreements for Smart Stickers and RNA extractions and analysis, with the exception of the Company’s project management fees, which the Company’s believes encompass a sufficiently narrow range of prices that are dictated upon factors of each agreement previously discussed above. Therefore, the Company relies on those transaction prices as the basis to allocate the stand-alone selling prices to the performance obligations of the agreement.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the Company’s agreements contain a discount that is allocated to items within the agreement, whether they are performance obligations or not. Those items that are not performance obligations (e.g., quality system setup and start up fees) have the associated discount allocated to the transaction prices of the performance obligations evenly.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recognize Revenue</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An entity should recognize revenue when (or as) it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is transferred when (or as) the customer obtains control of that good or service. The Smart Stickers are recognized at a point in time when shipped to the customer. The RNA extraction and analysis are recognized at a point in time when the extraction and analysis process is complete and the results are sent to the customer. The Company provides its project management service over the life of the agreement, providing equal benefit to the customer throughout the life of the project or study. Therefore, the revenue related to the Company’s project management fees is recognized straight-line over the life of the agreement.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:-3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">a</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disaggregation of Revenue</p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DermTech Melanoma Test</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA extractions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project management fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,885</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor A</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor B</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* <span class="MSWordContentControl" id="sdt_ed206504-51c2-4657-aeef-3d7bb9f069a4" title="Disclosure - The Company and a Summary of its Significant Accou">Less than <span class="MSWordContentControl" id="sdt_63513df4-2f80-49fc-a929-7fda547b3c93" title="Fact"><span class="MSWordContentControl" id="sdt_e2ca4cc7-c72f-43dc-aab3-8e940dba8fcc" title="Fact"><span class="MSWordContentControl" id="sdt_eb5516da-bf0b-491c-8966-8711e17ae9f4" title="Fact"><span class="MSWordContentControl" id="sdt_8455e3a6-8979-4045-a931-de10277d5680" title="Fact">10</span></span></span></span>%</span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other payors or customers that individually accounted for more than 10% of total revenue or accounts receivable for the periods shown in the table above.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">b</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Revenue and Remaining Performance Obligations </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a majority of agreements that produce contract revenue, the Company receives a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of December 31, 2021, and December 31, 2020, was $1.4 million and $0.9 million, respectively. Long-term deferred revenue as of December 31, 2021, and December 31, 2020, was zero and $0.6 million, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of December 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was approximately $0.4 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounts Receivable </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Assay Accounts Receivable </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.6 million and $1.0 million of gross assay accounts receivable as of December 31, 2021 and 2020, respectively.<span style="color:#000000;"> </span> </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Accounts Receivable </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of December 31, 2021, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reserve. The Company recorded $</span>0.2<span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</span>0.5<span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of contract accounts receivable as of December 31, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Freight and Shipping Costs </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records outbound freight and shipping costs for its contract and assay revenues in cost of revenues. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Comprehensive Loss </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net loss and the components of other comprehensive loss, including unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive loss. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment Reporting </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss Per Share </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the years ended December 31, 2021 and 2020, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the year ended December 31, 2021 excludes the effect of anti-dilutive equity instruments including 734,329 shares of common stock issuable upon the exercise of outstanding common stock warrants and 2,704,035 shares of common stock issuable upon the exercise stock options and release of RSUs. Diluted net loss per share of common stock for the year ended December 31, 2020 excludes the effect of anti-dilutive equity instruments including 3,885,311 shares of common stock then issuable upon the exercise of outstanding warrants and 2,112,980 shares of common stock then issuable upon the exercise of stock options and release of RSUs. Diluted net loss per common share for the year ended December 31, 2019 excludes the effect of anti-dilutive equity instruments including 615,385 shares of common stock issuable upon conversion of the Company’s preferred stock, 4,200,497 shares of common stock issuable upon the exercise of outstanding common stock warrants and 443,547 shares of common stock issuable upon the exercise stock options. The Company did not consider a two-class method of loss per share given that the Company’s convertible participating securities do not participate in losses. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of the Company’s common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. The Company recognizes stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock options and RSUs granted prior to January 1, 2020 will maintain the estimated forfeiture approach and will be recognized over the requisite service period using the straight-line method.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">0.52% - 1.39%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000609">0.36% - 1.69%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000610">1.68% - 2.50%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">74.88% - 83.32%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000615">64.03% - 73.44%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">72.30% - 73.50%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">6.08 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04 - 6.25 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.02 - 6.08 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05% - 0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.55% - 69.34%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 - 0.50 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 Employee Stock Purchase Plan (the “ESPP”), and consultant options of $13.3 million, $5.0 million, and $1.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The total compensation cost related to non-vested awards not yet recognized as of December 31, 2021 was $38.4 million, which is expected to be recognized over a weighted average term of 2.83 years.  </p> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:-3.4%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(s)<span style="font-weight:normal;font-style:normal;"> </span><span style="font-size:10pt;">Warrant Liability </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span> (“ASC 480”) and ASC 815-40. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants classified as liabilities and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a component of other income/(expense) in the consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes-Merton valuation model. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of its warrants. At that time, the portion of the warrant liability related to the Company’s warrants will be reclassified to additional paid-in capital.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">0.46% - 0.85%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000640">0.22% - 0.33%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000641">1.40% - 1.66%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000645">85.85% - 90.70%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">69.79% - 79.26%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">64.06% - 66.68%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000651">2.66 - 3.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000652">3.66 - 4.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000653">4.67 - 5.00 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:-3.4%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(t)<span style="font-weight:normal;font-style:normal;"> </span><span style="font-size:10pt;">Fair Value Measurements </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands): </p> <p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19,405</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">64,829</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,977</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Private SPAC Warrants was determined using the Black-Scholes-Merton valuation model and included a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unobservable input: expected volatility. Expected volatility is considered by the Company to be a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.44%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of warrant liability from exercise of Private SPAC Warrants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(434</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company maintains letters of credit of $3.0 million and zero, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the Company’s consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">u</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting Pronouncement Recently Adopted</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, FASB issued ASU No. 2016-02, <span style="font-style:italic;">Leases</span> (Topic 842) (“ASU 2016-02”), which supersedes FASB ASC Topic 840, <span style="font-style:italic;">Leases</span> (“ASC 840”), and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted ASC 842 during the third quarter of 2021 effective as of January 1, 2021. The Company has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adoption of ASU 2016-02 did not result in a cumulative adjustment to the Company’s accumulated deficit as of January 1, 2021. Adoption of ASU 2016-02 resulted in the recording of an operating lease ROU assets and lease liabilities of $2.8 million and $3.1 million, respectively. The difference between the operating lease ROU assets and lease liabilities are due to accrued deferred rent and unamortized lease incentives. Finance lease right-of-use assets and lease liabilities recognized as of January 1, 2021, included preexisting assets and liabilities of $0.3 million, related to finance leases accounted for under ASC 840. Adoption of ASU 2016-02 did not have a material impact on the Company’s results of operations or cash flows. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to use the transition package of three practical expedients, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, under ASC 842, the further practical expedient not to separate non-lease components from the lease components to which they relate and instead to combine them and account for them as a single lease component. The Company also elected the accounting policy election to keep leases with a term of 12 months or less off the balance sheet and to recognize payments for those leases on a straight-line basis over the lease term. The underlying assets of the Company’s leases as of the adoption date consisted of operating facilities and laboratory equipment.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment was exercised in the application of ASC 842 with respect to the determination of whether a contract contains a lease. While the ability to control and direct the use of an identified asset indicates that the contract, or portion of a contract, is a lease, a counterparty’s substantive substitution rights typically provide evidence that a lessee does not control the asset. Judgment was also exercised with respect to the determination of the discount rate used to determine the present value of lease payments. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a similar economic environment. The Company has no debt and has not had an established incremental borrowing rate. For the purpose of </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimating the incremental borrowing rate in the adoption of ASC 842, required management judgment including the development of a synthetic credit rating and cost of debt as we currently do not carry any debt. The Company calculates its incremental borrowing rates for </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments</span><span style="font-style:italic;color:#000000;">—</span><span style="font-style:italic;">Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) </span>(“ASU 2016-13”), <span style="color:#000000;">which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities</span>. Previously, when credit losses were measured under U.S. GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires companies to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.<span style="color:#231F20;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted the guidance under <span style="color:#231F20;">ASU 2016-13 </span>during the fourth quarter of 2021<span style="font-size:11pt;"> </span>and applied the modified retrospective method of adoption to the Company’s financial statements as of January 1, 2021. Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures and no cumulative adjustment was required to be recorded to the Company’s accumulated deficit as of January 1, 2021. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span> (“ASU 2019-12”). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. <span style="color:#000000;">The Company adopted this guidance during the fourth quarter of 2021</span><span style="font-size:11pt;color:#000000;"> </span>with no material impact to the Company's consolidated financial statements.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">v</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting Pronouncements Issued But Not Yet Effective </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share</span> <span style="font-style:italic;">(Topic 260),</span> <span style="font-style:italic;">Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span> (“ASU 2021-04”). ASU 2021-04 provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company plans to adopt the standard on January 1, 2022. The Company is currently evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company’s consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock (“Reverse Stock Split”). </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the end of the first quarter of 2020 and through the fourth quarter of 2021, there has been a widespread worldwide impact from the COVID-19 pandemic. The Company is considered an essential business due to the importance of early melanoma detection, which has allowed the Company’s CLIA laboratory to remain fully operational. The Company has implemented additional safety measures in accordance with Centers for Disease Control and Prevention (“CDC”), Occupational Safety and Health Administration (“OSHA”) and other guidance within its CLIA laboratory operations. Additionally, the Company has transitioned administrative functions to predominantly remote work. Beginning in March 2020 and continuing through the fourth quarter of 2021, the ongoing COVID-19 pandemic has reduced patient access to clinician offices for in-person testing and reduced access by the Company’s sales force for in-office sales calls, which has resulted in a reduced volume of billable samples received during the fourth quarter of 2021 relative to the Company’s pre-pandemic expectations. The Company expects the ongoing COVID-19 pandemic to continue to adversely impact billable sample volume until patient access to in-person testing fully resumes, in-office access by the Company’s sales force returns to pre-pandemic levels, or telemedicine options are more widely adopted. Additionally, the ongoing COVID-19 pandemic has negatively affected and will continue to negatively affect the Company’s pharmaceutical customers’ clinical trials. The extent of such effect on the Company’s future revenue is uncertain and will depend on the duration and extent of the effects of the ongoing COVID-19 pandemic on the Company’s pharmaceutical customers’ clinical trials.</p> one-for-two  <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Presentation</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of DermTech, Inc. and its subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”). In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.<span style="font-size:11pt;"> </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revision to Prior Period Financial Statements  </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed under the heading “Revision to Prior Period Financial Statements” in Note 1 of the Company’s Quarterly Report on Form 10-Q filed on May 13, 2021, during the course of preparing the quarterly report Form 10-Q for the three months ended March 31, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). The SEC Statement highlighted challenges associated with the accounting for complex financial instruments that may be common in SPACs, specifically accounting for warrants issued in connection with a SPAC’s formation and initial registered offering. In the SEC Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company previously issued warrants to purchase common stock in public and private placement offerings consummated on June 23, 2017 (the “SPAC Warrants”), which were originally classified as equity in the Company’s financial statements. As part of the aforementioned public offering, the Company issued 14,375,000 warrants (the “Public SPAC Warrants”) and as part of the aforementioned private placement offering, the Company issued 561,250 warrants (the “Private SPAC Warrants”). The SPAC Warrants have a <span style="-sec-ix-hidden:F_000449">five-year</span> life from the date the Business Combination was consummated and every four SPAC Warrants entitle the holder to purchase <span style="-sec-ix-hidden:F_000451_2">one</span> whole share of common stock at an exercise price of $23.00 per whole share.<span style="font-size:11pt;"> </span>The Company’s SPAC Warrants were accounted for as equity within the Company’s previously reported consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Private SPAC Warrants were recorded as a component of equity as opposed to liabilities on the Company’s consolidated balance sheets and the Company’s consolidated statements of operations did not include the subsequent non-cash changes in estimated fair value of the Private SPAC Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, <span style="font-style:italic;">Derivatives and Hedging, Contracts in Entity’s Own Equity</span> (“ASC 815-40”). The views expressed in the recent SEC Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for SPAC Warrants issued on June 23, 2017, in light of the SEC Staff’s published views. After discussion and evaluation, the Company concluded that, as a result of these differences in features between the Public SPAC Warrants and Private SPAC Warrants, the Private SPAC Warrants should be classified as liabilities, if still held by the original Private SPAC Warrant holder, with subsequent changes in fair value reported in the Company’s consolidated statement of operations. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company analyzed the impact of the aforementioned adjustments on its previously issued audited consolidated financial statements for the years ended December 31, 2020 and 2019 and previously issued unaudited consolidated financial statements for the periods ended September 30, 2020 and 2019, June 30, 2020, and March 31, 2020 (such years and periods, the “Affected Periods”). The Company concluded the adjustments are not material to any individual period prior to the period ended March 31, 2021, taking into account the requirements of ASC Topic 250, <span style="font-style:italic;">Accounting Changes and Error Corrections</span>, ASC Topic 270, <span style="font-style:italic;">Interim Financial Reporting</span>, ASC Topic 250-S99-1, <span style="font-style:italic;">Assessing Materiality</span>, and ASC Topic 250-S99-2, <span style="font-style:italic;">Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</span>. In accordance with the authoritative guidance, management evaluated the materiality of the adjustments from a quantitative and qualitative perspective. Based on such evaluation, the Company concluded that the effects of these adjustments were not material individually or in the aggregate to the Affected Periods and had no effect on the trend of financial results. While management concluded the adjustment was not material to any prior periods, individually or in the aggregate, based on our qualitative and quantitative analysis, management opted to make the adjustment by revising the respective amounts that were previously reported in the Affected Period. Accordingly, the Company has revised the prior period interim and annual financial information for the Affected Periods to reflect these adjustments.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,350</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,599</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,111</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,489</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,861</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,360</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,669</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,029</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100.4%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income/(expense):</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income/(expense)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,084</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share of common stock</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  outstanding, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.08</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.07</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated statements of cash flow are not presented because there is no impact on total cash flows from operating activities, investing activities, or financing activities. Certain components of net cash used in operating activities changed, as caused by the revision, such as incorporating the non-cash item from the change in fair value of warrant liability in the adjustments to reconcile net loss to net cash used in operating activities, but the net change amounted to zero for the Affected Periods.</p> 14375000 561250 4 23.00 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s accounting for the Private SPAC Warrants as components of liabilities instead of as equity did not have any effect on the Company’s previously reported operating expenses, total cash flows from operating activities, investing activities, and financing activities, cash or total assets. The impact on the individual line items of the Company’s consolidated balance sheets for each period presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,350</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,599</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,111</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,489</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,861</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet as of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders’ equity:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,360</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,669</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,029</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders’ equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact on the individual line items of the Company’s consolidated statements of operations for the periods presented from the adjustment was as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100.4%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Previously</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Revised</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income/(expense):</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income/(expense)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,084</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share of common stock</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  outstanding, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.08</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.07</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 628000 628000 5722000 628000 6350000 103599000 -187000 103412000 -91111000 -441000 -91552000 12489000 -628000 11861000 1650000 1650000 6290000 1650000 7940000 189849000 19000 189868000 -126360000 -1669000 -128029000 63490000 -1650000 61840000 441000 441000 1228000 1228000 -2084000 -441000 -2525000 40000 -1228000 -1188000 -19689000 -441000 -20130000 -35249000 -1228000 -36477000 -2.81 -0.06 -2.87 -2.08 -0.07 -2.15 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Use of Estimates </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to, those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Cash, Cash Equivalents and Restricted Cash </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with remaining maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the Federal Deposit Insurance Corporation legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of cash deposited with a financial institution as collateral for the Company’s letters of credit for its facility leases. Restricted cash is classified as noncurrent based on the terms of the underlying lease arrangement.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   reported in the consolidated statements of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   reported in the consolidated statements of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,753</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 24248000 176882000 15374000 24248000 4753000 15374000 3025000 24248000 179907000 15374000 24248000 4753000 15374000 <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(f)<span style="font-weight:normal;font-style:normal;">   </span><span style="color:#000000;">Marketable Securities</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.1%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers securities with maturities of greater than 90 days at the time of purchase to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, such marketable securities are classified as current assets on the accompanying consolidated balance sheets even if they have contractual maturities greater than one year from the date of purchase. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost basis, which </p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occur</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 202</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> Property and Equipment <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is recorded at cost less accumulated depreciation. Property and equipment consists mainly of assets such as leasehold improvements, <span style="color:#000000;">office, computer and laboratory equipment, including laboratory equipment acquired under finance lease arrangements. </span>Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to five years. Leasehold improvements are depreciated over the shorter of the remaining term of the lease or the useful life of the asset. The Company recorded depreciation expense of $1.0 million, $0.5 million, and $0.1 million, for the years ended December 31, 2021, 2020, and 2019, respectively, which includes amortization of laboratory equipment acquired under finance leases (previously referred to as “capital leases”) of $0.1 million, $10,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of assets that are recorded under finance leases in depreciation expense is included in cost of revenues on the consolidated statement of operations. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Maintenance and repairs are expensed as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. The Company disposed of $0.1 million, $0.1 million, and zero of equipment during the years ended December 31, 2021, 2020, and 2019, respectively. <span style="Background-color:#FFFFFF;color:#000000;">The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses for the years ended December 31, 2021, 2020, and 2019.</span></p> P2Y P5Y 1000000.0 500000 100000 100000 10000 0 400000 300000 100000 10000 100000 100000 0 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(h)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices and finance leases for certain laboratory and office equipment.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In accordance with Accounting Standards Update (“ASU”) No. 2016-02, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases</span><span style="Background-color:#FFFFFF;"> (Topic 842), as adopted on January 1, 2021, the Company determines if an arrangement is a lease at inception. Finance leases are included in the consolidated balance sheets as property and equipment, net and finance lease obligations at the present value of the lease payments. Operating leases are included in the consolidated balance sheet as ROU assets and operating lease liabilities at the present value of the lease payments. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, the Company has used a number of factors including the credit rating, and the lease term.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of less than <span style="-sec-ix-hidden:F_000535">2 years to 10 years</span>, some of which include options to extend the lease for up to 10 years. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest income, net on the Company’s consolidated statements of operations.</span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.</p> P10Y <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with research and development (“R&amp;D”) activities are expensed as incurred. R&amp;D expenses consist of (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; and (ii) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Concentration of Credit Risk </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2021, the Company maintained $100.1 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $60.2 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of December 31, 2021. The Company has not experienced any losses in such accounts. </p> 100100000 250000 60200000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for federal and state income taxes on the asset and liability approach which requires deferred tax assets and liabilities to be recognized based on temporary differences between the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to reverse. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year and prior year operating losses, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2021. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and deferred tax assets and liabilities are recognized based on the tax positions taken or expected to be taken in the Company’s income tax returns. U.S. GAAP requires that the tax benefits of an uncertain tax position can only be recognized when it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority. Tax benefits related to tax positions that do not meet this criterion are not recognized in the consolidated financial statements, of which there are none. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to income tax matters in income tax expense.  </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue Recognition </p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s revenue is generated from two revenue streams: contract revenue and assay revenue. The Company accounts for revenue in accordance with ASC Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers </span>(“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. <span style="font-size:11pt;color:#000000;"> </span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes revenue from its assay and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for Assay Revenue and then for Contract Revenue.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Assay Revenue </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company generates revenues from its Pigmented Lesion Assay (“PLA”) and PLA</span><span style="font-style:italic;Background-color:#FFFFFF;">plus</span><span style="Background-color:#FFFFFF;"> (now referred to as the “DermTech Melanoma Test” or “DMT”, which may consist at the option of the ordering clinician of either (i) the PLA or (ii) the PLA and PLA</span><span style="font-style:italic;Background-color:#FFFFFF;">plus</span><span style="Background-color:#FFFFFF;">) it provides to healthcare clinicians throughout the United States to assist in a clinician’s diagnosis of melanoma. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote collection on ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT. The DermTech Connect app and telemedicine service were initially beta tested in Florida and is currently available in a limited number of states where permitted by law and applicable standards of practice guidelines.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Once the sample is collected by the patient via the telemedicine solution</span><span style="Background-color:#FFFFFF;"> or by a healthcare clinician in person</span><span style="Background-color:#FFFFFF;">, it is returned to the Company’s CLIA laboratory for analysis. The patient’s </span><span style="Background-color:#FFFFFF;">ribonucleic acid (“</span><span style="Background-color:#FFFFFF;">RNA</span><span style="Background-color:#FFFFFF;">”)</span><span style="Background-color:#FFFFFF;"> and </span><span style="Background-color:#FFFFFF;">deoxyribonucleic acid (“</span><span style="Background-color:#FFFFFF;">DNA</span><span style="Background-color:#FFFFFF;">”)</span><span style="Background-color:#FFFFFF;"> are extracted from the </span><span style="Background-color:#FFFFFF;">S</span><span style="Background-color:#FFFFFF;">mart </span><span style="Background-color:#FFFFFF;">S</span><span style="Background-color:#FFFFFF;">ticker </span><span style="Background-color:#FFFFFF;">and analyzed using gene expression </span><span style="Background-color:#FFFFFF;">and sequencing </span><span style="Background-color:#FFFFFF;">technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, a final report is drafted and provided to the </span><span style="Background-color:#FFFFFF;">clinician</span><span style="Background-color:#FFFFFF;"> detailing the test results for the pigmented skin lesion indicating whether the sample collected is indicative of melanoma or not.</span></p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s customer is the patient. However, the Company does not enter into a formal reimbursement agreement with a patient, as formal reimbursement agreements are more commonly established with insurance payors. Accordingly, the Company establishes an agreement with a patient in accordance with other customary business practices.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of an agreement is established by the use of <span style="color:#000000;">the Company’s </span>Smart Sticker on a patient by an ordering clinician, which is then sent to <span style="color:#000000;">the Company’s </span>central lab for testing.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to perform <span style="color:#000000;">the Company’s </span>laboratory services upon receipt of a sample from a clinician, and the patient and/or applicable payor are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms are a function of a patient’s existing insurance benefits.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the Company delivers a patient’s test result to the ordering physician, the Company is legally able to collect payment and bill an insurer and/or patient, depending on payor agreement status or patient insurance benefit status.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">•</p></td> <td style="width:auto;" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s <span style="color:#000000;">consideration is deemed to be variable, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.</span></p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in an agreement to transfer a distinct good or service (or a bundle of goods or services) to the customer. The customer is able to order a DMT, which is treated as a single performance obligation. </p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transaction Price</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected from an agreement with a customer may include fixed amounts, variable amounts, or both.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration derived from the Company’s agreements is deemed to be variable, though the variability is not explicitly stated in any agreement. Rather, the implied variability is due to several factors, such as the amount of contractual adjustments, any patient co-payments, deductibles or patient compliance incentives, the existence of secondary payors and claim denials.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payor reimbursement agreements.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. Revenue recognized from changes in transaction prices was not material for the years ended December 31, 2021, 2020, and 2019, respectively.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for an agreement with a patient, it will account for the change as an increase in the estimate of the transaction price (i.e., an upward revenue adjustment) in the period identified. Similarly, if the Company subsequently determines that the amount it expects to collect from a patient is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price (i.e., a downward revenue adjustment), provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of a patient’s test result to the ordering physician, with recognition, generally occurring at the date of cash receipt.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocate the Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The entire transaction price is allocated entirely to the single performance obligation contained within the agreement with a patient.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recognize Revenue</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful test result is delivered to the patient’s ordering physician. The Company considers this date to be the time at which the patient obtains control of the final results of the promised test service.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Revenue </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression tests to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners, RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company’s contract revenue, the Company has established agreements and work orders with the Company’s third-party partners that fall under the scope of ASC 606.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 606 requires an entity to assess the goods or services promised in a contract and identify as a performance obligation each promise to transfer to the customer either a good or service (or a bundle of goods or services) that is distinct, or a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Based upon review of existing contracts, a majority of the Company’s contract revenue agreements contain three performance obligations:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA extractions and analysis</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="width:4.54%;white-space:nowrap;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td> <td style="width:auto;" valign="top"> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain project management fees</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Many of the Company’s contract revenue agreements contain promises such as start-up activities and quality system setup fees, which are activities that the Company performs to fulfill the agreement and they do not transfer any good or service to the customer. These promises encompass the administrative tasks associated with beginning and initiating a new project or study with a third-party company. In accordance with ASC 606, an entity does not account for these activities as a promised good or service within the agreement nor evaluate whether they are a performance obligation.</span> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in an agreement with a customer may include fixed amounts, variable amounts, or both.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction prices of the Company’s performance obligations are listed in its agreements on a per unit basis and are fixed for adhesive sample collection kits and RNA extractions and analysis. The project management fees are assessed based on a monthly service fee which range within the agreements depending on certain factors which include length of the project and the amount of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or RNA extractions and analysis promised within the agreement. The fixed and variable rates are materially consistent within the Company’s agreements. Therefore, the Company utilizes the prices listed in our agreements as the transaction price for each performance obligation.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the transaction price, ASC 606 requires an entity to adjust the promised amount of consideration for the effects of the time value of money if the agreement contains a significant financing component. The Company’s agreements state fixed transaction prices for each deliverable associated with the agreement and do not qualify for the significant financing component of ASC 606.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocate the Transaction Price</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s contracts have a directly observable transaction price pertaining to each promised good or service. Those prices are consistent across agreements for Smart Stickers and RNA extractions and analysis, with the exception of the Company’s project management fees, which the Company’s believes encompass a sufficiently narrow range of prices that are dictated upon factors of each agreement previously discussed above. Therefore, the Company relies on those transaction prices as the basis to allocate the stand-alone selling prices to the performance obligations of the agreement.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the Company’s agreements contain a discount that is allocated to items within the agreement, whether they are performance obligations or not. Those items that are not performance obligations (e.g., quality system setup and start up fees) have the associated discount allocated to the transaction prices of the performance obligations evenly.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:3.86%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recognize Revenue</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An entity should recognize revenue when (or as) it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is transferred when (or as) the customer obtains control of that good or service. The Smart Stickers are recognized at a point in time when shipped to the customer. The RNA extraction and analysis are recognized at a point in time when the extraction and analysis process is complete and the results are sent to the customer. The Company provides its project management service over the life of the agreement, providing equal benefit to the customer throughout the life of the project or study. Therefore, the revenue related to the Company’s project management fees is recognized straight-line over the life of the agreement.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:-3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">a</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disaggregation of Revenue</p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DermTech Melanoma Test</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA extractions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project management fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,885</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor A</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor B</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* <span class="MSWordContentControl" id="sdt_ed206504-51c2-4657-aeef-3d7bb9f069a4" title="Disclosure - The Company and a Summary of its Significant Accou">Less than <span class="MSWordContentControl" id="sdt_63513df4-2f80-49fc-a929-7fda547b3c93" title="Fact"><span class="MSWordContentControl" id="sdt_e2ca4cc7-c72f-43dc-aab3-8e940dba8fcc" title="Fact"><span class="MSWordContentControl" id="sdt_eb5516da-bf0b-491c-8966-8711e17ae9f4" title="Fact"><span class="MSWordContentControl" id="sdt_8455e3a6-8979-4045-a931-de10277d5680" title="Fact">10</span></span></span></span>%</span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other payors or customers that individually accounted for more than 10% of total revenue or accounts receivable for the periods shown in the table above.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">b</span><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Revenue and Remaining Performance Obligations </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a majority of agreements that produce contract revenue, the Company receives a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of December 31, 2021, and December 31, 2020, was $1.4 million and $0.9 million, respectively. Long-term deferred revenue as of December 31, 2021, and December 31, 2020, was zero and $0.6 million, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of December 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was approximately $0.4 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next two to three years.</span></p> 2 <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the Company’s revenues disaggregated by revenue source during the years ended December 31, 2021, 2020, and 2019, respectively (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DermTech Melanoma Test</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smart Stickers</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA extractions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project management fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,885</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 11023000 4241000 1403000 348000 213000 476000 300000 1172000 626000 166000 258000 336000 1000 1000 523000 11838000 5885000 3364000 <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the percentages of total revenue or accounts receivable for the Company’s third-party payors and pharmaceutical customers that represent 10% or more of the respective amounts for the periods shown:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assay Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor A</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payor B</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* <span class="MSWordContentControl" id="sdt_ed206504-51c2-4657-aeef-3d7bb9f069a4" title="Disclosure - The Company and a Summary of its Significant Accou">Less than <span class="MSWordContentControl" id="sdt_63513df4-2f80-49fc-a929-7fda547b3c93" title="Fact"><span class="MSWordContentControl" id="sdt_e2ca4cc7-c72f-43dc-aab3-8e940dba8fcc" title="Fact"><span class="MSWordContentControl" id="sdt_eb5516da-bf0b-491c-8966-8711e17ae9f4" title="Fact"><span class="MSWordContentControl" id="sdt_8455e3a6-8979-4045-a931-de10277d5680" title="Fact">10</span></span></span></span>%</span></p> 0.36 0.32 0.23 0.21 0.11 0.12 0.15 0.23 0.22 0.17 0.29 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 1400000 900000 0 600000 400000 P2Y P3Y <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounts Receivable </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Assay Accounts Receivable </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the nature of the Company’s assay revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.6 million and $1.0 million of gross assay accounts receivable as of December 31, 2021 and 2020, respectively.<span style="color:#000000;"> </span> </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Accounts Receivable </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and as of December 31, 2021, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reserve. The Company recorded $</span>0.2<span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</span>0.5<span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of contract accounts receivable as of December 31, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> 3600000 1000000.0 200000 500000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Freight and Shipping Costs </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records outbound freight and shipping costs for its contract and assay revenues in cost of revenues. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Comprehensive Loss </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net loss and the components of other comprehensive loss, including unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive loss. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment Reporting </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. </p> 1 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss Per Share </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the years ended December 31, 2021 and 2020, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. Diluted net loss per share of common stock for the year ended December 31, 2021 excludes the effect of anti-dilutive equity instruments including 734,329 shares of common stock issuable upon the exercise of outstanding common stock warrants and 2,704,035 shares of common stock issuable upon the exercise stock options and release of RSUs. Diluted net loss per share of common stock for the year ended December 31, 2020 excludes the effect of anti-dilutive equity instruments including 3,885,311 shares of common stock then issuable upon the exercise of outstanding warrants and 2,112,980 shares of common stock then issuable upon the exercise of stock options and release of RSUs. Diluted net loss per common share for the year ended December 31, 2019 excludes the effect of anti-dilutive equity instruments including 615,385 shares of common stock issuable upon conversion of the Company’s preferred stock, 4,200,497 shares of common stock issuable upon the exercise of outstanding common stock warrants and 443,547 shares of common stock issuable upon the exercise stock options. The Company did not consider a two-class method of loss per share given that the Company’s convertible participating securities do not participate in losses. </p> 734329 2704035 3885311 2112980 615385 4200497 443547 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation costs associated with stock option awards and other forms of equity compensation are measured at the grant-date fair value of the awards and recognized over the requisite service period of the awards on a ratable basis. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants stock options to purchase common stock to employees with exercise prices equal to the fair market value of the underlying stock. The fair market value of stock options is based on the closing stock price on the grant date.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated using the Black-Scholes-Merton valuation model. Such value is recognized as expense over the requisite service period using the ratable method. The expected term of options is based on the simplified method which defines the expected term as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The expected volatility of stock options is based upon the historical volatility of a number of related publicly traded companies in similar stages of development as well as the volatility of the Company’s common stock. The risk-free interest rate is based on the average yield of U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock options to non-employees using the fair value approach. The fair value of these options is measured using the Black-Scholes-Merton option pricing model, reflecting the same assumptions applied to employee options, other than expected life, which is assumed to be the remaining contractual life of the award. Options that are granted to employees generally have a requisite service period of three to four years. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs are considered restricted stock. The fair market value of RSUs is based on the closing stock price on the grant date. The Company recognizes stock-based compensation expense based on the fair value on a ratable basis over the requisite service periods of the awards. RSUs that are granted to employees have a requisite service period typically between two and four years. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock options and RSUs granted prior to January 1, 2020 will maintain the estimated forfeiture approach and will be recognized over the requisite service period using the straight-line method.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">0.52% - 1.39%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000609">0.36% - 1.69%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000610">1.68% - 2.50%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">74.88% - 83.32%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000615">64.03% - 73.44%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">72.30% - 73.50%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">6.08 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04 - 6.25 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.02 - 6.08 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05% - 0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.55% - 69.34%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 - 0.50 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense for employee options, RSUs, the purchase rights issued under the 2020 Employee Stock Purchase Plan (the “ESPP”), and consultant options of $13.3 million, $5.0 million, and $1.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. The total compensation cost related to non-vested awards not yet recognized as of December 31, 2021 was $38.4 million, which is expected to be recognized over a weighted average term of 2.83 years.  </p> P4Y P2Y P4Y <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of each option on the date of grant issued under the 2020 Equity Incentive Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">0.52% - 1.39%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000609">0.36% - 1.69%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000610">1.68% - 2.50%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">74.88% - 83.32%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000615">64.03% - 73.44%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">72.30% - 73.50%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000620">6.08 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04 - 6.25 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.02 - 6.08 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the 2020 Employee Stock Purchase Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.05% - 0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.18%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.55% - 69.34%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 - 0.50 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.49 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.0018 0.6844 13300000 5000000.0 1300000 38400000 P2Y9M29D <p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:-3.4%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(s)<span style="font-weight:normal;font-style:normal;"> </span><span style="font-size:10pt;">Warrant Liability </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span> (“ASC 480”) and ASC 815-40. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants classified as liabilities and are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a component of other income/(expense) in the consolidated statements of operations. The fair value of the warrants is estimated using a Black-Scholes-Merton valuation model. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of its warrants. At that time, the portion of the warrant liability related to the Company’s warrants will be reclassified to additional paid-in capital.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">0.46% - 0.85%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000640">0.22% - 0.33%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000641">1.40% - 1.66%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000645">85.85% - 90.70%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">69.79% - 79.26%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">64.06% - 66.68%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000651">2.66 - 3.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000652">3.66 - 4.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000653">4.67 - 5.00 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-weight:bold;;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">0.46% - 0.85%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000640">0.22% - 0.33%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000641">1.40% - 1.66%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000645">85.85% - 90.70%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000646">69.79% - 79.26%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000647">64.06% - 66.68%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000651">2.66 - 3.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000652">3.66 - 4.42 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000653">4.67 - 5.00 years</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.4%;text-indent:-3.4%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(t)<span style="font-weight:normal;font-style:normal;"> </span><span style="font-size:10pt;">Fair Value Measurements </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands): </p> <p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19,405</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">64,829</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,977</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Private SPAC Warrants was determined using the Black-Scholes-Merton valuation model and included a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unobservable input: expected volatility. Expected volatility is considered by the Company to be a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.44%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of warrant liability from exercise of Private SPAC Warrants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(434</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company maintains letters of credit of $3.0 million and zero, respectively, related to its lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the Company’s consolidated balance sheets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.</p> The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19,405</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">64,829</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, available for sale:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,977</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value on a recurring basis</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:11pt;"> </p> 16380000 16380000 3025000 15352000 15352000 7412000 7412000 25685000 25685000 48449000 48449000 19405000 48449000 64829000 146000 146000 146000 146000 448000 448000 8940000 8940000 7324000 7324000 23265000 23265000 39529000 39529000 448000 39529000 39977000 1650000 1650000 1650000 1650000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.44%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,228</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of warrant liability from exercise of Private SPAC Warrants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability due to Private SPAC Warrants not held by original holder</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(434</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 628000 206000 1228000 1650000 2158000 434000 1088000 146000 3000000.0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">u</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting Pronouncement Recently Adopted</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, FASB issued ASU No. 2016-02, <span style="font-style:italic;">Leases</span> (Topic 842) (“ASU 2016-02”), which supersedes FASB ASC Topic 840, <span style="font-style:italic;">Leases</span> (“ASC 840”), and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted ASC 842 during the third quarter of 2021 effective as of January 1, 2021. The Company has applied its transition provisions at the beginning of the period of adoption (i.e., on the effective date), and so did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC 840, including its disclosure requirements, in the comparative periods presented. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adoption of ASU 2016-02 did not result in a cumulative adjustment to the Company’s accumulated deficit as of January 1, 2021. Adoption of ASU 2016-02 resulted in the recording of an operating lease ROU assets and lease liabilities of $2.8 million and $3.1 million, respectively. The difference between the operating lease ROU assets and lease liabilities are due to accrued deferred rent and unamortized lease incentives. Finance lease right-of-use assets and lease liabilities recognized as of January 1, 2021, included preexisting assets and liabilities of $0.3 million, related to finance leases accounted for under ASC 840. Adoption of ASU 2016-02 did not have a material impact on the Company’s results of operations or cash flows. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to use the transition package of three practical expedients, which among other things, allowed the Company to carry forward the historical lease classification. The Company has elected, under ASC 842, the further practical expedient not to separate non-lease components from the lease components to which they relate and instead to combine them and account for them as a single lease component. The Company also elected the accounting policy election to keep leases with a term of 12 months or less off the balance sheet and to recognize payments for those leases on a straight-line basis over the lease term. The underlying assets of the Company’s leases as of the adoption date consisted of operating facilities and laboratory equipment.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment was exercised in the application of ASC 842 with respect to the determination of whether a contract contains a lease. While the ability to control and direct the use of an identified asset indicates that the contract, or portion of a contract, is a lease, a counterparty’s substantive substitution rights typically provide evidence that a lessee does not control the asset. Judgment was also exercised with respect to the determination of the discount rate used to determine the present value of lease payments. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a similar economic environment. The Company has no debt and has not had an established incremental borrowing rate. For the purpose of </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimating the incremental borrowing rate in the adoption of ASC 842, required management judgment including the development of a synthetic credit rating and cost of debt as we currently do not carry any debt. The Company calculates its incremental borrowing rates for </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specific lease terms, used to discount future lease payments, as a function of the U.S. Treasury rate and an indicative Moody’s rating for operating leases.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments</span><span style="font-style:italic;color:#000000;">—</span><span style="font-style:italic;">Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) </span>(“ASU 2016-13”), <span style="color:#000000;">which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities</span>. Previously, when credit losses were measured under U.S. GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires companies to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.<span style="color:#231F20;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company is no longer an emerging growth company as of December 31, 2021, the Company adopted the guidance under <span style="color:#231F20;">ASU 2016-13 </span>during the fourth quarter of 2021<span style="font-size:11pt;"> </span>and applied the modified retrospective method of adoption to the Company’s financial statements as of January 1, 2021. Based on the composition of its trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company's consolidated financial statements and related disclosures and no cumulative adjustment was required to be recorded to the Company’s accumulated deficit as of January 1, 2021. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span> (“ASU 2019-12”). ASU 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. <span style="color:#000000;">The Company adopted this guidance during the fourth quarter of 2021</span><span style="font-size:11pt;color:#000000;"> </span>with no material impact to the Company's consolidated financial statements.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">v</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting Pronouncements Issued But Not Yet Effective </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share</span> <span style="font-style:italic;">(Topic 260),</span> <span style="font-style:italic;">Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span> (“ASU 2021-04”). ASU 2021-04 provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company plans to adopt the standard on January 1, 2022. The Company is currently evaluating the effects, if any, of the adoption of ASU 2021-04 guidance on the Company’s consolidated financial statements.</p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Balance Sheet Details</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Short-Term Marketable Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Market</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities, available-for-sale:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,417</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,771</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,573</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2020 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Market</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities, available-for-sale:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,259</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, <span style="color:#000000;">the estimated market value of debt securities with contractual maturities of less than twelve months was $21.2 million; the remaining debt securities that we held at that date had an estimated market value of $27.2 million and contractual maturities of up to 23 months. As of December 31, 2020, </span>the estimated market value of debt securities with contractual maturities of less than twelve months was $37.3 million; the remaining debt securities that we held at that date had an estimated market value of $2.3 million and contractual maturities of up to 14 months.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized gains and losses on our debt securities for the twelve months ended December 31, 2021 and 2020 were not significant.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Prepaid Expenses and PP&amp;E</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated balance sheet details are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid trade shows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred issuance costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid employee compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,166</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,544</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,625</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accrued Compensation and Accrued Liabilities </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated balance sheet details are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued paid time off</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,245</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus and deferred compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,875</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,120</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,075</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,227</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2021 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Market</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities, available-for-sale:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,352</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,417</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,771</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,573</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,449</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2020 were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Market</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities, available-for-sale:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,325</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,259</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 15385000 33000 15352000 7417000 5000 7412000 25771000 1000 87000 25685000 48573000 1000 125000 48449000 8946000 6000 8940000 7325000 1000 2000 7324000 23259000 6000 23265000 39530000 7000 8000 39529000 21200000 27200000 37300000 2300000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated balance sheet details are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid trade shows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred issuance costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid employee compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,166</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,544</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,625</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1801000 1172000 440000 551000 214000 56000 238000 136000 79000 3166000 1521000 4805000 2544000 171000 38000 124000 109000 1074000 727000 6174000 3418000 1625000 687000 4549000 2731000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated balance sheet details are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued paid time off</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,245</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus and deferred compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,875</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,120</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,075</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,227</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1245000 606000 3875000 1469000 5120000 2075000 775000 285000 452000 478000 1227000 763000 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Debt</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2018 Convertible Bridge Notes </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From August to November 2018, DermTech Operations issued $6.8 million aggregate principal amount of convertible bridge notes (“2018 Bridge Notes”), resulting in $6.6 million in net proceeds. The 2018 Bridge Notes carried a 10% interest rate and matured on March 31, 2019. Since the 2018 Bridge Notes were not paid or converted by March 31, 2019, the interest rate increased to 15%. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Bridge Notes were subject to automatic conversion into equity securities of DermTech Operations at the closing of a single capital raising transaction or series of related capital raising transactions in which DermTech Operations issued equity securities with aggregate gross proceeds to DermTech Operations of at least $20 million (“Qualified Financing”) that occurred on or prior to the maturity date. Upon automatic conversion of these 2018 Bridge Notes, the note holders were entitled to receive shares of DermTech Operations’ equity securities equal to the quotient obtained by dividing the unpaid principal amount of these 2018 Bridge Notes plus interest accrued but unpaid by the lesser of: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the lowest price per share of the new stock paid in the Qualified Financing by investors multiplied by 70%. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the price per share obtained by dividing $45 million by DermTech Operations’ fully-diluted capitalization immediately prior to such Qualified Financing assuming exercise or conversion of all outstanding options and issuance of all outstanding restricted stock unit awards, including all shares of common stock reserved and available for future grant under any equity incentive plan of the Company, and/or any equity incentive or similar plan to be created or increased in connection with the Qualified Financing, but excluding any shares issuable upon exercise of the DermTech Operations’ outstanding common stock warrants or conversion of the 2018 Bridge Notes. </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the embedded features of the 2018 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2018 Bridge Notes as a derivative liability on the consolidated balance sheet. DermTech Operations assigned a value to the debt component of the 2018 Bridge Notes equal to the difference between the estimated fair value of the 2018 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2018 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2018 Bridge Notes was determined to be $2.5 million. DermTech Operations amortized the debt discount over the contractual life (i.e., March 31, 2019) of the 2018 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2018 Bridge Notes (i.e., the derivative liability) and changes in the fair value are recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were zero and $0.4 million for the years ended December 31, 2020 and 2019, respectively. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 23, 2019, DermTech Operations and the various convertible 2018 Bridge Note holders agreed to amend the outstanding convertible notes that were issued in the last half of 2018. As part of the amendment, the maturity dates of the notes were extended to the earliest of (i) September 24, 2019; (ii) the occurrence of an Event of Default (as defined in the 2018 Bridge Notes); (iii) the consummation of a liquidation or dissolution of DermTech Operations (iv) a Liquidation Transaction (as defined in the 2018 Bridge Notes); or (v) the consummation of a merger with or into the Company or any of its subsidiaries.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, immediately prior to the consummation of a DermTech Operations merger with or into the Company or any of its subsidiaries substantially on the terms contemplated as of the date of the amendment to the outstanding convertible notes on or before September 24, 2019 (a “Qualifying Merger”), the outstanding principal amount of and all accrued but unpaid interest on each of the convertible notes would automatically be converted into shares of the DermTech Operations’ common stock at a price per <span style="Background-color:#FFFFFF;">share equal to 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means (i) the lesser of $6.46 and (ii) the offering price per share of the private investment in public equity (“PIPE”) transaction to be consummated concurrently with the consummation of the Qualifying Merger multiplied by the Conversion Ratio. For the purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of fully diluted shares of the Company as of immediately after the conversion of the notes.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This new embedded Qualifying Merger feature of the 2018 Bridge Notes was identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract with the previously identified embedded features that met the criteria of being a derivative. In addition, this amendment was accounted for as a debt modification of the existing 2018 Bridge Notes.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2019 Convertible Bridge Notes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between June 5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and June 10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, 2019, DermTech Operations issued additional convertible bridge notes (the “2019 Bridge Notes”) to existing investors for aggregate gross proceeds of $2.6 million. These convertible bridge notes carried an interest rate of 10% and matured after the earliest to occur of: (i) September 25, 2019; (ii) the occurrence of an Event of Default; (iii) the consummation of a liquidation or dissolution of DermTech Operations; (iv) a Liquidation Transaction; or (v) the consummation of a merger of DermTech Operations with Merger Sub, a subsidiary of the Company, in accordance with the Merger Agreement.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unpaid principal amount of these convertible bridge notes together with any interest accrued but unpaid thereon, would automatically be converted into shares of DermTech Operations’ common stock immediately prior to the consummation of a Qualifying Merger. Upon the conversion of these notes, the note holders were entitled to receive a number of shares of DermTech Operations’ common stock equal to the quotient obtained by dividing (i) the unpaid principal amount of these notes plus interest accrued but unpaid thereon, by (1) if the Qualifying Merger consummates prior to the maturity date, the lesser of (x) $5.80 and (y) 90% of the Merger Consideration (as defined below), or (2) if the Qualifying Merger consummates on or after the maturity date, the lesser of (x) $4.51 and (y) 70% of the Merger Consideration. For purposes of the preceding sentence, the “Merger Consideration” means the offering price per share of the PIPE transaction between Constellation and the investors thereto, consummated substantially concurrently with the consummation of the Qualifying Merger, multiplied by the Conversion Ratio (as defined below). For purposes of the preceding sentence, the “Conversion Ratio” means the quotient resulting from dividing 8,000,000 by the number of the Company’s fully diluted shares immediately prior to the consummation of the Qualifying Merger, assuming exercise of all outstanding options, issuance of all common stock underlying outstanding restricted stock unit awards, exercise of all outstanding warrants, and conversion of all outstanding convertible promissory notes, including these notes and any other note of substantially the same form, but excluding all shares of DermTech Operations’ common stock reserved and available for future grant under any equity incentive or similar plan of DermTech Operations, and in each case as adjusted for stock splits, combinations and similar transactions, all calculated in accordance with the final allocation schedule delivered in connection with the Qualifying Merger.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the embedded features of the 2019 Bridge Notes were identified as meeting the criteria of a derivative and ultimately bifurcated from the host contract. DermTech Operations accounted for this by separating the derivative component of the 2019 Bridge Notes as a derivative liability on the consolidated balance sheet. The Company assigned a value to the debt component of the 2019 Bridge Notes equal to the difference between the estimated fair value of the 2019 Bridge Notes with and without the conversion features, which resulted in DermTech Operations recording the 2019 Bridge Notes at a discount. The total debt discount amount as of the respective date of issuance of the 2019 Bridge Notes was determined to be $0.3 million. DermTech Operations amortized the debt discount over the contractual life (i.e., September 25, 2019) of the 2019 Bridge Notes as additional non-cash interest expense utilizing the effective interest method. At each financial reporting period, DermTech Operations remeasured the fair value of the embedded features bifurcated from the 2019 Bridge Notes (i.e., the derivative liability) and changes in the fair value were recognized in earnings. Losses relating to the change in fair value of the derivative liability recognized as other expense on the Statement of Operations were of zero and $14,000 for the years ended December 31, 2020 and 2019, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exchange of Convertible Debt for Common Shares</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2019, immediately prior to the completion of the Business Combination, all unpaid principal and interest on the 2019 Bridge Notes and the 2018 Bridge Notes (collectively, the “Bridge Notes”) was converted into 2,267,042 common shares of DermTech Operations. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The conversion of the Bridge Notes debt for common shares of DermTech Operations was accounted for as an extinguishment of the Bridge Notes. The conversion resulted in DermTech Operations having legally settled the debt obligations. DermTech Operations’ equity was increased by the settlement-date fair value of the common shares issued. Certain bifurcated embedded derivative instruments also were settled as part of the transaction.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net carrying amounts of the Bridge Notes, including remaining unamortized debt discount and issuance costs, and the bifurcated embedded derivative liability were extinguished on the date of the Business Combination. A gain on debt extinguishment of </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million was recognized, which represented the unamortized debt discounts and issuance costs remaining at the time of the debt extinguishment.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no liability balance for the Company’s 2019 Bridge Notes or 2018 Bridge Notes as of December 31, 2021 and 2020.</p> 6800000 6600000 0.10 2019-03-31 0.15 20000000 0.70 45000000 2500000 0 400000 As part of the amendment, the maturity dates of the notes were extended to the earliest of (i) September 24, 2019; (ii) the occurrence of an Event of Default (as defined in the 2018 Bridge Notes); (iii) the consummation of a liquidation or dissolution of DermTech Operations (iv) a Liquidation Transaction (as defined in the 2018 Bridge Notes); or (v) the consummation of a merger with or into the Company or any of its subsidiaries. 0.70 “Merger Consideration” means (i) the lesser of $6.46 and (ii) the offering price per share of the private investment in public equity (“PIPE”) transaction to be consummated concurrently with the consummation of the Qualifying Merger multiplied by the Conversion Ratio. 6.46 8000000 2600000 These convertible bridge notes carried an interest rate of 10% and matured after the earliest to occur of: (i) September 25, 2019; (ii) the occurrence of an Event of Default; (iii) the consummation of a liquidation or dissolution of DermTech Operations; (iv) a Liquidation Transaction; or (v) the consummation of a merger of DermTech Operations with Merger Sub, a subsidiary of the Company, in accordance with the Merger Agreement. 0.10 Upon the conversion of these notes, the note holders were entitled to receive a number of shares of DermTech Operations’ common stock equal to the quotient obtained by dividing (i) the unpaid principal amount of these notes plus interest accrued but unpaid thereon, by (1) if the Qualifying Merger consummates prior to the maturity date, the lesser of (x) $5.80 and (y) 90% of the Merger Consideration (as defined below), or (2) if the Qualifying Merger consummates on or after the maturity date, the lesser of (x) $4.51 and (y) 70% of the Merger Consideration. 5.80 0.90 4.51 0.70 8000000 300000 0 14000 2267042 900000 0 0 0 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Convertible Preferred Stock and Stockholders’ Equity</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Classes of Stock </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s amended and restated certificate of incorporation authorizes it to issue 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both classes of stock have a par value of $0.0001 per share. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Series A Convertible Preferred Stock Financing  </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2019 private placement of equity securities of the Company on August 29, 2019, immediately following the completion of the Business Combination, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series A Convertible Preferred Stock (the “Series A Certificate of Designation”). An aggregate of 1,231 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $4.0 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 1,231 shares of Series A Preferred Stock into 615,385 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series A Convertible Preferred Stock.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(d)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">2020 PIPE Financing </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 28, 2020, the Company entered into a securities purchase agreement with certain institutional investors for a private placement of the Company’s equity securities (the “2020 PIPE Financing”). Cowen and Company, LLC (“Cowen”) served as lead placement agent for the 2020 PIPE Financing, with William Blair &amp; Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent. The 2020 PIPE Financing closed on March 4, 2020. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 PIPE Financing consisted of 2,467,724 shares of common stock at a price of $10.50 per share, 3,199 shares of Series B-1 Convertible Preferred Stock (the “Series B-1 Shares”) at a price of $10,500 per share, and 524 shares of Series B-2 Convertible Preferred Stock (the “Series B-2 Shares”) at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, reduced by $5.1 million in issuance costs. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of the 2020 PIPE Financing, the Company designated (i) 3,200 shares of its authorized and unissued preferred stock as Series B-1 Convertible Preferred Stock by filing the Series B-1 Certificate of Designation with the Delaware Secretary of State and (ii) 525 shares of its authorized and unissued preferred stock as Series B-2 Convertible Preferred Stock by filing the Series B-2 Certificate of Designation with the Delaware Secretary of State.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(e)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Series B-1 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-1 Convertible Preferred Stock (the “Series B-1 Certificate of Designation”). An aggregate of 3,199 shares of Series B-1 Convertible Preferred Stock for an aggregate purchase price of $33.6 million were issued to certain accredited investors. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Company’s annual meeting held on May 26, 2020, the Company’s stockholders voted to approve the 2020 PIPE Financing. As a result, on May 27, 2020 the <span style="Background-color:#FFFFFF;color:#000000;">3,199</span> outstanding shares of Series B‑1 Convertible Preferred Stock were automatically converted into an aggregate of <span style="color:#000000;">3,198,949</span> shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-1 Convertible Preferred Stock.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(f)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"/><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Series B-2 Convertible Preferred Stock Issued in Connection with 2020 PIPE Financing</span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2020 PIPE Financing transaction and on March 2, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for the Company’s Series B-2 Convertible Preferred Stock (the “Series B-2 Certificate of Designation”). An aggregate of 524 shares of Series B-2 Convertible Preferred Stock for an aggregate purchase price of $5.5 million were issued to certain accredited investors. On August 10, 2020, entities affiliated with Farallon Capital Management, L.L.C. converted an aggregate of 524 shares of Series B‑2 Preferred Stock into 523,814 shares of common stock. On September 9, 2020, the Company filed a Certificate of Elimination of Series B-2 Convertible Preferred Stock with the Secretary of State of the State of Delaware to eliminate its Series B-2 Convertible Preferred Stock.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(g)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">At-The Market Offering</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 10, 2020, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. During 2020, the Company issued an aggregate of 951,792 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $20.97 resulting in aggregate gross proceeds of approximately $20.0 million, reduced by $0.9 million in issuance costs, resulting in net proceeds to the Company of approximately $19.1 million. For the year ended December 31, 2021, the Company issued an aggregate of 530,551 shares of common stock pursuant to the Sales Agreement at a weighted average purchase price of $46.33 resulting in aggregate gross proceeds of approximately $24.6 million, reduced by $0.7 million in issuance costs, resulting in net proceeds to the Company of approximately $23.8 million.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(h)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">2021 Underwritten Public Offering</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 6, 2021, the Company entered into an Underwriting Agreement with Cowen and William Blair &amp; Company, L.L.C. as representatives of several underwriters (the “Underwriters”). The Company agreed to issue and sell up to 4,237,288 shares of its common stock including up to 635,593 shares that could be purchased by the Underwriters pursuant to a 30-day option granted to the Underwriters by the Company. On January 11, 2021, the Company closed the underwritten public offering of 4,872,881 shares of its common stock, which included the exercise in full by the Underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. The Company received aggregate gross proceeds of approximately $143.7 million, and net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Warrants </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SPAC Warrants </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company previously issued a total of 14,936,250 SPAC Warrants to purchase common stock in public offering and private placement offerings which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 Public SPAC Warrants and as part of the private placement offering, the Company issued 561,250 Private SPAC Warrants. The SPAC Warrants have a <span style="-sec-ix-hidden:F_000855">five-year</span> life from the date the Business Combination was consummated and every <span style="-sec-ix-hidden:F_000857_2">four SPAC Warrants entitle the holder to purchase one whole share</span> of common stock at an exercise price of $23.00 per whole share. </p> <p style="margin-top:6pt;margin-bottom:5pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 and 14,936,250 as of December 31, 2021 and 2020, respectively. Private SPAC Warrants that were still owned by the original holder totaled 80,350 and 323,500 as of December 31, 2021 and 2020, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Series C Warrants</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with DermTech Operations’ Series C Preferred Stock financing that took place between 2016 and 2018, each investor that purchased at least $1 million of Series C Convertible Preferred Stock in a single closing received a <span style="-sec-ix-hidden:F_000867">three-year</span> warrant to purchase shares of common stock at an exercise price of $9.54 per share in the amount equal to 20% of shares of Series C Preferred Stock purchased. Outstanding Series C warrants totaled zero and 97,563 as of December 31, 2021 and 2020, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Placement Agent Warrants</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling of common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 <span style="-sec-ix-hidden:F_000879">seven-year</span> warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 <span style="-sec-ix-hidden:F_000880">seven-year</span> warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 <span style="-sec-ix-hidden:F_000878">seven-year</span> warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled and 10,039 and 31,365 as of December 31, 2021 and 2020, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation </p></td></tr></table></div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.4%;text-indent:-3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2010 Stock Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Business Combination, the Company assumed the DermTech Operations’ Amended and Restated 2010 Stock Plan (the “2010 Plan”), which provided for the granting of incentive and non-statutory stock options and restricted stock purchase rights and bonus awards. Under the 2010 Plan, incentive and non-statutory stock options were granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. For incentive stock options granted to a ten percent shareholder under the 2010 Plan, the exercise price was not less than 110% of the fair market value of a share of stock on the effective date of grant. DermTech Operations initially reserved 1.0 million shares of common stock for issuance to its employees, non-employee directors and consultants. The 2010 Plan included a provision which annually increased the amount of common stock reserved for issuance under the 2010 Plan. The contractual term of options granted under the 2010 Plan was ten years. Vesting provisions varied based on the specific terms of the individual option awards. At the Company’s annual meeting held on May 26, 2020, the Company’s shareholders voted to approve the DermTech, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), which terminated the 2010 Plan. No additional awards will be granted under the 2010 Plan, however, all outstanding awards under the 2010 Plan remain in effect. No shares remained available for issuance pursuant to future grants under the 2010 Plan as of both December 31, 2021 and 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 26, 2020, the Company’s stockholders approved the adoption of the 2020 Plan, which provides for the granting of incentive and non-qualified stock options, restricted stock and stock-based awards. Under the 2020 Plan, incentive and non-qualified stock options may be granted at not less than 100% of the fair market value of the Company’s common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of the Company’s capital stock, the exercise price may not be less than 110% of the fair market value of the Company’s common stock on the date of grant and the term of the option may not be longer than five years.  </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Plan authorizes the Company to issue up to 1,900,000 shares of the Company’s common stock pursuant to awards granted under the 2020 Plan, plus the number of shares underlying any stock option and other stock-based awards previously granted under the 2010 Plan that are forfeited, canceled, or terminated (other than by exercise) on or after May 26, 2020; provided that no more than 1,400,000 shares may be added to the 2020 Plan pursuant to such forfeitures, cancellations and terminations. In addition, the number of shares available for issuance under the 2020 Plan will automatically increase on the first day of each fiscal year beginning in fiscal year 2021 and ending on the second day of fiscal year 2025, by an amount equal to the smaller of (i) 3.5% of the number of shares of common stock outstanding on such date and (ii) an amount determined by the administrator of the 2020 Plan. The 2020 Plan will expire on April 12, 2030 or an earlier date approved by a vote of the Company’s stockholders or board of directors. The contractual term of options granted under the 2020 Plan is not more than ten years. Vesting provisions vary based on the specific terms of the individual option awards. 602,955 shares remained available for future grant under the 2020 Plan as of December 31, 2021.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option transactions for the years ended December 31, 2021 and 2020: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value (in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443,547</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000922">7.80</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,285,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.25</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,995</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552,483</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000923">8.91</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">486,104</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121,622</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000924">8.31</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,698</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000925">8.31</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000926">7.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU transactions for the years ended December 31, 2021 and 2020: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average grant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date fair value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739,962</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175,527</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,938</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,497</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.75</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">718,053</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.09</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(277,259</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,888</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.03</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested, but not yet issued as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 26, 2020, the Company’s stockholders approved the adoption of the ESPP, which allows for full-time and certain part-time employees of the Company to purchase shares of common stock at a discount to fair market value. Eligible employees enroll in a six-month offering period during the open enrollment period prior to the start of that offering period. A new offering period begins approximately every March 1 and September 1. At the end of each offering period, the accumulated contributions are used to purchase shares of the Company’s common stock. Shares are purchased at a price equal to 85% of the lower of: (i) the fair market value of the Company’s common stock on the first business day of an offering period or (ii) the fair market value of the Company’s common stock on the last business day of an offering period. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP authorizes the Company to issue up to 400,000 shares of the Company’s common stock. In addition, the number of shares available for issuance under the ESPP will automatically increase on the first day of each of the Company’s fiscal years beginning in 2021 and ending on the first day of 2030, in an amount equal to the lesser of (i) 300,000 shares, (ii) 1% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the board of directors, subject to adjustment upon changes in capitalization of the Company. On February 28, 2021 and August 31, 2021, the Company issued 39,960 and 18,155 shares of its common stock, respectively, pursuant to scheduled purchases under the ESPP. As of December 31, 2020, 400,000 shares of common stock were reserved for future issuance under the ESPP. On January 1, 2021, an additional 207,404 shares became available under the ESPP pursuant to an automatic annual increase. 549,289 shares remained available for future grant under the ESPP as of December 31, 2021.</p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Management Warrants</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase DermTech Operations common stock were issued to executive officers of DermTech Operations in lieu of issuing certain stock options (the “Management Warrants”). The Management Warrants were assumed by the Company in connection with the Business Combination. The Management Warrants have a ten year life and are exercisable for Company common stock at $1.08 per share. The Management Warrants vested monthly over a <span style="-sec-ix-hidden:F_000962">four-year</span> period. Outstanding Management Warrants totaled 20,320 and 22,320 at December 31, 2021 and 2020, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consists of the following as of December 31, 2021 and 2020 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SPAC Warrants to purchase common stock*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized for future equity grants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized for future ESPP purchases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,591</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,332</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="-sec-ix-hidden:F_000980_2">Four SPAC Warrants are needed to purchase one share</span> of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.   </p></td></tr></table></div> 50000000 5000000 0.0001 0.0001 1231 4000000.0 1231 615385 2020-03-04 2467724 10.50 3199 10500 524 10500 65000000.0 5100000 3200 525 3199 33600000 3199 3198949 524 5500000 524 523814 50000000.0 951792 20.97 20000000.0 -900000 19100000 530551 46.33 24600000 -700000 23800000 4237288 635593 P30D 4872881 4872881 635593 29.50 143700000 134600000 14936250 14375000 561250 23.00 12120397 3030092 69700000 2815853 14936250 80350 323500 1000000 9.54 0.20 0 97563 168522 1 8.68 72658 1 9.54 15724 1 9.54 10039 31365 1 0.10 1.10 1000000.0 P10Y 0 1 1.10 P5Y 1900000 1400000 0.035 P10Y 602955 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option transactions for the years ended December 31, 2021 and 2020: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value (in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443,547</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.84</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000922">7.80</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,796</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,285,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.25</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,995</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552,483</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000923">8.91</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">486,104</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121,622</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000924">8.31</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,698</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000925">8.31</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000926">7.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 443547 3.84 3796000 1285183 12.25 143995 3.29 32252 8.28 1552483 10.76 33656000 486104 43.36 196333 5.98 121622 12.78 1720632 20.37 5698000 1720632 20.37 5698000 607127 10.16 3523000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU transactions for the years ended December 31, 2021 and 2020: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average grant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date fair value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739,962</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175,527</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,938</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,497</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.75</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">718,053</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.09</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(277,259</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,888</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.03</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested, but not yet issued as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 739962 12.47 175527 11.60 3938 11.41 560497 12.75 718053 34.09 277259 14.20 17888 38.03 983403 27.46 983403 27.46 12632 41.81 0.85 400000 300000 39960 18155 400000 207404 549289 P10Y 1.08 20320 22320 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consists of the following as of December 31, 2021 and 2020 (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SPAC Warrants to purchase common stock*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units issued and outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized for future equity grants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized for future ESPP purchases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">549</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,591</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,332</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="-sec-ix-hidden:F_000980_2">Four SPAC Warrants are needed to purchase one share</span> of common stock. The numbers presented above reflect the amount of shares of common stock underlying SPAC Warrants.   </p></td></tr></table></div> 31 151 704 3734 1721 1552 983 560 603 935 549 400 4591 7332 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported net losses since inception, and therefore, the minimum provision for state income taxes has been recorded. The following table provides a reconciliation between income taxes computed at the federal statutory rate of 21% at December 31, 2021, 2020, and 2019, and the Company’s provision for income taxes.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal tax benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance (decrease) increase</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31, 2021, 2020, and 2019 are shown below (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,886</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,422</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,631</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,417</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,972</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,004</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets before valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,413</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,413</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,082</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a full valuation allowance against its net deferred tax assets as realization of such assets is not more likely than not.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, 2020, and 2019, the Company had federal tax net operating loss (“NOL”) carryforwards of approximately $184.0 million, $110.8 million, and $79.4 million, respectively, as well as state tax NOL carryforwards at December 31, 2021, 2020, and 2019 of approximately $141.1 million, $84.3 million, and $53.4 million, respectively. Federal NOL carryforwards began to expire during 2021 while the Company’s state NOL carryforwards begin to expire during various years, dependent on the jurisdiction.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also had federal income tax R&amp;D and other tax credit carryforwards at December 31, 2021, 2020, and 2019 of approximately $1.4 million, $0.9 million, and $0.8 million, respectively, and state income tax R&amp;D and other tax credits of approximately $1.3 million, $0.9 million, and $0.8 million at December 31, 2021, 2020, and 2019, respectively. The federal credit carryforwards began to expire during 2021 and the state credit carryforwards do not expire. The Company has not performed a formal study validating its federal and state R&amp;D tax credits and upon preparation, such tax credit carryforwards could vary from what was originally claimed on applicable income tax returns.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The utilization of NOL and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (IRC), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of <span>50%</span> or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company conducts intensive research and experimentation activities, generating research tax credits for federal and state purposes under IRC Section 41. The Company has not performed a formal study validating such credits claimed on its tax returns. Once a study is completed, the amount of R&amp;D tax credits available could vary from what was originally claimed on the tax returns.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the net operating loss carryforwards, the U.S. federal and state returns are open to examination for all years since inception.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions on the basis of a two-step process in which it determines whether it is more likely than not tax positions will be sustained on the basis of the technical merits of the position and for those tax positions that meet the more likely than not recognition threshold the Company would recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it has no uncertain tax positions as of December 31, 2021, 2020, and 2019. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, President Trump signed into law the Consolidated Appropriations Act, 2021 (“CAA 2021”), which included a number of provisions including, but not limited to the extension of numerous employment tax credits, the extension of the </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 179D deduction, enhanced business meals deductions, and the deductibility of expenses paid with Paycheck Protection Program (“PPP”) loan funds that are forgiven. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he effects of the CAA 2021 have been incorporated into the income tax provision for the year ended December 31, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These provisions did not have a material impact on the income tax provision.</span></p> The following table provides a reconciliation between income taxes computed at the federal statutory rate of 21% at December 31, 2021, 2020, and 2019, and the Company’s provision for income taxes <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal tax benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance (decrease) increase</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> 0.21 0.21 0.21 0.210 0.210 0.210 0.048 0.049 0.011 -0.001 -0.008 0.006 0.004 0.002 -0.004 -0.005 -0.271 -0.257 -0.204 0 0 0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company’s deferred tax assets and liabilities from federal and state income taxes as of December 31, 2021, 2020, and 2019 are shown below (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,886</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,422</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,631</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,417</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,972</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,004</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets before valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,413</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,413</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,082</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 46886000 28422000 20336000 2411000 1631000 1400000 0 14000 33000 2126000 653000 119000 719000 422000 194000 1935000 0 0 340000 0 0 54417000 31142000 22082000 32000 0 0 1972000 0 0 2004000 0 0 52413000 31142000 22082000 52413000 31142000 22082000 0 0 0 184000000.0 110800000 79400000 141100000 84300000 53400000 1400000 900000 800000 1300000 900000 800000 0.50 0.50 0.50 0.50 0 0 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Leases, Commitments and Contingencies</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Finance Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases certain laboratory equipment from various third parties, through equipment finance leases (previously referred to as “capital leases”). These leases either include a bargain purchase option or the terms of the leases are at least 75 percent of the useful lives of the assets and are therefore classified as finance leases. These leases are capitalized in property and equipment, net <span style="color:#000000;">on the accompanying consolidated balance sheets</span>. Initial asset values and finance lease obligations are based on the present value of future minimum lease payments. Gross assets recorded under finance leases were $0.4 million and $0.3 million as of December 31, 2021 and 2020, respectively. Accumulated amortization associated with finance leases was $0.1 million and $10,000 as of December 31, 2021 and 2020, respectively. Total finance lease interest expense was approximately $17,000, $3,000, and zero for the years ended December 31, 2021, 2020, and 2019, respectively, and is included within interest income, net on the consolidated statements of operations. Long-term finance lease obligations are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of net minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of finance lease obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Del Mar Heights Lease</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2021, the Company entered into an Office Lease (the “Del Mar Lease”) with Kilroy Realty, L.P. (the “Landlord”), with respect to an aggregate of 95,997 rentable square feet consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130 (the “Entire Premises”). The Entire Premises covered by the Lease will serve as the Company’s new principal office.</p><p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease (the “Lease Commencement Date”). The Company has the option to extend the term of the Lease for two additional five-year periods, subject to the terms of the Del Mar Lease.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Landlord tenders possession of each portion of the Entire Premises for which the applicable improvements required by the Del Mar Lease are substantially complete, the Company will be obligated to make monthly payments of base rent with respect to such portion of the Entire Premises as set forth on Schedule 1 to the Del Mar Lease. In the event the Company exercises its option to extend the Del Mar Lease term, the Lease provides for monthly rent payments during the additional five-year periods at the then-current market rent as determined in accordance with the Del Mar Lease. In addition to rent, the Del Mar Lease requires the Company to pay additional rent amounts for taxes, insurance, maintenance and other expenses.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company took initial possession of the first phase of what is expected to become its corporate headquarters, and the Company capitalized a right-of-use asset and related lease liability of $5.7 million associated with the first phase. The extension option periods were not considered in the determination of the right-of-use asset or the lease liability as the Company did not consider it reasonably certain that it would exercise such extension options. Pending execution of the Landlord's obligations to prepare leased spaces for occupancy, the Company expects the operating leases for the additional office and laboratory space to commence on various dates in the year ending December 31, 2022. The Company has an estimated future lease payment obligation of approximately $63.3 million related to corporate office facilities that were in the process of being built-out as of December 31, 2021. The lease liabilities and the corresponding right-of-use assets associated with these lease obligations will be recorded upon the commencement date of the operating leases.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this operating lease, in lieu of a cash security deposit, the Company’s bank issued a letter of credit on its behalf, which is secured by a deposit totaling $3.0 million and is included in restricted cash on the consolidated balance sheet based on the term of the underlying lease. As of December 31, 2021, none of the standby letter of credit amount has been used.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:3.4%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Torrey Pines Lease</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. As part of the fifth amendment, the Company was entitled to a tenant improvement allowance for certain costs incurred while performing these improvements in the amount of $0.3 million, which amount may be increased by up to $0.1 million at the Company’s election and subject to corresponding increase in rent. Under the terms of the facilities leases, the Company is required to pay its proportionate share of property taxes, insurance and normal maintenance costs.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease term for all leased space has an expiration date of April 30, 2023, <span style="color:#000000;">and an option to extend the lease term on all leased space for one additional three-year term, which the Company is not reasonably certain that it will exercise. As such, the Company did not include this option in the determination of the total lease term.</span> On January 1, 2021, in conjunction with the adoption of the guidance in ASU 2016-02, the Company recognized a right-of-use asset and corresponding lease liability for its facility lease as the present value of lease payments not yet paid at January 1, 2021. The right-of-use asset and corresponding lease liability was estimated assuming the remaining lease term of 28 months at January 1, 2021, and an estimated discount rate of 4.04%, which was the Company’s incremental borrowing rate at the date of adopting ASC 842. The Company recorded a lease liability of $3.1 million and a right-of-use asset of $2.8 million, which is net of $0.3 million of the Company’s previously capitalized tenant improvement allowance and deferred rent, upon adoption.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense for the year ended December 31, 2021 was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:76.6%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of leased assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,619</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of operating leases (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001114">9.33</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of finance leases (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001115">2.34</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.78</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for finance leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.63</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s future minimum lease payments under operating and finance leases at December 31, 2021 are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations, including interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,802</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease obligations, including interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,271</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">734</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,280</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts presented in the table above exclude non-cancelable future minimum lease payments for operating leases that have not commenced as of December 31, 2021.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Underwriting Fees</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Merger Agreement, the Company, DermTech Operations and Cowen entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which the Company agreed to assign to DermTech Operations, and DermTech Operations agreed to assume, the Company’s obligations under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among the Company and Cowen. On September 4, 2019, the Company, DermTech Operations and Cowen amended the Deferred Underwriting Fee Assignment Agreement, pursuant to which the Company paid Cowen $0.8 million for the reduction of the balance owed by the Company to Cowen under the Underwriting Agreement to $1.4 million. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, as amended, if the Company were to raise at least $15.0 million in proceeds received from equity financings consummated prior to the one-year anniversary of the Business Combination, excluding the proceeds received from any financing consummated prior to or simultaneous with the Business Combination, then the Company would pay to the underwriters $1.4 million within one week of the one-year anniversary of the Business Combination. <span style="color:#000000;">In connection with the Company’s 2020 PIPE Financing, the Company raised $</span>65.0<span style="color:#000000;"> million in gross proceeds, which satisfied this condition of the Deferred Underwriting Fee Assignment Agreement. </span>On September 2, 2020, the Company paid the underwriters $1.4 million in satisfaction of the Company’s obligation of the deferred underwriting fees in full. No further payment will be required of the Company in connection with the deferred underwriting fees.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Legal Proceedings</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business.  Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.</p> 0.75 400000 300000 100000 10000 17000 3000 0 Long-term finance lease obligations are as follows (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of net minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of finance lease obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p> 274000 362000 17000 27000 257000 335000 121000 109000 136000 226000 2021-07-01 95997 The Del Mar Lease provides for a tenant improvement allowance of $125.00 per rentable square foot of the Entire Premises for a total of $12.0 million that the Landlord will use to fund the installation and/or construction of certain improvements to the Entire Premises in four phases, with each phase pertaining to a specified portion of the Entire Premises. The initial term of the Del Mar Lease is ten years and six months beginning on the earlier to occur of (i) January 1, 2023 and (ii) the date that Landlord tenders possession of the Phase III Premises (as defined in the Del Mar Lease) to the Company following the substantial completion of the improvements to the Phase III Premises required by the Del Mar Lease (the “Lease Commencement Date”). The Company has the option to extend the term of the Lease for two additional five-year periods, subject to the terms of the Del Mar Lease. 125.00 12000000.0 five-year 5700000 5700000 63300000 3000000.0 0 In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities in Torrey Pines (the “Torrey Lease”). In January 2014, DermTech Operations signed an amendment to the Torrey Lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the Torrey Lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the Torrey Lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the Torrey Lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the Torrey Lease, as amended, from DermTech Operations. 300000 100000 2023-04-30 an option to extend the lease term on all leased space for one additional three-year term P28M 0.0404 3100000 2800000 300000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense for the year ended December 31, 2021 was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:76.6%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,174</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of leased assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,619</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new finance lease obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of operating leases (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001114">9.33</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term of finance leases (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001115">2.34</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for operating leases</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.78</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate for finance leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.63</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 1517000 657000 2174000 75000 17000 92000 2619000 17000 171000 9044000 93000 0.0578 0.0563 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s future minimum lease payments under operating and finance leases at December 31, 2021 are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations, including interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,802</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease obligations, including interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,271</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">734</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,280</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1802000 1149000 688000 709000 730000 4928000 10006000 132000 122000 8000 8000 4000 274000 1934000 1271000 696000 717000 734000 4928000 10280000 800000 1400000 15000000.0 1400000 65000000.0 1400000 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Retirement Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an IRC Section 401(k) retirement plan, covering all eligible employees. The Company did not offer a contribution percentage match during 2021 and 2020.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Related Party Transactions</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019, 2020, and 2021, the Company engaged EVERSANA Life Science Services, LLC, (“EVERSANA”), to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s Chief Commercial Offer, is an employee of EVERSANA. The Company incurred $2.6 million, $1.3 million, and $0.4 million in costs for the year ended December 31, 2021, 2020, and 2019, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2019, the Company entered into a consulting agreement with Michael Dobak pursuant to which the Company will compensate Michael Dobak, in an amount not to exceed $100,000, for certain public relations and marketing services. On July 28, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to modify the terms of Michael Dobak’s compensation. The amended consulting agreement compensated Michael Dobak $15,000 per month for the period May 11, 2020 through September 30, 2020 and also granted him a restricted stock unit award that fully vested in a single installment on August 31, 2020 and represented the contingent right to receive 5,000 shares of common stock on January 2, 2021. On November 11, 2020, the Company and Michael Dobak entered into an amendment to such consulting agreement to extend the term through December 31, 2020 with a continued monthly payment of $15,000. On February 26, 2021, the Company and Michael Dobak agreed to extend his agreement through April 30, 2021 with a revised monthly payment of <span style="color:#000000;">$20,000</span>. Michael Dobak is the brother of Dr. John Dobak, the Company’s Chief Executive Officer. The Company incurred $0.1 million, $0.2 million, and $20,000 in costs for the year ended December 31, 2021, 2020, and 2019, respectively.  </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other related party transactions identified for the years ended December 31, 2021, 2020, or 2019.</p> 2600000 1300000 400000 100000 15000 15000 15000 15000 15000 5000 15000 20000 100000 200000 20000 0 0 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Subsequent Events</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considered subsequent events through March 10, 2022, the date the consolidated financial statements were available to be issued.</p> EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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
  •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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 358 518 1 false 91 0 false 9 false false R1.htm 100000 - Document - Cover Page Sheet http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage Cover Page Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Consolidated Statements of Cash Flows Sheet http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 100080 - Disclosure - The Company and a Summary of its Significant Accounting Policies Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies The Company and a Summary of its Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Balance Sheet Details Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 10 false false R11.htm 100100 - Disclosure - Debt Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureDebt Debt Notes 11 false false R12.htm 100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity Convertible Preferred Stock and Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Income Taxes Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 13 false false R14.htm 100130 - Disclosure - Leases, Commitments and Contingencies Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies Leases, Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Retirement Plan Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureRetirementPlan Retirement Plan Notes 15 false false R16.htm 100150 - Disclosure - Related Party Transactions Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 100160 - Disclosure - Subsequent Events Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 100170 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies The Company and a Summary of its Significant Accounting Policies (Policies) Policies http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies 18 false false R19.htm 100180 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables The Company and a Summary of its Significant Accounting Policies (Tables) Tables http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies 19 false false R20.htm 100190 - Disclosure - Balance Sheet Details (Tables) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails 20 false false R21.htm 100200 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables Convertible Preferred Stock and Stockholders' Equity (Tables) Tables http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity 21 false false R22.htm 100210 - Disclosure - Income Taxes (Tables) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes 22 false false R23.htm 100220 - Disclosure - Leases, Commitments and Contingencies (Tables) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables Leases, Commitments and Contingencies (Tables) Tables http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies 23 false false R24.htm 100230 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Details 24 false false R25.htm 100240 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details) Details 25 false false R26.htm 100250 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details) Details 26 false false R27.htm 100260 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 27 false false R28.htm 100270 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Details 28 false false R29.htm 100280 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) Details 29 false false R30.htm 100290 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details) Details 30 false false R31.htm 100300 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1 The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1) Details 31 false false R32.htm 100310 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) Details 32 false false R33.htm 100320 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details) Details 33 false false R34.htm 100330 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 34 false false R35.htm 100340 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Details 35 false false R36.htm 100350 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Details 36 false false R37.htm 100360 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Details 38 false false R39.htm 100380 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Details 39 false false R40.htm 100390 - Disclosure - Debt - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails Convertible Preferred Stock and Stockholders Equity - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details) Details 42 false false R43.htm 100420 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details) Details 43 false false R44.htm 100430 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail) Details 44 false false R45.htm 100440 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details) Details 45 false false R46.htm 100450 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details) Details 47 false false R48.htm 100470 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details) Details 48 false false R49.htm 100480 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails Leases, Commitments and Contingencies - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) Details 50 false false R51.htm 100500 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails Leases, Commitments and Contingencies - Components of Lease Expense (Details) Details 51 false false R52.htm 100510 - Disclosure - Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details) Details 52 false false R53.htm 100520 - Disclosure - Leases, Commitments and Contingencie - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails Leases, Commitments and Contingencie - Additional Information (Details) Details 53 false false R54.htm 100530 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 54 false false All Reports Book All Reports dmtk-10k_20211231.htm dmtk-20211231.xsd dmtk-20211231_cal.xml dmtk-20211231_def.xml dmtk-20211231_lab.xml dmtk-20211231_pre.xml dmtk-ex231_8.htm dmtk-ex311_9.htm dmtk-ex312_6.htm g4lv1dgrulou000001.jpg g4lv1dgrulou000002.jpg g4lv1dgrulou000003.jpg g4lv1dgrulou000004.jpg g4lv1dgrulou000005.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 358, "dts": { "calculationLink": { "local": [ "dmtk-20211231_cal.xml" ] }, "definitionLink": { "local": [ "dmtk-20211231_def.xml" ] }, "inline": { "local": [ "dmtk-10k_20211231.htm" ] }, "labelLink": { "local": [ "dmtk-20211231_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20211231_pre.xml" ] }, "schema": { "local": [ "dmtk-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 669, "entityCount": 1, "hidden": { "http://dermtech.com/20211231": 3, "http://fasb.org/us-gaap/2021-01-31": 63, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 71 }, "keyCustom": 97, "keyStandard": 421, "memberCustom": 54, "memberStandard": 35, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Balance Sheet Details", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Debt", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity", "shortName": "Convertible Preferred Stock and Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Income Taxes", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Leases, Commitments and Contingencies", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies", "shortName": "Leases, Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Retirement Plan", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Related Party Transactions", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Subsequent Events", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables", "shortName": "The Company and a Summary of its Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Balance Sheet Details (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Income Taxes (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Leases, Commitments and Contingencies (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables", "shortName": "Leases, Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "dmtk:NatureOfOperationsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "dmtk:NatureOfOperationsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "dmtk:WarrantLiabilityNonCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "dmtk:WarrantLiabilityNonCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtRestatementAxis_srtScenarioPreviouslyReportedMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "span", "span", "span", "span", "span", "p", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapPlanNameAxis_dmtkTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapPlanNameAxis_dmtkTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R33": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dmtkWarrantLiabilityMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dmtkWarrantLiabilityMember_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "shortName": "Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210111_20210111", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Debt - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20190829_20190829", "decimals": "INF", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapEmployeeStockMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapEmployeeStockMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_dmtkWarrantsToPurchaseCommonStockMember_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Leases, Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "shortName": "Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails", "shortName": "Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails", "shortName": "Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapBusinessAcquisitionAxis_dmtkCowenMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Leases, Commitments and Contingencie - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "shortName": "Leases, Commitments and Contingencie - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapBusinessAcquisitionAxis_dmtkCowenMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapSubsidiarySaleOfStockAxis_dmtkAtTheMarketOfferingMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapSubsidiarySaleOfStockAxis_dmtkAtTheMarketOfferingMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - The Company and a Summary of its Significant Accounting Policies", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 91, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dmtk_AccountingPronouncementsIssuedButNotYetEffectivePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting pronouncements issued but not yet effective.", "label": "Accounting Pronouncements Issued But Not Yet Effective Policy Policy [Text Block]", "terseLabel": "Accounting Pronouncements Issued But Not Yet Effective" } } }, "localname": "AccountingPronouncementsIssuedButNotYetEffectivePolicyPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_AccruedBonusAndDeferredCompensationCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued bonus and deferred compensation, current.", "label": "Accrued Bonus And Deferred Compensation Current", "terseLabel": "Accrued bonus and deferred compensation" } } }, "localname": "AccruedBonusAndDeferredCompensationCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AccruedConsultingServicesCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consulting services, current.", "label": "Accrued Consulting Services Current", "terseLabel": "Accrued consulting services" } } }, "localname": "AccruedConsultingServicesCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalAssumedInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital assumed in business combination.", "label": "Adjustments To Additional Paid In Capital Assumed In Business Combination", "terseLabel": "Additional paid in capital assumed in Business Combination" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAssumedInBusinessCombination", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital increase in carrying amount of convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Convertible Preferred Stock", "terseLabel": "Issuance of Series A preferred stock at $3,250 per share" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance cost related to registration.", "label": "Adjustments To Additional Paid In Capital Issuance Cost Related To Registration", "terseLabel": "Issuance costs in connection with Form?S-1?registration statement" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB1ConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance of series B1 convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Issuance Of Series B1 Convertible Preferred Stock", "terseLabel": "Issuance of Series B-1 convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB1ConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB2ConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance of series B2 convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Issuance Of Series B2 Convertible Preferred Stock", "terseLabel": "Issuance of Series B-2 convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB2ConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization of laboratory equipment acquired under finance leases.", "label": "Amortization Of Laboratory Equipment Acquired Under Finance Leases [Member]", "terseLabel": "Amortization of Laboratory Equipment Acquired under Finance Leases" } } }, "localname": "AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AreaOfBuilding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of building.", "label": "Area Of Building", "terseLabel": "Area of building" } } }, "localname": "AreaOfBuilding", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dmtk_AssayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay.", "label": "Assay [Member]", "terseLabel": "Assay Revenue" } } }, "localname": "AssayMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor A.", "label": "Assay Revenue Payor A [Member]", "terseLabel": "Assay Revenue Payor A" } } }, "localname": "AssayRevenuePayorAMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor B.", "label": "Assay Revenue Payor B [Member]", "terseLabel": "Assay Revenue Payor B" } } }, "localname": "AssayRevenuePayorBMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held under finance leases.", "label": "Assets Held Under Finance Leases [Member]", "terseLabel": "Assets Recorded under Finance Leases" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At-The Market Offering", "verboseLabel": "At-The Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureESPPPurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future ESPP purchases.", "label": "Authorized For Future E S P P Purchases [Member]", "terseLabel": "Authorized for Future ESPP Purchases" } } }, "localname": "AuthorizedForFutureESPPPurchasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureEquityGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future equity grants.", "label": "Authorized For Future Equity Grants [Member]", "terseLabel": "Authorized for Future Equity Grants" } } }, "localname": "AuthorizedForFutureEquityGrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_BrotherOfChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brother of chief executive officer.", "label": "Brother Of Chief Executive Officer [Member]", "terseLabel": "Michael Dobak" } } }, "localname": "BrotherOfChiefExecutiveOfficerMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_CashlessExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of common stock warrants.", "label": "Cashless Exercise Of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseOfCommonStockWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in unrealized gain loss on available-for-sale marketable securities.", "label": "Change In Unrealized Gain Loss On Available For Sale Marketable Securities", "terseLabel": "Change in unrealized loss on available-for-sale marketable securities" } } }, "localname": "ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ClassOfWarrantOrRightsIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights issued to purchase common stock.", "label": "Class Of Warrant Or Rights Issued To Purchase Common Stock", "terseLabel": "Warrants issued to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightsIssuedToPurchaseCommonStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommonSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares issued upon exercise of warrants.", "label": "Common Shares Issued Upon Exercise Of Warrants", "terseLabel": "Common shares issued upon exercise of warrants" } } }, "localname": "CommonSharesIssuedUponExerciseOfWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding percentage.", "label": "Common Stock Outstanding Percentage", "terseLabel": "Common stock outstanding percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_ComputerEquipmentGross": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10040.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Computer equipment gross.", "label": "Computer Equipment Gross", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentGross", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ContractRevenueCustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Revenue Customer A.", "label": "Contract Revenue Customer A [Member]", "terseLabel": "Contract Revenue Customer A" } } }, "localname": "ContractRevenueCustomerAMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueCustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue customer B.", "label": "Contract Revenue Customer B [Member]", "terseLabel": "Contract Revenue Customer B" } } }, "localname": "ContractRevenueCustomerBMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueCustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue customer C.", "label": "Contract Revenue Customer C [Member]", "terseLabel": "Contract Revenue Customer C" } } }, "localname": "ContractRevenueCustomerCMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueProjectManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue project management fees.", "label": "Contract Revenue Project Management Fees [Member]", "terseLabel": "Contract Revenue, Project Management Fees" } } }, "localname": "ContractRevenueProjectManagementFeesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueRNAExtractionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, RNA extractions.", "label": "Contract Revenue R N A Extractions [Member]", "terseLabel": "Contract Revenue, RNA Extractions" } } }, "localname": "ContractRevenueRNAExtractionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueSmartStickersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue smart stickers.", "label": "Contract Revenue Smart Stickers [Member]", "terseLabel": "Contract Revenue, Smart Stickers" } } }, "localname": "ContractRevenueSmartStickersMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractualActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract activities.", "label": "Contractual Activities [Member]", "terseLabel": "Contract Revenue" } } }, "localname": "ContractualActivitiesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "dmtk_ConversionOfPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of preferred stock.", "label": "Conversion Of Preferred Stock [Member]", "terseLabel": "Conversion of Preferred Stock" } } }, "localname": "ConversionOfPreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen Limited Liability Company.", "label": "Cowen Limited Liability Company [Member]", "terseLabel": "Cowen and Company LLC" } } }, "localname": "CowenLimitedLiabilityCompanyMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen.", "label": "Cowen [Member]", "verboseLabel": "Cowen" } } }, "localname": "CowenMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_DebtConversionRatioNumberUsedAsNumeratorToDeriveQuotient": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt conversion ratio number used as numerator to derive quotient.", "label": "Debt Conversion Ratio Number Used As Numerator To Derive Quotient", "terseLabel": "Debt Conversion Ratio Number Used As Numerator to Derive Quotient" } } }, "localname": "DebtConversionRatioNumberUsedAsNumeratorToDeriveQuotient", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DebtDiscountAndDerivativeLiabilityAtIssuanceOfConvertibleNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt discount and derivative liability at issuance of convertible notes payable.", "label": "Debt Discount And Derivative Liability At Issuance Of Convertible Notes Payable", "terseLabel": "Debt discount and derivative liability at issuance of convertible notes payable" } } }, "localname": "DebtDiscountAndDerivativeLiabilityAtIssuanceOfConvertibleNotesPayable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets depreciation and amortization.", "label": "Deferred Tax Assets Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxAssetsDepreciationAndAmortization", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets liabilities before valuation allowance.", "label": "Deferred Tax Assets Liabilities Before Valuation Allowance", "totalLabel": "Net deferred tax assets before valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating lease liabilities.", "label": "Deferred Tax Assets Operating Lease Liabilities", "terseLabel": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities depreciation and amortization.", "label": "Deferred Tax Liabilities Depreciation And Amortization", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating lease right-of-use assets,", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredUnderwritingFeeEquityPayableIfEquityFinancingLimitNotRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee equity payable if equity financing limit not raised.", "label": "Deferred Underwriting Fee Equity Payable If Equity Financing Limit Not Raised", "terseLabel": "Deferred underwriting fee equity payable if equity financing limit not raised" } } }, "localname": "DeferredUnderwritingFeeEquityPayableIfEquityFinancingLimitNotRaised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredUnderwritingFeesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees current.", "label": "Deferred Underwriting Fees Current", "terseLabel": "Underwriting fees" } } }, "localname": "DeferredUnderwritingFeesCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DenominatorForCalculatingCapitalizationValueForPricePerShare": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Denominator for calculating capitalization value for price per share.", "label": "Denominator For Calculating Capitalization Value For Price Per Share", "terseLabel": "Denominator for calculating capitalization value for price per share" } } }, "localname": "DenominatorForCalculatingCapitalizationValueForPricePerShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DermTechOperationsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DermTech Operations, Inc.", "label": "Derm Tech Operations Inc [Member]", "terseLabel": "DermTech,Inc." } } }, "localname": "DermTechOperationsIncMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_EVERSANALifeScienceServicesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EVERSANA Life Science Services, LLC.", "label": "E V E R S A N A Life Science Services L L C [Member]", "terseLabel": "EVERSANA" } } }, "localname": "EVERSANALifeScienceServicesLLCMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_EffectiveIncomeTaxRateReconciliationPermanentItems": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent items.", "label": "Effective Income Tax Rate Reconciliation Permanent Items", "terseLabel": "Permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "dmtk_EquityIncentivePlanOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity incentive plan option term.", "label": "Equity Incentive Plan Option Term", "terseLabel": "Term of the option" } } }, "localname": "EquityIncentivePlanOptionTerm", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of debt securities with contractual maturities of less than 12 months.", "label": "Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months", "terseLabel": "Estimated market value of debt securities with contractual maturities of less than 12 months" } } }, "localname": "EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 14 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To14 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 14 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To23 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfWarrantLiabilityFromExerciseOfPrivateSpacWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability derecognition of warrant liability from exercise of private spac warrants.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Derecognition Of Warrant Liability From Exercise Of Private Spac Warrants", "negatedLabel": "Derecognition of warrant liability from exercise of Private SPAC Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfWarrantLiabilityFromExerciseOfPrivateSpacWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantLiabilityDueToPrivateSpacWarrantsNotHeldByOriginalHolder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability reclassification of warrant liability due to private spac warrants not held by original holder.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder", "negatedLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantLiabilityDueToPrivateSpacWarrantsNotHeldByOriginalHolder", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Costs [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseCostsAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses.", "label": "Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses", "terseLabel": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses" } } }, "localname": "GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncentiveAndNonQualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive and non-qualified stock options.", "label": "Incentive And Non Qualified Stock Options [Member]", "terseLabel": "Incentive and Non-qualified Stock Options" } } }, "localname": "IncentiveAndNonQualifiedStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncentiveAndNonStatutoryStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive and non-statutory stock options.", "label": "Incentive And Non Statutory Stock Options [Member]", "terseLabel": "Incentive and Non-statutory Stock Options" } } }, "localname": "IncentiveAndNonStatutoryStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncreaseDecreaseInAccountsPayableAndAccruedCompensation": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10390.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accounts payable and accrued compensation.", "label": "Increase Decrease In Accounts Payable And Accrued Compensation", "terseLabel": "Accounts payable and accrued compensation" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedCompensation", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10400.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued liabilities and deferred revenue.", "label": "Increase Decrease In Accrued Liabilities And Deferred Revenue", "terseLabel": "Accrued liabilities and deferred revenue" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in stock issuance costs.", "label": "Increase Decrease In Stock Issuance Costs", "negatedLabel": "Decrease in issuance costs" } } }, "localname": "IncreaseDecreaseInStockIssuanceCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseInTenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in tenant improvement allowance.", "label": "Increase In Tenant Improvement Allowance", "terseLabel": "Increase in tenant improvement allowance" } } }, "localname": "IncreaseInTenantImprovementAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IssuanceOfCommonStockInLitigationSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in litigation settlement.", "label": "Issuance Of Common Stock In Litigation Settlement", "terseLabel": "Issuance of common stock in litigation settlement" } } }, "localname": "IssuanceOfCommonStockInLitigationSettlement", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_KilroyRealtyLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kilroy Realty, L.P.", "label": "Kilroy Realty L P [Member]", "terseLabel": "Kilroy Realty, L.P" } } }, "localname": "KilroyRealtyLPMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dmtk_LeaseTermExtendPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term extend period.", "label": "Lease Term Extend Period", "terseLabel": "Extend lease term" } } }, "localname": "LeaseTermExtendPeriod", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_LifeSciMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LifeSci.", "label": "Life Sci [Member]", "terseLabel": "LifeSci Capital LLC" } } }, "localname": "LifeSciMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_ManagementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management warrants.", "label": "Management Warrants [Member]", "terseLabel": "Management Warrants" } } }, "localname": "ManagementWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_MergerConsiderationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger consideration description.", "label": "Merger Consideration Description", "terseLabel": "Description of merger consideration" } } }, "localname": "MergerConsiderationDescription", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_MergerConsiderationMaximumPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger consideration maximum price per share.", "label": "Merger Consideration Maximum Price Per Share", "terseLabel": "Merger consideration maximum price per share" } } }, "localname": "MergerConsiderationMaximumPricePerShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "dmtk_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of operations.", "label": "Nature Of Operations Policy [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_NetChangeInNetCashUsedInOperatingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net change in net cash used in operating activities.", "label": "Net Change In Net Cash Used In Operating Activities", "terseLabel": "Net change in net cash used in operating activities" } } }, "localname": "NetChangeInNetCashUsedInOperatingActivities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_NumberOfRevenueStreams": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of revenue streams.", "label": "Number Of Revenue Streams", "terseLabel": "Number of revenue streams" } } }, "localname": "NumberOfRevenueStreams", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfWarrantsEntitleHolderToPurchaseOneShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants entitle holder to purchase one share.", "label": "Number Of Warrants Entitle Holder To Purchase One Share", "terseLabel": "Number of warrants entitle holder to purchase one share" } } }, "localname": "NumberOfWarrantsEntitleHolderToPurchaseOneShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due.", "label": "Operating And Capital Lease Liability Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10010.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due next twelve months.", "label": "Operating And Capital Lease Liability Payments Due Next Twelve Months", "terseLabel": "Total future minimum lease payments due in 2022" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueThereafter": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10060.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due thereafter.", "label": "Operating And Capital Lease Liability Payments Due Thereafter", "terseLabel": "Total future minimum lease payments due thereafter" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueThereafter", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10050.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year five.", "label": "Operating And Capital Lease Liability Payments Due Year Five", "terseLabel": "Total future minimum lease payments due in 2026" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10040.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year four.", "label": "Operating And Capital Lease Liability Payments Due Year Four", "terseLabel": "Total future minimum lease payments due in 2025" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10030.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year three.", "label": "Operating And Capital Lease Liability Payments Due Year Three", "terseLabel": "Total future minimum lease payments due in 2024" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10020.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year two.", "label": "Operating And Capital Lease Liability Payments Due Year Two", "terseLabel": "Total future minimum lease payments due in 2023" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_OperatingLeaseCosts": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Costs", "totalLabel": "Total operating lease cost" } } }, "localname": "OperatingLeaseCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OptionsGrantedToShareholderPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options granted to shareholder, percentage.", "label": "Options Granted To Shareholder Percentage", "terseLabel": "Options granted to shareholder, percentage" } } }, "localname": "OptionsGrantedToShareholderPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PaymentForDeferredUnderwritingFees": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for deferred underwriting fees.", "label": "Payment For Deferred Underwriting Fees", "negatedLabel": "Payments of deferred underwriting fees", "terseLabel": "Payments for deferred underwriting fees" } } }, "localname": "PaymentForDeferredUnderwritingFees", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PaymentInConnectionWithRestrictedStockUnitRelease": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10340.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment in connection with restricted stock unit release.", "label": "Payment In Connection With Restricted Stock Unit Release", "negatedLabel": "Payment in connection with restricted stock unit release" } } }, "localname": "PaymentInConnectionWithRestrictedStockUnitRelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PercentageOfPriceAtSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of price at shares purchased", "label": "Percentage Of Price At Shares Purchased", "terseLabel": "Percentage of price at shares purchased" } } }, "localname": "PercentageOfPriceAtSharesPurchased", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfPricePerShareOfNewStockPaidInQualifiedFinancingByInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of price per share of new stock paid in qualified financing by investors.", "label": "Percentage Of Price Per Share Of New Stock Paid In Qualified Financing By Investors", "terseLabel": "Percentage of multiplier on price per share of new stock paid in qualified financing by investors" } } }, "localname": "PercentageOfPricePerShareOfNewStockPaidInQualifiedFinancingByInvestors", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfUsefulLivesOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of useful lives of assets.", "label": "Percentage Of Useful Lives Of Assets", "terseLabel": "Percentage of useful lives of assets" } } }, "localname": "PercentageOfUsefulLivesOfAssets", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfWarrantsIssuedInConnectionWithPreferredStockPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrants issued in connection with preferred stock purchased.", "label": "Percentage Of Warrants Issued In Connection With Preferred Stock Purchased", "terseLabel": "Percentage of warrants issued in connection with preferred stock purchased" } } }, "localname": "PercentageOfWarrantsIssuedInConnectionWithPreferredStockPurchased", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PreferredStockDesignatedSharesAuthorizedAndUnissued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock designated shares authorized and unissued.", "label": "Preferred Stock Designated Shares Authorized And Unissued", "terseLabel": "Preferred stock designated shares authorized and unissued" } } }, "localname": "PreferredStockDesignatedSharesAuthorizedAndUnissued", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_PreferredStockValueOfSharesPurchasedByInvestors": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock value of shares purchased by investors.", "label": "Preferred Stock Value Of Shares Purchased By Investors", "terseLabel": "Preferred stock value of shares purchased in single closing" } } }, "localname": "PreferredStockValueOfSharesPurchasedByInvestors", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidEmployeeCompensation": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10110.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid employee compensation.", "label": "Prepaid Employee Compensation", "terseLabel": "Prepaid employee compensation" } } }, "localname": "PrepaidEmployeeCompensation", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidSoftwareFees": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10090.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid software fees.", "label": "Prepaid Software Fees", "terseLabel": "Prepaid software fees" } } }, "localname": "PrepaidSoftwareFees", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidTradeShowsCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10080.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid trade shows, current.", "label": "Prepaid Trade Shows Current", "terseLabel": "Prepaid trade shows" } } }, "localname": "PrepaidTradeShowsCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrivatePlacementOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement offering.", "label": "Private Placement Offering [Member]", "terseLabel": "Private Placement Offering" } } }, "localname": "PrivatePlacementOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private special purpose acquisition companies warrants.", "label": "Private Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Private SPAC Warrants" } } }, "localname": "PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ProceedsFromSaleOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of marketable securities.", "label": "Proceeds From Sale Of Marketable Securities", "terseLabel": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfMarketableSecurities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ProceedsReceivedFromCloseOfBusinessCombination": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds received from close of business combination.", "label": "Proceeds Received From Close Of Business Combination", "terseLabel": "Proceeds received from close of Business Combination" } } }, "localname": "ProceedsReceivedFromCloseOfBusinessCombination", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PublicFollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public follow on offering.", "label": "Public Follow On Offering [Member]", "terseLabel": "Public Follow on Offering" } } }, "localname": "PublicFollowOnOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "dmtk_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PublicSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public special purpose acquisition companies warrants.", "label": "Public Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Public SPAC Warrants" } } }, "localname": "PublicSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ReclassificationOfStockholdersEquityToWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of stockholders\u2019 equity to warrant liability,", "label": "Reclassification Of Stockholders Equity To Warrant Liability", "terseLabel": "Reclassification of stockholders\u2019 equity to warrant liability" } } }, "localname": "ReclassificationOfStockholdersEquityToWarrantLiability", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant liability due to private SPAC warrants not held by original holder.", "label": "Reclassification Of Warrant Liability Due To Private S P A C Warrants Not Held By Original Holder", "terseLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder" } } }, "localname": "ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_RevisionToPriorPeriodFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revision to prior period financial statements.", "label": "Revision To Prior Period Financial Statements Policy [Text Block]", "terseLabel": "Revision to Prior Period Financial Statements" } } }, "localname": "RevisionToPriorPeriodFinancialStatementsPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_RightOfUseAssetsRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right of use assets remaining lease term.", "label": "Right Of Use Assets Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "RightOfUseAssetsRemainingLeaseTerm", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_SaleOfStockClosingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock closing date.", "label": "Sale Of Stock Closing Date", "terseLabel": "PIPE financing closing date" } } }, "localname": "SaleOfStockClosingDate", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dmtk_ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum rental payments for operating and capital leases.", "label": "Schedule Of Future Minimum Rental Payments For Operating And Capital Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Under Operating and Finance Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long term finance lease obligations.", "label": "Schedule Of Long Term Finance Lease Obligations Table [Text Block]", "terseLabel": "Schedule of Long Term Finance Lease Obligations" } } }, "localname": "ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and PP&E.", "label": "Schedule Of Prepaid Expenses And Property And Equipment Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and PP&E" } } }, "localname": "ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "dmtk_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities purchase agreement.", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SeriesAAndBConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A and B convertible note.", "label": "Series A And B Convertible Note [Member]", "terseLabel": "Series A and B Convertible Preferred Stock" } } }, "localname": "SeriesAAndBConvertibleNoteMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A convertible preferred stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesB1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B-1 convertible preferred stock.", "label": "Series B1 Convertible Preferred Stock [Member]", "terseLabel": "Series B-1 Convertible Preferred Stock" } } }, "localname": "SeriesB1ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesB2ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B-2 convertible preferred stock.", "label": "Series B2 Convertible Preferred Stock [Member]", "terseLabel": "Series B-2 Convertible Preferred Stock" } } }, "localname": "SeriesB2ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesC2ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C-2 convertible preferred stock.", "label": "Series C2 Convertible Preferred Stock [Member]", "terseLabel": "Series C-2 Convertible Preferred Stock" } } }, "localname": "SeriesC2ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SeriesCWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C warrants.", "label": "Series C Warrants [Member]", "terseLabel": "Series C Warrants" } } }, "localname": "SeriesCWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "RSUs vested and expected to vest, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued", "terseLabel": "RSUs vested, but not yet issued" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssued", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssuedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued weighted average grant date fair value", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued Weighted Average Grant Date Fair Value", "terseLabel": "RSUs vested, but not yet issued, Weighted average grant date fair value per share" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssuedWeightedAverageGrantDateFairValue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardotherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award,other than options, vested and expected to vest, outstanding, number", "label": "Sharebased Compensation Arrangement By Sharebased Payment Awardother Than Options Vested And Expected To Vest Outstanding Number", "terseLabel": "RSUs vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardotherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "dmtk_SpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special purpose acquisition companies warrants.", "label": "Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "SPAC Warrants" } } }, "localname": "SpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPAC warrants to purchase common stock.", "label": "Special Purpose Acquisition Company Warrants To Purchase Common Stock [Member]", "terseLabel": "SPAC Warrants to Purchase Common Stock" } } }, "localname": "SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_SpouseOfChiefCommercialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spouse of chief commercial officer.", "label": "Spouse Of Chief Commercial Officer [Member]", "terseLabel": "Leana Wood" } } }, "localname": "SpouseOfChiefCommercialOfficerMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, common stock warrants exercised.", "label": "Stock Issued During Period Shares Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock from warrant exercises, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and RSU release.", "label": "Stock Issued During Period Shares Stock Options Exercised And R S U Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value common stock warrants exercised.", "label": "Stock Issued During Period Value Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock from warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and RSU release.", "label": "Stock Issued During Period Value Stock Options Exercised And R S U Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options and restricted stock units.", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock Options and Restricted Stock Units" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockPurchasedByUnderwritersPursuantToOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchased by underwriters pursuant to option granted.", "label": "Stock Purchased By Underwriters Pursuant To Option Granted", "terseLabel": "Shares purchased by underwriters" } } }, "localname": "StockPurchasedByUnderwritersPursuantToOptionGranted", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_TenantImprovementAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance.", "label": "Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovementAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_TenantImprovementAllowancePerRentableSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance per rentable square foot.", "label": "Tenant Improvement Allowance Per Rentable Square Foot", "terseLabel": "Tenant improvement allowance per rentable square foot" } } }, "localname": "TenantImprovementAllowancePerRentableSquareFoot", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Line Items]", "terseLabel": "The Company and Summary of its Significant Accounting Policies [Line Items]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Table]", "terseLabel": "The Company And Summary Of Its Significant Accounting Policies [Table]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "dmtk_TwoThousandAndTwentyPIPEFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 PIPE Financing.", "label": "Two Thousand And Twenty P I P E Financing [Member]", "terseLabel": "2020 PIPE Financing" } } }, "localname": "TwoThousandAndTwentyPIPEFinancingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandEighteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen convertible bridge notes.", "label": "Two Thousand Eighteen Convertible Bridge Notes [Member]", "terseLabel": "2018 Convertible Bridge Notes" } } }, "localname": "TwoThousandEighteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandNineteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen convertible bridge notes.", "label": "Two Thousand Nineteen Convertible Bridge Notes [Member]", "terseLabel": "2019 Convertible Bridge Notes" } } }, "localname": "TwoThousandNineteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTenStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand ten stock plan.", "label": "Two Thousand Ten Stock Plan [Member]", "terseLabel": "2010 Stock Plan" } } }, "localname": "TwoThousandTenStockPlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee stock purchase plan.", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "dmtk_UncertainTaxPositionsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Uncertain tax positions percentage.", "label": "Uncertain Tax Positions Percentage", "terseLabel": "Uncertain tax positions percentage" } } }, "localname": "UncertainTaxPositionsPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_UnderwritersGrantPeriodOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters grant period option.", "label": "Underwriters Grant Period Option", "terseLabel": "Number of days granted to underwriters option to purchase" } } }, "localname": "UnderwritersGrantPeriodOption", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_UnpaidDeferredIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unpaid deferred issuance costs.", "label": "Unpaid Deferred Issuance Costs", "terseLabel": "Unpaid deferred issuance costs" } } }, "localname": "UnpaidDeferredIssuanceCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability fair value disclosure.", "label": "Warrant Liability Fair Value Disclosure", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "dmtk_WarrantLiabilityNonCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails": { "order": 10010.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability non current.", "label": "Warrant Liability Non Current", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityNonCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability Policy [Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Warrants to Purchase Common Stock" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_WarrantsVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants vesting period.", "label": "Warrants Vesting Period", "terseLabel": "Warrants vesting period" } } }, "localname": "WarrantsVestingPeriod", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_WeightedAveragePurchasePricePerShareInOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price per share in offering.", "label": "Weighted Average Purchase Price Per Share In Offering", "terseLabel": "Issuance price per share" } } }, "localname": "WeightedAveragePurchasePricePerShareInOffering", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "perShareItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r62", "r64", "r114", "r115", "r247", "r287" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption Adjustment [Member]", "terseLabel": "Cumulative Effect Adjustment of Accounting Method Change" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r246", "r286", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r246", "r286", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r181", "r316", "r317", "r534", "r573", "r575" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r181", "r316", "r317", "r534", "r573", "r575" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r246", "r286", "r326", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r246", "r286", "r326", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r63", "r64", "r114", "r115", "r247", "r287" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r132", "r133", "r134", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r132", "r133", "r134", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r124", "r125", "r126", "r129", "r130", "r132", "r133" ], "lang": { "en-us": { "role": { "label": "Revision Of Prior Period Error Correction Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r118", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r132", "r133", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Scenario Previously Reported [Member]", "terseLabel": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r45", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r184", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Gross Current", "verboseLabel": "Accounts receivable gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r30", "r184", "r185" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization (Accretion) of discount (premium) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r14", "r48", "r325" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation Current", "terseLabel": "Accrued paid time off" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r223" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r66", "r67", "r68", "r71", "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Unrealized Investment Gain Loss [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r69", "r70", "r71", "r566", "r582", "r586" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r31" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r118", "r119", "r120", "r383", "r384", "r385", "r441" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition", "terseLabel": "Restricted stock unit release" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r351", "r353", "r389", "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r300", "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353", "r379", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r97", "r266", "r274", "r275", "r467" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive equity instruments excluded from diluted net loss per common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r164", "r173", "r179", "r204", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r423", "r427", "r457", "r497", "r499", "r548", "r565" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r61", "r112", "r204", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r423", "r427", "r457", "r497", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r444" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r195" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r196" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r193", "r213" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r191", "r194", "r213", "r553" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10040.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable securities, available for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r346", "r348" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r346", "r348", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment recorded in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r40", "r99" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r17", "r100", "r547" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r93", "r99", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r458" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r40" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10020.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash F D I C Insured Amount", "terseLabel": "Insured amount by FDIC" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash Uninsured Amount", "terseLabel": "Cash held in excess of FDIC limit" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r109", "r112", "r135", "r136", "r137", "r139", "r141", "r146", "r147", "r148", "r204", "r231", "r235", "r236", "r237", "r240", "r241", "r284", "r285", "r289", "r293", "r457", "r609" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r311", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Number of shares issued for each warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Total number exercised of public warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Leases, Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved for future issuance", "verboseLabel": "Common stock available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r118", "r119", "r441" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of December 31, 2021 and 2020; 29,772,922 and 20,740,413 shares issued and outstanding at December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r73", "r75", "r76", "r82", "r556", "r572" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r595" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r588", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r588", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r151", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r595" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt Current", "verboseLabel": "Liability balance" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r242", "r243", "r244", "r246", "r256", "r257", "r258", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r327", "r342", "r587" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r84", "r112", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r457" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10130.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost Of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost Of Sales Policy [Text Block]", "terseLabel": "Freight and Shipping Costs" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r154", "r183" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r102", "r104" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "verboseLabel": "Convertible debt converted in to common shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r108", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r260", "r267", "r268", "r270", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r468", "r549", "r551", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument Convertible Conversion Price1", "terseLabel": "Convertible notes conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r52", "r245", "r301", "r304", "r306" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument Convertible Conversion Ratio1", "terseLabel": "Convertible notes conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r52", "r301", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument Convertible Terms Of Conversion Feature", "terseLabel": "Debt conversion feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r243", "r272", "r273", "r466", "r468", "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Convertible note, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument Interest Rate Increase Decrease", "terseLabel": "Increase in interest rate if bridge notes not paid or converted" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r50", "r244" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r51", "r246", "r449" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Maturity date, description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r468" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r272", "r273", "r274", "r275", "r301", "r305", "r306", "r307", "r465", "r466", "r468", "r469", "r561" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r256", "r465", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Table [Text Block]", "terseLabel": "Schedule of Short-Term Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10100.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred Costs Current", "terseLabel": "Deferred issuance costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r24", "r25", "r399", "r550", "r563" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10040.0, "parentTag": "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue Current", "verboseLabel": "Short-term deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue Noncurrent", "terseLabel": "Long-term deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r400" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10030.0, "parentTag": "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets In Process Research And Development", "terseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r402" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net Of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r401" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsMoneyMarketDeposits": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deposits in accounts that offer many of the same services as checking accounts although transactions may be somewhat more limited, share some of the characteristics of a money market fund and are insured by the Federal government, also known as money market accounts.", "label": "Deposits Money Market Deposits", "terseLabel": "Sweep account" } } }, "localname": "DepositsMoneyMarketDeposits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r221" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r97", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Accumulated amortization", "verboseLabel": "Accumulated amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r433" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Derivative Loss On Derivative", "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Revenues Disaggregated by Revenue Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Domestic tax authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share of common stock outstanding, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r394" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Income tax expense" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r113", "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Income tax at statutory rate", "verboseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance (decrease) increase" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Reconciling Items Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State tax, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "Tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeLossOnEmbeddedDerivative": { "auth_ref": [ "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative Loss On Embedded Derivative", "terseLabel": "Loss on change in fair value of derivative liability" } } }, "localname": "EmbeddedDerivativeLossOnEmbeddedDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation", "totalLabel": "Total accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Related Liabilities Current [Abstract]", "terseLabel": "Accrued compensation:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Compensation cost related to non-vested awards not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted average term expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Stock Option [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r78", "r79", "r80", "r118", "r119", "r120", "r123", "r130", "r133", "r145", "r205", "r300", "r308", "r383", "r384", "r385", "r410", "r411", "r441", "r459", "r460", "r461", "r462", "r463", "r464", "r577", "r578", "r579", "r620" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Ownership interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections And Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections And Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r97", "r279" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "negatedLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r444", "r445", "r446", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]", "terseLabel": "Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r445", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Fair Value By Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r444", "r445", "r448", "r449", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r258", "r327", "r329", "r334", "r342", "r445", "r505" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r334", "r342", "r445", "r506" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r445", "r507" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r472", "r479", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10020.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease Interest Expense", "terseLabel": "Finance lease interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r471", "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10040.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease Liability", "totalLabel": "Present value of net minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease Liability [Abstract]" } } }, "localname": "FinanceLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10010.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "negatedLabel": "Less: current portion of finance lease obligations", "terseLabel": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10020.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Long-term finance lease obligations, less current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Gross finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10120.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due After Year Five", "terseLabel": "Finance lease obligations, including interest payments due thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10070.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "Finance lease obligations, including interest payments due in 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10110.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "Finance lease obligations, including interest payments due in 2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "Finance lease obligations, including interest payments due in 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "Finance lease obligations, including interest payments due in 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10080.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "Finance lease obligations, including interest payments due in 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10030.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r473", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r472", "r479", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10010.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate for finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r484", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term of finance leases (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r269", "r298", "r437", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r609", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10050.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r97" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain Loss On Disposition Of Assets1", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r97", "r276", "r277" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Gain on extinguishment of convertible notes", "terseLabel": "Gain on debt extinguishment of convertible notes", "verboseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r112", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r457" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit/(loss)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r97", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment Of Long Lived Assets To Be Disposed Of", "terseLabel": "Impairment losses" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r395", "r397", "r404", "r412", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r77", "r392", "r393", "r397", "r398", "r403", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10350.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10360.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r96", "r482" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10380.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10370.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest Income, Net" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r91", "r94", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest on finance lease obligations" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r58", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Holdings [Line Items]", "terseLabel": "Investment Holdings [Line Items]" } } }, "localname": "InvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTable": { "auth_ref": [ "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.", "label": "Investment Holdings [Table]", "terseLabel": "Investment Holdings [Table]" } } }, "localname": "InvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Fair Value Disclosure [Abstract]", "terseLabel": "Marketable securities, available for sale:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r13", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10060.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee Operating Lease Description", "terseLabel": "Lessee, operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee Operating Lease Discount Rate", "terseLabel": "Estimated discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "terseLabel": "Estimated future lease payment obligation", "totalLabel": "Operating lease obligations, including interest payments due, Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10180.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Operating lease obligations, including interest payments due thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10130.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "Operating lease obligations, including interest payments due in 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10170.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Operating lease obligations, including interest payments due in 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10160.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Operating lease obligations, including interest payments due in 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10150.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Operating lease obligations, including interest payments due in 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10140.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Operating lease obligations, including interest payments due in 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Option to extend the lease term" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r46", "r112", "r174", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r424", "r427", "r428", "r457", "r497", "r498" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r112", "r204", "r457", "r499", "r552", "r568" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r112", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r424", "r427", "r428", "r457", "r497", "r498", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r444" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value on a recurring basis" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as current.", "label": "Liability For Uncertain Tax Positions Current", "terseLabel": "Uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositionsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r230" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r13", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10030.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment Gross", "terseLabel": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r7", "r47" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Expected Dividend Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Assumed Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Assumed Risk-free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Notes [Member]", "terseLabel": "Municipal Securities" } } }, "localname": "MunicipalNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r72", "r74", "r80", "r81", "r98", "r112", "r122", "r124", "r125", "r127", "r128", "r132", "r133", "r138", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r443", "r457", "r555", "r571" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Accounting Pronouncement Recently Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Property and equipment acquired under finance leases" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "terseLabel": "Total other income/(expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income/(expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r172", "r175", "r178", "r180" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r480", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10030.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r474", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r470" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r97" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r484", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term of operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r3", "r117", "r160", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]", "terseLabel": "The Company and a Summary of its Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r59", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10120.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r66", "r69" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized loss on available-for-sale marketable securities", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r90" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Payments of issuance costs in connection with Form S-1 registration statement", "verboseLabel": "Preferred stock, issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r192" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r326", "r328", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r284" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "verboseLabel": "Preferred stock, par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "verboseLabel": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r38", "r39" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Assets Current [Abstract]", "terseLabel": "Prepaid expenses and other current assets:" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r8", "r10", "r218", "r219" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10070.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prior Period Adjustment [Abstract]" } } }, "localname": "PriorPeriodAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r89" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "terseLabel": "Proceeds from convertible notes payable", "verboseLabel": "Proceeds from issuance of convertible note" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "positiveLabel": "Net proceeds from issuance of common stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Gross proceeds from issuance of equity securities" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "verboseLabel": "Proceeds from issuance of Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds From Issuance Of Debt", "terseLabel": "Proceeds from issuance of convertible note" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds From Issuance Of Private Placement", "terseLabel": "Gross proceeds from PIPE financing" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds From Issuance Or Sale Of Equity", "terseLabel": "Proceeds from equity financing" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds From Repayments Of Notes Payable", "terseLabel": "Payments of notes payable" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r382" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from contributions to the employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds From Warrant Exercises", "terseLabel": "Proceeds from exercise of common stock warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product And Service Other [Member]", "terseLabel": "Contract Revenue, Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r72", "r74", "r80", "r92", "r112", "r122", "r132", "r133", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r422", "r425", "r426", "r429", "r430", "r443", "r457", "r557" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Disposals", "terseLabel": "Disposal of plant or equipment" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Gross assets", "totalLabel": "Total property and equipment, gross", "verboseLabel": "Gross assets" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Gross [Abstract]", "terseLabel": "Property and equipment, gross:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r224", "r499", "r560", "r569" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r224", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r222" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Useful life of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r186", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables Policy [Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r336", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r336", "r491", "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction Expenses From Transactions With Related Party", "terseLabel": "Related party transaction, other" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party", "terseLabel": "Related party certain marketing cost" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r336", "r491", "r494", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r489", "r490", "r492", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments Of Debt And Capital Lease Obligations", "negatedLabel": "Principal repayments of finance lease obligations" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r391", "r533", "r600" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r20", "r105", "r594" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10030.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "periodEndLabel": "Restricted cash, end of period", "periodStartLabel": "Restricted cash, beginning of period", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r308", "r386", "r499", "r567", "r581", "r586" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r118", "r119", "r120", "r123", "r130", "r133", "r205", "r383", "r384", "r385", "r410", "r411", "r441", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r171", "r176", "r177", "r181", "r182", "r183", "r315", "r316", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r162", "r163", "r171", "r176", "r177", "r181", "r182", "r183", "r315", "r316", "r534" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10120.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Remaining performance obligation, estimated revenue expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r483", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r483", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "positiveLabel": "Issuance of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "positiveLabel": "Public offering price" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r155", "r183" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Total Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Compensation and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]", "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities from Federal and State income Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r124", "r125", "r126", "r129", "r130", "r132", "r133", "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule Of Error Corrections And Prior Period Adjustments [Text Block]", "terseLabel": "Schedule of Revision to Prior Period Financial Statements" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule Of Product Information [Table]", "terseLabel": "Schedule Of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Schedule Of Product Information Table [Text Block]", "terseLabel": "Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Stock units Award Transactions" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r360", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Options transactions" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Assumptions Used to Estimate Fair Value of Each Option for Employees on Date of Grant" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r54", "r109", "r146", "r147", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r293", "r298", "r301", "r302", "r303", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r27", "r28", "r29", "r281", "r282", "r283", "r301", "r302", "r303", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule Of Stock By Class [Text Block]", "terseLabel": "Summary of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1", "terseLabel": "Requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted average grant date fair value per share", "periodStartLabel": "Beginning balance, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Released, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Assumed volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Assumed volatility,maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Assumed volatility,minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Assumed risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Assumed risk-free interest rate,maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Assumed risk-free interest rate,minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Common stock initially reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Options remain available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Options exercisable, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r362", "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise, Ending balance", "periodStartLabel": "Weighted average exercise, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Options vested and expected to vest, Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r352", "r358" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r354", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Issuance price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Contractual term of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r374", "r387" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected option term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Options exercisable, Aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Options exercisable, Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Options vested and expected to vest, Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Options granted, exercise price expressed as a percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares Issued", "verboseLabel": "Shares, issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Issuance price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r228", "r229", "r421", "r589" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters Of Credit [Member]", "terseLabel": "Standby Letter of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State and local jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r28", "r29", "r109", "r112", "r135", "r136", "r137", "r139", "r141", "r146", "r147", "r148", "r204", "r231", "r235", "r236", "r237", "r240", "r241", "r284", "r285", "r289", "r293", "r300", "r457", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r57", "r78", "r79", "r80", "r118", "r119", "r120", "r123", "r130", "r133", "r145", "r205", "r300", "r308", "r383", "r384", "r385", "r410", "r411", "r441", "r459", "r460", "r461", "r462", "r463", "r464", "r577", "r578", "r579", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r118", "r119", "r120", "r145", "r534" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r56", "r261", "r300", "r301", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Issuance of common stock through conversion, Shares", "verboseLabel": "Issuance of common stock through conversion, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common and preferred stock, net of issuance costs, Shares", "verboseLabel": "Preferred stock, shares issued during period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures", "terseLabel": "Restricted stock unit release, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r300", "r308", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r57", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Issuance of common stock through conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock, net of issuance costs", "verboseLabel": "Issuance of preferred stock, total offering amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r34", "r35", "r112", "r187", "r204", "r457", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r285", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r308", "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Conversion ratio of reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Description of reverse stock split of common stock" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r231", "r235", "r236", "r237", "r240", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodStartLabel": "Convertible preferred stock, Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodStartLabel": "Convertible preferred stock, Balance, Shares" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvements" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r269", "r298", "r437", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r609", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).", "label": "U S Government Agencies Shortterm Debt Securities [Member]", "terseLabel": "U.S. Government Debt Securities" } } }, "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r149", "r150", "r152", "r153", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r481", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10040.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants And Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants And Rights Outstanding Measurement Input", "terseLabel": "Warrant liability, fair value measurement inputs" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Warrants expiration period", "verboseLabel": "Expected term (years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r436": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/subtopic&trid=2229187" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r496": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r601": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r602": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r603": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r605": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r606": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r607": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r608": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r609": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r612": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r613": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r614": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r616": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r617": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 78 0001564590-22-009635-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-009635-xbrl.zip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

    ,(>.J$+M%L M9S(A8;(]$U$X &=?@(]181=E7,)5XN_$$/Z QYD6EY\]D;N/5W? Q,+8J=5W[;C2\%.:@QH(\A M& ;H*^@H;_U(]&?/S+3(E.VZG.@$$X8UD637Y 3K1Y]QI1\]L*0TP&K/]P>G MGSZ]O+Q4/:Y7GYSGJ@QRE%RF_L$%G_CL!X=O-0?4SI,H)*4F4 ($X M$A+=S8J'RA)/(2]1B44%/R0+@ 4MLPN/ U$F5=R452/!#M,B.0IO >G%5PO_ M!&1!EH.ALU2&F _^J*Q=_@1V&'=%A[; 3GR&Y^"YN.Z/L!T;K/ 9=_OW7.^! M)-D_;GS>C;[0KKC%;!B7=@\K/_YS!VV]H!_]T($'^T+"=4#1_N!N]--E ,8A M+)'\(A+&TB+4;#R8492$/0'F^@Y*7TS,! 0TX7>1I.EQ]]G4.9WP"TB*)B,3 M_/$C/%ACTJ-&P_1^( OA ,1:FD K7) =, 1RV\7> 37\*W M)S88X.6/HG#!=P-80;2G;:Q1,&3>:50S\6):A':X! @EV"Y<9=3TJ&(<8?2 M(($5!2&$.Q[2M$BTZ4 Q-,HQQ=Y_:"RZ_S!QVO/M2,BI %*,N[5]W;FR+:&WOU\\8:1?MWV\(-Q91S@)I--N9_ 1U-]GZ MQGU*XX,L"0D" E07KH8TD%_X;N@RR&] :(Q^%7C1-S*=7?[0$L([_!$,%#1; MI(R)%?Y(^6ZL_Q,:/](I-_'% [!GT/;:C;-=MP M9.&8YWC]F*1-!L;P>T!1=>!V< M77*B+-F<\5F&0F!5L2;ST70&WG!7PZA@W_P/'#SP;-!0 M$P-"9P+G"&,.115841::?*_A4V"8X("9&&@1XX1'"" :22D36SGHEVK29/VBQ<,QD.HQP<_?;8 M_96>@%R] 7SYC.5!\$!I/U#\^O[JRR=XPM=TG"+Y@C!B(P#6/H;01E:^ %VL(Z)DF6XK*@@ G7P3_ $-][J(J$<"0C$3F,-K" M,G@&]FV?^YK-N>&-\!?R+JQ[#RP_1-W I#@J4)L8"*@I&(O">Z ED/>IS,M M#XH($U[K#1Q?LDVV^Y1:\+.K^VB9Y?'TP$I2#85%S6C&>U[(]=ECH]7NR_>0 MPR);=(A2SS MX%#@ *#>%\,"!9# M!FDQ,RH*#\<]6V-AQ[M=BG[1\Q]=!\,9;SVZJMWCN40F8CAT14+-F6(/<="$ MA'Z(^1'.H-B#93DO\BP*"M@$"7JD^3N]3ACI=,T^5GR+?*\><)*8/I4#TH0P M_/W(APX:(K H3X)\J?ML[J.DD9)6T$D$($/R""L-%L4"V0[N'!8%8D#3YI9P M/D'J8O%YHI =0U+P 66P-"]><8,F5DJ)LYR($6#1995B*H;<"D%V&5]_T4PQ4W M<0[1@YJWZ>BLK+",GM3Q9>2LA?$?Q[5-E@QIRYB X!QAM(F@K5]QNA7Z7CXR M<'E2.Z*(^A.6AFC,+,\)U5OJ)"P1:Q!GF0" L&?- $M,F9$^U+L%F!VX"-#G8[*1P@B/+L\7 K9N2 J20V;&L 'FE[$6-Q%%NP M80*&&SP!2B8(^/F\TUB>C^3$+B<<6TD5(^#^[VAVREP?\#E)?I.*>X6:9+U5 F6R8&UMK!D\!J)G&R:X& M0#K93?J/M*?:I]TFL>_*/"WE?6I-"X00",0!AB/@-W=0C05JAI\J16N&?[VK M7=AZ->N-X<7BBNCQ&<^(7X(!R@"=#&D\$SF8J'04GC4HJ^3&:_/)Y3PZ7?#6 M8J3JK[C[A#Z+09>*;<(KT.8QM1Z%^R]"Q"G2G=W+V[5.\#@R]OB'R00A=4!N MO7#@T?D*!TFQ%=JN"V> 6\)B^UH[-UTOH3+Q[FFS2TU.HJ$>3D_&(N25T6.J MVFW@>@$33\^Z8C; (:=](M%\6-HJ3C0&Z)"OZ DKSV7PF3U;HM!?0X'AF MY NZ45'D99A!M<3:A_/)#'S $B$T;.'IQ:,%NPEH-/06B:;LCO"+RRL&^H2F M18?3^-&]N(WL];3?390>VH4'2V1XX:X:=:X3L?;(MP?[ ;C-$9:>=",B"^4, M3,@7L/I*Y7!E"2NSCZ8JS!J3+QRTL4W)A[.NSPN/&$EN^_G1R4%Q0PTNH@ A MR4=W]IN))]R%3VBE[[Y(WAVY6^@]B*0!?!SM.\GAAC&\!*M(*7*[" Z3CWPA M)'D]M%S#)"CM/$6^R0^)JDDFQ$E-;^RRQ+O+C\AL(;(4H'9);+!17$9Y&RE, MCL OT@=)Z)'FFQ>[Y,**K72&VXD5H%,%A:0K#2?/=_0?FD?FD]QJQ-B(8\M? MG#&RI08>V5]T,5EAX9BK6A.1*R+U(;G2UY=KHW#OG85*D]DJ-TR4E2FZ^5$1 M[(3 LX/^(Y@3J PLFF$*72XLR["V^"'Q\<&I:">9/N4^9 !129E M6C ,&-6X&/JN1AO=\?82C /#G525XZ&$<%+/<.)')"FP*X*UJ<> #2"?(J8B MH^1@'N@!F5&);3-R:^(PMT.)QQ0UOKH/3S_6N-W#BPV-,W2@#2Y[^R MPZ!\ M%#-/+E]T[C(^"8<=73TZ!,(%AB@QEDSA33LZ19D"[+1) %]Q<1-N#,K%C^J7 MX1I'%\=SRB[8MO;]=PQ)4YI@*(+PU9,VU*)5[X'(?&-'+16N#],*$QN(8K^$ M(O=A()](Z)F6@%TZFA]:> !;+_)^^:NH&--()S#7H-Q8*0910B"1<1H#X P, MH-)F)+7^ U\0B20W4,9CP#B%*/A+[FAB&S0D0U94%S<.)@6(P7F.P(2G"+4,&WG(=YSR]IJP+V!>+\!?/'F;7*'("O(GXCMGW%,+0TWO&Y%SK/,V)@0^B<;%J"GN^8COE?DQH^$Z:.5A5D S<@+Q 5CR1T>3*!A M?91/6.]OAPZA3/J.UC!C<_$QW$)'9'XP/T8[72AEV< TPEU8J3HD(1]_^KW_L'7^^2L8D M#;D?3OG1I@;&Z5RF,\2ZA>5I1U%.RP4'B!A:.<1 M0"O,B6B#_+M-'$L!KG!S-E9-L$JBXHA9^$A4"F"#N%K]0(-I6;A(41Y(DAL0 MG09EI@^X2X%G0Z3-#D KYZ-_3H-89[<$_(,C86"6$/5Y+Z_SRNU@E$!"Z0 M-K".Y.I'WK;8@VSJF'P[#*,H(55"]#2;9['3VY(L'5LO,/HX)\?TY%8O:JRH MBBJV9A!K06H'7_!-(D5M.GF0X";JJ"<\+2^VI_"]9/PX&G==2O2($^>Q^6#J M<.S8APGLN(VYD&C23HR&D7QWRLQ+*.Z4A9E*^Z&$?Y'G@VL[?YI/53L/7!0V MN*TNBZPD<^):AE,$O6K!*R(-&.:Y4+ F5. IPV\W-A"3I$X>,0BCMY."G%PS MCI4W^.H)ZY.E4D+S,&$C]2EO.PP9,]K3'8IR2*\GOOQ7\ZJ90J2,0:.))W(* MA)B7OEDSGQ87RSY_:RF5$6FLQXW?DZL )/ MNI(?(WF**BBT2,"?=:1J"6-2))^ /@,?OX4% _J[)@J)?B#;(T>\=]^^NT]& MR"Q62W2PF*ERK(,?E22V8AU(K7=YW[/,;R8CP77XC,CF/G# M@N]V^BCXX:]QJ;\RPU7[4J,5;[?OUO0E;[<4.,^[GOQ_2JE-*BFQ6 MH3F$(@V3@B)O3.HJF6$&NEIFRGK,#]S8^Q8V=7A70KTD0C64=Q99&'$.GT,. M1:PF'%L7'V2Q&^9716$#JO2AK6D]WMD2@8RL6%&Z492 .7NDB2Z7.7*TF<6$GYK(/11;[LR.GT-9<%0<2)V5@0)4 9Q\]@=> M?:KNIA/SXF>*[8U$;S<#9D7!70/_>9+97\& 2L=(OT3)QWY\<1_\#"N1)BJC M ,,*J91/+O?!EI"O#4,*<'$F'ZYI,;)4:FS%.:0%1&G%1V M8GQCRY:*Y(ET2=3M8A5$.K@7@%87TQB)V)")C\XI_)),**63$J+ P*XFSCU( M-,@+=^&X7.'0R4YD=5.Z:Z38QR99*@<-2S9=$\8[FJTK3,DX8Y-VJF^C).!+ M"E\!?#U,77;1C!->&OPA+1@T'B,$YE0ZL MT4M$D\;CA2V*ARG$+>QE'*YX*(_B&@GC]O+BNE6K'=3C]%/\)K(5Q1'BG-HN MR(1G^0R*-ODFR#:TL:,IA4^YO6M>M:/'H"@/ PYH-0/0HV,]HE"8K P8MV_A MHLK;L96[^THBND(A$0JZ*[<,1@3AH"P7L+5\>)G$[4X:E)R4GI.'VFA?8M6[MM=\SP.*MD\ M<)U'BP'=X.:[9F?2 \+;K^&:%VQ&0&Y^7='"% /"0Y4/M'#8]283,H^8G MX49&*O(>"FQ:[ 0D: R&*4J+P\AI8K'I-N $4?Z,+GR8#C6.0B3L->:,8YRA M46O4I'O/J5<(%NG%O35&?5<19T?T5X0I13_@ )$2N_,ZIDNJRZ'=AB;8"Q;. MIQ[)U'F&(I92'GT=LM.HRTPH"'1[@/\].?J)0&"C M1VX_<3<6+\@3J#\0W ++(2^_B*=(S,E=@S1JXCH5F+Z.LNO1%28'7AM"=!&B M>V&^X83:#B?:PQ,+BRI6W(>#1=4B7HW:@7(Q,6(,K"*"#>$HY3M@@+MR)Y;: M*OL MW[$:D[NR(@KO)5VX9- :T91R#W>CE!RP!Y[!RL==XDLZQKGER #]&<#$[8?% MU9'=UHKBZZ"?67>D((Z^25[3C7E5^_ 6*X$]U<9M!&D*ZM&>-MX=MMC ,#H0 M;- +:[>I%57BPK?>0D;;#5A!0MN%N?O1#L.5W$IIROWVY/2;5U'15!BH-K Z M341JHPV'6QEBAJ?NB;I&]Q%.3JLI:P$O)*,Q3A8#=,YX[I4]OLRD9 18:/X4NV\$R,>7RI, M%(']*$HOC5>IL>"2AE .T0BQ8X&%X$R1\SS\-H8L!5NHYU+*G02[BW$+$4+?90*O&@"\X2A43 D[2LL-X1N")D18/K MN#/STN,4_&()QU3XI&&[FTT)+!< M;O8? _#5:*=2)-!2=Q\;X/+H!LA-]=HN@4)L>HGSZ*,'--,=+5LRW<,!U_4: MG'8#M[Y_C8-''<<*9%7%Y64KMO_EI1%,L'<>NIL#& A)9<%WV1(X3O>089CX M0&,$,#.<01@OB 9RFA0!?3\:CQK>? M.4)2E*MB\"8B9@BSY"Q)=XEQ:/\* +5'NY+SHG$\@N%@1RN$[PV\E 03U3$9 MZW3MT*-IF%YB XQ9V496S(DDZ1U/&FI)/)7)IK@1RT8G5+^:Z#5J^]7:^+:\ M9+/LG7@,>TP('=$^_TGM)V$5AO;?6% 7$"R+L%5?W9,@Q8@<[,Y9&7IFH@E MG53Z'E:]/PY%WFZXB$E;$HU94^S?12/"/46,X9#Q6:_"Z#\@? (O22U)7[DCZWNPZ(P@\D]$'%@472 M.#BM4[:?^%0]J!Q4:Z?UCR.9-7X6+:.0RP#3L&1^ K."6$_>WOX>!RA2], Q M51*CV:OL)Z@3[J!&DXW\5E(9]>-J2$L8U,>)M0<%FZ"A]3WPBT# M(8-M#*)CD6A(&9]:'QHDW'8="C%B9.\)_*4G*5L%R^V"#15I:H+? M$--RR1;W':P&Q>!A T;%W8IH$HD18,JB2X3!G$%%;$:%B3_)[9*_P &'D6%^ MPUI3%2:ZR*D,BLA+))^ C'C)4+%''EG[-'S,LWNR*99+>1V46!!V>UI79H&0 M<>&7S>99_*JGP,1=))LZ PM?6O)7-[#H!$:0R(/[%HTN9!M$2.3I]6ZCB2* MZ+5JR/0^_"FVX&_#K;Q?DH30;L)MS>0#$]>(UZ5<13T "($Y/2N=G$0O:#DI JP(3-8G+LDLZ7EUU3I*/ITTR:[C+IBS6$HU456 M'W_5K4""R?6Q^6G/' C17*Z\FP-5WK>Y1&0*R MH3CFT8O-CK6JY'IY,[PD+ M@I!+"DS1LIN4O0-V%684[$8]&%J.!8Z3R43XZ<;VL9AEEVIF<*)<9O[+ MAOR)0 FI,"?*"S?2(9^<+Z/V=G%FX;RB/T*[TX]BFW&+/I9T!:+ _(04B,.1 M CR951=7;"23CA(I0MZ$$H8PT.YSUJ<2_I2?>U33/&:1ER[#%J3YHQYMX:Y M^I'"^\&P9:*[&[V :H.$UX!'Y4Q_C"Q)$8'G/\(JNB@*&0)\-ZHWDY,)NY)1 M)0[PQVO]L,7?D-WO^4ZX+30GYT>NHZ9&Q7X.]7[Q=U]:*)/KO."0^M& MEN8SLJW@N[@4".P2UTNEM"7<8K&Q%_FF*?8%1_D''XZ0)E%M-F!#QTTGL84] MSYG>H\]>0!W8T.R-HYCAR2MALH3'HP9\Y%=3W ;;_C;V$4I[A[!NMM_#6'AX M0(]-99;@_%$BE+05GTP1$V7B3(ATL#D62@BS9ZSHHY'B+O$C!N!+5F8D55+< M#)*2.XBC0F)3 9^<_21J^7$5IK@Y^0M+V=^BW&B/@B+)PWE=IRN\9*1YF!7[ M'WD00#+4D5WG5+)%2?*@B!')ZJDTFX7"E8)6X,?YPU0L'L\JP=ZI_VQ4#Q*5 M5DFOVN/R=!1Z.I@FEO%"M3CBR710B9 :U/,*(SH6*OQV@.[0VVQXKT)XF;TNWR.33)1.X$G5Z89X6D0?/.DKVP9Q6?.YI'\"I MQ/@1ESMZ'BCH/H8*Z!MY%5991@N144I\D5G2-Q)T;TS9G2"FSMBA2$;NTH\[ MJ.Y'SYLXNRH6D Y'8V49&Q0A(W@\39WTN!S<1?;ZW)>=^6'1#!B/WW0N;/MK!P=/^L)Z^14H'$024A#TK9EWJT2T-43C&2P9_>VTHU M9R?RQQW:0Z# CP,L%2'MA2Z3L+D\4(9,%#^*S+N, MV2A>! 2I(-(*D\7&!Y0)B.A8&Q&D?QSEU'KC)^KMT#,M T0(#>L(-^>P5-*@ M=#9AM:?N.JP>1OP=;8> #*3@IV-@(BD'(%7(/.;A/+*F$5%PXO#3;VY4&S]E MC:A>W7MS1%$;X7A$9>,!Q'\?#UX+Q4HDH.*V-H3PL&HW#G&F-NDG=UD>XZ6$ MK@F[6HBF&,+]Q,X*8D=AM-XH/ALA5(:@<:C$1 #>BR.A6EB,'(\6M6&B/;3L MP1)S5-AI PLM %(@:?&8-IDU(=@OR@NVS!^<3G7#6XS$D2)B_)E:-53ZLI.= M[*Q!7SGVDR,KICFE%M()UH].V"R0X"L\QMGI;+HS4)J>,TKLT9;T8IN0\A:Q MQP]YI&0_XM%;;D"N^B ;$OD=.U./1XZ/T MP.T2BS,C;(:/!,57X>Z+$YY/1E5EJ3KPJ'D/[;"G!RR!$^V?),B#N#-,@^K2 MS2YF%V.=2"_L_!][NXE*.W&(A>/\0#L#O9Y_UJI'D;Q!5\@EV P2#6(3JQ^& M#$Q;;NK) T6&29*$%Z$>ZX/@-2MA0P80ED]^KVRR2G@+R-0CQ8\22_!+*F@X M"6^*&O#,-\((C7/= M%A?_S7>;0WN*\U'=M.=ZQR73_H7K]]/7 ]7,]G^RA^5[A=%=)X]G98618X)S-]0+19&JN6Z*#*.8D6*)U MU0*(F7#"13+76917>#Z>">E0/I*XE0YFDC6.%)'-:&,5,;7)10@6@Z#87DU8 M1F%N2Z(CF#0@*#S?@W6RQHS_@QH%[^(2',Q:1K43%;!+JSSJ1=851<*NC"-U M,7$$Z<+#YIUHE62-(V(^3AW11X#;Z'9;-Y1;X779T5!6M!_4+(G-IM%M06!:7 M.IE+ H^L(6D28FYJ(D""62;TUD!$<,3YKKA26%]5Z3DO@"H\\C>9!Q2^Q(NB M89'7(G,ZPI8$1"/T9N,F9 1L&=04G>^' Y%T3U3*&C"U?HR*.4)HBVT$D7#NX:;T@PJ2:J*0U]I2HD0%8_UAD%B7GD&\H9X/% YBDELBP)*+( M('+8LX?HABOIO;!'&:I(G"J9WNX1>T6)8Z&B FNY73$%V1FN9[+,61YS!?AR MQ4EBZ:8%T;EZ"2HFOGRA%*J(!.A:4M=.:N?E@K=$[R1O"XS])S9^9&2QDW(. MU]H,9_-MC,<3PC8_)I3MF.')?1&W;N)14^1M+R]-86RJZYI.3GZ25281><8R]\.3RHG=8K[XCAD-X^P M58S',[L\R#!0:O]"& XC32VD[1O7AH;%'%&716;(PPJIG0^U%8HJ6R9635PG MJB:P2FNDOGDW/K]SM$(ERCK%DFS*87&#\'B:U%F.B?@>5>!7L+!6GF91H78' MF**?R*AYNU!6(*@KFBTF2A_Q!JS*AEDE'T@5+HD$+)%D%6: I%!)W>KQGHAT M]092M;$O,RKB^@#:QI,-/Z(PF2A_('LZ3 S"Z<4-FI/4$#.G]TXI$7B;&N R MN:)A,M4/P.13E4RQDL=._F.E,5@9LZO%E3&AX1_Z0V'WWZ@8)ND99)?NS##F M<5:S4^5>80$1E2:%&>7)#J 9VYR[HM=[6(*4F,-8*U/9D3W%8J/E456M0WM7 MB3'H5.\GVP*D[':JQ/!HNR2N 10Y'4(4>T//YWV)/;37XA:C?<=]- TR=ST1 MK)45(<+(2KBP1"$F_(A[VFJHB[Z=X6W>[&NP2WNB _%%0LQ]3'9X2Q1#A2[$ MY*[EW:C8-=)2HTUMS$DU>=4LO9.I:=Y(.5S9L86&^8S_^$3V1XI7_[Q3VZ%, M AG8B#X/1+L3^IP:WBD+?.>SN+M"4?R!QT_#/SYKLGLD#&^'7N;2?PV4V@"V MGW?$[**'/C+]QQ.Y@Q6IH\_I?Y_E "H6[_HT^?"+.YIOK7ITD/CR'BDDOA(# M.#RLGNS_]%E.,Z2IYUBFH8D+I2?)D+W$6-_3]U-^C$:;7BO\XFVS:F6M0&,4 M?/GD&YM9D'KUL+'H>BR+^AGVO2SY2+0J6J4%O-F%"+_Z%M-1KLU^]?AX^N+$ MM3'K892-+Y5T!Q33;'PE%-,49JE^)RMU"6VTBS+A9FR/T[$76S3U\##YX1;- M^8-L$+5%4^Y('^EC4@!_DF;]J'&//1PGB^+6^7GMO+4"42R-_OU%=>#*""_LD[+2_7V&Q^J(GC8\D*PS6!WE69;[H.^X<\=."C.];V:D M5?,%.\7K6\3K[UN%)<:NP,S$LIH5\'MNIGC'=>?)IAV(]QM9*_-WWV]DU?>J M1WF6 9UP0R9L_XKG08MV6X4[I_<*W4T M(^^*]C8LX8N;J^?/\E:29V/N3EFI/B)W\D%RA?/RX#PW&O;Z4U.YLIO<,L#J M8:RC.$M60%R(GK&8K98_HU/)H?)8^CFA^COTK<*YPGF!]*WR:#?LT4:=-V_9 ML"\S1/)EUS0G7EPRJ< M*\VJ?-@UI%>*8ZFO.3=$9.,$.J)#NXV;U>?/:E6"ISRN@J*Z@GK>B%YV'3M.]](YQ8VCZMY!GK%_ M??O[>SW@/>4!%T]J%G\)NEGYT.^H9XI/ MJWJOCCY0OG3Q)%?AW(N<4%V<7ID_JBNHEP?JN5'2AP>5XV4HZAP[T;G&?0L/ M',Z=::I$37G\@9Q0_9]'A[7WFJ&'*E2D&&9[=/,_3_:/2NU"YQKU+38P?69I M[;\#Z M5]W;^VD<7Z.S3:[]LM\ER=S8JY\WUGAJ'E)/JW_Q!LQ.V?GI==OY6M7PZ&N# M^4SS@CY,#\9F:.S1>>::[O3QK&E/\\7IV-J+Z??H W\U/1_0^G_8^]+NMI&K MS;^"X\09Z1R2$;58DCW).;+4[KCC;2QW][SS#22*)-H@P&"1FOGUT)0&%JEMW7VEIF1>*'B)#>C:BG44QC\G%GTU<9G,Z1#PVT=1D M<4XGB](\FJ5CR''Z4O61?LQ,A2[5/;(I:+___$/7L/?X,V\7BYSX-8.O+"S[ MQV[R*Q),ZU;YO<0,"^F/]I18DBEAQ-&#+XJBSHL:-UA$BA)/VT F\K(KB7T' MCB',ABE09]']X]'>HVAHLHS>'=+-NI^5;?'/EC?*]#H"5Q;/*O/4_N-9I QM M;T_9V8WZLSPL5'4]26O3Q;4<65" M5R'U]'9TSHC47\#6%7)H&4*'O:/#S8#09Y#$'P'F @'F:FUEYB_2J@BUF^9^I^3J1]LF?I=,_5WOQ"CCJO&>J:(B0_B09JE]9Q^CNLHCG(SIH]?&=+: MJR:KHY2>+)ML_B6,_> S&+O][I:OWU<,W_+U/R=?/]SR]3OFZ^]NP==G!>?1 M?W>^;K^[Y>OW%<.W?/W/R=>/MGS]COEZ4/RTQ-]G18EOPD,3#^L&'AGEM)6R M_!)AZ+(TPSJ;1RE"L>DH182Z^A*>?W3T&4R_:H:3+<._KZB_9?A_3H;_9,OP M[YCAOTC'Q.-)19\1IR>&74%Q+XO?B(<3X_XY3_&?RSJN.:J:3@=-6=%O9F4Z M-!UB^T4S1I81Z?;\JV@25P2>.IJ;.AH8D\.[4]1IC&4X(VD:_U:4"PO/XGE1 M5KWH'2V!3"22,*A[X/PD")]WK\ZB\R(QT36M/FL&65I-Z&V211=F:#ALL'_8 MB?;W^J>WD18+]];=DXKD1_^DU6]G8<1EC4UB;^>O+Z-7\0#W4Y3SZ(4QT>60 M=M=DDE^UO[>_%\5Y0I(Q'Z7EE/:MO^Y+.M=KDZ2'!^QR5\[@'71U/P+DE==>H,@7?.W/_SP_L,N MWD MG3U99@2WR/[[#+ZWAMW>+B7L;4-H;8:3G AV/(]F65SC':8=UK6*&JH3(4-= M1&[)B#2,*2$9O9,.B=IDW.9MD@9_-:R:86G"0$("8$J1DX[&28/Y'-\I1B-" M)MHV >DJKF"WCTU>3.E;0!R0)3TUS-*W$6QNWHO.&U(""6]6[AA^ M@$%<"?U6S0"L!E^[2BOHE)*/.&56A#Q%4KB:+"ZCX23.Q\8KFL2DZX912@_QKY-T1.9AFB>7__-IF1GXOE7S$7\EB/,RGM>6;$Z;J#TL0?N_&( MCO,TSJ[C>?4H^OOG4?>=T?*GZ6]@:*/K#:#%QX&F5RD,C!8Q=J+"4DJ'\7Q: M$+((YM=$4SDW5@9N02H3(A'Z#5NZTLSW<>;\JQF)*D)*$,_MSWFK_.'-9N27#4$B);EI%+1-=2N&# ;3 MXK2!;?TL"!GKBGI&+S'>;$UVF5:9HWQ*M[T5F6\3UY MSD;:UK3JT#O#K&'1VGN6R^ M("!\3&M1@E8=N0..2*S2(VS$9K8(20BE#D.%$;0%&N6N,Z('PI*__>5DOW_\ MK(HFX+6LA/H5QTV: (][#P(?911WZB=PX]]6:K,(O+W6(%*0:!I83;?0PACA M''3C&5G?6JIL_)D9D[Q@!";CG44(L2C2U*%*S+2K5/"5E(: 3H'GI-6@U@*')1!4*=TT M:3"X"%6,[#WP-BJH1%5#QV(:*5/6+ "T.!HTQ!:6KL^J"IZ1DVIBT;V*2)L@ MDF>60-^LZ,?<\X:;T=PB]4VZWYC1G+E&(\H=T7\]QS]4R;JE:CR) MH20RD/@:2"\MB:=DQ?62 4P0!H [2"7F1+5).IRP/@M)"P4O+<5PAN)."-:( M6 "32NBB]4:4V2F[KRQ;!":^?W,6CQ1 M-\]V=GP=EQB%I'N$&E+JQ6G, 38 M_JB#.B#>%&26_)5S M.!F$(XR+L#F M&1<&9@CEA&W"K!C0[V''$OH2!UAEDU?.*,<5M^QLXB9"1!4C+2E?*6$K4TU9 MD#RIUS%.2TL=+VR]%=P1UP&!MPO5T! J)U=T)++?A,#%=\FF'+8%;V)<6L8P MBH=(#0!'88?4<((]B6]I)'8S@-&++B%Q1V)9,X.3UTDL,T=C%T8!&F(WH;6( MJJ=?#1ON JV?-VD&CF7M*!1U5C$(F5X=JI.#9%[2#.4>9_QO8HZLW0$HH=DF M]_,YTD\8JQ'6ZLI%19C97=7SUI[BR@DB0J*VNW!H79AP:(EPD@LG-GI.>$GK MXS'6Q/%%JQ7)^I42N+]^R$=27Q@0M*62N!NV3'S0D'YG8>5#!* M9.&BF:#^Q\G5$%@5'9$HZ'I26%#HZ6<38IIL(I1&%$M8-&V:NH;ATN#N(!3@ MQ>%C,SZ'P((KJ )'3FD-ABP=,ATTK#^VEA>@9-Z?+!ZZU/FL"JB$9$)556C) MT!4$/ Z.YVI(B*/I@41.CO06)=_&/H?G8C$/2M=ZU!/;%8N;X[GU><0 XGM ML8$.5YIQH#/$BNIT(5-3@B(T;"$Z-N]H%%_1O0W8A-=]).K%KUPP8\&U/N)M MZN5\4/<]" VL;<1E!NB&6% 9 !1K%RX3%PAO=306]>'/#9J8"S&R6\-8C"U M6?$"*7;5C)A2T0@Z^2K]*D+7(VMHM^Z@Q;'L]H5M65\Y;Z&*X=]CQ7-,4KP6 M(S^/_OKD:(_,QRQCVX%^.R?!SM;IF)X;8Z?Z:L?[]4F7+HO?4VBK=*A#]_YR MJ:;WVKBUP>81/L/%>G.#M7HRT*;6"\E-#N)%]6FIR<%*F'QE+G@W.N0JDJ33 MOF:]"R'!3O2ZR"[^KT5C!745!C?"< M0*HSYP"TH%G$C>O\P/I$41?;)^*7F0_SY>LT9=Q&<_TL4K"7,&#G]J) MQ0Q8VAEP^RWI!QQF97CB-3 )<=+#_JM\HPT;IKYE()L8A;'TLAS'CODP/LS\ MZL6EBR<+XY!X,5V$ZN:W"1)WO*Y73P(QQ>E=E7B=&%3^DJ$U<:@-8 *-)@ + MW/ZFO$KU&JX+%1JK'F K-!I"DJ3,0A"ZPE=AFZO32NE;W2YAB*(0KZ^_:@;( M7/TVWG:N/D)7Q"I>-^1@'4G@A%UF[$18Q54GS T'QG(E<0$Q9="_!W/[;2^@ MOSQXKA<(^R\KP G=:V<)L;:4U5^(#]*4V3]0E)WH35&25(_S#I &7+.9T;), MW();JPD:K%SHN2N<6>X(,)JP E_,K'[AD,F2/)V:U^^YC_,[^M<4JU_G_$*< MYV3Z,;X[?%*L99C] ->:RQ0Q\.QHR-@KH'XC=WE3\'?Y#"+*"3RJ :[@% &E,7_A%@/ U$ ^/0PY M$S@=F1P;>!RF12Z66K)*^5Q2/%.!Z!2:!BF!10G_>!378@>)E]3#MV4M>295 M9*!UY;BJO8(2X69-ZW!3"/9<$^\BU=:PAN;,N8J=9J63'J5AC9YT!IO<:J-+ MSF\I]0O8BH1!A:Z)E;E3DD2! B(.6L'6:Q-H\.P5]'E+H'U8&?2-E1KZ/*"? M6Z7R6#%">EO6O2[*+ GME*8BZ(%WT27P!="9V5A:\^T\.N@<]D](?:K8.UV6 M!=NC] /R&%+BHHOV! [8 K]$ECT;OPW0<5H.:[/>>7KRV-T&(;CGO:M5[U5I M'MB57IF@G]9RUTA'B>O)=3QG*"Y)A# P]4KZ73EH(:*S1@UGD>3*&;%709V* MXYV$Q='IWF-13"MX**!_:V)-O*@SXTD^FX;Q5JC.&D3E##.^.D:_G^* J*.VU:]'6L=_"$&%=>3Z#&9JKJY&SY M-R5BT)5-WQBGH@PA%)3/USFOF!.0,*T$P>F]8B")$P]#H?!15[C-$HZ^EK$X M>J'R5F&J\(PMN9*3CMGH*@GR9'"4'ZL@?ML,IFG=4D98>J_2B^DBAQ\)S!*$ MNTK/(7+$404]O!.]>G7N3&;Y),=HP- E*0MD3ROQJ*A=CZD\K)0.NK7(#*/<@VK"F[@^D3G*-YQ)RHI[ 7;3/#49K.[]??F(C3/#WBYF:Q;\VU^.3I]%^WV(:@(' M&-9M?!B:WVM6O+;>[V'5*V>#[3BZ8Q^F\U^(AZ R5O?;;:4#(O(AV31B0PJW M1&Y%?H6(Y=@BO[YM"8V4!F1%)*P(.<0HMI:YEP2ZA1:/VUKJ^9>(XI.T-!K7"M;GK+;@NZQ($+B:D'YYL.04""&L[,+?[?($S3HU K? M2\(8)6E61]UC]EIKR@@=@+WWBG"+L?M6(HX-X:MNP*ER,0<* L??#4ES*VV7 MZA->CL!"$//@S?GY&V^0!912,C4W1 5(!>#'( 4-"<)*0[$%T MJA^0Y)2@BF!BLIE U&:^ML-DPX8$@ $';[O_4V0=6-\ELAC**R0JB5L"+BG> MY(_^JE8OUC*3" C[#@CQ2$MTL%B3QWDZ93GBCKU@N&H-A.D&AF4(@?;)IV1N M#@R??M1P<<=GP<#%;EM)8#%8:V)FABF'OIB;#!?A,)>]H?#,2@)!LO8T\MW/ MMO7*45 O6#0A46_GCT;S./ MWLZ(9 E>KSB5AR0J9"L1X;_?OJKXG_UGNZPOAA%'GZ(-ISJ'QE@'KKB>NK)W M0\S))H]B.61IQ!_]OA!)'.#:BC6U+&&Q&.$P3M[2F"3+5:6.X^WM_,/:?QX< MB^RGF=0B2%:'72KT$5D%:P0^"0EU@S)UGS7<'RR^.!%O)!H)SL1R _5,1*HD M+S]=*B&ZKX'5*9 M!EQUXI,Q.ZS4?2 D1DPD)].JHPG0Q-C4ZB--,XLE^U+?A%_>VA&5"P9+>J9F M47N9WHM^YCC"\H=BJW6RE!8S,YI-BKJHI/6P\P2J^%5G7LB3?;4!THQL@OBP M3 <^4WCQRXY2-4G +8%MH(Z,3LZ7I]&PQ)@IY*.J943_+F.DLQ1#XS"Q<&UX M(I>2^\]]-<:_4V[<,XV1!6LWJR#I:"Z>P)^X"!=85"8;=8-Z#C8[2E+%:]3X ME9QT6*%P1O)O^55_? OM+(V)K^9?/5_ISB(H/A1KZ8!]DRPIU?]+5H\X@AAD MS]/BY?^)=O 'S?BINERRB)*#6:/%#DIW6LBYZRLY+7._2F,FM+4(1D^6[+"2 M#RI%"ZE,9-3"X&*]@H MC&S:>#LSF+U;Q!Q(UK*[X2+;6LI060L8[F1H1Y# MG*L,CG92\CRH$ 1[+@CC&64T@LJ^_$X8K=$T395@EGG3X5R-"V-;4';7L:]* MY*M1274=$__B/=G"'=&!+9L9<;Z1K8(D(&I!M/@^X(%E.*\ZR8/14%K9J%#D M1,[*BQ$],=]:P8+6DQEV1@OM%9CK9+[$_F:U16Z4J%ZE6WPUF[MT^"M?L#K< 0G^96N;!3*$'DCEVP]!!92 3Z0]3*G/R7'V M]4MQJ >P,T,#'O;&;/F0-3RY**UA;;F0,F;G[6@KD=[4U/K0I>)F<7%J8H)[ M//2&U:[4*IHB!6,F_E4)%PQ"ZJ^0CK7N$\Y[Q-F FN]<^5*WH+JJ_&A*32F5 MW'%?K'S^ZN59%S)3FIKY)'T7^PED9B'ETYQ<*UD@]B0V[3N(Q-LC65>*6&IL M,H?N/G&O=9<\?LRG"1KP$AK-@:M( Q#?%7XC324J7,4U/U%Y,/*U?V$.MJ8V M$U7*%_!!"TMIV(%OPD7L&P!531[]_ N81('VFUH&JDF6#+->"QCF>\3K7@59,@2IL] M08FN;)/".7RP0OQ1C>1W_@(!;09?*=$EPM(?HXH'4W#Z8N7DGKSO%%,MC,>; MSEZ6K0F?:(FU@ >XLI[PC&WIS(D+TMJA,JV;9-GL+2DGI MJ[ULCJX5(V -SE3D6LM&G(6L&177P8-^[VXK7'-"U@2K]*FIK(O2NJDXG4&Y MFWH2K-]0LYR"5>T)N'.6I'Q7SO((HU*VB*;EW.1TIK@.%[0AJV"]L.08N@<[ M+M&\<: -UVRR81NX#[([S^FWS3S:S.X\UMYAE=,VJK;M*J3FTJ*8"')N#P&C MM+2\JLA7J;4N(=E^0=T@(9^"7$[2Q"=,$JB'$XTRN]P08>1?K;/./:CS?BV6 MU%O.(VARN"88>OUGT274SW/;(^L^.W9>!\5;7G'4I@IEV@ZXLD7!U*^\81B8;@B=;?%5#'>P*HO=/[ M[G1\O>IZ8,'$"&*DD8@<,@*7J#Y0&S=/R +VW"CE51]W$$QX\P4,!-9&4E2 M+0P/)QXC)X!,C)'+\4G4>3AE!Z,T\Z/G4FZV4V2-FB%H5\5M/G,?*RD:Q&JX MP)*G)\>(EDFZ/)SA:FIJ9!AIWFG=:' XVKE$F90T1][;[7@E$\H8O"RVUXQT M)D&*^%5ZA7PW39[2'&NTGX;)I':Z/6K0MIL=9%([1=PC\:EXS6RFVY=R:&\R MH:8W"0\ENXWZNX3S "UOBNNBI22@555ZBAW]J[C&I:.5S%#T0>4FDW _'K-HVL\D[$V4LU<5<"A^KQ@H^6 M(2B":3=P@Y8MB9FE@E1F&QT?]'Z;C1]%=5KCE(\0"<=_VDW5 M3PYGOS^;R'[Z3P[H!ZBQ&SJ]/( 4^I:EPZ\ZS_PSH/X"K/%YG"%N^+H3/6_^ MBQ9_9^>=Z+* &+SL_A:A%TSV5"L(?R'R#$IZSDB)A5H2_00'=71.*@@"]ER< MJJP;7(,[$LY)W9FRVGSNN]RGGR0O! N?V\R2M_E0LV;.FC$ZVY#L[:^H M-0A1SCLO[K>(/LL136#!ED#WZ!SO[6G%5LB1; &!EV16H/8N>U[6O1U)!6,G MDGB_7YI%!"U_NF^7MTNJL(IV A\P":E% 4B,$ZX86G2'?2'%3.6%,O%=X<"G MIYWCD^5/V.ZG,Y,;KHS5XDJ_JL\:I\5A-P&*_*US=P=?!E0X.^29YOW51.\,M*@(S!C*YW1JAM[?<'&%ATBGT M(+BP:O8_+6E#-ZJX%<>##7=]BGZE_YHRCWYHT/0)5(/LZ"S5]$HBR#B)V6%D M[]\E@[+#B;O6<7DACVB5\[D6#I*JW>\=W=#M()R:BTB ZZOG.&F%OOE K)[+[ M1&B@)$L+@-YEG%]F%*V&+O8";0/-]3/8T(5]T=!(0)K@V'+S 9%'Q4W 34:909R61.[ M%43TY<.!#5QYE>HC+C? 'JW! 0M*' ]7+E\)*A3C^OY3.C)U>>( M.Z<4=\RBDFXU]&9 M/= R0G!V;RW. #"\25P."@Y4^?J),[;[NV%* _3-+M>=%CY3?01ODJ\8@=/ MA+'BG?;JW-JYM3PM_IJ.-79-Y>+UD"(A0$!%.DV321J';[/%Z:+Q\BR.5J9O MFTU+,A4=@LB(&)$&7%]*0I ZQ;S'B4MDW60XE8SXI,Y\= XGSATKB##8B8,TQH1UPE1:KUVR-SJV9V#!S-%( MIAQQ]:$62SM",$J%9PQ28SHMT^!A!07[>]M^!-]N'YXNO*YZBQ%)WW.+"T@/ MZMBP'8KP5SIV_;'9J\TR1?..A(-UFUF;$X3&]@XJ-$MF /S*'ED@?=)SA]-( MT+?:?2 %"G76#XTK-Z18]&7K#@@F)?$BZZ@2^D7]&$ M!ZGC4CF#2NOHS;M?I U4P%8U92O:^^7WQR^]J]B#7YTLNNGJ#L$ZEW:35 M@EE]OIV#;G_OL2MC##KVJ$3Q1JXS2U"V8G)BZ5[.YN8J=;5.2Y+"?0X51>L\ ME.KJ??3/BBXILRE6_O.>6TSA[!R$DM0&/PD0W%H*UY %>TX6=^IB+Z[2-PPB MPY63Q3-KV2V>)[A"JQ;2=NIKC@:'WY&8T@K'68=]>_0>C/:@#](HSJJ@AY)E MBY4:J585DY)\9Q/C@G>>''5/#A\31OR0L7;+?NE>]/SU3]'._E[_>#U-JDQPQ:2Q]$^.(P=T.#V0P95>:3_.57!*.<534+,7_6H;/K2-J95^ M3-J,PQ2G4B^&3X\>"XF[S]+"2:KCV^*L,2US[)CNX_3Q?0^%_VHR;0[":<7Q MN#$NE2=LIO8F^B$?9]%/Z.<8<58;<:D=*?8Z.#E\>KS?/3[=E43]*I**ZKA> M=B2[/@(V-\$'SI]PJRS?@(C,OAKI!]Q^0!QR<4/H G^4:ZS'+,&NQAGS6,\V MD= 1=2@'H">,#'CB9A=1*/,Y.:.B'X5+\T@GR2TIRIEE"C[A5_TOKJ1'7%/P MSO&]F+S5I^>:1'6NQ4LJ8%8T-0CYE8,O6?F2%ZFCJ&1/J&G*VNZ3L+,&._1< MBQF6,T!>\:4MFTO:<=-WDR?F;Z4(6%V\OI"?+$XNPO9>VM5VJZ,\3O]JI3U< M$@_308?.C3HRU]90WM_;8V_Y)RHOR)H?89\EHK^ MH9RSU5"EQTST9#?J'QWN'.T^/7IRVCTZ/K"5LVWO8BMGW542"+0X@;355A7F MVL2>J U:=W@!\%*COJ76";8=8'Q5I(G$[^WAI3W+-.4Y3@I$!RWT[+4#5]V, MC59FEIUD):Y9]L%RXJG&(%VO%2&#Q.;^R3!(H*#-*T8FA@[HXM:EK7X+.DEM M<2>H0!)*71HE&4*>TU*0)FRQV]4ZAR!6YI2-!$-_3FC;,K,YDKJ7:BYS]=,($>$H$> M]PDVIZ=H>OO$:1GL*;=JQ@Y)A>%'9KI^AN!>[_@HFDYW Q;"/3V\:?J]X\?K:/%VJ2^'O:/#D!:/ M/IW\\@4Y-2M6U;G/FIK%[N5_/-I[Q+$?G3;M?I[A/O3GUEZ>\FAU>9M;%<2S MRCRU_W@62ZARZFU?-A[2_> M,UL"S06__ "(R*\T;6F_U]]__$Q/:F%(3#A-(GE0Y@_/H$/5LM<_DN^E/[K= MMN\&O_ATP,M-N/_:_-3.T M$W@P_O%H_]'WNR7[J^<>IDI)_4]2D@7:H\]C7_?EDFP(6]>G=TYL[HMY?R9F=K?54M>U)7I9#=< MT?F+%WLOSK\%X8CN?'?@_[8)8A]@1+Z3Z-T:\IBF29*9NX ]2YNO#OD_!NAO M;8FL$AMWA?IMF0$(?Q^!L3$W]+[)3+=H:KDIZR)90R=W=$O?20?>F#NY40W> M\JHMK]KRJBVOVI [^5K:[;^BHVC@"W?V?*=A\UW3D^W M?&?#*&#K(_V>RN:[LACH]"1DG+].*R2'OS;9UC5QUX2P=4U\UPOH'W^9*-CZ M'39"!=WRG2W?N9<7T-^RG0TC@*V[\RXU4)/9OH1IM?5'W#4M;/T1W_4"#K?N MB,TC@"W;V;*=A\UVN)I_RWDVBP:VCM#O&G67%GEO7,?YYYPZMW5'W#49;-T1 MW_4"]H^V[HB-(X MV]FRG0?.=GK'6[ZS612P=8/>J?[Y YJ+;ZOR[YP,MJZ( M[WH!1[W]K2-BXRA@RW>V?.=A\YU^[\F6[VP6!6P=H-]3 3W'( (,7'PE;='1 M&\HD6T?$75/!W2/^GXT3_76SP'^PQWSG3W4%IX=;=]#F\J$M]]]R_P=[!UON M?^=79&?1;':'Q9?,Y@B$\H=FSB'%?91;(FF\I MI/X_^>1'7F)@TI:/1OA(,M+G"I*0I>D3+C+*/ M9KY^1J99/P.V_:DVSM&';S=OYI:K/_KGE2FKIEHY7V=G>5H-3QAJCS3Z>[MM MU:Y,S\&@ZK0U:XT'4-E1;P]BP"I/)0UGF:X"(L8U#ADO\E2F9BV-'&WRW P) MPG$9S-WV(VL[43S&N+ND3*],;F>J\0C6VPP_E;%%_FOMZ\/0M-S%M'36Z)QG MF[N90S&F8&'JW_X1(T X )*AR5.7PMGN!WM18F9&1F86,OS)#0.L3(VI:+WH M15-B8%EGY?C1TERE='/A=%,WW+R*Z))*,^41H1@":.=6[3_&S"T>=Z7@T!ER ME0Q2 Z%B6*G, L1L\LS$/'L^*9I!C;&&=)1K'MI(=S_T:GDXD9-EKEQQSI!7A<.QBKR /2]WCX/'/-# MP?J]/9YG:C?3@)CCN,,:N7@408C,&# 4GUHK/V@-/> M_AI(\0F48V/6FPD'N0;S[,UT-HF)Y0 K)D3^J\A^B=#DTBRVMGEFR&'=F&2> MX0G&D9G?9W/F6H<7PO'6.M1/ZN MNWC;E-&[LDB:85U]E6GGZT'*.]2QUY]QO,\X#,:7?C#$$5Y;:N6Y"3M,QYA# MR+/T7IV!BOY.\H'^.^:Q\R?! *!H:(@B_8!GVB#3*;UI&BU=),T>6I MK3S=U&2S:GGL._]-QD*;1&<2+O(WR\)9>UD>[LM#(@-U6&4H[@6#R9L91@B+ MAB33CTD2$LNC@Z1CGE@*U:%NDA0:DT[O>C?9F[/RPL0U)IJ6*:S6@15 M8'S0 <1T.2 Q2 JI %N1PXW^C>GRKJ-9%M>X _K<<)++^?#1UG!?BQC8$JMP M M>DJ2FY"^JMW$V;8T[;A)FQB^&T=TVW-1HJ%Y[[14S]/3Q[N"R?A[:WC\:;][ M>O3XD]>U2Q(^)^3&P?5;4/)G[3I8.V/84HB#N0X.KW0#@8:^\^2T>]J_Q08B M,QJ9H>IZ=MIQW=+B93:\T\PLL%4I8\UDI4*-;6)8^)2.K6O@.,^N\6!S,.Y6&/VI\N"_PI.9$/R36"=TS1I;C+\"5U:1$S/BLS"Q$",9I:R]BTVI+"*XV12,$*.;N]=%F276&I6- M$5SB/"\:DD]8 8/8"8?)'&.[K\EJ%A879%HP'>[O[>_UHK>A,5AYXQ+'GII8 MAM,OG-+Q?D:V_&]_>=)_=K"W3ZP'B"I7/X+K%!Q1;$AO%!8#!HT7SLU,;6RU M"1T+*DU-DLMQ55ZB8X&$?:A%RR=3(%E,&DX(9QS7^ '4-N_F 4AWU#GOM,+ ME3\Z;]O=.NWIIE,#WOT^C%%^S;*R7O3.,K76LLX+L&3[DB9"BV<\D#M9R_;> MMC=NU[:PWQ4"5%QS?'7%&=KCLHE.+WGB]E['FJAT@DE1%V3YSB8M1X;08VF, M?84,5[!1;UOJ8'G&,NF=4O8ENI6SIJD'1-74@>-W/ TIA=H M]\N^E!SJ#LY,HHXXHQ'>#VU@<>8T]"[Z?M:P!@/+E!$TI_.I&9W*[.EI04*( MUE2]LA?]R(XK[$244)E1OJ/PVK6P\:Q/M%116]KP%SK-3#ZF#^(]D@W^H"%4 MHAW2!M1UQ9/*CR+FG14165J#?2?IB"0SX3XVC4^")HCX)H89G^"VWY2Y*K(K M &HDRL;"YT@P""(3/;&K5(0';W"!M.32,-\\GS,.B((S2M5A-E(T\=]FKC4L M)G2O^#.Q"G>#+5I80%;+PY7BJV#&NB5#UMKA=: CG)["$\0Z?/2#S(CAD_*_^V^=V0M@(WH_6>8"/+WD=B\4D_:V M *B25$-(,\M1E[1 P)R10_PY:AI!/L M5AKF2F0=$+Q)VTP06U".OK049L+O M/"^+9A)'AK LZW6BRW^_?-.)?B(# 2YDDDK]3G2TT]]]VC_H]D]V56;RLI6 MG !ZT'_B(!P(EZJIR(1C^<*.? L0?J?-B9UE,6[21&VZ$;O?Z&0+MN6.8ZER MUX()!+.)5=RMXUIM44(JLRL?)#./%!)0WIIY]]CH(M\?$3+!>\ZZNM71)6!U M8]CJGNBL8!Y)DL* %>;1LM_8' V.F\B3.&-)]/&,B8LH MGG$$,&BASW[OV'LUW%Z]9UCWF%9N45JBWWM"JL0G3HY]PR4M[ZT.[SA0!'SN M%E1(YSK=>VQ5]!5<.H:"?QPH'?V3SC&)/D>T2YX9V; ^N@B \-&4NU"1' -JTZ(U]&6Z7C#*(=9@\ M$5QD0_G\_$WT8VM'M)F :>^+2N"H.@:!2AA-")$ *S&4M*Y).YBPHD1F3S%3 MM9B]6M7$QHMR!'8;$KS#,B4)25S5!BEO1UF]^\TB+\2%PW8174>^8 9#2"[8 M>V1RQ/3OB<628J9^QY5>O1UZ)(\^YJ!]N@I,L%[R[;>\WX_^";>S>MMW23>- MTXS==HS',#9Y/&+ _KRG($L1J"?3[S=Q#/%]Q\S&>8DT9\(9HEWNEB2<$A'2Q/XC*)WM-*JWA 3[Z8BMURE28-DR@1;S$49P8S MP9MT@7@\YA7)(D$ 5.*;@$137J5DND,HMGUZ>MJ$=T#::T86?FT4K[S'C'5B MN/?H8*?'C]5GF^9UG(KO5552.A"97/Q/> K8." ;=/_9Z2DQ=M&,--XZB!F5--"0J(WG MK4<;<>A%#RUW'NEXY8_<>CO4><=H"$.,(&][.F MT/'/K*8#6N&SCV>5>6K_\2S21+N]/%W M!_3CWOX#KHC[#,(@^5]M+F6+*E#*8,VDNTD^]N*FWL]_8>\#5M M*&T<'6[U*1#'.Y\DM((^OK#]TOD//VR5X,^_M#,8JIQ6'/U"@$[T5KZ,S?1&_=&,!O(K)_([5U M8V#>7]O>]N[P?)4.&C@N2ZR[PD]Y?R_A#W88^U8:SK=22S<&[O\3%]'_TZ2. M*%!XD(D7#Q'!0V&51#'@C%\;+HVK*I:L[C7EEWK#GPI7G?$Z%V4SCB[,5?1! M,L95%^XATOR$4^+[ASM/=I\>'!UU#YX<]#:X1=0#5Y+/;;S/J\C==S8M<./, MS*VR_& #[S^Q_!5UYZU#^>KKRA22OO=;LJ'7C M3;?^Y0W4(K;^Y:U_^7X!?A.1_:&KS$_VUW61W_J7-P/QM_[E;P;W%Z8LTRIZ M957F-X%*'';N0-YWEY[\N)C-+^GRB][F65F,TDR*EF=E.D4YRQ]1HU]RTY>5 M6O2I=&#I'YSN'$&/WC_N]OL'AUN7\]VKT3_77)BP<8;P5F7>>IDW367>>ID? M$+(_=)7Y\(A%\1<[0[:NYH>,_7\ZI5GUG#_H5)8VQ-SES7;ZL(6YJ!^5CHJ] M3RK+T4]GK\^O3J9F91BVUC5*]'LHTY7-)FZK;/9-8Q_;ZK0SWRBG;Y/X&8^ M/#[I'IY\C5R-K9-Y,[3GK;/Y 7D@MMKSUMG\IT'VAZX]]X\.MCG-=WX+&SI< M^,&KSYF31+?NDF<@2:$GI.0]%^Y_M] M.W7WPHUIB]X%$S[>ZZB1YS+0YWE3$I!63<-<4*/1?SI0G_?[T:69B0I]1!KT MUN]\9YISO_L_)BZ%GE_(U(Z?9YOE$-KJS%N/\Z;IS%N/\P-"]H>N,Q\?'&X< MGF]5YJW'^4X\SB^GLUAR*ESS\QF:9Z0R<3)>:F+=\C5[SW*3F2XWQS<5?6[% M9#<,2;(MO;D'MIUI$CJW>>2*C#V,,@*JB7Z^]'->>([,IY,\!+4N@GF4;W,> M2?:3C*5M.4[ZW#^@$A^T-7 MOOM'QUN']9W?PM9AO=6^'Y[VO75Z;X;VO75]/R!OX%;[WKJ^_S3(_M"U[X/# M_LG&(?I6^][ZOK\+W'4*^/,5V=:+V=4WC]9MS?)=W\+CZ0UZ]*V[>Z";=+6J MNUN4*;A7?;M77X3.OFS8.2/[2'P2.+G6>[> MU-.Q\,#5-/=3JC6/_^G*":9VLNN(GY^5Q,0Y3#9_"0T; M#[K]DVTXY>Z&_R03P\SK'<_9_N0 H&TP9=,TW&TP91M,N5^ WT1D?^CFW)N_ MGVT=25QFO\1" M^ 52P[3[Z*EKP->WRAEEQ5 MQ3"5EO>_IO4DNC17IC1:)+)9CLFMJKR-?&R:JKR-?#P@9'_HJG)_[V#C\'RK M*F\#']\%[C\1+"O2Q^5P(CKSX<[^ M-CW_+A.$AL5T:O)$N]K7D[B.+IO9K"CKZ.+UA^CG:IT6L74M;YH*L74M;UW+ M]POPFXCL#UU?WKJ6-^ 2MJ[E.TK+@/[!WI-MEM*])(V0"[D=D9KS^H=OO;_'F/N+-Y;6IB4]&EZ\M(WWMF)9# MDY&)ZX;8(7-*99SI;1P&/\\^%!=Q[7G.KW%&ANFT$[T^ZZ&A5FVF _IZO\_N MA&V<[:Z\!Q]^>/_AC^:@;0-K#RC6L'44; -K?QID?^B.@FU@;0,N81M8N]O MVGF392G]HQ-=]J+WO4[T4PP;O!,]IW__3UQTHO]'__C;7PY.GD72 Z 3O>I% M_^Y%.]!-=^\@(G?+A+;/LOL[MUST4)_?V=_M1/W]P[_]Y62_WW_6WS]=U-+I M_^)!9NB_27JUCIZ'F&51AFC4WY_=0."?4IGOB)$>J"TX*>T99_'8= >EB3]V MXQ$=\6F<75>6K_\2Q2Q6%O3\EX&W']+C;3,@G=_9[^96!@1S\,"RY2 MLP-@-BLNL[7GMH'?3;/GMH'?!X3L#]V>.^B?;AR>;^VY;>#WN\#]7T69#TPY M-F7T$]ERJ1F;++KH^6@%CZ%6!2A*22RHK58MS^7S-4:^_MZ/N#9QF:$D*1A2 M8B.ZMZXU"F=9+T_CZQ\=[ISN/NUWMS5&=Z5MY..[P/W7>#BID"3YJ^;V\/B]L&L:J\A_ M2,%]7J9U6DW"T$/05SC4>/NVM/[PZ?'I]@X/' MR_KEXF5\<8+7+;ZE6+!_T'^Q_QWS>#C0<+ J-:N-6(_^>=E,Z52TI2KZ:.:^ MN;5V4Y"LV&;@K:=*BHF(ECC]]>+UAUYT1K2EB8>M9X?T\0'Z.! AHW4V80=G M)L;Y/+HV@RJM32_P3:\ /H>(3F:K.&&+XE: ?AE//P/\GY,[1UNKH\LZ'7XD M8_2&7)SQO_K/=K4OGL'J0-(LI>_7!7:( MV9^,?-@#X2+](9ZQ1P!T\A\Z![KT57-Z>UK1.O]ITI)3NJL.[^!:]U=D?$3S M^S!KF'DFV%$Z:'A/++(K!PCZ5B]Z2Q]M0R1&HW?_5 @ B_W-*EBJ.:5P &G MG@+.=&[DF-,7A\64WJ;%SZ**R##C3_$&XY2(CCY@;RHW2!_GEI=$=73O="* M9*C*/S\DGPLW@KT!6C%'H!$!3W,Z<6)IOG4@_BM!H1D*S>/EIC($N(@>^XAW M9D;6E-:':,4)+I./!;@QW9#IDGA&%-PDFH=O9G&:T%40MA!$)NELQBN17M#C M('>3I_]IC$4_<"H]B\C#FK*=3D2BE=^)BG(RWE_$Y=EW-Q M ZV,%98X1\)1-/;%/O;6M:3M_.TO+R^Z_5-4J24&QB&)9M)S,/\&(O(C%!_( MN":KZ8!=DL!(K8N'7*Q&B\CM#4F57"O?[@E)_; ^^-.1\K^B(J7,Q$DF@^;C M\9BS^:ZX?=W4*75#+L'J@ 90DR@%-03- 9J46]0AS8B(B>E&5 ^F8OKG*"WI ML<5NYV*W^PI&;GB.14FHX(;1\]RUHT8GB X3B1IKN"B"O"HK2^I-QR%V;/?G M%)QE74@(BV ?A&298_T^-(N0#KMI H\J*.")M3 *VN#>"6!YL!6Z+-7F.T MT@A:_'71IO6JR)J@P87LE*[!NAP(RU71S4GW)YJD)4NV5\(O6$O#@I]?X"/1 M+P-5O&/Y1FL/P>G92K$"Y;S(2>\F];PE]^\U%?Q<6=7_$X H9H(Z<< !X008 M3HI"6+&4LHK\6<0J0)P[.S85":X4::MB,NQ4NXQ8;=2"#5<0?V4630L2+I4E M1(F*$5*3RI K$_9#ZT\@J4P"EC\@/NGOOUO-S! YO1'G6&*W[E);YL!+*/X@ MY%CLG+;)<>[!\6]:7B@X)[:99I[%>G.NI&>S>2^Z:"!;HC@8!;;NL&WX6NM+ MNV(V,\@T G+K.P%J"UR4A"VD0(US0L]E\< 'LZT,_F5RLN[\'*&D(_)#A8S\$2<19*PL<046E0^*7*C^,]$S;BOKX/K M@$P2,S-\E0&2M#F2+-R+SIPW(4$C ?YW"C5)]+.E$]#?BARR;.45 "+V@U#( M!J*,)BW*<$OE$6,,(%JK_Y68+GMVK%Z;@M$:\8010"]UQ1;Z5S(HY;_XY=)' M2./&- FA1"@W=-FH1XBG19/7CME96G?& #:3$R?)XG1:+5'3E^3YWVR!?D_J MZA]^9E+_[;G('9YJ1>3F3O8!CB"D"02V_HH-V1P]L&$[VC0(E2:=#IJRGO;?X#/42_L\2^9F2M8LL;!J3> MANV'];6V'AYG51$YAL\*,2O.B3'3*(6UF*C'R(4..A!3JA"+ LQ6Y/4$PXZ@ M =]" 5ZI^W94TQ4=(ZZ[$^[B;K)1-[ H6,BKU6%M.*OCXN]XU6.(E5A9&J/( MKQ>]1JB112FT&"M.QTVF[I%T.H-A N!!LPA#/PA8BIO,C_D-,;VC!A$O5I10 MD_*D&L8S=G29JR*[8H5^A6VX:>2=5ANVH4T#$&G>&[8C\4D2$X4K90 ?K-FX M'3IM&&98EJE*NW%L]?%[+(8ID9S2Y9+V3N2;%1-##?N*T;= M JI##GC"<(\!["*7G!'V7\:UM\K91Z&F.F%.RO$GTBO8:Z\*!RLC[,YB=_HH MXM5+Y"YPT0BB6$$B5+0#U(+7';^(DZ1KIY#B &BNM*O9)SX %:@RBZYS]<"S M$L'*$&_7%ZM@9?R1'6;#85-"RW'^?A>S8'?&# J:@OW.5TL4_ M+^(R<6DU+]\_=VDU\8QIB&"<9D7-B6%$,/M')Q%!;9SRGNQ'JX8.F6&-R*3M?LJ'YJ=S%*RZGJF6WGS\"$CJ4P\U'-E\"1ABU(/,$Y.0/?M\4% MJ^LYM_9"^D\=L9XK>,#Y-P$*L*?+;W YF/)>/:$\%93?QG5$U83U:,;P5@Z1 M]\K2V=U9Q.,&'L4ANU&3,?I:A(+"/_@-QV)FZN;GNFM6>6[M0+X75D/058M;5NEZ4?S@W\-LG8KIJ-+HW M@R;YT3O.1JN7O6?WBZ.[\ZB19*.1@[A*1 MP\-I8R+2K&4N&61* ]S %3GF,PTBL@1W^6*\"*'E#"U:5^PI;?-4,T)*'KM] M.1@>9UA$S6EF9?%L'GJ%E3UP/(K0'&9M;DQ2]6 C5F2&&D (QG>1<2@S [ MH^OYC$W2TMZ$DAGK&Z)EW/> QZ\V_@O!DHHC?F;IIPT2)U =.(0;(XW19:3, MG>?(YYTJ'AG)0T3K8%,C8=*VWF74T)S-AK]*^X='P*&\]@VN#<;1N?1!\.=B M*?E3V%_#>@\PUZ:>8@WZ-Z%P/5HCW+&CT4[3E% MJ%^VS@HM0RL5H8+M%8D"%-Z]ZCH>5*LN8FDPMG1OGC3 M'<=3I&+@O/2'8R0H9?@5>V10SGO-D;]?C=6L:Q9.NB9 /8EIMT/32$[&D-/3 MD4^J&W(VW98 .>U.TDT) N@T#OTW]/\^18#TZ-!W6CO!BPFAP@,\J0E M=5?R9/E713XNL$N'^MP3:%!H@$CN1^:'KSWL(H-!4"W<(=TW;"KAJJQI@*/Q M.LL >;N:Z%@4#(S!T[.LF$LDZQW]UDB21-]%*X-?'GC:1G?N,IXZU[(PW8K= M(.S9S$SLO(PI\K63QJ7M".!P&)"WA#/Y]/3G((?&WO*-O'/#M8Y7:$46CX$3 MN(IW%OY L[=LTKZ4+ A&CWLO(P9DA\#J7F:W;/-/66]WJJ;#1H3,?0";L":' M/8.]C=BGG#<3&O M$T4#B"WPVQ;Q,<=HL+QTYI8-QM"I/&=@BP*1<^0\T%D&4K$A5ENX'(S)*[=6 MBV%:K:WC)ZPR'H'BX-06+4=\'2 X/CJ..RN0%@#))_J[]7PK V-1W#J%Y>8+ M3.9V5.I?7\,OK785,F[<1H+.QISN269ZEDCP@\ XG&@.RY10@%T2(BT6F/N M-%2(+LV>A8*@C@%K;VF^'OW(H0&RJ3GOWV83"'@#U!+YN^9V&,Z9$+.@MY.F MRM]Q9V$JP/>HHOKBDK;/23C[);J(IS@U-!ONN'CF9B!8&RK:>=5,TYPN=/) ,SH!VN*, 9-25S2/5),)UY?FN# M?4S!"7>T!S=QV=[6O!\/]AB61WL=_"1^QO92QWN/U1H7MZ8HNJ2< MBH]24]9"!&S8M8XRZ[UJ0/Z%$M_DF>5F1#'QB4CAYQ] MB36^2@SCK_V]O<[>WIYZ.ECV#31Y/4L_8B7)EN8J$>?5]IR U0ROND!W&ILN MNT]8K0]U&-$\X_QW]MWKJ0!!=DW0N8DJ32X!=1C3*7UUR"O(IL=6>1 8,LJB MSG&N^X*9W)6G0F] 5A0?HWG1$.O37%4_-D<%,$2WM6!:/,6J-&3F!QZ92LM' M8^L)E=('CBR4*8>5R&BJ=7A/0KHF.Y\CDLV-R[,%O4L]Q!*9W?.$N:.OD#!W MK[22FUN]WLV>T%K:E;!= METV,^%MVFMS_GKQ1(WAMM_* *3P<>.U#)C&\7G MP;9<78&#@BO$1$L*&8J+>Z#NQH>X5@KPZC\-DM;$H)V+#L'5:=[P0-A+V49.-3L0VUMQPB347A8=P M=(54,, T#$8+P\6M">6B+G[@>6N_%27X]Y\OB[]\8 MZ;UW:'_&6F!_#,X,?134!'Z*ZH3#+)-9!XT4)EH#)8%;4HKH[TTN8/UFZ07? M6Q7T&5(?HG- X-5\.IN YA\262VYQX@*LD)K)P,0=!D),@L"F]ET_N'\E>\8 M9#4\>-5Z$?[&80&1 3;"WM;XU.*7]2M-O8U2M$#@RF/1.L1D%"NVKKD,TC%6 M_HS->*$%R[B:=$$-\J72)(@ =$@V 6CP*\4I.[M*4!Y^YGY:L[@>3DP5,NV. ME+FZ)@L=6;%NB. <9;LQCB()*C/E%"YP#*9+U<%:<0$! 6F2J3B:OW)I\\8@ M%P_QB4/-< QI1KCC4M+(2W.+*@;Z!/!L[:8B. M[-I?N,_S/VO$T":$V29GOXL-A*"-$B$Q@=353@_#!MRVGS;]WJ*=3[A[\+H MOPUK?QD2X\,)WIZQ"UM#J^@@*4A#FD3*>63,Z">N\\P"/W(I9F(GDRF-DF8Q M5AE_U>RRKD14O2(;M>34%D(3 LN$K#&+K-+_+?P49\_:^"H:XI'F,&:O_IKI MX)53JK%!]L#>>$).Z.04,_8X#%(E%ILPIG%E# 8WG-X+^X,'C3&/J+P1[("A M*3P,[$%FD\KGT76,S'5.N$NGVI;#_*[]+5BY/-CK'HJVZI+D^. D#HM!(V7X MO%?.ZTDE!@U?[(ZUC[!1;K4G7UUP((P=_CEEZ^ZA^^C0I>B MG_H'NPOK+ %1V!;\(FY+I2O49FCP^T,VO@!R4O9()'*&'9MV'!?VD64;9_:1 MYQ49(8)F-M%0OXS\5 ['18X!VKN+;41-.P>YO5;!-3Q\^F71 S_4(O6%(0,S M2WF1K$5[ CZ;DU:U\M%@"(_26AKYT:IH5BD)[0)_=F)=N-A#&L3.XX%!GQ#I MU-0*ZPWBLDSAFFE5"31Y.T2B_31*,E6D5U93LMH'\IU5\S"NZ-(4FA*FFL0W M^ :"&),\6FF2-=9U>6G:J6M< AK!%V-H.9[%58FT%N2=V79KI42(YN'YD)V#%,0J-=C6YOB'X-M-XL*[* MK\_M(6WE)"M83GIK_CV9407Q5*SR??*2OHWF_=KG/#\/<<")*I=*2X#!)9[[?G\A337%SN;Y2XL3E1%98YY59H-AV M(4BE5CC"10A%V;Q,IXF)5$Y,.W-.JI^,X993M"%C.RRCQC]UC=I\,D6@/KNC MJRRUR)ZFT1&&YAO11W>GVXC1(/.;* U"D)DA)(+(I7Z[P M0"\IFM(M-*Z30?B*6 :IU!V4IB6<^;*NXX&F--B]L2R5AZ(82@AUA8%4Z M;3+UG6AKQ%"QX< DY^2JPV("]P?;*I[@5$/9961B-7Y$7H?<2UE<0XBUBQ-%JXU9*$$^,6<#1!U$E#JET!?X? MAO@#YUZ[T:F&T9#Q)F5U=G ?CYH8:ND)]VX!%S#> 2X$*>__ITF''Z$.P8W/ M:0GP4OIL5I^Z[UL%LZ^(+P&&5+60&H?\.F,=)]JEWJ>^SUU4CCNZ#G48!IW M%OX3/) "V[("UP)!.$\9=CWE\[-O)JB;": @30C"6H95-0DC4;KUA*VGM**+ MN:O-XUT,3MQO*K!J!MUN;+L;Q&Q$2*R+9#62)V$NQ])>F%$11IM8*9C'L+!,@05#_!$W$^2';M(#]-JTWZN49&D]F?\08^EL0EB335N?UN-8QPG$/:'CSSDW M/KR4!C) 63$R$15KM,Z'-+ZY?WO(Q;#H.,'?HG_T.^KG0_(K.A.0<:(EBC/> MSB<6V@?I7J,9P1")W&V\'!9:I<%N%&]IA24ELWC.8;C[C9\?UN1/]P\XP=BW M_EY 206M9.*UZZFL;K1\RY49V\2^RG?BTN+M>E(:)"K49DSBPE1/Z8$4PXQ8 MN904L."=G?Y>MW_T>+=#6N+OK-PF/A5NQ>-'>]UC?IRU4GV8O0KAFD?=?7J( M-RO%4!Q();+DC-&6"5B MK1J::S08%:[#(9KIN7B;'P:@LJF:T-[@PK>,?3@?9O>^83OX5N4TI*G3D)C( M*Y%?"-G"O44&2MK%$"IU5/E+DOPKB4MR:K>_F=S4UT7Y$=[1F]^7BMM/K"(I MY?1NFY@(IW@-PM<..WUL,XZ.C=Y*3]A%_FVKUC1)PB6NXUO:V<-MR&;+_ MBD%(AK"T%=9I".PA],]9H WF7L+S+;8F207^%758!J7:8""N\%**-&R(FS72 MB!N%NP8VSF:VQ9'.F0I!R/\^W-OK/B'FO4J52&WURQCUC+4D!-Y\.$UM16S" MLANON$A+!TG7"50]DO<^UF%K3L[@Q,ECB_K7;0A/H!G(EDL#]RIB=YS%@$ - M-ZAIWU&4%,.ZN+FAS#U TK>NK(E%:>4% D] 27_7/AGN$GW1RS F+.)"&Y^X M D26 1X>C5#(IO5&+:DT9U=:W G'_+50%[G.EE>@ ,^OXQJ>F7Q,BI*;J^(> M6;DY=YXD'\X*Y+'[G-J3\+ND+! M(V39-5< J2I8!\7.7 (4X%#P'F]!DF.T[7C%;3TX#!P/*NX3(KJL1T]<4JV. M2;\#I.WS( S1O/_]]A5K3/%'.S9Q8$A5YHHN:_98M2%8IF._(YDPK@G)8I1. M->%)G)96$Y86';)B<"4%-%QF-(XZ%UOG:+B* MDH(H8>XM@%(:JMD&,N)&4-5?[U;U!:>)C+ .]D/D<79VP;?(@3=MN6X=X'[T M3)B3*,K*/P2,7BS:3 MF2O6$P6I)&*A#!H; 6+X.0JD" [07Y*] R7/X"+TE,,SW;\Y/W\3_1@\+\Z4 MH5BKR&*H4#+.B-A^7_A:4#N%7H97F+)8Z786CR6\5B9,X6]QP,N1*>'*,;PS MPLUE2:Z*83R MCK8OC)DWIXM[$]"E;[C<$1O5[4C'"*XB1ZV(FFD1[,_<-N71(*TJ(JT%7(4Z MLA^!FRWWFPR#P106WQTT +Q(*):>HGGYV2ZZG&!HR!I\!:SZ3$$Y7%$FS:R& M\8S#I_]U1*0NRY;_49-MJG:D1QOTNQ;TOP+PF)ZJ\YN2QU35ZO5_KX '(_6M9JZPBQL@SQ3<1Y36?D!;:= MNJ:<*%KVGTJ6SW4ABT#5XUL4Y<%.\3XOLF8ZP*@>>O\M$N+20M0MU;P5"94Q M>5U4>:1UY3EW,'LB2A[2VM20;,ON'AV@@CC12O LOX#-N5.HHYEWR72B!I)S MPDBFO1G[H6'J!N'T# ( Y*W4I#M6XGK@V-H56U9SUD"WRQ1"OZ+$O\RC'QH, MH_5;T*PQCDBWS#MGB*7665/QB,4 3M;_NL6E\WR+H21NVDO4%V'FU3ZX8#K(D *>9RB"=$&GRJ[0L\JE3 M6OTT2-_/5H;O559OLR6P;H"D'W$F>BQ MUV \X<(:44C\V+-.6^8M-ZG]F%KMQ$[\M/9RNUS<\8^P&S2G'C.+-L'$06][ M(UE,(76/^]V^;PF;2^9#= 7WFP[?YM%/<=[ ]#O:!-S5LA?G\%3)^7;,;HL MN.ZAKSRS.G-=;(N$<&QG;^_D].?=3JMY_*?[AFL#-JRA&EHV]PF@U6>L)$X7 MQ>!&RPZR5J *3XRA0^0:"S,HA?+V+.EQ^W\HOF?)E'!.FCL3PSZG12"@"-'?Q1G9(D=QXS^^K\PA'?NY3CB_2'5S)3\ Q]6J.=5PT?]W0V; M=0$)A9(7$F>E32/\#,K?L-/T-FWPRML-VP^)G28W#O.C-Z0+P]CI;!K@7,HZ MI,.GR7/C]H_^>47.=4D;MC/X7,"O6"=G1K9A&^19<$9++Z6QCU,1\MA5&[!' M0MUC;?<)PG0.93BIT>//%7T+?@:3E]#"MZ.C;I-!Z6?B+'A^"-BXFG>OSE05 M94V4)]+_]?B)I$E=QS;X)I859 GQG@T[9G_#]F,SS#9L6YNVG^C\U8O+AS'0 M:GEH 6V66W NY@7&,W&]<=0U:/@J(Y1U)"ZZ'?BQ[\PD48V6<9N(H>M&RW:: MI*O)*/=E"G>CFM4YGS@WL:_A@)+(_?PYPT=DRQ19R$NYBI'-B]3D,[OMV+4) MX7Y<>8KOO"0<2^O&-M24,>+QG+>65OJ8>/[PV7 PN5U6#^UF;SB/MEVG?429 M-*$3AY;>EO8FW&3"511QBILB%#X2.Q32GQ)7NV MR)7HZ!TZ.,$OSJ2@BF'#TUO"Q*?E\(6+;&C0W?=<5=?S4K+M^]7O!R\693C) MV!86^%12#4R*H\,]R9%1Y G;C K;R<]E3%D?7Y#ZI!W_$.&11'H?S[WOSNH/ MX:!FUY#T \'SZ0U.H-^:"L7%*PX7G'Z=$^A&!V90IMIR127IE=V'; &-^N@A M^I,$- ;LUOK'H[U'TN5[%@\)2]W/,Z0/Z,^ZCKS!0XOC666>VG\\(W)/Z@G= M!>U8OE#R_R>>N_*,;'N2N#O5YNNG2YX$X)_O[3YX%^N0:!'JHE-."W9K; M78D)JZ&OK^WQ_]8\L[@<%V%#?BVBSN)B%SXN74G(?4F2QO3$V,<1;F7L+WXF M>HNJBL/.T=[>0A,CKD4/35O.N=LYW%TKTC5+( @7QG6P/3^]GHN%29#'FC_ MW<>T8)@+VT]/'DL7XTK:;4AKCR;3\.7IWF-;;X>6*/CT3MHSO2B^*FA5%DKZ MAUU2.%=T;99YPY*5>&7< >ST4QU9R@^&Z6]2L1-D[[0IB?ZOQ/]A!_1?DISK M]).]E?J)_@9D]K1_W#OL/VZ)\>Y![WA)9=E*Z\WF.5MIO9766VG]T*7U#S9- M-[/2,/DB:;S>*/3]871]+RQ;0LDFU'(*MA?D53.%=?Y?>6]_7ZI-?-IUG#W+I7[7:^]PJS!L%8:MPK!5&+8*PY]>8;CDO&0RX,U\8:S- M:D_X%R@3$N2!F*V"CPUTZJ)-E!X6E=1J-7EN(%R1.^;,:DY]_-UZ_EW\");Q MP.2$-.BI+A509UE5=- S56>_DS+4F& M#W8G._OQ[F)Y;]0DFTIAJ^4[^"C@!"95QM7?VV MEVJ<3(RM44;C)&E+WN%:-20XD'Q%&Y(!ILME,V1V8(850&9[FKOL M(C5A[! M-5OG0^HX>*.=W2'FR3"7MK&N4ML5\X7M[ET/Z5F):=-;N;Z5ZUNYOI7K6[G^ MIY?KBW*<;,S1*&5K5_J6$&QX=(27,+8#!VD"+:E_FSSB^R7U_>E18&'/S4]_ M6O8C"]!:[#$4"/I:AF" ?+I61T"H6:Q>]3.TB,^4ZU^281>*^B>])\=M2;]< M>+D5\YO-K+9B?BOFMV+^H8OY\V"L" ]&J@V&V)$]F6)T4<[-4$SY11+\>>R: M2LJPF%8H_34)+RG(=K%Z\7UGF#LXM]YUM+89=9>;:8@-)'D9RQ6+O M#QBS]R!?WE80^;(<*75)?*U*D6L#2:W0^4WZ2&KUMQ;XE$%#8KNF5A69I#V, M-6AI%?0%(RKY&(^E-XJY2L\QT,LW\;;M'5VO+^Y,EFF?55>*PRTNN>)"QR/H M&6P)Z(K2(EF7][L^Q2 CT48I'CP 5'ZL&4_B)-Y4=6S"T MA[Z25C[RL]%1;.AO.:"[13 MSIL1:H%*H]5GKG%6(:,K;IH'@HQ75,A51!/7 M@O)E[+)=?9OU*]>C6]J3.<)P6;\\8,J/:L*DYZ#9C\_S\62$EKNNF81&$=TP MIM94Y:"CV(KB/#S.977!:!#NF*P-XI8G0]HY(([6%P8Z^%[.O>A?Q;7A>8ZO M?G@;O4/=>QR=_?V2B%9;@%_$.;IPS?A/0QZ!)=2+O0AMOP8"EG%$G&*F\@KO M5U-86F&\D_Z_K,DJZT@OO7IZ%W<4$F;C2 M<&%4I4[*Y$D&M!54_ZW; )_6#9IQ'?%X7$N-45,Y^O[7,:Q$])QT3;JY&3N: MX D,7729K$[)R.(A-79C=D?2R>T!U)"5MC;0RL!6UW/;<)XGF=OBV[!S<4C; MA%UCZ8M89)6%_#!HSQ57;5I\R4V.\=W.TH(BJZ599H2BTIG6$]JFFNC&3W?( M-0!:=3J5CJ%)P26AON\^,RF>8+$PH6>H'='T#?EFAJF44^)0H$QIWJ;".%"; MM+:R)RVWXNBRC8W%=2Z-8DK<%:\!,3NBB\<7HQ<79UT.(UQQ[S1N\L< UR3 M"BW6YMR#E/:$(?#UA'F95D9P'U$P;25-AKU9-7A-:V^E)H$;=L<9IG?4$QZ\ M/94\">V8U:(6YJ,$0<,U%OH=D@X%QLYHXJ-CN&[0LU"N)%0L=/N5E FN3.8# MMUHG"J70LP^L@]7)-^M@=8>GVI0&!UH$/=7.?K?0$#I>11 D1%HT:)^SG'DR MBP_-MMN?VKG:B0PQ8D>FCG?61I^9C&@@T/3]8-D)B0INQ>++GBJS<:V8B'_! M^MRP745GSR,W]H3=OWDPN9Q;N)8RCIA@+.5@/+FE+*:FEJD(.J=R"1$V[*06 M6S9L6U#K4L@H$E@2][Z*LPW;HTP+ Z/=J&UM'(G_8LJTHE]M')%_<&X2U9[ MDQWFE6:,N;(P%"P"XL:E]S-S<]\<.ISJV-*J*@G(9=V:#A.]CZ822H1CBI7*>(F]DY N9Q<][XJH MU-9'S^)B:$=R"TY41=;4KF6)RP.V9DY+O6!T<+G,GVZYM.%.L_>F(BMH*!/& M+X)YV_?;WG6C/GE.2UJYCOKA2'&ZUT7?!9PZ:=9R8;G<-;:=@@;R+==3,"IV M:*?$+,SROE[J;/4Q+ZZ[$VX\FDE;^4)3[9TSWS(@VU&^J630BD2]JX7VW7[I MUL'9%5+5-E.=;.6IG5>A%N(*YYQM]F3/C[E']]T-\C88H1!B@CUKFE\5&4H@ MK)>$744RWECG"HOSR#T8"WQ,]QHLJQJ6L"Z (G=:N9.!/ M*662>%+:,]5H1IW'9Y.N#3HC]+_&S4:J=,BH#'F2 MA2L[%9I7U_X*VO<)CBA26(J\Y6KE: R79D@>2)E8!PU7@,2AAT=GVBVWCJN: M =[F.VA11$+D,Y9^8=YIXLLTEWM +'2PN.=MQ=SD4]OF/ F;5_ 5RV [YQV< M1Z.F9#RS_/&E:MTI&= !3L(JT"[$KSE2.I[!VVYJ[8\73, -VX%?MEGNXI M8]CL"#;VH8D(,$S0;LK2@FA ;,'/4 J'G@1AE=84IM;(L<49W-&*RULKQK@U MJ0Z*L2MTW+"56464&],V.Q%]:P8FSV(,LVK$?^(4(#O:I!==RG3+:]/R($H& MM?J8KU+.2UH:8FK'KW@0VFPO.U_$[_':WPT"HVF +'BA%= (\"L$U.H9ES(T M)F3^=F8,1J&0)9&SB%W>=;TX]---]+Z_ZM]+TFE9UT"+0(Q9(!9YWX=*+(L! MF1)5FHF=D$8W.RJRM!!B"T P4Q!TY V9#@9E(+=M[@O?A?'GWF7/"0:,3.&@ M1!\M$W+N7+#B 9BV=KQGU9%62:W'13*M?KI*7;=]@H+QS^&S?;=.^V\+:S"7 MNRZ0N(D_GA;2C*:#OSC]H5N=N:XU[+ONX -0A@!L4J8",.-UB M"6XZ0,Z&K>%0<',+1<9QH'8I%Z>:5[69+FCMHM85B; 5)#U-65Q5)!>\3M+4 M=B05)W5*88L*@W!P#FI2P\PD7=M_A*T3+JNEY?)FF!E8,\,T:6F&P=/_:: R MC>8Z)5:UT6C0E G<'C(3T*^ML@Y[+3U'MSZ1Q8F"OE%O:QC86B'9 23BW&"M M#PR**)M/9Q.>U?GS+V263&T%,""93J?H[,_1JX1'%=YO;&U9D-(O> 6[6H70 M2- P$,$(E(9,!0B#OR$MJC0:9+6F:&MJXOKOT>N$)=SNA'Y7"SD$\VD7LJ(Z M3KXE)UQ1N9TX;+XF"RT5O+ MDZM[CKXPN!>S0+)B:+7S5W'T$U+/.^RTH]5R3, NAL-FQDT%6GUUI'U117A' M*N;(&#$8$&5.N1^W!/X1]^:^T&RY$3?BR4?(DNB8(W> MRR+XF,IX^)'/8$?OVBP76D-VMV):X-Q.Z(7&/2'*T';;MD12#J$JM&0]VDQ5 M?$I+,^X[0[ZA\18K CZQ@Z^'>2 Z0:DE[9!#9_;:N7^,CPU*9X9NS+*U<8#_ MR*OPM:TL(*%.E-Y*;@V6M,TP@R\X'Y?\EA0&I,)-8L0RQER)$\Y/#97G63!^ M39BP^K_88=)4=$_<+XSH8>PZB[G<(.O.=W,MW7'FJ5(G,[1)!OAHN?UJ0K:Q(NE7-RV'OZ/!K'?C/G?GR934C MFXQ*[]^ISC)/35^ST:<;*M-%MCU 5Z*SLLMMT-II-T%1H:965PZ MSXAVD1[,N<>S>A^\[Z>KS@-Y_&QJD/2;1\^+N$SP]&NM'?F1P,_U<'CL1RW7 MZ@X1W^=X:.!*NV#'?5'Z\1!V:U/X0/W(3,V]<0V;?0D([784_]Y!6%-&F2&L M2$B A5#14I3\)\E2+G)8[+I/--J@G:OGA?A49L1LE^J95CF+Q;!_<84HV<)5 M4W)(^QT^,]!)'BJD'E#=Q.FV;N(;$NR0R]0M^IP-ZVAGP](^-=JX8;OZU\MW M9V<;MB>-QF[8KC9O^#EC=-R4XMH>\#EUJ['"O2=\3=)%8;,TCEB= &"3X-L(S>T;P NR8EPP M=*32NI!^*X14TI="ZJ)+,T;G.>[,HB -4WRQ#O);6BD)S$'HMQIWY;Q IM9S M(MKE07FY#Q.9W,YW5PF50X49FB68GYH6W"5OZN-H+-ET\;=7U) @R%S*? M1@T'6A8"NG_\K+*I0S K+)6H#?#_V7O7YK:M+%WXKZ R_,>S\1M'\OIKO?3%$ALDHA!@(V+%/:O/^M9E[TW0%"6DTXBTI@Z)VU))+"O MZ[Z>)SR#A4KO?4B6'UH7W]=MK:\;( $)[CW6QF20K Y)W*II?78WG%<@T$"G MV:ALM;CGJ;0B7.@[@!&=V>2C)RQ$\(H<.]'!75YP+I(&SO@2)-E(4:^8 M%WF5YF6#+OFF[K:MM>L<^>T,:";2]('6)4?_(<7I FZ174X/CF@@5GMY8@^3 M@F0,DU+9ED+-2($QXR=5@!Z2UX3#(._1, ?'\&@Z0^RZ9;HG.;#90/29RB< M1&\#4=BAM=>*\U+-?W(\O*,NM?T+.+A*#CL7R1NY$J2QJOB&WOJ#R -7;!W]MV6&\J)J%+0#X:L.X%X:C+)@(PH]%PL2Z7D;?N-^-L)R5DQA M"10F+%D(7[IT;)V ^(H+"WMR:"8]$(;_$Y>XBB*?,1[[(2W/!V^@YJMY2QI M+&%3]KZOF)GI2:MP@,TGCDE9B?<($V'!;0Z9 Z+MR(C#8%[8*+#'#5>RRCC4 M@KCE!ZFJUV,H.');XF[OWAJ[,"E[5ZW5=DX;:_BE11%S"NI&H(4>(/:-:[T3)=+ M7%/\V5@)8;_X2L@C+SN'P<.YAE&X+#G=D2,;'%'VI:TF_X=GH2;?#GU0MT'6 M2G,5ZA>Y#68-!]&.N-A;9$+6;&3Q4]0(4[&[$TDI#TOHGA7491L96TY8*YPM6^M^B],^F,^F^8J-*_$[G=<,\]>Q0$/6-O MPD]TKD.2WXF;B,N!2L./=[UKC]B.6+Z,WCQNV[CPJ W?(R>6^]=/E MFQJ@;08-SW@V)LT3-G$ ,#P,:2!5QT>HJS2CRXOVSQ+[N^KPP=:%3C!^'K\$ M4%@:S>"11N9@))'&W\5*83 J.=H#[8^W18I?)>^^D-3E.2@D0^7 _07;>P77 M;V:TLB@";EJ^^!#1]B&8FJB QE09&BDV6VF*/LL&0_ZXI?/57K4SYK3I0*=; MX230K4?9:=^ E8A8P7 25O8\L/RTXVJ+W'*K1Y ]>:_[SOOKR!?(ZJ8MTPK_ MNC,H$P9(]#[>MJNWE72LBMG-F=FH['L/KF!F31AFAG+/C@D(Z^)FK$ UG6G4 MHDKX./@29@ZQ]A9,XN)!1&J 4U0&SN&MX \F]K?,;?#/G"=3<55@/83?CV1RY)77M\0#X:.OD@L7# MB(K)W""VN6J#-3[N*E>"P+QE"&1O20PNH=X_:[J(30[/,-'9 ]0?W0#>&8BZ M)8K@^^>,H>** V^X31G^B.:RJ3).5(V\;X ETK^(+H7*&C&#Y%RC-X5[X\:E%CR^[#RYWI,4O'Q@ MWZQ8N1?RQ4B^>5@H]LY2&&)MDTO__=[+QI J2WF'>EH,T:G:>8[N%PXNIFW_ MJPS_0X9'IV3???1:?'R9YM+6@+8;QR&X;2I9EF:!$\"@[L,QLB520$Q#"=0& M[3D4\X9$92O,]CWC3CT7\(49OW\D&"(]_N/RSEM%H?%?NRO6^5QAKDK!VZC% M]^M-X"S(#W,'NS*L#H3!'KL>"8%BF<*C2VR&;@?7AL>(2/G^_+ MTCV9==Q5+X\?_695+P]*5C^4H@ @Y80N9)S!_2,F_;5Q\UP36T"D7&\\!S-W M@'-6EBR:G5X_I"EF,>B(:'J!E?;/B5R/KH3[U G8F'\F683?*0.Q>742RY*L M4X@AFGEU=?G:_!8)DKV\#IC#_6_$TD[F.Z=+7G(+HLQ/\FJP4,5^HX>?GT11 MPZO^YN[I;WC]L5H5S1T96YJZW,4[V+9^Q,Q7YMB*:D3O:,/MEU$,J<+1\S$V%+\ RI;?)3:HE5N>)Z^ MZM09N19. 7;B_Z_J=P'>UK[KH]PQ-)/!APW,(+9\O!>9RRI)]?U .QVY5?IJ M3W;X6E:]IONMLFB77.0!@E*WEWZ2)0?&3N4W< ;#3'PNOP$]*^O%X6"D3J6[WYJ1X;%_=]E4KAR=ZM M'K[KF"./EH8[[@MU_]P+:XB#^9>@7WO8B5& O^])#?(H3'LS5QOL+7IM07KPFA!9R$8FJ+BAXSGC.0$ _WG@.8(%9$H2Q+_'??OCL05 M["/V3GGUM;Q7@TPT4G&(HZP#.\!UNG%*&/:B3/ZK*\#C=O$H&JQC2["]KHX=8&"G+%I\+)J]L^#D*RD]<:8A*Z[>4,2A_./ M,YZC I1E-7FQS+K* HKQF; :7R;/:*4[26B]3K<*WL]2$.\SF$E=FRQ\F(Y" MU_H@EAI2R&7!9&DXIL)_217-&*2ON50?KFIC:N)\(!C<%((CP/SM>DGTI$ 1 M7J%D;(H/3=/-,1E,8Y91<^.,Z2*2-/9D/[F6W@G,$J/UP M=#UG,#*?BIR.!>-M[LT68UNGF2Q)3=7P2B&C/' EM0+S+$;73 M)]:1GKP M6;0U 01'!+MF)40?,7 .AX&C6P2'/'G)P.R?SY0,E.$AWSA4 Z!*C@LB29C2 MB:8%^0N869-/GYU=O?I,L-QKY#1JNMS?=0O2%F7RZ9NS%W_]3%I=A!RNM?85 M=K#H=IZ1R9\+N+X?"D*YC&V%#X%:0CHR+GTV[ >70C.!*EV";SFRU(-<;Z RHNN[AYOTVVJ";1HJ&K/7]-%:GUY=[.E/:IJ M$3.\3OQW'(B7Y$BGKDB^H._U!FM3UUCPM@X25'@,6!5*>*[9IUI<50KA M28!: M3:^)3EG3==4PB5PC]9LNJK,3G&A9X-"F*VDG7[TO%WE09X> :@[#E5W,QZ#&5X.F<'!"RIPL_29HU(C9NMC #PGZ MP8E1'/; 5BQ!9M:TJ2^UZ\H-NAU,C9I_C1R7+V_A G"P.D+=9<,K&>T*T[:< M]6\EWQ6R2@']ADBF*?L*EG!)1M-3%F079&)PV1J]APGX;M>.E6P[LO%S-NE' MS(<\'"L6: S G:]*0P'$M5#_Z#5]A\7,>?(CS;$(VXTJ7D9JXZ1RP56[Y0.%;DS,"\EX1.L5]Y1 MC&!562N?[",/F?N3%NXL999T-HV3NB/G+GT7-?G1?J*.7O>N7_.L=K">*S(= M];:EB'F^D^04R@?,QM4A>,\MJQ:=1JZB@)-T$,J=D"N@-4>%S90#5QJ&TD7A MLS[\,PFTC$,*6D?GK:+X3IE4';LH<5([7$W20-IZ27[CC7"Q_!44@F(W/KZ0 MS?X.HB&Y[%41<9""Y.>M;! -?G3W. Y):JAL\CGKMJ9E$Z3O#GBI$KQ4'?F1 MQXI?++U RMR"&+01$=)D+@;O[K2,%B'\IZ MJDU8'0J(Z=WV\30KC"OR=TYL,$YS]QHUBK&FS%"U(O%O7]H=+BZ"1"=6+'(Q M0:3\=N.(HBY1 9F>_#C=LH';98=2W8;( H^+S2V(B6>S"](T5I8>8&W%Q-4K M@+)94B;:TPN7X@SMS=V&:__05"F5]B1E?)7J P/>4!G_P$8E@IPD5H@26N87 M.V8!WTKT2&<$;STP>_N"?=CD-%O(R@EB]3;J=7 D''D.*0_FAC/ C8>(.TVV M1$4?:96QYTBO\WGR/7./+"/O47*0^U^965!)!HW9"=_QZ/.70F0"/!1/["%= M$]+5$#4_TO Y4<_/5P$M!EG:^A"! ?RG&0,RXB"_OZ'K!,J*AA4%(Z (H2%V MR,N1L]-N@-G]SKAZ5LQ5XNQ]X9Y\[L@+"X[\V$.5(&=2>AYN3_JCEV+5&O M-U&]#EX_,*AGB@RO^2SLB<>(Z!N$',]T;"T:- >VK-M694Q.@)02N5*=G*1T M4\$<9_T6V7JV(,=<<\"@7[PJKWAZK]%9L1"5_ RADVM'!Q<[\0-J?XY;<,ED M?1!254+KB2X]:%#@S3(O2RE?8L=\&RU58ZM$$DU;6**&)#&"Y.VA?E 2V1[Q MH]UM)8P8%ZR&(,L57#@:\?< ,]=8Q&7;^Q]#!XQBV4GZT!NZ. 0I1S^$=EJ M\53MTK+*R^B3O+RIUNGTH\DTM[RE"_OB!0>+,$?1RG& @1;R&@GZ8$R2.SN3 MJJ*\;&0D;"]JU8?&U<*!P M51YG F?(KW)$S"K*>E2+W(LQ$-(N=&BDROC"3QX;HG\YU[X@Y5A4#6/$C1Y^ M\QMP&C;=QK((I<-K4FG8 ;(0CD>S-K113KIKHU_O^MB.AWMD'@A>XJM _"ZE MO6,X4XQ39#L\7Y,P9*9+AYY>G:1@R8@I@#G5(I<261('&U\)R.8JW5/$'CD"U!,/M^N(;L2# MDE3[KPWT):T1?M;1YFDSY<%3-Y/HA43FTR;YSL9]:>,^A2S[XT>/OHZJ7*QR MX;J;MRSDGNTAUH9C_M93?[&&^)Z$FY)H9XGOM=7O,2BI1<]?O/W^ZC]# #V( M0GV7QP1^0Y>0>R\XE>N (=1(F)Z#@TL>/@X@'DCW3"Z1U_!].P:AN15) 6&! MU:(UNB:N7*&3S+XXTR1D)LZD,N1RTUBH))OY/@!.ZO7*I6G%(S.OEP34SR.F MLU@?1B7CQ^R=9SQI]!#&IF*O\'Z3_B1$K-'ZZEK=PG:TY!BW4/X7@OUHSP(X M^V,N2+AXXN.V4JG5:^Z297ZU*7X#[;7(M=Z7U&-Z+(^ M$H\F*CYD(41VT#'>JF^VK00H0F$I:QB V3JU*Y]-HA15,\8] MJZ5-.-?#$2O27'#]HTA!$!JQ; M.S+QV@A!Y!<=$KTQ>G_.%,4@TX?';^=X&"R%N4M$03$VH;K[9:D^E+C[P;:O M%2C%K"N>&Z8\-B5Z'SYH\:0_)$+#Z[TD3?G8)4O=;-%G=)&'Z=\2SH MS0U)1YDQ8P"7NQE=>A_4)J4J?]R@C!0A81\ BV?@JU\C$(\J"G#/P2-/]E9U MBS+]6>(T;LUQ]G=15,V0N?>^'!C:V_T\:/](LM6.92_8>]4%Y\*ZEHO<.9@: M&0WT4J4Q!JQ&6F]T:"BTJM'F+KR99-"=-23D%*K()-=Q:_L7_8;DN!1IQ"%G M)5#K!=.X *]F:!D,*;$/B_Q8*TC#NR"8=-;6$D4[VVHDYLQ(D+ 0(T$_PI[1 MR!![0BJ4YNHY&4]\S[RK>V>+XRTYEYJEDZ*]D=GS*O&]RQLEE*4I.O4YSY/G MC/W(8?X9L\O71@$;E4S$K<"<'??V.\?I>WSV.HC1CD1>M? P.'1+"?U(4#FB M58D].'A1XL@T7-I"7IK.WFNTO/1XQ:;,LI\]%6:Q@_]E-MXD"Z]Y5 MO_@JQ':O7E_Z ( 4X!V"ZA',VJ>ACLV*"N@$5K>?17,.,83&EQ++3/JM7 NU MI"W,%AK/1_$'R(3B<(<4CX;8R(D5USR>BFM^NW'T2]W&I.4L'%].1#CI; JF MBT@BA.0[9,S5^8QRNHQ]H$*''RM]"WG)RD&<'COB_&Z6I49@ M 1\5VMFI2&!0#1&C@ZOEC01_P?EF*L!U?.,\BE2_3S-T:491=1](U[@ZAP^< MLFHSA%]LITK0^4$5W\0UMRSG46,=*80;6NFZ"44I WUA:N*-G($X4'SU^LUE MZ%Y1N QN[8*SL>SH7Z(N(.),7<@0GJCHI"=H39?V@O*6]>I>9KVS(%4L"M1E MTACEP)SZ8M#!"%:T:K284A%#&X5@"UU"@CXCQS#ZYH _!E1[MY[O[-#.Q IITMN;(GZ8]JT>6?E ZPL[1['H9S@ M)/-P/.8N6[9>M?2B%#:HAWBJ;;L>V,AFTH7SMQRJB-D*,S*Z"G*ALLH;,GLB MENWAX14*MP=7QJ*V:&/*:2II[?-W/6&'S978IB ?R1>"'TZW;4GRM.0R%2]Z M(Y^.S#82WAS@3Q9+EDE!_8RI]&,=M+%$H.'=&7@)U>K,G, M;>$E"_$(=V5&#FD,"V#=1KWSU5?92U1(J0<$!;V'F"E>["#O974G<#>Y#5K* M"D6>,RWGMDA9S%N 0_)XWNG3UJT8%R;O*,&+ZB'"J*V961JG)-0M\>QT0(4*FO2Z39;7H MV!"RQ=>1*)^;7%D+_LHS1XDS*JBU,L1XO/@_8,:I#->2,H8/8B0P79N9.N!! MMR%*UUB-H4_\2^TIUSPT^7)WY"TR;]/#*P;4AX](:WZ: _9.(H3:\Q7 M*Y4M .@S//&=&GD!ND=K-P!*ZU'&C#R)2\(MC6RH>MS%8EU$_2AGE)BQ99CI M20T(ISZ-@@S,2"8EX,4K[RQ\!4':L]H6GDU09GUS7,V7^F_3G71S(C<+$_MVK>;$UD^* MA9J]"A_R+58;'^GAU?%?\2N3;[A@!/@A?(IF@H=7)E'Y'@L?O#HO=7"0)Y;R MKJ&U^7,LKT#3UI6%E4?'?T?K1B.!:P!,1MF.Z+@\%?)P926<5>NTI4U+=LK!6.3DV1RP?9?"RR=/C?( MD'=PQ(0?6;"]@[>_27U#6'L\E4(ES;58+@+_%+LFHE3JC;[52J.]7J+>RV=R M/!@Q)19O8B4<]WV06J)8'VAGB5CS+"@\ 0$B[DW4]6+V1.W4IS'!+1\7X7V> M_)4ST)E2[O(QD5 "NVINL-,10K.>)";^"X[=@-D#V@"/WL\HA&?ZNC(<-6<: MCHMH!!+)AXI#V-5,A^?T18?.N'S#$?4C=[&O:<]")URTK/NK9@#4O-E68/F- M'?@LO[$5D%QFX98MO8#^U+*1+<;\?WSRZ!.ZG471;%-@0?F?M]A"_5F?(]\X M0SHJW3;N&_O'M_#BVS4M%MF2\H::_YLQ#.&J_(]/:/7]8^3#LM+DW;3N#._& M8MW6Z?:30[E8'O_^[@VV]U[[L4 (^9M_ QG]_?>F ")=?:;K],V]#H:]7EZ_OG3A[ ^OX7A/[*48RG>>UVK#,U+?$/DA=^EBW>K MNNH8=25,XP^9$B?TOO@V"J4?V/I3/?.]/3VP,Z.[2%\=R8?HUQ[Q_QWXS&!S MAU\A*9\+*9#Q)IN^]&:.-_[R%)XD\1&?RDD2 M3Y)XDL1_M"1.>Z3@DOR59*_4YW&CB9K(":U&(YG+=F@7"SHE1Y8FJ7S$)W22 MRI-4GJ3R'RV5W<^+HF/,>LZ)]GG4!S3J?<0?GS)%O'^8,VU$-.-/DW@^RJ,Z MB>=)/$_B^8\6SX=,9BMVM:Y5[B+4JFQ4)C2+M1/^T45>+[K-C8"L]R(:UE;; MK^VXC[#^%V8^8T%S0BV23WYEB^3X[3DTR0^7Z<>;O@Y5_/UP'5=H<('E)F\R M.OQIR356V8&ZXT&=L94??(\U^+8'FVNE,/T"NEZQ69<.>*)J*6ZW)?" M<&&*M.88"!/X=R,*]+@6->HH*]+;\^3OZ[P([/8IR;D- \.,E-H,RU:X&%WK M5H3 NL]&;,0Y- [PH+F(1'Z@A#88\U] .V"#CN7*!CY?L&*KZ$D+ZSE,>J=@-*%+?M M"/MO5*L+".73JG9]7J>=])A)F.;M!B/F+-@2"B"1: M1_V5"*TQ@FKU=UT; +7A=*%\7]IS.>M5V_'Y A12P9*$"=]LZ5->^KP+=W.RM?C @$O<75 M: 6DUB-K'9M"Y4"XH2E[!RY=]+/1GT@=07WPOZ3[07ZIL)29 /1LNE+K^&>D M;T!Q*FP*J,"3GYC%BSQ_;N@1\H9:D5LZ.F$NMVIJ'VE5VIT [>*IW98=*2E& M(I@%*E>E'Q)MH>R,=%M6595)3Q!'>06\1?2EU4IHOR%C\TDI7GI'4")T7([4 M;Y] 9>: ^$@[^>,M-B06C^(RKZLT$ZY2:<\4(\%*^4CO<:<['DCTPW M=%;YDBG,M+"6<14[AGWJ[SMWCP*"')QX!3=ZHGQ3Z1?KJ-YX48.CL6=$S/S. M W@B;=9J :3Y#=-W^RH:,&>._G]I;&;PF/VE3X>0&;7:\88D_^S>/QA/[5& MED[SZT-MCK:WAWKHV-YM?-FGW1DV=1E[M\Y)"@D2KS3>JB$X" [:)9N%<%^ MI;HCB SP_#(>I#QN@F'VYIQL[$57=0P,/GFLC*X7X8SBYN& MQFP$-P! R,86241IY(=O7AF)4]JN+.K7Z-% <-N[1Z_O]62PHUSQ(-0"XCX8+M:)=B$: MME*)F8^PB(P*FT)B!0LFRHV+Q #V>!P[: M]0@4X$BG"+OYP4[$4=OF'H(B4@AT[S=-;!+09_/-G Z*%6/!VNW8M\+N<[/? M^W-- _U"!^ 5":/ =L_H<>J608+:1+F5W:/BCR'K??_?;R)DO31 ^J<-WW!? M)R9A6I*&/S;N[!FI4VYC?BV04Q[#^S5=]0H;\FJ; Q&WA\C_%N 8OE[XM>?> M8$ :%BU\1&-(I^L?7[]^]>8M?A<0MS%F#H1Q\_^9]"D"!B2FO4C^?7YP/= M_%\=:+I$P9^IOD*QO\K5=CK' 4)5K5 M1C9"+[FKNL23V,;M<'MATADIKH)%'PVI$:Z9&QCBZZK9(MP"1XF6N@)NGV\4 M5NQ7YFSCH6G;8Q0C\KH.3C4^0@.[$0#:P#EF8%%J9?!R2QCIQ=+'HI?Z4FGX MFT6^0[!-^,3T< A*-N9O#N$/''G;W%\B$.^EV,EZ.!E 2&SBO,=KHL!U'N)" MF/K48XZYHDPD*@B%LN#%="L<>V0%,%,8&<6-%19@,;6$DX"N $BQ!/HB+?U7 M3**$&(X65A*'22I[=DI*EL]*(RH!9Q M1$')E?VQ5F _36,H*/]"H-VQB &7YGB#FX?:1X_13 O\.O%[X-]J46),*0]1,O9\[\&JV<_+3T:!?#9W@] MI!;3[9J.8N'F!?DDM3F%=$3US^36)6VZ"?#&YA"*T[6WE0;W'=J'&3QEIS>' M#[]T%XA#.<:@%,*^J@]$Z'..PQK4]2^E\1]"6]Z::(G-FG!N,#^3%",8HQE. ]!%"T>$6QZAP$":]>$9&YF29 M83,1_+*XUX'1*-K(6DZ98&D8?8998B(4L3\%@"6E1 MK:JN.70O9A( &H5Y9Y].4,)2/5B2C%+^)Q28E+M]#!0&^*\ (U(SWO^=I^_$ MZCV>_F:0V _J1#X4[-"_ V,G:MUJF,V%O)=2SB??CCLE"!<]:+(I1IN RRMD M 4JKRC-AI)Q%VS&6F:!9-Z38A&I-8_M!MI'?6]#5&ZO7TB8'TF@B0]5W1 8E MW&$.:",L.??@@0\.T?>AD=8#0:[74F+=?CU^)'+9.HZ#]XB23@.)UE<(8<9= MF=ZF&AZ&K!;0/$#%M>Q5AH\I?.06J;D%HU>Q=1*5U\1L8'MNX)YFYD3O'DR. M3Q>3Q91*H$UBK49V&X+$#$??"$J0F 2,@8M/BX:;Q5""'#+T[JDZL(8UV4,F M5RMU4-!$AAJ#%M(M_'V<#:WP?/SDXCD9G+^-ZQ$!M74(0I3_NKJ?7SS\W[+, M(LSWM2:+P\3[K#QC-$8P5R-J>W!HEZ/GV:W> $9\P\ M%U#)^FEFW#5<$Q8 T16J>I![([AR9&VZ@O5<5.RGY5(T\"%$G8+:J<\4UMQJ M-C[MH0R^(H$=MDT_\QD'L)64SQ+H5R^OSQ,K_F(07+]G?*GQT!^>O0679.%4 MQN.C,2QI79N -'QW,6*H!S'(WK#O)F1>)3 M@--PWE1"TR3[W&)K$XRY.F;/(G9H,?"KN9Q >CQ'ENQ.?5:Z3X\ Q/N_RG)O+^"E25R GTV/T(#E\60LV/I3& ^ M:IJ95XCIC&V!..2WV1;53JNV& 20+VRX[6PAZ.K:-V<1N*:D@M0Y;(8X-CXD M*#+(6#8,W-#O(R%%BH8K.?F=95BTT4U;FA'F M$3GBKW @[3SYVP":HWGO8?#T!OK]X$/C3B\_X_/C$2M4'01]FX-->Q:NX62-%A:&H M"S'X&'65P\Y2B[%F7PD_:W4/&/ZDK ,NDY\+%#_/"K7$1<5A/+FGK!JH M(M.3'4$M%*U[I9)6"B+=OKO>!-/#4_1HQCW07LG::A?RIX\_ZVLXX/S62KLD ML+F]M%@_:F_WFB=S8-D:*95$;8'H65X&P/!SG6BY%PSM34%'^>0S#TF][-?( M_*-S33LJ'2.(:5T &86--[1A?_JT_WA5@ 403ZW4:^=?>BZM8O+?MX<87E5? MZ6'W=:B^;'36@_PP68LD9ZCY/1!LX^@-#QCN_!Y;>IFV6OUFMX;68R_#?-02 M]8V51GD&\N]D^XY;G.Y/*SZ5D;GCSS_=KC6]OM@9=4+OY],E MG)J(3.$H:Y&S3JY[P 8TXW3%F706/*NTS/^IA2A6=/7RZI4O"8OMAB%CRX$B M[[V.A7X[$EOC"!+#:#Q6ESZNII"B>G2#@7W/>A4KHUH?-AY%]9=C-$@]4TI),8KX(5MN9@FU#DK7R$2 GB%0]UG)Y5GUZ-35 M/._-^KCOPXLRN21;OT#AX=.HV'J;-EI4XJD$:?Z7"_9.:%7\^0EUBT_]&7U] M^7*/ZU&E<]:'85).'UWFVY1Q\.0+^Y3BNZA4!8<:19@2R[#1G"<_\L\80"AB M&R4GYT?$J1<)EN!?"(+LI1=-9]2I<2G=5$6W<1Z///>AC9Y,Z-&'VCO6T:OM MP3%]S3[MV7XGOL\W>]T8U:1UT3+XK:I[LF\@[\2]P\?F7"&AFDZ.FLO.6&.G M 2;60F;<*C7?S\?Z=6F$;<>-):6P_SEC_V/K7,_(G^FJ-&9&Y6=^)OE,DS,G2Y M8??B$7_Q8C84L#VU?$F'$"<_>9[67+;&QOVUVN-U?+%Q://9'&< M\1^,!']C_=@&LKL8=/3B\_^/#'N2 732Z*NH!I2VD):UQ.,GEJ_D4!GO <.4 M,!OY#\^O54*VZZ[IE8K&Y)/^88_O,IJ/L1+C\ZD2XW?-.D=0#?T,,K?V"A62 ME*M)Q,-7KEKQ4J]?XU*HS;@:VCWRPTL*/4LZMR ZH+VLL:%A' M5JJP@4@VN&LD@&NE&)J #F917V=;50&;/G&0@G4M"RTS\"OZ4E^5>W,WZCFC M*\X"E!/6#ZRF(D'/C,4_V.I#58"!?%CPE]:J7CG+[ZOCCF"0CQ#OFST^#=5G M'V1AY[2$GE1VYQ[8BI %-'2QFE[!*[LW.W]^/")*NI'.$^V!T.:' T???RL^ M^SV8E'M4K!Q5#N\5BP:N4;@,#B8=+D!B?*8P0]I84/-[.T>(^(H M=3.WZX@/JF(ZHF[&;UQ))K1UR(<2=VD62Y>NY4I:"3$[%Z!D2 ID!?=5\.!A M#@9^S2RG7S32,FG92&;ZIM=P3(IKZBLEPUZG_TSK##_=IF1[:A=(FN65P-)X M%M!FD)#<[[A^M5AT6Z,JO9;A<\.U3.I2RRXTV> [N:__,[1"(HE))X=N:=ZL M729M4XWT&D6A)NF#BAC,V2M#KU55O]L6Z<+9\@T:174II5%D;P:P]G,/>]#T MWTE/U]8$*65%5&;AI2\YS MKJN5B]/K__GB;[)'#LO:TM"^D[;-?C)5>D$E X$EWD@_/^R5\#)U;TKG,K0X MDR_TCAX"!F>G.ZLP%5*IWSM6,Y$I5I]$N^L/A?*6ASB.0G7P_5@4Y#'FRUSZ M6L-)ZW][<),B^PB. (:A%UHO:SWO[V*6"?YJ4YK*[3:A^O'#O.1C\FV0[)]'%^0;8:'DO^X M!)MQJS#PRQ#3VP5,"#IQ*/CZH#E^\= \.9@X/H]W)A!-N(G1]*U\XYFK-V\= M"9V7)%A+&DWRELEDN05]@W[T:P@,)[T8,*-'0K?]VK^N5HPH6IPS(:#&UZ.7 MLY*K.!;'$4AM1N([U1<)YI>U==>N:7W/XL?PZ;0&6K-*K$>.KF#FN,T]Y^() MKW6>O[T:2[9P:V,M*!#L ?J11\I;VEI_W.-SW'L9A[WX$V^O.)>[V:(]C+NM M1G+U---/T\]\=5%7+M,<^532"YE%+[>N#34Y^@F$>QTGJ&^XFZ 1X"XI76F4 MO#>TTFD,U&EV>/X9[:![%W4L)8M1U4=V@ADBQ2!L26GL[SS"IO0P!_:*58QQN] MQ5K+*DU#C1\J!BL*545I9##=L!K\J[4U!#G/+:12 * #RKMJ+E:,45DL./1:NI.6+( M__(U?PJ4"+O+X$[\MT2)AL\"$24T N]5M5J;94"YJ089/?J%[AP>,YS[S%J4 M@9G!Q,:")GS'5Q&::MDH%1.VBI:,$32JI7]J_PDD[K(\XP)_H;H?/(\?XZ)N M:NT0E;ESB(]$E=$T2^ZG**2NBU,DU3"KZ:._?#RAB#F%9U"7=#!]'RH\#VT MCL[)JF))2V->5>(ZV348+&1CPXY:FNBF^%HFF5O-IRPX^%SKEGG79::P(WHJ M0)B.7Z?2$;Z,3G]H$I0C@<)?&]K@BS:P'I[;@BO59&AL^9RA>R/SH? S=AU M<)=YQ7J>O-BP3R50+WTW*4:_RASY%QORFP8=N[ZB-38V>HMATXLA3#C@Q$GG MQG&R3I%[K/C#QSP6ZZHJ&E'['8T^=X:9(KY>-!BMM-4_(%HL-DJS:QA:2KKE M=3V'=^; 5@-;VY50K5RO N'#;_=SNFLM;'(6JG "="%6CD?[Z"*5G/)F M$^=F179+Q]93,%%02-DT:LT4Z4W>K($!AWTEW:7)%DX.0D)J]03LI5+-)%[! M0RL AR*R5EA 1VG2S ,1\>2T?<4@&' Y6>!5= 96?(8]T EJ]=',+OEL"V\4 M>1,%T/O'?^A-+_@(^N+W1LU;P5>2]> 2.6=C*M/:R+Q+L FBF'3H<&=)6, MQ@VI+;<#[_$56=%$56(TVA,;OPU:T@"C_F[0\Y;C8/$".:/7C4&GOL/94OPK M_H4:*Q%2K:#+DRO#:RD ?T,(>[F7QV^6OHFBS,=MC)J,5&_#)_# T-?DF8_Z M]:[7[$ ;L8G6'O9^Y)&)EI2H@8]?^"Z*6;)F:- #B=2=^9!91@A;"90)0LY MC&2^I"88=K.!@#[4(O=66_^BH=W ]2:/$FYUDPGQPVR,UF%$VMAK_6Q5GH08 M=90;C&HF2?(VK Z@^J15)OXD:8,SOQ9QV8VN"\,C8C#?=[![:>5H5)H>V:]S M*]UME)R/<^B"_ZFMM"=6-?+%;U8U,M6(_)\^7*Y838$T!?48OADOX* Q'3,I MIJ@J3.-6? [C@ZD2ANL*!7LN9V1P+HQ+/HVZ'>P-G_$KN*#L4U%[^R_[C.]- M@57P?0:E^!57K_[VXMD#*TV >GWT];<77Y,/15=JDR]FX<+;:B%E(=@HE28\ MN6!-DIQ^Y=C5TRF3./ -C,]T>][LI7YV9 0GGZ(JF1[V^ NIK?OL@:T0B5^# M",7$,4G,D(>,DS!8 NZTR'X&Y^-9Z$\,5H!!":EP,Z55O[WP"9^&O@FP\P^ MWWKV!.9[Y<3?G_]X[K'(GT'UOPXAW&CSX@#97YZ]?N,#9&*D]N!#++FGW[_MN3'FKXR%_>$:<+>PHI;J-#U2A38"1@"5B2(+[P!I M5!CN J\9\$CI?%C G8S\F?BJ>WY4\+YF/I?%&,9S=3!B:+[?RD^X_S'_I6?Z M>Q]$.>Z[>K*^NUK+LBYD0EI&F_?RK$#"BOWW^.3YO.0V43Y(;>(;VO_AC MP0E^?!%GAWQ$B0]CP*&<)1=?)'&[2?!?9\F7C_ G#:A+9*&7MYDE3_C+D<<1 M?QU?N+CXG)%;_$7P'H1<,EPP&::DC@J$W#B(8]UH*= OSY._*A'@7!D8>3=*5=R0BKY"ZXX<&3HYH"F !X$[AX?K/$SV]_/'SWY4E[5NL)MU[AU2MB6-\FG7WW^U6?)T\\? MG3U]3-:?:9E;-V_P7+(U:N5AN[V]/<]HH4"D!M]V,0<0V-M6W#BY54X2 MB77BJW0OG2 R1P47DH**%>TO\&66@!@3:%I T["*#L5&SI:'_/]E420Z1_>]&FD\Q\Q3Z30,;!/ M>U;[D.V74P>D7D#YNV[;[3=__C-.!TWRSZOJ1NUL-1\AO05))104 M<&\I-R_QCLYZ&^8A< +O16Y3"S8:XP )8(18XG:-++(6/2ZF8Y@[V0DMA\.R MR[FWQR%)>FJM2E_^TJ#3/C7U<_Z_N[FW'Y#Z3O+L/SYY\?;[E_]S)<_%A-D["N];D@]7_",]$-I) M^.O.S ="SUQQN-&6FN!5EG]2H8,DUIS<\HP&3:+ZDK0SC@16D'IM'" M:=]*/=PP?2[M=6%(<;UM@I-?P�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�V2F!D P2.CL1"D2# =<,) ,)1"208)DB% @ M&@0XX(*1;S.PK;L9R!9>)1)* ?8:F_,Z*;V]1A:J^Q=I+-M(O _F7,X:VW/\ M*A4#46.IRF4B40XX:ZS?#1,D)0\2NF$1"D2# @<.4Z(8.B D8Z2.LX:CK'A= M41@5Z4V# P-2J0&40$@&21UG#0T0!(0(!QI'1$,'A&2,,"#5558TCL*H2&\: M'&@+Z%8NB T(P1%$.# M$@P %[@I^>]8M[8B#98>Z! M9!>+ \E>&#[VAS^:& T[@B5'F+7J[<)&F)&!2IZ!L")0 4% 2'# BH N3@F$ M9)#0Q8E0(!H$.&!%@&0H@9 ,$B1#A +1(, !*X)<&W\=H8T_MNNJE3?RV0ZL MZP$QYS%P>V)L=HOGSHQEEW5C5_HX*3.7]R;Q1F$* @&('0]?EZ 0P4)3,!8!TS.[PHQ(I 2LZ9DJ14M!14++4S *=4J.#3I6!%1TS,E4" M.@HR1<=<(H!TS.[PHQ(I :O,GX-*A$K$<3J[%[*IBP)"?C07AM?@WCN""KT \F\8.Q M&;[UH[$E'"_K$1IG"V]_2?>!9KW6:-4+LQ] LC>Z5G]PADN5,HBH J#6[K": MN@&AUIM0ZUY>M49JD=IUG'_6]6)ZSOEG&$XN1L9K'CPOO*5"\HL_\L<#4_/> MF$%6#'NM1LU+@S.7%U!!>$"SMJQNTK3L%DYZ5Y9:[ MB'JFAOIR$8V"./5+C.>*J/ZW153FJ1B?3I(X\<!3 MMN4QO$X^G9LH,/'1<3C^;*(DL-#.(G-IHL@,LR]\L/_Q;2UV\O[=+*ND'V$893I;PA*@RH?!Z8W^EQ?'A&&7W?V7-W!*[$670])R9D4!+@ MTN_\PF_G_"ACJ@!S?O TQ0S%#.&W'2U$Z53HH'0T[&@<&N<^'06-RS?6&AF4 M!$C#[@X_RI@JP*1AIY@A_+:EA8]82:%T.Z>#TM&PHW%HG/MT%#2.AKU$ &G8 MW>%'&5,%F'-&5=0RU#)$W\;@/.9DA=#MG Y"5_I^_:'+%2*'R)4S\A1$+J\- M%CHH"9"&W1U^U#%5@#GODT4QL\WW]_OU(M_??VYLH?W3ZW"\]AO[S5JKW:[U M&CU>VW=C32I4 +RV+X@&<2_])@6'"C8MZX^/-NPW%E0]U=VK<&3O=#Q5Z:W* M>C84\6[@(2-W'%EX:#=HT.XJ:O>\Y1KBO4WQ;FY-O(\L_?1#^:,S/QB>C(_] MFR#Q1R\(^5)#C1OU5JW=:*+T;JQ2":5_S)L.L=\Y'<2^Y&(_[UN'V'.:H)R1 M)R%R*)P>&A2NY HW;WJ'PFW39Z??VEH_^XPUWOHV/?U&[?"0AM:1=9K;$0^9 M1^:1>3=E?MXM#YG?YJYU>RV57V^ON5'K=7BH[,C26M2 ?"YZF_-'G1KKE1C! M21Q/4L<\+[RT(9D>X+"7::/5\Q/ONZ5"_XGSI,WVXL.K[&O2GVB&9U$P,&1FRFCZ MN:/A?R9QDF**/X9//%',\$S7P.W:.P[CI"A+],?7P,RB=7$Q[!_>J4=G[W7S M8'%->!;.R/ZB.FLC&'O!;588I&AR66=NTK.ZQ/E8U'SZF[:(ED<5U*(#)CU- MX0_G-AEF1)$&AVJ%@RH%1,<)4-^^WH'FH#G"("2#J+ZLWV*U@L8!5D_/D0#5 MSE%11#@":M%=@2J"*D(8A&04396I6A$A"0+=<044S2NRXQ (R2!:VLJ@6D'C M "N:5V%4%!&.@*)YI8IP"H1D%$U-_ZH5$9(@T!U70-&\(CL.@9 ,(II75UG1 MO JCHHAP!-2"31Y%!$6$, C)()H:X%4K(C1!(#N.@%IPKD-WT!UA$))1M+0G M7;6"Q@%6-*_"J*@B' &U:!E'%5&('=SAHU-\II,;WDPB"^/,1$$XG$[UL!\] M^ZO-S7&X_>[)11P, S_Z>NZ/S.EE]B4/O_,L"C[;'W VLJC3G[+,&(B7O.:: MM7:G6^LVVX5-%J(N*WE>XA5B$0K(N!.@>)#-7H!#(#2#",W1H(#FN !JT=D, MT2EB_FMGR<[Q#W\T,44WCD?#YXS,-ME$+CVDMMFJ]7I]6DFYI2Z:IZ9N:%7* M.:H@4'8W0"W:F*'LM)/"("2CB'92A *BXP*H16VZCW,337_^RWTCC M^[.)DL"FV.HX MU$YM)$D1D6Y@VV:!%8@#?8\^Y88*->.ZP_8ADU[ZY5G762ST9LX:#IEFS$UEXN2[N*=9YT%2O( M;&N3=K@E3OFZ'L15KWXD.$R]M"K>.JVY7T>0E#Q(V*\3H4 T*'!(C[&C&"B& M!@C)&*EC=.4H*]Y8%T9%>M/@,!T%7O$:(,?[YKV-OV^^N0V_ES:*6[5&O[C' M;J20DJ>0.B9>&B ("!$.M-6TU3H@)&.$*>:NLJ*M%D9%>M/@0%M-#: $0C)( M,- 2 4% B'"@<40T=$!(Q@B-HZNL:!R%49'>-#AD[E:4 )0 &B D8P3S*A40 M!(0&A\R;"M5 -31 2 8)UE.NLJ)Q%$9%>M/@,'66H@:@!M (1DDO/XI0H%H M4.# XT840P>$9HR@&!H4B 8!#E,/HHI+QNKC.?NW+PNFK_ M-3#L=DK8Z>6+ M;_QMQ8FHF(&>K7JMW^GQ9J']-F M.]NS/BWAXL5J$ Z/,7A\V%P^(R*U.LH0&!_QT1$ 0$"(< MZ)SIG'5 2,8(G;.KK.B#9"B!D P2)$.$ M$@P $[G5R;?*T=;?*Q-5>M')'/ M36=S_D:5<=-)/4$&X?6US093[YC+*+RND"/*398(S1<3#8+8_EQ_//0^G/_N M169D?/L'N>P^MF>16$(RF)W!X5$.V'VLW_43)"4/$KI^$0I$@P('#H.B&#H@ M)&.DCMV'HZQXA5 8%>E-@P-36ZD!E$!(!DD=NP\-$ 2$" <:1T1#!X1DC#"T MU%56-(["J$AO&AQH'*D!E$!(!@EN%R(@" @1#C2.B(8.",D8H7%TE16-HS J MTIL&!]PN* &$0$C&"&X7*B (" T.N%V@&D(@)(,$MPM76=$X"J,BO6EPP.WB M^1D57RZB41!?^9&)YX94M.>&5&2C)=+7V\WPS22R-_K,1$$X/,^^+_O+T^RE M[_CM[*7OX=%X^.'\]P_3-[X+FCQ[G+U3G_VX9:;-GKQ_]]Q,B]>M1K]VV&P6 M-LN"7%+R7,)[H"(4B 8%#CR5I;G6 :$9(RB&+?U&=A5:#,T] 2+MS)BB2E!6 M'U!WN$SM_X<_FIBME?Y'P[5,)^['U[6[+0I^N36JFK[QE1 !04!(<,!7@J)? M"81DD%#TBU @&@0XX"N!9"B!D P2)$.$ M$@P %?B5S;=IWM;-NQV>;XRBK* M*6)SWATX193VRN><(O[V(_M-R;U51"YGB.VY?960!,8]<'B4 \X0Z_?M!$G) M@X2^780"T:# @1.!*(8.",D8J>,,X2@K7K<31D5ZT^# @$]J "40DD%2QQE" M P0!(<*!QA'1T $A&2,,^'25%8VC,"K2FP8'&D=J "40DD&",X0(" )"A .- M(Z*A T(R1F@<765%XRB,BO2FP0%G"$H (1"2,8(SA H( D*# \X0J(80",D@ MP1G"558TCL*H2&\:''"&R.<,T5W>&>*!8<._IZ]ZWX^;T/2$:+;JM4ZC7]C4 M"K)(R;,(;X"*4" :%#CP/):V6@>$9HR@&!H4B 8!#JW,CZ/BDK'ZK+_>TK/^ MMM"#'0T+,N?HM8MSXR-SE#QS8,ZA H* D." .0?=EQ((R2"A^Q*A0#0(<,"< M \E0 B$9)$B&" 6B08 #YARY-NSZF]ZP8YO-\355E"W'YHQ2JF/+,0CC)/:" M<1IN8S.-\;^#Y*HZUASO[)].?WF^WYC^(C)_!;']I[*[$=\^&,AEV;$]([42 M$L)!"0Z/9#0S8M0(!H4.'!@$\70 2$9(W4L.QQEQ7N0PJA( M;QHM/@0.-( M#: $0C)(L.P0 4% B'"@<40T=$!(Q@B-HZNL:!R%49'>-#A@V4$)( 1",D:P M[% !04!H<,"R ]40 B$9)%AVN,J*QE$8%>E-@P.6'=0 2B D@X07'$4H$ T* M''CW9C)42$ MVQ <'N6 A<7ZW3Y!4O(@H=L7H4 T*'#@A">*H0-",D;J6%@XRHKW H51D=XT M.#")](4-_R\7T2B(K_S(Q',[_LW;'?_92=FGC*G/LV^]WVH\O3R^WU(\-P/[ MI4F0_MM+G]<]'OEQ?'J9_;SLK&[ZS&&Z>_E+X\$_?G:[BY=]Y3)'=D_>OWOP M[""];7[R\U[PQ=[ER?4P3&9?N?>Z56OT^QAARRWDW.=X-RS)54HFHHF^FYY;!X1DC##$U556]-S"J$AO&ASHN:D!E$!(!@GN'R(@" @1#C2.B(8. M",D8H7%TE16-HS JTIL&!]P_* &$0$C&".X?*B (" T.N'^@&D(@)(,$]P]7 M6=$X"J,BO6EPP/W#7FF.0[ZMG1WR?6XH[W'V OYJIWI?.,S;J_7;'.C56[.B M^837:$4H$ T*''@R^YRX/C$RJ[VDMO[ACR9&5%JS65MW([8:"*C#[C],I:C/I\-BB;\Z2II@W*D>>/A]XO M^\WJN)X\L'JY=T"YMSFIQDTHPM]E>UY])>2 *1<<'N6 OTO.2;V=;1_B_34< M_Y68Z/J-N4@^?KTQWPSI/3H:#W]Y\$^_#Q,S.VRTPJC?H^U,^FW4['?B'"@7 M"+DG_6*D6VJ5J%P@J'+@3##6ZSH@)&.DCK6.HZQXZ?9)5/;CV;1B637W!+"U MLU&SU8*"Z(B $$YDU8H(21 $A @'.A5$0P>$9(PP5]955G0JPJA(;QH<,"3) M^6BQ6\I'B[\TBWNV^/JPV>;QH=QBUWM\B-^+"(C*Q8(J!_IR^G(=$)(Q0E_N M*BOZ5$ 0$!H<\'M!-81 2 8)?B^NLJ)Q%$9% M>M/@@-]+/K^7GKO/<[=H&-.H-5K]6J-?G&$,":GD"8F70T4H$ T*''BT2X>N M T(S1E ,#0I$@P ''%*0#"40DD&"0XH*" )"@@,.*:B&$@C)(*'1$*% - AP MP"$%R5 "(1DD2(8(!:)!@ ,.*4B&$HAB#$4V9_%2>D.1]+R,/QZ8U$[D6S.) MTE[TG(O&911>>[\&E\8['P1>;))DE!W2R66GL3VCMQ("*6(ZYP;M* \K-XL0 M[TD1$))N>W16(A2(!@4.G!-#,71 2,9('1,!1UGQ)IC/=V9!'+:;C>[OYV\>-F;-^I*-V1_^:&)VTI<=6>#IQ?BC,S\8GHR/ M_9L@\4?+]&C[K>=:-"\>^.F2:*5^5O5&@UY-;CV+YAK&S*N (" D.#!FGGY- M"81DD-"OB5 @&@0X,&8>R5 "(1DD2(8(!:)!@ -CYG-M\35VLL7'QERU,D2^ M&?N;W[B^=49N3_]=\W0\S^;R/_+>#=1,+4@^&ZI MI/G4X;5V[S:!IEGNU;]G/^9H^E/.)M'@RH_-6?K#;"+-3K"=C$\O+TV:6I]) MH^L=3KO][LE%' P#/_IZ;G/FZ67V)7&5^\Z-/)KG]0,N>;7O=K!_T MNX^FWFHLI^3*9JJ_KFP0[2=79O\ZNXMV-4UO8\T;FZ0Z-V/I()H+G(53GT?# M_TSB)%WL\T, M[/_=VJ8,T@O.916R/<>S$BYVO)O@\"B'9F;34O'.$X,S&1"20<)FI0@%HD&! M R?840P=$)(Q4L>YQ5%6O"PNC(KTIL&AE&I76=$X"J,BO6EPH'&D!E "(1DD^!J)@" @1#C0."(:.B D M8X3&T556-(["J$AO&ASP-:($$ (A&2/X&JF (" T..!KA&H(@9 ,$GR-7&5% MXRB,BO2FP0%?HUR^1LUFX;Y&NN^RO^1XU#]LU+K]9F'3>D@Z)4\ZO# J0H%H M4.# XUNZ:JOH>:C%N1EM=!39TC-7^[5&O4T; M)[?41=,0;D@J( @("0ZX(='**8&0#!):.1$*1(, !]R0D PE$))!@F2(4" : M!#C@AI1K]Z^]J=T_]NQ('ILS2MJ<=57IC9(^F,'(C^/@,ACX69((+[V__ MQ5,%1A +1H,"!QXTHA@X(S1A!,30H$ T"'/ )R34I M\/!V4F ZP._5MU/$3B]G0[-^O1TA]F9B/H:SL5KI5*W;H5KOP^1?9C3\Y>OI M;,[4O[(Q4ULQ%'EQNN#]",%FO5/8_$!22LE3"IX?*B (" D.>'[0EBF!D P2 MVC(1"D2# <\/Y ,)1"208)DB% @&@0XX/F1:R>OL[.=//;?'%]L1?EW;,Y1 MI?3^';^/(V/O\7_-T!N%<>S9D/<_^\'(OQB9??O=^[$-H>HX5UQG+D+IQ7NQ M&4RB( E,G,NS8GM&;26D@;42'![E@&?%^FT]05+R(*&M%Z% -"APX$@GBJ$# M0C)&ZGA6.,J*%P&%49'>-#@P>I0:0 F$9)#4\:S0 $% B'"@<40T=$!(Q@BC M1UUE1>,HC(KTIL&!QI$:0 F$9)#@62$"@H 0X4#CB&CH@)",$1I'5UG1. JC M(KUI<,"S@A) "(1DC.!9H0*"@-#@@&<%JB$$0C)(\*QPE16-HS JTIL&!SPK MJ &40$@&"2\XBE @&A0X\+@1Q= !H1DC*(8&!:)!@ .>%4B&$@C)(,&%004$ M 2'! 1<&>Z7?KSX@M7L[('5F*O3J-+DR46HX%)DK,XZ#S^9D/ BOS?TLQG3T MJ67P3S\8_QK&\>GX_&X8X5$4Q/:OWMC?CO\Z,U$0#M^;Y/3RH_^E*-.CP6!R M/1G9KTS_Y?L/=3+^;.(D_>[;S[6T#U*V%KDZ]EZ CT;;54YEM]<6Y7/X&)S MEB.E-[@X3\+!I_T+/S9#&VK7-S9X,V.:7*8.VW/B*A4#4<.GRF4B40Z8.JS? MUQ(D)0\2^EH1"D2# @?./*(8.B D8Z2.J8.CK'A33A@5Z4V# [,YJ0&40$@& M21U3!PT0!(0(!QI'1$,'A&2,,)O3558TCL*H2&\:'&@]'0W_,YF.N8X_AD?V9J?_D#\Z\X/AR?C8OPD2 M?W1^Y4*,PCG-9010$ M Q!K"^LFG6J>@W-[YZJ>S"1833TD"L%5[D)IQ_Z)*Z<]HDL83K4"1S+Q(5(. ML4H/=:)1:)3C=':O4?5EO2U0,A< /OT6(?S4^%&)E(#5= 8JI0BEB.-TU)0, MG5*A@TZ5@14=,S)5 CH*,K7D;%:4S 6 =,SN\*,2*0$K.F9*D5+045"RU%L$ MG5*C@TZ5@14=,S)5 CH*,D7'7"* =,SN\*,2*0&KS"Z%2H1*Q'$ZNQ>RJ:D* M,J5&!YDJ ZO,H 6=0J<>?83BY&!FO>?"\ M\)8*R2_^R!\/3,U[8P99,>RU&C4O#$A700.@2MG MX"D(7#VG%1$R* EPZ9=>X;=S?I0Q58 Y/WF98H9BAO#;CA:B="IT4#H:=C0. MC7.?CH+&Y9OKC Q* J1A=X\E%"ZG=-!Z6C8T3@T MSGTZ"AI'PUXB@#3L[O"CC*D"S#FG)FH9:AFB;V-P'K-R0NAV3@>A*WV__M#F M"9%#Y,H9>0HBE]<'"AV4!$C#[@X_ZI@JP)PWBJ*8R0_XF2% 7RZB41!?V0P6 MSTT!:GT[!>@\^YK321(G_C@%5M#&@W:-#N*FKWO.<8XKU-\3[$/*EIOHV>OU:K]-#Z=U8I1)*_Y@Y&V*_K- M/CKOQD)%YQ6IH/,E@JFG\_-V>>C\-G?M>VO)_%I[[9U&K=>NH\QN+*U%#9C9 MZ/V8^/;^V#\=!I]7N_RYJ_V?!U?7N$GF?N(3 3RPWVBBA_]JHWGS6$0__8/J M6[Z+W/:K66K/7B#K_N1-4[SW_1MS&0R" MY ?O>_NO),%X8H8_E.BN?1^,O>0JG,3V/L0USWP9&)O-LX/EV:VY,='L=_;& M^INZ\NQ"NXL1-\N<62*=J<_/>W6KNV8T2O7%*M7=[V?*E?U^+C6\\B=)^--, MNZQNC/R;V+RZ_<5/WDS?ZO;#9#*U8'^Z+85]U %U=>OQ94&\++(KI,IR=59K M^L 7=>L?)H0U"YY".=C/8B_<@NCL"71)W:5-Q;<5,@+N28>J02UTT]HL](0_>6 M'%,,!;U9PU0?@M5'G]V0QTY-IO/>T")90 I9D(-P+R6XYA83W.V0CW2B5X4R MU?UPJVKU"WXPM!_,F01 ;M[%E*T*Y0&U1'SX8EE9T0>D#^8352ICA\F5B2IU MQ8/P^B8R5V8JG:)G T]X<5X?E70452AD=J6F3SX=;4?7EDVR\P DYXD.F:A0 M*.AQX17.ZIICV$MY>'' MF#@WE(P*G@H>*2L\%?9R.."Q!R^8'ZGTW:WT27NB%7R%0D&/"V,"7-:C]L&Z M3_HE7/9R+U-=L/FGEOZ>%<%'QR MM);=-R\[!"V9.CQHL4ON:MF-3&DF/HZIER,YLD7N;@E/SI.5HVIQT$IIT_&% MI*SY.4K^33![Z]^) "*W,>NOZHGLY?%_%4QDHS"F*U4$(Y'%J-!<2&POCY"K M8&(;FLM@$-!5[CQ6R%D:'+1RUG1*'#EKCIOYWTF0?/6^G^6N'W8>2=5.7D\- M2[/7]LS-/W[WKO[N>.V;_^BDM&$XN1@9KWFP\52V)H09S]G-78O++_[('P], MS7MC!N;ZPD1>JU'SFO5F_8GPV H>T*RM]^N2>%);CH''Y!J$B@Y( :=C=X4<94P68-.P4,X3?MK2PMWA.'Z7; M.1V4CH8=C4/CW*>CH'$T["4"2,/N#C_*F"K ;.49>DTM0RWC&IW=2^'\S&R$ M3H4.0E?Z?CW/)'1$#I%SC<[N12[O@'1T4!(@#;L[_*ACJ@"SG6M>/L7,(N!_ M!%_2OW\7^8,D",?>9!PD'\SESWN___GE(AH%<39C?\\+AC_OO?O3?MKF87O/ M&_O7]LY,XOV_?/_FU70._^DDB1-_G +;\P;VI]D/D?U+Q^FW-3J'C7Z[_>?L M>\X3/S'7]GZ\S<;S'(?7-_9#CI/XZ$L0WWZ1_=/K<'R>A(-/OV532OY,)Y0T MFJW&GC0?SSWLG[=WM>>IU^\O->\,7>ELGU,$QF7[#WNEFO==OU6KO1 M^L>/\Q?[FA).M!'+:;C>[OYV_F5/UP0=53 MW;T*1_9.QU.5WJJL[[?L ASX*:J6%7&TVXV%AW:#!NVNHG:WYCQ-$.]MBG=G M:^)]9.FG'\H?G?G!\&1\/#5M>4'(GV[/'VA\H]>O]3H]E-Z-52JA])DE#&*O M1@>Q+[G8M^=\?Q#[_&R_7UWMN]M3^\%@V M)O ?3&(%W S?^M'8KH.E97RYAK[9J]6;?73>C86*SBM20>=+!%-/YP_G/./0 M^6WNVO?7DOFU]MH[C5JO74>9W5A:1=GH;IHU6ST\\/R53VBN?+K[I?WLW43"]!]\ME>Z>/$-P?'"ZFQIHW-LGR5SYWM8UOK_9H^)_)=/\T_A@^\4@U M^ZS3&W*[^([#.(DW>D/J]C^/WIG]PSOYZ.R][A\L[MYZ=C6.["^J$PS!V MN MT\(@19/+/'-S2;G4"7FWOMC+]D7T/*J@%CTP:6H*?]=YDV%&%&EPJ%8XJ%) M=)P ]>W[+6@.FB,,0C*(ZLL:3E8K:!Q@]?0@#5#M'!5%A".@%NTEJ"*H(H1! M2$;15)FJ%1&2(- =5T#1O"([#H&0#**EO1RJ%30.L*)Y%49%$>$(*)I7J@BG M0$A&T=3UL%H1(0D"W7$%%,TKLN,0",D@HGEUE17-JS JB@A'0"WX!%)$4$0( M@Y ,HJD#8+4B0A,$LN,(J 7K/G0'W1$&(1E%2YOR52MH'&!%\RJ,BBK"$5"+ MGGE4$47XX7469UG<3VYX,XDLC#,3!>%P.N+"?O3LKW8TQ^$EM[QVK==MUGJ] MXJ;S4EB5/+'P#K (!738"5 \B=[ ,+W.PHRE)U3X#W\T,3L6X7EO.Z16;_VI MY@ZD5H,"4NL"J$5+.K2V"*UM[E)KCX8O.- ]K[O+3:YOM6N'],""BU4TTTR- MZ*J4-51!H,UN@%ITD$.;>:@M#$(RBF@(12@@.BZ 6G0U0W00'6$0DE&$Z(A0 M0'1< +5HL87H%+$+V2IZ%[+(O<,F>X=R2ZPH&ZW-F2IBHU7:*Y]S#IK^NV;H M^9]-Y/]E"O/5NGLR,[Q./KWZ]^S''$U_RMDD&ESYL9GSUSH9GUY>FC1;+O%\ M9G(1!\/ C[Z>VVQW>IDEW.S93/KCCI*/5^8W/_IDDMM_3*[%]G=]&NA^EMS+S'JG,S\IFL+90#&S99VT0LS+NL M6;EXTF6M(/.Q3?H#EUC&=$V9JU[127"8>HM5O*%;1("EYD+"+*$*!:%#@ MD+X5@&*@&!H@)&.DCO&7HZQX@U\8%>E-@\-T-#HU #6 !@C)(*ECVZ4!@H 0 MX4#CB&CH@)",$>:6N\J*QE$8%>E-@P.-(S6 $@C)(,$R2P0$ 2'"@<81T= ! M(1DC-(ZNLJ)Q%$9%>M/@D/E940)0 FB D(P1[*I40! 0&APR-RI4 ]70 "$9 M))A-NE-@\/42ZKB-4 .JZBVF%74IN=+AA5$1"D2# @<>W]*%ZX#0C!$40X,"T2# 8>J&5'')6'W,Z*&NV=%&1Y$M M.^^TV:KU6AW:.+FE+IJ&L$I2 4% 2'"8.B%57)=IY61 2 8)K9P(!:)!@,/4 MQPC)0#(T0$@&"9(A0H%H$. P=2&JN&2LOOO7V=3N'WMV)(_-611MSC2JNA9% MEU%X72$3EILL0YHO)AH$L?VY_GCH?3C_W8O,R/CV#W+YC6S/D[*$9'"0@\.C M'/ ;67\[@" I>9"P'2!"@6A0X,#Q411#!X1DC-3Q&W&4%2]Q"J,BO6EP8&PL M-8 2",D@J>,WH@&"@!#A0..(:.B D(P1QL:ZRHK&41@5Z4V# XTC-8 2",D@ MP6]$! 0!(<*!QA'1T $A&2,TCJZRHG$41D5ZT^" WP@E@! (R1C!;T0%! &A MP0&_$51#"(1DD. WXBHK&D=A5*0W#0[XC>3S&^G>3J](ATH\;S:2_>5I]M)W M_';VTO?P:#S\3 F$9)#0@XE0(!H$..#_@60H@9 ,$B1# MA +1(, !_X]4]LKGC#O^]B/[3OW[01)R8.$OEV$ M&@P($#FBB&#@C)&*ECU.$H M*]Y^%$9%>M/@P+Q5:@ E$))!4L>H0P,$ 2'"@<81T= !(1DCS%MUE16-HS J MTIL&!QI':@ E$))!@E&'" @"0H0#C2.BH0-",D9H'%UE1>,HC(KTIL$!HPY* M "$0DC&"48<*" )"@P-&':B&$ C)(,&HPU56-(["J$AO&APPZLAEU-&M+V_4 M\< _X]_35[WOQTUH6G2T:HUZNW;8K!8<*" )"@@/F'?1F2B D@X3>3(0"T2# ?,.)$,)A&20(!DB%(@& 0Z8 M=^3:SFMN>CN/3;B*98-\IAZ;LUG!U*.T5SYGZO'V^F84?C7&RU*4=S:)!E=^ M;+RSD3_.Y>^Q/=>U$D+!;@D.CW+ WV/]UIX@*7F0T-J+4" :%#APMA/%T $A M&2-U_#T<9<5+D\*H2&\:'!C32@V@!$(R2.KX>VB ("!$.- X(AHZ("1CA#&M MKK*B<11&17K3X$#C2 V@!$(R2/#W$ %!0(APH'%$-'1 2,8(C:.KK&@[C*BL91&!7I38,#_A[Y M_#U:MY,H9K-=G[?XN'W;._NBVW>]TU>]8TV#C\->K=$X+&R !5FDY%F$-T!% M*! -"AQX'DM;K0-",T90# T*1(, !]P]ZG!_8[ M'3HON=4IFCGP[U !04!(<,"_@^Y+"81DD-!]B5 @&@0XX-^!9"B!D P2)$.$ M M$@P '_CEP;=H>;WK!CF\WQ-5640\?F/%-*[]#Q^S@R]A[_UPR]41C'GHUL M_[,?C/R+D=FWW[T?VQ"JCE.'_>"?3))>O!>;@4U226#B7!8=V_-6*R$-S)/@ M\"@'+#K6[]X)DI('"=V[" 6B08$#!S11#!T0DC%2QZ+#45:\]RB,BO2FP8%) MJ]0 2B D@Z2.18<&" )"A .-(Z*A T(R1IBTZBHK&D=A5*0W#0XTCM0 2B D M@P2+#A$0!(0(!QI'1$,'A&2,T#BZRHK&41@5Z4V# Q8=E !"("1C!(L.%1 $ MA 8'+#I0#2$0DD&"18>KK&@,%1A +1H,"!QXTH MA@X(S1A!,30H$ T"''"@0#*40$@&"68+*B (" D.F"W8*_U^]3FHG6_GH)XF M5R9*?84B/X='Q^-XSP* IB^U1H/!Y'HRLE^9_LOW'^ID_-G$2?K=MY]K:;NC;.7N/QS( M:K^LL(&L9)ZB5O,BO2FP8'YG-0 2B D@Z2.L8,&" )"A .-(Z*A T(R1IC/Z2HK&D=A5*0W M#0XTCM0 2B D@P1C!Q$0!(0(!QI'1$,'A&2,T#BZRHK&41@5Z4V# \8.E !" M("1C!&,'%1 $A 8'C!U0#2$0DD&"L8.KK&@,%1 MA +1H,"!QXTHA@X(S1A!,30H$ T"'#!VL%>Z^JRWWK>SWHZ&_YE,1UW''\,C M>[/3?\@?G?G!\&1\[-\$B3\ZO_(CD\V4.GXP4NJ#^=])$-O[?VZBS\' 3&>] M?3"#\*]Q]J_\X8\FIJA)W8]_LF7'SOY^;)M6K- M;J>PD7*DH)*G(&PS5$ 0$!(44&GOP'013O_;&TZ,EX3>611\]A/CG9\='7O_GMZ. MN#IW81PFWI49#;V+KUYH13&PZ=Z["D=#$^7R!]F>KUD)F>!4!(='.> /LOZ6 M"$%2\B!A2T2$ M&@P('CLRB&#@C)&*GC#^(H*UZZ%$9%>M/@P)A7:@ E$))! M4L,HC(KTIL$!?Q!* "$0DC&"/X@*" )"@P/^(*B& M$ C)(,$?Q%56-(["J$AO&ASP!Z$&4 (A&22\X"A"@6A0X,#C1A1#!X1FC* 8 M&A2(!@$.^(/DF1+8J]]."1Q>)Y]>?3M%[/1R-C3KU]L18F\FYF,X&ZN53M6Z M':KU/DS^94;#7[Z>SN9,_2L;,Z7A!G(_0K#=:AN:HG,PE64Y>'0G"5N_+9L3GFRFF/Z!*&4ZW D4Q\B)1#K-)C MEV@4&N4XG=UK5'U9]PF4S 6 3[_G!S\U?E0B)6 UG5)**4(IXC@=-25#IU3H MH%-E8$7'C$R5@(Z"3"TY/14EQ>IY8V6D'*7 !(Q^P./TJ1$K":.KE0BE"*.$YG]TK& M2\R":!"I,K#B 3,:50(Z:!1HT*ARLIJZU2!2B)3C= 1$*G-I0:?4Z*!3)6 U M=7Q!I] IQ^D(Z!0BI8<&D2H!JZG'#"+U(K_O5W<5:-ZZ"LR<.%^]-\G)>!!> MFU_#."[(WO.#2?Q@;(9O_6AL"<=+^WIF"V]_STNOW$]^W@N^V!LUN1Z&R>P+ M'WH/='NU5NNP,/L!)'NC:_4'9[A4*8.(*@!J[0ZKJ;T/:KT)M6[E56ND%JE= MQ_EG72^FYYQ_AN'D8F2\YL'SPELJ)+_X(W\\,#7OC1EDQ;#7:M2\-#AS>0$5 MA YBZ@=6^^NG#@)/V$XU0H< MRQX>'=!$X!*Z<@:<@EHV-$X-,Y].@H:EV^N,S(H"9"&W1U^E#%5@$G#3C%# M^&U+"Q_Q4D+I=DX'I:-A1^/0./?I*&@<#7N) -*PN\./,J8*,.> M*(IB)C_@9X8 ?;F(1D%\93-8/#<%J/WM%*#S[&M.)TF<^.,46$%S^^R?7H?C M\R0JJ[5^'(WNEXJM);E?5L*N#=Q+\6VNW&PD.[08-V5U&[ MYSW'$.]MBG=G:^)]9.FG'\H?G?G!\&1\[-\$B3]Z0C*R7SE\;Y+?QY&Q'/YK MK.Y_-G&2?O<__6"<#O]_J9._G>]_+_>-9ANI=V.-YC;+H9]'XI%X-R5^WO8. MB=^JQ/>V)O'/F..M;]33K'=JK0XZ[\A"1><5J:#S)8*II_/SAGGH_#;W[?MK MR?Q:N^W-9K_6Z?>0YCQKJ[%S"9CYZ/V8^/;NV#\=!I^?BK2!O1P3O1QJFZ,YP\&MB[VQU_M>K1_D]@?F(1IS&59,-WY\BZ# ML3\>!/[(7O.LHHX/-GD?FENZW[E^3OJO-IHWC^7NYU?0-LEV.[/KN8IN+^C& M_\OL7T3&_[3O7]KK>>6/_O:_QGO>CZMEC<0SNXLDRECT_?GY_^>O+FZ./;-W^> M?[3_\]O;]Q_/_SP^.O_7G^]^/?WW^=[KXX>9XJ[CCKWPTCOVXROOW2C\.R[1 MC7G]?3#VDJMP$OOC8?S#[,)F\I.IT4S ?]ZKV]K%C$:I1-OD>O?[F?AGOY\+ MNE?^) E_FLF_E=Z1?Q.;5[>_^,F;E0AU>_69TB^8R+Y8I!3C]'O8.VB^X#&] M5*^Z;+"_7*>LD(2TNM."K)?G7@=:C4=1=_]A*#Y5-O8V&9>/@K"?Q%ZV)=&P MP;9[<_96_Z"U.*[QT7YS6U&S#+>EZM*\W/Z?\2/OK?U8PSDWYIV;F6^CO](@ M\&1WA<"H@T)K!+6FJ2 UC<;!X>K;FM66HG1#$=VI6#K+,ZL>*2(#EA*KS8!U M,F#%,N!2LT2J1( \YCK69KW1WWD>6[9HJ'*^>VJGP5[93@Z#3'<>MO8@?:DN MM<#=ZNR1S&7V2.8R"J^]\,9$?I(^^DV//WP.DL#$K^2.Z$PEJK10'#[@MLM# M*&":/0]*V[7JT,E/M5VLT!R-2[ MTN*\^JR+?OW;EV#/HO R2-*I4B^\_%JW_REH4D6W5VNU#@M[&Y88W_%$B@U* M&[NE"ABJ%0=HG2"4'%K7R*MU]5NMJZ^O=:U.K=WMHG5BRTE1ZVCC6/9(&]*V MA+0UM ZE(;PQ-Y$9!'ZZ=:ZW_5GXT\M_3Q/?6F,&EGHMI5&K]W2LM@EX M[8!GBU@" \&@0 'U6UW]N@6JW_-[QDNJ7[.)^JDM*]6 I]5C[5>5 F*WNMCU MBA.[I7>8V^T&>B:V^P]V 2Q%=I^*6;S#;L/ILH"2[2 ML0-A8AA:N_/XT+CK5<]2&A2H//[O_^DU&TU!- 2( @4V924P$ P*%% +U$($ M@V: T$JP]JM* 7'(,3VU_^TN9KJ3$J?#4TU\.GX[MYUR>OG&7"3%[&3V"WPR M1V S+;4,FYA/G9,=FBCX["?!9\-163=%CV3J^_WTQNY>MP^(L M>PEHSF&69@OSZ#J,DN"_V5"-Z=;E1>(-@WA@[W#B^>.A%\3QQ!\/C(W#..$P MYLZ#1..N5SU5:5"@]N!XC0@&S0!A&U," \&@0 &U0"U$,&@&"*T$:[^J%!"' MU;,_?' WN[C=.?D:#Q\,]M76>OE\B4GJ?1[+O7YD_-AX65[;#R_W_S][[]Z"/N9,^D MRG&2F;R5'?L7)V?J_+5+2(W11$B,+G8\G_Y=:W7K!@(#!M.@5:?.GAB0U.IU M>=:]$_C#BB*Q>]"3$Z[GE>JKN[;2@PILJ6QOJ;07+97K5.M]0:5'Q+B>_(C$ M)2J\HHK\^&LN_&A]&G8_DT_;H_V-8V<=<-XZ@..Z6I"!A4$'*C @KRL5&!P8'#0A Y=['IT(MW%@_VR.P>5WP*&?H6M/7KY^F0'&;,[' MU)4*C-G;1S@[BQ'.VZD5BO>HZ:X*BN[P<]U]X-X>SF[J-D9]/DY9-W[25=+9NV/>KRL5&.6V1[G>'E!N/W6U M@+B,AV+F)K,W>/83O-]/$5MX MT%,D["1T8W?WTYXX>WQ>>7VH*P;Z-)W;J1: MC#[[]T*>1/G$:%P/%J+-QU6':ZI)M*3QG.E;TI3 M$B+SY4*TYO[&U[/*XU=CT:._!6OV0!&RFL<#+VTY4<@(A2W<>YP\VC!\L7/C M.B5I <5&+)W2%":BTU[GWT[Q-3C!R'_][.?:K]OF?([^&%8[4:G M/^"TI&;LI>.$-8YGZD"&>LF!KE1@ -P! -O[!\!-AX@.6RW&.,TX2$>,8Y^. MV;ZF5&!(VP'2EHXT?C:D/5%J6J@G94C3CH/.NYI4_^@Q#I_WXR!\U"^7PJ8% M9[#J2@4V+78P+99.C5XV+5)UYXKG'465V12=09_GMVG&.CN[R5S:>N9JM5YR MH"L5&-QV +>EPZ*? 6Z;QH#WV'W),GV^V,9^&K-]3:G 4+8]DBT=);P[DCT5 M^MUJ$C>?1J$;;W%]L09$N G%W'(=0_R:"S\2I%2]]YQI5HCP^Y. ER&9C MP+EL[1A.Q_(LCCOK0(9ZR8&N5&!(W $2ETZ// 0D;AJ0[@ZY\48WGM(1]=CO M8[:O*148Y'8 N:73(0\ R=IZ:25=J< &RO8&2KOUM(&2:<$O^/<7I0,?GU7FO-U)UHUNEP^SUHW9 M="P8XZ"T#F2HEQSH2@6&0S[86A,RZ"D@["LQ[]>5"@P.# Z:D($K<8].A&S2 M[]QZQ*DH5(EKV7:8" >\_!EF)"QTNO5+"#"(6I"!A4$'*C H;@^*[<.# MXL;3@=M_7E0H,<]O#7.?@,+>?4MQ.AS%0-V[;5YSZN7F# M4E#:& >A(\)T@Z/ ER/#9"['8."H:1]VGC2-4LU]R+0OV M4=JT]$VJV#U-/N[I,_EX(_50U-RL(EX:5[L[X^HY*P!=U3<#[:E0BH'V,$#; M.SC0KH^U;QB$Z'?W%X1@%#Y;_<'>K3:D8- ]?4HQZ!X&=/N'!MV-SPKLCDS& MU5-@,ETJTU\ZXM_K7@RT)LQ7$1NV%4V-)!*.X?I&D(WI0'FZ)_$]5KZ,[:$3 M2)[GI,$]K<17-IA.@Y0E@^FPU#QGBVJ'R2%+(ZU!+U^!6KX)@WO7$<[[QQ^@ MGPOC0RXSY?QRHT/Z[8;9VE\Z84_HP :75O,^.9-PBIJ?0?QL2,D@?BP07QK" MO2\0?Z+>?RL0;P\;_6&70?P4>/#H(+Z[XWW.JD%7S<\@?C:D9! _%H@O#1G? M$XCO]1!,<] 8[#'UP2#.<\?/P8R7@UDEOZ4JFS4RC6IL]NI*N[EV.>E"!)]QH00:&FY,@$\/-R9*.X48' M*K SP^C"9&)T.3?2U1U=SFZTN-G1O%;[)@GMJ17!,X*) 2O_*6(:,!X).PF/ M6JC-Z*_7KM==-^E!!1XKMWW^M;-TAN*-]3B#%XN^!Y?VOQ,W%']DFN\V4WR' M'R(^;+1&;6TRKBSZ1ZZ0XO"JYLJW7G*@*Q48 G> 0/, $+B',29=LS'0J/V' M15]?"&2GC]F^IE1@Q'OF89 L('I%;#4N/M4^8GL+MM/^H[64RV?=743!K803O0I#&:H^:XG1PG5FHU^JZ7-6# 6>[W%GL.U6I"!A4$' M*C &/M-Y90$Y;P%A!XEYOZY48'!@<-"$#%R+>FP:_&'%RI_G8E1-2*)K1JSN MRDD/*C!Z;Q_>["P5XBQ$."]]1RG"QR,%.SO]QF"/T4[6 N>M!3C:J0496!AT MH )#XO:0V#TP).ZA3K7=:#,B:L=JNBH!]@F9]^M*!09 KE75A QZU*J^]/%P MVH=Y2R,'YB$>#A<_&I;O&.+?B3O'KB0^+%<#.NF:,^3#*+UZX\'#P'_^F*K6@T>/VXU!6Y]261XC?X@VSWWA+!_H=DKJG('W5"C% MP'L@X.T?"GCW$*,V&\/._@YA8^ ]9^!E!U=C[RJ48IP]$,XNG5V^)YQ] MZL2TW(LUV8<]">;:PU%H^SFJ[N4B_+VNYA'^KR(V;#PF+8F$8[A^Y1EIIWL. M[1E)CZY99#YV]FQ(RI3'\\@KC.([^YX MG[-JT%7S,XB?#2D9Q(\$XMVE XCV!.)/I3-2$#],7H-A6N^\AL93MO7>>Q1- M8^(%#Y$Q"8.9,7%]R[?+Z8NW^F6CN>WPN-4:*R&U3GI+5S+QJ<@G2[JZ]RWJ M004>\Z(%&1AN3H),##6:=N![PN9TWAPXZDQ#]U[*Q;&W ->Q=X* MN&@B0MC(AN&+G:>T\."U\\HKUEVEZ4$%'KS&@] L(!3"W(P,*@ Q48 M+;:OXC'7S:G^K.SJZ\D56=6W:%2O*=Y1][A-QI'KN%;X*$^WIBL-=J^8]^M*!09,=J\T(8,>ZX-UIGG!0]-^'0O$55.PW*2B*G D']\'[G]HCZR,XM_WI!&_40* M]=J_5NHT=Y/W,-+:['0;O>'^AE2PXCAOQ<&19BW(P,*@ Q4819_I.+. G+> ML(O%O%]7*C X,#AH0@8N5#TV#59'56_!IX='OV^:QE7@WXLP=L>>,&Y" =Y^ M*!R#0@)%0H19D8&'0@0J,%MLGW#J; M)MPRLSFSFC=-O\563*6G5YX518OI-VF:OS=7/F"O!:N=5F/4'W+!JF9LJZM" M8=>+>;^N5& P9==+$S)PP>JQ:;!!:+5]L- JIT[/*VE7=_6E!Q48WSEUJ@D9 M]!00#JUJ0086!AVHP&BQ?6BUJT=HM?TRH=5>HS4PN<5!,Z[559^PY\6\7UT8"+,);JI#%3V%L1/H0N'N5F3(2(],M!,(!SYJ>N M5& Y]2H)F304T X=*H%&5@8=* "H\4.)Q[WTM@I!C+?*B/Y4Q!^4";RCX*% M_$D\<3672ZJ[.]* "X_WVCNO@Q4]PNHR_3\4?I$P/FP:;A9CU2\8P@',*K*Y48 #G'+$F9-!30#@^J@496!ATH *C!:.%)F30 M4T#8E6#>KRL5&!RV3YZ-]ID\:[?,DWP:E .< MXI<(;3=:KJ%]L$*X7MT5E1Y48/-D:_.DUUIGGOQ3JKF/2@T^ MT=:YA\K60:O1WN.A'2SPYRWP'+G5@@PL##I0@=%O>_0S]X=^FPXU&';WYWFS M2)^W2+,SQ[Q?5RHPG&T/9^V]P=D38>;"*8L,9IJQ#=?)'I\&J\/(,GXE"!+8[M+8[..HN#LMG74M6E9H?SG!AR(5 \VM_9)RS7 MYRW7'"76@@PL##I0@4%N>Y#K[AGD-@T5=P<,\"B$BB'/ MD]">6I$PYI[EZY=T88.$4UUUI0(;)-L;),OGRRP:)#>@YYY5@ERP0OH\/E@H(NSW,^W6E H,#@X,F9. 2V&/38"F@ M>2_"V!U[ GX2PY/GUJ,%?^D7^V<$YXQ+7:G ",[3_S0A@YX"PL% + L*N!/-^7:G X+!]#<3:HXJO\A#*!S&.#SXEMMWHMUIG(\TJ$U5TEZ4$%MD X':D)&?04$ YF:D$& M%@8=J,!HP6BA"1GT%!!V)9CWZTH%!H?7VT'"3'T*,UUU AW&,F]%Z,*C+XU"JL&X"<5$A*%P M#&K"U"_^SW8)9UWJ2@6V2[@"1Q,RZ"D@'.+4@@PL##I0@=&"T4(3,N@I(.Q* M,._7E0H,#MM'.$?K(IR?563E>E((IV31% JF'+R&L]MH<0VG=HS&-9S'I\%- MZ/JV.[<\(\PR$1@#G;@^A4,]@:,U@S'0P7K664V5&!K9?N$ M;+^U:*X4D[#84W+I.U?6W(TM[PNJO^M<^^UG[*8Y,#D;JQD?O=&/ !RTU8(, M]9(#7:G 2+<#TIF'0KI-CV[:WR$7+-_GBW/LP#';UY0*#&O<;J$)&?28%5J* MO!KC('1$F&YP%'BN8\@?&O1:!O>N(QQC_*@J@&'K#)2I>S=VQ=&*?]E0.H%4 M9DX:W--*X&5+ZC1(6;*D#DM--K6*IE9GL6 +5/,5:.8;I9C?/_Z(A//9_Y0J MY\M,-S^G-'FS0?B=5J,]&&A3T<6VEK::A0/O^M*& ;P&I&0 /Q* =P\%X.LK MKC<"\,&P,1P-&;]/@?/TP._=_>USU@JZ*GW&[[,A)>/WD?"[=R#\WLM)=,-& MO[V_7 ?C]PGD.C2>\'P2:0W7MT,:8>+ZE.)HR$2'^'?B @%HVHGE.T8HHCAT M[5@X]+U^N6WND3MN[<=*#*ZW4M.#3)M92VP);64)]17(%$__K*GEG\GOEFQ^#B9"'O]N;[[ M2&>8O5ZCW]M?@SI/A3MO)B47 M3JV10F^J7&V<7F@88P$OY6-S13 QYB3WIUOK<48TU+4>@)M03X52W(1Z&%-K MZ8R99YE:F5'UP8WF061Y?P?VF,,5\#?:5*Z?".<:%/-&PW!WK^CH-MI=KL@\ M"9;5HR*3.RKTHPW#]NE3BF'[(+ ]6#IK11O8?DY8I-?H[#%1P;!]M@J'G6MM M2,$H??J48I0^#$HOG1.C#TH/GW'HZZ#789 ^!8[5I5MB74+#"9*Q)XSV16WP M>IN$AH /GYW*.. \S?I13]="A.W[&DNTJZ,Y]M_Z47&G!M7=",FF6M%4:VMK MJCVG%V,P:HQ:^QLM=:@QGBM1I$[:2(^9V16)D TQ_ISU"8/^V9"20?]M?BEZ'E1U_-&? MM;>C="73DC'%AM*ID*[N':9Z4(&',&E!!H:;DR 3P\W)DH[A1@G5G\\VUJ)%]/KLA$OD4+^;/_);./;S/S^#FUD)O-5&NT M3)-+)37C,%V5+\<]M2!#O82!,5!#HK"SI D9SKY44ON8YTT2VE,K@F?@&69A M,!=A_$AED7CPV1S-.",4-DZV<# .:MDV;'T<&7/KT1I[0K^\ 8= .5NC+:IS M(E,GSW:X/&A\[L:6]_'77/B.&R>AP/'A21@*YWT2?PWB_Q/4Z*==RSH+]GFK M5X[?:D&&>@D#HYR&1-D>Y4:'0;E->]D'^XO0LF"?MWKE"*T69*B7,##*:4B4 MK5%NV#H(RIDCA7+5)S_E*-?O,LSIQD1<4WM\&GP3MF=%D3MQ;5D]&TR,!RN$ M:V/#?Z MEF=, \\1H7X9'(X^<]Y,6XN%<\HZ62QFJ:YJ45%>3Y0"_))JR0^)^!XH%8D: M,E608,K\ ]3C^\=KI1S_0;IQ/S'J;D>?,RM9_O76PARDUH(,]1(&!D,-B;(] M&+:/"88;CV5M]1D,-6,U7;4PQ[*U($.]A('!4$.B<+6Q)F3@:N-CTP"/OO)$ M%!GBEPAM-UH>M:!BPSN?>,5UQ9R+/ETJ<"Y:0Z)L[\QV2LYLJO0^*IU7ZIQ- M_=;G1&LWZI5M-\S>D%/4FO&6KFJ70[E:D*%>PL#HIR%1GNF]LFRF >U-,Y@TDT@85A2).#*"<6RYOARB('[94\N_ M$^BY&YZP, XZ]M3\K)U#GUS4RJG+TZ4"IRXU),KVH<_N8AL.;?_UY$:J+9E\H8+O_(QS#"Z+( $O0NK=<#\_^:L)]FA$870:\W$\1XV=&).PD M!/MN]^@MU[%R'O9TJLGI\B=!CU^NEESC[JB%1./NJ"1GT MU%!HE# P4&A)E^]#FJ!3:E!;Q!V40?U;V\!6:P_NI/NWM[Y H%N3S M5J<73-J\*AOU'K"GSJN/>KA,V&UQ'AT])6>ON_ M%-YV],)O>RN$8=EV,)M;_B.07\41XP#Y.PH\U[%BX:AQJZ[EP3O#!SB1-;K M/=IH'_"MS?:\2@NMW BS]<([,1BH]YF&Z0O-K3O1'(?"^MFT)O ^;RWOP7J, M7AF_'8+^ZEW&@>=LO0\[QYT_?OOC^\>K?S2,SU^O+HRM*-K?F*!'>#-2_U^O MOW^\_?/[]9]7UU]OK[]\_G#Y_>.'/S]]_GKY]>KSY9<_;[_#!W]\_/KJW=>4 MZZ^*7/\IX_K;C.L7M\AS?=&[(&DTXO&AW_I)^0D -'YFCOZP1"Q2C MDI*2\/$UF0&.V474ZRR.6;L.[RS?_0\='I>_)_P!*'@3B@@>1G]>3[(7S]\; M$=,+HB04\.M;X AWXMJPY9CJ^HEP+N/\A?YT;#_^6%\GPK@0M+'E BRC-MD!BM^Q(R/&T=&8?.-?/>-=/O7,46W MU2Z90E^M& AZ/5'G:@%/T%T>]T%"I @94H#J460ZZ7I((? C(/0$>'?7K7@ M0<+ST,* =\G^5C8)_9T:/G0%&CV>-8_$V_0?OQNI@=Q2?N+:]*7\<>>B6V7< MK.2>:I6W@EN(!=P8'FYOPS_;6,*P:#]=YM%6\=IZ\]??<"6K3%?<][WOZ,8+ M?%I6LPT!'""!0$G+1<+(7HLLP=5VX%;82*QW1'/GVCO.I95Q9@Y8HJ$R$< M5T,;(KVK2.JSV=RC;\>/](/+NU (>M0C63@C<<(G? MTE[ U>LVIK0OBI7,=&?@4WPA]8P&"++9XK0NC2ANYLYD ZH"Z>03-X'G!@ZO$;)?-JGZ] MI_19Z8TS.?9)K_B&F$R NB@$RAY?979UET8>W\9@70$S@BT3??QWXL:/W\0] M_%O0%[=SSXVWLKW>@:JG,7O 7JES4%K-NU#>'\ *'F!$^(34HH3]!!6FODF5 MCUJ/00LR:$6I%EIV%$\*^HK"C=K1F 6>L!// IWF6G=^@$)EV*F4P3YXP9Q4 M"!!^1D-,\"_.+!8:I%0>@2S[/YF%P+]5FIDU)2YJCX3#;WZLO MGR_3#36\_/)(@,:R80-J&T2?I'H")C/0!N2$^%V] M@4L/!.X"&,0+Z(5\QY6R7K@UZ 0?=KFL\J:@V-1[(W>#J@I 6XD85&4#]M$' M2MY;$=:FQ2 7OOOO1!Y1'ED@F*F4@NJ%M0EXMT?4GTI2HY\X+#*2VVE8SE30 M?>#%0*7 3GH*M#,U5OPJ2$*"M_#.3 ME"^ '+26("NM- _$]$\%!8@>A!Z#OX-2A[\KCA'KZOK__W\H6F.@"%@8V:N M769,EPPX0&V!/>K 0*#S8?N05N,4 AQ@1H6J<'> I+1<4EAH6Z8<#PP>2VP& M\V'J J?A6BW$&<6"!?/5'/P.P@X26Y14>$@H9F@Z31(RZU) M+QE<7(1LE 3 MX+H=*8@83K4F(L9%61A:(2;#<&SHT*+):+BBR%M$O/G!C?# *\2M. P\:9:A M9O>)?3/=\N$JMQBO;3N9JW49M_)Y>-T_A.7![2^=&>BP*)9+SVYQ??N/7#WA MSP,DJ'&7N/G28+&D!!?V)2A8I9?9JWJ/94#&32'>I.]I5_*%@$:8)+XRV6&? M@6W VL&H%!H8L.L!J#O@HI\7QGL!8N630O;!/@^!D!F?JBB2U$@;L:P!IGR MOU]B1%HP+".Q8:VXG_)4,AM9#G4,(8%+%O*$]#?2"P0>-B."?45]G6)(>A=U MM?)"%MD-!^;276R1WDO>6GV#RC(J\B[P3^(A?R$390^Y#SRP / EQZ[GR=&[ MJ*8%7F +V&H'1"9,M7;UWL!//4D6)5F+BP4"-;.=$K_F(%E5CHG\)GIBIV7V M@>)_^&_+(4L$"*^TQ<*+I*^(@3"O@C3+1)#RBOL%6K51V-G-*1**. DSYLS? MW4/8A'NB:2]0X@$M0"^!4$AF!OL;\#P4I YA$98#WPBG2E+6LZ(O[H@B>(_, M#O716_*\TO8M_;":@%,+H, 624SH9H,M#NY%&*D?*/Z&;V* #D^1%? %MQJ8 M)$J ":4]C*.?JYXP22BV0MH*5@:J'"1<^9[9PATQ)P22MP"^E%J)S@+,'D8X M1<_*S(K5>[5B-=N^KPP"E4WJU6'6I=C[>S"7HNO)0K3\D<.MZ\*MYI#CK17Q MUO$SXJV[;^EA JXD%RC$Q034609S';AN6AV*:O" M+F8-"0*B35XJOQU Y=P*E8FR8.?^N+B],.Z$#\8CHC-"\3R65E*:XP(G%&Z. MMDL>"J;+_GYY>9-')SY+E8].NXH1 4&MNS0$"KMD.?\"A4^K2RVH=.<#'QXN MJ88&4A*2:52XH.B!^ +M!8P@HH5F@3/NAOB2&2LW"B^OG@">XI(>D2QIDD@8 M)>G>%'&ZI<3>-W'O1O#X[\$-1AEOX->!4Y'5W1_^5&1L85$R8VM:C3G/4=T1S/&R/;<<>=\S.^.P K+H"P!PR@+VV=P2PYVWI80 LE32T MM$G6#"ELE<4C,C*[4&%V3B!W&5$7:Q)%V4G=J(FGPJ)H8QY:WF;/2*TC8F"5 MCF$N)&LRB_[_29<5M/X2I=+/_YW=-Y3W+=PTD.\73T.!;IT?3R-#9M=D)*)C-@JQ!8#$R21= M?CX#F]#YXR^9H<#7FKD1;4\IROGQ"C=E,LDCG%&4R.AL,@;^S@%7HCB^;GHM M/3?;4MR%0N$(/EWN&#E0"MQ4T!/?\)]6",1'XT0^$;SC6W#CD4PW23@/8-,* MIS4JNN![I1!]>W-YE>5G4WI6O)Q<7H[C:#*5OC*FP*D>+3)?9L>4MJ!1 M_ BH*GZAN1&IS-:]"Z)=RNK"/6=1&@Q+X__J%4'\<&GY2^ .A(*.V*3'9%_ M+W%G/-AHV F9]DW;TI'2RLDNO:@R/HUH*D1,>>(Y\HJ#-Q.4\DI#YHM&SN+? MYU)A.MRFPA1-/653278IEO9M40FWKI2NU6^;3J=K-\W>9 (W& Z;5J_?:[9% M>S*RS4&[WQ>OUJQD.PMOG8DHAJWQ:#*QFD-X)*S$@96(7J\Y'O3MMMFUA^/1 MZJ(^_7&Q& ,%>;UW@R3">*94&D4QFR> &U8DRDE9$&2EY5&2Y]2Q((RY!S:H MU.A*9T2EXA>X_/]+?&&T">[,05GGHN2GJCW/%DAGZ %S-T'HPI:2UBM+OI3> M-"&V%.>KJA4W+G$X19B%[RPL$9C)M 7&T^7+I:]1SA2H75K3]_%K''IN- 7/ M,GI53+LOG,V$+W$]4>]\'5)'1/29[@Z.DMKX*]IWRGJO<8=47"]3R^K>=-GE M+S?Z$Y^H4%*!9 $C,XA,]_\/,1N+,+MK5IB"QV8LWO6&]NI:;96Z>=V6UT!KT&O-Y2-TK.FT7>D4LP*EE(ED2MI_9*_MT7X8=G27BY;3?I MKNV3!7I]L]'N;4Q_1N SKZK:+*> W$* MN[MAT/%[!:"7>8!, ^4%8< 7XYZ92:"J E9DB%.S1_K1PBF'CDO^PG)WVY5*DO*_+JY1)A=E-KT*3QO&.*%4[:/QVGU#URE1H$BH<*D>@UQ;*YIBOAE= M2OK#HQPV95:LN""L&2UD,KH!-U9W]H,8"P:$F,DP:RG_3($MH*<_[4'R9 MJ?"R0NK4FTTU I9]483$#3'W#-ZB%:MX![#GS(VI1)MV%+@*H_KX%:P*EJ6\ M\2@9_XMRUG*G,!VA*@OP?3/E@$N3;KITP@O>:U[^?.)UB_]P02^&,@XA#:5J M%B,)#05F5Z2];E'T ^XLT^=*5LL>>84WORC!:Z0UK8E=?TTA)03+R,N$#,=U MB 6+V2],;<%*<7Y9''0F0,-+CO6("/QOL _B>+9WVZO'V?F;N5O[\*'(H8E4JJ+F^SJBSC M>S '@1^:/?!U&T:%;BY&KG$^8-JD'JG:+>>.S&4J!+-LRAP:9)#D>W_] !\1 MK5.T+:Q$/;MLM&'X*"J&E"0C8)T0D*$JHK(U.'"4^ M^UE]:9EI+-CCQ_^HVE9525?MGQ>3W8$4P.6@E97 0Q9MN,KT?YHE09L4OK(6RPGD,]L+3RS(04X_5R:(:4, M3LMX3::/? =EP.#-Y1ZG>C4MQ)/YK 67N$IZ16FS4U,,@0W+SJCZ$0,A>>&Z M?&RY>4A]MB+Q9/V4Q;%X+ZG-E%*G.'\&QZ@I)2JU>YM 4@'WKI0L4AXK#&%A M5T$8RAQ(I+"G47S 8),'?$:@<&<%:,ZR5%7W[+6:MZ-1T]QDZ:3A<>5_J(W. M,5+2?OF^[0WNF^;.TLSAQ[Q&4:8Y_P^XQ_@#.#KGU0=L)/I_V!+G3F@ 1_EK MT&-7">PE$(TNKAY)0"NG?-%B40UQ6!)/0!N%(IB4J!1+#G+=R73 M$ 4NI4B,A7E1M#?D77'3X ,O_1L+;K'4%_Y]8;Q/#2]9);H1J%44>4;E960& M2"8MN9A@-7Z8@H!U!U!_1U$C*2^+8DJKGUIH@R[4L,:AZH?(]8R$64")?TY= M3Q0W<95<4TRJ2JRE$&>*Y*GE+UBPQ>U6VU^D!RA[,,M*5*9*8WSXS/HI%ABH!8+)9D65+:]BIG7BUW87,OR$ .,?U?U0% CU0[5MP.:2:" M]%,TV?=1]153M^66G4JB4GO&Q%,%SV7FN5@[):&]W*YG@ZF68$B6]%M!O='L MC*S$ZC)_Q*&*JMI]F3%SVB-'=.Q><]3I=9O=[E TK8DPFR/+:EF3?D=,AIWS MR)CEMGW9&%]MC%(,6'F\I#V*WBWF_;$)"3[. U>I!RH#U=BIL+:6O8K_E04) MB\,N!S]"@S<.L).4?->)%SPHW9G_$H-U]ZEQ[-^G/2*%3Y'_%>,O?).&?>0S MT&N)55E^:MSY*BB3&0\XK ;,.3&+5A71K//Q<<^%!1H\LT&HSK'8?+R@]*Q( M=>Y&QFM2#[!EV(W\YJTRL56QTZ[%?9*%WP+ !;\_H]#OX+/5Y KZ\-=??E>O MFK!_IM.F/JZ9%K2T5SJV:P;325[#1'7:;C15OM74ES MWH2 E:!U^;=7[5M)R2H M?MHM,K[)*" K-QWILZ_S(0]V7J>,JYSI[I<&4K]7 ;G;K*5FLIA)-4?ZG:=* MP94SI8^F1U5+959G):4%&13>;W->R[G!NZ:480'1@@SFFD.]6!)8$NI#!K-U MT6XS5&A(&180+G 0N#)H3@ M$."K=QM-]2Y-\NZ4QK,KL_A+:A5_#7PU.FW-!*8HA ^S>6LTG9L^DC-(KR>% MV4X+DY_RIMQL0+M=O#Y?F=&O'BJP3-"$$ASR9]^M* M" YY[H*'W>?C(8/8B7++^==FM@<7G9[6-/A.DQ@+M9G:Y2LX,,M9HAH3@@.S MNY@5O<5IR%]R#;>U:WUK"Q_6%.0C"],Y?D^XT:L/KRL8)[W&H-W>FWG""N'L M%0('H8]. Q8&30C!0>A=T''IK(#GH.,)!)Y9#YR]'F /D7F_IH3@P/,N&#C8 M#0.?Y>KU&YV*\\JU8RB6[/.K$-9[_^F<<7EL9J3.]5&G'.T\*H +A<\JN\HZ M21-"<#Q:6]*PC&A"" [1'I\&+ R:$()#M-J2AF5$$T)P^))YOZZ$X/"EMJ1A M&3F_DE3M1P5+ MB<=G0:L#!H M0@@.B+YZ]WI[W!R] &[NMY:5^*Q90L[A@%%3/VY\HQT-."#,;%]70G! > >W MLM_:*SP^VS_LFMS3J"%?G7^AJ_[Q;=M.9HD'EJ<#PC5Q;3?6+O'#@6U.M]68 M$!S8WL5#[YN+)L@W$5NN+YR/5NC#1D<%U?=!:KZ7BVQGWOA&)LS(;)BFR4.C M]./+G7UUKO8]8XU=/SG0E! VVIFJY M?FRO*2$XN+T3/G;VBH][\Q%[O?U%N5GV#P-YYU; ?2HSA:.5,QVTRP-QN)NS M;S4F!(>[=TFX=Q=-DN(0FX^DZ'2KVVXWND,NV]:0^W15#!S9/CH-6!@T(01' MMG?RW)\!)@\=R>;9PUIR'Y=ILQJN(=MK2@B.9._B-2Z-WM\*#I_G_IF- M87]_*5J6<*[*/I^J;%W3A1R9YHQ9?0G!D6EM2<,RH@DA.$A[?!JP,&A"" [2 M:DL:EA%-",%!2^;]NA*"@Y;:DH9EY/QJ5:OWO[B/X\!SGD>077?_*O"CP',= M&L3PWO(LWQ;&[52(V+ B(Y@8'X1-F6.C8S:,=JO=TBY2?J#HH![TT33M]7)J MBLFPW\B@#3LKPGT@.5.&!41W,JP+"[(DL"34APP[Q 190%A ZD.&0P0$><.9 M[W4GPP[!0 8&%I 7(<.Y%0#J'8G]$OAW!@CVS/!<:^QZ;NR*Z*UV(7*N!N3$ M1(T)P=6 VI*&94030G UX/%IP,*@"2&X&E!;TK",:$((K@9DWJ\K(;@:4%O2 ML(R<7S6@]DW _[1"^%VM7H]UH\]$H_KM158;![Q;Q?4T)P/'07L!P^'RP9X>HAY>=6U7DJ9Q$5JCJU MRW1P2)?S2S4F!(=T=[$Y1HMCI+_D&NX0IPX]PSSI-]JC_9DGK!#.7B%P^/KH M-&!AT(00'+[> 1T'K7VBXZF'K%E)G+V28/>1>;^FA."0]2X :>X&D,]"M4%C MU&54TY!]SK_P6._]+YX 1L5]@]\-02>![3R!@.N/SRHORSI)$T)PL%I;TK", M:$((CM\>GP8L#)H0@N.WVI*&94030G#XDGF_KH3@\*6VI&$9.;]Z5>TG$%S" MFV-4ZL$;#MN9N;'G:!VXN)QUSAW8"^^^Q? M26UW% MS;W6N1;PDJ%20Q;453NP0\F\7U-"<"AX%V3L[A49G^\9]H<,=_KQU?F7N.H? MV;;M9)9X8'0Z(%P3UW9C[5(^'-+F1%N-"<$A[5?O7F]O@O0639!O(K9<7S@? MK="'C8X*JN^#U'PO%]..B*>:FYHP[7ZCT^=A4AHRYAOM:,!Q[>/3H'YRH"DA M.*Z]$W;V7P []QO8W@Y/&_W^_N+?K$7JA*9GM-N:ZNSZL;VFA.#0]T[@.=@K M>.[+@QPV6FW&/ TY[,TY5W:?RB3B:.6P!^W21!P-Y^1.[GN2_/[]P"3QXUS M\\1B'5ESYS@WH^<9*^WZR8&FA.# ]PX^YG!IO/]6X/D\9]%L#'F*\29L9!Y= MPE6(^[?8&GL"/G7<^S4O;[;+;T]_%]^V<]']2_']6B\=/YX*PYT!+6,#I"3& MOWQX)==)Z( ['_X&>S R@@E]>17 ;_U'%6..4!ZBP',=*L#.;$?Z>3 7H85\ M'*$0T-5S,AXC8QZ*"'X&ETS"8$9?69D):3Q8D6'A19X7/$3&:Q?7%221Y3O1 M&QI>C/LO9>5K,H-[VN_H;Q1.UT\L)3Q+GU0I/AO7$2Z1:)F%2RQZ5)(-1FH/ MIF'Z0G/K3C3'H;!^-JT)O,];RWNP'J-7QF^D"(O;D*N\SJCSIV/[\9^M?MMT M.EV[:?8FDV:W-1PVK5Z_UVR+]F1DFX-VOR^DZH.;".:7:L_;([&8M@40G3[8M(9FU;WU9J5=%M=>2,Q;(U'DXG5',(C824.K$3T M>LWQH&^WS:X]'(^&:V_4[LL;.>V1(SIVKSGJ]+K-;G)L"%_:! 3SBT\6W:U MO5 6F^=H^J=%1TI9IOFUL=_V0Q'SPNSN2I ];']Q2\=@ZZQ$WN$F6FZOA("5 MP&L#)4R0M^.G]COMB]YZ0J6;]@)2HP?9_D]8H?$1EN48'X1-H1^C8S8,,(5' M1Y:JES%3]2"#'FJL?4PU5K'O:J>O8!_&H7L4*-%0@_59A6VHPMJMHZNP3<6I MSJIN5N*3B075X M[[1&Z^C87&?,/;9[L9.*8!C64_L/+T;/)6W]M'^6+8E8$=9,$9J;2$N=*,#J M[-3)"L8LE1EJ8-9QR$5/K=?NODS3F$Y18RWT&3CG&R$.*S3VSO7QSEF-ZZG& MGZU*V(O7$R9&%ZT^HP1[\?KO^MDKPO.F%*N]4R>K1MY^G;6>9K-Z5"'%\;9_ MHPZE7;?_JM@G<5OJD[C.^B2TZ_>1,'6F)-&U>6\#.-%*;=612*.-"E:V:< \ M LC7D7"Z87XM:5 1S&=)8)QA(BT1:;!9,IF!1CO*,=!H0 -V7QA6F$@,*^=# M.885#6APF&(DWG.&E=,FTFBSK";#BG:48UC1@ 85W@I+ @,-$ZFBQV*CJ@L& M&NTHQT"C 0T8:'2@ @.-_D1BH#E5RM4<:'8K[CO,H#9<1T(8.N!]'RJ0@:4(%J]FI])H*FA&'QT((* MZZOR6!A8&.I#!5D@P6"A'V58/K2@ OL1S/LUI0)C@ZZ48?G0@@HO-JN+=YUY M7R\JR HXQ@;]*,/RH045UI<>L#"P,-2'"K*X@,%"/\JP?&A!!0XR,>_7E J, M#;I2IO;R<9RY<7LX;6\KJIB=BX'6A+F:6OZ=,%S?F%ANB%1(!(Z3>[!"N#XV M/-<:NYX;/QZK-%.+,_ATH9:^5;*;C":MD\+[;^V(5!HV]RPRG;>Y,&R;[:.) MF)8G#^A#FV-JO^H6W,/L]<]3M_AF%\&&4#IR^_.5& M\J-[-X*57$]N0C<(;P3\U_D8AD%X%82AH%7F#_I#S,8B_+/=,D6&I\HRTN\?Z?N'0_H#E8JGZ'^8TC<&^',&>';<]04!QO.S(27C^='P?+ / M/-^["]YK]QBA3X'CCH[07)RNKUIGA#X;4I9+V!FA=R7O]@ ]/&IH_8G*AH)/ MW6+ /@4&/*Y^X4)^?6G#,'[^I-SPE&F&\?T[VB/M N=/8?M6/OM^RQ?9!#AG MGYVCZOHB!(/]V9"2P?Y88#]J[2>JOF>$-H>,T"?!<7MH,#CD%'0G2,:>,-H7 MM6HP^"IBPPNB2,.6RD,01&\)T;^E 7/4Z ]'VC=QKH2+.JF=HX]&J*A [$LC;I^'["?9*\!X?LYXSGXYP_^ M6P-:#;.SOU)#1N1S1N3=/>PSH@(C\MF04C]$WJTM@!%Y#XB\-+[PX*'RO58C M='J-=I=#Y2?!G4<'\MU=ZW-6&HSL9T-*_9!]M^)!1O8](/OR,+UCA,HU[@Y@ ML&>P9Z^=L?TT2,G8SMB>8?OR^+R-X^C[=;_[C>Y@P(A\"FRFP7$#*U6):A X MV[U/B_Z-N0B-: K,9P03D-+9#,0]B@/[)Q+G3%]>&B'ROT$2@V?A(Q5=^E[WR0BN^%6Q+:N9WWKGTQU&>,,:N$ M9T9/#HB$[24D/&<%P-"H Q7T@T99/,C8N#LV+DTBW#-P2'I<&_.T.C]OX@/L+XK-PGR^F+?N 9[3AC&DZ4$$_ M3)/5Z8QINV):K[4TQ^X(X= U>>\R%+;TF6['.D%?*%QV[\Y9 3 VZD %_;!1 MUH Q-NZ.C4NSRC0)AVZ(EZV+%KN.NK'D:>#E&6TXPZ,.5&!XU) HSX3'I8%? MSPF';NP#FOJ<&\K"O;I\^;?8&GL"/G7<^W=$,22^ZR<6D:QB)_"]^_,J 2N^ M>.<"P"I_5;/UPN_Z?2J0C:F= JPYQ\B,NHCJAJUH:DR\X,' 0F(_B(TYB U\ M"[\<"]M*(F'$4P'?N1%\;;@SX)#8 -F+@]CR\NLC8Q(&,R,[4L! 7K]W8U=$ M# <(PDV^$ M'\N;XC,GEANBP"94=?U@A4"$V/!<:^QZ;OR(/\$+K,P(CF"CX-% MOU!+T$ M56_#IQN]4,,8)[%<&_Y<+L2:@5I $L%=MNWXZ+6RR4G.+/Z)[1Y7=-?//OX3 MUO,#EO/9OTX7-8_$V_0?OQM*<;=:RA1>VWZA.B,N*F//E6H>E9LYK-1N10TU#CRG MJ)]W#CJ?'CXO9".JY_O[R\ ;S[=^*"'0%:VXH-6+AU1]?"/W\*0V1[ MBOTZ5A0ELSD^7?W<(BVO(%MF7A3@D1D OQ>QO#2%75?=RG$C&\ U25NB$!/N M\+&KKI%/P5?%"^)%4ZGR[?$F!/'YDL"R$'ZB%B'D*4I1OG@G"5/[8D[ =6%< M^_!;L*+N OP&FY< Z O[)-#$H"V"JZ+%+?M7XMS18M"RLKW$H9N F8#VF^<" M6<@T:,#%082[Z%G*6("-L![3]39DNU@3'@_?HK$%"R<^@&^FL/9F+,(9+"O\ M*22 7##NTBSQ+)MN0%@W CW'K]O+!M$#8.\T&8P::(I^?I__FO8;K=^_W;] M@_YE_OZF2!Q)7#J#=W)<8)LP M-=F"XIY=&)F=D)L%:ZR$I8Y8-(K +<3_^0B,#;3!SH(T7ZY,Y/=G:VU< P;>)(_G9L>8#]TD@86_Y/2:;< M(H ?QVZ3&QF?\!5X JU!! M"$ \3]S!;PC#5RVQO#QE80'0HC6#!&R "6(+?/.I&V4+D;=:P@4 Q M_"7RQP0@EH(]G@ . ^HO+@RVW?; 5G$G+MJN&#CSP7#",1&&-+8"&29"^RI* M3<\$=CGT'I'+Z<8&V5+2()21CE462WNI1_36G@HG\<3UI-HV^8[JY#ML_7L/ M+,!GVBBGR4TH7!-@@^"!C',RIN9A< ]*"40X"]FYN6-$VGM1D9!:"!<8@(02 MW)I4]F6L5-$Y DIEW@/8V0]^&C7<)$X;&:_IUT$2P9.C-V^WGO:@$Q'R9*>T M=9]CU\K7?&LE^]K]HE&Z*EDVW$1$]TH(6 E:X'][!8ZQ!KG*T<5@N)Y0 MZ::]E- H<&-"04 MF]?Z$"+#I;8.N#3:?IIXO4'KO8!E4HHMF"R&E,_XM65!SM%1NVPEOI-^ M8"W/6OX$:0I>">MWUN^UT.]UVF!6RR=-4S:^.22F$V'T4>)/ZI$Z48"U_$G3 ME(UOUN]Z$$8__E+BE>>]+R MP0YM5W5*9SLFCAJQL;UOL>=O32OZ$'-L[#4Z@RY#HTX\I:.> M9FAD:&1H9&@\J-NX=%@C1U09&K77TPR-#(T,C0R-!_4:-SR 8RNO<;@S-'8; M@UZ'D5$GEM)133,R,C(R,C(R'M1I7#K"F..I#(T'J1K68)3A&5%EX828G23D M+-HN=2'(,\R90Y["ODF+3;VUV?')M.&XXUI;-G2*5OLXA-.R[U\?PAQ-H!A_ M]* #X\]IDXGQYQ">=6?1LRX?[_PU.\'Q4(6[G4:KW=N/+\T(>IXJ@1%4#SHP M@IXVF1A!V8,[8<(P_M2<#HP_ITTFQA_&GQ,F#.-/S>G ^'/:9&+\8?PY8<(P M_M2<#HP_ITTFQA_&GQ,FC!YC6=<56#I!,O:$T;[8(QJ9G8N!UH3Y'L261^65 MC:6)K33&-5PNPCS?W9!L*O\+;SX/0GQOUS?BJ< ,-LFRA9]%,?S/C'9I>:#U M&6\*\WJ:'.NZD,Z'A4W M:47:"Q7/V23=OI%W4-6NM-"K5*ZSNO2=\@>%7W[V;2]!^GYPHWD06=[?@7GF M< 7\C359KI\(YWHN0@N7%^DQ*N.%0&396%^)('721,<%%<9W;4C!^,[XSOB^ M[Z+IRE,!],#WYTQ0'C5&K0$#_"GP+ ,\DX(!G@&> ?X@#OQ06X!_L;$EC._U M!17&=VU(P?C.^,[XOF\'OO)\!BWPG0/TM=!$C.],"L9WQG?&]X/X[R-M\?VE M!G(SO-<74QC>M2$%PSO#.\/[OMWWRH,R](!W#L\?0Q.91P<5U0SS6VS![L"G MCGO_+J7EUV0F@/.J-@-?O3^O$N?2N_^E^*[X;7D)YG4?1*:RSA_])^V'_]I M;L$1YJI=4'0%>Z3YFA7[W+"6+D%$DO7$%KM=VDG4K45EN^@AX.?MOI]WJ]8;_=M$RGU>RV M.E;3L@=6<] ;3'#CJ0&:.OT[F!AWH;!B$1KQ%(@V:DE2.M9C9%@Q]13%L&C\ MX3P)[:D5P0>!,19PEXR0^0,NY.7%=< E=!MK['IN_-@PW(GA"UM$D17"7W S MSP6HPI8E W\/3W+CJ+K1J_*9>(N9$#%=)N\%SX%G""=*^Z)\V$/#;,O5S6#S MIM&%<6G;H/@!%3Q81Y38TQ7W!^UOV)X51>[$%8X![Z,FAL(_(X'=5?(A%MR/ MWAEN6>[$&EN>Y=MPTZG WXM[X>,VP$6X/_?4MQ4C'B:65R1/B39 =^-16*$Q M"8,9/9#VK$"9Y=VG9M/![]&*-R,>B6*\QX^+VPOC.SPO2L)'VFSK3OCV8^'G M#?C]#*32=F&5S!*/=CJ ?0EQG?-03 6\'6PN M7@KO!KL"!A(8)?B[PB,#(L2*'7(C>"D@P!=YC3$'187" M%!JX"Q%:0T;D@L0#L6#]@!G4A2?7D,J%P*?3SQ?EL_#^ZJV!P[-5& ]302]) M'"M_0$(%-VW0_C@)R:@="A"$9B@\]<9V'(0+BY!;B3ML6)X7/!"7XO+EQ>GS MX9%^Q;(V>-BWM90$T]!6A$LBE!HD1#0'TW%"N Z[AO^2BG\&KQTXJN$S91Z4 M<-@8("S\ \@ND KBUQQ(+\JOZ@3P4#^(#6!KL'0][Y$NA;O!\B/A>?1PU[^' M>\TRC0-[ "PP"V"QGOM3P$4DBW@?^(=4D.D3'ERX"7XS1AX%/01[LO+F8S$) M%"_?B_!1<2$PI04/BVG+[ #>"EC.!?J"[0G45DV6]P!P]/U#(RGIZ+"M_-$(+.)ZJ;E# #_@?/\#KP-\ P\81M@<_(M,QMQ*B MU"XMZO"UV(?8!-=\ %-W-@:X[I@- _Q)K??/U'IU%XMN8@GQ0%$Z[GVZ: EX M&&B1,1IIV,E S]]>M4## RAC* >LCNQO%22BO].PDPP-P1YXUCP2;]-__&ZH M\%&KI0)G8>5Z'RT&,'* ,'+1BJJF/1HJ[G3:C5O M2B)2.5UH_\RV\?J>5!;%\-_J(-]2[OLF#, 9C1]OP,N.+WT'0]]S5-$RTO<= MUO?>"^R?^P[YC=*07[H ,M>'*8 +^IZ#(QSS!4 QYL-88XQT!N&W9 AKH M?\HL2^7W\$;*(TR (J$Q<7URMFE5X S#+MX)%2900ORA\-ZX4VH-)5\9=A]I MU$23)?60T:&D;_-P1Q*)2>*!"WLO+1D*5]'VI*XE/5^&EE9)7L]<"J^OE+P? M], O[F3=&;51&'_#QU[^W>ZUP+N*'X(E*06+;O4. M+/7-['D'K%\[[\"["5"W4HMLNAL47HQ6A!<*6W1A?*F4)1D02KE6%#@QFN*8 MJC!EO5"@E!(3@TF>?BI%(9!79!P[$26&K8I?+>B(-/Z#U_WW]KG7)7@IRN%V M$%)(DO:R3&@?[.R+UE(:U ][,$_&CNLN=W:?, M:G&'=9L[K]L8.Y :5.I_C&S*")[D1>#!K>$@,E[#+MR[01)YR.,3$:I0(L 8AO3;K=_! M-D'S2UU 'YJ_O]F-Y=M+IX]O2 ;U\Y4Z\/WC]\>Y5&[.+/YY6=B8Z\F7;%NR MWU^J3?F!>_));@FIFFBU1MR-[CMLTM)!ML=2(M9*I:3%[% IZJW\(;[TV?4J)+M=KI4IT5\Q?JFW3:T>>-(.6*]3S M':D,^9I*OE'2R_)]6?!R2U8#L&2@;&A*"2\R(SQHAYU?X#U73ERR:G3:%_VC.1;L^@?%F7)B?MDZGUNN:%T]91.5FEX*HIQ&JI01V53 MEMQ#9;=B@OO"^"?6%2CU*R$A)IL8L),*.1Y^ MS+Y-4F"VW/]TDC -(E:9J+*2;&,[M1A"?;_JV(+%V&I1(E )4%D0%?$%6,_M MWI-FD4%*%=[%)<]#V(30E3'>>64T6/KUH'M 5=';4@%3II305HRI7LN>8O2- MA-9V0] F(-:^31\X6'[,M+GKY_6L]+V+[$43-C/2ZQ14@=X MB25G?T\OL5H_/?D2_K)(/_U!40A4X=TZSW2]V*]/P*],V)E+BO$+RKHR=?:7 MH^,2@-J4 $S/*-$MQ6!M;OAY,2!M"G@V,Q,6# ,[CF3V%E4& C59"#)K>A>* M-(M;BL&G]CCF8N7N4DUS5J?LCRU1\#2X05/K- M5KM1656X+']K%B2%J.HV:RXR7G\/Y@!5PV[[30.9S'*">2PK_/\_"W -")]! M8;'2.RLEC&3A?3%_CZZCE3(H5:6+N:Q<^%3F-'12BZ',)1=SH6L$UK?*VO65 M0ULN*@C&H R55ZJ,6/"1(UQCJ?-!_GIN/:KR@^M%X=ENI;C0;]<_,K\>):=\ M1\-S93<0-8-LL;+";4.17E$@3-;N0BW$F#!+D J^#.EZ9+[3]9D1))] 66BJ M[%A:7OX<;,')=I2:CJR?BTO,.T0JWVGAQUEZ/%_%A7&E.HWL/'^XO&=@M[FR MTT5U(L'K@%PWTS_=A95@I(9"&;$[PTU SRE=!5:QRI!WU4X6F*C&^NX2>T!D MIJ%JDY2<. &YA!CQKV@HB%I$+ 107@"8,' M)!4!5HF8KB_=!(ITW5NN1X8ME4_-X');JB%2O)1%D;HJ]?:?8$H9J%JS%%>V M\RD@]6!;=;UA#XOOGEX);[P0STN_#OW3#P";.-SQCD(VXO-E51 M?E4+PE]? M 4.FR[2[ 0YQD%?T!=3;IO8)\=2/J8XM!*<5O7#)LODV*H)@97[:7T8;7;@_ M!;)EX+BL71\+)J1$3K@-O"[VB062(P%CU0WEI11;) MB5_81AFI\%*@# 1E)7U;NHLRFLBTD($R1PJ>3WULF79(.1Z+$9TDBK'!5O6D M-JA6,!9W( ^R:3/O."VU!BI=1J*;UVD5=Y=T1D297%\UZ1>IC(&+IONK.74= M8,BW*J#2>_5.M=_*N$,66-566S-A<_Q<2]&O:,Z6MJH!L$48W M2K"L4I(KEX%)ZF6#BQEDR;AN^!?Y,0C2-I4-7M2\-['56EZ1J4*[" MDCXL9@WAV9@JA4=AL;4GLM_/YO AW02^GLLT'C7YSJV2P**@HDF^]H7'RN7>;'5.!1S*13_#6P_*[1Q6M '<2^\@!S(CU)TGST7 MA0.PM0G :M7UY&JUFC,*3:?J@I1906'L$JS>8-3 L2L6KX(HSBM99'FA[PL[ M4\R8]LXWQ"EL2!KA_/8__]49_OXABW(B^-SG4T^J*F8N#'51^FUI+LMK]XTA M9G,O>!0B:S%.?UAL.HHL\'EI2LM8^ +@$QW5$*QXCQ8;Q8']LRD]!00CN+Y4 M6/D__]4;_4Z_?.W"(\$ER()-?CI6)7]LV2YWP!*P54F-0K9\C02ELY;PZ;ZDMK3(4& M(Z!41OV4!/G7QD2H794&TIWEI8Y?6O&4K2+E*QG4)&ZBIKG"P][(@ 5]KA:\ M$!56 M-#N.!3?H.*/F>-0;-D6_-VF-^Z9C=KMKNF_-I9&/Z\HSH7_ M8EN2;!,JJ"SH? R8CO/$ T M=REZ&R7C?R%V%X/$&% "E,:4#:WYWM'\98TEX";EUJ+I<)(FI](>+\P2/'" MN*PN 2_G-9I@"+"@G4'7:K\C"'3Q\^7WT&4PT(?4F)KRWW:7U[0+NWHC_ Q4?*^*X[<[-D MIF.,91#PDW#(RE/4,SYGO[]2Y35D>V(%OR_ !G6R67OT*BI6G0J%&RW7G"7;D3(5'AK#XA=--TUSQ M9AN6;H_<]!5-&LLSK3! B\8U.'YP1]G1H,H\82'2B%N3V-+$L@PY M%IIJN[*)S%AB@K%>,%A]2Y:9Y@5Z<]>GIK6G1A533<4<*P<"ZG/$T*.R4:HX MK3S-N*J+,9\P3R-^["F\AB<<12R+[EZZ)H5Q:4MG; M) %&J=IAI?(JU=@J _>DY?LJ/1: DD-/*^^%PH=2D2=Q/C$.53Q1X8<:;9XJ MQ;%0G[O5Y30Y_F!C=1+BQ L:\__WR\N;'&:R"C52]2IW)(ONP._*ZM@*ZP%O M&8\CP,JST@L4*N'63TPOW8P4#=PH2B(5<$CFE)>RJ-0.?S)."U \@:4O>#V5 M-MP"Z[YDWSA^5ZY&V00K0>BSRS]US%JS*=,NR,!^.!.6Z:8M!N=H?C2=,2G5ZS90_'[>%HT+,' M0_9SV<\]RFH\K59S1GZNTC9&0=UL[.Z>>:%JWH.E]@@05I8&Q.DTEC7172S* M5IO[YVT,!NJL%.4U2\7;7ZGAXGJB+I"_WWG4R9,-^(5AL7D .'W+2#[\;5:J MF7U#]1!19#VFGY0-ZBR%(.MDU)Y5]%?>7AFR7;'?ZB],+5YF^YQ%:<>O@K3, ME>YU!:86P' 8I8V7>8/F%=X^+5^2*[71E@-_!TR>N2?2:E_XF>P%6NAO*!@) MZ=M0IPVL7!E_Q%&R40:*%3=VG 9,,/D6>R(-UT_E\&,*4F"!\M)JY$:DKYV^5[$@>A8X MPBOUK.#3)P%Z0VBKXG!>()>8 XN\-M](FT>=N8F*]T/+N^HR\O]3D0()8)TA!7\LJM^6:I07OIAVGVUX0ID65E/ MW3ICD&P?R6]X3177;V2[(I+GT< *M6A"GM**1UU4R0%I0'/I.)S\1,G:] _L MTG!?(;^D0EQRVU&-%=N'WP@ I M'NA*I-?E.,_RV]>TH3!EZ=3\R#@ZREGZQKU#_QUXZ8N(4,')G4L!\>;+95[+ M"SP$?S][5L'<2[:?5 #>V.(D:!06M

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�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

    •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end GRAPHIC 10 g4lv1dgrulou000001.jpg GRAPHIC begin 644 g4lv1dgrulou000001.jpg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�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dmtk-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Cover Page link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - The Company and a Summary of its Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Leases, Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Retirement Plan link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Leases, Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Balance Sheet Details - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Debt - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Leases, Commitments and Contingencie - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 12 dmtk-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 dmtk-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 dmtk-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Warrant liability non current. Warrant liability fair value disclosure. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Well Known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Current Fiscal Year End Date Current Fiscal Year End Date Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Public Float Entity Public Float Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Document Annual Report Document Annual Report Document Transition Report Document Transition Report Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Auditor Name Auditor Name Auditor Location Auditor Location Auditor Firm ID Auditor Firm Id Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term marketable securities Marketable Securities Current Accounts receivable Accounts Receivable Net Current Inventory Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use assets Operating Lease Right Of Use Asset Restricted cash Restricted Cash Noncurrent Other assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued compensation Employee Related Liabilities Current Accrued liabilities Accrued Liabilities Current Short-term deferred revenue Deferred Revenue Current Current portion of operating lease liabilities Operating Lease Liability Current Current portion of finance lease obligations Finance Lease Liability Current Total current liabilities Liabilities Current Warrant liability Warrants And Rights Outstanding Long-term deferred revenue Deferred Revenue Noncurrent Long-term finance lease obligations, less current portion Finance Lease Liability Noncurrent Operating lease liabilities, long-term Operating Lease Liability Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders Equity [Abstract] Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of December 31, 2021 and 2020; 29,772,922 and 20,740,413 shares issued and outstanding at December 31, 2021 and 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Assay. Assay Revenue Assay [Member] Contract activities. Contract Revenue Contractual Activities [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Total revenues Revenue From Contract With Customer Including Assessed Tax Cost of revenues Cost Of Revenue Gross profit/(loss) Gross Profit Operating expenses: Operating Expenses [Abstract] Sales and marketing Selling And Marketing Expense Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income/(expense): Nonoperating Income Expense [Abstract] Interest income, net Interest Income Expense Nonoperating Net Change in fair value of warrant liability Fair Value Adjustment Of Warrants Gain on debt extinguishment of convertible notes Gains Losses On Extinguishment Of Debt Change in fair value of derivative liability Derivative Loss On Derivative Total other expense Nonoperating Income Expense Net loss Net Income Loss Weighted average shares outstanding used in computing net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Net loss per share of common stock outstanding, basic and diluted Earnings Per Share Basic And Diluted Net loss Unrealized loss on available-for-sale marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Adjustments to additional paid in capital assumed in business combination. Adjustments to additional paid in capital increase in carrying amount of convertible preferred stock. Reclassification of stockholders’ equity to warrant liability, Adjustments to additional paid in capital issuance of series B1 convertible preferred stock. Adjustments to additional paid in capital issuance of series B2 convertible preferred stock. Stock issued during period value stock options exercised and RSU release. Stock issued during period shares stock options exercised and RSU release. Stock issued during period value common stock warrants exercised. Stock issued during period, shares, common stock warrants exercised. Adjustments to additional paid in capital issuance cost related to registration. Reclassification of warrant liability due to private SPAC warrants not held by original holder. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common stock Common Stock [Member] Additional paid-in capital Additional Paid In Capital [Member] Accumulated deficit Retained Earnings [Member] Accumulated other comprehensive loss Accumulated Net Unrealized Investment Gain Loss [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A convertible preferred stock. Series A convertible preferred stock Series A Convertible Preferred Stock [Member] Series B-1 convertible preferred stock. Series B-1 Convertible Preferred Stock Series B1 Convertible Preferred Stock [Member] Series C-2 convertible preferred stock. Series C-2 Convertible Preferred Stock Series C2 Convertible Preferred Stock [Member] Series B-2 convertible preferred stock. Series B-2 Convertible Preferred Stock Series B2 Convertible Preferred Stock [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Private Placement Private Placement [Member] At the market offering. At-The Market Offering At The Market Offering [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] LifeSci. LifeSci Capital LLC Life Sci [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Series A and B convertible note. Series A and B Convertible Preferred Stock Series A And B Convertible Note [Member] Convertible notes Convertible Debt [Member] Cumulative Effect, Period of Adoption Cumulative Effect Period Of Adoption [Axis] Cumulative Effect, Period of Adoption Cumulative Effect Period Of Adoption [Domain] Cumulative Effect Adjustment of Accounting Method Change Cumulative Effect Period Of Adoption Adjustment [Member] Convertible preferred stock, Balance Temporary Equity Carrying Amount Attributable To Parent Convertible preferred stock, Balance, Shares Temporary Equity Shares Outstanding Balance Balance, Shares Shares Outstanding Issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Issuance of common and preferred stock, net of issuance costs, Shares Stock Issued During Period Shares New Issues Issuance of Series B-1 convertible preferred stock Adjustments To Additional Paid In Capital Issuance Of Series B1 Convertible Preferred Stock Issuance of Series B-2 convertible preferred stock Adjustments To Additional Paid In Capital Issuance Of Series B2 Convertible Preferred Stock Issuance of common stock from option exercises and RSU releases Stock Issued During Period Value Stock Options Exercised And R S U Release Issuance of common stock from option exercises and RSU releases, Shares Stock Issued During Period Shares Stock Options Exercised And R S U Release Issuance of common stock from warrant exercises Stock Issued During Period Value Common Stock Warrants Exercised Issuance of common stock from warrant exercises, Shares Stock Issued During Period Shares Common Stock Warrants Exercised Issuance of common stock from Employee Stock Purchase Plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock from Employee Stock Purchase Plan, Shares Stock Issued During Period Shares Employee Stock Purchase Plans Issuance costs in connection with Form?S-1?registration statement Adjustments To Additional Paid In Capital Issuance Cost Related To Registration Issuance of common stock through conversion Stock Issued During Period Value Conversion Of Convertible Securities Issuance of common stock through conversion, Shares Stock Issued During Period Shares Conversion Of Convertible Securities Additional paid in capital assumed in Business Combination Adjustments To Additional Paid In Capital Assumed In Business Combination Issuance of Series A preferred stock at $3,250 per share Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Convertible Preferred Stock Reclassification of warrant liability due to Private SPAC Warrants not held by original holder Reclassification Of Warrant Liability Due To Private S P A C Warrants Not Held By Original Holder Reclassification of stockholders’ equity to warrant liability Reclassification Of Stockholders Equity To Warrant Liability Restricted stock unit release Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition Restricted stock unit release, Shares Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Unrealized loss on available-for-sale securities Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Balance Balance, Shares Weighted average purchase price per share in offering. Series A Convertible Preferred Stock Common Stock Issuance price per share Shares Issued Price Per Share Issuance costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance price per share Weighted Average Purchase Price Per Share In Offering Payment in connection with restricted stock unit release. Increase decrease in accounts payable and accrued compensation. Increase (decrease) in accrued liabilities and deferred revenue. Proceeds from sale of marketable securities. Payment for deferred underwriting fees. Proceeds received from close of business combination. Issuance of common stock in litigation settlement. Cashless exercise of common stock warrants. Change in unrealized gain loss on available-for-sale marketable securities. Unpaid deferred issuance costs. Debt discount and derivative liability at issuance of convertible notes payable. Statement Of Cash Flows [Abstract] Public follow on offering. Public Follow on Offering Public Follow On Offering [Member] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Change in fair value of warrant liability Gain on extinguishment of convertible notes Change in fair value of derivative liability Amortization of debt discount and issuance costs Amortization Of Financing Costs And Discounts Amortization of operating lease right-of-use assets Operating Lease Right Of Use Asset Amortization Expense Stock-based compensation Share Based Compensation Amortization (Accretion) of discount (premium) on marketable securities Accretion Amortization Of Discounts And Premiums Investments Loss on disposal of equipment Gain Loss On Disposition Of Assets1 Payment in connection with restricted stock unit release Payment In Connection With Restricted Stock Unit Release Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Operating lease liabilities, net Increase Decrease In Operating Lease Liability Accounts payable and accrued compensation Increase Decrease In Accounts Payable And Accrued Compensation Accrued liabilities and deferred revenue Increase Decrease In Accrued Liabilities And Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of marketable securities Payments To Acquire Marketable Securities Sales of marketable securities Proceeds From Sale Of Marketable Securities Maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Proceeds from issuance of Convertible Preferred Stock Proceeds From Issuance Of Convertible Preferred Stock Payments of deferred underwriting fees Payment For Deferred Underwriting Fees Payments of issuance costs in connection with Form S-1 registration statement Payments Of Stock Issuance Costs Proceeds from exercise of common stock warrants Proceeds From Warrant Exercises Proceeds from exercise of stock options Proceeds From Stock Options Exercised Proceeds from contributions to the employee stock purchase plan Proceeds From Stock Plans Proceeds from convertible notes payable Proceeds From Convertible Debt Payments of notes payable Proceeds From Repayments Of Notes Payable Principal repayments of finance lease obligations Repayments Of Debt And Capital Lease Obligations Proceeds received from close of Business Combination Proceeds Received From Close Of Business Combination Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash, end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest on finance lease obligations Interest Paid Net Supplemental disclosure of noncash investing and financing activities: Noncash Investing And Financing Items [Abstract] Issuance of common stock in litigation settlement Issuance Of Common Stock In Litigation Settlement Purchases of property and equipment recorded in accounts payable Capital Expenditures Incurred But Not Yet Paid Cashless exercise of common stock warrants Cashless Exercise Of Common Stock Warrants Right-of-use assets obtained in exchange for lease obligations Right Of Use Asset Obtained In Exchange For Operating Lease Liability Property and equipment acquired under finance leases Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Change in unrealized loss on available-for-sale marketable securities Change In Unrealized Gain Loss On Available For Sale Marketable Securities Unpaid deferred issuance costs Unpaid Deferred Issuance Costs Debt discount and derivative liability at issuance of convertible notes payable Debt Discount And Derivative Liability At Issuance Of Convertible Notes Payable Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] The Company and a Summary of its Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Stockholders Equity Note [Abstract] Convertible Preferred Stock and Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Leases, Commitments and Contingencies Commitments Disclosure [Text Block] Compensation And Retirement Disclosure [Abstract] Retirement Plan Pension And Other Postretirement Benefits Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Nature of operations. Nature of Operations Nature Of Operations Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Revision to prior period financial statements. Revision to Prior Period Financial Statements Revision To Prior Period Financial Statements Policy [Text Block] Use of Estimates Use Of Estimates Cash, Cash Equivalents and Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Marketable Securities Marketable Securities Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Leases Lessee Leases Policy [Text Block] Research and Development Research And Development Expense Policy Concentration of Credit Risk Concentration Risk Credit Risk Income Taxes Income Tax Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Accounts Receivable Receivables Policy [Text Block] Freight and Shipping Costs Cost Of Sales Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Segment Reporting Segment Reporting Policy Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Warrant liability. Warrant Liability Warrant Liability Policy [Text Block] Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Accounting Pronouncement Recently Adopted New Accounting Pronouncements Policy Policy [Text Block] Accounting pronouncements issued but not yet effective. Accounting Pronouncements Issued But Not Yet Effective Accounting Pronouncements Issued But Not Yet Effective Policy Policy [Text Block] Schedule of Revision to Prior Period Financial Statements Schedule Of Error Corrections And Prior Period Adjustments [Text Block] Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Cash And Cash Equivalents Table [Text Block] Schedule of Revenues Disaggregated by Revenue Source Disaggregation Of Revenue Table [Text Block] Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers Schedule Of Product Information Table [Text Block] Assumptions Used to Estimate Fair Value of Each Option for Employees on Date of Grant Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block] Summary of Assets Measured at Fair Value On Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of Changes in Fair Value of Level 3 Liabilities Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Schedule of Short-Term Marketable Securities Debt Securities Available For Sale Table [Text Block] Schedule of prepaid expenses and PP&E. Schedule of Prepaid Expenses and PP&E Schedule Of Prepaid Expenses And Property And Equipment Table [Text Block] Schedule of Accrued Compensation and Accrued Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Summary of Stock Options transactions Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Stock units Award Transactions Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Summary of Common Stock Reserved for Future Issuance Schedule Of Stock By Class [Text Block] Schedule of Reconciliation of Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Deferred Tax Assets and Liabilities from Federal and State income Taxes Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of long term finance lease obligations. Schedule of Long Term Finance Lease Obligations Schedule Of Long Term Finance Lease Obligations Table [Text Block] Components of Lease Expense Lease Cost Table [Text Block] Schedule of future minimum rental payments for operating and capital leases. Schedule of Future Minimum Lease Payments Under Operating and Finance Leases Schedule Of Future Minimum Rental Payments For Operating And Capital Leases Table [Text Block] The company and summary of its significant accounting policies. The company and summary of its significant accounting policies. The Company And Summary Of Its Significant Accounting Policies [Table] The Company And Summary Of Its Significant Accounting Policies [Table] Special purpose acquisition companies warrants. SPAC Warrants Special Purpose Acquisition Companies Warrants [Member] Public offering. Public Offering Public Offering [Member] Private placement offering. Private Placement Offering Private Placement Offering [Member] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Amortization of laboratory equipment acquired under finance leases. Amortization of Laboratory Equipment Acquired under Finance Leases Amortization Of Laboratory Equipment Acquired Under Finance Leases [Member] Assets held under finance leases. Assets Recorded under Finance Leases Assets Held Under Finance Leases [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Conversion of preferred stock. Conversion of Preferred Stock Conversion Of Preferred Stock [Member] Common Stock Warrants Warrant [Member] Stock Options Employee Stock Option [Member] Stock options and restricted stock units. Stock Options and Restricted Stock Units Stock Options And Restricted Stock Units [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Stock Units Restricted Stock Units R S U [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Restricted Cash. Restricted Cash Restricted Cash [Member] The Company and Summary of its Significant Accounting Policies [Line Items] The Company And Summary Of Its Significant Accounting Policies [Line Items] Conversion ratio of reverse stock split Stockholders Equity Note Stock Split Conversion Ratio1 Description of reverse stock split of common stock Stockholders Equity Reverse Stock Split Class of warrant or rights issued to purchase common stock. Number of warrants entitle holder to purchase one share. Warrants issued to purchase common stock Class Of Warrant Or Rights Issued To Purchase Common Stock Warrants expiration period Warrants And Rights Outstanding Term Number of warrants entitle holder to purchase one share Number Of Warrants Entitle Holder To Purchase One Share Number of shares issued for each warrant Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercise price of warrant Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Prior Period Adjustment [Abstract] Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table] Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table] Revision of Prior Period Restatement [Axis] Revision of Prior Period Restatement [Domain] As Previously Reported Scenario Previously Reported [Member] Adjustments Revision Of Prior Period Error Correction Adjustment [Member] Error Corrections And Prior Period Adjustments Restatement [Line Items] Error Corrections And Prior Period Adjustments Restatement [Line Items] Long term liabilities: Liabilities Noncurrent [Abstract] Warrant liability Warrant Liability Non Current Total other income/(expense) Net change in net cash used in operating activities. Net change in net cash used in operating activities Net Change In Net Cash Used In Operating Activities Cash and cash equivalents, beginning of period Restricted cash, beginning of period Cash and cash equivalents, end of period Restricted cash, end of period Useful life of the assets Property Plant And Equipment Useful Life Depreciation expense Gross assets Property Plant And Equipment Gross Accumulated amortization Depreciation And Amortization Disposal of plant or equipment Property Plant And Equipment Disposals Impairment losses Impairment Of Long Lived Assets To Be Disposed Of Right of use assets remaining lease term. Lease term extend period. Remaining lease term Right Of Use Assets Remaining Lease Term Extend lease term Lease Term Extend Period Sweep account Deposits Money Market Deposits Insured amount by FDIC Cash F D I C Insured Amount Cash held in excess of FDIC limit Cash Uninsured Amount Number of revenue streams. Number of revenue streams Number Of Revenue Streams Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Contract revenue smart stickers. Contract Revenue, Smart Stickers Contract Revenue Smart Stickers [Member] Contract revenue, RNA extractions. Contract Revenue, RNA Extractions Contract Revenue R N A Extractions [Member] Contract revenue project management fees. Contract Revenue, Project Management Fees Contract Revenue Project Management Fees [Member] Contract Revenue, Other Product And Service Other [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Total revenues Revenue From Contract With Customer Excluding Assessed Tax Schedule Of Product Information [Table] Schedule Of Product Information [Table] Assay Revenue Payor A. Assay Revenue Payor A Assay Revenue Payor A [Member] Assay Revenue Payor B. Assay Revenue Payor B Assay Revenue Payor B [Member] Contract Revenue Customer A. Contract Revenue Customer A Contract Revenue Customer A [Member] Contract revenue customer B. Contract Revenue Customer B Contract Revenue Customer B [Member] Contract revenue customer C. Contract Revenue Customer C Contract Revenue Customer C [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Total Revenue Sales Revenue Net [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Product Information [Line Items] Product Information [Line Items] Concentration risk, percentage Concentration Risk Percentage1 Remaining performance obligation, estimated revenue expected to be recognized Revenue Remaining Performance Obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Accounts receivable gross Accounts Receivable Gross Current Accounts receivable Number of operating segments Number Of Operating Segments Anti-dilutive equity instruments excluded from diluted net loss per common share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Requisite service period Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand twenty equity incentive plan. 2020 Equity Incentive Plan Two Thousand Twenty Equity Incentive Plan [Member] Two thousand twenty employee stock purchase plan. 2020 Employee Stock Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Assumed risk-free interest rate,minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Assumed risk-free interest rate,maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Assumed volatility,minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Assumed volatility,maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Expected option term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Assumed risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Assumed volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Stock-based compensation expense Allocated Share Based Compensation Expense Compensation cost related to non-vested awards not yet recognized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted average term expected to be recognized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Assumed Risk-free Interest Rate Measurement Input Risk Free Interest Rate [Member] Assumed Volatility Measurement Input Price Volatility [Member] Expected Term Measurement Input Expected Term [Member] Expected Dividend Yield Measurement Input Expected Dividend Rate [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Warrant liability, fair value measurement inputs Warrants And Rights Outstanding Measurement Input Expected term (years) Fair Value Disclosures [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Corporate Debt Securities Corporate Debt Securities [Member] Municipal Securities Municipal Notes [Member] U.S. Government Debt Securities U S Government Agencies Shortterm Debt Securities [Member] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Recurring Fair Value Measurements Recurring [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets: Assets Fair Value Disclosure [Abstract] Cash equivalents Cash Equivalents At Carrying Value Marketable securities, available for sale: Investments Fair Value Disclosure [Abstract] Marketable securities, available for sale Available For Sale Securities Debt Securities Total assets measured at fair value on a recurring basis Assets Fair Value Disclosure Liabilities: Liabilities Fair Value Disclosure [Abstract] Warrant liability Warrant Liability Fair Value Disclosure Total liabilities measured at fair value on a recurring basis Liabilities Fair Value Disclosure Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability reclassification of warrant liability due to private spac warrants not held by original holder. Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability derecognition of warrant liability from exercise of private spac warrants. Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Warrant liability. Warrant Liability Warrant Liability [Member] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Reclassification of warrant liability due to Private SPAC Warrants not held by original holder Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder Change in fair value of warrant liability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings Balance Derecognition of warrant liability from exercise of Private SPAC Warrants Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Derecognition Of Warrant Liability From Exercise Of Private Spac Warrants Letters of credit Letters Of Credit Outstanding Amount Investment Holdings [Table] Investment Holdings [Table] Investment Holdings [Line Items] Investment Holdings [Line Items] Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Gross Unrealized Gain Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Gross Unrealized Loss Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Estimated market value of debt securities with contractual maturities of less than 12 months. Estimated market value of remaining debt securities with contractual maturities of up to 23 months. Estimated market value of remaining debt securities with contractual maturities of up to 14 months. Estimated market value of debt securities with contractual maturities of less than 12 months Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months Estimated market value of remaining debt securities with contractual maturities of up to 14 months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To14 Months Estimated market value of remaining debt securities with contractual maturities of up to 23 months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To23 Months Prepaid trade shows, current. Prepaid software fees. Prepaid employee compensation. Computer equipment gross. Prepaid expenses and other current assets: Prepaid Expense And Other Assets Current [Abstract] Prepaid insurance Prepaid Insurance Prepaid trade shows Prepaid Trade Shows Current Prepaid software fees Prepaid Software Fees Deferred issuance costs Deferred Costs Current Prepaid employee compensation Prepaid Employee Compensation Other current assets Other Assets Current Total prepaid expenses and other current assets Property and equipment, gross: Property Plant And Equipment Gross [Abstract] Laboratory equipment Machinery And Equipment Gross Computer equipment Computer Equipment Gross Furniture and fixtures Furniture And Fixtures Gross Leasehold improvements Leasehold Improvements Gross Total property and equipment, gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total property and equipment, net Accrued bonus and deferred compensation, current. Accrued consulting services, current. Accrued compensation: Employee Related Liabilities Current [Abstract] Accrued paid time off Accrued Vacation Current Accrued bonus and deferred compensation Accrued Bonus And Deferred Compensation Current Total accrued compensation Accrued liabilities: Accrued Liabilities Current [Abstract] Accrued consulting services Accrued Consulting Services Current Other accrued expenses Other Accrued Liabilities Current Total accrued liabilities Debt Instrument [Table] Debt Instrument [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Two thousand eighteen convertible bridge notes. 2018 Convertible Bridge Notes Two Thousand Eighteen Convertible Bridge Notes [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Other Expense Other Expense [Member] Two thousand nineteen convertible bridge notes. 2019 Convertible Bridge Notes Two Thousand Nineteen Convertible Bridge Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Convertible note, principal amount Debt Instrument Face Amount Proceeds from issuance of convertible note Proceeds From Issuance Of Debt Debt instrument, interest rate Debt Instrument Interest Rate Stated Percentage Debt maturity date Debt Instrument Maturity Date Increase in interest rate if bridge notes not paid or converted Debt Instrument Interest Rate Increase Decrease Percentage of price per share of new stock paid in qualified financing by investors. Denominator for calculating capitalization value for price per share. Gross proceeds from issuance of equity securities Percentage of multiplier on price per share of new stock paid in qualified financing by investors Percentage Of Price Per Share Of New Stock Paid In Qualified Financing By Investors Denominator for calculating capitalization value for price per share Denominator For Calculating Capitalization Value For Price Per Share Debt discount Debt Instrument Unamortized Discount Loss on change in fair value of derivative liability Embedded Derivative Loss On Embedded Derivative Maturity date, description Debt Instrument Maturity Date Description Merger consideration maximum price per share. Debt conversion ratio number used as numerator to derive quotient. Merger consideration description. Convertible notes conversion ratio Debt Instrument Convertible Conversion Ratio1 Description of merger consideration Merger Consideration Description Merger consideration maximum price per share Merger Consideration Maximum Price Per Share Debt Conversion Ratio Number Used As Numerator to Derive Quotient Debt Conversion Ratio Number Used As Numerator To Derive Quotient Proceeds from issuance of convertible note Debt conversion feature Debt Instrument Convertible Terms Of Conversion Feature Convertible notes conversion price Debt Instrument Convertible Conversion Price1 Convertible debt converted in to common shares Debt Conversion Converted Instrument Shares Issued1 Gain on debt extinguishment Liability balance Convertible Debt Current Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] 2020 PIPE Financing. 2020 PIPE Financing Two Thousand And Twenty P I P E Financing [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Securities purchase agreement. Securities Purchase Agreement Securities Purchase Agreement [Member] At-The Market Offering Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Cowen Limited Liability Company. Cowen and Company LLC Cowen Limited Liability Company [Member] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Public special purpose acquisition companies warrants. Public SPAC Warrants Public Special Purpose Acquisition Companies Warrants [Member] Private special purpose acquisition companies warrants. Private SPAC Warrants Private Special Purpose Acquisition Companies Warrants [Member] Series C warrants. Series C Warrants Series C Warrants [Member] Series C convertible preferred stock. Series C Convertible Preferred Stock Series C Convertible Preferred Stock [Member] Placement agent warrants. Placement Agent Warrants Placement Agent Warrants [Member] Two thousand ten stock plan. 2010 Stock Plan Two Thousand Ten Stock Plan [Member] Incentive and non-statutory stock options. Incentive and Non-statutory Stock Options Incentive And Non Statutory Stock Options [Member] Incentive stock options. Incentive Stock Options Incentive Stock Options [Member] Incentive and non-qualified stock options. Incentive and Non-qualified Stock Options Incentive And Non Qualified Stock Options [Member] Management warrants. Management Warrants Management Warrants [Member] Class of Stock [Line Items] Class Of Stock [Line Items] Preferred stock, shares authorized Preferred Stock Shares Authorized Common stock, par value per share Preferred stock, par value per share Preferred Stock Par Or Stated Value Per Share Preferred stock, shares issued during period Issuance of preferred stock, total offering amount Issuance of common stock through conversion, Shares Sale of stock closing date. PIPE financing closing date Sale Of Stock Closing Date Issuance of stock Sale Of Stock Number Of Shares Issued In Transaction Issuance price per share Share Price Gross proceeds from PIPE financing Proceeds From Issuance Of Private Placement Preferred stock, issuance costs Preferred stock designated shares authorized and unissued. Preferred stock designated shares authorized and unissued Preferred Stock Designated Shares Authorized And Unissued Convertible preferred stock, shares outstanding Preferred Stock Shares Outstanding Gross proceeds from issuance of common stock. Increase decrease in stock issuance costs. Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common Stock Decrease in issuance costs Increase Decrease In Stock Issuance Costs Net proceeds from issuance of common stock Stock purchased by underwriters pursuant to option granted. Underwriters grant period option. Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses. Shares purchased by underwriters Stock Purchased By Underwriters Pursuant To Option Granted Number of days granted to underwriters option to purchase Underwriters Grant Period Option Public offering price Sale Of Stock Price Per Share Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses Common shares issued upon exercise of warrants. Total number exercised of public warrants Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Common shares issued upon exercise of warrants Common Shares Issued Upon Exercise Of Warrants Warrants outstanding Class Of Warrant Or Right Outstanding Preferred stock value of shares purchased by investors. Percentage of warrants issued in connection with preferred stock purchased. Preferred stock value of shares purchased in single closing Preferred Stock Value Of Shares Purchased By Investors Percentage of warrants issued in connection with preferred stock purchased Percentage Of Warrants Issued In Connection With Preferred Stock Purchased Options granted to shareholder, percentage. Options granted, exercise price expressed as a percentage of fair market value Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Options granted to shareholder, percentage Options Granted To Shareholder Percentage Common stock initially reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Contractual term of options granted Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Options remain available for future grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Equity incentive plan option term. Term of the option Equity Incentive Plan Option Term Common stock outstanding percentage. Shares, issued Shares Issued Common stock outstanding percentage Common Stock Outstanding Percentage Stock Option [Member] Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised Stock Issued During Period Shares Stock Options Exercised Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Ending balance Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Options exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted average exercise, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted average exercise Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted average exercise, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted average exercise, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted average exercise, Ending balance Options vested and expected to vest, Weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Options exercisable, Weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted average remaining contractual term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Options vested and expected to vest, Weighted average remaining contractual term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Options exercisable, Weighted average remaining contractual term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate intrinsic value, outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options vested and expected to vest, Aggregate intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Options exercisable, Aggregate intrinsic value Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Share-based compensation arrangement by share-based payment award,other than options, vested and expected to vest, outstanding, number Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending balance RSUs vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Awardother Than Options Vested And Expected To Vest Outstanding Number RSUs vested, but not yet issued Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, weighted average exercise price. Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued weighted average grant date fair value Beginning balance, Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Granted, Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Released, Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Forfeited, Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending balance, Weighted average grant date fair value per share RSUs vested and expected to vest, Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price RSUs vested, but not yet issued, Weighted average grant date fair value per share Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued Weighted Average Grant Date Fair Value Percentage of price at shares purchased Percentage of price at shares purchased Percentage Of Price At Shares Purchased Common stock available for issuance Common Stock Capital Shares Reserved For Future Issuance Warrants vesting period. Warrants vesting period Warrants Vesting Period Warrants to purchase common stock. Warrants to Purchase Common Stock Warrants To Purchase Common Stock [Member] SPAC warrants to purchase common stock. SPAC Warrants to Purchase Common Stock Special Purpose Acquisition Company Warrants To Purchase Common Stock [Member] Authorized for future equity grants. Authorized for Future Equity Grants Authorized For Future Equity Grants [Member] Authorized for future ESPP purchases. Authorized for Future ESPP Purchases Authorized For Future E S P P Purchases [Member] Common stock reserved for future issuance Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Domestic tax authority Domestic Country [Member] State and local jurisdiction State And Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Federal statutory rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Effective income tax rate reconciliation permanent items. Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract] Income tax at statutory rate State tax, net of federal tax benefit Effective Income Tax Rate Reconciliation State And Local Income Taxes Permanent items Effective Income Tax Rate Reconciliation Permanent Items Tax credits Effective Income Tax Rate Reconciliation Tax Credits Other Effective Income Tax Rate Reconciliation Other Reconciling Items Percent Valuation allowance (decrease) increase Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Income tax expense Effective Income Tax Rate Continuing Operations Deferred tax assets depreciation and amortization. Deferred tax assets operating lease liabilities. Deferred tax liabilities depreciation and amortization. Deferred tax liabilities operating lease right-of-use assets, Deferred tax assets liabilities before valuation allowance. Components Of Deferred Tax Assets And Liabilities [Abstract] Deferred tax assets: Deferred Tax Assets Net Of Valuation Allowance [Abstract] Net operating loss Deferred Tax Assets Operating Loss Carryforwards Research and development credits Deferred Tax Assets In Process Research And Development Depreciation and amortization Deferred Tax Assets Depreciation And Amortization Stock based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Accruals and other Deferred Tax Assets Other Operating lease liability Deferred Tax Assets Operating Lease Liabilities Deferred revenue Deferred Tax Assets Deferred Income Total deferred tax assets Deferred Tax Assets Gross Deferred tax liabilities: Deferred Tax Liabilities Net [Abstract] Depreciation and amortization Deferred Tax Liabilities Depreciation And Amortization Operating lease right-of-use assets Deferred Tax Liabilities Operating Lease Right Of Use Assets Total deferred tax liabilities Deferred Income Tax Liabilities Net deferred tax assets before valuation allowance Deferred Tax Assets Liabilities Before Valuation Allowance Less: valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Liabilities Net Operating loss carryforwards Operating Loss Carryforwards Tax credit carryforwards Tax Credit Carryforward Amount Ownership interest Equity Method Investment Ownership Percentage Uncertain tax positions percentage. Uncertain tax positions percentage Uncertain Tax Positions Percentage Uncertain tax positions Liability For Uncertain Tax Positions Current Percentage of useful lives of assets. Commitments and contingencies. Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Interest Income, Net Interest Income [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Kilroy Realty, L.P. Kilroy Realty, L.P Kilroy Realty L P [Member] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Letter of Credit Letter Of Credit [Member] Standby Letter of Credit Standby Letters Of Credit [Member] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Cowen. Cowen Cowen [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Percentage of useful lives of assets Percentage Of Useful Lives Of Assets Gross assets Accumulated amortization Finance lease interest expense Finance Lease Interest Expense Finance Lease Liability [Abstract] Gross finance lease obligations Finance Lease Liability Payments Due Less: imputed interest Finance Lease Liability Undiscounted Excess Amount Present value of net minimum lease payments Finance Lease Liability Less: current portion of finance lease obligations Lease commencement date. Area of building. Lease commencement date Lease Commencement Date Area of building Area Of Building Tenant improvement allowance per rentable square foot. Lessee, operating lease, description Lessee Operating Lease Description Tenant improvement allowance per rentable square foot Tenant Improvement Allowance Per Rentable Square Foot Tenant improvements Tenant Improvements Option to extend the lease term Lessee Operating Lease Option To Extend Lease liability Operating Lease Liability Estimated future lease payment obligation Lessee Operating Lease Liability Payments Due Security deposit Security Deposit Tenant improvement allowance. Increase in tenant improvement allowance. Tenant improvement allowance Tenant Improvement Allowance Increase in tenant improvement allowance Increase In Tenant Improvement Allowance Lease expiration date Lease Expiration Date1 Remaining lease term Lessee Operating Lease Remaining Lease Term Estimated discount rate Lessee Operating Lease Discount Rate Operating lease cost. Finance lease cost. Operating lease cost. Finance lease cost. Cash paid for amounts included in the measurement of lease liabilities. Lease Cost [Abstract] Operating lease cost Operating Lease Cost [Abstract] Operating lease cost Operating Lease Cost Variable lease costs Variable Lease Cost Total operating lease cost Operating Lease Costs Finance lease cost Finance Lease Costs [Abstract] Amortization of leased assets Finance Lease Right Of Use Asset Amortization Total finance lease cost Finance Lease Cost Cash paid for amounts included in the measurement of lease liabilities Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Operating cash flows from operating leases Operating Lease Payments Financing cash flows from finance leases Finance Lease Principal Payments Right-of-use assets obtained in exchange for new finance lease obligations Right Of Use Asset Obtained In Exchange For Finance Lease Liability Weighted-average remaining lease term of operating leases (in years) Operating Lease Weighted Average Remaining Lease Term1 Weighted-average remaining lease term of finance leases (in years) Finance Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate for operating leases Operating Lease Weighted Average Discount Rate Percent Weighted-average discount rate for finance leases Finance Lease Weighted Average Discount Rate Percent Operating and capital lease liability payments due. Operating and capital lease liability payments due next twelve months. Operating and capital lease liability payments due year two. Operating and capital lease liability payments due year three. Operating and capital lease liability payments due year four. Operating and capital lease liability payments due year five. Operating and capital lease liability payments due thereafter. Operating lease obligations, including interest payments due in 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months Operating lease obligations, including interest payments due in 2023 Lessee Operating Lease Liability Payments Due Year Two Operating lease obligations, including interest payments due in 2024 Lessee Operating Lease Liability Payments Due Year Three Operating lease obligations, including interest payments due in 2025 Lessee Operating Lease Liability Payments Due Year Four Operating lease obligations, including interest payments due in 2026 Lessee Operating Lease Liability Payments Due Year Five Operating lease obligations, including interest payments due thereafter Lessee Operating Lease Liability Payments Due After Year Five Operating lease obligations, including interest payments due, Total Finance lease obligations, including interest payments due in 2022 Finance Lease Liability Payments Due Next Twelve Months Finance lease obligations, including interest payments due in 2023 Finance Lease Liability Payments Due Year Two Finance lease obligations, including interest payments due in 2024 Finance Lease Liability Payments Due Year Three Finance lease obligations, including interest payments due in 2025 Finance Lease Liability Payments Due Year Four Finance lease obligations, including interest payments due in 2026 Finance Lease Liability Payments Due Year Five Finance lease obligations, including interest payments due thereafter Finance Lease Liability Payments Due After Year Five Total future minimum lease payments due in 2022 Operating And Capital Lease Liability Payments Due Next Twelve Months Total future minimum lease payments due in 2023 Operating And Capital Lease Liability Payments Due Year Two Total future minimum lease payments due in 2024 Operating And Capital Lease Liability Payments Due Year Three Total future minimum lease payments due in 2025 Operating And Capital Lease Liability Payments Due Year Four Total future minimum lease payments due in 2026 Operating And Capital Lease Liability Payments Due Year Five Total future minimum lease payments due thereafter Operating And Capital Lease Liability Payments Due Thereafter Total future minimum lease payments Operating And Capital Lease Liability Payments Due Deferred underwriting fees current. Payments for deferred underwriting fees Underwriting fees Deferred Underwriting Fees Current Deferred underwriting fee equity payable if equity financing limit not raised. Proceeds from equity financing Proceeds From Issuance Or Sale Of Equity Deferred underwriting fee equity payable if equity financing limit not raised Deferred Underwriting Fee Equity Payable If Equity Financing Limit Not Raised Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] EVERSANA Life Science Services, LLC. EVERSANA E V E R S A N A Life Science Services L L C [Member] Spouse of chief commercial officer. Leana Wood Spouse Of Chief Commercial Officer [Member] DermTech Operations, Inc. DermTech,Inc. Derm Tech Operations Inc [Member] Brother of chief executive officer. Michael Dobak Brother Of Chief Executive Officer [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related party certain marketing cost Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party Related party transaction, other Related Party Transaction Expenses From Transactions With Related Party EX-101.PRE 15 dmtk-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cover Page - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Mar. 08, 2022
    Jun. 30, 2021
    Cover [Abstract]      
    Document Type 10-K    
    Amendment Flag false    
    Document Period End Date Dec. 31, 2021    
    Document Fiscal Year Focus 2021    
    Document Fiscal Period Focus FY    
    Entity Registrant Name DERMTECH, INC.    
    Entity Central Index Key 0001651944    
    Entity Well Known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Current Fiscal Year End Date --12-31    
    Entity File Number 001-38118    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 84-2870849    
    Entity Address, Address Line One 11099 N. Torrey Pines Road    
    Entity Address, Address Line Two Suite 100    
    Entity Address, City or Town La Jolla    
    Entity Address, State or Province CA    
    Entity Address, Postal Zip Code 92037    
    City Area Code 858    
    Local Phone Number 450‑4222    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Public Float     $ 978,378,259
    Entity Small Business true    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Document Annual Report true    
    Document Transition Report false    
    Entity Common Stock, Shares Outstanding   29,850,730  
    Title of 12(b) Security Common Stock, par value $0.0001 per share    
    Trading Symbol DMTK    
    Security Exchange Name NASDAQ    
    ICFR Auditor Attestation Flag true    
    Auditor Name KPMG LLP    
    Auditor Location San Diego, CA    
    Auditor Firm ID 185    
    Documents Incorporated by Reference

    DOCUMENTS INCORPORATED BY REFERENCE

    The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2021. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.